0000721748-13-000671.txt : 20131010 0000721748-13-000671.hdr.sgml : 20131010 20131010123156 ACCESSION NUMBER: 0000721748-13-000671 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20110930 FILED AS OF DATE: 20131010 DATE AS OF CHANGE: 20131010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONAL SCIENTIFIC CORP/AZ CENTRAL INDEX KEY: 0001022505 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] IRS NUMBER: 860837077 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28745 FILM NUMBER: 131145326 BUSINESS ADDRESS: STREET 1: 8361 E. EVANS ROAD STREET 2: SUITE 106 CITY: SCOTTSDALE STATE: AZ ZIP: 85260-3617 BUSINESS PHONE: 480-948-8324 MAIL ADDRESS: STREET 1: 8361 E. EVANS ROAD STREET 2: SUITE 106 CITY: SCOTTSDALE STATE: AZ ZIP: 85260-3617 10-K 1 nsct10k11.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended September 30, 2011

OR

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the transition period from N/A to N/A

Commission File Number: 000-28745

Cloud Medical Doctor Software Corporation

(Name of small business issuer as specified in its charter)

(Formerly National Scientific Corporation)

 

Texas   86-0837077
State of Incorporation   IRS Employer Identification No.

 

1291 Galleria Drive, Suite 200

Henderson, NV 89014

(Address of principal executive offices)

(Former Address 8361 East Evans Road, Suite 106, Scottsdale, AZ 85260-3617)

 

(702) 818-9011

(Issuer’s telephone number)

(Former telephone number (480) 948-8324)

 

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value per share

(Title of Class)

Common Stock, $.001 Par Value

   
 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

[ ] Yes [x] No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

[x] Yes [ ] No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ ] No [x]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [x]

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,”“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer [ ] Accelerated filer [ ]
Non–Accelerated filer  [ ] Small reporting company [x]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).  Yes [ ] No [x]

 

Aggregate market value of the voting stock held by non-affiliates: $5,087,389 as based on the closing price of the stock on September 26, 2013. The voting stock held by non-affiliates on that date consisted of 169,579,649 shares of common stock.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of September 25, 2013, there were 214,634,216 shares of common stock, par value $0.01, issued and outstanding 4,000,000 shares of preferred stock, par value $0.10.

   
 

 Documents Incorporated by Reference: None

 

THE COMPANY PREVIOUSLY HAD INSUFFICIENT WORKING CAPITAL TO PAY FOR THE PROFESSIONAL SERVICES REQUIRED TO PREPARE, AUDIT, AND FILE THE QUARTERLY AND ANNUAL REPORTS REQUIRED BY THE SECURITIES ACT OF 1934. AS A RESULT, THE AUDITORS WHO AUDITED THE SEPTEMBER 30, 2007 FINANCIAL STATEMENTS AND REVIEWED THE QUARTERLY REPORTS THROUGH JUNE 30, 2008 RESIGNED EFFECTIVE DECEMBER 13, 2011.

 

IN FEBRUARY 2010 THE BOARD OF DIRECTORS VOTED TO DISCONTINUE THE MOBILE DVR AND LOCATION PRODUCTS LINE OF BUSINESS REPORTED IN THESE FINANCIAL STATEMENTS DUE TO THE CUMULATIVE EFFECTS OF SEVERELY DECLINING REVENUES RESULTING FROM THE 2008 RECESSION. SINCE THIS DECISION WAS MADE SUBSEQUENT TO THE YEARS ENDED SEPTEMBER 30, 2008 AND 2009, THE QUARTERLY AND YEAR END STATEMENTS FOR THOSE YEARS ARE BEING REPORTED ON A GOING CONCERN BASIS RATHER THAN AS DISCONTINUED OPERATIONS. THEY WILL, HOWEVER, BE REPORTED AS DISCONTINUED OPERATIONS COMMENCING WITH THE FISCAL 2010 FILINGS.

 

NEW MANAGEMENT HAS SUBSEQUENTLY INFUSED SUFFICIENT WORKING CAPITAL TO BRING THE 1934 ACT FILINGS CURRENT. ADDITIONALLY, A NEW LINE OF BUSINESS HAS ALSO COMMENCED WHICH WILL BE REPORTED ON IN THE FISCAL 2011 AND 2012 FILINGS.

 

ACCORDINGLY, THIS FILING IS BEING SUBMITTED ONLY TO COMPLY WITH SEC RULES AND REGULATIONS AND SHOULD NOT BE RELIED UPON FOR YOUR INVESTMENT DECISIONS. THE OPERATIONS REPORTED ON IN THIS DOCUMENT HAVE BEEN DISCONTINUED AS OF FEBRUARY 4, 2010. NEW MANAGEMENT ENCOURAGES THE READERS OF THIS DOCUMENT TO SUSPEND ANY INVESTMENT DECISIONS PERTAINING TO THIS STOCK UNTIL THE FILINGS ARE BROUGHT CURRENT.

 
 

Cloud Medical Doctor Software Corporation

FORM 10-K ANNUAL REPORT

FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2011 and 2010

TABLE OF CONTENTS

 

PART I    
ITEM 1.   BUSINESS   2
ITEM 1A.   RISK FACTORS   7
ITEM 1B.   UNRESOLVED STAFF COMMENTS   12
ITEM 2.   PROPERTIES   12
ITEM 3.   LEGAL PROCEEDINGS   12
ITEM 4.   REMOVED AND RESERVED   13
PART II    
ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES   14
ITEM 6.   SELECTED FINANCIAL DATA   17
ITEM 7.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   17
ITEM 7A.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   19
ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA   F-1
ITEM 9.   CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE   20
ITEM 9A.   CONTROLS AND PROCEDURES   21
ITEM 9B.   OTHER INFORMATION   22
PART III    
ITEM 10.   DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE   23
ITEM 11.   EXECUTIVE COMPENSATION   25
ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS   29
ITEM 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE   31
ITEM 14.   PRINCIPAL ACCOUNTANT FEES AND SERVICES   32
PART IV    
ITEM 15.   EXHIBITS AND FINANCIAL STATEMENT SCHEDULES   33
    SIGNATURES   34

 

CERTIFICATIONS

 

Exhibit 31.1 – Management certification

Exhibit 31.2 – Management certification

Exhibit 32.1 – Sarbanes-Oxley Act

Exhibit 32.2 – Sarbanes-Oxley Act

 
 

Special Note Regarding Forward-Looking Statements

 

Some of our statements under "Business," "Properties," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations,"" the Notes to Financial Statements and elsewhere in this report constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to certain events, risks and uncertainties that may be outside our control. Some of these forward-looking statements include statements of:

 

·management's plans, objectives and budgets for its future operations and future economic performance;
·capital budget and future capital requirements;
·meeting future capital needs;
·realization of any deferred tax assets;
·the level of future expenditures;
·impact of recent accounting pronouncements;
·the outcome of regulatory and litigation matters;
·the assumptions described in this report underlying such forward-looking statements; and
·Actual results and developments may materially differ from those expressed in or implied by such statements due to a number of factors, including:
othose described in the context of such forward-looking statements;
ofuture service costs;
ochanges in our incentive plans;
othe markets of our domestic operations;
othe impact of competitive products and pricing;
othe political, social and economic climate in which we conduct operations; and
othe risk factors described in other documents and reports filed with the Securities and Exchange Commission.

 

In some cases, forward-looking statements are identified by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology.

 

Although we believe that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor anyone else assumes responsibility for the accuracy and completeness of such statements and is under no duty to update any of the forward-looking statements after the date of this report.

 

PART I

 

ITEM 1. BUSINESS.

  

General

The financial statements presented in this report of Cloud Medical Doctor Software Corporation, a Texas corporation. When the terms “Cloud, the Company,” “we,” “us” or “our” are used in this document, those terms refer to Cloud Medical Doctor Software Corporation.

 

Our Company

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research.

 

Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue is derived from sales of electronic devices, recognized as the product is delivered.

 

In February 4, 2010 the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, decided to discontinue and wind down the operation of the Company's Mobile DVR and Location Products business and operate these remaining Company assets in a Limited Liability Company named NSC Labs, LLC controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC was to pay the Company 2% of revenues and $100,000. However, Mr. Grollman nor NSC Labs, LLC never paid consideration for this transaction.

 

In November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management has deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet. Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.

 

Our Current Business of the Company – Cloud Doctor Medical Software

 

In 2011 Cloud-MD Software Solutions introduced the Cloud-MD Office, a “Cloud Based”, 5010 and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

 

Cloud-MD Billing Services provides: Management of Medical Claims from posting physician charges into our medical billing software to posting of payments; Continuous Insurance Claim Follow Up to track and research all rejected or denied medical claims; Comprehensive Reporting including monthly financial Statements sent to our clients so they can see how their practice is doing and a variety of detailed reports give our clients the important information and tools used to assist in the increased production which leads to more profit; Patient Account Inquiries & Support to assist patients with their billing and insurance questions.

 

Cloud-MD Medical and Pharmaceutical Supply Management Software Services provides: a ground breaking cloud-based Medical Supply Inventory Management System, specifically designed for small and medium Medical Practices, DME’s, Home Health, Long-term Care, and Surgery Centers that offers:

 

Centralized management control over your medical supply and drug inventory

Real time utilization and financial inventory summary

Low price notifications

Par level/reorder tracking

RX expiration tracking

Auto supply re-ordering

 

Based on a barcode scanning system, designed to reduce workloads by automating inventory control processes, the Cloud-MD® Inventory Management System requires no installation, on-site software or special hardware. The Cloud-MD® application suite is fully delivered via the Internet and requires no special computing environment at the end-user facility.

 

Cloud-MD Healthcare Systems Consulting Services specializes in the implementation of sustainable, comprehensive solutions that increase financial and operational performance in healthcare businesses. By partnering with clients, we deliver solutions across the healthcare enterprise that improve quality, increase revenue, reduce operational expenses and attract physicians, patients and employees. We bring resources, in-depth knowledge, and significantly deeper experience than most in the field.

 

Cloud-MD Acquisition Services provides medical supply acquisition services that are fully integrated with Cloud-MD Office’s Medical and Pharmaceutical Inventory Management software and offers a full range of medical, surgical, and laboratory supply products and equipment for medical offices and surgery centers. Cloud-MD Acquisition Services easy-to-use and seamless process makes supply purchasing quicker and more cost efficient.

 

Item 1. Description of Business

 

Discontinued Operations of the Business up through February 4, 2010

 

Mobile DVR and Location Products

 

Most of our customers require monitoring and or tracking of a person or object, and reporting this information back to a central location.

 

Our current MDVR technology has not been awarded any patents as of the date of this report and has been awarded trademark protection on one other. We use a combination of confidentiality agreements, copyright and other trade secret management techniques to protect our trade secrets.

 

Location Products

 

GPS GRAPHIC

  

Overview of This Technology

 

We have developed a group of mobile products with the capability to record high quality digital video, determine location and identify individuals and concatenate this information into a homogeneous information stream that can be easily displayed on a remote computer. We use a technology called Global Positioning System or GPS to determine location. These products report the location information as well as other desired information back to the user through a radio network. The products typically contain a small computer to provide the overall control and data processing capacity for the device. The products can be thought of as having three distinct pieces or systems. These are the data collection system, the data control & processing system, and the data transport system. This design concept is the basis for our Mobile DVR products. The diagram below shows in a general way how the system works with our products:

 

Data Collection System

 

This system can be thought of as the “eyes and ears” of the product. It is comprised of two systems. One determines location of the product, while the other system records specific events that the customer may be interested in, such as a door opening on a school bus or the speed of the bus at a certain location. The location system determines the position of the product using a technology developed by the U.S. Government called the Global Positioning System, or GPS, as it is commonly known. The U.S. Government developed the system which consists of approximately 24 satellites that orbit the earth rapidly. It is a worldwide navigation support system that allows users of GPS receivers to determine their precise geographic locations to within a few meters in most cases. The network of satellites and their ground control and monitoring stations are maintained and operated by the United States Department of Defense, which maintains an ongoing satellite replenishment program to ensure continuous global system coverage. Access to the system for all users is currently provided free of charge by the U.S. Government.

 

GPS works by ranging and triangulating the product’s position from a group of satellites. Of the 24 GPS satellites in orbit, a minimum of four is needed to reliably determine the product’s three-dimensional position. A GPS receiver measures distance by calculating the amount of time it takes a navigation and time reference radio signal from the satellite to make a one-way trip to the GPS receiver.

 

GPS receivers typically are very compact; and it is not necessary to have a large dish antenna to receive GPS signals. Typical information that can be obtained from these GPS signals are latitude, longitude, elevation, speed, direction, date, and time.

 

The second part of this Data Collection System is customer specific. Many customers have additional types of data that they want to know or want collected relevant to a location. An example of this is, every time a child enters or leaves a school bus or the time and location that the bus stops. This data input system can therefore be customized to meet the exact needs of a customer.

 

Another kind of data collection technology we use in some of our products is called RFID, which stands for Radio Frequency Identification. RFID devices are small radios that could be used to track information about people or objects. RFID provides a low-cost solution for certain kinds of tracking activities, especially short-range activities, typically less than a hundred feet. RFID devices are primarily used to determine if the object is close to a given location.

 

Another kind of data collection technology we use in some of our products is called MDVR, which stands for mobile digital video recorder. MDVR devices use a small digital camera that takes up to 30 pictures per second and then stores these images electronically. When these individual pictures are ‘played back’, you see a movie of the recorded event. Schools are particularly interested in this type of technology in conjunction with GPS to monitor what is happening on their buses.

 

Data Control & Processing System

 

This system can be thought of as the “brains” of the product. A technical term for this system is an embedded system, meaning one that lives deep inside the overall product. An embedded system is a small special-purpose computer system built into a larger device. The reason we use an embedded system in our products is to keep cost to us low, so our products stay more competitive in price. Simple embedded systems can cost us as little as a few dollars each and use very little power compared to the desktop computers that many people are familiar with, which usually cost much more. On our embedded systems there is typically no disk drive, operating system, keyboard, or screen. Our embedded systems instead communicate with other computers by radio. These other computers typically have a keyboard and screens, and they are used to display our information.

 

The programs that we run on these systems are custom designed and built by our software engineers. These programs are called firmware. The firmware controls how the data is collected, what data should be collected and what events should be monitored and reported, what should be ignored, and how, when and what data should be sent back to the user. As mentioned above, the system is relatively easy to customize, and the firmware is also easy to customize as it has been written in a modular fashion that allows changes to one section to be implemented without the need to completely re-write the program. This also helps us keep costs down.

 

Data Transport System

 

This system can be thought of as the “mouth” of the product. It communicates to the outside world where it is and what has happened. There are many different types of technology that can be used to transport this data back to the user, generally using some kind of wireless technology based on radios. We currently use cellular radios, satellite radios, Wi-Fi radios, and other special purpose radios.

 

We use a cellular radio based on GSM cellular technology. GSM, or Global System for Mobile Communications, is a second-generation digital mobile telephone standard. GSM was initially developed as pan-European collaboration, intended to enable mobile roaming between member countries.

 

The cellular radios typically operate in “real time.” When an event occurs, the data is immediately transported back to a user at a remote location.

 

While cellular coverage and reception is good in urban areas, it is less effective in rural areas and is non-existent in most wilderness areas. Sometimes our products are used in areas where there is poor or no cellular coverage. To overcome this we sometimes use a special radio that communicates with satellites orbiting the earth. This form of communication has the advantage that our products can be used in very remote areas almost anywhere in the world. The major downside is that these radios are large and expensive and the airtime usage costs can be high. Another problem associated with this technology is that, like GPS, these satellite radios work best when there is a clear line of site to the satellites; as such they may not work well indoors, or under dense foliage or in deep valleys. The satellite radios typically operate in “real time.” When an event occurs, the data is immediately transported back to the user. Some of our customers do not want to have the expense of a real time cellular or satellite connection, nor are they interested in having the data in real time. For this we use either a special purpose radio or a Wi-Fi radio.

 

The Wi-Fi radio operates in a very similar manner to cordless phones found in many households. These phones typically consist of a base station and handset. Our system is very similar; it consists of a base station unit that receives data from the mobile unit that would be on the asset or vehicle being tracked. The base station is typically attached to a personal computer that takes the raw data from the radio and re-formats it into information that can be displayed by other computers on the Internet. Wi-Fi stands for “Wireless Fidelity” and is a technology in very common use to wirelessly connect personal computers to other computer networks, including the Internet.

 

Our special purpose radios work in a very similar manner to the Wi-Fi radio, except that they can sometimes transmit data over longer distances.

 

Wi-Fi radios operate in an unlicensed part of the radio spectrum and as such do not have any special government licensing fees associated with them. Because they operate in a license-free spectrum, the Federal Communications Commission (FCC) imposes some restrictions on the use of these radios. One major restriction is that the radio signal range is limited to about 300 feet.

 

Since most of the time our product operates well beyond 300 feet from the base station, all the collected data is stored within the device for later transmission when the product comes back into that range again. When the vehicle or asset comes back into base-station range, the mobile units automatically download their information. We call this mode of operation “near time.” These “near time” products do not incur any special airtime usage charges. As such, they can be significantly cheaper to operate than the cellular or satellite equivalents.

 

Once the data is transmitted back to the user they can either display the information on our software or on some other computer application.

 

Personnel

 

As of the date of this report, we have twenty full time employees.

 

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this Form 10-K in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

 

In an effort to keep our stockholders and the public informed about our business, we may make “forward-looking statements.” Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. As indicated previously, forward-looking statements are often identified by words, “will”, “may”, “should”, “continue”, “anticipate”, “believe”, “expect”, “plan”, “forecast”, “project”, “estimate”, “intend” and words of similar nature. Forward-looking statements generally include statements containing:

 

•   projections about accounting and finances;
•   plans and objectives for the future;
•   projections or estimates about assumptions relating to our performance; or
•   our opinions, views or beliefs about the effects of current or future events, circumstances or performance.

 

You should view those statements with caution. Those statements are not guarantees of future performance, circumstances or events. They are based on facts and circumstances known to us as of the date the statements are made. All phases of our business are subject to uncertainties, risks and other influences, many of which we do not control. Any of these factors either alone or taken together, could have a material adverse effect on us and could change whether any forward-looking statement ultimately turns out to be true. Additionally, we assume no obligation to update any forward-looking statement as a result of future events, circumstances or developments.

 

Outlined below are some of the risks that we believe could affect our business and financial statements for 2011 and beyond. An investment in our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, before investing in our common stock. If any of the events anticipated by the risks described below occur, our results of operations and financial condition could be adversely affected which could result in a decline in the market price of our common stock, causing you to lose all or part of your investment.

 

The Report Of Our Independent Registered Public Accounting Firm Contains Explanatory Language That Substantial Doubt Exists About Our Ability To Continue As A Going Concern

 

The independent auditor’s report on our financial statements contains explanatory language that substantial doubt exists about our ability to continue as a going concern. We have a net loss for the year ended September 30, 2011of $356,629, an accumulated deficit at September 30, 2011 of $26,229,970, cash flows used in of $220,628 and need additional cash flows to maintain our operations. We depend on the continued contributions of our executive officers to finance our operations and need to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of our products and business. If we are unable to obtain sufficient financing in the near term or achieve profitability, then we would, in all likelihood, experience severe liquidity problems and may have to curtail or cease our operations altogether. If we curtail our operations or cease our operations, we may be placed into bankruptcy or undergo liquidation, the result of which will adversely affect the value of our common shares.

 

Because We Are Quoted On The OTCBB “OTC Markets “formerly known as “Pinks Sheets” Instead Of An Exchange Or National Quotation System, Our Investors May Have A Tougher Time Selling Their Stock Or Experience Negative Volatility On The Market Price Of Our Stock.

 

Our common stock is traded on the OTCBB “OTC Markets”. The OTCBB “OTC Markets” is often highly illiquid, in part because it does not have a national quotation system by which potential investors can follow the market price of shares except through information received and generated by a limited number of broker-dealers that make markets in particular stocks. There is a greater chance of volatility for securities that trade on the OTCBB “OTC Markets” as compared to a national exchange or quotation system. This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume, and market conditions. Investors in our common stock may experience high fluctuations in the market price and volume of the trading market for our securities. These fluctuations, when they occur, have a negative effect on the market price for our securities. Accordingly, our stockholders may not be able to realize a fair price from their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our common stock improves.

 

We depend significantly upon the continued involvement of our present management.

 

The Company’s success depends significantly upon the involvement of our present management, who is in charge of our strategic planning and operations. We may need to attract and retain additional talented individuals in order to carry out our business objectives. The competition for individuals with expertise in this industry could be intense and there are no assurances that these individuals will be available to us.

 

Our Common Stock Is Subject To Penny Stock Regulation

 

Our shares are subject to the provisions of Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), commonly referred to as the "penny stock" rule. Section 15(g) sets forth certain requirements for transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act. The Commission generally defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. Rule 3a51-1 provides that any equity security is considered to be penny stock unless that security is: registered and traded on a national securities exchange meeting specified criteria set by the Commission; authorized for quotation on the NASDAQ Stock Market; issued by a registered investment company; excluded from the definition on the basis of price (at least $5.00 per share) or the registrant's net tangible assets; or exempted from the definition by the Commission. Since our shares are deemed to be "penny stock", trading in the shares will be subject to additional sales practice requirements on broker/dealers who sell penny stock to persons other than established customers and accredited investors.

 

Compliance with changing regulation of corporate governance and public disclosure will result in additional expenses and pose challenges for our management.

 

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations promulgated there under, the Sarbanes-Oxley Act and SEC regulations, have created uncertainty for public companies and significantly increased the costs and risks associated with accessing the U.S. public markets. Our management team will need to devote significant time and financial resources to comply with both existing and evolving standards for public companies, which will lead to increased general and administrative expenses and a diversion of management time and attention from revenue generating activities to compliance activities.

 

We rely heavily on international third parties to manufacture subsystems of our available on acceptable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to continue, products.

 

We currently rely on international third-party contractors to manufacture key sub assemblies to satisfy the needs of such customers. Reliance on one or more international third-party manufacturers exposes us to the risk that delivery schedules cannot be met, and that we cannot fulfill orders for some of our products in a timely way at the right price in U.S. dollars. This risk includes the concern that:

 

•   Third-party manufacturers might be unable to manufacture our products in the volume and of the quality required to meet customers’ needs;
•   Our existing and future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our customers;
•   If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.

 

Each of these conditions could delay the shipments to our customers, approvals required by regulatory authorities, and the commercialization of some of our customers’ products. These risks could also result in higher costs to the customer or could deprive us of potential product revenues.

 

Risks Relating To Our Industry

 

There are substantial inherent risks in attempting to commercialize new technological applications, and, as a result, we may not be able to successfully develop products or technology for commercial use.

 

Our company conducts ongoing development on our medical billing software. Our product development team is working on developing technology and products in various stages. Software development requires significant amounts of capital and takes an extremely long time to reach commercial viability, if at all. During the development of our software, we may experience technological barriers that we may be unable to overcome. Because of these uncertainties, it is possible that none of our product candidates will be successfully developed.

 

Risks Related to our Securities

 

The market price for our common stock may be volatile, and you may not be able to sell our stock at a favorable price or at all.

 

Many factors could cause the market price of our common stock to rise and fall, including:

•   actual or anticipated variations in our quarterly results of operations;
•   changes in market valuations of companies in our industry;
•   changes in expectations of future financial performance;
•   fluctuations in stock market prices and volumes;
•   issuances of dilutive common stock or other securities in the future;
•   the addition or departure of key personnel;
•   announcements by us or our competitors of acquisitions, investments or strategic alliances; and
•   it is possible that the proceeds from sales of our common stock may not equal or exceed the prices you paid for the shares after including the costs and fees of making the sales

 

Substantial sales of our common stock, or the perception that such sales might occur, could depress the market price of our common stock.

 

We cannot predict whether future issuances of our common stock or resale in the open market will decrease the market price of our common stock. The consequence of any such issuances or resale of our common stock on our market price may be increased as a result of the fact that our common stock is thinly, or infrequently, traded. The exercise of any options, or the vesting of any restricted stock that we may grant to directors, executive officers and other employees in the future, the issuance of common stock in connection with acquisitions and other issuances of our common stock may decrease the market price of our common stock.

 

Holders of our common stock have a risk of potential dilution if we issue additional shares of common stock in the future.

 

Although our Board of Directors intends to utilize its reasonable business judgment to fulfill its fiduciary obligations to our then existing stockholders in connection with any future issuance of our common stock, the future issuance of additional shares of our common stock would cause immediate, and potentially substantial, dilution to the net tangible book value of those shares of common stock that are issued and outstanding immediately prior to such transaction. Any future decrease in the net tangible book value of our issued and outstanding shares could have a material adverse effect on the market value of our shares.

 

We do not intend to pay cash dividends to our stockholders, so you will not receive any return on your investment in our Company prior to selling your interest in the Company.

 

The Company has never paid any cash dividends to our stockholders. We currently intend to retain any future earnings for funding growth and, therefore, do not expect to pay any cash dividends in the foreseeable future. As a result, you will not receive any return on your investment prior to selling your shares in our Company and, for the other reasons discussed in this “Risk Factors” section, you may not receive any return on your investment even when you sell your shares in our Company.

 

Certain shares of our common stock are restricted from immediate resale. The lapse of those restrictions, coupled with the sale of the related shares in the market, or the market’s expectation of such sales, could result in an immediate and substantial decline in the market price of our common stock.

 

Most of our shares of common stock are restricted from immediate resale in the public market. The restricted shares are restricted in accordance with Rule 144, which states that if unregistered, restricted securities are to be sold, a minimum of one year must elapse between the later of the date of acquisition of the securities from the issuer or from an affiliate of the issuer, and any resale of those securities in reliance on Rule 144. The Rule 144 restrictive legend remains on the stock until the holder of the stock holds the stock for longer than six months (unless an affiliate) and meets the other requirements of Rule 144 to have the restriction removed. The sale or resale of those shares in the public market, or the market’s expectation of such sales, may result in an immediate and substantial decline in the market price of our shares. Such a decline will adversely affect our investors, and make it more difficult for us to raise additional funds through equity offerings in the future.

 

Our common stock is subject to restrictions on sales by broker-dealers and penny stock rules, which may be detrimental to investors.

 

Our common stock is subject to Rules 15g-1 through 15g-9 under the Exchange Act, which imposes certain sales practice requirements on broker-dealers who sell our common stock to persons other than established customers and “accredited investors” (as defined in Rule 501(a) of the Securities Act). For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to the sale. This rule adversely affects the ability of broker-dealers to sell our common stock and purchasers of our common stock to sell their shares of our common stock.

 

Additionally, our common stock is subject to SEC regulations applicable to “penny stocks.” Penny stocks include any non-Nasdaq equity security that has a market price of less than $5.00 per share, subject to certain exceptions. The regulations require that prior to any non-exempt buy/sell transaction in a penny stock; a disclosure schedule proscribed by the SEC relating to the penny stock market must be delivered by a broker-dealer to the purchaser of such penny stock. This disclosure must include the amount of commissions payable to both the broker-dealer and the registered representative and current price quotations for our common stock. The regulations also require that monthly statements be sent to holders of a penny stock that disclose recent price information for the penny stock and information of the limited market for penny stocks. These requirements adversely affect the market liquidity of our common stock.

 

Our Articles of Incorporation allow us to sell preferred stock without shareholder approval.

 

Our Board of Directors has the authority to issue up to 4,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any additional vote or action by our shareholders. The rights of the holders of the common stock will be subject to, and could be materially adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. For example we could issue preferred stock that has superior rights to dividends or is convertible into shares of common stock. This might adversely affect the market price of the common stock.

 

If we experience delays and/or defaults in customer payments, we could be unable to recover all expenditures.

 

Because of the nature of our contracts, at times we commit resources to projects prior to receiving payments from the customer in amounts sufficient to cover expenditures on projects as they are incurred. Delays in customer payments may require us to make a working capital investment. If a customer defaults in making their payments on a project in which we have devoted resources, it could have a material negative effect on our results of operations.

 

If we do not effectively manage our growth, our existing infrastructure may become strained, and we may be unable to increase revenue growth.

 

Our past growth that we have experienced, and in the future may experience, may provide challenges to our organization, requiring us to expand our personnel and our operations. Future growth may strain our infrastructure, operations and other managerial and operating resources. If our business resources become strained, our earnings may be adversely affected and we may be unable to increase revenue growth. Further, we may undertake contractual commitments that exceed our labor resources, which could also adversely affect our earnings and our ability to increase revenue growth.

 

SHOULD ONE OR MORE OF THE FOREGOING RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD THE UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED, EXPECTED, INTENDED OR PLANNED

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

This Item is not applicable to us as we are not an accelerated filer, a large accelerated filer, or a well-seasoned issuer.

 

ITEM 2. PROPERTIES

  

During December 31, 2010 the Company uses the Chief Financial Officers office as the Corporation’s office at no cost to the Company.

 

Since January 2012, the Company uses the office at 1291 Galleria Drive, Suite 200, Henderson, NV 89014. The office is at no cost to the Company.

 

ITEM 3. LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company’s or our company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

On July 5, 2013 the Company filed a complaint for the collection of $150,000 of unpaid medical billing fees that were seriously delinquent. After many attempts by the Company to begin collections, the Defendants refused to pay the outstanding balances, however expected the Company to continue to bill for them. The Company’s complaint was filed against Krooss Medical Management Systems, LLC, William F. Krooss and Marie W. Krooss in the United States District Court, District of Nevada Case No. 2013-CV-01187-ABG-VCF.

 

On August 13, 2013 Krooss Medical Management Systems et al filed a Complaint in Chancery Court of Rankin County, Mississippi Case No. 13-1372 as a strategy to keep the collection matter in Mississippi Chancery Court.

 

Case No. 13-1372 was remanded to the United States District Court, Southern District of Mississippi Jackson Division Case No. 3:13CV507-HTW-LRA.

 

This litigation is a collection matter of unpaid fees by the Defendants and the Company vehemently denies the allegations filed in Mississippi Chancery Court related to this collection matter. The Company does not expect the cost to litigate this matter to adversely affect the Company’s operations.

 

ITEM 4. N/A

 

PART II

 

ITEM 5. MARKET FOR REGISTANT’S COMMON STOCK, RELATED STOCKHOLDER MATTERS AND ISSUERS PURCHASES OF EQUITY SECURITIES.

 

Cloud common stock is traded in the over-the-counter market, and quoted in the National Association of Securities Dealers Inter-dealer Quotation System (“Electronic Bulletin Board) and can be accessed on the Internet at OTCmarkets.com under the symbol “NSCT.”

 

At September 30, 2011, there were 180,526,879 shares of common stock of Cloud outstanding and there were in excess of 8,000 shareholders of record of the Company’s common stock.

 

The following table sets forth for the periods indicated the high and low bid quotations for Cloud’s common stock. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown or commission and may not represent actual transactions.

 

Periods   High   Low  
Fiscal Year 2011              
First Quarter (October – December  2010)   $ 0.01   $ 0.01  
Second Quarter (January  – March 2011)   $ 0.01   $ 0.01  
Third Quarter (April - June 2011)   $ 0.01   $ 0.01  
Fourth Quarter (July – September  2011)   $ 0.00   $ 0.00  

 

Fiscal Year 2010

              
First Quarter (October – December  2009)   $ 0.0008   $ 0.0008  
Second Quarter (January  – March 2010)   $ 0.0012   $ .0012  
Third Quarter (April - June 2010)   $ 0.0008   $ 0.0008  
Fourth Quarter (July – September  2010)   $ 0.0004   $ 0.0004  

 

On September 25, 2013, the closing bid price of our common stock was $0.03

 

Dividends

 

We may never pay any dividends to our shareholders. We did not declare any dividends for the year ended September 30, 2011. Our Board of Directors does not intend to distribute dividends in the near future. The declaration, payment and amount of any future dividends will be made at the discretion of the Board of Directors, and will depend upon, among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other factors as the Board of Directors considers relevant. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend.

 

Transfer Agent

 

Cloud’s Transfer Agent and Registrar for the common stock is Pacific Stock Transfer located in Las Vegas, Nevada.

 

Recent sales of Unregistered Securities

 

2013

In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.

 

In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.

 

In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.

 

In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.

 

April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.

 

April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.

 

May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.

 

Fiscal Year Ended 2012

 

During the ten months ended July 31, 2012 the Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $3,325,949. The Company also issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees. The Company issued 706,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $10,401.

 

The Company issued 90,000 common shares for $18,000 in cash.

 

The Company issued 200,000 common shares to Kroos Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Kroos Medical Management of $4,000.

 

Fiscal Year Ended 2011

 

In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.

 

The Company issued 250,000 in common stock for $25,000 in cash.

 

Fiscal Year Ended 2010

 

No common stock was issued.

 

Common Stock

 

On April 11, 2011 the Company amended its articles of incorporation to increase the authorized shares to 650,000,000, at $0.01 par value and 180,526,879 are issued and outstanding as of September 30, 2011. The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

 

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $.001 par value and 4,000,000 are issued and outstanding as of September 30, 2011. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.

 

Warrants and Options

 

All warrants issued have expired.

 

Stock Option Plan

 

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminates in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan therefore it is terminated.

 

ITEM 6. SELECTED FINANCIAL DATA.

 

The following information has been summarized from financial information included elsewhere and should be read in conjunction with such financial statements and notes thereto.

 

Summary of Statements of Operations and Financial Position of NSCT

Years Ended September 30, 2011 and 2010

 

   September 30,
Operating Data:  2011  2010
       
Revenue   —     $—   
Operating and Other Expenses   340,417    21,964 
 Discontinued operations   16,212    35,121 
Net Loss   (356,629)  $(57,085)

 

   September 30,
Balance Sheet Data:   2011    2010 
           
Current Assets   —     $—   
Total Assets   11,016    2,597 
Current Liabilities   1,200,106    1,788,741 
Non-Current Liabilities   —      —   
Total Liabilities   1,985,790    1,788,741 
Working Capital (Deficit)   (1,974,774)   (1,788,741)
Shareholders’ Equity   (1,974,774)  $(1,786,145)

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

 

The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto and other financial information contained elsewhere in this Form 10-K.

 

Business

 

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue was derived from sales of electronic devices, recognized as the product is delivered.

 

In February 4, 2010 the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate these remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. Since as of this filing neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction the transaction has not been recorded in the accounting records of the Company.

 

In November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management has deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.

 

Critical Accounting Policies

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

 

These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period.  Management evaluates these estimates and assumptions on a regular basis.  Actual results could differ from those estimates.

 

Revenue Recognition

 

Revenue includes product sales and provision of services. The Company recognizes revenue from product sales and provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.

  

RESULTS OF OPERATIONS FROM DISCONTINUED MOBILE DVR AND LOCATION PRODUCTS BUSINESS

 

Fiscal Year Ended September 30, 2011, Compared to Fiscal Year Ended September 30, 2010

 

General and administrative expenses increased to $21,964 from $0 for the years ended September 30, 2011 and 2010, respectively. Our General and administrative expenses is related to the new medical billing company operations.

 

We recorded a loss from discontinued operations for the year ended September 30, 2011 of $16,212 of $35,121 for year ended September 30, 2009. The Company is currently engaged in the medical billing operations.  Until October 1, 2009, the Company’s sole sources of revenues were from GPS operational device business.  The Company discontinued its GPS operational device business in February 2010 (See “Note 3 - Discontinued Operations” to the accompanying Financial Statements).   The Company’s GPS operational device business was its primary operations and only sources of revenues for the year ended September 30, 2009.   

 

Liquidity and Capital Resources

 

The Company has material notes, one from our prior Chief Executive Officer for approximately $59,704, one convertible note with an investor relationship with Strategic Working Capital Fund, LP $175,000 net of discount and beneficial conversion feature of $0.00 with a total balance due of $175,000, and three notes with shareholders of $31,625. As of September 30, 2011 the Company was in default on all notes since the Company has not paid the required quarterly interest payments. In July 2010 our new CEO advanced $159,515.

 

Our cash (used in) provided by operating activities were ($220,628) and ($31,518) for the years ended September 30, 2011 and 2010, respectively. The decrease in cash flows used in operations was primarily attributable to the changes in operating assets and liabilities, primarily related to increases in amounts payable, in 2011 as compared to the 2010 period.

 

Cash provided by (used in) financing activities was $229,050 and $21,281 for the years ended September 30, 2011 and 2010, respectively. We received advances from our CEO of $159,515.

 

There is a strong possibility that we may not be able to satisfy our cash requirements over the next twelve months and may be required to raise additional cash from outside sources.

 

In the event that we are required to raise additional cash from outside source, we may issue equity securities or incur additional debt. There is no assurance that such funding, if required will be available to us or, if available, will be available upon terms favorable to us.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We do not hold any derivative instruments and do not engage in any hedging activities.

 

ITEM 8. FINANCIAL STATEMENTS

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

 

TABLE OF CONTENTS   Page
     
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS:   F-2
FINANCIAL STATEMENTS:    
Balance Sheet at September 30, 2011 and 2010  

F-3

Statements of Operations for the year ended September 30, 2011 and 2010   F-4
Statement of Stockholders’ (Deficit) for the year ended September 30, 2011 and 2010   F-5
Statements of Cash Flows for the year ended September 30, 2011 and 2010   F-6
NOTES TO FINANCIAL STATEMENTS   F-7

 

 

 

 

 S.E.Clark & Company, P.C.

image_001

Registered Firm: Public Company Accounting Oversight Board

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors

Cloud Medical Doctor Software Corporation,

fka National Scientific Corporation

Phoenix, Arizona

 

We have audited the accompanying balance sheets of Cloud Medical Doctor Software Corporation, fka National Scientific Corporation (the “Company”), as of September 30, 2011 and 2010, and the related statements of operations, stockholders’ deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Cloud Medical Doctor Software Corporation, fka National Scientific Corporation, as of September 30, 2011 and 2010 and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has a net loss for the year ended September 30, 2011 of $356,629, an accumulated deficit at September 30, 2011 of $26,229,970, cash flows used by operating activities of $220,628, and needs additional cash flows to maintain its operations. Those conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ S.E.Clark & Company, P.C.

 

Tucson, Arizona

September 30, 2013

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
BALANCE SHEETS
   September 30,
   2011  2010
       
ASSETS          
           
CURRENT ASSETS:          
  Cash  $11,016   $—   
  Net assets of discontinued operations   —      2,597 
      Total current assets   11,016    2,597 
           
  Proprietary technology   1,200,106    —   
           
    TOTAL ASSETS  $1,211,122   $2,597 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
CURRENT LIABILITIES:          
   Advances from officers  $180,795   $21,281 
   Line of Credit   44,535    —   
   Net liabilities of discontinued operations   1,760,459    1,767,460 
      Total current liabilities   1,985,790    1,788,741 
           
   Note payable affiliate   1,200,106    —   
           
      TOTAL LIABILITIES   3,185,896    1,788,741 
           
STOCKHOLDERS' DEFICIT:          
Preferred stock, $.10 par value, 4,000,000 shares authorized; none issued and outstanding as of September 30, 2011 and 2010   40,000    —   
Common stock, $.01 par value, 650,000,000 shares authorized; 180,526,879 and 165,276,913 issued and outstanding as of September 30, 2011 and 2010, respectively   1,805,269    1,652,769 
    Additional paid-in capital   22,409,927    22,434,427 
    Accumulated deficit   (26,229,970)   (25,873,341)
      Total stockholders' deficit   (1,974,774)   (1,786,145)
           
    TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $1,211,122   $2,597 
           
The accompanying notes are an integral part of these financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
STATEMENTS OF OPERATIONS
   Years Ended September 30,
   2011  2010
       
OPERATING EXPENSES:          
    Total operating expenses  $340,417   $21,964 
OPERATING LOSS   (340,417)   (21,964)
           
(LOSS) INCOME BEFORE TAXES AND DISCOUNTED OPERATIONS  $(340,417)   (21,964)
           
(LOSS) INCOME FROM CONTINUED OPERATIONS   (340,417)   (21,964)
           
(LOSS) INCOME FROM DISCONTINUED OPERATIONS   (16,212)   (35,121)
           
NET LOSS  $(356,629)  $(57,085)
           
NET LOSS PER COMMON SHARE:          
   Basic          
           
   Continuing operations  $(0.00)  $(0.00)
           
    Discontinuing operations  $(0.00)  $(0.00)
           
NET (LOSS) INCOME PER COMMON SHARE          
   Basic  $(0.00)  $(0.00)
           
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING          
   Basic   180,526,879    165,276,879 
           
The accompanying notes are an integral part of these financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
STATEMENTS OF STOCKHOLDERS' DEFICIT
FOR THE YEARS ENDED SEPTEMBER 30, 2011 AND 2010
  Preferred Stock   Common Stock   
    Shares  Amount  Shares  Amount  Additional Paid-in Capital  Accumulated Deficit  Total
                      
SEPTEMBER 30, 2008   —     $—      137,276,879   $1,372,770   $22,658,682   $(25,491,084)  $(1,459,633)
Options expired             —           19,945         19,945 
Common stock issued for back pay of officers             28,000,000    280,000    (244,200)   —      35,800 
Net loss                            (325,172)   (325,172)
SEPTEMBER 30, 2009   —     $—      165,276,879   $1,652,769   $22,434,427   $(25,816,256)  $(1,729,061)
                                    
Net loss                            (57,085)   (57,085)
SEPTEMBER 30, 2010   —     $—      165,276,879   $1,652,769   $22,434,427   $(25,873,341)  $(1,786,146)
                                    
                                    
Common stock issued for compensation             15,000,000    150,000    (45,000)        105,000 
Preferred stock issued for compensation   4,000,000    40,000              (2,000)        38,000 
Common stock issued for cash             250,000    2,500    22,500         25,000 
Net loss                            (356,629)   (356,629)
SEPTEMBER 30, 2011   4,000,000   $40,000    180,526,879   $1,805,269   $22,409,927   $(26,229,970)  $(1,974,775)
                                    
THE LINE OF BUSINESS REPORTED ON THESE FINANCIAL STATEMENTS
WAS DISCONTINUED IN FEBRUARY 2010.  SEE NOTE 1
The accompanying notes are an integral part of these financial statements

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
STATEMENTS OF CASH FLOWS
       
   September 30,
   2011  2010
       
  Net Loss  $(356,629)  $(57,085)
  Adjustments to reconcile net loss to net cash          
     (used in) operating activities:          
  Discontinued operations   16,212    35,121 
  Changes in assets and liabilities:          
    Stock issued for compensation   143,000    —   
    Net assets and liabilities from discontinued operations   (23,214)   (9,554)
          Net cash used in operating activities   (220,631)   (31,518)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
  Common stock issued for cash   25,000    —   
  Advances from affiliates   159,515    36,000 
  Line of credit   44,535    (14,719)
          Net cash provided by financing activities   229,050    21,281 
           
INCREASE IN CASH   8,419    (10,237)
CASH, BEGINNING OF PERIOD   2,597    12,434 
CASH, END OF PERIOD  $11,016   $2,197 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
           
Interest paid  $—     $—   
Taxes paid  $—     $—   
Purchase of proprietary technology  $1,200,106   $—   
           
The accompanying notes are an integral part of these financial statements.

 

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

NOTES TO FINANCIAL STATEMENTS

FOR THE YEARS ENDED SEPTEMBER 30, 2011 AND 2010

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

THE COMPANY PREVIOUSLY HAD INSUFFICIENT WORKING CAPITAL TO PAY FOR THE PROFESSIONAL SERVICES REQUIRED TO PREPARE, AUDIT, AND FILE THE QUARTERLY AND ANNUAL REPORTS REQUIRED BY THE SECURITIES ACT OF 1934. AS A RESULT, THE AUDITORS WHO AUDITED THE SEPTEMBER 30, 2007 FINANCIAL STATEMENTS AND REVIEWED THE QUARTERLY REPORTS THROUGH JUNE 30, 2008 RESIGNED EFFECTIVE DECEMBER 13, 2011.

 

IN FEBRUARY 2010 THE BOARD OF DIRECTORS VOTED TO DISCONTINUE THE MOBILE DVR AND LOCATION PRODUCTS LINE OF BUSINESS REPORTED IN THESE FINANCIAL STATEMENTS DUE TO THE CUMULATIVE EFFECTS OF SEVERELY DECLINING REVENUES RESULTING FROM THE 2008 RECESSION. SINCE THIS DECISION WAS MADE SUBSEQUENT TO THE YEARS ENDED SEPTEMBER 30, 2008 AND 2009, THE QUARTERLY AND YEAR END STATEMENTS FOR THOSE YEARS ARE BEING REPORTED ON A GOING CONCERN BASIS RATHER THAN AS DISCONTINUED OPERATIONS. THEY WILL, HOWEVER, BE REPORTED AS DISCONTINUED OPERATIONS COMMENCING WITH THE FISCAL 2010 FILINGS.

 

NEW MANAGEMENT HAS SUBSEQUENTLY INFUSED SUFFICIENT WORKING CAPITAL TO BRING THE 1934 ACT FILINGS CURRENT. ADDITIONALLY, A NEW LINE OF BUSINESS HAS ALSO COMMENCED WHICH WILL BE REPORTED ON IN THE FISCAL 2011 AND 2012 FILINGS.

 

ACCORDINGLY, THESE FINANCIAL STATEMENTS ARE BEING SUBMITTED ONLY TO COMPLY WITH SEC RULES AND REGULATIONS AND SHOULD NOT BE RELIED UPON FOR YOUR INVESTMENT DECISIONS. THE OPERATIONS REPORTED ON IN THESE FINANCIAL STATEMENTS HAVE BEEN DISCONTINUED AS OF FEBRUARY 4, 2010. NEW MANAGEMENT ENCOURAGES THE READERS OF THESE FINANCIAL STATEMENTS TO SUSPEND ANY INVESTMENT DECISIONS PERTAINING TO THE STOCK OF THIS COMPANY UNTIL ALL REQUIRED 1934 ACT FILINGS ARE BROUGHT CURRENT.

 

 

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue is derived from sales of electronic devices, recognized as the product is delivered.

 

In February 4, 2010 the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate the remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. Since as of this filing neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction the transaction has not been recorded in the accounting records of the Company

 

In November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management has deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet. Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.

 

NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

 

In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

 

NOTE 3 - GOING CONCERN ISSUES

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has a net loss for the twelve months ended September 30, 2011 of $356,629, an accumulated deficit at September 30, 2011 of $26,229,970, and needs additional cash to maintain its operations.

 

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

 

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

 

Revenue Recognition

 

Revenue includes provision of services. The Company recognizes revenue from provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.

 

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged off against the allowance when it is probable the receivable will not be recovered. 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Income Taxes

 

Deferred income taxes are provided to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company adopted the provisions of ASC Topic 740, Accounting For Uncertainty In Income Taxes-An Interpretation of ASC Topic 740 ("ASC Topic 740"). ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2011, the Company did not record any liabilities for uncertain tax positions.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.  The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.

 

Basic and Diluted Net Loss Per Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  

 

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

 

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt.  The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

 

The Company adopted ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

•Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
•Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
•   Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

 

The following table summarizes fair value measurements by level at September 31, 2011 and 2010 for assets measured at fair value on a recurring basis:

 

at September 30, 2011               
   Level 1  Level 2  Level 3  Total  
Proprietary Technology             1,200,106   1,200,106  
Total Proprietary Technology             1,200,106   1,200,106  
                      
at September 30, 2010                     
    Level 1    Level 2    Level 3   Total  
Proprietary Technology                     
Total Proprietary Technology             —     —    

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current year presentations.

 

Recent Accounting Pronouncements

  

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

 

NOTE 5- DISCONTINUED OPERATIONS

 

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC by prior management in which he was to pay $100,000 for that technology the former officer never paid the required compensation. The Company discontinued these operations and began selling Medical Business Software and is the current operation of the Company.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and operations from discontinued operations in accordance with ASC Topic 360, Accounting for the Impairment or Disposal of Long Lived Assets.

 

Details of those classifications are shown below.

 

 

   September 30, 2011  September 30,
2010
Net assets of discontinued operations:          
Cash  $—     $2,197 
Accounts receivable   —      —   
Deferred offering costs   —      400 
Net assets of discontinued operations  $—     $2,597 
           
Net liabilities of discontinued operations:          
Accounts payable and accrued expenses  $169,176   $195,072 
           
Disputed salaries & vacation of former officers   968,645    968,645 
Disputed salary – former employee   20,256    20,256 
           
Disputed payroll taxes for back pay of former officers   84,701    84,701 
Disputed interest   209,215    191,346 
Interest expenses   42,137    42,137 
Former officer note payable at 8% interest rate   59,704    59,704 
Shareholders demand note payable at 12%   11,625    11,625 
Shareholders demand note payable at 12%   20,000    20,000 
Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010   175,000    175,000 
Note discount   —      (860)
Note beneficial conversion feature   —      (166)
Net liabilities of discontinued operations  $1,760,459   $1,767,460 

 

 

   Years ended
September 30,
   2011  2010
Discontinued operations:          
Revenues  $3,400   $58,788 
Cost of sales   —      25,462 
Operating expenses   —      36,485 
Interest expense   19,612    31,962 
Interest income   —      —   
Loss from Discontinued Operations  $16,212   $35,121 

 

Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:

 

On September 7, 2005, we entered into a factoring agreement with United Capital Funding (UCF) of Florida. UCF is a specialized financial services firm offering Accounts Receivable Management and working capital funding via factoring. We expect to improve our cash flow with this arrangement.

 

Under the arrangement, we sell to UCF as absolute owner, invoices that we submit to UCF to be factored. Upon purchase, UCF assumes the risk of non-payment on purchased invoices, so long as the cause of non-payment is solely due to the occurrence of an insolvency event. As collateral securing the obligations, we grant UCF a continuing first priority security interest in all accounts and related inventory. Notwithstanding the creation of the above security interest, our relationship with UCF is one of Seller and Purchaser of accounts, and not that of lender and borrower. However, as there is certain recourse for non-payment, the accounts receivable are recorded at the estimated realizable value, net of allowances and the net advanced amount from UCF is recorded as an obligation at the end of fiscal 2010 and 2010. The initial and periodic factoring fee is .45% of the face amount of factored invoices. The factoring period is five days and the purchase price is 80% of the face amount, excluding sales tax.

 

UCF typically advances to us 80% of the total amount of invoices factored, excluding sales tax. UCF retains 20% of the outstanding factored invoices as a reserve, which it holds until the customer pays the factored invoice to UCF.

 

On November 1, 2005, as an important phase in the current year’s financing plan, we entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program include a five-year Note payable at maturity in November 2010 for $175,000, at an effective annual interest rate of 8%. Interest is due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares include weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the Note has various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs are being amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs.

 

On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 our Chairman Michael Grollman made new personal loans to the Company totaling $159,000 to assist us with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company’s iBus software and designs.  During the quarter to September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.  On September 30, 2007, the Company converted unpaid interest of $13,300 on demand notes payable to Michael Grollman into a new demand note of $13,300 that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1st. The balance of the note at September 30, 2011 is $59,704.

 

On April 27, 2006, we secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer’s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer’s purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009. The note had an approximate maturity date of June 15, 2006. At September 30, 2006 and September 30, 2007 this note was in default. As of September 30, 2011 $11,625 of this loan was in default.

 

On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA’s order and b) in any receivable resulting from the fulfillment of the Clover Park purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009. The note had a maturity date of July 10, 2006. At September 30, 2011 this note was in default.

 

 

NOTE 6– COMMITMENT AND CONTINGENCIES

 

Rent expense for the years ended September 30, 2011 and 2010 was approximately $0.00 and $7,245 respectively

 

NOTE 7– RELATED PARTY TRANSACTIONS

 

In September 30, 2009 the Company issued 28,000,000 common shares at the trading price of the common stock of $0.0012785. The Stock was issued for unpaid compensation to officers and reduced accrued compensation by $35,800.

 

On July 19, 2010 the Company assumed the line of credit of new management from Chase Bank of $36,000 to fund transitional expenses of which the net advance totaled $44,535.

 

In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.

 

In April 2011 the Company issued 4,000,000 common shares at the trading price of the common stock of $0.0095. The stock was issued for compensation to new management and recorded and expense of $38,000.

 

The Company entered into an employment agreement with its Chief Executive Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement, will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 5,000,000 for DNA, 5,000,000, and 1,000,000 for MediSouth, LLC
v.An automobile allowance of $1,500 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation.

 

The Company entered into an employment agreement with its Chief Financial Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

 

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 3,000,000 for DNA, 3,000,000, and 750,000 for MediSouth, LLC
v.An automobile allowance of $1,000 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation

 

NOTE 8 - EQUITY

 

On April 11, 2011 the Company amended its articles of incorporation to increase the authorized common shares to 650,000,000, at $0.01 par value and 180,526,879 are issued and outstanding as of September 30, 2011. and 4,000,000 preferred shares outstanding at a par value of $.01.

 

The Common stock holders have right to vote one share for every share that is issued.

 

The Preferred stockholders have designated rights and preferences of a Series A Convertible Preferred Stock, and reserved 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock.

 

2013

 

In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.

 

In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.

 

In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.

 

In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.

 

April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.

 

April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.

 

May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.

 

2012

 

During the ten months ended July 31, 2012 the Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106. The Company also issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees. The Company issued 706,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $10,401.

 

The Company issued 90,000 common shares for $18,000 in cash.

 

The Company issued 200,000 common shares to Kroosss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.

 

In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).

 

2011

 

In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.

 

The Company issued 250,000 in common stock for $25,000 in cash.

 

2010

 

No common stock was issued.

 

Common Stock

 

The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

 

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $.001 par value and zero are issued and outstanding as of September 30, 2011. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been issued to our CEO & CFO on April 11, 2011 valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.

 

NOTE 9 – STOCK-BASED COMPENSATION

 

Options

 

The Prior board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminated in accordance with the plan provisions on December 1, 2010. The Current Board of Directors did not extend the Stock Option Plan, allowing it to terminate.

 

Under the 2000 Stock Option Plan, the purchase price must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option was granted (if the option is a nonqualified grant), or such higher price as may be determined by the Board of Directors at the time of grant. If however, an incentive stock option was granted to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all our classes of stock, the purchase price of the shares of common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option was granted. As the price of the Company’s common stock was quoted on the OTC Bulletin Board, the fair market value of the common stock underlying options granted under the 2000 Stock Option Plan was the last closing sale price of the common stock on the day the options were granted. If there was no market price for the common stock, then our Board of Directors may, after taking all relevant facts into consideration, determined the fair market value of our common stock.

 

 According to Section 10. Of the agreement captioned “Exercise of Options Upon Termination”

             “(a)   Subject to Section 10(c), upon the termination of a Grantee’s relationship with the Company and its Subsidiaries, the period during which such Grantee may exercise any outstanding exercisable installments of his Options that were exercisable at the date of termination of his relationship with the Company shall not exceed (i) if such termination is due to death or permanent and total disability, one year from the date of such termination, and (ii) in all other cases, three months (six months for Nonemployee Directors) from the date of such termination, provided, however, that in no event shall the period extend beyond the expiration of the Option term. Notwithstanding the foregoing, all Options shall immediately terminate upon a termination of a Grantee’s employment if the Committee determines, in its sole discretion, that such termination is for Cause.

             (b)   In no event shall any Option be exercisable for more than the maximum number of shares that the Grantee was entitled to purchase at the date of termination of the relationship with the Company and its Subsidiaries.

             (c)   The Committee may, in its discretion, extend the period of exercisability set forth in clauses (i) and (ii) in paragraph (a) above; provided, however, that such period may not be extended for Options granted to Nonemployee Directors or for ISOs.”

 

Accordingly, upon termination of employment with the Company, whether through dismissal or resignation, the options granted to former management expired. All remaining options expired three months after the resignation of Mr. Grollman in 2010. Additionally, current management did not extend the options of any prior management.

 

A summary of Options activity for the year ended September 30, 2011 and 2010 is presented below:

 

     Outstanding Options
    

Shares

Available for

Grant

 

Number of

Shares Granted

 

Weighted

Average

Exercise Price

 

Weighted Average

Remaining

Contractual Life

(years)

 

Aggregate

Intrinsic Value

 October 1, 2008    7,000,000    5,271,756    0.43    4.75   $—   
 Grants         40,000   $0.15         —   
 Forfeitures         —                —   
 September 30, 2009    —      5,311,756   $0.43    3.75    —   
 Grants         —      —             
 Forfeitures         (5,311,756)-   .64-           
 September 30, 2011    7,000,000    —     $—      —      —   

 

The Company values all warrants using the Black-Scholes option-pricing model.  Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company’s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.  The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.  No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.

 

Warrants

 

During the year ended September 30, 2011, no awards were granted, no share purchase warrants were exercised, and no warrants were forfeited.

 

Summary of warrant activity for the year ended September 30, 2011 and 2010 is presented below:

 

   Number of
Shares Granted		  Weighted
Average
Exercise Price		  Weighted Average
Remaining
Contractual Life
(years)		  Aggregate
Intrinsic Value
 October 1, 2009    2,308,497   $.10   $58   $—   
 Grants    —      —             
 Expired    —      —             
 September 30, 2010    2,308,497   $0.10    .38    —   
 Grants    —      —             
 Expired    (2,308,497)   —             
 September 30, 2011    —     $—     $—     $—   

 

 

The Company values all warrants using the Black-Scholes option-pricing model.  Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company’s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.  The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.  No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.

 

Stock Option Plan

 

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminates in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan therefore it is terminated.

 

NOTE 10 INCOME TAXES

 

    September 30,
   2011  2010
Current:          
Federal  $0   $0 
State   0    0 
   $0   $0 
           
Deferred:          
Federal  $8,378,837   $8,264,131 
State   44,703    25,445 
    8,423,540    8,289,576 
Valuation allowance   (8,423,540)   (8,289,576)
Provision benefit for income taxes, net  $—     $—   

 

The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows:

 

   September 30,
   2011  2010
 Statutory federal income tax rate   34.0%   34.0%
 State income taxes and other   9.0    9.0 
 Valuation allowance   (43.0)   (43.0)
 Effective tax rate   0.0%   0.0%

 

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:   

 

   September 30,
   2011  2010
 Net operating loss carryforward  $25,866,296    25,331,677 
 Valuation allowance   (25,688,296)   (25,331,677)
 Deferred income tax asset  $—     $—   

 

The Company has a net operating loss carryforward of approximately $25.0 million available to offset future taxable income through 2030. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.

 

ASC 740 requires the consideration of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considered available positive and negative evidence, giving greater weight to its recent cumulative losses and its ability to carry-back losses against prior taxable income and lesser weight to its projected financial results due to the challenges of forecasting future periods. The Company also considered, commensurate with its objective verifiability, the forecast of future taxable income including the reversal of temporary differences. At that time the Company continued to have sufficient positive evidence, including recent cumulative profits, a reduction in operating expenses, the ability to carry-back losses against prior taxable income and an expectation of improving operating results, showing a valuation allowance was not required. At the end of the year ended September 30, 2007, changes in previously anticipated expectations and continued operating losses necessitated a valuation allowance against the tax benefits recognized in this quarter and prior quarters since they are no longer “more-likely-than-not” realizable. Under current tax laws, this valuation allowance will not limit the Company’s ability to utilize U.S. federal and state deferred tax assets provided it can generate sufficient future taxable income in the U.S.

 

The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.

 

NOTE 11 – SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL

 

On January 2, 2011 the Company entered into an asset purchase agreement with certain private companies owned by Michael de la Garza (“MDLG”) whereby NSC acquired the rights to proprietary medical billing and practice management software developed by the private companies.

 

The Office of the Chief Accountant (OCA) of the Securities and Exchange Commission was consulted by Company management to insure that the transaction was recorded correctly on the books of NSC. The OCA considered the facts and circumstances as described below in their deliberations.

 

January 1, 2011 Acquisition Of Software A Business Combination Under Common Control

 

On August 24, 2010 –National Scientific Corporation (“NSC”) signed a letter of intent for NSC to acquire the Private Companies’ assets.

 

On November 19, 2010 – NSC and MDLG signed a revised letter of intent with the Private Companies.

 

In accordance with the revised LOI the following occurred and on December 1, 2010 the NSC reported that change on Form 8-K:

1.On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.
2.On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.
3.On November 30, 2010 – 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.
4.On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.
5.On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.

 

On January 18, 2011 the prior CEO of NSC resigned from the Board of Directors and a Form 8-K was filed on February 8, 2011.

 

On October 5, 2011 the Company issued Absolute Medical Software Systems, LLC 30,000,000 common shares in full payment of this promissory note.

 

On January 3, 2013 the Company engaged a valuation expert to assess the value of the software for impairment purposes at September 30, 2011 and 2012. The Company valued the software and source code on the development cost of the software provided by Absolute Medical Software Systems, LLC of $4,296,000 for September 30, 2011 and September 30, 2012. This valuation was done by an independent Certified Valuation Analysis.

 

Prior Public Company Transaction

 

Michael de la Garza (“MDLG”) is the owner of three related private companies, Absolute, PayMed, and MedPay (“the private companies”) who own and operate medical billing software. On September 10, 2008 the private company entered into an asset purchase agreement with a prior public company. On September 10, 2008 prior publicly traded companies, purchased all the private companies’ assets, for 10,000,000 shares of common stock per the purchase agreements. On the date of that sale, September 10, 2008, the stock was trading at $.10 which valued the transaction at $1,000.000. This value was based on the software before the update to operate on a Cloud based platform. Management considers the price to represent the fair value of the software at that point in time.

 

This transaction was an arms-length value since MDLG was not a shareholder, officer or director of this prior public company. On June 9, 2009 the transaction was rescinded and the assets returned to The Private Companies. The private companies impaired the GAAP basis software development cost to the value of the prior public company transaction value of $1,000,000.

 

During the period of 2009 through 2010 the software was updated to operate on a Cloud based platform and had additional software development costs of $200,106.

 

The Office of Chief Accountant (“OCA”) has determined that due to the voting rights of the Preferred A shares that the transaction occurred between parties under common control. Accordingly, they have determined that the GAAP basis software development cost of the private entity sellers should become the cost basis of NSC.

 

Since these costs ($1,011,223) exceeded the transaction price ($1,000,000) with the prior public company, the prior costs incurred have been impaired to the September 10, 2008 value of the share received in the prior transaction.

 

The related convertible note which was subsequently converted to common shares has been discounted to the cost basis used to value the transaction which is less than the fair value of the software as determined by independent appraisal.

 

The cost basis was determined as follows:

 

Cost Basis for assets acquired  under Common Control  Cost Basis
Cost basis of Consideration:     
Absolute Medical Software Systems LLC development costs from inception  $1,011,222 
      
Impairment of software on September 10, 2008 to value   (11,222)
      
Total Value at September 10, 2008  $1,000,000 
 
Software Update to Operate on Cloud Based Platform		     
Absolute Medical Software Systems LLC development costs  $200,106 
      
Total Cost Basis at January 1, 2011  $1,200,106 

  

 Purchase Price Allocation  January 1, 2011
Value of Consideration:   
Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control  $1,200,106 
Total Purchase Price  $1,200,106 

 

Cost Basis of Assets acquired under common control:

     
Assets:     
Software source code and development costs of software  $1,200,106 
Cost Basis of total assets  $1,200,106 

  

 

NOTE 12– SUBSEQUENT EVENTS

 

In accordance with the Subsequent Events Topic of the FASB ASC 855, Management has evaluated subsequent events, and have determined that the following events are reasonably likely to impact the financial statements:

 

2013

 

In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.

 

In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.

 

In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.

 

In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.

 

April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.

 

April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.

 

May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.

 

2012

 

During the ten months ended July 31, 2012, the Company issued the following shares:

 

The Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106.

 

The Company issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees.

 

The Company issued 1,055,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $20,871.

 

The Company issued 90,000 common shares for $18,000 in cash.

 

The Company issued 200,000 common shares to Krooss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.

 

In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).

 

Software asset purchases:

 

On June 22, 2012

 

The Company acquired Doctors Network of America in Flowood, Mississippi for 500,000 common shares and the acquisition was valued at $10,000.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

   June 22, 2012
Fair Value of Consideration:     
Common Stock (500,000 common shares valued at $.008)  $10,000 
      
Total Purchase Price  $10,000 

 

Fair Value of Assets acquired:

     
Assets:     
Software  $10,000 
Fair value of total assets  $10,000 

 

The acquisitions terms are as follows:

1.Cloud-MDs will provide medical billing services under Cloud-MDs Corporation. No need for a wholly owned subsidiary to be formed to accommodate medical billing.
2.DNA will provide personnel, network access, facilities and expertise to deliver contracted billing service support to Cloud-MDs for clients that Cloud-MDs sends to DNA for billing support. DNA will be compensated on an agreed upon schedule. All revenue will be reported as Cloud-MDs revenue and tracked separately.
3.Goal is to grow DNA related gross revenue within Cloud-MDs to 3X, or greater, current DNA gross revenue over the next 3 years.
4.Cloud-MDs will acquire the assets of Kroosss Medical management Systems, LLC once the revenue goals in item #3 are achieved. As consideration to Bill Kroosss and Marie Kroosss (collectively “Ownership”) of Kroosss Medical Management Systems, LLC for the acquisition of DNA, Cloud-MDs proposes the following:

 

a.Current Ownership will remain in their current roles at Kroosss Medical Management Systems, LLC with current responsibilities and will take on additional responsibilities of sales and marketing in the territory of the state of Mississippi and surrounding states and will assume new responsibilities within Cloud-MDs corporate.
b.Current executive management will remain for a period of not less than 1 year after the acquisition and Ownership salary will be established as $200,000.00.
c.Current Ownership will be awarded NSCT class 144 stock in the amount of 500,000 common shares, with anti-dilution clause, that is restricted for 12 months during which time Ownership may not sell the awarded stock. These shares will be awarded as follows:

i.Upon acquisition, 200,000 shares of class 144 common stock with a 12 month restriction with applicable anti-dilution clause. This stock is non-refundable to NSCT in the event of any misrepresentations by NSCT to Kroosss Medical Management Systems, LLC during the acquisition or the first 90 days following the acquisition;
ii.After the first 90 days following the acquisition, NSCT will award to the Ownership 300,000 shares of class 144, common stock with a 12 month restriction with applicable anti-dilution clauses.

d.For one (1) year after the acquisition, current Ownership will have the opportunity to earn up to 125,000 shares, per calendar quarter, of addition shares of NSCT common stock based on meeting certain performance criteria. The shares will be issued with applicable anti-dilution clause.

5.The acquired assets and customer base of Kroosss Medical Management Systems, LLC will be merged into the current asset and customer base of Cloud-MDs.
6.Upon the purchase of DNA by Cloud-MDs, all liabilities of DNA as of the date of asset transfer will be the responsibility of Kroosss Medical management Systems, LLC.
7.DNA cannot add new clients. New clients will be sent to Cloud-MDs.
8.DNA ownership may be called upon to act as a reference for Cloud-MDs and/or work with Cloud-MDs senior management in an advisory capacity.
9.DNA will become a Cloud-MDs software (PM/EMR/RM) reseller and will acquire an enterprise license with unlimited use:

a.Enterprise license is $100,000 and includes all updates, hosting, etc. and DNA receives 100,000 shares of Cloud-MDs 144 class stock if done prior to stock roll-back. If after roll-back, stock award shall equal $100,000/then current share price. Leasing is available.
b.DNA can resell licenses to current DNA clients or other clients:
i.MSRP of software license is $50,000/provider, leasing is available
ii.A commission of up to 40% of revenue on each software license sold goes to DNA + up to 3,000 shares of stock per software license sold and support will be provided by DNA staff after training.
iii.All revenue other than commissions goes to Cloud-MD
iv.DNA takes 1st support call on all software licenses it sells
v.Primary, non-exclusive, territories are the states of Mississippi, Alabama and Louisiana with additional non-exclusive territories permissible based on a specific sales opportunity

c.DNA will become official beta site for Cloud-MDs PM/EMR/RM software releases.

 

10.Upon acquisition of DNA by Cloud-MDs, Cloud-MDs will assume employer responsibilities for all current Kroosss Medical Management Systems, LLC employees. All employees of Kroosss Medical Management Systems, LLC will remain employed by Cloud-MDs in their current positions for at least 180 days after the acquisition after which time each will be evaluated for their then current responsibilities or considered for new responsibilities.
11.Independent Medical Practice Support, LLC (“IMPS”) assets and customer base are not part of this acquisition discussion or negotiation and any IMPS related expenses or liabilities must be removed from DNA accounting records and will not be considered in future acquisition discussions or negotiations.

 

On August 14, 2012

 

The Company through a comprehensive agreement with MediSouth, LLC, has purchased a complete source code license and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

 

   August 14, 2012
Fair Value of Consideration:   
Common Stock (100,000 common shares valued at $.025)  $2,500 
Total Purchase Price  $2,500 

 

Fair Value of Assets acquired:

     
Assets:     
Software source code  $2,500 
Fair value of total assets  $2,500 

 

2.4. Principal Conditions and Consideration. Subject to all of the terms and conditions set forth in this Agreement, and in consideration of the sale, assignment, transfer and delivery of the Purchased Assets by Licensor to Licensee, as of the Effective Date of this agreement Licensee and Licensor agree to the following (the "Purchase Consideration"):

 

a) MediSouth will provide Cloud-MD with the software source code for the License, expertise to install and integrate the License into Cloud-MD product offerings and deliver the MediSouth software source code to Cloud-MD.

 

b) For as long as Licensee makes use of the License, Licensor agrees to provide Licensee with all software updates for the License within 5 working days of Licensor implementing those same software updates in its own production version of the License.

 

c) Licensor agrees that Licensee shall have the right to modify the software contained in the License to meet Licensee's operational needs.

 

d) Cloud-MD shall provide back to MediSouth, with the permission of each affected Cloud-MD client, the de-identified purchasing data it collects as a result of Cloud-MD clients utilizing the embedded Medical Supplies and Pharmaceutical Inventory Management functionality provided by the License.

 

e) MediSouth shall receive 100,000 shares of non-diluteable, Class 144, Cloud-MD stock with a one (1) year trading restriction if this agreement is executed prior to Licensee's planned stock roll-back. If this agreement is executed after the Licensee's stock roll-back, the stock award shall equal $300,000/then current share price of Licensee's publicly traded stock. MediSouth shall complete the Subscription Agreement.

 

f) MediSouth will grant Cloud-MD all necessary rights to use the License and related patents and those rights shall be transferable to any Licensee who may purchase Cloud-MD and its assets.

 

g) In the event that Cloud-MD is acquired by another entity, the use of the License shall transfer to the acquiring entity with the provision that the License may be used only within the Cloud-MD software application as it was used at the time of the acquisition.

 

h) Other than 2.4.g above, Cloud-MD may not sell the License, transfer the License, allow any other entity to use the License as part of that entity's software application or transfer any rights to another party to use the License separately from Cloud-MD products in which the License is embedded.

 

i) If from the Effective Date of this agreement through the end of the 1st year following the Permanent Transfer, Licensee discovers any misrepresentations on the part of Licensor to Licensee or Licensor, Licensee or Licensor will have the right to dissolve this agreement. Should this occur, Licensor will be required to forfeit the stock awarded to it as described in item 2.4.e above with that stock having an established per share value equal to the value of a share of Licensee's stock as officially recorded on the date of Licensee's stock rollback and any assets from the original acquisition that still remain under the control of Licensee will be returned to Licensor and in their then current condition or status and both parties will exit the relationship holding each other harmless in all matters.

 

j) Licensor agrees to provide a software device in the licensed software that will offer an automatic logon from Licensee's software.

 

k) Licensor agrees to provide software operations, communications and hosting services for the licensed software in same computing facility as Licensee has its operational software until Licensee and Licensor mutually agree that this service is no longer necessary,

 

1) Licensee and Licensor agree to execute sales agreements for each other's products and services.

 

m) Licensee agrees that if due to Licensee modifications to the Licensed software, data from the modified Licensed software cannot be processed by Licensor, Licensee shall provide data in original Licensed software format and make that data available to Licensor as in 2.4.d.

 

n) Licensee shall have the right to copy and use all forms of documentation, marketing information and data related to the License.

 

o) Licensee shall have the right to brand the License with a product name selected by the Licensee and Licensor.

 

p) Licensor shall change the appearance of the License's end-user computer display screens to match the appearance of the Licensee's computer application's end-user computer displays, including the branding described in 2.4.0 above.

 

q) In the event that Licensor should cease doing business, Licensee shall have the right to continue usage of the License and all associated documentation and related marketing material without recourse from Licensor or any entity representing Licensor's interests.

 

r) The "powered by MediScan" text or graphic must always be displayed on modules and application web pages provided by Licensor.

 

2.5 Holdback Stock. Pursuant to the terms and subject to the conditions of this Agreement, no provisions shall be made for the purpose of withholding previously awarded stock by Licensee to Licensor other than those already cited in section 2.4 of this Agreement.

 

Cloud-MD Inventory Management System is a ground breaking Cloud-based Medical Supply Inventory Management System, specifically designed for small and medium Medical Practices, DME's, Home Health, Long-term Care, and Surgery Centers that will offer:

 

1. Centralized management control over medical supply and drug inventories 
2. Real time utilization and financial inventory summary 
3. Low price notifications 
4. Par level/reorder tracking 
5. RX expiration tracking 
6. Auto supply re-ordering from a practices established suppliers

 

Based on a barcode scanning technology, Cloud-MD Inventory Management is designed to reduce workloads by automating inventory control processes. The Cloud-MD's Inventory Management System requires no installation, on-site software or special hardware. The new Cloud-MD Office application suite, of which Cloud-MD Inventory Management is a part, is fully delivered via the Internet and requires no special computing environment at the end-user facility.

 

Manual inventory is time consuming, labor intensive and leaves room for error. Benefiting healthcare professionals across the country, Cloud-MD's Inventory Management System is a low-cost, low-maintenance, easy to use automated system that can provide effective solutions.

 

On November 21, 2012

 

The Company through a comprehensive agreement with CipherSmith, LLC, has purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks,, service marks, internet domain names or world wide web URS. This security software will be part of its ever expanding Cloud-MD Office product suite.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

 

   November 21, 2012
Fair Value of Consideration:   
Common Stock (800,000 common shares valued at $.018)  $14,400 
Total Purchase Price  $14,400 

 

Fair Value of Assets acquired:

     
Assets:     
Software source code and security software  $14,400 
Fair value of total assets  $14,400 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

Effective May 26, 2012, the Registrant engaged S. E. Clark & Company, P.C. The previous auditor Semple, Marchal & Cooper, LLP resigned as auditors on December 16, 2011 a letter was delivered to the Company via certified mail.

 

During the period January 26, 2007 through December 16, 2011 through the date they resigned Semple, Marchal & Cooper, LLP there have been no disagreements with Semple, Marchal & Cooper, LLP (as defined in Item 304(a)(1)(iv) of Regulation S-K) on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Semple, Marchal & Cooper, LLP would have caused them to make reference thereto in their report on financial statements for such years.

 

During the period January 26, 2007 through December 16, 2011 through the date of the resignation of Semple, Marchal & Cooper, LLP, there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

 

(b) New independent registered public accounting firm.

 

On May 26, 2012, and effective the same date, on the recommendation of the Registrant’s Board of Directors, the Registrant engaged S. E. Clark & Company, P.C as its independent registered public accounting firm to audit the Registrant’s financial statements for the fiscal year ended September 30, 2009 and to perform procedures related to the financial statements included in the Registrant’s quarterly reports on Form 10-Q, beginning with the quarter ending December 31, 2008 through current.

 

Prior to the engagement of S. E. Clark & Company, P.C, neither the Registrant nor anyone on its behalf has consulted with S. E. Clark & Company, P.C, regarding either:

(a)The application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrant’s financial statements, and neither was a written report provided to the Registrant nor was oral advice provided that S. E. Clark & Company, P.C, concluded was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing, or financial reporting issue; or
(b)Any matter that was either the subject of a disagreement or a reportable event, as each term is defined in Items 304(a)(1)(iv) or (v) of Regulation S-K, respectively.

 

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission, known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was not effective as of September 30, 2011.

 

The Company’s material weaknesses in financial reporting were:

 

The inability of the Company to prepare and file its financial statements timely due to its limited financial and personnel resources and delays in the Company’s ability to respond to SEC inquiries regarding financial and accounting presentation. Further, the Company is delinquent in filings for fiscal year ended 2011 through and 2012.

 

There were no changes in our internal control over financial reporting that occurred during the year ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

ITEM 9B. OTHER INFORMATION

 

There are no events required to be disclosed by the Item. 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT.

 

Director and Executive Officer

 

Set forth below is information regarding the Company’s current directors and executive officers. There are no family relationships between any of our directors or executive officers. The directors are elected annually by stockholders. The executive officers serve at the pleasure of the Board of Directors.

 

Name   Age   Title
         
Michael De La Garza   55   Chairman, CEO,  President, Chairman
Pamela J. Thompson   50   Chief  Financial Officer, Secretary, Treasurer, Director

 

The chief executive officer and director and officer of the Company will hold office until additional members or officers are duly elected and qualified. The background and principal occupations of the sole officer and director of the Company is as follows:

 

Michael De La Garza

Cloud Medical Doctor Software Corporation – 2010-Present. President, CEO, Chairman of the Board,

Card Activation Technology Corporation. - President, CEO, Chairman of the Board a gift card technology company- 2008-2009

MedCom USA, Corporation. -President, CEO, Chairman of the Board of a medical software company - 2008-2009

PayMed USA, LLC President and co-founder of a medical software company -2003-2012,

Providers Solution, Corporation. President and co-founder of a medical software company -2000-2012,

Accident and Injury Medical Centers, Corporation, President and co-founder of a medical rehab company 1993-1999

Medical Synergies, Corporation. COO, President, a medical billing company. 1991-1999

The Center’s for Diagnostic Medical Services, Corporation. COO and President, a medical imaging group company 1991-1999

 

Pamela Thompson

Cloud Medical Doctor Software Corporation; 2010-Present; Chief Financial Officer

Ms. Pamela J. Thompson, CPA, P.C. has been Chief Financial Officer, Treasurer, Secretary and Director of Cloud Medical Doctor Software Corporation since November 19, 2010. Ms. Thompson is the Founder of Pamela J. Thompson CPA PC and serves as its Principle Executive Officer.

 

Ms. Thompson formed Pamela J. Thompson, CPA, P.C. in 1990 and has over 20 years of experience in SEC compliance, tax and accounting for publicly traded companies. Her Sarbanes-Oxley Section compliance implementation experience is focused on assisting publicly traded companies with performing risk assessment on critical business process and documenting business process controls. She served as Chief Financial Officer, Secretary and Treasurer of several public companies. Ms. Thompson started her career in 1986 with the international accounting firm of Arthur Andersen and was subsequently with Pannell Kerr Forester, and one of the larger regional firms Eide, Bailey and Company. Ms. Thompson is featured in Arizona Republic, New Jersey Star, Arizona Women's Success Magazine, National Basketball Players Association Magazine, and Behind the Bench: National Basketball Wives Association Magazine and Wall Street Journal. She is a Certified Fraud Examiner Candidate. Ms. Thompson is also a Member of the Arizona Women's Society of Certified Public Accountants and Behind the Bench: National Basketball Wives Association. She is a Member of the American Institute of Certified Public Accountants. She is also a Member of the Association of Certified Fraud Examiners and Arizona Association of Certified Fraud Examiners. Ms. Thompson holds a Bachelor of Science from Minnesota State University - Moorhead in Accountancy in 1986 and holds her licenses as a Certified Public Accountant in the State of Arizona in 1993.

 

Audit Committee Financial Expert

 

The Company does not have an audit committee or a compensation committee of its board of directors. In addition, the Company’s board of directors has determined that the Company does not have an audit committee financial expert serving on the board. When the Company develops its operations, it will create an audit and a compensation committee and will seek an audit committee financial expert for its board and audit committee.

 

Conflicts of Interest

 

Members of our management are associated with other firms involved in a range of business activities. Consequently, there are potential inherent conflicts of interest in their acting as officers and directors of our company. Although the officers and directors are engaged in other business activities, we anticipate they will devote an important amount of time to our affairs.

 

Our officers and directors are now and may in the future become shareholders, officers or directors of other companies, which may be formed for the purpose of engaging in business activities similar to ours. Accordingly, additional direct conflicts of interest may arise in the future with respect to such individuals acting on behalf of us or other entities. Moreover, additional conflicts of interest may arise with respect to opportunities which come to the attention of such individuals in the performance of their duties or otherwise. Currently, we do not have a right of first refusal pertaining to opportunities that come to their attention and may relate to our business operations.

 

Our officers and directors are, so long as they are our officers or directors, subject to the restriction that all opportunities contemplated by our plan of operation which come to their attention, either in the performance of their duties or in any other manner, will be considered opportunities of, and be made available to us and the companies that they are affiliated with on an equal basis. A breach of this requirement will be a breach of the fiduciary duties of the officer or director. If we or the companies with which the officers and directors are affiliated both desire to take advantage of an opportunity, then said officers and directors would abstain from negotiating and voting upon the opportunity. However, all directors may still individually take advantage of opportunities if we should decline to do so. Except as set forth above, we have not adopted any other conflict of interest policy with respect to such transactions.

 

Compliance with Section 16(A) Of the Exchange Act 9.A. Directors and Executive Officers, Promoters, and Control Persons:

 

As of September 30, 2011, the Company is aware that all filings of Form 4 and 5 required of Section 16(a) of the Exchange Act of Directors, Officers or holders of 10% of the Company's prior management and board of directors have not filed the requirements timely.

 

Code of Ethics

 

We have adopted a code of ethics that applies to all of our executive officers, directors and employees. Code of ethics codifies the business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge, to any shareholder requesting a copy in writing from the Company. A form of the code of conduct and ethics was filed as Exhibit 14.1 to this Annual Report on Form 10-K for September 30, 2004.

 

ITEM 11. EXECUTIVE COMPENSATION – PAID TO FORMER OFFICERS AND DIRECTORS

 

Executive Officers and Directors

 

Summary Compensation Table

 

The following tables set forth certain information concerning all compensation paid, earned or accrued for service by (i) our Principal Executive Officer and Principal Financial Officer and (ii) all other executive officers who earned in excess of $100,000 in the fiscal years ended September 30, 2011, and each of the other two most highly compensated executive officers of the Company who served in such capacity at the end of the fiscal year whose total salary and bonus exceeded $100,000 (collectively, the “Named Executive Officer”):

 

2011 and 2010 SUMMARY COMPENSATION TABLE

 

Name and Principal Position   Year    

Salary

($)

    

Bonus

($)

    

Stock

Awards

($)

    

Option

Awards

($)

    

Non-Equity

Incentive Plan

Compensation

($)

    

Change in

Pension

Value and

Nonqualified

Deferred

Compensation

Earnings

($)

    

All Other

Compensation($)

    

Total

($)

  
                                                       
Michael De La Garza CEO, President & Chairman  

2011

2010

      

-

-

      

-

-

      

70,000

-

      

-

-

      

-

-

      

-

-

      

-

-

      

70,000

-

  
                                                                       
Pamela Thompson, CFO, Secretary, Treasurer & Director  

2011

2010

      

-

-

      

-

-

      

 

 

 

 

35,000

-

      

-

-

      

-

-

      

-

-

      

-

-

      

35,000

-

  
                                                                       
Michael Grollman, former CEO & CFO, Director  

2011

2010

      

42,176

10,000

      

-

-

      

-

-

      

-

-

      

-

-

      

-

-

      

-

-

      

42,176

10,000

  
                                                                       

 

 

2011 and 2010 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE

 

     Option Awards  Stock Awards
Name  Year  Number of
Securities
Underlying
Unexercised
Options
(#)		  Number of
Securities
Underlying
Unexercised
Options
(#)		  Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)		   

Option

Exercise

Price

($)

   Option
Expiration
Date		  Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)		  Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)		  Equity Incentive
Plan Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
(#)		  Equity
Incentive
Plan Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)
      Exercisable  Unexercisable                       
                                 
Michael De La Garza  2011
2010		  -
-		  -
-		  -
-		   

-

-

   -
-		  -
-		  -
-		  -
-		  -
-
                                 
Pamela Thompson  2011
2010		  -
-		  -
-		  -
-		   

-

-

   -
-		  -
-		  -
-		  -
-		  -
-
                                 
Michael Grollman  2011
2010		  -
-		  -
-		  -
-		   

-

-

   -
-		  -
-		  -
-		  -
-		  -
-
                                 

 

Compensation of Directors

 

Our current compensation policy for directors is to compensate them through options to purchase common stock or through common stock as consideration for their joining our board and/or providing continued services as a director. We do not currently provide our directors with cash compensation, although we do reimburse their expenses, with exception for a chairman of the board. No additional amounts are payable to the Company’s directors for committee participation or special assignments. There are no other arrangements pursuant to which any directors was compensated during the Company’s last completed fiscal year for any service provided except as follows:

 

On November 19, 2010, the Board of Directors appointed Michael De La Garza as the new Chief Executive Officer, President and Chairman of the Board of Directors.  

 

On November 19, 2010, the Board of Directors appointed Pamela Thompson as the new Chief Financial Officer, Secretary, Treasurer and member of the Board of Directors.

 

Employment Contracts

 

The Company entered into an employment agreement with its Chief Executive Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 5,000,000 for DNA, 5,000,000, and 1,000,000 for MediSouth, LLC
v.An automobile allowance of $1,500 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation.

 

The Company entered into an employment agreement with its Chief Financial Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

 

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 3,000,000 for DNA, 3,000,000, and 750,000 for MediSouth, LLC
v.An automobile allowance of $1,000 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

 

The following table lists stock ownership of our Common Stock as of September 25, 2013 based on 214,634,216 shares of common stock issued and outstanding on a fully diluted basis. The information includes beneficial ownership by (i) holders of more than 5% of our Common Stock, (ii) each of our directors and executive officers and (iii) all of our directors and executive officers as a group. Except as noted below, to our knowledge, each person named in the table has sole voting and investment power with respect to all shares of our Common Stock beneficially owned by them.

 

Name and Address of Owner  Title of Class  Number of Shares Owned (1)  Percentage of Class
              

Michael De La Garza(1)

c/o Cloud

736 East Braeburn Drive

Phoenix, AZ 85022

 

 

  Common Stock   40,000,000    18.63%

Pamela Thompson(2)

c/o Cloud

736 East Braeburn Drive

Phoenix, AZ 85022

 

  Common Stock   5,000,000    2.32%
   Common Stock   45,000,000    20.95%
All Officers and Directors
As a Group (2 persons)
  Common Stock   45,000,000    20.95%

 

 

(1)Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.
(2)Pamela Thompson does not have beneficial ownership to the stock issued to her; those shares are held in an irrevocable trust for the benefit of her minor children, that she does not have control or voting control of those shares.

 

 

Changes in Control

 

We are not aware of any arrangements that may result in a change in control of the Company.

 

DESCRIPTION OF SECURITIES

 

General

 

On April 11, 2011 the Company amended its articles of incorporation to increase the authorized common shares to 650,000,000, at $0.01 par value and 180,526,879 are issued and outstanding as of September 30, 2011.

 

Common Stock

 

The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

 

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $.001 par value and 4,000,000 are issued and outstanding as of September 30, 2011. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been issued to our CEO & CFO on April 11, 2011 valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.

 

Warrants and Options

 

All warrants and options issued have expired.

 

Stock Option Plan

 

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminates in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan therefore it is terminated.

 

Voting Rights 

 

Each holder of Common Stock is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders.

 

Dividends 

 

Subject to preferences that may be applicable to any then-outstanding shares of Preferred Stock, if any, and any other restrictions, holders of Common Stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Company’s board of directors out of legally available funds. The Company and its predecessors have not declared any dividends in the past. Further, the Company does not presently contemplate that there will be any future payment of any dividends on Common Stock.

 

Convertible Securities

 

The Company has one convertible security with Strategic Working Capital Fund, LP.

 

Amendment of our Bylaws

 

Our bylaws may be adopted, amended or repealed by the affirmative vote of a majority of our outstanding shares. Subject to applicable law, our bylaws also may be adopted, amended or repealed by our board of directors.

 

Transfer Agent

 

On August 31, 2011, the Company engaged Pacific Stock Transfer to serve in the capacity of transfer agent.

 

Their mailing address and telephone number are as follows: Pacific Stock Transfer, 4045 South Spencer #403, Las Vegas, NV 89119 - (702) 361-3033.

  

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

  

During September 30, 2009 the Company issued 28,000,000 common shares at the trading price of the common stock of $0.001. The Stock was issued for unpaid compensation to officers and reduced accrued compensation by $35,800.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees. The aggregate fees billed by S. E. Clark & Company, P.C. for the audit of the Company’s annual financial statements for fiscal year ended September 30, 2011 and 2010 were approximately $19,500 per year.

 

Audit-Related Fees. The aggregate fees billed by S. E. Clark & Company, P.C. for assurance and related services that are reasonably related to the performance of the audit or review of the Company’s financial statements for the fiscal year ended September 30, 2011 and 2010, and that are not disclosed in the paragraph captioned “Audit Fees” above, were $0.

 

Tax Fees. The aggregate fees billed by S. E. Clark & Company, P.C. for professional services rendered for tax compliance, tax advice and tax planning for the fiscal years ended September 30, 2011, and 2010 were $0, and $0, respectively.

 

All Other Fees. The aggregate fees billed by S. E. Clark & Company, P.C. for products and services, other than the services described in the paragraphs “Audit Fees,” “Audit-Related Fees,” and “Tax Fees” above for the fiscal years ended September 30, 2011, and 2010 approximated $0 and $0, respectively.

 

The Board of Directors has received and reviewed the written disclosures and the letter from the independent registered public accounting firm required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), and has discussed with its auditors its independence from the Company. The Board of Directors has considered whether the provision of services other than audit services is compatible with maintaining auditor independence.

 

Based on the review and discussions referred to above, the Board of Directors approved the inclusion of the audited financial statements be included in the Company’s Annual Report on Form 10-K for its 2010 fiscal year for filing with the SEC.

 

The Board of Directors pre-approved all fees described above.

 

 

PART IV

 

ITEM 15. EXHIBITS AND REPORTS.

 

Exhibits

3.1   Articles of Incorporation(1)
3.2   Bylaws(2)
10.1   Employment Agreement between National Scientific Corporation and Michael A. Grollman dated January 2001(4)
10.2   Employment Agreement between National Scientific Corporation and Graham L. Clark dated January 2003(6)
10.3   NSC Consulting Agreement dated August 2001, and Amendments dated August 2002 and July 2003, with Dr. El-Badawy El-Sharawy(6)
10.4   Amended and Restated 2000 Stock Option Plan(3)
10.5   Form of 2004 Stock Retainage Plan Agreement(6)
10.6   Agreement Regarding Management Consulting Services with Stanton Walker of New York dated May 2003(6)
10.7   Agreement Regarding Distribution and Marketing of Gotcha!® Child Safety Product and other products dated December 2002 with FutureCom Global, Inc. (6)
10.8   Purchase Order from Verify Systems, Inc, dated March 2003 for IBUS™ School Child Tracking Systems(5)
10.9   Letter of Understanding and Agreement dated April 2004 Regarding Sales and Distribution of Verify School safety products, and an Unlimited Software License with Anthony Grosso and CIS Services, LLC(6)
10.10   Letter of Intent from Positus, Inc. dba Bike & Cycle Trak, dated February 2003 for Design of Power Sports Tracking System(6)
10.11   Purchase Order from Positus, Inc. dba Bike & Cycle Trak, for Design of Power Sports Tracking System dated March 2003(6)
10.12   Employment agreement of Michael De La Garza
10.13   Employment agreement of Pamela Thompson
14   Code of Ethics(7)
31.1   Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2   Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1   Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2   Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

____________

(1) Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
(2) Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended March 31, 2001 and filed on or about May 15, 2001.
 (3) Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
(4) Incorporated by reference to the Registrant’s Form 10-KSB for the year ended September 30, 2000 and filed on or about December 19, 2000.
(5) Incorporated by reference to the Registrant’s Form S-8 filed on or around June 3, 2003.
(6) Incorporated by reference to the Registrant’s Form SB2 filed on or around June 24, 2004.
(7) Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended June 30, 2004 and filed on or about August 16, 2004.

 

 

ITEM 15: SIGNATURES

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Registrant

Date: October 10, 2013

 

  

Cloud Medical Doctor Software Corporation

By: /s/ Michael De La Garza

    Michael De La Garza
    Chairman, Chief Executive Officer (Principal Executive Officer), President

 

Date: October 10, 2013

 

   By: /s/ Pamela Thompson
    Pamela Thompson
    Chief Financial Officer (Principal Accounting Officer), Secretary, Treasurer

  

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

  

Date: October 10, 2013

 

   By: /s/ Michael De La Garza
    Michael De La Garza
    Chairman

 

Date: October 10, 2013

 

   By: /s/ Pamela Thompson
    Pamela Thompson
    Director

 

 EX-10.12 2 mdlgagmt083013.htm EMPLOYMENT AGREEMENT OF MICHAEL DE LA GARZA

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made as of the date of the last party to sign and is made effective and commences as of the date specified and defined below, by and between:

 

Cloud Medical Doctor Software Corporation, a Texas corporation with its principal offices currently in Henderson, Nevada (the “Company” or “Employer”), and

 

Michael DeLaGarza , an individual, residing in Henderson, Nevada (“DeLaGarza” or “Employee”),

 

The Company and DeLaGarza may sometimes be referred to herein individually as “Party” and collectively as “Parties.”

 

I. Recitals

 

A. Company desires to employ DeLaGarza for the purposes set forth herein, and DeLaGarza is willing to accept said employment on the Terms and Conditions specified herein.

 

B. This Agreement has been authorized and approved by the Company’s Board of Directors in full compliance with the organizational documents of the Company, as amended as evidenced by that certain Board Resolution No. _______, dated __________, 2013.

 

NOW, THEREFORE in consideration of the mutual covenants, conditions, and promises herein contained, the receipt and sufficiency of which are hereby expressly acknowledged, Employer and Employee (collectively the “Parties”), do hereby agree as follows:

 

II. Terms and Conditions

 

1.0. Ratification. The Recitals set forth above are hereby adopted as true and accurate by the parties hereto, and are incorporated herein by this reference.

 

2.0. Employment. The Company hereby employs DeLaGarza as Chief Executive Officer and DeLaGarza hereby agrees to accept such employment by the Company upon the terms and conditions stated in this Agreement.

 

2.1. At all times material hereto, DeLaGarza is under the control and supervision of the Board of Directors of the Company, and:

 

2.1.1. No action against DeLaGarza in derogation of this Agreement may be taken without full compliance with the board of directors with the organizational documents of the Company.

 

3.0. Commencement Date/Effective Date. The Commencement/ Effective Date of this Agreement is January 1, 2013.

 
 

4.0. Term. The Term of this Agreement shall be five (5) years (the “Employment Period”) commencing on January 1, 2013 and expiring at the close of business on January 31, 2018. The term of this Agreement shall begin on the Commencement Date and shall terminate on the fifth anniversary hereof, unless sooner terminated by either party in the manner set forth below. During its Term, the Agreement automatically renews without notice.

 

4.1. Employer shall not have the right to terminate Employee’s employment except for cause. Employer shall have the right at any time to terminate Employee's employment immediately for cause on not less than 30 days advance notice. Any action by Employer to terminate Employee's employment shall be deemed "for cause" if:

 

(a) Employee is unable to perform the essential functions of her job, with or without reasonable accommodation, (i) either as a result of physical or mental illness or other cause continuing for a consecutive period of more than ninety (90) days; or (ii) repeated and substantial failure to perform his or her duties after prior written notice of such failure of not less than fifteen (30) business days;

 

(b) Employee has disclosed any material secret or confidential information of Employer or any subsidiary thereof without the consent of Employer or has violated or disregarded any other material duties, obligations or expected conduct as an employee of Employer;

 

4.2. Employee may terminate his employment for any reason at any time by giving ninety (90) days' prior written notice to the Employer.

 

5.0. Duties and Responsibilities. DeLaGarza shall perform such services and duties as may be assigned to him as set forth below by the Board of Directors of the Company. Unless otherwise modified or superseded by those persons, and agreed to by DeLaGarza, DeLaGarza’s Duties and Responsibilities are designated as the Chief Executive Officer of the Company:

5.1. DeLaGarza shall devote a requisite amount of his time, attention, skill, and energies to the performance of duties hereunder.

 

6.0. Compensation.

 

6.1. Base Salary. The Company shall pay DeLaGarza for his services a Base Salary of Two Hundred and Fifty Thousand ($250,000.00 US) Dollars per year with a ten percent (10%) cumulative annual increase at each one year anniversary date of the Commencement Date of this Agreement.

 

6.1.1. The base salary shall be payable by the Company in substantially equaling installments on the Company’s normal payroll dates and shall be paid to PayMed USA, LLC.

 

6.1.2. Any Base Salary not paid when due, if any, shall bear interest at the rate of fifteen percent (15%) per annum using a 360 day year until paid in full.

 
 

6.2. Executive Bonus Plan. In addition to the Base Salary provided for herein, the Company shall pay to DeLaGarza as a bonus twenty-five percent (25%) of DeLaGarza’s annual Base Salary, if during any twelve month period with the fiscal year ended September 30, that DeLaGarza is employed by the Company, any one of the following occurs:

 

i. The Company posts annual gross revenues on a consolidated basis of at least $5,000,000; or

 

ii. The Company’s Earnings Before Income Tax and Amortization and Depreciation (“EBITA”), including cash extraordinary items, but before officers’ bonuses, on a consolidated basis for any year is at least $1,000,000; or

 

iii. The completion of the delinquent SEC filings for five (5) years through September 30, 2013; or

 

iv. The company obtains FINRA approval for any reverse stock split.

 

6.2.1. DeLaGarza shall be eligible for the bonus for each year he is employed under this Agreement, including any extensions or renewals hereof.

 

6.2.2. The bonus calculation with respect to DeLaGarza shall be made no later than September 30, 2013, and on each September 30 thereafter for each subsequent year.

 

6.2.3. The bonus payment for DeLaGarza shall be paid in a lump sum on October 5, 2013, and on each October 5, thereafter, unless otherwise agreed to in writing by the Parties.

6.2.4. The criteria set forth in this paragraph 6.2.i.-iv. shall be used for determining bonus eligibility each year DeLaGarza is employed by the Company.

 

6.3. Fringe Benefits. DeLaGarza shall be eligible to participate, in accordance with their terms, in all medical, health, and disability plans, life insurance and pension plans and such other employment benefits or programs (other than executive bonus plans) as are maintained by Company for its employees provided that Company shall at all times be free to modify or amend such plans on a Company wide basis in accordance with the provisions thereof. Notwithstanding the foregoing, in no event shall such fringe benefits (other than executive bonus plans) be less favorable to DeLaGarza than those accorded to any other employees of Company.

 

(i) DeLaGarza and any of his legal dependents or spouse, at her option, may decline to participate in the Company’s medical, dental, and disability plans. In lieu thereof, the Company shall pay, when due by the provider, to or for the benefit of DeLaGarza and his dependents and family, the monthly medical, dental, and disability plans, as presently specified:

 

a. Anthem Blue Cross Blue Shield: coverage period of September 1, 2012 through September 1, 2013 which automatically renews with an adjusted premium which the current premium is $700.00 per month;

b. AFLAC coverage period is monthly which automatically renews premium is $300 per month;

 
 

c. Colonial Life Insurance: coverage period is monthly which automatically renews, premium is $500.00 per month. 

 

(ii) DeLaGarza shall be paid an automobile ownership/rental/capital expense reimbursement of $1,500 per month.

 

(iii)In the event of a "Change of Control" (as defined in Exhibit “A” attached hereto and incorporated herein as Exhibit A) or if Company exercises its Termination Rights under Section 7.0 below, the entire contract is due and payable.

 

6.4. Equity Compensation. In addition to the Compensation described in paragraphs 6.1 through 6.3 above, DeLaGarza shall receive restricted stock grants approved by the Board of Directors. The Company will disburse the following stock grants:

 

6.4.1. Recent Company Acquisitions.

 

(i) Granted 5,000,000 common shares for the acquisition of Doctors Network of America in Flowood, Mississippi on March 15, 2013;

 

(ii) Grant 5,000,000 common shares for the acquisition of the software of CipherSmith, LLC on November 21, 2012;

 

(iii) Grant 1,000,000 common shares for the acquisition of software from MediSouth, LLC on August 14, 2012;

 

6.4.2. Annual Grant of Company Common Shares. On the annual anniversary of the Commencement of her Employment by the Company:

 

(i) DeLaGarza shall be granted 5,000,000 common shares for every acquisition completed by the Company unless separately negotiated by amendment hereto;

 

(ii) DeLaGarza shall be granted the greater of 3,000,000 restricted common shares, or 1% of the outstanding shares, of the Company at a price of $.001 per share.

 

All stock issued pursuant to this Equity Participation section shall be issued under restricted legends and shall contain provisions preventing any future dilution, and any reverse stock splits and all effects similar or related thereto. Said shares shall be issued to MSR Trust, LLC an irrevocable trust (not controlled by DeLaGarza), or to its assigns. 

 
 

6.5. Stock Options.

 

(i) As additional consideration under this Agreement, the Company has granted annually to Employee a non-qualified option for the purchase of 5,000,000 shares of the Company's Common Stock pursuant to the terms and conditions of the Company's Stock Option Plan once implemented. The exercise price for said option is cashless per share. The grant of said option shall occur once the Stock Option Plan has been implemented. The options shall vest on an equal monthly basis over the five (5) years of the Agreement. The options will have a floor of $0.01

 

(ii) In the event of a "Change of Control" (as defined in Exhibit “A” attached hereto and incorporated herein by this reference) or if Company exercises it’s Termination Rights under Section 7.0 below, the then unvested portion of the stock option held by DeLaGarza shall have the vesting accelerated by 100% of the remaining unvested shares under the option and shall be fully vested under the equity compensation portion of this Agreement.

 

6.6. Paid Vacation. DeLaGarza shall be entitled to a reasonable paid vacation of not less than forty five (45) days each calendar year (prorated for the first calendar year), exclusive of holidays and weekends, which vacation shall be taken by DeLaGarza in accordance with the business requirements of the Company at the time and its vacation plans, policies and practices as applied to other officers of the Company then in effect relative to this subject. DeLaGarza may accrue four weeks’ vacation to carry over to the next fiscal year.

 

6.7. Directors and Officers Insurance. The Company shall, as further consideration for this Agreement, obtain and maintain directors’ and officers’ liability coverage naming DeLaGarza as an insured for acts and events occurring during the term of this Agreement. The director’s and officer’s insurance coverage shall be no less than $1,000,000.00 per claim and $3,000,000.00 annual aggregate, or in an amount otherwise agreed to in writing by the DeLaGarza and Company.

 

6.8. Hold Harmless and Indemnity. The Company shall hold harmless and indemnify DeLaGarza against any and all expenses (including attorney’s fees), costs, judgments, fines, penalties, settlements and other amounts incurred by, or assessed against, DeLaGarza in connection with the acts or omissions of DeLaGarza wherein DeLaGarza acted in the course and scope of her employment with Company, in good faith and in a manner he reasonably believed to be in the best interests of the Company and, in the case of a criminal action or proceeding, had no reasonable cause to believe DeLaGarza’s conduct was unlawful.

 

No determination in any proceeding against DeLaGarza by judgment, order, settlement (with or without court approval) or conviction or upon a plea of nolo contendere (no contest) or its equivalent, shall create a presumption that DeLaGarza did not act in good faith, in the course and scope of her employment and in a manner which she reasonably believed to be in the best interests of the Company, or, with respect to any criminal action or proceeding, that DeLaGarza had reasonable cause to believe that her conduct was unlawful. This hold harmless and indemnity shall be in addition to any and all rights offered to DeLaGarza by statute or other law.

 
 

7.0. Company Severance and Termination Rights. If Employer should terminate Employee's employment for any reason other than for cause pursuant to the preceding paragraph 4.1., Employee shall be paid an amount equal to his or her then-current monthly salary multiplied by the number of months remaining under this Agreement. Employee shall also be paid all unpaid annual bonuses, stock and options for the remaining years under this agreement, in cash.

 

7.1. The following shall apply to this Agreement. 9.0 IRC 409A. This letter Agreement is intended to comply with the short-term deferral rule under Treasury Regulation Section 1.409A-1(b) (4) and be exempt from Section 409A of the Code, and shall be construed and interpreted in accordance with such intent, provided that, if any severance provided at any time hereunder involves non-qualified deferred compensation within the meaning of Section 409A of the Code, it is intended to comply with the applicable rules with regard thereto and shall be interpreted accordingly. A termination of employment shall not be deemed to have occurred for purposes of any provision of this letter agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered “nonqualified deferred compensation” under Section 409A of the Code unless such termination is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this letter agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” If you are deemed on the date of termination to be a “specified employee” within the meaning of that term under Section 409A (a) (2) (B) of the Code, then with regard to any payment that is considered non-qualified deferred compensation under Section 409A of the Code payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which is the earlier of (A) the date that is immediately following the expiration of the six (6)-month period measured from the date of such “separation from service” of you, and (B) the date of your death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this paragraph (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this letter agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A of the Code,

 

(i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit,

 

(ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause

 
 

(ii) shall not be violated without regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of your taxable year following the taxable year in which the expense occurred. For purposes of Section 409A of the Code, your right to receive any installment payments pursuant to this letter agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may you, directly or indirectly, designate the calendar year of any payment to be made under the letter agreement that is considered non-qualified deferred compensation. In the event the time period for considering any release and it becoming effective as a condition of receiving severance shall overlap two calendar years, no amount of such severance shall be paid in the earlier calendar year.

 

III. General Provisions.

 

The Parties hereto expressly agree to be bound by these General Provisions, where the term ‘Agreement’ refers to this Employment Agreement:

 

1. ATTORNEYS' FEES. In the event any Party thereto shall employ counsel or bring legal action in any court of competent jurisdiction, including federal bankruptcy court, to enforce any part of this Agreement, or any other documents executed in connection herewith, the prevailing Party shall be paid by the non-prevailing Party (ies) all of its costs and reasonable attorneys' fees, and out of pocket expenses incurred therein or in connection therewith.

 

2. BINDING OBLIGATION. The Parties agree to cause to be prepared all documents required to carry out the intent and purposes of the Parties as set forth herein; provided, however, this Agreement and the parts thereof shall constitute a binding obligation of the signatories hereto.

 

3. BUSINESS DAYS. In the event the time for performance of any provision of this Agreement, or of any of the documents executed in connection herewith falls on a non-business day, the time for such performance shall be extended to the next business day. For purposes of this paragraph, "Business Day" shall mean all days on which banks and savings and loan institutions in Henderson, Nevada are open for general transaction of business.

 

4. CAPTION HEADINGS. Caption headings in this Agreement are for convenience purposes only and are not to be used to interpret or define the provisions of this Agreement.

 

5. CONSTRUCTION OF LANGUAGE. The language of this Agreement shall be construed according to its fair meaning and not strictly for or against either Party.

 

6. CONTROLLING LAW. This Agreement shall be deemed to have been made in the State of Nevada, and its validity, construction, and effect shall be governed by and construed in accordance with the laws and judicial decisions of the State of Nevada. 

 
 

7. COUNTERPARTS. This Agreement may be executed in counterparts, each of which so executed shall be deemed to be an original, but such counterparts shall together constitute one and the same document. In making proof of this Agreement, it shall not be necessary to produce or account for more than one counterpart. This Agreement may be executed and delivered via facsimile or email.

 

8. CUMULATIVE REMEDIES. No remedy herein conferred upon any Party is intended to be exclusive of any other benefits or remedy, and each and every such remedy shall be cumulative and shall be in addition to every other benefits or remedy given hereunder or now or hereafter existing at law or in equity or by statute or otherwise. No single or partial exercise by any Party of any right, power or remedy hereunder shall preclude any other or further exercise thereof.

 

9. BINDING DATE. Unless otherwise specified in the first paragraph of this Agreement, the binding date of this Agreement shall be the date of the last Party to sign.

 

9. ENTIRE AGREEMENT. This Agreement embodies the entire agreement of the Parties hereto in relation to the subject matter hereof, and there are no representations, warranties or agreements, express or implied, or otherwise, in relation thereto, except as expressly referred to or as set forth herein.

 

10. FURTHER ASSURANCES. Without thereby increasing their respective obligations hereunder, the Parties hereby agree that they will do such acts and execute such documents, if any, as may be necessary or appropriate to implement this Agreement, and the parts thereof according to their terms, and the requirements of law.

 

11. GENDER. This Agreement shall apply to the Parties hereto according to the context thereof without regard to the number or gender of words or expressions.

 

12. HEADINGS. The headings or captions of this Agreement are for convenience and reference only, and in no way define, limit or describe the scope or intent of this Agreement, or the provisions of such sections.

 

13. LEGAL CONSTRUCTION/SEVERABILITY. If a court of competent jurisdiction finds any provision of this Agreement to be invalid or unenforceable as to any person or circumstance, such finding shall not render that provision invalid or unenforceable as to any other persons or circumstances. If feasible, any such offending provision shall be deemed to be modified to be within the limits of enforceability or validity; however, if the offending provision cannot be so modified, it shall be stricken and all other provisions of this Agreement in all other respects shall remain valid and enforceable.

 

14. LIMITATION OF RIGHTS. Nothing in this Agreement, except as specifically stated herein, is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the Parties and their respective permitted successors and assigns and other legal representatives, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any third persons to any Party to this Agreement, nor shall any provision give any third persons any right of subrogation or action over against any Party to this Agreement.

 
 

15. MODIFICATION. This Agreement shall not be changed except by an amendment hereto, in writing, duly executed by each of the Parties. No representations, warranties, or agreements made subsequent to the execution and delivery of this Agreement, and the documents executed and delivered in connection therewith by any Party hereto, and no revocations, either partial or otherwise, or alterations thereof, shall be valid and binding unless made in writing and signed by each of the Parties. The Loan & Security Documents and this Agreement embody the entire agreement of the parties with respect to the subject matter hereof. There are no representations, promises, warranties, understandings or agreements, express or implied, oral or otherwise, in relation thereto, except those expressly referred to or set forth herein. Borrower acknowledges that the execution and delivery of this Agreement is its free and voluntary act and deed, and that said execution and delivery have not been induced by, nor done in reliance upon any representations, promises, warranties, understandings or agreements made by Lender, its agents, officers, employees or representatives, except as are contained herein.

 

16. MULTIPLE PARTIES; CORPORATE AUTHORITY. All obligations of Borrower and Holder under this Agreement shall be joint and several, and all references to Borrower or Holder shall mean each and every Borrower or Holder. This means that each of the persons signing below is responsible for all obligations in this Agreement. Where any one or more of the parties are corporations or partnerships or limited liability companies or limited liability limited partnerships, it is not necessary for Borrower or Holder or Lender to inquire into the powers of any of the parties or of the officers, directors, partners, or agents acting or purporting to act on their behalf.

 

17. NO PARTNERSHIP/NO THIRD PARTY BENEFICIARY. The Parties acknowledge and agree that neither this Agreement, nor the transactions contemplated hereby, is or shall be deemed to create or to constitute a partnership, joint venture, common business enterprise, principal and agent, or similar relationship between the Parties; nor are they intended for the benefit of any third party.

 

18. NOTICES. All notices given in connection with this Agreement shall be in writing and shall be delivered either by personal delivery, by telecopy or similar facsimile means, by certified or registered mail (postage prepaid and return receipt requested), or by express courier or delivery service, addressed to the applicable Party hereto at the following address:

 

If to the Company:

Cloud Medical Doctor Software Corporation

PO Box 90358

Henderson, NV 89009

Attn: Michael De La Garza, CEO & President

Ph: (702) 818-9011 Office

Fax:

   
 

If to DeLaGarza:

Michael DeLaGarza

504 Via Palermo Drive

Henderson, NV 89011

Ph: (702) 818-9011

Fax: (602)283-5122

 

or such other address and number as either Party shall have previously designated by written notice given to the other Party in the manner hereinabove set forth. Notices shall be deemed given when received, if sent by telecopy or similar facsimile means (confirmation of such receipt by confirmed facsimile transmission being deemed receipt of communications sent by telecopy or other facsimile means); and when delivered and receipted for (or upon the date of attempted delivery where delivery is refused), if hand-delivered, sent by express courier or delivery service, or sent by certified or registered mail.

 

19. ORDINARY COURSE OF BUSINESS. The performance of the transactions contemplated by this Agreement is in the ordinary course of business of the Parties.

 

20. PRIOR AGREEMENTS SUPERSEDED. This Agreement constitutes the sole and only agreement of the Parties regarding the subject matter hereof, and this Agreement supersedes any prior understandings or written or oral agreements between the Parties regarding these matters. The foregoing notwithstanding, this Agreement only modifies the content of the Loan and Security Documents as expressly stated herein.

 

21. RECITALS. The Recitals are hereby incorporated herein by this reference as agreed terms, conditions, and provisions of this Agreement as applicable. Further, they are represented and warranted as true and accurate and in all respects valid by Borrower and Holder, and Holder’s agent, as of the date of execution of this Agreement.

 

22. SUCCESSORS. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties hereto; provided, however, neither this Agreement nor any rights hereunder may be assigned by DeLaGarza or by the Company without the prior written consent of the other party first obtained.

 

23. TIME OF ESSENCE. Time is of the essence of each and every provision of this Agreement. Time of the Essence is hereby expressly reinstated with respect to all instruments previously executed and entered into by these Parties. Further, it is expressly understood and agreed by the Borrower that in consideration for the grant of this modification and the additional advance referred to herein by Lender, Lender has not and does not waive any legal or equitable right or remedy available to it, at law or in equity, under the various Loan Documents or this Agreement.

 

24. VENUE. The Parties expressly consent to jurisdiction in either the U.S. District Court for the District of Clark County, at Las Vegas, Nevada if allowed by applicable law; and only if the former is not available then the state court of general jurisdiction for the County of Clark, Nevada with regard to any matter arising from, connected to, or relating to this Agreement.

   
 

 25. WAIVERS. No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself or a waiver of any right under this Agreement. No waiver shall be binding unless executed in writing by the Party making the waiver. 

 

26. WARRANTIES. Each Party hereto represents and warrants to the other Party, that each Party is under no disability, restriction, or prohibition, whether contractual or otherwise, with respect to their rights to execute this Agreement and perform its terms and conditions. Each Party shall indemnify and hold the other harmless from any loss or damage, including attorneys’ fees, and costs arising out of or connected with any claim by a third party which is inconsistent with any of the warranties or representations made by the Parties in this Agreement.

 

IN WITNESS WHEREOF, the parties have caused this agreement to be executed and delivered by their proper and duly authorized officers as of the day and year set forth below:

 

Signatures

 

THE COMPANY:

 

Date: _______________, 2013.

 

CLOUD MEDICAL

DOCTOR SOFTWARE

CORPORATION

 

_________________________________________

By:

Michael De La Garza

President, CEO,

Chairman

 

***************************************

 

Date: _______________, 2013.

 

Thompson:

 

_________________________________________

Pamela J. Thompson

 
 

 

Exhibit A - CHANGE OF CONTROL SPECIFICATIONS

 

For the purposes of this Agreement, a "Change of Control" shall mean a change in control of

Employer of a nature that would be required to be reported assuming such event has not been "previously reported") in response to Item 1(a) of a Current Report on Form 8-K pursuant to Section 13 or 15(d) of the Exchange Act of 1934 (the "Exchange Act"); provided that, without limitation, a Change in Control shall also be deemed to have occurred at such time as:

 

(a) Any "person" within the meaning of Section 14(d) of the Exchange Act, other than Employer, a subsidiary, or any employee benefit plan(s) sponsored by Employer or any subsidiary thereof, is or has become the "beneficial owner," as defined in Rule 13d-3 under the Exchange Act, directly or indirectly, of fifty percent (50%) or more of the combined voting power of the outstanding securities of Employer ordinarily having the right to vote at the election of directors; or

 

(b) Individuals who constitute the Board of Directors immediately prior to any meeting of stockholders (the "Incumbent Board") have ceased for any reason to constitute at least a majority thereof, provided that any person becoming a director whose election, or nomination for election by Employer's stockholders, was approved by a vote of at least three-quarters (3/4) of the directors comprising the Incumbent Board (either by a specific vote or by approval of the proxy statement of employer in which such person is named as a nominee for director without objection to such nomination) shall be, for purposes of this Agreement, considered as though such person were a member of the Incumbent Board; or

 

(c) Upon approval by Employer's stockholders of a reorganization, merger, share exchange or consolidation, other than one with respect to which those persons who were the beneficial owners, immediately prior to such organization, merger, share exchange or consolidation, of outstanding securities of Employer ordinarily having the right to vote in the election of directors own, immediately after such transaction, more than fifty percent (50%) of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors; or

 

(d) Upon approval by Employer's stockholders of a complete liquidation and dissolution of Employer or the sale or other disposition of all or substantially all of the assets of Employer other than to a subsidiary thereof.

 EX-31.1 3 nsct10kex311.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULES 13A-14 AND 15D-14

OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Michael De La Garza, certify that:

 

1.I have reviewed this annual report on Form 10-K of Cloud Medical Doctor Software Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By /s/ Michael De La Garza

Michael De La Garza

Chairman, Chief Executive Officer, President

October 10, 2013

 EX-31.2 4 nsct10kex312.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULES 13A-14 AND 15D-14

OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Pamela Thompson, certify that:

 

1.I have reviewed this annual report on Form 10-K of Cloud Medical Doctor Software Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By /s/ Pamela Thompson

Pamela Thompson

Chief Financial Officer, Secretary, Treasurer

October 10, 2013

 EX-32.1 5 nsct10kex321.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Cloud Medical Doctor Software Corporation (the “Company”) on Form 10-K for the period ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael De La Garza, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, That to the best of my knowledge:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By /s/ Michael De La Garza

Michael De La Garza

Chairmen, Chief Executive Officer, President

October 10, 2013

 EX-32.2 6 nsct10kex322.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Cloud Environmental Services, Inc, (the “Company”) on Form 10-K for the period ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pamela Thompson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, That to the best of my knowledge:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By /s/ Pamela Thompson

Pamela Thompson

Chief Financial officer, Secretary, Treasurer

October 10, 2013

 EX-101.INS 7 nsct-20110930.xml XBRL INSTANCE FILE 0001022505 2010-10-01 2011-09-30 0001022505 2013-09-26 0001022505 us-gaap:CommonStockMember 2013-09-25 0001022505 us-gaap:PreferredStockMember 2013-09-25 0001022505 2011-09-30 0001022505 2010-09-30 0001022505 2009-10-01 2010-09-30 0001022505 us-gaap:PreferredStockMember 2010-10-01 2011-09-30 0001022505 us-gaap:PreferredStockMember 2008-09-30 0001022505 us-gaap:PreferredStockMember 2009-09-30 0001022505 us-gaap:PreferredStockMember 2010-09-30 0001022505 us-gaap:PreferredStockMember 2011-09-30 0001022505 us-gaap:CommonStockMember 2008-10-01 2009-09-30 0001022505 us-gaap:CommonStockMember 2010-10-01 2011-09-30 0001022505 us-gaap:CommonStockMember 2008-09-30 0001022505 us-gaap:CommonStockMember 2009-09-30 0001022505 us-gaap:CommonStockMember 2010-09-30 0001022505 us-gaap:CommonStockMember 2011-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2008-10-01 2009-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2010-10-01 2011-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2008-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2009-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2010-09-30 0001022505 us-gaap:AdditionalPaidInCapitalMember 2011-09-30 0001022505 us-gaap:RetainedEarningsMember 2008-10-01 2009-09-30 0001022505 us-gaap:RetainedEarningsMember 2009-10-01 2010-09-30 0001022505 us-gaap:RetainedEarningsMember 2010-10-01 2011-09-30 0001022505 us-gaap:RetainedEarningsMember 2008-09-30 0001022505 us-gaap:RetainedEarningsMember 2009-09-30 0001022505 us-gaap:RetainedEarningsMember 2010-09-30 0001022505 us-gaap:RetainedEarningsMember 2011-09-30 0001022505 2008-10-01 2009-09-30 0001022505 2008-09-30 0001022505 2009-09-30 0001022505 us-gaap:FairValueInputsLevel3Member 2011-09-30 0001022505 us-gaap:FairValueInputsLevel3Member 2010-09-30 0001022505 2005-11-01 0001022505 2005-11-02 2010-11-01 0001022505 2005-02-24 2005-05-27 0001022505 2007-07-01 2007-09-30 0001022505 2007-09-30 0001022505 2007-10-01 2011-09-30 0001022505 2006-04-28 2006-06-15 0001022505 2006-04-27 0001022505 2006-06-01 2006-07-10 0001022505 2006-05-31 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2011-09-30 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2010-09-30 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2010-10-01 2011-09-30 0001022505 us-gaap:SegmentDiscontinuedOperationsMember 2009-10-01 2010-09-30 0001022505 2010-07-30 2010-07-31 0001022505 2010-07-19 0001022505 2011-04-02 2011-04-30 0001022505 2011-04-01 0001022505 2011-09-01 2011-09-30 0001022505 2011-04-11 0001022505 2012-10-01 0001022505 2012-10-02 2012-10-31 0001022505 NSCT:CipherSmithMember 2012-12-06 0001022505 NSCT:MedicalMember 2012-12-06 0001022505 NSCT:CipherSmithMember 2013-01-22 0001022505 2013-03-21 0001022505 NSCT:KroossMember 2013-03-21 0001022505 NSCT:KroossMember 2013-04-17 0001022505 2013-04-17 0001022505 NSCT:CipherSmithMember 2013-04-17 0001022505 NSCT:MedicalMember 2013-04-17 0001022505 2013-05-10 0001022505 2013-06-26 0001022505 2013-08-26 0001022505 2012-07-31 0001022505 2011-10-01 2012-07-31 0001022505 NSCT:ConsultingMember 2012-07-31 0001022505 NSCT:MedicalMember 2012-07-31 0001022505 2011-10-01 2012-09-30 0001022505 2012-01-01 0001022505 2012-08-01 0001022505 2011-10-05 0001022505 2008-09-10 0001022505 NSCT:MedicalMember 2012-10-15 0001022505 NSCT:CipherSmithMember 2013-02-22 0001022505 NSCT:SoftwareInvestmentMember 2013-03-21 0001022505 NSCT:KroossMember NSCT:CompensationMember 2013-04-17 0001022505 NSCT:SoftwareInvestmentMember 2013-04-17 0001022505 NSCT:SoftwareInvestmentMember 2013-05-10 0001022505 NSCT:SoftwareInvestmentMember 2013-06-26 0001022505 NSCT:SoftwareSalesMember 2013-08-26 0001022505 us-gaap:ThirdPartyPayorMember 2013-07-31 0001022505 NSCT:KroossMember 2012-07-31 0001022505 NSCT:MedisouthMember 2012-08-02 0001022505 2012-06-22 0001022505 2011-01-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NATIONAL SCIENTIFIC CORP/AZ 0001022505 10-K 2011-09-30 false --09-30 No No No Smaller Reporting Company FY 2011 5087389 214634216 4000000 11016 2197 2597 11016 2597 1200106 1200106 1211122 2597 10000 180795 21281 44535 1760459 1767460 1985790 1788741 1200106 1200106 3185896 1788741 40000 1805269 1652769 105000 1200106 204 10401 4000 2500 1000 20871 4000 2500 10000 22409927 22434427 -166 -26229970 -25873341 -1974774 -1786145 40000 1372770 1652769 1652769 1805269 22658682 22434427 22434427 22409927 -25491084 -25816256 -25873341 -26229970 -1459633 -1729061 1211122 2597 .10 0.10 4000000 4000000 0 0 0 0 .01 0.01 650000000 650000000 650000000 180526879 165276913 180526879 165276913 340417 21964 -340417 -21964 -340417 -21964 -340417 -21964 -16212 -35121 -356629 -57085 -325172 -57085 -356629 -325172 16212 35121 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 180526879 165276879 4000000 137276879 165276879 165276879 180526879 19945 19945 28000000 280000 -244200 35800 15000000 4000000 15000000 28000000 4000000 143000 40000 150000 -47000 38000 105000 25000 250000 137500 90000 90000 250000 2500 22500 46000 18000 18000 16212 35121 -23214 -9554 -220631 -31518 159515 36000 44535 -14719 229050 21281 8419 -10237 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 1 - DESCRIPTION OF BUSINESS</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">THE COMPANY PREVIOUSLY HAD INSUFFICIENT WORKING CAPITAL TO PAY FOR THE PROFESSIONAL SERVICES REQUIRED TO PREPARE, AUDIT, AND FILE THE QUARTERLY AND ANNUAL REPORTS REQUIRED BY THE SECURITIES ACT OF 1934. AS A RESULT, THE AUDITORS WHO AUDITED THE SEPTEMBER 30, 2007 FINANCIAL STATEMENTS AND REVIEWED THE QUARTERLY REPORTS THROUGH JUNE 30, 2008 RESIGNED EFFECTIVE DECEMBER 13, 2011.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">IN FEBRUARY 2010 THE BOARD OF DIRECTORS VOTED TO DISCONTINUE THE MOBILE DVR AND LOCATION PRODUCTS LINE OF BUSINESS REPORTED IN THESE FINANCIAL STATEMENTS DUE TO THE CUMULATIVE EFFECTS OF SEVERELY DECLINING REVENUES RESULTING FROM THE 2008 RECESSION. SINCE THIS DECISION WAS MADE SUBSEQUENT TO THE YEARS ENDED SEPTEMBER 30, 2008 AND 2009, THE QUARTERLY AND YEAR END STATEMENTS FOR THOSE YEARS ARE BEING REPORTED ON A GOING CONCERN BASIS RATHER THAN AS DISCONTINUED OPERATIONS. THEY WILL, HOWEVER, BE REPORTED AS DISCONTINUED OPERATIONS COMMENCING WITH THE FISCAL 2010 FILINGS.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">NEW MANAGEMENT HAS SUBSEQUENTLY INFUSED SUFFICIENT WORKING CAPITAL TO BRING THE 1934 ACT FILINGS CURRENT. ADDITIONALLY, A NEW LINE OF BUSINESS HAS ALSO COMMENCED WHICH WILL BE REPORTED ON IN THE FISCAL 2011 AND 2012 FILINGS.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>ACCORDINGLY, THESE FINANCIAL STATEMENTS ARE BEING SUBMITTED ONLY TO COMPLY WITH SEC RULES AND REGULATIONS AND SHOULD NOT BE RELIED UPON FOR YOUR INVESTMENT DECISIONS. THE OPERATIONS REPORTED ON IN THESE FINANCIAL STATEMENTS HAVE BEEN DISCONTINUED AS OF FEBRUARY 4, 2010. NEW MANAGEMENT ENCOURAGES THE READERS OF THESE FINANCIAL STATEMENTS TO SUSPEND ANY INVESTMENT DECISIONS PERTAINING TO THE STOCK OF THIS COMPANY UNTIL ALL REQUIRED 1934 ACT FILINGS ARE BROUGHT CURRENT.</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <hr size="1" noshade="noshade" align="center" style="width: 547px; width: 410.6pt; color: black" /> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden&#8217;s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue is derived from sales of electronic devices, recognized as the product is delivered.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In February 4, 2010 the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate the remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. Since as of this filing neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction the transaction has not been recorded in the accounting records of the Company</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In November 19, 2010, the prior management was terminated and new management began working on operations related to the Company&#8217;s medical billing software. In fiscal 2011, the year of termination of prior management, new management has deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as &#8220;disputed accrued expenses &#8211; related party&#8221; on the Balance Sheet. Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.</p> <p style="margin: 0pt">Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect (i)&#160;the reported amounts of assets and liabilities, (ii)&#160;the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii)&#160;the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In managements&#8217; opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 3 - GOING CONCERN ISSUES</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has a net loss for the twelve months ended September 30, 2011 of $356,629, an accumulated deficit at September 30, 2011 of $26,229,970, and needs additional cash to maintain its operations.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">These factors raise doubt about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company&#8217;s continued existence is dependent upon management&#8217;s ability to develop profitable operations, continued contributions from the Company&#8217;s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company&#8217;s products and business.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 4 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Use of Estimates and Assumptions</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect (i)&#160;the reported amounts of assets and liabilities, (ii)&#160;the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii)&#160;the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Revenue Recognition</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Revenue includes provision of services. The Company recognizes revenue from provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Accounts Receivable and Allowance for Uncollectible Accounts</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Substantially all of the Company&#8217;s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged off against the allowance when it is probable the receivable will not be recovered.&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Cash and Cash Equivalents</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&#160;&#160;At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Income Taxes</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Deferred income taxes are provided to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company adopted the provisions of ASC Topic 740,&#160;<i>Accounting For Uncertainty In Income Taxes-An Interpretation of ASC Topic 740&#160;</i>(&#34;ASC Topic 740&#34;). ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2011, the Company did not record any liabilities for uncertain tax positions.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Share-Based Compensation</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. &#160;Compensation cost is recognized over the vesting or requisite service period. &#160;The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Basic and Diluted Net Loss Per Share</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period.&#160;The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. &#160;Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Concentration of Credit Risk</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">All of the Company&#8217;s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management&#8217;s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Fair Value of Financial Instruments</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company's&#160;financial&#160;instruments&#160;consist primarily of cash, accounts&#160;payable and&#160;accrued&#160;expenses,&#160;and debt.&#160;&#160;The&#160;carrying&#160;amounts of such&#160;financial&#160;instruments&#160;approximate their respective&#160;estimated fair value due to the short-term&#160;maturities and approximate market interest rates of&#160;these instruments.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company adopted ASC Topic 820,&#160;<i>Fair Value Measurements</i>&#160;(&#8220;ASC Topic 820&#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&#160;&#160;The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The three-level hierarchy for fair value measurements is defined as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">&#8226;</td><td style="width: 5pt"></td><td style="text-align: justify">Level 1 &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">&#8226;</td><td style="width: 5pt"></td><td style="text-align: justify">Level 2 &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;</td> </tr> <tr style="vertical-align: top"> <td style="width: 20px; padding-bottom: 6pt; font-size: 12pt; text-align: right">&#8226;</td> <td style="width: 7px">&#160;</td> <td style="font-size: 12pt; text-align: justify">Level 3 &#8211; inputs to the valuation methodology are unobservable and significant to the fair value measurement</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The following table summarizes fair value measurements by level at September 31, 2011 and 2010 for assets measured at fair value on a recurring basis:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center">at September 30, 2011</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right; border-bottom: Black 1pt solid">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: center">Proprietary Technology</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,200,106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Total Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: center">at September 30, 2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 1</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 2</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 3</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Total Proprietary Technology</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td> <td>&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Reclassifications</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to current year presentations.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Recent Accounting Pronouncements</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">No accounting standards or interpretations issued recently are expected to a have a material impact on the Company&#8217;s financial position, operations or cash flows.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Use of Estimates and Assumptions</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect (i)&#160;the reported amounts of assets and liabilities, (ii)&#160;the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii)&#160;the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Revenue Recognition</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Revenue includes provision of services. The Company recognizes revenue from provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Accounts Receivable and Allowance for Uncollectible Accounts</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Substantially all of the Company&#8217;s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged off against the allowance when it is probable the receivable will not be recovered.&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Cash and Cash Equivalents</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&#160;&#160;At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Income Taxes</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Deferred income taxes are provided to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company adopted the provisions of ASC Topic 740,&#160;<i>Accounting For Uncertainty In Income Taxes-An Interpretation of ASC Topic 740&#160;</i>(&#34;ASC Topic 740&#34;). ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2011, the Company did not record any liabilities for uncertain tax positions.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Share-Based Compensation</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. &#160;Compensation cost is recognized over the vesting or requisite service period. &#160;The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Basic and Diluted Net Loss Per Share</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period.&#160;The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. &#160;Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Concentration of Credit Risk</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">All of the Company&#8217;s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management&#8217;s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Fair Value of Financial Instruments</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company's&#160;financial&#160;instruments&#160;consist primarily of cash, accounts&#160;payable and&#160;accrued&#160;expenses,&#160;and debt.&#160;&#160;The&#160;carrying&#160;amounts of such&#160;financial&#160;instruments&#160;approximate their respective&#160;estimated fair value due to the short-term&#160;maturities and approximate market interest rates of&#160;these instruments.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company adopted ASC Topic 820,&#160;<i>Fair Value Measurements</i>&#160;(&#8220;ASC Topic 820&#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&#160;&#160;The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;&#160;The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The three-level hierarchy for fair value measurements is defined as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">&#8226;</td><td style="width: 5pt"></td><td style="text-align: justify">Level 1 &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">&#8226;</td><td style="width: 5pt"></td><td style="text-align: justify">Level 2 &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;</td> </tr> <tr style="vertical-align: top"> <td style="width: 20px; padding-bottom: 6pt; font-size: 12pt; text-align: right">&#8226;</td> <td style="width: 7px">&#160;</td> <td style="font-size: 12pt; text-align: justify">Level 3 &#8211; inputs to the valuation methodology are unobservable and significant to the fair value measurement</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The following table summarizes fair value measurements by level at September 31, 2011 and 2010 for assets measured at fair value on a recurring basis:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center">at September 30, 2011</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right; border-bottom: Black 1pt solid">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: center">Proprietary Technology</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,200,106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Total Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: center">at September 30, 2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 1</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 2</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 3</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Total Proprietary Technology</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td> <td>&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Reclassifications</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to current year presentations.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Recent Accounting Pronouncements</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">No accounting standards or interpretations issued recently are expected to a have a material impact on the Company&#8217;s financial position, operations or cash flows.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center">at September 30, 2011</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 1</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 2</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: right; border-bottom: Black 1pt solid">Level 3</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: right; border-bottom: Black 1pt solid">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: center">Proprietary Technology</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,200,106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Total Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,200,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">1,200,106</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: center">at September 30, 2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 1</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 2</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 11pt Times New Roman, Times, Serif">Level 3</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">Total</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Proprietary Technology</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1pt">Total Proprietary Technology</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td> <td>&#160;</td></tr> </table> 250000 1200106 1200106 1200106 1200106 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 5- DISCONTINUED OPERATIONS</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company&#8217;s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC by prior management in which he was to pay $100,000 for that technology the former officer never paid the required compensation. The Company discontinued these operations and began selling Medical Business Software and is the current operation of the Company.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations. &#160;Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and operations from discontinued operations in accordance with ASC Topic 360,<i>&#160;Accounting for the Impairment or Disposal of Long Lived Assets</i>.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Details of those classifications are shown below.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2010</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Net assets of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Cash</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,197</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net assets of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,597</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Net liabilities of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Accounts payable and accrued expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">169,176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">195,072</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Disputed salaries &#38; vacation of former officers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">968,645</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">968,645</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Disputed salary &#150; former employee</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,256</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,256</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Disputed payroll taxes for back pay of former officers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">84,701</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">84,701</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Disputed interest</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">209,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">191,346</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,137</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,137</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Former officer note payable at 8% interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shareholders demand note payable at 12%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,625</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,625</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shareholders demand note payable at 12%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note discount</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Note beneficial conversion feature</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(166</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,760,459</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,767,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">Years ended <br />September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,788</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25,462</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36,485</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19,612</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,962</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest income</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss from Discontinued Operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">16,212</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,121</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On September 7, 2005, we entered into a factoring agreement with United Capital Funding (UCF) of Florida. UCF is a specialized financial services firm offering Accounts Receivable Management and working capital funding via factoring. We expect to improve our cash flow with this arrangement.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Under the arrangement, we sell to UCF as absolute owner, invoices that we submit to UCF to be factored. Upon purchase, UCF assumes the risk of non-payment on purchased invoices, so long as the cause of non-payment is solely due to the occurrence of an insolvency event. As collateral securing the obligations, we grant UCF a continuing first priority security interest in all accounts and related inventory. Notwithstanding the creation of the above security interest, our relationship with UCF is one of Seller and Purchaser of accounts, and not that of lender and borrower. However, as there is certain recourse for non-payment, the accounts receivable are recorded at the estimated realizable value, net of allowances and the net advanced amount from UCF is recorded as an obligation at&#160;the end of fiscal 2010 and 2010. The initial and periodic factoring fee is .45% of the face amount of factored invoices. The factoring period is five days and the purchase price is 80% of the face amount, excluding sales tax.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">UCF typically advances to us 80% of the total amount of invoices factored, excluding sales tax. UCF retains 20% of the outstanding factored invoices as a reserve, which it holds until the customer pays the factored invoice to UCF.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On November 1, 2005, as an important phase in the current year&#8217;s financing plan, we entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program include a five-year Note payable at maturity in November 2010 for $175,000, at an effective annual interest rate of 8%. Interest is due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares include weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the Note has various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs are being amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 our Chairman Michael Grollman made new personal loans to the Company totaling $159,000 to assist us with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company&#8217;s iBus software and designs.&#160;&#160;During the quarter to September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.&#160;&#160;On September 30, 2007, the Company converted unpaid interest of $13,300 on demand notes payable to Michael Grollman into a new demand note of $13,300 that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1<sup>st</sup>. The balance of the note at September 30, 2011 is $59,704.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On April 27, 2006, we secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer&#8217;s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer&#8217;s purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009. The note had an approximate maturity date of June 15, 2006. At September 30, 2006 and September 30, 2007 this note was in default. As of September 30, 2011 $11,625 </font>of this loan was in default.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA&#8217;s order and b) in any receivable resulting from the fulfillment of the Clover&#160;Park purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009. The note had a maturity date of July 10, 2006. At September 30, 2011 this note was in default.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, <br />2010</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Net assets of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Cash</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,197</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net assets of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,597</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Net liabilities of discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left">Accounts payable and accrued expenses</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">169,176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">195,072</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Disputed salaries &#38; vacation of former officers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">968,645</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">968,645</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Disputed salary &#150; former employee</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,256</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,256</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Disputed payroll taxes for back pay of former officers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">84,701</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">84,701</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Disputed interest</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">209,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">191,346</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,137</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,137</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Former officer note payable at 8% interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">59,704</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shareholders demand note payable at 12%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,625</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,625</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shareholders demand note payable at 12%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note discount</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Note beneficial conversion feature</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(166</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,760,459</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,767,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 4.5pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">Years ended <br />September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-weight: bold"> <td style="text-align: left">Discontinued operations:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%">Revenues</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,788</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost of sales</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25,462</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36,485</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19,612</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,962</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest income</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss from Discontinued Operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">16,212</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">35,121</td><td style="text-align: left">&#160;</td></tr> </table> 175000 8. 12. 1200000 0.043 51600 -860 9933 24000 159000 13300 16625 20000 0.06 0.08 0.08 12. 11000 13300 500 500 100000 100000 0.036 0.036 11625 0.0525 400 2597 169176 195072 968645 968645 20256 20256 84701 84701 209215 191346 42137 42137 59704 59704 11625 11625 20000 20000 175000 175000 1760459 1767460 3400 58788 25462 36485 19612 31962 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 6&#8211; COMMITMENT AND CONTINGENCIES</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Rent expense for the years ended September 30, 2011 and 2010 was approximately $0.00 and $7,245 respectively</p> 0 7245 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 7&#8211; RELATED PARTY TRANSACTIONS</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In September 30, 2009 the Company issued 28,000,000 common shares at the trading price of the common stock of $0.0012785. The Stock was issued for unpaid compensation to officers and reduced accrued compensation by $35,800.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On July 19, 2010 the Company assumed the line of credit of new management from Chase Bank of $36,000 to fund transitional expenses of which the net advance totaled $44,535.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In April 2011 the Company issued 4,000,000 common shares at the trading price of the common stock of $0.0095. The stock was issued for compensation to new management and recorded and expense of $38,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company entered into an employment agreement with its Chief Executive Officer (the &#8220;Executive&#8217;) on January 1, 2013 (the &#8220;Employment Agreement&#8221;). &#160;The Employment Agreement, will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">i.</td><td style="width: 5pt"></td><td style="text-align: justify">A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">ii.</td><td style="width: 5pt"></td><td style="text-align: justify">A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">a.</td><td style="width: 5pt"></td><td style="text-align: justify">The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">b.</td><td style="width: 5pt"></td><td style="text-align: justify">The Company's earnings before the deduction of income taxes and amortization expenses (&#8220;EBITA&#8221;), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">iii.</td><td style="width: 5pt"></td><td style="text-align: justify">The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">iv.</td><td style="width: 5pt"></td><td style="text-align: justify">The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 5,000,000 for DNA, 5,000,000, and 1,000,000 for MediSouth, LLC</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">v.</td><td style="width: 5pt"></td><td style="text-align: justify">An automobile allowance of $1,500 per month.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">vi.</td><td style="width: 5pt"></td><td style="text-align: justify">A medical insurance allowance of $1,500 per month.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">vii.</td><td style="width: 5pt"></td><td style="text-align: justify">In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company entered into an employment agreement with its Chief Financial Officer (the &#8220;Executive&#8217;) on January 1, 2013 (the &#8220;Employment Agreement&#8221;). &#160;The Employment Agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">i.</td><td style="width: 5pt"></td><td style="text-align: justify">A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">ii.</td><td style="width: 5pt"></td><td style="text-align: justify">A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">a.</td><td style="width: 5pt"></td><td style="text-align: justify">The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">b.</td><td style="width: 5pt"></td><td style="text-align: justify">The Company's earnings before the deduction of income taxes and amortization expenses (&#8220;EBITA&#8221;), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">iii.</td><td style="width: 5pt"></td><td style="text-align: justify">The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">iv.</td><td style="width: 5pt"></td><td style="text-align: justify">The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 3,000,000 for DNA, 3,000,000, and 750,000 for MediSouth, LLC</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">v.</td><td style="width: 5pt"></td><td style="text-align: justify">An automobile allowance of $1,000 per month.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">vi.</td><td style="width: 5pt"></td><td style="text-align: justify">A medical insurance allowance of $1,500 per month.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">vii.</td><td style="width: 5pt"></td><td style="text-align: justify">In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation</p> 35800 36000 44535 0 0.007 0.0012785 0.0095 1200106 59704 148000 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 8 - EQUITY</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: black">On April 11, 2011 the Company amended its articles of incorporation to increase the authorized common shares to 650,000,000, at $0.01 par value and 180,526,879 are issued and outstanding as of September 30, 2011. </font> and 4,000,000 preferred shares outstanding at a par value of $.01.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Common stock holders have right to vote one share for every share that is issued.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Preferred stockholders have designated rights and preferences of a Series A Convertible Preferred Stock, and reserved 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="background-color: white">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2013</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of <font style="color: black">Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: black">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2012</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">During the ten months ended July 31, 2012 the Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106. The Company also issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees. The Company issued 706,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $10,401.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 90,000 common shares for $18,000 in cash.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 200,000 common shares to Kroosss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2011</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 250,000 in common stock for $25,000 in cash.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2010</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">No common stock was issued.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>Common Stock</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>Preferred Stock</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company has authorized 4,000,000 shares of preferred stock, at $.001 par value and zero are issued and outstanding as of September 30, 2011. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been issued to our CEO &#38; CFO on April 11, 2011 valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="background-color: white">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="background-color: white">The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See &#8220;Risk Factors&#8221; above.</font></p> 1 4000000 150 15000000 10000 500000 200000 200000 270000 500000 167000 378500 220004 95000 20000 25000 120000 30000000 706333 200000 100000 30000000 10000000 10000 200000 270000 167000 95000 20000 25000 120000 1055333 200000 100000 4000000 1045500 200000 19000 0.007 0.0102 0.0160 0.020 0.0160 0.020 <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 9 &#8211; STOCK-BASED COMPENSATION</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>Options</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Prior board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. <font style="color: black"> The 2000 Stock Option plan terminated in accordance with the plan provisions on December 1, 2010. The Current Board of Directors did not extend the Stock Option Plan, allowing it to terminate.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: black">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Under the 2000 Stock Option Plan, the purchase price must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option was granted (if the option is a nonqualified grant), or such higher price as may be determined by the Board of Directors at the time of grant. If however, an incentive stock option was granted to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all our classes of stock, the purchase price of the shares of common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option was granted. As the price of the Company&#8217;s common stock was quoted on the OTC Bulletin Board, the fair market value of the common stock underlying options granted under the 2000 Stock Option Plan was the last closing sale price of the common stock on the day the options were granted. If there was no market price for the common stock, then our Board of Directors may, after taking all relevant facts into consideration, determined the fair market value of our common stock.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 20pt"><font style="color: black">&#160;According to </font><b>Section 10. Of the agreement captioned &#8220;Exercise of Options Upon Termination&#8221;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;(a)&#160;&#160;&#160;Subject to Section 10(c), upon the termination of a Grantee&#8217;s relationship with the Company and its Subsidiaries, the period during which such Grantee may exercise any outstanding exercisable installments of his Options that were exercisable at the date of termination of his relationship with the Company shall not exceed (i) if such termination is due to death or permanent and total disability, one year from the date of such termination, and (ii) in all other cases, three months (six months for Nonemployee Directors) from the date of such termination, provided, however, that in no event shall the period extend beyond the expiration of the Option term. Notwithstanding the foregoing, all Options shall immediately terminate upon a termination of a Grantee&#8217;s employment if the Committee determines, in its sole discretion, that such termination is for Cause.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;In no event shall any Option be exercisable for more than the maximum number of shares that the Grantee was entitled to purchase at the date of termination of the relationship with the Company and its Subsidiaries.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;The Committee may, in its discretion, extend the period of exercisability set forth in clauses (i) and (ii) in paragraph (a) above; provided, however, that such period may not be extended for Options granted to Nonemployee Directors or for ISOs.&#8221;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Accordingly, upon termination of employment with the Company, whether through dismissal or resignation, the options granted to former management expired. All remaining options expired three months after the resignation of Mr. Grollman in 2010. Additionally, current management did not extend the options of any prior management.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">A summary of Options activity for the year ended September 30, 2011 and 2010 is presented below:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td colspan="19" style="margin: 0; text-align: center"><b>Outstanding Options</b></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Shares</b></p> <p style="margin: 0; text-align: center"><b>Available for</b></p> <p style="margin: 0; text-align: center"><b>Grant</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Number of</b></p> <p style="margin: 0; text-align: center"><b>Shares Granted</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Weighted</b></p> <p style="margin: 0; text-align: center"><b>Average</b></p> <p style="margin: 0; text-align: center"><b>Exercise Price</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="margin: 0; text-align: center"><b>Remaining</b></p> <p style="margin: 0; text-align: center"><b>Contractual Life</b></p> <p style="margin: 0; text-align: center"><b>(years)</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Aggregate</b></p> <p style="margin: 0; text-align: center"><b>Intrinsic Value</b></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 28%; text-align: left; vertical-align: bottom">October 1, 2008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">7,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5,271,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">4.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.15</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Forfeitures</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2009</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,311,756</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.75</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Forfeitures</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,311,756</td><td style="text-align: left">)-</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">.64-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2011</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company values all warrants using the Black-Scholes option-pricing model.&#160;&#160;Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company&#8217;s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.&#160;&#160;The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.&#160;&#160;No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>Warrants</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">During the year ended September 30, 2011, no awards were granted, no share purchase warrants were exercised, and no warrants were forfeited.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Summary of warrant activity for the year ended September 30, 2011 and 2010 is presented below:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td colspan="3" style="text-align: left; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Number of <br />Shares Granted</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted <br />Average <br />Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average <br />Remaining <br />Contractual Life <br />(years)</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Aggregate <br />Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left; vertical-align: bottom">&#160;</td><td style="width: 28%; text-align: left; vertical-align: bottom">October 1, 2009</td><td style="width: 1%; text-align: left; vertical-align: bottom">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,308,497</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Expired</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2010</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,308,497</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">.38</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Expired</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,308,497</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2011</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company values all warrants using the Black-Scholes option-pricing model.&#160;&#160;Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company&#8217;s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.&#160;&#160;The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.&#160;&#160;No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>Stock Option Plan</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminates in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan therefore it is terminated.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td colspan="19" style="margin: 0; text-align: center"><b>Outstanding Options</b></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Shares</b></p> <p style="margin: 0; text-align: center"><b>Available for</b></p> <p style="margin: 0; text-align: center"><b>Grant</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Number of</b></p> <p style="margin: 0; text-align: center"><b>Shares Granted</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Weighted</b></p> <p style="margin: 0; text-align: center"><b>Average</b></p> <p style="margin: 0; text-align: center"><b>Exercise Price</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="margin: 0; text-align: center"><b>Remaining</b></p> <p style="margin: 0; text-align: center"><b>Contractual Life</b></p> <p style="margin: 0; text-align: center"><b>(years)</b></p> </td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><p style="margin: 0; text-align: center"><b>Aggregate</b></p> <p style="margin: 0; text-align: center"><b>Intrinsic Value</b></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 28%; text-align: left; vertical-align: bottom">October 1, 2008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">7,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5,271,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">0.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">4.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.15</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Forfeitures</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2009</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,311,756</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.75</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">Forfeitures</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,311,756</td><td style="text-align: left">)-</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">.64-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2011</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td colspan="3" style="text-align: left; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Number of <br />Shares Granted</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted <br />Average <br />Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average <br />Remaining <br />Contractual Life <br />(years)</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Aggregate <br />Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left; vertical-align: bottom">&#160;</td><td style="width: 28%; text-align: left; vertical-align: bottom">October 1, 2009</td><td style="width: 1%; text-align: left; vertical-align: bottom">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,308,497</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Expired</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2010</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,308,497</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">.38</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Grants</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">Expired</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,308,497</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: bottom">September 30, 2011</td><td style="text-align: left; vertical-align: bottom">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 10 INCOME TAXES</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center; vertical-align: bottom">&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td> <td colspan="7" style="text-align: center; vertical-align: bottom">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="padding-left: 0.5pt">Current:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 0.5pt">Federal</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">State</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt">Deferred:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">Federal</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,378,837</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,264,131</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">State</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">44,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,445</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,423,540</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,289,576</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,423,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,289,576</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">Provision benefit for income taxes, net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 0.5pt">&#160;Statutory federal income tax rate</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.5pt">&#160;State income taxes and other</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">&#160;Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(43.0</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(43.0</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">&#160;Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:&#160;&#160;&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="11" style="text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 0.5pt">&#160;Net operating loss carryforward</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">25,866,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">25,331,677</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">&#160;Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,688,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,331,677</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">&#160;Deferred income tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company has a net operating loss carryforward of approximately $25.0 million available to offset future taxable income through 2030. For income tax reporting purposes, the Company&#8217;s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined.&#160;The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">ASC 740 requires the consideration of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considered available positive and negative evidence, giving greater weight to its recent cumulative losses and its ability to carry-back losses against prior taxable income and lesser weight to its projected financial results due to the challenges of forecasting future periods. The Company also considered, commensurate with its objective verifiability, the forecast of future taxable income including the reversal of temporary differences. At that time the Company continued to have sufficient positive evidence, including recent cumulative profits, a reduction in operating expenses, the ability to carry-back losses against prior taxable income and an expectation of improving operating results, showing a valuation allowance was not required. At the end of the year ended September 30, 2007, changes in previously anticipated expectations and continued operating losses necessitated a valuation allowance against the tax benefits recognized in this quarter and prior quarters since they are no longer &#8220;more-likely-than-not&#8221; realizable. Under current tax laws, this valuation allowance will not limit the Company&#8217;s ability to utilize U.S. federal and state deferred tax assets provided it can generate sufficient future taxable income in the U.S.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is &#8220;more-likely-than-not&#8221; the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company&#8217;s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center; vertical-align: bottom">&#160;</td> <td style="text-align: center; vertical-align: bottom">&#160;</td> <td colspan="7" style="text-align: center; vertical-align: bottom">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="padding-left: 0.5pt">Current:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 0.5pt">Federal</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">State</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.5pt">Deferred:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">Federal</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,378,837</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,264,131</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 0.5pt">State</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">44,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,445</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,423,540</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,289,576</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,423,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,289,576</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">Provision benefit for income taxes, net</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="7" style="text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 0.5pt">&#160;Statutory federal income tax rate</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.5pt">&#160;State income taxes and other</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">&#160;Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(43.0</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(43.0</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">&#160;Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td>&#160;</td> <td colspan="11" style="text-align: center">September 30,</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 0.5pt">&#160;Net operating loss carryforward</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">25,866,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">25,331,677</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">&#160;Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,688,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,331,677</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5pt">&#160;Deferred income tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 11 &#8211; SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On January 2, 2011 the Company entered into an asset purchase agreement with certain private companies owned by Michael de la Garza (&#8220;MDLG&#8221;) whereby NSC acquired the rights to proprietary medical billing and practice management software developed by the private companies.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Office of the Chief Accountant (OCA) of the Securities and Exchange Commission was consulted by Company management to insure that the transaction was recorded correctly on the books of NSC. The OCA considered the facts and circumstances as described below in their deliberations.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>January 1, 2011 Acquisition Of Software A Business Combination Under Common Control</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On August 24, 2010 &#8211;National Scientific Corporation (&#8220;NSC&#8221;) signed a letter of intent for NSC to acquire the Private Companies&#8217; assets.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On November 19, 2010 &#8211; NSC and MDLG signed a revised letter of intent with the Private Companies.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In accordance with the revised LOI the following occurred and on December 1, 2010 the NSC reported that change on Form 8-K:</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">1.</td><td style="width: 5pt"></td><td style="text-align: justify">On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">2.</td><td></td><td style="text-align: justify">On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">3.</td><td></td><td style="text-align: justify">On November 30, 2010 &#8211; 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">4.</td><td></td><td style="text-align: justify">On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">5.</td><td></td><td style="text-align: justify">On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On January 18, 2011 the prior CEO of NSC resigned from the Board of Directors and a Form 8-K was filed on February 8, 2011.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On October 5, 2011 the Company issued Absolute Medical Software Systems, LLC 30,000,000 common shares in full payment of this promissory note.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">On January 3, 2013 the Company engaged a valuation expert to assess the value of the software for impairment purposes at September 30, 2011 and 2012. The Company valued the software and source code on the development cost of the software provided by Absolute Medical Software Systems, LLC of $4,296,000 for September 30, 2011 and September 30, 2012. This valuation was done by an independent Certified Valuation Analysis.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>Prior Public Company Transaction</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Michael de la Garza (&#8220;MDLG&#8221;) is the owner of three related private companies, Absolute, PayMed, and MedPay (&#8220;the private companies&#8221;) who own and operate medical billing software. On September 10, 2008 the private company entered into an asset purchase agreement with a prior public company. On September 10, 2008 prior publicly traded companies, purchased all the private companies&#8217; assets, for 10,000,000 shares of common stock per the purchase agreements. On the date of that sale, September 10, 2008, the stock was trading at $.10 which valued the transaction at $1,000.000. This value was based on the software before the update to operate on a Cloud based platform. Management considers the price to represent the fair value of the software at that point in time.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">This transaction was an arms-length value since MDLG was not a shareholder, officer or director of this prior public company. On June 9, 2009 the transaction was rescinded and the assets returned to The Private Companies. The private companies impaired the GAAP basis software development cost to the value of the prior public company transaction value of $1,000,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">During the period of 2009 through 2010 the software was updated to operate on a Cloud based platform and had additional software development costs of $200,106.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Office of Chief Accountant (&#8220;OCA&#8221;) has determined that due to the voting rights of the Preferred A shares that the transaction occurred between parties under common control. Accordingly, they have determined that the GAAP basis software development cost of the private entity sellers should become the cost basis of NSC.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Since these costs ($1,011,223) exceeded the transaction price ($1,000,000) with the prior public company, the prior costs incurred have been impaired to the September 10, 2008 value of the share received in the prior transaction.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The related convertible note which was subsequently converted to common shares has been discounted to the cost basis used to value the transaction which is less than the fair value of the software as determined by independent appraisal.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The cost basis was determined as follows:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Cost Basis for assets acquired&#160;&#160;under Common Control</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Cost Basis</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left; padding-left: 5.4pt">Cost basis of Consideration:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Absolute Medical Software Systems LLC development costs from inception</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,011,222</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Impairment of software on September 10, 2008 to value</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,222</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Value at September 10, 2008</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">&#160;<br />Software Update to Operate on Cloud Based Platform</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Absolute Medical Software Systems LLC development costs</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">200,106</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Cost Basis at January 1, 2011</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid"><font style="font: 12pt Times New Roman, Times, Serif; color: black">&#160;<b>Purchase Price Allocation</b></font></td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">January 1, 2011</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Value of Consideration:</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">1,200,106</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Cost Basis of Assets acquired under common control:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Software source code and development costs of software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,200,106</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Cost Basis of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">1.</td><td style="width: 5pt"></td><td style="text-align: justify">On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">2.</td><td></td><td style="text-align: justify">On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">3.</td><td></td><td style="text-align: justify">On November 30, 2010 &#8211; 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">4.</td><td></td><td style="text-align: justify">On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">5.</td><td></td><td style="text-align: justify">On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Cost Basis for assets acquired&#160;&#160;under Common Control</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Cost Basis</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="text-align: left; padding-left: 5.4pt">Cost basis of Consideration:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Absolute Medical Software Systems LLC development costs from inception</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,011,222</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Impairment of software on September 10, 2008 to value</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,222</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Value at September 10, 2008</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">&#160;<br />Software Update to Operate on Cloud Based Platform</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Absolute Medical Software Systems LLC development costs</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">200,106</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Cost Basis at January 1, 2011</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid"><font style="font: 12pt Times New Roman, Times, Serif; color: black">&#160;<b>Purchase Price Allocation</b></font></td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">January 1, 2011</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Value of Consideration:</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">1,200,106</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Cost Basis of Assets acquired under common control:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Software source code and development costs of software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,200,106</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Cost Basis of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,200,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> 4296000 .10 1000000 200106 -1011223 ($1,000,000) <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>NOTE 12&#8211; SUBSEQUENT EVENTS</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In accordance with the Subsequent Events Topic of the FASB ASC 855, Management has evaluated subsequent events, and have determined that the following events are reasonably likely to impact the financial statements:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2013</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of <font style="color: black">Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares. </font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>2012</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the ten months ended July 31, 2012, the Company issued the following shares:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 1,055,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $20,871.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 90,000 common shares for $18,000 in cash.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company issued 200,000 common shares to Krooss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>Software asset purchases:</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>On June 22, 2012</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company acquired Doctors Network of America in Flowood, Mississippi for 500,000 common shares and the acquisition was valued at $10,000.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">June 22, 2012</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="padding-left: 5.4pt">Fair Value of Consideration:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Common Stock (500,000 common shares valued at $.008)</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Fair Value of Assets acquired:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Fair value of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The acquisitions terms are as follows:</p> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">1.</td><td style="width: 5pt"></td><td style="text-align: justify">Cloud-MDs will provide medical billing services under Cloud-MDs Corporation. No need for a wholly owned subsidiary to be formed to accommodate medical billing.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">2.</td><td></td><td style="text-align: justify">DNA will provide personnel, network access, facilities and expertise to deliver contracted billing service support to Cloud-MDs for clients that Cloud-MDs sends to DNA for billing support. DNA will be compensated on an agreed upon schedule. All revenue will be reported as Cloud-MDs revenue and tracked separately.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">3.</td><td></td><td style="text-align: justify">Goal is to grow DNA related gross revenue within Cloud-MDs to 3X, or greater, current DNA gross revenue over the next 3 years.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">4.</td><td></td><td style="text-align: justify">Cloud-MDs will acquire the assets of Kroosss Medical management Systems, LLC once the revenue goals in item #3 are achieved. As consideration to Bill Kroosss and Marie Kroosss (collectively &#8220;Ownership&#8221;) of Kroosss Medical Management Systems, LLC for the acquisition of DNA, Cloud-MDs proposes the following:</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0">&#160;</p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">a.</td><td style="width: 5pt"></td><td style="text-align: justify">Current Ownership will remain in their current roles at Kroosss Medical Management Systems, LLC with current responsibilities and will take on additional responsibilities of sales and marketing in the territory of the state of Mississippi and surrounding states and will assume new responsibilities within Cloud-MDs corporate.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">b.</td><td style="width: 5pt"></td><td style="text-align: justify">Current executive management will remain for a period of not less than 1 year after the acquisition and Ownership salary will be established as $200,000.00.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">c.</td><td style="width: 5pt"></td><td style="text-align: justify">Current Ownership will be awarded NSCT class 144 stock in the amount of 500,000 common shares, with anti-dilution clause, that is restricted for 12 months during which time Ownership may not sell the awarded stock. These shares will be awarded as follows:</td> </tr></table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">i.</td><td style="width: 5pt"></td><td style="text-align: justify">Upon acquisition, 200,000 shares of class 144 common stock with a 12 month restriction with applicable anti-dilution clause. This stock is non-refundable to NSCT in the event of any misrepresentations by NSCT to Kroosss Medical Management Systems, LLC during the acquisition or the first 90 days following the acquisition;</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">ii.</td><td style="width: 5pt"></td><td style="text-align: justify">After the first 90 days following the acquisition, NSCT will award to the Ownership 300,000 shares of class 144, common stock with a 12 month restriction with applicable anti-dilution clauses.</td> </tr></table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">d.</td><td style="width: 5pt"></td><td style="text-align: justify">For one (1) year after the acquisition, current Ownership will have the opportunity to earn up to 125,000 shares, per calendar quarter, of addition shares of NSCT common stock based on meeting certain performance criteria. The shares will be issued with applicable anti-dilution clause.</td> </tr></table> <p style="font: 10pt Tms Rmn; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">5.</td><td style="width: 5pt"></td><td style="text-align: justify">The acquired assets and customer base of Kroosss Medical Management Systems, LLC will be merged into the current asset and customer base of Cloud-MDs.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">6.</td><td style="width: 5pt"></td><td style="text-align: justify">Upon the purchase of DNA by Cloud-MDs, all liabilities of DNA as of the date of asset transfer will be the responsibility of Kroosss Medical management Systems, LLC.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">7.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA cannot add new clients. New clients will be sent to Cloud-MDs.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">8.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA ownership may be called upon to act as a reference for Cloud-MDs and/or work with Cloud-MDs senior management in an advisory capacity.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">9.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA will become a Cloud-MDs software (PM/EMR/RM) reseller and will acquire an enterprise license with unlimited use:</td> </tr></table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">a.</td><td style="width: 5pt"></td><td style="text-align: justify">Enterprise license is $100,000 and includes all updates, hosting, etc. and DNA receives 100,000 shares of Cloud-MDs 144 class stock if done prior to stock roll-back. If after roll-back, stock award shall equal $100,000/then current share price. Leasing is available.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">b.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA can resell licenses to current DNA clients or other clients:</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">i.</td><td style="width: 5pt"></td><td style="text-align: justify">MSRP of software license is $50,000/provider, leasing is available</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">ii.</td><td style="width: 5pt"></td><td style="text-align: justify">A commission of up to 40% of revenue on each software license sold goes to DNA + up to 3,000 shares of stock per software license sold and support will be provided by DNA staff after training.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">iii.</td><td style="width: 5pt"></td><td style="text-align: justify">All revenue other than commissions goes to Cloud-MD</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">iv.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA takes 1<sup>st </sup>support call on all software licenses it sells</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 55pt; text-align: right">v.</td><td style="width: 5pt"></td><td style="text-align: justify">Primary, non-exclusive, territories are the states of Mississippi, Alabama and Louisiana with additional non-exclusive territories permissible based on a specific sales opportunity</td> </tr></table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 99pt; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right">c.</td><td style="width: 5pt"></td><td style="text-align: justify">DNA will become official beta site for Cloud-MDs PM/EMR/RM software releases.</td> </tr></table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">10.</td><td style="width: 5pt"></td><td style="text-align: justify">Upon acquisition of DNA by Cloud-MDs, Cloud-MDs will assume employer responsibilities for all current Kroosss Medical Management Systems, LLC employees. All employees of Kroosss Medical Management Systems, LLC will remain employed by Cloud-MDs in their current positions for at least 180 days after the acquisition after which time each will be evaluated for their then current responsibilities or considered for new responsibilities.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">11.</td><td style="width: 5pt"></td><td style="text-align: justify">Independent Medical Practice Support, LLC (&#8220;IMPS&#8221;) assets and customer base are not part of this acquisition discussion or negotiation and any IMPS related expenses or liabilities must be removed from DNA accounting records and will not be considered in future acquisition discussions or negotiations.</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b>&#160;</b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>On August 14, 2012</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company through a comprehensive agreement with MediSouth, LLC, has purchased a complete source code license and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">August 14, 2012</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Fair Value of Consideration:</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Common Stock (100,000 common shares valued at $.025)</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">2,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Fair Value of Assets acquired:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Software source code</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Fair value of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">2</font><font style="color: #000001">.</font><font style="color: #000002">4.<u> Principal</u></font><u><font style="color: #1E1D1F"> C</font><font style="color: #000002">onditions a</font><font style="color: #1E1D1F">n</font><font style="color: #000002">d Consideration</font></u><font style="color: #000002">. Subject to all of the terms and conditions </font><font style="color: #1E1D1F">s</font><font style="color: #000002">et forth in this Agr</font><font style="color: #1E1D1F">e</font><font style="color: #000002">em</font><font style="color: #1E1D1F">e</font><font style="color: #000002">nt</font><font style="color: #1E1D1F">, </font><font style="color: #000002">and in consideration of the sale</font><font style="color: #1E1D1F">, </font><font style="color: #000002">assignment, transfer and delivery of </font><font style="color: #1E1D1F">t</font><font style="color: #000002">he Purchased As</font><font style="color: #1E1D1F">sets by L</font><font style="color: #000002">icensor </font><font style="color: #1E1D1F">t</font><font style="color: #000002">o Licensee</font><font style="color: #1E1D1F">, </font><font style="color: #000002">as of the Effective Date of this agreement </font><font style="color: #1E1D1F">L</font><font style="color: #000002">icensee and Licensor agree to the following </font><font style="color: #1E1D1F">(</font><font style="color: #000002">the <i>&#34;Purchase Consideration&#34;)</i></font><i><font style="color: #1E1D1F">:</font></i></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><i><font style="color: #1E1D1F">&#160;</font></i></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">a) Me</font><font style="color: #1E1D1F">diS</font><font style="color: #000002">outh wi</font><font style="color: #1E1D1F">l</font><font style="color: #000002">l pro</font><font style="color: #1E1D1F">v</font><font style="color: #000002">ide </font><font style="color: #1E1D1F">C</font><font style="color: #000002">loud-MD with the software source code fo</font><font style="color: #1E1D1F">r </font><font style="color: #000002">the License</font><font style="color: #1E1D1F">, </font><font style="color: #000002">expertise to </font><font style="color: #1E1D1F">i</font><font style="color: #000002">ns</font><font style="color: #1E1D1F">t</font><font style="color: #000002">all and integ</font><font style="color: #1E1D1F">r</font><font style="color: #000002">ate the License into Cloud</font><font style="color: #000001">-</font><font style="color: #000002">MD product offerings and deliver the MediSou</font><font style="color: #1E1D1F">t</font><font style="color: #000002">h s</font><font style="color: #1E1D1F">o</font><font style="color: #000002">f</font><font style="color: #1E1D1F">tw</font><font style="color: #000002">a</font><font style="color: #1E1D1F">r</font><font style="color: #000002">e </font><font style="color: #1E1D1F">s</font><font style="color: #000002">ource code to Cloud-MD</font><font style="color: #1E1D1F">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #1E1D1F">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">b) For as </font><font style="color: #1E1D1F">l</font><font style="color: #000002">ong as </font><font style="color: #1E1D1F">L</font><font style="color: #000002">icensee makes use of the License, Licensor agrees to provide Licensee </font><font style="color: #1E1D1F">w</font><font style="color: #000002">it</font><font style="color: #1E1D1F">h </font><font style="color: #000002">a</font><font style="color: #1E1D1F">ll s</font><font style="color: #000002">o</font><font style="color: #1E1D1F">f</font><font style="color: #000002">t</font><font style="color: #1E1D1F">w</font><font style="color: #000002">are updates for the License within 5 working days of </font><font style="color: #1E1D1F">L</font><font style="color: #000002">icensor </font><font style="color: #1E1D1F">i</font><font style="color: #000002">mplementin</font><font style="color: #1E1D1F">g </font><font style="color: #000002">th</font><font style="color: #1E1D1F">o</font><font style="color: #000002">se s</font><font style="color: #1E1D1F">a</font><font style="color: #000002">me soft</font><font style="color: #1E1D1F">w</font><font style="color: #000002">are updates in its own production version of the License</font><font style="color: #3E3E3E">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">c</font><font style="color: #1E1D1F">) </font><font style="color: #000002">Licen</font><font style="color: #1E1D1F">s</font><font style="color: #000002">or </font><font style="color: #1E1D1F">ag</font><font style="color: #000002">r</font><font style="color: #1E1D1F">e</font><font style="color: #000002">es that Licensee shall have the right to modify the software </font><font style="color: #1E1D1F">c</font><font style="color: #000002">ontained in </font><font style="color: #1E1D1F">t</font><font style="color: #000002">he </font><font style="color: #1E1D1F">Li</font><font style="color: #000002">cense to meet </font><font style="color: #1E1D1F">L</font><font style="color: #000002">icensee's operat</font><font style="color: #1E1D1F">i</font><font style="color: #000002">onal needs.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">d</font><font style="color: #1E1D1F">) C</font><font style="color: #000002">lou</font><font style="color: #1E1D1F">d</font><font style="color: #000002">-MD sha</font><font style="color: #1E1D1F">l</font><font style="color: #000002">l </font><font style="color: #1E1D1F">p</font><font style="color: #000002">rovide back to MediSouth</font><font style="color: #1E1D1F">, </font><font style="color: #000002">with the permission of each affected </font><font style="color: #1E1D1F">C</font><font style="color: #000002">loud-MD </font><font style="color: #1E1D1F">cl</font><font style="color: #000002">i</font><font style="color: #1E1D1F">e</font><font style="color: #000002">nt</font><font style="color: #3E3E3E">, </font><font style="color: #1E1D1F">t</font><font style="color: #000002">he de</font><font style="color: #000001">-</font><font style="color: #1E1D1F">i</font><font style="color: #000002">dent</font><font style="color: #1E1D1F">i</font><font style="color: #000002">fied purchasing data it collects as a result of Cloud-MD clients utili</font><font style="color: #1E1D1F">z</font><font style="color: #000002">ing t</font><font style="color: #1E1D1F">he </font><font style="color: #000002">embedded Medical Supplies and Pharmaceutical Inventory </font><font style="color: #1E1D1F">M</font><font style="color: #000002">anagemen</font><font style="color: #1E1D1F">t f</font><font style="color: #000002">un</font><font style="color: #1E1D1F">ctio</font><font style="color: #000002">n</font><font style="color: #1E1D1F">a</font><font style="color: #000002">lit</font><font style="color: #1E1D1F">y </font><font style="color: #000002">pro</font><font style="color: #1E1D1F">v</font><font style="color: #000002">ided b</font><font style="color: #1E1D1F">y </font><font style="color: #000002">the License</font><font style="color: #1E1D1F">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">e</font><font style="color: #121113">) </font><font style="color: #000001">MediSouth shall recei</font><font style="color: #121113">v</font><font style="color: #000001">e 100</font><font style="color: #121113">,</font><font style="color: #000001">000 shares of non-diluteable</font><font style="color: #121113">, </font><font style="color: #000001">Class 144</font><font style="color: #282728">, </font><font style="color: #000001">Cloud-MD </font><font style="color: #121113">s</font><font style="color: #000001">toc</font><font style="color: #121113">k </font><font style="color: #000001">with a on</font><font style="color: #121113">e (1</font><font style="color: #282728">) </font><font style="color: #121113">y</font><font style="color: #000001">e</font><font style="color: #121113">a</font><font style="color: #000001">r tradin</font><font style="color: #121113">g </font><font style="color: #000001">restriction if this agreement is executed pr</font><font style="color: #121113">i</font><font style="color: #000001">or </font><font style="color: #121113">t</font><font style="color: #000001">o </font><font style="color: #121113">L</font><font style="color: #000001">icensee</font><font style="color: #282728">'</font><font style="color: #121113">s </font><font style="color: #000001">plan</font><font style="color: #121113">ned </font><font style="color: #000001">s</font><font style="color: #121113">t</font><font style="color: #000001">oc</font><font style="color: #121113">k </font><font style="color: #000001">roll-b</font><font style="color: #121113">a</font><font style="color: #000001">ck</font><font style="color: black">. </font><font style="color: #000001">If th</font><font style="color: #121113">i</font><font style="color: #000001">s agreement is executed after the Licen</font><font style="color: #121113">s</font><font style="color: #000001">ee</font><font style="color: #282728">'</font><font style="color: #121113">s s</font><font style="color: #000001">tock roll-b</font><font style="color: #121113">a</font><font style="color: #000001">ck</font><font style="color: #4A4A4B">, </font><font style="color: #121113">t</font><font style="color: #000001">he s</font><font style="color: #121113">t</font><font style="color: #000001">ock awa</font><font style="color: #121113">r</font><font style="color: #000001">d shall equal <i>$300</i></font><i><font style="color: #121113">,</font><font style="color: #000001">000</font><font style="color: #121113">/</font><font style="color: #000001">then </font></i><font style="color: #000001">current share pri</font><font style="color: #121113">c</font><font style="color: #000001">e of Licen</font><font style="color: #121113">s</font><font style="color: #000001">e</font><font style="color: #121113">e'</font><font style="color: #000001">s </font><font style="color: #121113">p</font><font style="color: #000001">ub</font><font style="color: #121113">l</font><font style="color: #000001">icl</font><font style="color: #121113">y t</font><font style="color: #000001">ra</font><font style="color: #121113">d</font><font style="color: #000001">ed stock</font><font style="color: #121113">. M</font><font style="color: #000001">ediSouth shall complete the Subscription Agreement</font><font style="color: #282728">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #121113">f) MediSo</font><font style="color: #000001">u</font><font style="color: #121113">t</font><font style="color: #000001">h </font><font style="color: #121113">wi</font><font style="color: #000001">l</font><font style="color: #121113">l g</font><font style="color: #000001">rant </font><font style="color: #121113">C</font><font style="color: #000001">l</font><font style="color: #121113">o</font><font style="color: #000001">ud-MD all nece</font><font style="color: #121113">s</font><font style="color: #000001">s</font><font style="color: #121113">a</font><font style="color: #000001">r</font><font style="color: #121113">y </font><font style="color: #000001">rights to use the License and </font><font style="color: #121113">r</font><font style="color: #000001">ela</font><font style="color: #121113">t</font><font style="color: #000001">ed pat</font><font style="color: #121113">ents an</font><font style="color: #000001">d </font><font style="color: #121113">t</font><font style="color: #000001">ho</font><font style="color: #121113">s</font><font style="color: #000001">e </font><font style="color: #121113">r</font><font style="color: #000001">igh</font><font style="color: #121113">t</font><font style="color: #000001">s </font><font style="color: #121113">s</font><font style="color: #000001">hall be transferabl</font><font style="color: #121113">e </font><font style="color: #000001">to an</font><font style="color: #121113">y </font><font style="color: #000001">Licensee who ma</font><font style="color: #121113">y </font><font style="color: #000001">purchase </font><font style="color: #121113">C</font><font style="color: #000001">loud-</font><font style="color: #121113">M</font><font style="color: #000001">D </font><font style="color: #282728">a</font><font style="color: #121113">nd i</font><font style="color: #282728">t</font><font style="color: #121113">s assets</font><font style="color: #000001">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">g</font><font style="color: #121113">) </font><font style="color: #000001">In </font><font style="color: #121113">th</font><font style="color: #000001">e e</font><font style="color: #121113">ve</font><font style="color: #000001">n</font><font style="color: #121113">t t</font><font style="color: #000001">hat </font><font style="color: #121113">C</font><font style="color: #000001">loud-</font><font style="color: #121113">M</font><font style="color: #000001">D i</font><font style="color: #121113">s </font><font style="color: #000001">acqu</font><font style="color: #121113">i</font><font style="color: #000001">red b</font><font style="color: #121113">y </font><font style="color: #000001">another entit</font><font style="color: #121113">y, </font><font style="color: #000001">the use of the License </font><font style="color: #121113">s</font><font style="color: #000001">hall trans</font><font style="color: #121113">fer </font><font style="color: #282728">t</font><font style="color: #121113">o </font><font style="color: #282728">th</font><font style="color: #121113">e </font><font style="color: #000001">a</font><font style="color: #121113">c</font><font style="color: #000001">qu</font><font style="color: #121113">ir</font><font style="color: #000001">ing </font><font style="color: #121113">entit</font><font style="color: #282728">y </font><font style="color: #121113">w</font><font style="color: #000001">ith th</font><font style="color: #121113">e </font><font style="color: #000001">provision that the License ma</font><font style="color: #121113">y </font><font style="color: #000001">be used onl</font><font style="color: #121113">y wi</font><font style="color: #000001">th</font><font style="color: #121113">i</font><font style="color: #000001">n t</font><font style="color: #121113">he </font><font style="color: #282728">Cl</font><font style="color: #121113">o</font><font style="color: #282728">u</font><font style="color: #121113">d</font><font style="color: #000001">-</font><font style="color: #282728">M</font><font style="color: #121113">D softw</font><font style="color: #000001">are </font><font style="color: #121113">app</font><font style="color: #000001">lica</font><font style="color: #121113">t</font><font style="color: #000001">ion </font><font style="color: #121113">a</font><font style="color: #000001">s it </font><font style="color: #121113">w</font><font style="color: #000001">as used at </font><font style="color: #121113">t</font><font style="color: #000001">he </font><font style="color: #121113">t</font><font style="color: #000001">im</font><font style="color: #121113">e </font><font style="color: #000001">of the </font><font style="color: #121113">a</font><font style="color: #000001">cquis</font><font style="color: #121113">i</font><font style="color: #000001">tion</font><font style="color: #4A4A4B">. </font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">h</font><font style="color: #121113">) Ot</font><font style="color: #000001">h</font><font style="color: #121113">er than 2</font><font style="color: black">.</font><font style="color: #121113">4.g </font><font style="color: #000001">above</font><font style="color: #121113">, </font><font style="color: #000001">Clo</font><font style="color: #121113">u</font><font style="color: #000001">d-</font><font style="color: #121113">M</font><font style="color: #000001">D may not sell the License, transfe</font><font style="color: #121113">r </font><font style="color: #000001">the License</font><font style="color: #121113">, </font><font style="color: #000001">allow an</font><font style="color: #282728">y </font><font style="color: #121113">o</font><font style="color: #282728">t</font><font style="color: #121113">he</font><font style="color: #282728">r </font><font style="color: #121113">e</font><font style="color: #000001">n</font><font style="color: #121113">ti</font><font style="color: #282728">ty </font><font style="color: #121113">to </font><font style="color: #000001">us</font><font style="color: #121113">e </font><font style="color: #000001">the </font><font style="color: #121113">L</font><font style="color: #000001">i</font><font style="color: #121113">c</font><font style="color: #000001">en</font><font style="color: #282728">s</font><font style="color: #000001">e </font><font style="color: #121113">as pa</font><font style="color: #000001">rt </font><font style="color: #121113">o</font><font style="color: #000001">f</font><font style="color: #121113"> </font><font style="color: #000001">that entit</font><font style="color: #121113">y</font><font style="color: #282728">'</font><font style="color: #000001">s software application o</font><font style="color: #121113">r t</font><font style="color: #000001">ransf</font><font style="color: #121113">er an</font><font style="color: #282728">y r</font><font style="color: #121113">i</font><font style="color: #282728">ght</font><font style="color: #121113">s </font><font style="color: #282728">t</font><font style="color: #121113">o a</font><font style="color: #000001">not</font><font style="color: #121113">h</font><font style="color: #000001">e</font><font style="color: #121113">r p</font><font style="color: #000001">a</font><font style="color: #121113">r</font><font style="color: #000001">t</font><font style="color: #121113">y t</font><font style="color: #000001">o </font><font style="color: #121113">u</font><font style="color: #000001">se the </font><font style="color: #121113">L</font><font style="color: #000001">icen</font><font style="color: #121113">s</font><font style="color: #000001">e s</font><font style="color: #121113">e</font><font style="color: #000001">pa</font><font style="color: #121113">r</font><font style="color: #000001">atel</font><font style="color: #121113">y </font><font style="color: #000001">from Cloud-MD </font><font style="color: #121113">p</font><font style="color: #000001">roducts in </font><font style="color: #282728">w</font><font style="color: #121113">hi</font><font style="color: #282728">ch </font><font style="color: #000001">t</font><font style="color: #121113">h</font><font style="color: #282728">e </font><font style="color: #000001">Lic</font><font style="color: #121113">e</font><font style="color: #000001">nse i</font><font style="color: #121113">s </font><font style="color: #000001">embedded</font><font style="color: #121113">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #282728">i) </font><font style="color: #121113">If fr</font><font style="color: #282728">o</font><font style="color: #121113">m the Eff</font><font style="color: #000001">e</font><font style="color: #121113">c</font><font style="color: #000001">ti</font><font style="color: #282728">v</font><font style="color: #121113">e </font><font style="color: #000001">Date </font><font style="color: #121113">o</font><font style="color: #000001">f </font><font style="color: #121113">t</font><font style="color: #000001">his a</font><font style="color: #121113">g</font><font style="color: #000001">r</font><font style="color: #121113">e</font><font style="color: #000001">ement </font><font style="color: #121113">t</font><font style="color: #000001">hrough the end of the </font><font style="color: #121113">1s</font><font style="color: #000001">t </font><font style="color: #121113">y</font><font style="color: #000001">ea</font><font style="color: #121113">r </font><font style="color: #282728">f</font><font style="color: #121113">ol</font><font style="color: #000001">lo</font><font style="color: #121113">wi</font><font style="color: #000001">ng </font><font style="color: #282728">the </font><font style="color: #121113">Pe</font><font style="color: #282728">r</font><font style="color: #121113">m</font><font style="color: #282728">a</font><font style="color: #121113">ne</font><font style="color: #000001">nt </font><font style="color: #282728">T</font><font style="color: #121113">r</font><font style="color: #000001">an</font><font style="color: #121113">s</font><font style="color: #000001">fe</font><font style="color: #121113">r, </font><font style="color: #000001">Licensee discovers an</font><font style="color: #121113">y </font><font style="color: #000001">misrepresentat</font><font style="color: #121113">i</font><font style="color: #000001">ons on </font><font style="color: #121113">t</font><font style="color: #000001">he par</font><font style="color: #121113">t o</font><font style="color: #282728">f L</font><font style="color: #121113">i</font><font style="color: #000001">cen</font><font style="color: #121113">s</font><font style="color: #000001">o</font><font style="color: #282728">r to L</font><font style="color: #121113">i</font><font style="color: #282728">c</font><font style="color: #121113">en</font><font style="color: #000001">s</font><font style="color: #282728">e</font><font style="color: #121113">e </font><font style="color: #000001">or </font><font style="color: #121113">Lic</font><font style="color: #000001">ensor</font><font style="color: #282728">, </font><font style="color: #000001">Lic</font><font style="color: #121113">e</font><font style="color: #000001">nse</font><font style="color: #121113">e </font><font style="color: #000001">or Licensor will have the righ</font><font style="color: #282728">t </font><font style="color: #000001">to dissolve thi</font><font style="color: #121113">s </font><font style="color: #000001">agree</font><font style="color: #121113">me</font><font style="color: #282728">n</font><font style="color: #121113">t. </font><font style="color: #282728">S</font><font style="color: #000001">ho</font><font style="color: #121113">ul</font><font style="color: #000001">d </font><font style="color: #121113">t</font><font style="color: #000001">h</font><font style="color: #121113">i</font><font style="color: #000001">s occu</font><font style="color: #121113">r</font><font style="color: #000001">, Licensor will be required to forfeit the stock awarded </font><font style="color: #121113">t</font><font style="color: #000001">o it a</font><font style="color: #121113">s </font><font style="color: #000001">des</font><font style="color: #121113">crib</font><font style="color: #000001">e</font><font style="color: #121113">d </font><font style="color: #000001">in </font><font style="color: #282728">i</font><font style="color: #121113">te</font><font style="color: #000001">m </font><font style="color: #121113">2</font><font style="color: black">.</font><font style="color: #000001">4</font><font style="color: black">.</font><font style="color: #000001">e abo</font><font style="color: #121113">v</font><font style="color: #000001">e </font><font style="color: #121113">wi</font><font style="color: #000001">th that stock having an established per share valu</font><font style="color: #121113">e e</font><font style="color: #000001">qual to th</font><font style="color: #121113">e </font><font style="color: #282728">v</font><font style="color: #000001">a</font><font style="color: #282728">l</font><font style="color: #121113">ue of </font><font style="color: #282728">a </font><font style="color: #121113">s</font><font style="color: #000001">hare o</font><font style="color: #121113">f L</font><font style="color: #282728">i</font><font style="color: #121113">c</font><font style="color: #000001">ens</font><font style="color: #121113">e</font><font style="color: #000001">e</font><font style="color: #282728">'</font><font style="color: #000001">s </font><font style="color: #121113">s</font><font style="color: #000001">tock a</font><font style="color: #121113">s </font><font style="color: #000001">officiall</font><font style="color: #121113">y </font><font style="color: #000001">recorded on the date of </font><font style="color: #121113">L</font><font style="color: #000001">icensee</font><font style="color: #4A4A4B">'</font><font style="color: #000001">s </font><font style="color: #121113">s</font><font style="color: #282728">t</font><font style="color: #121113">ock </font><font style="color: #282728">r</font><font style="color: #000001">ol</font><font style="color: #121113">lba</font><font style="color: #000001">ck and an</font><font style="color: #121113">y </font><font style="color: #000001">assets from the original acquisition that st</font><font style="color: #282728">i</font><font style="color: #000001">ll remain under th</font><font style="color: #121113">e </font><font style="color: #000001">c</font><font style="color: #121113">on</font><font style="color: #000001">t</font><font style="color: #121113">r</font><font style="color: #282728">ol </font><font style="color: #121113">of L</font><font style="color: #000001">icensee </font><font style="color: #121113">w</font><font style="color: #000001">il</font><font style="color: #121113">l </font><font style="color: #000001">be returned to </font><font style="color: #121113">L</font><font style="color: #000001">icensor and in thei</font><font style="color: #121113">r </font><font style="color: #000001">then current </font><font style="color: #121113">c</font><font style="color: #000001">ondition o</font><font style="color: #121113">r </font><font style="color: #282728">s</font><font style="color: #000001">t</font><font style="color: #121113">atus and </font><font style="color: #000001">bo</font><font style="color: #121113">t</font><font style="color: #000001">h parti</font><font style="color: #121113">e</font><font style="color: #000001">s </font><font style="color: #121113">wi</font><font style="color: #000001">l</font><font style="color: #121113">l </font><font style="color: #000001">e</font><font style="color: #121113">x</font><font style="color: #000001">it the </font><font style="color: #121113">r</font><font style="color: #000001">elat</font><font style="color: #121113">i</font><font style="color: #000001">onship </font><font style="color: #121113">h</font><font style="color: #000001">oldin</font><font style="color: #121113">g e</font><font style="color: #000001">ach othe</font><font style="color: #121113">r </font><font style="color: #000001">harmles</font><font style="color: #121113">s in a</font><font style="color: #000001">l</font><font style="color: #121113">l </font><font style="color: #000001">ma</font><font style="color: #121113">tt</font><font style="color: #000001">e</font><font style="color: #121113">r</font><font style="color: #282728">s</font><font style="color: #000001">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #121113">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #121113">j) L</font><font style="color: #000001">ic</font><font style="color: #121113">e</font><font style="color: #282728">n</font><font style="color: #121113">sor ag</font><font style="color: #000001">r</font><font style="color: #282728">e</font><font style="color: #121113">es t</font><font style="color: #000001">o pro</font><font style="color: #121113">vide a softw</font><font style="color: #000001">a</font><font style="color: #121113">re </font><font style="color: #000001">device </font><font style="color: #121113">i</font><font style="color: #000001">n the licens</font><font style="color: #121113">e</font><font style="color: #000001">d </font><font style="color: #121113">s</font><font style="color: #000001">oftware that wil</font><font style="color: #282728">l o</font><font style="color: #121113">ff</font><font style="color: #000001">e</font><font style="color: #121113">r </font><font style="color: #000001">an </font><font style="color: #121113">a</font><font style="color: #000001">u</font><font style="color: #282728">tomat</font><font style="color: #121113">i</font><font style="color: #282728">c </font><font style="color: #121113">lo</font><font style="color: #282728">g</font><font style="color: #121113">on fr</font><font style="color: #000001">om </font><font style="color: #121113">L</font><font style="color: #282728">i</font><font style="color: #000001">cen</font><font style="color: #121113">s</font><font style="color: #000001">ee</font><font style="color: #282728">'</font><font style="color: #000001">s soft</font><font style="color: #121113">wa</font><font style="color: #000001">r</font><font style="color: #121113">e</font><font style="color: #4A4A4B">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">k</font><font style="color: #121113">) </font><font style="color: #282728">L</font><font style="color: #121113">i</font><font style="color: #000001">c</font><font style="color: #121113">en</font><font style="color: #282728">s</font><font style="color: #121113">or </font><font style="color: #282728">a</font><font style="color: #121113">g</font><font style="color: #000001">re</font><font style="color: #121113">e</font><font style="color: #000001">s to pro</font><font style="color: #121113">v</font><font style="color: #000001">ide sof</font><font style="color: #282728">t</font><font style="color: #000001">ware operations</font><font style="color: #121113">, </font><font style="color: #000001">communications and </font><font style="color: #121113">h</font><font style="color: #000001">osting </font><font style="color: #121113">s</font><font style="color: #000001">ervices fo</font><font style="color: #121113">r t</font><font style="color: #282728">h</font><font style="color: #000001">e </font><font style="color: #121113">lic</font><font style="color: #000001">e</font><font style="color: #121113">nse</font><font style="color: #000001">d </font><font style="color: #121113">s</font><font style="color: #000001">oftw</font><font style="color: #121113">a</font><font style="color: #000001">r</font><font style="color: #121113">e i</font><font style="color: #000001">n same comput</font><font style="color: #121113">i</font><font style="color: #000001">ng facilit</font><font style="color: #121113">y </font><font style="color: #000001">as Licensee has its </font><font style="color: #121113">o</font><font style="color: #000001">perationa</font><font style="color: #121113">l </font><font style="color: #282728">so</font><font style="color: #121113">f</font><font style="color: #000001">t</font><font style="color: #282728">wa</font><font style="color: #121113">r</font><font style="color: #000001">e </font><font style="color: #121113">u</font><font style="color: #000001">n</font><font style="color: #121113">t</font><font style="color: #000001">il </font><font style="color: #121113">L</font><font style="color: #000001">ic</font><font style="color: #121113">e</font><font style="color: #000001">ns</font><font style="color: #121113">e</font><font style="color: #000001">e </font><font style="color: #121113">a</font><font style="color: #000001">n</font><font style="color: #121113">d L</font><font style="color: #000001">icenso</font><font style="color: #121113">r </font><font style="color: #000001">mutuall</font><font style="color: #121113">y </font><font style="color: #000001">agree </font><font style="color: #121113">t</font><font style="color: #000001">hat this serv</font><font style="color: #121113">i</font><font style="color: #000001">ce is no </font><font style="color: #121113">lon</font><font style="color: #000001">ger ne</font><font style="color: #121113">c</font><font style="color: #282728">ess</font><font style="color: #121113">a</font><font style="color: #282728">ry</font><font style="color: #000001">,</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">&#160;</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #121113">1</font><font style="color: #282728">) </font><font style="color: #121113">L</font><font style="color: #000001">ic</font><font style="color: #282728">ens</font><font style="color: #121113">ee </font><font style="color: #282728">a</font><font style="color: #121113">n</font><font style="color: #000001">d </font><font style="color: #282728">Li</font><font style="color: #121113">c</font><font style="color: #000001">ensor a</font><font style="color: #121113">g</font><font style="color: #000001">ree t</font><font style="color: #121113">o </font><font style="color: #000001">e</font><font style="color: #121113">x</font><font style="color: #000001">ecute sale</font><font style="color: #121113">s </font><font style="color: #000001">agreements for each oth</font><font style="color: #121113">e</font><font style="color: #000001">r</font><font style="color: #121113">'s </font><font style="color: #000001">products </font><font style="color: #282728">a</font><font style="color: #000001">n</font><font style="color: #121113">d </font><font style="color: #000001">se</font><font style="color: #121113">rv</font><font style="color: #000001">ic</font><font style="color: #121113">e</font><font style="color: #282728">s</font><font style="color: #000001">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000001">m</font><font style="color: #282728">) L</font><font style="color: #121113">icen</font><font style="color: #282728">s</font><font style="color: #000001">e</font><font style="color: #121113">e </font><font style="color: #282728">a</font><font style="color: #121113">gree</font><font style="color: #000001">s th</font><font style="color: #121113">a</font><font style="color: #000001">t i</font><font style="color: #121113">f </font><font style="color: #000001">du</font><font style="color: #121113">e </font><font style="color: #000001">to L</font><font style="color: #121113">i</font><font style="color: #000001">censee modificat</font><font style="color: #121113">i</font><font style="color: #000001">ons to the Licensed software, data from th</font><font style="color: #121113">e </font><font style="color: #000001">m</font><font style="color: #121113">od</font><font style="color: #000001">ifi</font><font style="color: #121113">ed </font><font style="color: #000001">Li</font><font style="color: #121113">c</font><font style="color: #000001">ensed so</font><font style="color: #121113">f</font><font style="color: #000001">t</font><font style="color: #121113">wa</font><font style="color: #000001">re cannot be processed b</font><font style="color: #121113">y L</font><font style="color: #000001">icensor, Licensee </font><font style="color: #121113">sha</font><font style="color: #000001">ll pro</font><font style="color: #282728">v</font><font style="color: #121113">ide d</font><font style="color: #282728">a</font><font style="color: #121113">t</font><font style="color: #282728">a i</font><font style="color: #000001">n </font><font style="color: #121113">or</font><font style="color: #282728">ig</font><font style="color: #121113">inal </font><font style="color: #000001">Li</font><font style="color: #121113">censed </font><font style="color: #282728">s</font><font style="color: #121113">o</font><font style="color: #282728">f</font><font style="color: #000001">t</font><font style="color: #121113">w</font><font style="color: #000001">a</font><font style="color: #121113">re </font><font style="color: #000001">format and mak</font><font style="color: #121113">e </font><font style="color: #000001">that data av</font><font style="color: #121113">ai</font><font style="color: #000001">lable to </font><font style="color: #121113">Lice</font><font style="color: #000001">nsor </font><font style="color: #121113">as i</font><font style="color: #282728">n </font><font style="color: #121113">2</font><font style="color: black">.</font><font style="color: #121113">4</font><font style="color: #000001">.</font><font style="color: #121113">d.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #121113">n</font><font style="color: #282728">) </font><font style="color: #121113">L</font><font style="color: #000001">ic</font><font style="color: #121113">e</font><font style="color: #282728">ns</font><font style="color: #121113">e</font><font style="color: #282728">e sha</font><font style="color: #121113">ll ha</font><font style="color: #282728">ve </font><font style="color: #000001">the </font><font style="color: #121113">righ</font><font style="color: #000001">t </font><font style="color: #121113">t</font><font style="color: #000001">o c</font><font style="color: #121113">o</font><font style="color: #000001">p</font><font style="color: #121113">y </font><font style="color: #000001">and u</font><font style="color: #121113">s</font><font style="color: #000001">e all forms o</font><font style="color: #121113">f </font><font style="color: #000001">documentat</font><font style="color: #121113">i</font><font style="color: #000001">on</font><font style="color: #121113">, m</font><font style="color: #000001">a</font><font style="color: #121113">r</font><font style="color: #000001">k</font><font style="color: #121113">e</font><font style="color: #000001">t</font><font style="color: #121113">i</font><font style="color: #000001">n</font><font style="color: #121113">g </font><font style="color: #000001">in</font><font style="color: #282728">fo</font><font style="color: #000001">r</font><font style="color: #282728">ma</font><font style="color: #121113">ti</font><font style="color: #282728">o</font><font style="color: #121113">n a</font><font style="color: #000001">nd da</font><font style="color: #282728">t</font><font style="color: #121113">a r</font><font style="color: #000001">el</font><font style="color: #121113">at</font><font style="color: #000001">ed </font><font style="color: #121113">t</font><font style="color: #000001">o </font><font style="color: #121113">t</font><font style="color: #000001">he L</font><font style="color: #121113">i</font><font style="color: #000001">cense.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">o<font style="color: #000002">) L</font><font style="color: #1E1C1E">i</font><font style="color: #000002">censee shal</font><font style="color: #1E1C1E">l </font><font style="color: #000002">have the right to brand the License with a product name selected b</font><font style="color: #1E1C1E">y </font><font style="color: #000002">the Licensee a</font><font style="color: #1E1C1E">n</font><font style="color: #000002">d Li</font><font style="color: #1E1C1E">c</font><font style="color: #000002">ensor.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">p</font><font style="color: #1E1C1E">) </font><font style="color: #000002">Lic</font><font style="color: #1E1C1E">e</font><font style="color: #000002">nsor shall change the appearance of the Lice</font><font style="color: #000001">n</font><font style="color: #000002">se</font><font style="color: #1E1C1E">'</font><font style="color: #000002">s end-user com</font><font style="color: #1E1C1E">p</font><font style="color: #000002">uter display screens to </font><font style="color: #1E1C1E">m</font><font style="color: #000002">atch the appearance of the L</font><font style="color: #1E1C1E">i</font><font style="color: #000002">censee</font><font style="color: #1E1C1E">'</font><font style="color: #000002">s computer application</font><font style="color: #1E1C1E">'</font><font style="color: #000002">s end</font><font style="color: #000001">-</font><font style="color: #000002">user computer d</font><font style="color: #1E1C1E">is</font><font style="color: #000002">pl</font><font style="color: #1E1C1E">ays</font><font style="color: #434243">, </font><font style="color: #1E1C1E">i</font><font style="color: #000002">nc</font><font style="color: #1E1C1E">l</font><font style="color: #000002">uding the branding desc</font><font style="color: #1E1C1E">r</font><font style="color: #000002">ibed in 2</font><font style="color: #000001">.</font><font style="color: #000002">4.0 above</font><font style="color: #1E1C1E">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">q) In the e</font><font style="color: #1E1C1E">v</font><font style="color: #000002">e</font><font style="color: #1E1C1E">n</font><font style="color: #000002">t that Licensor should cease doing business, Licensee shall have the </font><font style="color: #1E1C1E">r</font><font style="color: #000002">ight to co</font><font style="color: #1E1C1E">nt</font><font style="color: #000002">in</font><font style="color: #1E1C1E">u</font><font style="color: #000002">e </font><font style="color: #1E1C1E">u</font><font style="color: #000002">s</font><font style="color: #1E1C1E">a</font><font style="color: #000002">ge o</font><font style="color: #1E1C1E">f t</font><font style="color: #000002">he License and all associated documentation and related marketin</font><font style="color: #1E1C1E">g m</font><font style="color: #000002">a</font><font style="color: #1E1C1E">teria</font><font style="color: #000002">l </font><font style="color: #1E1C1E">wi</font><font style="color: #000002">thout recourse from Licensor or an</font><font style="color: #1E1C1E">y </font><font style="color: #000002">entit</font><font style="color: #1E1C1E">y </font><font style="color: #000002">representing Licensor</font><font style="color: #1E1C1E">'</font><font style="color: #000002">s interest</font><font style="color: #1E1C1E">s</font><font style="color: #000002">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #1E1C1E">r) T</font><font style="color: #000002">h</font><font style="color: #1E1C1E">e </font><font style="color: #434243">&#34;</font><font style="color: #1E1C1E">powe</font><font style="color: #000002">red b</font><font style="color: #1E1C1E">y </font><font style="color: #000002">M</font><font style="color: #1E1C1E">ed</font><font style="color: #000002">iScan</font><font style="color: #1E1C1E">&#34; t</font><font style="color: #000002">ext or graphic must alway</font><font style="color: #1E1C1E">s </font><font style="color: #000002">be display</font><font style="color: #1E1C1E">e</font><font style="color: #000002">d on modules </font><font style="color: #1E1C1E">and </font><font style="color: #000002">ap</font><font style="color: #1E1C1E">pli</font><font style="color: #000002">c</font><font style="color: #1E1C1E">a</font><font style="color: #000002">t</font><font style="color: #1E1C1E">i</font><font style="color: #000002">on web pages pro</font><font style="color: #1E1C1E">v</font><font style="color: #000002">ided b</font><font style="color: #1E1C1E">y </font><font style="color: #000002">L</font><font style="color: #1E1C1E">i</font><font style="color: #000002">censor</font><font style="color: #1E1C1E">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><font style="color: #000002">2.5 Ho</font><font style="color: #1E1C1E">ld</font><font style="color: #000002">b</font><font style="color: #1E1C1E">a</font><font style="color: #000002">c</font><font style="color: #1E1C1E">k St</font><font style="color: #000002">ock</font><font style="color: #000001">. </font><font style="color: #000002">Pursuant to the terms and subject to the conditions of this </font><font style="color: #1E1C1E">A</font><font style="color: #000002">greement, no pr</font><font style="color: #1E1C1E">o</font><font style="color: #000002">vis</font><font style="color: #1E1C1E">i</font><font style="color: #000002">ons shall be made for the purpose of withholding previousl</font><font style="color: #1E1C1E">y </font><font style="color: #000002">awarded </font><font style="color: #1E1C1E">s</font><font style="color: #000002">tock b</font><font style="color: #1E1C1E">y L</font><font style="color: #000002">icensee </font><font style="color: #434243">t</font><font style="color: #1E1C1E">o </font><font style="color: #000002">L</font><font style="color: #1E1C1E">ice</font><font style="color: #000002">ns</font><font style="color: #1E1C1E">o</font><font style="color: #000002">r other t</font><font style="color: #1E1C1E">h</font><font style="color: #000002">an those </font><font style="color: #1E1C1E">al</font><font style="color: #000002">read</font><font style="color: #1E1C1E">y </font><font style="color: #000002">cited in section 2</font><font style="color: #000001">.</font><font style="color: #000002">4 of this Agreement</font><font style="color: #000001">.</font></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Cloud-MD Inventory Management System is a ground breaking Cloud-based Medical Supply Inventory Management System, specifically designed for small and medium Medical Practices, DME's, Home Health, Long-term Care, and Surgery Centers that will offer:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">1. Centralized management control over medical supply and drug inventories&#160;<br /> 2. Real time utilization and financial inventory summary&#160;<br /> 3. Low price notifications&#160;<br /> 4. Par level/reorder tracking&#160;<br /> 5. RX expiration tracking&#160;<br /> 6. Auto supply re-ordering from a practices established suppliers</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Based on a barcode scanning technology,&#160;<font style="color: #005790">Cloud-MD Inventory Management</font>&#160;is designed to reduce workloads by automating inventory control processes. The Cloud-MD's Inventory Management System requires no installation, on-site software or special hardware. The new Cloud-MD Office application suite, of which Cloud-MD Inventory Management is a part, is fully delivered via the Internet and requires no special computing environment at the end-user facility.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">Manual inventory is time consuming, labor intensive and leaves room for error. Benefiting healthcare professionals across the country, Cloud-MD's Inventory Management System is a low-cost, low-maintenance, easy to use automated system that can provide effective solutions.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"><b><u>On November 21, 2012</u></b></p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The Company through a comprehensive agreement with CipherSmith, LLC, has purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks,, service marks, internet domain names or world wide web URS. This security software will be part of its ever expanding Cloud-MD Office product suite.</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:</p> <p style="margin-top: 0; margin-bottom: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">November 21, 2012</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="border-bottom: Black 1pt solid">Fair Value of Consideration:</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Common Stock (800,000 common shares valued at $.018)</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">14,400</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-weight: bold">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Fair Value of Assets acquired:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Software source code and security software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-weight: bold">Fair value of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-weight: bold"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">June 22, 2012</td></tr> <tr style="vertical-align: bottom; background-color: White; font-weight: bold"> <td style="padding-left: 5.4pt">Fair Value of Consideration:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Common Stock (500,000 common shares valued at $.008)</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Total Purchase Price</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><u>Fair Value of Assets acquired:</u></b></p></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Software</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Fair value of total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> 200000 204 500000 10000 0 0 0 0 0 0 8378837 8264131 44703 25445 8423540 8289576 -8423540 -8289576 0.340 0.340 9.0 9.0 -43.0 -43.0 0.000 0.000 25866296 25331677 -25688296 -25331677 <p style="margin-top: 0; margin-bottom: 0; text-align: justify">In accordance with the revised LOI the following occurred and on December 1, 2010 the NSC reported that change on Form 8-K:</p> <table cellpadding="0" cellspacing="0" style="font-size: 11pt; margin-top: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">1.</td><td style="width: 5pt"></td><td style="text-align: justify">On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">2.</td><td></td><td style="text-align: justify">On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">3.</td><td></td><td style="text-align: justify">On November 30, 2010 &#8211; 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">4.</td><td></td><td style="text-align: justify">On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td style="text-align: right">5.</td><td></td><td style="text-align: justify">On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p> 10000 1200106 10000 1011222 -11222 1000000 200106 1200106 1200106 1200106 1200106 2308497 2308497 .10 0.10 -2308497 7000000 5271756 5311756 0.43 0.43 40000 0.15 -5311756 .64 P58Y P3M P4Y8M P3Y8M 11016 2597 12434 EX-101.SCH 8 nsct-20110930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Shareholders Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - NOTE 3 - GOING CONCERN ISSUES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTE 6 - COMMITMENT AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTE 7 - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTE 8 - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NOTE 10 - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - NOTE 10 - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTE 3 - GOING CONCERN ISSUES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Summarized by Level (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS - Discontinued Operations Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - NOTE 6 - COMMITMENT AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - NOTE 7 - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTE 8 - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION - Outstanding Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NOTE 10 - INCOME TAXES - Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - NOTE 10 - INCOME TAXES - Income Tax Expense Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NOTE 10 - INCOME TAXES - Tax Credit Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL - Assets Acquired under Common Control (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS - Fair Value of Consideration and Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nsct-20110930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 nsct-20110930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 nsct-20110930_lab.xml XBRL LABEL FILE Common Stock Class of Stock [Axis] Preferred Stock Equity Components [Axis] Additional Paid-In Capital Accumulated Deficit Level 1 Fair Value, Hierarchy [Axis] Level 2 Level 3 Discontinued Operations [Member] Disposal Group Name [Axis] custom:CipherSmithMember Legal Entity [Axis] custom:MedicalMember custom:KroossMember custom:ConsultingMember custom:SoftwareInvestmentMember custom:CompensationMember Subsequent Event Type [Axis] custom:SoftwareSalesMember Third-Party Payor [Member] custom:MedisouthMember Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Net assets of discontinued operations Total current assets Noncurrent ASSETS: Proprietary technology Total noncurrent assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES CURRENT LIABILITIES: Advances from officers Line of Credit Net liabilities of discontinued operations Total current liabilities NONCURRENT LIABILITIES: Note payable affiliate Total Noncurrent Liabilities TOTAL LIABILITIES STOCKHOLDERS' DEFICIT: Preferred stock, $.10 par value, 4,000,000 shares authorized; none issued and outstanding as of September 30, 2011 and 2010 Common stock, $.01 par value, 650,000,000 shares authorized; 180,526,879 and 165,276,913 issued and outstanding as of September 30, 2011 and 2010, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstandng Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] OPERATING EXPENSES: Total operating expenses OPERATING LOSS (LOSS) INCOME BEFORE TAXES AND DISCOUNTED OPERATIONS (LOSS) INCOME FROM CONTINUED OPERATIONS (LOSS) INCOME FROM DISCONTINUED OPERATIONS NET LOSS NET LOSS PER COMMON SHARE: Basic Continuing operations Discontinuing operations NET (LOSS) INCOME PER COMMON SHARE Basic WEIGHTED AVERAGE COMMON SHARES OUTSTANDING Basic Beginning Balance, Shares Beginning Balance, Amount Options expired Common stock issued for back pay of officers, Shares Common stock issued for back pay of officers, Amount Shares issued for compensation, Shares Shares issued for compensation, Amount Common stock issued for cash, Shares Common stock issued for cash, Amount Net loss Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] Net Loss Adjustments to reconcile net loss to net cash (used in) operating activities: Discontinued operations Changes in assets and liabilities: Stock issued for compensation Net assets and liabilities from discontinued operations Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Common stock issued for cash Advances from affiliates Line of credit Net cash provided by financing activities INCREASE IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid Taxes paid Purchase of proprietary technology Accounting Policies [Abstract] NOTE 1 - DESCRIPTION OF BUSINESS Notes to Financial Statements NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES Organization, Consolidation and Presentation of Financial Statements [Abstract] NOTE 3 - GOING CONCERN ISSUES NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Discontinued Operations and Disposal Groups [Abstract] NOTE 5 - DISCONTINUED OPERATIONS Commitments and Contingencies Disclosure [Abstract] NOTE 6 - COMMITMENT AND CONTINGENCIES Related Party Transactions [Abstract] NOTE 7 - RELATED PARTY TRANSACTIONS Equity [Abstract] NOTE 8 - EQUITY Disclosure of Compensation Related Costs, Share-based Payments [Abstract] NOTE 9 - STOCK-BASED COMPENSATION Income Tax Disclosure [Abstract] NOTE 10 - INCOME TAXES Business Combinations [Abstract] NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL Subsequent Events [Abstract] NOTE 12 - SUBSEQUENT EVENTS Use of Estimates and Assumptions Revenue Recognition Accounts Receivable and Allowance for Uncollectible Accounts Cash and Cash Equivalents Income Taxes Share-Based Compensation Basic and Diluted Net Loss Per Share Concentration of Credit Risk Fair Value of Financial Instruments Reclassifications Recent Accounting Pronouncements Fair Value Measurements Summarized by Level Discontinued Operations Balance Sheet Outstanding Options Warrant Activity Income Tax Expense Income Tax Expense Reconciliation Tax Credit Carryforwards Business Acquisition Information Assets Acquired under Common Control Fair Value of Consideration and Assets Acquired Compensation Related Costs Accumulated Deficit Proprietary Technology Total Proprietary Technology FDIC Insured Amount Accounts receivable Deferred offering costs Net assets of discontinued operations Accounts payable and accrued expenses Disputed salaries & vacation of former officers Disputed salary - former employee Disputed payroll taxes for back pay of former officers Disputed interest Interest expenses Former officer note payable at 8% interest rate Shareholders demand note payable at 12% Shareholders demand note payable at 12% Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010 Note discount Note beneficial conversion feature Net liabilities of discontinued operations Revenues Cost of sales Operating expenses Interest expense Interest income Note Payable, Fair Value Effective Interest Rate Shares Issued, Lending Arrangement Per Share Conversion Price Price per share issued, lending arrangement Debt Discount Beneficial Conversion Feature Deferred Financing Costs Related Party Debt Related Party Interest Rate Repayments of Related Party Debt Accounts Payable, Related Parties, Current Interest Expense Related Party Origination/Placement Fee Warrants Issued Warrant Exercise Price Debt Default Amount Rent Expense Stock Issued During Period Compensation, Shares Price Per Share Issued, Compensation Increase (Decrease) Deferred Compensation Line of Credit Assumed Due To Related Parties, Current Stock Issued During Period Compensation, Value Compensation Expense Preferred Stock, Shares Outstanding Prefered Stock, Par Value Common Stock, Voting Rights Preferred Stock, Shares Reserved Preferred Stock, Voting Rights Stock Issued, Shares, Cash Stock Issued for Cash, Value Shares, Issued Shares Held by Shareholder Equity Cancellation, Shares Shares, Issued, Value Stock Issued During Period for Services, Shares Shares Issued, Price Per Share Compensation, Price Per Share Share Based Compensation Expense Shares Available Shares Granted Weighted Average Exercise Price Weighted Average Remaining Contractual Life October 1, 2008, Value Grants Grants, Per Share Grants, Value Forfeitures Forfeitures, Per Share Forfeitures, Value Shares Available Shares Granted Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Grants Grants, Per Share Expired Expired, Per Share Current: Federal State Current Tax Expense Benefit Deferred: Federal State Deferred Tax Expense (Benefit) Valuation allowance Provision benefit for income taxes, net Statutory federal income tax rate State income taxes and other Valuation allowance Effective tax rate Net operating loss carryforward Valuation allowance Deferred income tax asset Cost Basis for assets acquired under Common Control Cost basis of Consideration: Absolute Medical Software Systems LLC development costs from inception Impairment of software on September 10, 2008 to value Total Value at September 10, 2008 Software Update to Operate on Cloud Based Platform Absolute Medical Software Systems LLC development costs Total Cost Basis at January 1, 2011 Purchase Price Allocation Value of Consideration: Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control Total Purchase Price Cost Basis of Assets acquired under common control: Assets: Software source code and development costs of software Cost Basis of total assets Shares Issued Asset, Fair Value Share Price Common Stock Value Impairment Payments to Develop Software Acquisition Costs Acquisition Purchase Price Business Acquistion Terms Fair Value of Consideration: Fair Value of Assets acquired: Software Fair value of total assets Stock Issued Cancellation of Shares Stock Issued, Price per Share Stock Issued for Services, Value Stock Issued for Acquisition, Shares Stock Issued for Acquisitions, Value Assets, Current Assets, Noncurrent Liabilities, Current Accounts Payable and Accrued Liabilities, Noncurrent Accounts Payable and Accrued Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Earnings Per Share, Basic Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Cash1 Assets, Net Debt Instrument, Fair Value Disclosure Accounts Payable Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Temporary Equity, Shares Issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price WeightedAverageRemainingContractualLife Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Deferred Federal Income Tax Expense (Benefit) DeferredStateAndLocalIncomeTaxExpenseBenefitContinuingOperations Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Tax Credit Carryforward, Valuation Allowance EX-101.PRE 12 nsct-20110930_pre.xml XBRL PRESENTATION FILE EX-10.13 13 pjtagmt083013.htm EMPLOYMENT AGREEMENT OF PAMELA THOMPSON

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made as of the date of the last party to sign and is made effective and commences as of the date specified and defined below, by and between:

 

Cloud Medical Doctor Software Corporation, a Texas corporation with its principal offices currently in Las Vegas, Nevada (the “Company” or “Employer”), and

 

Pamela J. Thompson, an individual, residing in Phoenix, Arizona (“Thompson” or “Employee”),

 

The Company and Thompson may sometimes be referred to herein individually as “Party” and collectively as “Parties.”

 

I. Recitals

 

A. Company desires to employ Thompson for the purposes set forth herein, and Thompson is willing to accept said employment on the Terms and Conditions specified herein.

 

B. This Agreement has been authorized and approved by the Company’s Board of Directors in full compliance with the organizational documents of the Company, as amended as evidenced by that certain Board Resolution No. _______, dated __________, 2013.

 

NOW, THEREFORE in consideration of the mutual covenants, conditions, and promises herein contained, the receipt and sufficiency of which are hereby expressly acknowledged, Employer and Employee (collectively the “Parties”), do hereby agree as follows:

 

II. Terms and Conditions

 

1.0. Ratification. The Recitals set forth above are hereby adopted as true and accurate by the parties hereto, and are incorporated herein by this reference.

 

2.0. Employment. The Company hereby employs Thompson as Chief Financial Officer and Thompson hereby agrees to accept such employment by the Company upon the terms and conditions stated in this Agreement.

 

2.1. At all times material hereto, Thompson is under the control and supervision of the Board of Directors of the Company, and:

 

2.1.1. No action against Thompson in derogation of this Agreement may be taken without full compliance with the board of directors with the organizational documents of the Company.

 

3.0. Commencement Date/Effective Date. The Commencement/ Effective Date of this Agreement is January 1, 2013.

 
 

 

4.0. Term. The Term of this Agreement shall be five (5) years (the “Employment Period”) commencing on April 1, 2013 and expiring at the close of business on March 31, 2018. The term of this Agreement shall begin on the Commencement Date and shall terminate on the fifth anniversary hereof, unless sooner terminated by either party in the manner set forth below. During its Term, the Agreement automatically renews without notice.

 

4.1. Employer shall not have the right to terminate Employee’s employment except for cause. Employer shall have the right at any time to terminate Employee's employment immediately for cause on not less than 30 days advance notice. Any action by Employer to terminate Employee's employment shall be deemed "for cause" if:

 

(a) Employee is unable to perform the essential functions of her job, with or without reasonable accommodation, (i) either as a result of physical or mental illness or other cause continuing for a consecutive period of more than ninety (90) days; or (ii) repeated and substantial failure to perform his or her duties after prior written notice of such failure of not less than fifteen (30) business days;

 

(b) Employee has disclosed any material secret or confidential information of Employer or any subsidiary thereof without the consent of Employer or has violated or disregarded any other material duties, obligations or expected conduct as an employee of Employer;

 

4.2. Employee may terminate her employment for any reason at any time by giving ninety (90) days' prior written notice to the Employer.

 

5.0. Duties and Responsibilities. Thompson shall perform such services and duties as may be assigned to her as set forth below by the Chief Executive Officer and/or the Board of Directors of the Company. Unless otherwise modified or superseded by those persons, and agreed to by Thompson, Thompson’s Duties and Responsibilities are designated as the Chief Financial Officer of the Company:

5.1. Thompson shall devote a requisite amount of her time, attention, skill, and energies to the performance of duties hereunder.

 

6.0. Compensation.

 

6.1. Base Salary. The Company shall pay Thompson for her services a Base Salary of One Hundred and Fifty Thousand ($150,000.00 US) Dollars per year with a ten percent (10%) cumulative annual increase at each one year anniversary date of the Commencement Date of this Agreement.

 

6.1.1. The base salary shall be payable by the Company in substantially equaling installments on the Company’s normal payroll dates and shall be paid to Pamela J. Thompson, CPA P.C.

 

 
 

6.1.2. Any Base Salary not paid when due, if any, shall bear interest at the rate of fifteen percent (15%) per annum using a 360 day year until paid in full.

 

6.2. Executive Bonus Plan. In addition to the Base Salary provided for herein, the Company shall pay to Thompson as a bonus twenty-five percent (25%) of Thompson’s annual Base Salary, if during any twelve month period with the fiscal year ended September 30, that Thompson is employed by the Company, any one of the following occurs:

 

i. The Company posts annual gross revenues on a consolidated basis of at least $5,000,000; or

 

ii. The Company’s Earnings Before Income Tax and Amortization and Depreciation (“EBITA”), including cash extraordinary items, but before officers’ bonuses, on a consolidated basis for any year is at least $1,000,000; or

 

iii. The completion of the delinquent SEC filings for five (5) years through September 30, 2013; or

 

iv. The company obtains FINRA approval for any reverse stock split.

 

6.2.1. Thompson shall be eligible for the bonus for each year she is employed under this Agreement, including any extensions or renewals hereof.

 

6.2.2. The bonus calculation with respect to Thompson shall be made no later than September 30, 2013, and on each September 30 thereafter for each subsequent year.

 

6.2.3. The bonus payment for Thompson shall be paid in a lump sum on October 5, 2013, and on each October 5, thereafter, unless otherwise agreed to in writing by the Parties.

6.2.4. The criteria set forth in this paragraph 6.2.i.-iv. shall be used for determining bonus eligibility each year Thompson is employed by the Company.

 

6.3. Fringe Benefits. Thompson shall be eligible to participate, in accordance with their terms, in all medical, health, and disability plans, life insurance and pension plans and such other employment benefits or programs (other than executive bonus plans) as are maintained by Company for its employees provided that Company shall at all times be free to modify or amend such plans on a Company wide basis in accordance with the provisions thereof. Notwithstanding the foregoing, in no event shall such fringe benefits (other than executive bonus plans) be less favorable to Thompson than those accorded to any other employees of Company.

 

(i) Thompson and any of her legal dependents or spouse, at her option, may decline to participate in the Company’s medical, dental, and disability plans. In lieu thereof, the Company shall pay, when due by the provider, to or for the benefit of Thompson and her dependents and family, the monthly medical, dental, and disability plans, as presently specified:

 
 

 

a. Blue Cross Blue Shield coverage period of September 1, 2012 through September 1, 2013 which automatically renews with an adjusted premium which the current premium is $700 per month;

b. AFLAC coverage period is monthly which automatically renews premium is $300 per month;

c. Colonial Life coverage period is monthly which automatically renews, premium is $500 per month.

 

(ii) Thompson shall be paid an automobile ownership/rental/capital expense reimbursement of $1,000 per month.

 

(iii)In the event of a "Change of Control" (as defined in Exhibit “A” attached hereto and incorporated herein as Exhibit A) or if Company exercises its Termination Rights under Section 7.0 below, the entire contract is due and payable.

 

6.4. Equity Compensation. In addition to the Compensation described in paragraphs 6.1 through 6.3 above, Thompson shall receive restricted stock grants approved by the Board of Directors. The Company will disburse the following stock grants:

 

6.4.1. Recent Company Acquisitions.

 

(i) Granted 3,000,000 common shares for the acquisition of Doctors Network of America in Flowood, Mississippi on March 15, 2013;

 

(ii) Grant 3,000,000 common shares for the acquisition of the software of CipherSmith, LLC on November 21, 2012;

 

(iii) Grant 750,000 common shares for the acquisition of software from MediSouth, LLC on August 14, 2012;

 

6.4.2. Annual Grant of Company Common Shares. On the annual anniversary of the Commencement of her Employment by the Company:

 

(i) Thompson shall be granted 3,000,000 common shares for every acquisition completed by the Company unless separately negotiated by amendment hereto;

 

(ii) Thompson shall be granted the greater of 3,000,000 restricted common shares, or 1% of the outstanding shares, of the Company at a price of $.001 per share.

 

All stock issued pursuant to this Equity Participation section shall be issued under restricted legends and shall contain provisions preventing any future dilution, and any reverse stock splits and all effects similar or related thereto. Said shares shall be issued to Carmel Trust an irrevocable trust (not controlled by Thompson), or to its assigns.

 

6.5. Stock Options.

 
 

 

(i) As additional consideration under this Agreement, the Company has granted annually to Employee a non-qualified option for the purchase of 3,000,000 shares of the Company's Common Stock pursuant to the terms and conditions of the Company's Stock Option Plan once implemented. The exercise price for said option is cashless per share. The grant of said option shall occur once the Stock Option Plan has been implemented. The options shall vest on an equal monthly basis over the five (5) years of the Agreement. The options will have a floor of $0.01

 

(ii) In the event of a "Change of Control" (as defined in Exhibit “A” attached hereto and incorporated herein by this reference) or if Company exercises it’s Termination Rights under Section 7.0 below, the then unvested portion of the stock option held by Thompson shall have the vesting accelerated by 100% of the remaining unvested shares under the option and shall be fully vested under the equity compensation portion of this Agreement.

 

6.6. Paid Vacation. Thompson shall be entitled to a reasonable paid vacation of not less than forty five (45) days each calendar year (prorated for the first calendar year), exclusive of holidays and weekends, which vacation shall be taken by Thompson in accordance with the business requirements of the Company at the time and its vacation plans, policies and practices as applied to other officers of the Company then in effect relative to this subject. Thompson may accrue four weeks’ vacation to carry over to the next fiscal year.

 

6.7. Directors and Officers Insurance. The Company shall, as further consideration for this Agreement, obtain and maintain directors’ and officers’ liability coverage naming Thompson as an insured for acts and events occurring during the term of this Agreement. The director’s and officer’s insurance coverage shall be no less than $1,000,000.00 per claim and $3,000,000.00 annual aggregate, or in an amount otherwise agreed to in writing by the Thompson and Company.

 

6.8. Hold Harmless and Indemnity. The Company shall hold harmless and indemnify Thompson against any and all expenses (including attorney’s fees), costs, judgments, fines, penalties, settlements and other amounts incurred by, or assessed against, Thompson in connection with the acts or omissions of Thompson wherein Thompson acted in the course and scope of her employment with Company, in good faith and in a manner he reasonably believed to be in the best interests of the Company and, in the case of a criminal action or proceeding, had no reasonable cause to believe Thompson’s conduct was unlawful.

 

No determination in any proceeding against Thompson by judgment, order, settlement (with or without court approval) or conviction or upon a plea of nolo contendere (no contest) or its equivalent, shall create a presumption that Thompson did not act in good faith, in the course and scope of her employment and in a manner which she reasonably believed to be in the best interests of the Company, or, with respect to any criminal action or proceeding, that Thompson had reasonable cause to believe that her conduct was unlawful. This hold harmless and indemnity shall be in addition to any and all rights offered to Thompson by statute or other law.

 
 

 

7.0. Company Severance and Termination Rights. If Employer should terminate Employee's employment for any reason other than for cause pursuant to the preceding paragraph 4.1., Employee shall be paid an amount equal to his or her then-current monthly salary multiplied by the number of months remaining under this Agreement. Employee shall also be paid all unpaid annual bonuses, stock and options for the remaining years under this agreement, in cash.

 

7.1. The following shall apply to this Agreement. 9.0 IRC 409A. This letter Agreement is intended to comply with the short-term deferral rule under Treasury Regulation Section 1.409A-1(b) (4) and be exempt from Section 409A of the Code, and shall be construed and interpreted in accordance with such intent, provided that, if any severance provided at any time hereunder involves non-qualified deferred compensation within the meaning of Section 409A of the Code, it is intended to comply with the applicable rules with regard thereto and shall be interpreted accordingly. A termination of employment shall not be deemed to have occurred for purposes of any provision of this letter agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered “nonqualified deferred compensation” under Section 409A of the Code unless such termination is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this letter agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” If you are deemed on the date of termination to be a “specified employee” within the meaning of that term under Section 409A (a) (2) (B) of the Code, then with regard to any payment that is considered non-qualified deferred compensation under Section 409A of the Code payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which is the earlier of (A) the date that is immediately following the expiration of the six (6)-month period measured from the date of such “separation from service” of you, and (B) the date of your death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this paragraph (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this letter agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A of the Code,

 

(i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit,

 

(ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause

 

(ii) shall not be violated without regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments

 
 

shall be made on or before the last day of your taxable year following the taxable year in which the expense occurred. For purposes of Section 409A of the Code, your right to receive any installment payments pursuant to this letter agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may you, directly or indirectly, designate the calendar year of any payment to be made under the letter agreement that is considered non-qualified deferred compensation. In the event the time period for considering any release and it becoming effective as a condition of receiving severance shall overlap two calendar years, no amount of such severance shall be paid in the earlier calendar year.

 

III. General Provisions.

 

The Parties hereto expressly agree to be bound by these General Provisions, where the term ‘Agreement’ refers to this Employment Agreement:

 

1. ATTORNEYS' FEES. In the event any Party thereto shall employ counsel or bring legal action in any court of competent jurisdiction, including federal bankruptcy court, to enforce any part of this Agreement, or any other documents executed in connection herewith, the prevailing Party shall be paid by the non-prevailing Party (ies) all of its costs and reasonable attorneys' fees, and out of pocket expenses incurred therein or in connection therewith.

 

2. BINDING OBLIGATION. The Parties agree to cause to be prepared all documents required to carry out the intent and purposes of the Parties as set forth herein; provided, however, this Agreement and the parts thereof shall constitute a binding obligation of the signatories hereto.

 

3. BUSINESS DAYS. In the event the time for performance of any provision of this Agreement, or of any of the documents executed in connection herewith falls on a non-business day, the time for such performance shall be extended to the next business day. For purposes of this paragraph, "Business Day" shall mean all days on which banks and savings and loan institutions in Henderson, Nevada are open for general transaction of business.

 

4. CAPTION HEADINGS. Caption headings in this Agreement are for convenience purposes only and are not to be used to interpret or define the provisions of this Agreement.

 

5. CONSTRUCTION OF LANGUAGE. The language of this Agreement shall be construed according to its fair meaning and not strictly for or against either Party.

 

6. CONTROLLING LAW. This Agreement shall be deemed to have been made in the State of Nevada, and its validity, construction, and effect shall be governed by and construed in accordance with the laws and judicial decisions of the State of Nevada.

 

 
 

7. COUNTERPARTS. This Agreement may be executed in counterparts, each of which so executed shall be deemed to be an original, but such counterparts shall together constitute one and the same document. In making proof of this Agreement, it shall not be necessary to produce or account for more than one counterpart. This Agreement may be executed and delivered via facsimile or email.

 

8. CUMULATIVE REMEDIES. No remedy herein conferred upon any Party is intended to be exclusive of any other benefits or remedy, and each and every such remedy shall be cumulative and shall be in addition to every other benefits or remedy given hereunder or now or hereafter existing at law or in equity or by statute or otherwise. No single or partial exercise by any Party of any right, power or remedy hereunder shall preclude any other or further exercise thereof.

 

9. BINDING DATE. Unless otherwise specified in the first paragraph of this Agreement, the binding date of this Agreement shall be the date of the last Party to sign.

 

9. ENTIRE AGREEMENT. This Agreement embodies the entire agreement of the Parties hereto in relation to the subject matter hereof, and there are no representations, warranties or agreements, express or implied, or otherwise, in relation thereto, except as expressly referred to or as set forth herein.

 

10. FURTHER ASSURANCES. Without thereby increasing their respective obligations hereunder, the Parties hereby agree that they will do such acts and execute such documents, if any, as may be necessary or appropriate to implement this Agreement, and the parts thereof according to their terms, and the requirements of law.

 

11. GENDER. This Agreement shall apply to the Parties hereto according to the context thereof without regard to the number or gender of words or expressions.

 

12. HEADINGS. The headings or captions of this Agreement are for convenience and reference only, and in no way define, limit or describe the scope or intent of this Agreement, or the provisions of such sections.

 

13. LEGAL CONSTRUCTION/SEVERABILITY. If a court of competent jurisdiction finds any provision of this Agreement to be invalid or unenforceable as to any person or circumstance, such finding shall not render that provision invalid or unenforceable as to any other persons or circumstances. If feasible, any such offending provision shall be deemed to be modified to be within the limits of enforceability or validity; however, if the offending provision cannot be so modified, it shall be stricken and all other provisions of this Agreement in all other respects shall remain valid and enforceable.

 

14. LIMITATION OF RIGHTS. Nothing in this Agreement, except as specifically stated herein, is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the Parties and their respective permitted successors and assigns and other legal representatives, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any third persons to any Party to this

 
 

Agreement, nor shall any provision give any third persons any right of subrogation or action over against any Party to this Agreement.

 

15. MODIFICATION. This Agreement shall not be changed except by an amendment hereto, in writing, duly executed by each of the Parties. No representations, warranties, or agreements made subsequent to the execution and delivery of this Agreement, and the documents executed and delivered in connection therewith by any Party hereto, and no revocations, either partial or otherwise, or alterations thereof, shall be valid and binding unless made in writing and signed by each of the Parties. The Loan & Security Documents and this Agreement embody the entire agreement of the parties with respect to the subject matter hereof. There are no representations, promises, warranties, understandings or agreements, express or implied, oral or otherwise, in relation thereto, except those expressly referred to or set forth herein. Borrower acknowledges that the execution and delivery of this Agreement is its free and voluntary act and deed, and that said execution and delivery have not been induced by, nor done in reliance upon any representations, promises, warranties, understandings or agreements made by Lender, its agents, officers, employees or representatives, except as are contained herein.

 

16. MULTIPLE PARTIES; CORPORATE AUTHORITY. All obligations of Borrower and Holder under this Agreement shall be joint and several, and all references to Borrower or Holder shall mean each and every Borrower or Holder. This means that each of the persons signing below is responsible for all obligations in this Agreement. Where any one or more of the parties are corporations or partnerships or limited liability companies or limited liability limited partnerships, it is not necessary for Borrower or Holder or Lender to inquire into the powers of any of the parties or of the officers, directors, partners, or agents acting or purporting to act on their behalf.

 

17. NO PARTNERSHIP/NO THIRD PARTY BENEFICIARY. The Parties acknowledge and agree that neither this Agreement, nor the transactions contemplated hereby, is or shall be deemed to create or to constitute a partnership, joint venture, common business enterprise, principal and agent, or similar relationship between the Parties; nor are they intended for the benefit of any third party.

 

18. NOTICES. All notices given in connection with this Agreement shall be in writing and shall be delivered either by personal delivery, by telecopy or similar facsimile means, by certified or registered mail (postage prepaid and return receipt requested), or by express courier or delivery service, addressed to the applicable Party hereto at the following address:

 

If to the Company:

Cloud Medical Doctor Software Corporation

PO Box 90358

Henderson, NV 89009

Attn: Michael De La Garza, CEO & President

Ph: (702) 818-9011 Office

Fax:

 
 

If to Thompson:

Pamela J. Thompson

736 East Braeburn Drive

Phoenix, AZ 85022

Ph: (602) 488-4958

Fax: (602)283-5122

 

or such other address and number as either Party shall have previously designated by written notice given to the other Party in the manner hereinabove set forth. Notices shall be deemed given when received, if sent by telecopy or similar facsimile means (confirmation of such receipt by confirmed facsimile transmission being deemed receipt of communications sent by telecopy or other facsimile means); and when delivered and receipted for (or upon the date of attempted delivery where delivery is refused), if hand-delivered, sent by express courier or delivery service, or sent by certified or registered mail.

 

19. ORDINARY COURSE OF BUSINESS. The performance of the transactions contemplated by this Agreement is in the ordinary course of business of the Parties.

 

20. PRIOR AGREEMENTS SUPERSEDED. This Agreement constitutes the sole and only agreement of the Parties regarding the subject matter hereof, and this Agreement supersedes any prior understandings or written or oral agreements between the Parties regarding these matters. The foregoing notwithstanding, this Agreement only modifies the content of the Loan and Security Documents as expressly stated herein.

 

21. RECITALS. The Recitals are hereby incorporated herein by this reference as agreed terms, conditions, and provisions of this Agreement as applicable. Further, they are represented and warranted as true and accurate and in all respects valid by Borrower and Holder, and Holder’s agent, as of the date of execution of this Agreement.

 

22. SUCCESSORS. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties hereto; provided, however, neither this Agreement nor any rights hereunder may be assigned by Thompson or by the Company without the prior written consent of the other party first obtained.

 

23. TIME OF ESSENCE. Time is of the essence of each and every provision of this Agreement. Time of the Essence is hereby expressly reinstated with respect to all instruments previously executed and entered into by these Parties. Further, it is expressly understood and agreed by the Borrower that in consideration for the grant of this modification and the additional advance referred to herein by Lender, Lender has not and does not waive any legal or equitable right or remedy available to it, at law or in equity, under the various Loan Documents or this Agreement.

 

24. VENUE. The Parties expressly consent to jurisdiction in either the U.S. District Court for the District of Clark County, at Las Vegas, Nevada if allowed by applicable law; and only if the former is not available then the state court of general jurisdiction for the County of Clark, Nevada with regard to any matter arising from,

 
 

connected to, or relating to this Agreement.

 

25. WAIVERS. No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself or a waiver of any right under this Agreement. No waiver shall be binding unless executed in writing by the Party making the waiver.

 

 

26. WARRANTIES. Each Party hereto represents and warrants to the other Party, that each Party is under no disability, restriction, or prohibition, whether contractual or otherwise, with respect to their rights to execute this Agreement and perform its terms and conditions. Each Party shall indemnify and hold the other harmless from any loss or damage, including attorneys’ fees, and costs arising out of or connected with any claim by a third party which is inconsistent with any of the warranties or representations made by the Parties in this Agreement.

 

IN WITNESS WHEREOF, the parties have caused this agreement to be executed and delivered by their proper and duly authorized officers as of the day and year set forth below:

 

Signatures

 

THE COMPANY:

 

Date: _______________, 2013.

 

CLOUD MEDICAL

DOCTOR SOFTWARE

CORPORATION

 

_________________________________________

By:

Michael De La Garza

President, CEO,

Chairman

 

***************************************

 

Date: _______________, 2013.

 

THOMPSON:

 

_________________________________________

Pamela J. Thompson

c:\users\larry\desktop\employment contracts\employment agreement.docx

 
 

 

Exhibit A - CHANGE OF CONTROL SPECIFICATIONS

 

For the purposes of this Agreement, a "Change of Control" shall mean a change in control of

Employer of a nature that would be required to be reported assuming such event has not been "previously reported") in response to Item 1(a) of a Current Report on Form 8-K pursuant to Section 13 or 15(d) of the Exchange Act of 1934 (the "Exchange Act"); provided that, without limitation, a Change in Control shall also be deemed to have occurred at such time as:

 

(a) Any "person" within the meaning of Section 14(d) of the Exchange Act, other than Employer, a subsidiary, or any employee benefit plan(s) sponsored by Employer or any subsidiary thereof, is or has become the "beneficial owner," as defined in Rule 13d-3 under the Exchange Act, directly or indirectly, of fifty percent (50%) or more of the combined voting power of the outstanding securities of Employer ordinarily having the right to vote at the election of directors; or

 

(b) Individuals who constitute the Board of Directors immediately prior to any meeting of stockholders (the "Incumbent Board") have ceased for any reason to constitute at least a majority thereof, provided that any person becoming a director whose election, or nomination for election by Employer's stockholders, was approved by a vote of at least three-quarters (3/4) of the directors comprising the Incumbent Board (either by a specific vote or by approval of the proxy statement of employer in which such person is named as a nominee for director without objection to such nomination) shall be, for purposes of this Agreement, considered as though such person were a member of the Incumbent Board; or

 

(c) Upon approval by Employer's stockholders of a reorganization, merger, share exchange or consolidation, other than one with respect to which those persons who were the beneficial owners, immediately prior to such organization, merger, share exchange or consolidation, of outstanding securities of Employer ordinarily having the right to vote in the election of directors own, immediately after such transaction, more than fifty percent (50%) of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors; or

 

(d) Upon approval by Employer's stockholders of a complete liquidation and dissolution of Employer or the sale or other disposition of all or substantially all of the assets of Employer other than to a subsidiary thereof.

 GRAPHIC 14 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`JE M-JNGVTIBGO[6*5?O)),JD?@35VO!_P!I5%^P^'GVC=YDXW8YQA*`/:CK.EJ% M8ZE9@-RI,ZC/TYJ:VO+6\#&UN89PIP3%(&`_*O(/C7KFB:A\-VM;&9'D2XB, M:"%EV@9'&0`..*W]$\4Z9X)^"^@:I>JQ0V<*10Q+\\TK+G:!ZGDD^Q-`'I%% MU73Q9ZC>P&:SVSB2*4C.4+X!5ACI@CT)K#T[XLPZC9^(IET6 M>&?04+W=K+.HD(!8-MX(.-ISSZ>M`'I-%<3H/Q`7Q)X=T_5]/TYF%[>FS6W: MMG:R7!7U"*6Q^E`#[W5-/TU5-_ M?VMJ&^Z9Y53/TR14UM=6][`L]K/%/"WW9(G#*?Q'%>0_`U9?$B:WXRU=A=:K M/>&V65QDQ(JABJ?W5^<#`_NU0\37[^`?COI,FF8AT_7$B6]M4XC9FFS1QV#R*T$D@#/L17."..C M&\O?L!=3UBW`-S$BI!N&0'9@H/X9 MS^%`&W>ZOIFG.J7VHVEJ[?Z1J^K/)-V!G'O73:;X0L-(\67NN:?$EO\` M;;=8IX8UPI<-G>!T!(//TSU)H`U?[;TG_H*67_?]?\:NJRNH96!4C((/6OGW MPC/H=C\9?'8U@V4=D1.OEW"J5;]Z,@+W.,\`&G^!-&\8Q_#KQG'80WUK:W"' M^R;>8%9,9;?L!Y&4P,]STZ4`>YQZOILUS);Q:C:23Q9\R)9E+)CKD`Y%7%8, MH92"",@CO7S_`.'?'_A+Q%X.B\#^*+%-(N(H/LL<\B`1+(!M#YZQMGDYXZY/ M->^6J"*SAC#!@D:KN'0X%`!,$JOCZX)KQCPWJ#_$#XZZJVJ8FT[0EE%E:ODQJZN(P^T\9/S-D]\>@Q M?^.:R>'8=$\8:2PM=4M[P6[31\&5&5FVOC[R_)T/J:`/9**\_N_B?;V%WX2M MYM-E?_A)(X&@DCD&(S(4'S`\\;Q5W1?'T>L^,-9\-IILT=WI:,[OYBE9,$`! M>G7/>@#LZ@N;NVM$#W-Q%`I.`TCA03^->6_#SQMK7B/QMXL>_M5CM;1X;+OA/XCO-/TN9M(61;>.[9QN=E=#OV8R$S@ M9SG)Z=<`'L,4T4\2RPR))&PR'1L@_C4E>8>'/%MAX/\`@UXL:D6,$`?8JH`27=L'"\'H">#QQ0!TU%>ZE\4[2WM=?O-.L#>VV@SK!?9G$;@EM MN47!W#.1DD9P<9JOX]^(-UI_PPA\2>'X-R7Z*(YY2`;??T.W^)@>,=,C//<` M]#NKRVLHO-N[B*"+(7?*X49/09/>IZ\:\9ZOIR_"7P_-XOT*YN[.1[=5$-YB M1G\G;%;F38D404G>[8.!\I` MP"3@T`=717'V7CZVO+/7P+-X]3T(.;RR>0D@X.J60/\`UW7_`!JX MCK(BNARK#(([BO!_$$,1_:BTA#&A5XD+`KD,?*?KZ]!0![M#/#<1B2"5)8ST M:-@P/XBI:\)\>W1^&WQ4T35]&/V6RU4;;ZSB&V*7#!6;:.,D,#GU'N:]&U;Q MY#:>(+S1-,LFU&^L+-KR\42B-8D`!"YPGTSU(UZ>6\TFWM;%)AJ%JUSY@G^6) M1LSGY>0=Z@$=>>F*`-:"\MKHR"WN(IC$Y201N&V,.QQT/L:L5Y3\._$7A6TM M/%VHV6GSZ5%:7)EU!YYO-W-\_P!WV&#@=3FMBR^)L-QJ7A^&YTBYMK7Q`K-I M\QD#L<'CS%`^7.01@MU&<4`=]17`:A\4;.W&LW5GI\M[I>BRI#?7:2A2&9MI M\M2W^TQ+)Y,OWDSV/O7 MC7QDT]O"GC;P]X^LX,JLZQW85?O,O(_%DW#/^R*`/9Y-7TR.1HY-1M(W4X96 MF4$'W&:?+J5C`L9FO+>,2C*%Y0N\>H]:\+^.!BDOM"\5:)$)I[**.ZGN5&5$ M3N#;EOJP?%>E)J5GXRO_``S)`J/:I"-8DW#.P[2D2GT.YG/_`&R-`':T5P`^ M)UO<:/J>O6&FRW>@Z;<>1-=+*%DDQMW/'&1\RC<#DL">PJ3Q7\3]-\,:1I&K MK;/?:?JF/)FBD"[<@')![8/X8-`':SW,%K'YEQ-'#'G&Z1PH_,TL,\5S$)89 M$EC;HZ-D'\17EOC'Q;)XA\%^--/DT'4+**RLU>*XNDPLX;!4@=CT..3ZX(Q4 MOP^UV72/A=X2M[6P:_NKS?&D$I44R,N8U,BA7(R MR@Y`/U[T^@`HHHH`****`"O$?C_INI:]#HMKI&DZE?RV\DK2FVLI9%4$)CY@ MN.WK7MU<5JOPG\$ZUJEQJ6H:+YUYFZI=W-Q/%(D,>GS;@H))W#9\OT.*YWQ%X7U;7O@WX82QT^].H:+Y33V,MN M\4C`+M8*'`)(..G49QFNT_X4E\//^A?_`/)VX_\`CE'_``I+X>?]"_\`^3MQ M_P#'*`,?6=-NO&7Q9\,:GI]O=)IFE1>?<74T#Q+NR2(QO`);@9`Z`\U#=^!+ ML?'4W]O&XT;4;07%]A/D9D9?W9[";_`,,^(O$<5UO&FVMXRZ>C+PY=03(, M]]FQZD5BX(1@&"[F')`R% M&.M;O_"DOAY_T+__`).W'_QRC_A27P\_Z%__`,G;C_XY0!R=_8ZIH_QYUG5V MT?4+JTU'3O*M9+6`NK/Y4:X+=%Y0]3QP>]-^%VF:GI/P=\4:?J&E:C;WDCW# M);R64H>0/`BKM7;ELE2.,X[UUW_"DOAY_P!"_P#^3MQ_\)N<8/S`9X]*ZKQEX;B\7>$ M]0T25Q&;F,>7(1G9("&4_3(&?;-<]_PI+X>?]"__`.3MQ_\`'*4?!3X>A2O_ M``C_``3G'VVX_P#CE`&?\/9[CPSX37PIXLTVYAFLF=4D%J\T%Q$6+#:Z@J2, MXP<'IQUK'^%>AZS:^+O$.JZM8ZC'IJL_]GF[63A=[?A^&M.N-'\+Z5IMU-YM MQ:VD<,DF<@LJ@&N5_P"%)?#S_H7_`/R=N/\`XY1_PI+X>?\`0O\`_D[Z\/ZND@G:VC,CVKLP'[K3_`!!\/[_3]-N[K3-&N(TE M6UA:5HXT>(CY5&?NJ?Q%/\!6FII\:O%&J7>C:E96E]$WD2W%JZHWS(?O8V@D M#.,^W6NC_P"%)?#S_H7_`/R=N/\`XY1_PI+X>?\`0O\`_D[CWNFWML=5D8071A/DA29_FW]#G>N`.?R.,;3[;6-/^"NO^"[G0-5. ML1W!")':.Z2(70[E<#:>01@$D\8'7'HW_"DOAY_T+_\`Y.W'_P`#3KPWNARJ]S8-"5E9A- M;NJ:-<^,OC'HNKV4%U'I&FV1\Z\DA:(%SYF$7>`2?F7.!QSGFMG_`(4E\//^ MA?\`_)VX_P#CE'_"DOAY_P!"_P#^3MQ_\">:*U@>8 MQY65F!*`@8,@7W[9KO?^%)?#S_H7_P#R=N/_`(Y2GX*?#U@`?#_`&!_IMQ_\ M()M1L]-AA:T31KH,9$C52NXQ[>HZYKG+G1=:MOB#X( M\;ZC;W4L7]G+#J02$L]M,T3YR@&0NZ7'0XVG-=+_`,*2^'G_`$+_`/Y.W'_Q MRC_A27P\_P"A?_\`)VX_^.4`<8_@35_%6O\`C_6(H9;6WU.U^RZ?]H4Q_:"# M&V[#`$*3$!DCH_&:W?A5KNIV_AVR\,:IX:U6+4-.?RO-EMBD(CW'YMYX!"DC M`ZXXSGC6_P"%)?#S_H7_`/R=N/\`XY1_PI+X>?\`0O\`_D[.K:[\-ZI#(I7[%;VMMY<#A7RTCD8\YRH4C[W7@>E_6=)U75/V<+&PMM M*OC>VHBWVSP,LA"MR0I&2.>WO79_\*2^'G_0O_\`D[O#X*?#U00/#_!&#_IMQ_P#'*3_A27P\_P"A?_\`)VX_^.4`=IIC M[]+M&VNF84^5T*,.!U4\@^QKQ?7+:_D_:$TW7X]'U=]+MT1)+E--G90?+8=D MR>6'2NT_X4E\//\`H7__`"=N/_CE'_"DOAY_T+__`).W'_QR@#!\1>%]1^(_ MQ'TF]DL;FT\.:2H8RW<1B>Y?<&*K&V&`.%&2!T/M6/JFD7?ACXS:EJ^I^'KW M5]!UB/9YEK;M,8R0O4+W!4C!Z@Y&:[;_`(4E\//^A?\`_)VX_P#CE'_"DOAY M_P!"_P#^3MQ_\-FVKCKG);ZC;Z5+_PI+X>?]"__P"3 MMQ_\<^&O"&M:MX2^(6D'3K^SN=1G2>S^UVLD M(F"2,^`S*!S@#\:[7X6^(-1_X1S3O#NH^&M6@U'3L0-+/;&.$("0&WMW"\8' M)[<'C1_X4E\//^A?_P#)VX_^.4?\*2^'G_0O_P#D[I^[@C!Y^Z1SCK6SXW\(:5KLOV:32;[1=1T MVSC^P7EC;22P,0N[R,HO53TQ@\\=,5U/_"DOAY_T+_\`Y.W'_P`.W=_M;=N??--\>^&U\6 M>"M2TC`,TD1>W)[2K\R_J,?0FL3_`(4E\//^A?\`_)VX_P#CE*WP4^'K,6/A M_))R3]MN/_CE`&=X)\"RS?"&32-:\S[9JMMB3SE(:`!<0K@\C8`IQV.:?\)/ M!][HWP^GMM5$L-[>F2-E?[T,8+*JCVR7?_@=7?\`A27P\_Z%_P#\G;C_`..4 MH^"GP]4\>'\=O^/VX_\`CE`'!Z3I.JZ#\(O$G@VYTN]?69+IX[>*&W=TG5]@ M$BN!MV\,221C'.*C\>^$=7L?AWX*T&'3KW4;JQDWW0M;5YE3/+`E01@$D#U` MKO\`_A27P\_Z%_\`\G;C_P".4I^"GP]8`'P_P!@?Z;_#;6( M;2VN;B>YMML4,-N[R,21@;`,C\1QWKQFRT#Q1X4TWP?XKT?3];N;^!7M;[3' MMIBRIO8X";?E0J?INP1DYKU8?!3X>A2O_"/\$YQ]MN/_`(Y2?\*2^'G_`$+_ M`/Y.W'_QR@#M=.O5U&PANUAN(!*N[RKF)HI$]F5@"#5NJ&CZ/8Z!I4&EZ9!Y M%G`"L4>]FV@DGJQ)/)/4U?H`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KF_&LVLV^AI+H M?6'CN62+38].@N_.OM:^Q7-MJSE9K(B,,8^A)!VD@G^]Z]-1/B7 M:31ZE<0Z9=26EG!=3+.`=K_9SAU/&$+8)7)YQSCI6]/X2TBY\EYH96FANQ>B M83N)#,%V;BP()^4!<=,`#M5+4/!=G_8.OV.DJ;>758+A=CS.84EE0JSA.0N< MY.!].M`#O#_C!=:U8:=-8/:3R:?#J4(,HK$GAS3)-;EUEH9?[0EMC:-*+B09BR3MV[MHY)/2@#7HJGIFG6VD: M9;:?:!Q;VZ".,.Y<@#W.2:N4`%%%%`!1110`4444`%%%%`!47:/\,M-T]1-KLPNY^#]F@.V, M?5NI_#`J'QA\/+OQ5K]I;P0PZ7HUG;QH9`@52QRQ"*.3U_/O7-]6HJ:7*T^ES-M&[[T9]&JL/A<+7J>SC4:? MFO\`@C`5/3W%`'EFB^)-:L_!/@GQ`U_<7<^IZA'97L$S;Q.LC MNNY<_=9=H/RX!QS72R_$55O+^S72W2YM[.ZNHTEE`SY#%2KX'RD\,,;N#SBH MM,^'EUI"6*6>J602PW?9$ELI95A+$Y*!YR`>3SUYJ"U^&,UFZ-#JMK\L4\`# M6!XH;$Z>H-M-_J"0=G^OZ`J/RK9N_"NLW^D_P!EWNLZ?<6>T+Y!C;S MYV/#9Z8('//;',Z]XU MN9[O3K&W\RQOH-KPW`+8S@9R`P(Q_#6O)X/UFYM9;6\\06UW#+$ MT+)J)^'-TQ5I=7M9)%N8;KS7LY2YEA&V(EO/R0HZ#IU. M,F@"EH7CN73])\N^\^_OKK5K^WM49B/DAW-@G!/"J`."22/-FUG43: M:9H]S+Y*VQNQ,XBDMO/C9UW(>NT`;N<_-P#BLO\`X5M<\C./:K,7@?4X=:.KQ:W;1WKQI%*\=E(!,$^[O'GX^!HP_$JSETY[ MUK&18VTJ;5K9=_,L,1(8'CY6(P0.1SUXJ"V^'-U:0V,$6K6@BL+E[NU0V7UK]A>UDM8+6XYD#ADGC+KZ8(P01^IKF[SQ%J6E^+VM-PK5TKP3J>B74]SIVLV<,L\4,,K&PD M?L:9%>ZEL%VUK8N-P0 M;4PWFJP('<8(SUIB?#V]CN+2XCUBS2>TN9+J.5;%U;S9!M=B1-SN'!%`#3\4 M[-M+OM2ATNZELK>"6>.4<"01R^6P)QA6/WE&3D=<5+#\2`VJ164NDO'NU2+3 M7<3AMKRQ&1&`P,C`P>F.V:A_X5O<_P!G7VFG5[;[!?,[36PM)1'ECN;:!/\` M+DC/RX[^IR#X;3_:A<_VI:&87<=[N-I,?WT:E$?_`(^,<*<8Z>M`'H5%,C#K M&HD8,X`!8#`)]<4^@`HHHH`*Y_QDS+X=E96((=3D'&*Z"N>\:?\`(MS?[RU4 M/B0,X:P\0W=I\LA\V,]0>XKI-.U&&Y!:PF$3GAK>3E&_PKAQ`S0F5/F4<,!U M4T03/!,LD9P0>GK76U+#646YL MW_U5UT9&QZ_PD>OYUTT<7.EI+5?B8SI*6JW/$B,]@?K43DCK-@>B+S6YXB\. M7OAB^$%T?.M92?L]T!@/[-Z-60V0.&Q]!DU[$)QG%2B[HY&FG9E1@KG_`%=Q M+]3@5$Z,O(@BC'^TP)J>0,V>)W'UVBHH+2XN[@06ED\\Q!(2,&1B/H*O;<$) M90M=:E:6P`D,LZ)L`ZY8<5]!7!BTY18V$$=M`G1(DV@?E7D?A7PGKH\3Z?7;Z"IDU*UU&01L)K=C\L;%LC\1VS6!+*6 MD,LTC2RGN3D__6ID*W-],(K:-G;/(3H/'1],_MB]AGN8XH@ MIAME+&1O<]E]Z^#J5JBJ+1)GF M5)):&M\%O^2B6?\`P+_T%J^J:^8_A1916/Q(TU(;VWO!)!YC-!G"$HV4.1U' M>OIRM,Z:>(3785+9A1117D&H4444`%%%%`!1110`45'+-';Q-+-(D<:C+.[8 M`'N:9;W5M>(7MIXIT!VEHW#`'ZB@">BBB@`HJ'[3!]I-MYT?G@;O*WC6%SH&FV)+^VTNU\01Z=K=ZFHVFB7,_V-Y9)"C!=R3` MMDC!7'7!SZYS':_$.&QT>(W4,EP+&RT^34;DOAE:YPJD+CYN?F/(X/&>E=$W M@_1II;Z:Y@EN)[^T-E`_P9!&!R>1@^]-?P9H3&,&S/EI'!$T?FMME M6$YB#C/S[3R,Y]\T`6NW'*Y)YS MQGIZ2:K\0#>:=X@L+:VN+*_MM%N[^&3S!NC,3-'AA_"P8*V`3P>??IX?"&BP M7[7BVS^8UXU^5,KE#<$8\W:3C=C@=AQW%4[;X=^&K2$Q1V<_E&SEL2INY3F" M1MSI][.":`,[Q!JE_;_!A]7ANY8[]=*BG$ZMAMY123[]:HV>OZUH?F:I?+2J>E=1+X*T.:T>UEMI'AE>22=6F"M!NYKB:6TD$MQ>17TDBW$@;SH_N./F^7`XXQ0!AP>,(;+7M4L,7 MEQ>2ZM%9113S@Q*S0A_D(7*(%4DC!.X^]1W'Q2MDLH;BWTR69GL[RZ=#*%V? M9B1(N<'/3@]^,XKHG\'Z(]Q<7(MI%N;BZ2\>83ON$R#:KKDG:<<8'!'!S4+^ M`_#;P0P-I[;(K::U4"XD&8Y<^:#AN2V223S[T`8EYXWMK'5;O4-E_(B>'8]5 M%N9E$7E%ST7&1)UYR1@"IA\1XQ;:H\FE3+-8RVD93S05/VA59&9L?*`&^8X. M,<9K8F\#^'IU<26#L'T]=,8?:9>;93D1_>]>_7WJEJO@2PFT^]ATL36_K0!+=3L;J6RUK3-7BU^RT^61[227?!J.TINEA(:58:/'J3O#+O>0OG`7`VGI@G0:# M;Z3Y1C@C=Y2D#LBEWW[QQU4[V&#GMW`I'\%Z`\C$V`"/8KISQ+*PC:W7A4*Y MP<`G!ZC\*`,=/B&SO9PC1IQ<7=\+*,.Y6-B8_,5PY7E<9!(&00>#4GA3X@P^ M*;^SMDTZ2V%YIIU&)VE#?*LOE,I&.#NY!YR/3I6LOA#1Q%IT6*8-$,L1R MA_C%/O+0*OVFV!,#Q'8UY- MX@T"Z\-:J;&Y8R1."UM/C'FK[_[0[BO6'F@5/.7#038#@#*M[^Q%,U'2[;7- M-;1+]_O#?97(^\C=OR_4<5MAZ[H2_NO?_,BI3YUYGA5RC'.2,^A65AG:H+!1QVXZ=RU<#J6G7=E>SZ;=)LO(7$;*,X;/0C MU![5Z>-&FL_!UEICR$R605YBJYQ@EV`^A..?2NK,ZB]BDGN_P,L.O>=RMI_B MG78+Y8[FV,B$$NABV$+W/I^=;.K10_98+^Q.;>XQA5&<'V^M58Y8-<@E>ZG? M84.V!0RA1[GC)]NE0VWB)/"G@""^N[8W#FX*6\1.,GG!YZ`8/(KYZ>']O:"W M>QZ$*OLGS="Y:Z(S()]1P'5_J?Z=:Y?0/'V MD^(+I$U%197S$`)(^8G/^RQZ'V/YUM^+/&.F^$=/+W3'S74F.V5OGD]V/9?? MJ>U=%+`.A)04?>9%3$NJKMZ%S5-5TSPOI3W5W\ M:>(;/Q'K\]W8Z;!90,WRK&,%O<^YI/%GC'4O%FH-<75Z&E+8***Q9?%>B07=W;3:A'%+9E!= M!U91!O&5WL1A01R"2,UXYJ;5%-5@RAE(((R".]`=2Y4,"R]1GI0`ZBH;BXBM M;:6YG<)#$A=W/\(`R3^59<'BO1;B\>TBO'HX&U5M+G:ZB:VN]H*),K;TW@\%=RC]*X*XUC7X;>QB MU.6VL9SXHM[>]OM-8""\4Q;@Y+`X(V1@]N.17LF`>HIGDQ!%01IL4@A0.`10 M!YI_PF7B"XU'Q#YE66FVQ/E6\26\1/1]-U*SUC3H=0T^=9[2< M;HY5SAAG'>KE48=4T]]1.F0SQFY6!;CRD'2,D@,.V,@T`7J**0D*"2<#WH`6 MBLVSUS3K^XC@MKC=)+"9X@491)&"HWH2,,OS+R">H]:TJ`"BF;U#A,@,02!Z M@?\`ZQ3Z`"BBB@`HHHH`*X37-9U,>+]7MK-&=M+T![RU@QD2W#EPI]\;-H_W MFKNZSI=(@?7H-70E+J.!K9R!Q)&2&VGZ,,@^[>M`'`V-SH=K\._#>IZL+F>[ MU(VY:^BYF:Z?#;6;(."P*X^[@8.!BLW4M-U+7/B#XSTK3'$%P;:R:"=IC']D M8C+2+MYW''0=>YQ7IQ\/:,9UF.F6A=9?.7,(P)/[X'3=_M=:FATK3K>_FOX; M"UCO9QB6X2%5DD_WF`R?QH`\TU&75]%\0/>7]K'KNB2ZC;AM1MW\NZL959$V M,O>/>H.T<$.?[U=9X7OYW\2^*M%D9I+?3KN)H"W\*2Q+(4^@8M@=@0.F*W1H MVF"[-T+"V$Y?S#((QDO_`'CZGW/-,TW2+?3'O9(\O/>SFXN)".78@*!]`H`` M]!ZT`>:^#?%5]8^#=`L8566YN8M3N6GN=S@+!,^%Z@Y.5'7@#I70:%XYO_$^ MIQP:;96T$<=K97EPEV[!VCG#,Q0CCY`%ZC#9[5T[>&]$:RCLCI%B+6(L8X5M MU5%W9W8`&!G)SZY-2OHFER7\%\^GVQN[=!'%-Y0W(HY`![`'D#M0!PT'Q$U& M\GU*WCM[16CT>ZU&WF0F1`T4ICVYSB0'@[ACG(Y[9J^,9M(MM%UB_M%O[]O" M;7S3J[HS$>6Q4KDKR6!+8R,''!Q7HEKX7T&Q96M-'L(&6-XAY<"KA'.67IT) M[4^#P[HMLL0ATBQ00PFWCQ;KE8SU0'&=I[CI0!QNH?$'4=.M]4C:SMIKRPGL M$W`,D)19VEO;": M1I9!#$$WN>K''4GUH`\I7QAQBF&_#I;J&&\_-@XX!YR!UJ6UT'2;.Q>QMM-M8K5_O0I$`A[\CI0!Q^L M>(SI?B73[Z]TX22C2;Z[4H[JZ11[7V;,[2S#;G(X(.*5O&^K6^D:->3VMDXU MR>VCLI(-S!/,B+MO4GD@@J`&&[VZ5VTVG64]Y'>RV=O)=Q(T<<[Q`NBGJ`W4 M`]Q5)?"^@KIQT]='L5M&GI0!S?BS6KA?A+=ZOJ^CA+E84 M:XL&G8`.)%!&]"#UYX/U[U7U+Q_J-CXON=*6SM6M;?5K#3FP:9I4F:1K M9"Q=!A&SCJHZ'MVH`\[\2?$+6;;0O%D:11Z?J6G1E[8-$S;XC+L65&SM<%2# MGLW!!Q6YXB\;WV@ZW%9>1:W$:S6<4Q0GNX8P>>:`.<\#R7#>*O&D=S,)#'J$84+G8/W* MG@$G&3SC/6NYJC8:/IVEF4V%A;6K3$&5H8@ID(&`6(Z_C5Z@`K&\4#/A^Z'^ MS6S6/XG_`.1?NO\`=K2E_$CZH3V/%+34[O3V4[LQG&<E687DLI66-V6.4%3@_I7U=7#QK6GLTS@A4<=. MATOA_P`326J'_`UYD4=;MA&<$Y(S MT-;%CX\L_#MLT6I%Y-RE4MHQND<_W0/Y'M7'C\-&SJQTMOYFM&HW[K.@T34W MLWDMYG54&21(<*`.H.>U6;3QOI?B2ZGL]*2=_L14_:U3]PQ_NJ_: M+K/B:XBOO$43:=IKN"FFQ/AW'K*WN/\`(KU>YL;*TTNVM;2VCMK98P(EA4*H M'&1Q^>:\>[;.D353I30P>*[RQEN;S2E.](`"S#LQ!QD#EAZG8QJN45>)T=O\6-,:WS=Z-1LT#PVL`(AM8@7V^I)Z9-9UQ%R22`?=\G\A5-@2,;B/<5Z M='!T*4N>,=3&564E9LHW%S?QX"Z9,FY0P,P*Y!Z'Z&L?4KB_O'WWMPK%0`%, M@.,?F:V[VW-QM,WVN[8`*H>;@`=!ST`]!67/I[JC.+:""-<;F>0L17I4G%`K M%.;47FTJUL#!;JMN[L)4BQ(^['#-W`QQ5&GR*J-A7#^X'%,KJBDMBST7X+?\ ME#L_^!?^@-7U17RO\%O^2AV?_`O_`$!J^J*^2SO_`'GY&U+9A7E9AN8/%OQ+ MDET?4;B'4[>TAM`ME(4N6%NR,`VW;@,0"2<5ZI7,W'A?P@+^*&XTK3Q=W9=H MT:,;I".6QZXSFO'-3SVZ;Q7X=TW2]+MWU5[G3;*P$IAA=XL^;B0(5!$F$.#N MZ!1@%LY_L&QS_UR%`%+P#/J=UH%W'K0N&FBO[B%?M,;*3$'.S[ MPRPQW.?K6)IUI>Q>.?B1=_8KU([F"T-G,;=P)6C@8'RSCYB&QT[]*T;;3/A[ M>R6<=O8Z8[7CR1VZB+_6-%DN!QU7!R/:M*Z\(>$;.UEN;C1;".&%"\CF(?*H M&2?RH`Y>U.O6WA30+N]O-?EU'4I;6.\A:)@L&%?=N"J'C!R-Q')*KT!-82ZA MXUO/#.CLYUT7G]B7YN#';R*QNDSY`;"_>R./[W?->B6GA'P??6<%Y:Z-I\MO M/&LL4BQ@AU8`@CZBI_\`A!O"W_0!L?\`OT*`.7L;OQ-_PE.@33_;9[2XM88[ MNW9)(3;R>2Q9R,;'4EOF!PRLJCV.#X;U?Q9?Z5HM]IES?7UY-;:F+L3Y:$%& MD%MU&T'>%&1R1NSG''HI\#>%B/\`D`V/_?H5#:?#SPC96X@@T&S\L$D;U+GG MGJV30!PEY?\`C$>&]1?33J\C+8Z*YB\/Q:F84\+1O;"2&3:+KS"&P7'^ ML"=%^F!7=?\`"#>%O^@#8_\`?H4?\(-X6_Z`-C_WZ%`'%WMUXF-U(FFMJKZ2 M=?L8[>94D>0VQC'V@DD%M@;/S'H<\UT/A";4YO`ER-:M[V:XC>Z3RKI'266( M.VP']!]6DO]-32+&26V98[E$C*F,L`R\C M';!X-7U\">%D0*-!L<`8'[H=*`.&O#XD37-4U&QL]3CU&3PQ"UHDN^0)/\V] M.FPN..".6P<=7@@,)WH[$;L;P#N.,$D`\<= M3J?AGP5H^GRW^H:3IUO:Q`&25XAM4$XY_$T7WACP5IIMS>:1I\7VF=+:+=%] M^1L[5_'F@#F/AY<^*GUC2?[;&L>5+H;M=?;(9%07*W&U<[@`K>7V[CDYZUZG M6';^#_#MIXC`(Y)('7U/.*Z6J=_I=CJ<:)?6D-PJ,642(#M)!!QZ9!(^A M(H`\RU#XL:A%I@O[73;<1#0X=7=)F;=\\_E&,$8]R&^G%=;X_P!6U#1]$LY- M.FCAEGU&VMG=X]V$>0`XY&#[^F>AY&Q<>'-$NR3EXTR.[NK.2;=AH9(2`N M[)YW_,<`?+@9SFM]_#VBR3M.^CZ>TS2I*9&MD+%T&$;.,Y4<`]NU2V^D:=:W M\]]!8V\=W.6)-OS!E=LWAS1&AGA;1M/: M*Y96G0VJ;92OW2PQR1VSTHD\/:-+IQ-I6C6&F&\:WTRQN+EF;#.D@`9@20!M`SDYR>..M=!X@\27]IXBL= M`TJWM7OKNUFN4:[9@C&/;\@V\Y.2<\X`Z'-:_P#8&D&YM;G^S+,3VL8B@<0J M#&@Z*O'`'4#H*EOM(T[4V@:_L;>Y:W??$98PQ1NY&>E`'(_\)SQB-D MVN_V&4&XR;S#YGFYZ%<\8QTYSVKBO!FKSVL'@F^GEN)PNB:C/*N\EI=CY&?4 M]<9]:]B.C:8;[[<=/MOM7_/7RANSC;GZ[>,]<<=*CMM`T>S>W:VTFQA:V1D@ M,=LB^4K?>"X'R@YY`ZT`<1;?$;4WTO3+RZTR*"+5Y[*&SN27Q#XH@\8+83I8F6'P[<7[6D)/ERSK*JJ-[$8!P.2.-S9SUKK%\+ MZ"NFRZW$"[&..JSR7!8F8"3;L!SP>&))SVXYKU6#3K.VMGMX;6)(9,ET"C#9&#G MUR..:J-X;T1HK>'^R+$0VZE(8Q`H6-20Q4`#`&0#CID"@#"TCQ??:[K5]'9V MUI'I^GS+%UZ2"&T@N;728[^">, M%T!9V4@9.'`QD/P#UVD5Z4^B:7)J,FH2:=:M>21^6\S1`LRXZ$]^.*JQ^$_# MT$3Q1:+8(DD'V9U6!0&BR3L/'3)SB@#B;_Q8WAW5M9NY+%+F]@T>SE,RO(!( M7D**"A8@`%B21SC/I5Z[\>:C;7XTU;6V>Z77H=(>4JPC*RQ&02`9SD8P5S^- M=>/#^C*)0NDV(\V`6TA^SK\\7]QN.5]CQ2C0-($449TNS9(IOM$8>%6VR_\` M/09'WO\`:ZT`4/!/B"?Q1X2LM7N88X9IFE5TC)V@I(R<9]=N?QKH:JV.GV>F MVJVMA:06MNI)6*",(@).3@`8Y-6J`"LCQ+_R`;G_`':UZR/$G_("N/H*NG\: M]4)['@]J"),C@]/8U;E`:,Y(``SN/&*R+C6;/1X6>Z<@L?DC49=SGL*H"TU+ MQ&ROJ+-9:>V2EFC8>7_?/;Z5]A[917)%7EV_S['G1CI=[!>:]/J$P@T*,2RI M\LMVP_=1Y]^Y_P`\U-8Z(-.N?MVMHK,6]K$D46/E M11T-7])CCNKFWBG)"$[3@XS4.C_R\JN[W\EZ+]1\WV8Z'1VLS:IH),@S,JD' M/7(KI$G6XTFVCD(VR1@*>F''^(K)M+*&RB:.'=M9BW)S4A=%MS8EL%P6C/IB MO!K.$JC<-CMC>RN8MS/)::EN(/F)\K9_C7_'%;/B2Q_X23P5YL`WWNF?OHL< METQ\R_B/U`K$NW^UVPE/_'Q"=DGJ?>MGP?J7D7OV>0Y1OEYZ8)_H:S4G%J2W M0VKJS/+6/F1JT;-AAD;<#BEL?#^JZX\G]FV4MSY>`[*P('L2<#/M6GXBTC^P MO$M_IA4>4',T'&!Y;<@?AT_"NMBAENOAKID>GR720)% M-8\/1_9KO2-55+YE0J'RDS`_*#M)R<\@5[/HFCG1?B+96WV^\NXSI+LANV!> M,%Q\OT^MTCBTK0]`6_U65-1%UNOFVLQ!)\M?\_SK.&,J.5HJZW[=_NV M->5):GE.K^!/$VE::^HWGA^>TLT`+2,P8J"?XNS&G2H\4QO3(ICD M#C8$P=P*XR3G'.:]W\4Z7;>(O#OB37(HO$&CW<"9NK:\=A#U>G@J\J\'S;K_A^[N.2ML>A?!;_DH=G_`,"_]`:OJBOE M?X+?\E#L_P#@7_H#5]45X&=_[RO0UI;,*\N\=6VL7AMO%>E:?<2WFB7ZFU@$ M. MW(.3M`W+AMN<K6$NI_V;'=1M>>0+GRAU,1.`X[$9XH`\H\,Z5J46J>##-I M>H1)!J>KO,SVTB")9%?86.!M#;A@G%)HMYXMO]+>WU6+5Y0_AB\2X66UDP;P M3$*/N_?V<`#J/6O9JI7NJ6>G-`ES.$DG8I%&%+/(1R=JC).!R<#B@#R.:^\2 MZ;HFAVNGPZU#)8Z5I8DB%I($5MRK*``OS';PP;I@8')QV?ANWUB\\4:U<:C> M:K%:V>I.+*WD4I#-$T0'\2Y=0Q)&#P16[+XIT6WLKJ]FOA%;VCB.Y9XV7R6. M"`X(RO4=?4>M.C\3:/*LVR^1GA9$DBVD2*7^X-F-V6[<<]J`.?\`(U>]^(FJ M1RW>KV^DVT-KM>-VM-4>P35WDET(SP?:K M5P_V@3LI."-JR>7SL7CI@&O7;/4;6_CF>VD+B%S'(-A#(X`)!4C.<$?G2Z;J M5GJ^GPW^GW"7%K,"8Y4^ZP!QQ^(-`'D5W_;%M/XWU'P_!KA>X72?L,QMYFDE M"DB7&YS_2_-_M_9Y6UO(_LSR/O_`-W._O\`>W<> MU>CT4`<-XCFU1_&UK8O-JEIH\M@6ANK"-F(NQ*I*O@$8*#`##!RW?IEPWOBD MZZ$=;WS3?WRW4>Q_*2T$?[@IQC.=F"O))/OCOX]6L9M3;3H[A'NU@6X,8Y_= ML2`V>F"15Z@#QC3W\87>B:A;WJZXTEQX3>0^='*A%\'D`53@;7V[?E'48X-+ MKFH>(+#PGIMOH*:TD]OH,4ZJ+>4J)1)&#S@EF`##8WRA2",\"O9JI_VG9_VL M-*^T)]N,!N1#_%Y>[;N^F3B@#S?6[[Q2=9UP62ZPMJ-4TT6ACMI"!"R#SROR M\KG=GKCVXJJ+[Q6]Q.\$IFCAPPMV)`WE,E3N]@"<5Z]5/ M^T[/^U_[*\]?MOD?:/)P<^7NV[O3KQ0!Y#XUC\27VA:_I.H+J=]*=+LAI_V6 MTD"7,F[]^S(H(W$[3M;H,8`KT#QI<:K##H+Z0MX2VL6HN1;Q,Q%N6_>;P!PN M.I-=510!Y7X;NO%1\6:2;T:R;26[U..Y%Q#((UB7:;?.1@9YPQY/K7JE%%`! M1110`4444`%>4Z]XCN]9U31VC"VUO:>,4TW:I(DDV(VXL=N.RG->K5D MOX;T.2_-])I%B]V95G\YH%+^8HP'SC[P'?K0!Q9^(>HR7=];1VUF"NGWUU!* MA,B*T$A4#=D"0$8)(Q@Y'.*@N/'VK:)X(T6^E6UO;F30UU&8MD.Y`BX*@_*# MO.7Z9P,'6ACA;1+`Q1P& MV13`N%B/5!QT]J`,GQMJ<=MH6DWDEFLZR:E:!4:1TVLSC#94C."RMA;2ZGJ&GYCW&3_`$9-P?KCYN1MQ^-=Q<:7I]Y:Q6MS8VTU MO"5:.*6)65"OW2`1@$=C55=(T"UOX'33M-AO#+)-"PAC60R,/WCKQG<1U(Y/ M>@#SRS\17?B#Q1X:U9Q'%!?:/?3+;QLW"@KM#\\D#OQU.,5<\(^+[R_M-'TC M1M/L[=ETJ&^,-Q-(P,;2^655SEOE52M=G!H/AJTU`+#IFF17I21E58 M4$FQC\Y`QG:2><<`-'9KY2)L!Y*H/3/.!0!R@^(%_+K ML^G1VUGL,-\T,R$R*K6Y`&2"`^<\@8VGC)(K/L?$EV8?!-_?117>HWVE7ER+ MDET\LK$CD;`VULD@GR[E/([B@#B]/^)6KW>F:A<_V1;S31:)#J ML,,+L,[]P*,3UQC.1CT]ZZSPUJ^JZM)J?VVV2."WF$5K?2IK+[%IU@EU&EH62%(]\8.1%D8.TX(V@COC!YJ7PUX4L_#/ MVK[%\@N-FZ-&D\L;=W(#NV"=W)!Y`''%`''1?$S51J<-E1)@?3^58>)-1T'XCZ\@$4]O=`,LG.%^;G'.<_C7I M_P#9UD9&``&?057ET#1Y[E[F;2+"2=Y4F:5[9"S2) MPKDXR64=#U':@#D?^$]U.>ZUE[725:QTV:]MI)6.#')!'N4MSR'.1@#(&#GG MB$^.]?6QT"9],LA)K\2R62QN[[/]',I#@[>2VT+@]"2U.@:0US=7+:99 MF:Z4I<.85)E!&/FXYR..>U1OI.A:A:1Z>UE8SV]DZ^7;A%*V[+]W:!]PCMC% M`'/^+O$.KV/@*UU*WC6PO[B6VBFCD`D,)D=5=000,C)&?Y=N><]!]:],N]+L+^P^P7=G!/:84>1)&"GRD M$<=.,#%02>'-$FD>271].>1RC.S6R$L4X0GCG;V].U`&!HWC#4-:\3W5G#I? M_$NM[^XL)9L@-$\2@ACD\ACN``&0,'//'9U0BT?3;?49M0AL;>.\F_UDZQ@. MYZ1@J* M,LQ.`!7E'BOXCRZW)O1;#PUI.E:(FD6%FEM9)C"1\9/J3U)/J:<79 MI@?-^GZ`+.X-WL09`.?X1VK5Q+@C8WWMP/H:]Z_X1?3/^>3?G1_P MB^F?\\F_.O:AF=&"M&+^\Y7AY/=GA$;2JX)0XSD@"K41:&Y9EX!(=3Z&O;?^ M$7TS_GDWYT?\(OIG_/)OSK59Q37V7]XOJS[G%32EK)+E>1M#,H[J>M8LMZ[I M$"Y\R%CM?N17J'_"-Z?C&V3;C&-_%,_X132?^>!_.O)=:%]#ILSRYK@M3?G1_PBNE?\\6_.E[6(6.%^)5F MMYHNE>(8E)>%A!,P_N-W_!O_`$*N"M]0OM.+-97MS:EAAOL[%2WY5[W=>'[* M\T.YTB0/]FG4@\\K[CZ8KEQ\)]'``_M#4<#_`&T_^)KNPN-I0I^SJ?TC"I2D MY1GL/:L?S)(9Q)',PD4Y$B,00?8U[?_ M`,*GTC_H(:C_`-]I_P#$TQ_A#HDGW[W4#[[T_P#B:ZEF&&6WY&?L9GB^I:S> M:C;O'J]YJNHQ"-EBA6Z(5'XPQZYQZ&N$NXC%+CR9(@>0)#DFOJ#_`(4YH'_/ M[J/_`'\3_P")JJWP+\*,26DOB3U)D7G_`,=K:CFV&IZ*_P!Q:ISZGDWP6_Y* M'9_\"_\`0&KZHK@_#WPIT'PSK$.IV$MWYT6<*[J5.01SQ[UWE>1F6)IXFMST M]K&U.+2U"BBBO/-#G/'D%U<^`]=BL5G:Z:RD\I8"=Y;!X&.?P[]*\R\06NNP M74FI:%::TMQ#X6M8[:6&"8L9AS%O:2&2\574B0+R<8_EUJ[J_@O3Y[%=0O)=8;4+\V MZ?;+6,K)8F-&*,J*N0`>#D$_-U%>E44`1(E9C@%F8*H^I)`JQ0!Y[I%UKUQXMN(]>?4[22 MW6VFMDM8RUO.AAQ*A(!7B0DG.",+@XKE6O?%6IZ7K=N5UMX;KP[)+$LL$B2& MY$SC'0!7*8RB?+T'->IZWXFTO0-/OKV]F)CL$22X2(;G17.%./>MF@#R6\N? M%=O%'XM3,*>%HWMA)#)M%UYF&P7'^L"=%^G%37MUXF-U(FFMJKZ2=?L8[ M>94D>0VQC'V@DD%M@;/S'H<\UZI10!QGA&XU]_`=R;I+HZK$]TMN+Y&5VP[> M5G=@D$;>37"6K>)'OAJ^GVNK2ZN/"#QR2W5M)Q>^:C,@WC&[(8A1QQP*]NHH M`\MC/BN'2M.UFQO;^_1=0A9[!XY(V,,@5'C8ORQ5_FR>!EAT'%G7G\6Z?K%U M:Z.U_-KSS5P0QR-^W<0N?3BO2:*`/*[^[UI=-T273KW6SI]]< M,;YYX93+:%H=J+PH?8).2>F>,XXKT;2%NET>R6]G\^Z6%!+,8_+,C8&6V_PY MZX[5>K+T;6[/7([Q[/S,6EW)9S!UP1)&<,/<9[T`:E%%%`!1110`4444`%%% M%`!44Z2202)%+Y4K*0L@7=M/K@]?I4M%`'E__"8^);;X>ZIK5S;_`/$QTL/: MW$9A^1IA-M:1>Y54PWH>?2LK7-4U&77?"]W<:E:>;%/JC6EU;R))F(6NY"W& MS=S@X&.E>QX`&`!BD1%C4(BA5'`4#`%`'DL?C;4I&T?5([2SNM1G\*SWVU8` M9&E7:=JD?-M)R2H/;CD4MWJLFIW7@:]EUNVU&.YU:*6+8BHT6;=MRM@X)W9[ M`C.#FO7*8D:1KM1549S@#`H`X/X?^*-:\2R&YOFM%@>*3S;4,/.M9UF*[-H& M0NS'+'.1D<'C!U/Q7JFFZCXH_LL6*M::H@E6)(HYYHOLY9B"1AW4X.#R50@' M->M*B(S,JJ"QR2!UH>-)!AU5AZ$9H`X#XAW:7'@[0KEF*B;5+"3]XNQN9%/( M['VJHGC;71JVQ+<7$K7]_;-IRJ-T<<,9:-^/FRQ"Y).#Y@QCBO3:8(T$A<(H M967C.^;PKIFK2^(+.5]2FLX3`(55X)7SYT0/0'(.TN.-K9)JEI7 MBO5-;F^'EW>ZEY`NKN_BO!#M5'>-9%C#9'4CMQDG(`.,>LB&,#`C3!;?]WOZ M_6@11C`"*`K%@,=#Z_J:`/(K?XA>)9?"UWK;&R1`NR:(D&2PD^TB-B4QG:L; M9^8]5S]TUJ^#M:TZQ\4^+3"7(/G2-"-H&T8R=I'IP:])\J/Y_ MD7Y_O^OK0(D"JH10%.0`.E`#Z0G`R3Q6#XJ\8Z-X.TTWFK700GB*!.993 MZ*O?Z]*\1\=:UXW\8OHMO-%)HFGZO=B"ST\,1-,N1F27V&1QQ].]`'T;320J MDD@`#//:N?UWQ+HW@?0XYM6OB%CC"1HS;IIRHQP.K'W_`#K@EL?%WQ8(EU%I M_#GA1NEHAQM`&EKGQ+NM3U.7P[X!LQJNJJ2);MO^/:V&<$EN MC$?E]>E7?"WPS@T^^&N>);MM=\0L0QN;CF.'VC4\#'K^0%=9H?A_2_#>FI8: M3916MNO\*#ECZL>I/N:U*`"BBB@`HHHH`****`"BBB@`HHHH`**P]=\7^'_# M3Q1ZQJD%K)*"4C;+.P]=H!./>M'3=2L]7T^&_P!/N([BUF&Z.6,Y##./YT`6 MZ*P-3\7:3I&JS:==R2BYBT^346"QD@0H3N.?7CI6GI>I6VL:5::E:,S6UU$L MT19<$JPR.*`+E%8Y\2Z2/$UM>!5FCC46NU?-VJ'X&O?FHSX5\4IX M;TF&.TF6_L;J[>.WGDCD@>-Y041]KY7Y3\K*:S2W2>ZCN9 M98?/MXR\<31Y#;V'W>5*_7BM*@#R"VT_4=5\3:R=.6;[5:>*(G%SYF%@@"(T MHZ]&!(V@?,2/3(N:?X;\313P":.0SQP:FNHSF1=M\97S;@<\X'3.-HXXKTN" MSM;62:2"VAB>=M\K1QA3(WJV.I]S534]&-%U?3 MO&FKW,T3_P!F7)ED1KC;YL;F0812I(>,J-PR,KPM=L[K$A=V"HHR6)P`*;;S MQ7=M%<0.)(94#HXZ,I&0?Q%`'E'BCP=K%Z_Q#CL='\V36$M#92*\2B3:J"09 M9@0/+;VC[);AP9 M@-^5R5XR!@#'3`K$O_#'B&ZMM5;2;2YCM;F73G@A%PJ,70YGE&7PN5P#SECD M^Y]-U.;3S$;._6&82QO)]FD4-YBI@M\IX../S%)H>J66M:'9ZEIP(L[B,/"" MFTA>W':@#@_$_A'4H;FY@T.VG>RDTN:*S59R3;7KS;S*6=LC(/WATVD<9`,U MIX?UX^(-8DU&.>6^($FF:I%.%CC)@\LHR[@+9F5/M+1F41Y^8J"`3],D"IZ`/(;+PSXEM_#VGR-;:BTR MW5D=5L))8BLZPY$A3#?.6.UF+'YMH'/-==\/M'OM&L=:CO;%K,7&L75S!&SJ MW[IV!7[I('';-=A10`45!:W<%[`)[:9)8BS*&0Y!*DJ?R((J>@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBL+Q-XNT7PAIWVW6;Q84.1'&/ MFDD/HJ]3_G-`&VS!%+,0`!DD]J\TUWXEW6H:DV@>`;-=8U/D2WG6VM?M>DZ#X>TKPSIJ:?I%G M';6ZG)5>K'U8GDGW-`'*>%_AC;Z;JA\0>(KMM;\0R?,UQ,,QQ'TC7MCL?R`K MSW7O$NM:S\;KD^'='&I7>E0-969R1EHU*XWIN`X).3_^NN<\6ZY/J%]I::;?R>'O"US9S36DY:2U1[CS M'&6**3_M!3@'/O7MVIZC::3IMQ?WSE+6W0R2,$+8`]ADFN=TCXE^$M?U.+3- M.U%I[N5BJQ_995Y`).25`'`/6@#S;49I[S58[B>[^W2OX#N=UTJ,HF.6^;!` M//7D"H+/Q!-H,-K%=W]W:VUSX'1+)07V&Y"D_*!P'&.M>_8'H.GZ48''`]J` M/G*TU.[@U"TU2X_M&XF_X0G,DMO(?/),Q!8.0<$#G)SC%6?#FO:GY?BVVM=9 MNY['_A'GO8%-Y).T$N`,"1@&W#OCC-?0>T>@Z8Z4;0.BC\J`.2^&]I)%X)TV M]N+Z^N[B^M89Y6NYC)M;8.%ST%=?2`8&!2T`%>7GPWK\>K:G.UDYL9O$B7LL M*R(QN;81!"&Y"RV; MM.)(FSO'(150%3\O(SCK<8#`=<@>PT4`<1X M&T75M(UC76O;66WL[A;-K8/,K@NL"K*2WYECVM:LK"/&6SA00-N.,''7GU>B@#QF#PQXHNQJRW&E7,,5_P"' M[VV\F>XCDQ)KGPS86.E:-=P3V^AQJC+/&H M2Y65"0J[OD?"EMXR2&QP(T\61W#)(I76I[F2Z+C8UBT6U(>N3@X&W&`5)]"?2**`.&U M_0KRX^(EAJT.F_:;9=+N+9I5V920LI3.X@^N"*Y'1?!GB_3=(FM[.UDL+A_# M`M-XN8^;P2L?X6/.P@!^W'(Q7L]%`'*>"]*GTW29S<1WJ&Z99&M+DQ_NFV!6 M5`I("DC/7DY/?)X!?!WBZ7PSI%IU44`>5S>%_$3:P;V"T:*_E\)+8K>%T+17H)SN;.26/..:]8HH`\A\9>!]9>ZU"'PYI M]P;--&B@L<7@&VZ%UYA(WOD-L/WCVX![5MGP_K-Y\0;R[OQ>?8O/AGLY8GCV M>4(RDD$@)R%)))`!#'!SQ7H=%`'!?#JRU;PWX4T'0[K0I(G_`'ZWDXDCQ$RD ME6."2V[@`CD8YXKO:**`"BBB@`HHHH`AN+B.VB\R4D+G'`S57^V++_GHW_?! MI-:_Y!Y_WQ7&->YB!)PP)C<>A[&NS#X958W,YSY6=I_;-G_ST;_O@TG]LV7_ M`#T;_ODUPHU%E8D=,A@/_0A3!?%21R5!.#_+_"NK^SD9^V.^_MFS_P">C?\` M?)H_MBR_YZ-_WP:X`7LA(`R2<#'KV_45H1:;J5Q&'DD6$$#[YY-3+`TXZR=A MJJWLCK_[8L_[[?\`?!H_MFR_YZ-_WP:Y*6POUR8[B*0]C?]\&N3.F:CMR;B'=_=+\U M2G.H69_?QD`8^;J#_P#KHC@J;ZMX@CT33C>ZE*+:'HK-UD([*.I/TKDY+KQ#XV4)<_:-$T%B,QCBYN5_\` M90?\YJ98.*?*M7V&JCW9V_B/XH-)?/H7@RT_M;5R,//Q]GMO=VZ$CTZ>_:F^ M$_`=D-6&M>*+\Z]XAD^8/,A\F#OB-3QQZX&.P%1^'H=-T2QCTZSMH[:!>C*/ MOGU8]2??PJ*F$]G%N6XU4YMCIJ***X34****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`KS/P4UW'>?$9[%%>\&K3&W5^C2>6-H/ MMG%=QK^KQ:%H=WJ4JAA"F57.-S=`/Q)%8/AKQ;/=^#9]>UBWCMTB+G='P)0. MX'KGBH=2*ERO?#K5*/MHK2ZCZM]%W/-O"=_?:KJ^BV-GK6MW&HWD%S'X MCBN7DVVI*G:P!P$8-]W;Z"L6U\7>)K>QM=9N)[_R?#`_L^^A,SDW,C^:N\]B M1^[Z]#^OT#H6K0:YI$.I6\3QQS@G:XPW!Q^-:6Q2"-HP>O'6J335T<\X2A)P MDK-:,^>-3F\0:3I_ANTU?7+RTTZXTMKE[Z2YN%!NW)8!W0%OE4KA3@<&M[29 M+_7O'?ANQO==U&>VD\/">26VFEMUN'65L.5X/(`ZCG\:]0\1>(+#PY8)=:@' M,3N(U")N.3_];-8?CW7K_2O#=MJ>C-&8WD0M.`#A#R,>QZ?C43J1BFWT.G#X M*M7G",5;G=DWM<[>BLO0-7AUW1+74H)989$DC895T M;((^M24R`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@#.UK_D'G_?%4-.=IIT@C4@L[ M]`*XI_$VEPR.J6]S<`#Y7W!`Q^G7%=-+&4\/3M*5FS*4.9FQY%I"/+$404<= M,U6@L;)+II'C!P"0/X<_2J::_8R)G[-<(#]TK*K9_/%3+JFG,Q!EGCXSEX_YGC]#7/ZGXI2TA:]U6^F2->C-*KMTX]`?QKE9?$/B7QC;_9UOKK3?#S$9+'-QN*`): M***`"BBB@`HIDDB1J6D=54=V.`*YG5OB+X0T21X[[7[))5&3'&_F,.,]%R:` M.IHKRZ7XXZ'<2B#0M)UC6)V8*@M[;:I)Z=>?TI'\4?%'6B!I'@VUTN(G/FZG M<9(!']T$$'/L?I0!ZE4%S=VUE&9+JXB@C`R6E<*./K7F)\'?$W623J_CF'3X MG`W0:=!T!'(#84_J:L6_P2\/2212ZWJ&KZU,IRQO+LE6/T'(_/M0!+XZ^)^@ MZ9X=OUTCQ+9_VPBYMUA(FW."#M.`1@CCGUK3^&_CV+Q_H+WOV5[:ZMW$5PG5 M"V,Y0]Q['D?K5ZP^'GA+2XF2RT"PC++M\QH0[CC'WFR:F\%^%;7P;X8MM'M2 M'\O+2R[<&1R>6/\`+Z`4`9_Q(19/"FU@&4W,?RGH>>,_C69K8B3X2Z?]G(-N M(K8L>JCD9S[;NM=AKVD0Z]HMSIT_"S)@-W5ARI_`@&N&\#P:C$=2\&:Y9&:T MA0L)"?EVL>@/<'.1Z_@:L?JBDGK2FI-=UHKKS1NZ??BV^& MMA M&K?PMHUY:O=RW-HS/)LE^ZB>@'TZ^M<59NL=Y'.T&;,R$NG8J,9'X`UT4[\B MYMSR<8Z;Q$W3=XMMI^IU/B*+*SMQ?/;VL%!3C!]`HY]\^U<]=-.4K=+>MSV,LJ4Y0I4.>S4^=WT245^;\C< M^'2-'H%RF08A>S"+'0+D9_\`'MU:^N^%=!\30^5K&EVUV!T9T^=?HPY'X&K. MC:7!HNDVVGVX_=PH%S_>/<_B>:T*Z*<>6"3/'QE95L1.I'9L\J?X17F@2M<^ M!O%%]I4F/^/6X/G0-^!_J#35\;^/_"K;/%?A/^T+1?O7^DG=QZE/\=M>KT59 MS'(>'_B=X1\2$1V>KQ17!X-O=?N9`?3#<'\":ZX'(R*Y;Q!\.O"GB<,VHZ/; MF9L_OX1Y#?%TLMLARNG:K^\0CT#\X_`#ZT`>K MT5Y4OQ4UKPULA\=>$[RRYP;ZQ'FP-^O'_?1-=MX?\:>'?%$>[1]5M[EL9,0; M;(/JIP:`-^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@#`\9(K^%[LG^':P_[Z%>/:AJEEI<0DO;E(@>%4\LWT4.,SZAJ$J6UE;KUEE+#`^@ZFN"T_P"&NM6#_;KRU%[J,;59A#>Q76G2,<*MY%L M4_\``N1^9KIW\.ZRC$'3+DGU5-P_2K:>#GFMB-:>&UMW&/*E7S&?_@-G\]CQIIEQXRT*32[B^>$,ZR`A,J"O;;Q3]G M"+7,[KR%=(Y77M173[\:1I#1ZSK)^]#:$M%#[N_3CT_,BM;0OA_I:SIJ7BV^ MFU;4@0R0PKMMX>^%S][Z\?UJ;P3X@:E M*-M:F48D$$8Z$H$`_3-3)I\\A`N-1N''7"N0/UKGM1^)G@S36/VCQ!;2,.JV M^9FST_AR*PC\6IM0G:+PYX1UO4(L'$HC\O>?][!VC'XUNJ"6]V.QZC:V%O:J M#&C`CDLS'D_C5M6^<#YN?7I7E:ZO\6M8&RST+1M&0_=:[F\QUQ]">WM55?!W MBKQ'J30:UX_O3$0<+IR>0N1SV(S^5:WC"RV&>K7NJZ=IJ%[^_M;5?6>54'ZF MN.U3XR>!]+^7^V!>2$XV6<9D)_'I^M4['X&^#;9Q)>0WNI3`Y+WERQS_`-\X M%=GIOAC0=(`&G:-86I&<&*!5//OC-6!P7_"W-5U,X\.>`M:OE/26=?)0\X/. M"/UISM\8=<1?+CT/P^AY)+>=(.>G\0Y%>I44`>!>.-`U;P]HOVKQ)X^UC4;Z M.`3P,\G']*Z_P"$7P[;P9I#:EJ1?^V+Z,>KS5['D@'W^\:]4HH`\LB^".GW;I)XB\1ZWK+`ABL MUP51C].3TXZ_C73Z7\-/!NC[3:>'K(L,8>9/-;(]WS7644`1000VT2Q011Q1 M*,*D:A0/H!4M%%`!1110`4444`%%%%`'->-+PP:.+="=]PV#CLHY/]*SI]*% MGX0LIR,/$XFE!'57X8?D1^50>)+Z.XU69),F&-X[8[1DX^\^/?H*UKSQ'87& MG30-9WPC>,IDP<#CZT`7O#%V+K0H1OW&$F$L>^WI^F*V:X;P'=[)KJR;JP$B M_AP?Z5W-`!1110`4444`%%%%`#619$*NH92,$$<&OEWQ9?:%XN\8G2-'T?3/ M#$\,IW:G>2FV)*G'W5PH)ZC.3[BOJ2LC6_#&B>([MR:I*J%C>2,7\S)/0Y/`Z#GM6Q_:]C_P`]O_'37D^I M?"UO#U]YG@_Q!?:42`_V>9O.A/7L?ZYJA_PE'C3P_P`>(?#:ZA;+UO-+;/'J M5Y_DM#^!-="44\E0<]ZR>)J1T:`ZG^U['_GM_XZ:/[7L?^>W_`(Z: MY)HAVCS]'Q41C'_/*3\&S4_6Y]A7.R_M>Q_Y[?\`CIH_M>R_Y[_^.FN)(`ZK M(/K3>.Q-+ZY/L+F.X_M>R_Y[_P#CIH_M>R_Y[_\`CIKAJ4`L<`$GT%'UR?8. M8[C^U['_`)[C_ODT?VO8_P#/H&:A>*1#AD(_"G];J+ MH%SMO[7L?^>X_P"^31_:]C_SW'_?)KAP"QP`23V%7[?2I9,&3Y%]#UI+%U'T M&FWLCJ?[7L?^>X_[Y-2PWD%PY2)\L!G&".*QH+2&W`VIDCN:M:=_R%9O^N0K M:G7G*23*:LKFQ11178(*0G`R:6FN@=2IZ'K@T`>?:@(]7^+UJ)!NCT?2C/"# MT$LSE=WX*IKH-1UFST:V\^^O5MXR<`LW+''8=2:Y;6KV+PU\6X;F[1_L>K:3 M]GB,?)\V)RV.?9JE\1VWA;Q=9QP7M[>VS1$M')$I5@3U'0@U,N:WN[FE'V?. MO:WY>MM_Q*EQ\7+6*YVVEE<7$(X\QG"$_0'^M=#IWCS1-3M8Y6OK:%SUAN6" MNI]/3\:\^/PGL3&1IOC5"`,A;J)6./[S1:7;?UU:^Y(]`\5Z59:_X/U2T%O!F>U=XY8U M'#`%E8?B`:A\)?8];\&Z-J-U$WVFXM(WE=&QE\#=W]:L>*+N/P]X,U*[9/+B MM[1DC0<`L5VHH^I(%'A/3)=%\(:/ILX`FM[2-)`.S8!/ZUNZ<7NCPVD/$M8R,&+2X M]I'MN^6H[CX,:#%";F_CU;7KQF(S=7AZGN=N.*]!)QS@GZ#-)]H"_P`3KZ\$ M5;5U9#.?T3P'H>@-]HCT:S2[8REEO)#L2U\QMX?T//3WK+TZ*V;39XWA:>^GE"6R1DAD('+>PY_SUJ8 MRLMRUM;W*/J$^5FO7.%W8^XC>_3=WH`9I+'2O%%NK/&3O$<@C)*KNXQ^!KTZ MO+=1A@:>RCLXFMYU0QRQ/]Y9%YY]<^M>D:==?;=.MKD'/F1JQ(]<<_K0!:HH MHH`****`"BBB@`HHHH`YW7?^/Y?^N?\`C68"0>. MGK^%7K_Q_P"#)'TC^S-4CN/[0O%MY`E@.UGT&]BR8R7'^RV:S);:>)B)$(([$*/$%]?Z##:?V7:M(L\>XW0B\PAO[H';ZD5 MU0M=-U!7,:,C*,G'&/Z5@ZW=W%MX:A,$[1$W6`5;!P`3@?C7(Z,J#?/V.C"I M>U6ESSZ?Q3XACE!GOKZ)CR`TC)D?3@?I6]X=\;SW5[!I^LN)H9F$8F8?/&QZ M?,,9&?6N@M?%%I>:=;V&J6C7DDI\J0LHP03@$^_/:O/5T8MXV.D6;>8%O2BM MUPH;))^@JE*]G%W/8M"HG&I"UOZN>MP6Z6UQ)"R+YBG(;'459J&2;[7JDD@& M%C4J#Z]:FK)V3=MCQH[!3M._Y"DW_7(?TJK.Y55F3G:<,/459TMUDU&1UZ&( M?SJZ7\1"D]#:HHHKTB`HHHH`Y7QWX6C\4Z`(5G6VO[:59[*Y/_+.4=,^QZ'Z MUYA8:LTET^FZI`;#68>)K.4@$_[2?WE/7(S7L?B6(3^'+Y"<'R\@^A'(KAOL M^C^+[%=*\56T;W$8(MKX_*Z_\#'(/Z&LI5HQGRRZ@9!'8C\Z1Y5MXFFDE6"- M1EY&?8H'N>!4\/PV\B;RXO'=S%9CHHEC=A[?,#^>32?\(7X8MKL7%R]_X@N( MVW*^HS?N$_X`H`;Z8IRJPBKMBN4=+TS6?B+X9PM],I^4J M#_`OKW_EWYA\7VI(#PW2@=]I_G@YK3MKZZCL8H72..3 M#@L#]15Q=U<9S_\`:OB"#BXT-9!CJB'^F:8?%$:D"[TBXBR.H;K^8%=*=1*( MS.JD`9X.*A?6X%U&&P:&1IY5!*J`0F?7\.:4I*.X&)%XCT29L/\`:(#C)+)D M#\JM)>Z/.0(M5121G#,5Q^=:;KIMQGS+.)PI(!,8(-5'T'090";,+DY^4L/Y M&J`:MM'/@07T\L(& MN-+U"XD=/^68;!Q[8[^U`%Q["=/X0?TIB6<\DJH$.6.,]0*YJ+Q)K%N<"^D. MWC$BAOYUUOA35;K58[DW?EEHBH5E3;G.:`-^"%;>%8DZ*/SJ6BB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"N6\5WBQW-E$2/W2R7.#ZJ,+^ MIKJ:\_\`%L%Y=^(4BA@F8>6L:LJG!R3GVH`@T"QFU*`VUHC0JW_'W=GDD?W$ M_K79RZ#I\NE#3O("P@?*0/F4_P![/K5RRM(;&TCMH%"QH,`"K%`'FNM0W6ER MV\=W'YLD#@P78X,B#^%O<5UGA.Z6YTEP@PD<[JHQC`)W#^=6O$-H;W0KJ)4+ MN$W(`,G<.1BL'P*D\7VU)8)$4E&!=2.>>.:`.RHHHH`****`"BBB@`HHHH`R M)P#XAM\C/R9_G7FU_)O\3:C(KE,W+CB4+T..]>F2#/B&+/:+_&O,%>6;5;MR M'C:29W,1"Y&23T/-94MY>H$>N,=MLI8GACDG/I6.3@9K4UP_OX5[B//3'>LH M_=/TK4#V3P_$UMXZ+%;0^9YD$K3J#MV MJTIRWX8%1:_J]S?&YM98W@6.=($5FRQQEF)^N%KACF%2G1YW)W_"]KE\B;L= MA`+5-(N+BUF\V-U(#'\JYS5;674-%\F!'DFMY!(J(,DJ>#^7!K8ME$'A"V7` M!D`/UR64]VM?F*$O9S4H]#C`;K3+Q6*-!<1$,` MZ<@_0UU^B:A;102:G>:9;Q7YRL&-9!GEM;LS3B.:?&06?>!^5D#H9(6/[Z/E M3_>'K6L:D*D>:']?\.>=6HSHRY9(BDE4$2#F*4;7'H:GT,;;V89SA.H[\U1D M=3DC_5RC)'H:NZ#_`,?WM[KD5YN-^-$2)(H,?,ZXQSG=C%;6G6P M2-;^X3(/_'M&>Y_OGV':H=-L4NY6>88LX.9"!CS#V6AO$-C>3R$2D!3MX0[0 M!V'M4T(0C:=1I+I<2:6YI+,0Q.XEBP_B/\` M2G:FLCPVFE0\SW;"27'9?X<_S_"K%TR(RV\(Q#`OEH/7'4UA\=7RC^8NI8BE M4*.<(2<9[*.]O>ZA/$=+O-,6\6[A\LNR[?F M!!QGTKEHH@Z#S54L.A!YKJ?";/\`Z8C2.ZJR;0S9QD&MJ.*I:;>^)[B<1SP6FH6MC:0^64\OS0IW-SVWG(QR0!D#IWLV MBZ7<73W,VGVSSN07D:(9?'3=ZXP,9Z5'<>'M&NGO6N-+LY6O0JW1>%3YP&,; MN.<8'7T'I0!RK>+?$1U/1-)?3;2SOM1^V!C<$E4\@*R/A6SAPRG!.5]ZT=-U MNS\6?#JWUK5#)I]G=6QEN0DS1[5&=XWC#!>#R"#BIM1\&65_K>B7H\N*VTN. MXC%H(05D$JJ#SGC&T'I6K-8Z-=6O]B3VEA-;I&I^P/&C*$!^4^6>,`CCCM0! MS?PZD@L_#:V\FLI=B6\E%LDETLSQ(262$OD[G"8)&>,^F*[:LJW\-Z':+;K: MZ/80+;2F:%8K9$$65<[D20,RXX.0/? MBK5`!1110`4444`%%%%`!1110`4444`%%%%`!1110!C7MP+35EG9"X$8'!Z9 M)I7FTG5&5+FW1W)P/-C!(/UI-0027LD9Z&)?YFJ,K2.R\1R00@K$(D*J3G&0?6L#!=I&'ELNSY55P:F@M]-L[7@%0`5'L,5%9?Z M'937S#Y@-D>>Y/\`]>I=:#37\,*?>*X'U)_^M1JX6&.SLUZ#+'WP/\37+5]S MFFOLZ+UV-*,.>HDS+NR)ES>*\.:NQ MM+IK_0;>]4YF@/EN?45S>F^'+[4H%N%,4-L>DDC=??%='IR66AVTUNL[WIF( M+!0`OX5TX9.E>53W8M=?P\SFS&=*<.1.\DR(DLY"`D,<[0,G-:FA`K>2JP(( M3H1C'-4(M7EGO([>T2.$;@"$7/YFMJVD$FN71`X5`OU((KNPE2%67-![/L>* MXM;FI1117KDA1110!0UD;M&NQC/[IOY5Y]:QR/L6-?GI->C:E_R"[O_ M`*XO_(UQ6B^58Z?/RKE/EL[)I!C>1M3!S_@:?Y[:O?27DGS^8>^UJ489CY4`/09_P%(AW*#Z\TZ]'V+3K:P7AD0!O=VY-1J096`Z(`/QHI M1Y8:[@CQOX\IMNM!E7()CF4D?5?\:H_`R%KKQ7=[V+*D"LY2P0S@": M&.0#(`=`P_6EM+*RLIC-;6EO"Y0AFCB"D]>N*J45)69<)N#NBSJDZ;;]"=TA!Z_YYKFJ\O%RO5L92W+MN4`Q'&WNQ MKJ?"7W[_`.J?R-$OOW_U3^1HPO\`%0+&?#)@M[D6MO=W^IRZ3#-'B0VD:%HMN\;0H;G!&2I&VO3[WPY!?WCW+ MW^JQ,^/D@OY8T&!CA58`57/@^S<@MJ6MDKDC.J3+[V77;?5;O5 MDMXG\&KJ2Q,,P"=B=_RCYB!M!(!W<=:Z+P#XJOM?U+6[.]GCE2T%K)`PV[BL ML*NV=O!`;IQQG!)Q5V/PWHKF)8];U(EPT<876)3D#&5'S=N,@597P;9(+_&'CW2%OX[>"34+*9Y4&Z8"-0W[OD;3D8W,O$S0ZO;K);R7T,T4ELR21B&XA:23Y8G(PLA5=NV0$AE/7.!5O/&]W'+>: MC:^0EP/",>H+-/:HDQE\QAM;_9/7;DCYN.HKO3X+L"K`W^LD-]X?VG-AOK\U M/'A"U`P-4UP`?]12?_XJ@#AU\=:VMEX@!U&S8V,NG;+APB%4N(T:3;_"2"QV M[OQSBNJ\-ZI>:AX7U2\U6[6:$37`ADMI(V<6ZYVDE/E$FWDC/!].E)JG@C1] M1A73[W5=683'AHTSX<:/I$$D-E>:M"LK[Y/+OWCWM@ M#)"8'0`=*`.4\/)XCL;F+2+/4-,U6(:5*-&U>*,>;`BE-L";!8%A_M#6B@Z@ZG-R?7[W4GF@#BKW MQ;JEMKFIZE;W,TYB\,Q7UG931A-[MDL2@YXVAB`<\8SBIU\7Z\!H2OJMB;?5 M-16&.YA*.WD-#N.>-H<,..O##(]>MB\,:;/-*(M8U>26$^7)MU:8LAZX/S<= MCBI$\&V<0VIJ6MJO95U28`?^/4`(=9TJ#4;N&6.]T-[UT6-5VRI M<>5QCGE56Q'+4<>5'J4<#"=-3;>IZ[:>)-&F=+>&]4MC"[P5S^)%;5 M>=>%+'39[*\O+VV\][8@[2,C;CTZ$]:Z\:T5`+V%RJXSE0&Q^1KNP\Y3AS2. M+$4X4Y\L>AH7%S%:6[SS-MC099L9P*Q!XST0R;?M#X_O>4V/Y4MZ-&UQHTN; MB12G2-I&C_3C-9-[X3T2WE2,WMS#(^=JG!#>PXQFIKSJPUC:WF.E&BU^\;N= M9:7]K?0F:UG25!U*G.*C75;!L8NXL_[U9WA[2X]+TR=(6ED:1BQ\R,QMG&,8 M-<7=KJEFV;BSDB0'&2F0?QKFQ&+JTHQDHWON=&'PM*M*2YMMCT5[G3S,LK2Q M&11PV(P8-(L(2,?N<^O4U5M0MW M.D43!BS!>.<9I?&%P'U!H5_@PH_`?XFN>+_=3D^ME^OZ'2HVJP@NEW^ANHAA M\&V,6""X7*]^%;.%5V7,J$R;>_0"MO4(REGI=LG)&T<]>`*PM;=KK MQ%(`6V0J$^4X]_ZU6/LI2OT45^%SPG+FDWW;+WA^U6"1YC]V!"Q)[DY_^O6A MH;%KV9B7MAH/A.6RNC_H:QB& M7C.2_!)Q]:]&KQ3XG:]!I=@'U"W-S;W$XC>/CD07U MGH=M;//HFK79N`I98XGR!@9.X\$#BO;_``9:$V"ZC(,M-&HC)ZXP,G\37`Z- M::%XEMI1HE@EE]IC:"7"C>H[G&3Q7K.GVT=C:6UC$1"[JB\EB`!4<@2^\5QPX7D_K5NW< M0)/>-]VWC+8]3V_6L_1$\K3;N]D;YYCY0)[CJQK>M[TXT_G]QNQ+J=(I/G@!95& MUB/FQD#T4"KVI^*=6L?&NH:>TR_8!`YMGA".(G6W\QEF!^9#_$#RI!`QFNYN MK^SL0OVNZ@M]_"F60)GZ9J%M2TN,)<->V:^8"$D,JC.-\2O$*: M-+>G4[NW:<^H/<#BNG\2>.;W3?&<6GVE[;&"/4;"V MGB*`;(Y]V_<3R3C:05.!WR>*]!DU"SBMTN)+N!(7^Y*T@"M]#T-))/8B`W;R MP"'@F8L-O!X^;IUH`\8T*:(ZGX8Q(ASXJU/&#UX?_$?F*[OQ#X@U"#QK;:#% MJ$&E12Z>;J&ZGB#I/*)5#1)K:TF*A9]3O;.:UVJ&MH8DRDN>O.%)))!\P8[5QL7Q,\2RZ`+ MXZI;K,V@/J>T0)A94N?*"CV*]0ZB-!(7"*'(P6`Y-1Q7,$SRQQ31N\ M+;9%5@2AQG!]#@YH`\T\2>--8L]1UE+._@@CL]&AU&WC,2MYTK,?DYY*D#&! MSSUJ.^\?:U:^)YM/DDA@5=7TJW$,B#7P-Q&,XZB@#R1?%NJ:-9^)[EKYYI$\4K M9R-,5Q:6I$2^9C'`QP"?ESS@\YT8==\4WFO:9H']K:?;7-UI]Q,US%$LZ[DE MPC*.`25X8=,@XQBO0TDM9I)XD:%W!Q,@()&1_$/IZU.JA5"J``!@`=J`.`\< MG;X]\#M]L^Q@27V;CY?W>;N:N/B+XDM]"LKNYD@MYY]"N[Q0T0 M`DEBD`C9<]F3#;??BO71+:W4DL`:&5XL++'D,4S@@,.W8\U.45F#$`E>AQTH M`\/\>ZVU[I'B>"3[&3)X?L;EI4B42,S2C@N.2HZ@'IN]Z[O0;ZXG^*7BNUFU M"1X(K:R-K;L5V[65RQ48R<$]1Z\]L=O3=B[R^!N(QG'44`>4:AXMO-,U#Q%] MB>QMWB\06=H76!`TBR*H8OC[Q'.">?E]JA_X2K5-1L_#[W.K&*/_`(26:QGF MC$:B2./>4W'&W/RJ>``?3I7K]-9%;&X`X.1D=#0!YWH7B_6;[Q-IUI6W'//`))P=XQBJWB74+C_A,/%%E<:C(EK'X:>6"V8J$+,)` MQ'&3]T'\/3BO3!&BNSA%#MU8#DTNU=^_:-V,9Q0!XIHWC?5]$\&7L-M+%=C3 M?#^F7%NIC!,/F*JOG;R0H^;GGCWKT_PM>7]]IT\M]<6MR!<.+>:WD#[X>"A8 MJ`N[GG;Q6Z1D8--1%C4(BA5'`4#`%`#Z***`"BBB@`HHHH`****`/+OB1_R& MX/\`KB/YFN0CM0QM*%-0=[HX+2M>O=+,AMFA`E`#JWS`]>U=%#XXR0)["$C_ M`*92%?YUM_\`"`:+Z3_]]C_"C_A`-%])_P#OL?X54*&)@K19-3$82H[R113Q M3I%RN+B*=,XSOC#C]*E-]I\L!_L_5DMR/F*NY4`?0]_I5M/`>BHV2L[#T,F/ MY5*/!.B#I#+_`-_6KHC]9ZV.:7U5[7,.35=*C;-UJ=Y>L`1MA!"_F:>?'4<$ M20VFG'RE&!YLO;]:VO\`A"M%_P">,W_?YO\`&C_A"M%_YXS?]_F_QJ91Q+ZI M%1>$6Z;,E-?\-ZG\M_IX@=N"Y3(_[Z7FISX3T;45$FG7I48S\CB0?XU?_P"$ M*T7_`)XS?]_F_P`:6/P;I$3AXUN$4OXD4_P9?UB$/X4Y+\4- MTGPU;:)))=/.T[*N1E>K5ZC;VPMX?+$DL@]97+ M'\S5$^'M,-\MX+8+,K!@0<#(]JSKX'G453LDNA5#'*,AD MZ$L:Y\3E]6M4OI9N[_KT.&,TD9VL,JRPVR?=B0<4_0?^/N3_`*Y_UK1GTFWN M)FED:33\DJ!AW]:]'K@-5&+^3W)_F:`,/2]"TC1[J2XT_3X;:24`/Y8QN M`Z#T_*MN`D[1G)=B['V%4ZOZ;$T\^!U8A10!)K4IM]'@MA]^YW6FCGFI$SNR'5<=S7@-W M=S,MP!>JQ,/]IC72^$O^/J_^B?UKFHF!.#.7/H.!71>$B?MM\.V$/\ZZ,-_% M0UN=91117KEG`:7--9?$WQ5+JSQI*\%O_9;3N$1H`K;PC'T?[WOCMBN3U36[ M/5M$\`:EIUE%I=O<>(/.AMY7QM!:3R7GP!U*ZN+&'3Y9+.3=;Q',:GS",IU^5NJX[,,5Z)9W= MCK.G17=K)'=6)/\`ZQQU;CD`C@;#G--C\:ZF^B>(-7N-8LK*33S=0MI\]MN:!E<" M)OE.X@J1G(()88P*]$L;NQU:T@U&RDCN()%W0SJ,@J>X-3F&(E\QIEQA\K]X M>_K0!Y!?>+]7O[3RI=2:W2U\56=J\T9C#?9VV/\`.P&W@]Q@'&#D==!?%-Y; M>)M6LK46L,+Z_;VD]Y%%&K(CP[MSG&&8L`@+`^G7%>GM%$`Q**`2&;CJ1W_2 MJJ:EI]WJ$^EK-'+4 MI,GV8$Q2+NX`;&3V(Z5T^H^*]0MOA!#XH@2*2_DT^WG8[2.U=$FN^+;?4=&MKJ2WN(M4BN+5)K10Z1W*DM'(S8P5\L$D`=5;''% M=RM_IQU)]&$D7VL0"9K;;SY1.W=CIC(Q^%6SY<:`G:JIT)X`H`\MU/Q==:+K MOBI(5MDAMM3TV">\2!!)'%*B^9+(0,,5^Z">G%6-2\4^(K+6;+1K;4].N96L M&NXKV0+%#>.)]IC_`(ND?4)R6.>@Q7IC*KJ5905(P01UIIBC(3**0G*\=/I0 M!ROB_6;_`$W6O#=E:7BVL.HW4D$\C(K%5$98$;N`H-,M=37? M($0N'&L7%@U@J`-Y,<.]91@%@6.&R>,.!CO5&+QWK">"[37VU.UF^USVL-U$ M(E5M.W2%9B?0#@#<.#R89-J[\8W8YQ3-L(+1;8\R99DP/F[$X[]J` M/.8_%7B.UU[1+74)[6>WN"D4[:>R2,&>9U1W4@'8RJ`60X5E;M@5G0_$+78/ M#MQ/>%&GBO;2*:[C"-;);S,V9HW`QC:.C#*DC.:]9\J,%2$7*#"\=![54TV^ MT[5K$W%A)%/;.[HQ5>"P)5@1ZY�!P4?BKQ':Z]HEKJ$]K/;W!2*=M/9)&# M/,ZH[J0#L95`+(<*RMVP*],J/RHP5(1FRSZA*423`8X(3(-=?10!PPT2Z89"2D?\`7.M#3[.;3HI[AX9"T<;,@VP'$:'9SQ6M[=2PRB:3]TH9"#SRQI)-*N))&VN0\3@B`JI(QDUT=%)JZ`\NCTK477Y;&X.,9_=D5(FD:DIRVFW#?5#7IM% MR8K?\+V=W;SW4MS;O"L@4*'ZG&:Z:BKIX6,)'IXXVC$C1^=YJDKA>`2HZ=\#N!7?44`>) M>&E\8Z/X?:UTZUU5'3PL)(8;BW?:EX)7&%##`?9C"]^#@UWGA?\`M&7PW?S7 M5Y?2NBTV\UZ7Q/=KKKZK:RVR6\]M'9Q%X+A? M)Q*G`*D^82><'A<'%>BT4`>'37/BK5/#7B&UE76I4N-!CFA62&19&F\Q@_;A MBN,HOR^@(YK3RMP;!.0$^M=Q10!XK#-JL=_>:U%#X@,Y\(Q1ORT4`>8?VIKW_"?6@M_P"U_P"S1JKVTHGMY`OE?9P5XQMV;QD.?F)) MS@==;Q'-JC^-K6Q>;5+31Y;`M#=6$;,1=B525?`(P4&`&&#EN_3N:*`/,8KO MQ0^M^5*EXSM?7ZW<1CQ7] MOX-F@A,UJZA;GS@RQDL,;N,@'^5>WT4`>2I>>)$TW3+F2[U672KN\A^VB.WE M6XLU,)5ADC>1YN&)`P.@XXIVHV_B#3_$.L3Z8VJWEXOAR-;"XGCL44`>617GB&&ST>>2\U&XTFZU%&NMEM,L]O$8C^[)/[PKY@ M!)`XSC..*T?AK<2Z9H5II-WI^I1SW-U>RJ\MJZJJB4L"[$#&X,"/6O0J*`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B )BB@`HHHH`__9 ` end GRAPHIC 15 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#EA<`(!`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'_ M"TU33T9&24-%.2XP&`````QM XML 16 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL
 12 Months Ended
Sep. 30, 2011
Business Combinations [Abstract]  
NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL

NOTE 11 – SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL

 

On January 2, 2011 the Company entered into an asset purchase agreement with certain private companies owned by Michael de la Garza (“MDLG”) whereby NSC acquired the rights to proprietary medical billing and practice management software developed by the private companies.

The Office of the Chief Accountant (OCA) of the Securities and Exchange Commission was consulted by Company management to insure that the transaction was recorded correctly on the books of NSC. The OCA considered the facts and circumstances as described below in their deliberations.

 

January 1, 2011 Acquisition Of Software A Business Combination Under Common Control

 

On August 24, 2010 –National Scientific Corporation (“NSC”) signed a letter of intent for NSC to acquire the Private Companies’ assets.

 

On November 19, 2010 – NSC and MDLG signed a revised letter of intent with the Private Companies.

 

In accordance with the revised LOI the following occurred and on December 1, 2010 the NSC reported that change on Form 8-K:

1.On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.
2.On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.
3.On November 30, 2010 – 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.
4.On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.
5.On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.

 

On January 18, 2011 the prior CEO of NSC resigned from the Board of Directors and a Form 8-K was filed on February 8, 2011.

 

On October 5, 2011 the Company issued Absolute Medical Software Systems, LLC 30,000,000 common shares in full payment of this promissory note.

 

On January 3, 2013 the Company engaged a valuation expert to assess the value of the software for impairment purposes at September 30, 2011 and 2012. The Company valued the software and source code on the development cost of the software provided by Absolute Medical Software Systems, LLC of $4,296,000 for September 30, 2011 and September 30, 2012. This valuation was done by an independent Certified Valuation Analysis.

 

Prior Public Company Transaction

 

Michael de la Garza (“MDLG”) is the owner of three related private companies, Absolute, PayMed, and MedPay (“the private companies”) who own and operate medical billing software. On September 10, 2008 the private company entered into an asset purchase agreement with a prior public company. On September 10, 2008 prior publicly traded companies, purchased all the private companies’ assets, for 10,000,000 shares of common stock per the purchase agreements. On the date of that sale, September 10, 2008, the stock was trading at $.10 which valued the transaction at $1,000.000. This value was based on the software before the update to operate on a Cloud based platform. Management considers the price to represent the fair value of the software at that point in time.

This transaction was an arms-length value since MDLG was not a shareholder, officer or director of this prior public company. On June 9, 2009 the transaction was rescinded and the assets returned to The Private Companies. The private companies impaired the GAAP basis software development cost to the value of the prior public company transaction value of $1,000,000.

 

During the period of 2009 through 2010 the software was updated to operate on a Cloud based platform and had additional software development costs of $200,106.

 

The Office of Chief Accountant (“OCA”) has determined that due to the voting rights of the Preferred A shares that the transaction occurred between parties under common control. Accordingly, they have determined that the GAAP basis software development cost of the private entity sellers should become the cost basis of NSC.

 

Since these costs ($1,011,223) exceeded the transaction price ($1,000,000) with the prior public company, the prior costs incurred have been impaired to the September 10, 2008 value of the share received in the prior transaction.

 

The related convertible note which was subsequently converted to common shares has been discounted to the cost basis used to value the transaction which is less than the fair value of the software as determined by independent appraisal.

 

The cost basis was determined as follows:

 

Cost Basis for assets acquired  under Common Control  Cost Basis
Cost basis of Consideration:     
Absolute Medical Software Systems LLC development costs from inception  $1,011,222 
      
Impairment of software on September 10, 2008 to value   (11,222)
      
Total Value at September 10, 2008  $1,000,000 
 
Software Update to Operate on Cloud Based Platform		     
Absolute Medical Software Systems LLC development costs  $200,106 
      
Total Cost Basis at January 1, 2011  $1,200,106 

  

 Purchase Price Allocation  January 1, 2011
Value of Consideration:   
Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control  $1,200,106 
Total Purchase Price  $1,200,106 

 

Cost Basis of Assets acquired under common control:

     
Assets:     
Software source code and development costs of software  $1,200,106 
Cost Basis of total assets  $1,200,106 

  
EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"$YM"'"`(``((;```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%NVC`8A>\G[1TBWT[$ MV,[:;B+THNTNMTIK'\!+?DA$8ENVV\';SPDMJBH&0D/:N2$BL?_S8:3O(F=V MO>Z[[)E\:*TIF:S6UKHIRYF=^MT>TOBJ0LLN]DN'+)*IIWKVDK'1,J?3?TN9?*2D*>=XYK0 MM"Y\2AB,[TT8GOP]X&7?CW0TOJTIN]<^?M=]PN#KCO^V?O7+VE5^>,@>2KM8 MM!75MGKJTPGDP7G2=6B(8M_EXS7O=6M>N0_DCXL#'R_BS"##[QL'G\@A03@4 M"$8HH"@&%6@*%6@.%6@2%6@6%6@:%6@>%6@ MB%6@F%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6AF%6AF%6AF%6A MF%6AF%6AF%6AF%6AF%6AF%6AF+5`,6N!8M8"Q:S%_S)K3`T#\?'SW_^4<P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B]. MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4 M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^^CSY MLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P`` M`/__`P!02P,$%``&``@````A``IZ.`0S`@``J1H``!H`"`%X;"]?$TCZG$#PG,#2D<`X$Z1U;:"N MC70O86`OP=*)R3`Q[:*)F?*K`7^QG-.E/OUBB"6=M_C&PO=V]R:V)O;VLN>&ULE)==<^(V%(;O.]/_ MX/%]%_R!\S$A.PZ(U--B*!))O4JE1M1?RFWLH`[Z[+:"`7#ZKU7 M;RLIDCJ54FWRGMOO![V-R`K[H'!?_1^-Y?#E$9(GM-A8;\/V1VU8N:D623,ED:`]@6.YEZT*UVS[MLASNWGE] MS^X]GH*<5U8BUV*7*P;A'=4A7Z[OND'S9).*ETSNZ_.D9FA]O&9%4NZ;1R&U MGZ>1!P;V^M9KEJ@4[O?[_=.UWV7VGJKC19#O(7V=05A'?UN%#N^8$0Z5XJ10 MF?KD47'(?E9""9NL1Q"9[]M6=9_!KRI*G,8YEGD2N2A6DM/F\1I-<]$L][]G M\;FHH#:I5-E*0-9/2WM(0V<7KTR54)#90M6\7//95E:'FJ+YV+E_Z8&FL&I: MY@D4GI-_=I``-!42>PIZ<#6UM?1(U"F?`!LX_`#-U^7&UN,9(]SA8T)'BVC. MHEG,9Q/^M*113"A%+GQLX^;2AI9Q^5-((]H(S!>$DIB%6C#$,MC-K5'&X\^S M*'[FHUD\(HN81Y0N2-\&!YC-! M?@:PQ\Y^KD#5.C=\0?X,&5B9APOVQMDBC&DX8A'6<;#.%:Q:YY:3OY81>\/3 M\#9QKAC5T^XX9;/1'U!F<``1S0FLWM08ZWAX^2M@M8[3YU$,\PEGX=^MV@[P M1G$Z<'4XG4W8:[@@/!Q!'#32G#'L`N/JF'EU7*#DB4(FFJJ0%_C$=1U@5!TS MJYV<00U.O6.`>75^$EBHRED($PLM^:(!ZM1V$MMRA)%US!&?PPHPL*X96*>KYBTW&&'7C+"IZ-H2-H01=CL0[NJ9V!"\7L]; M^O"NO6J^YG;'QQ(99AJUY%FH19&:Z$T7,M(<) M@H$IM$XA')J'*8*!2:BS#>.B>9@B&)B$.OMP2PACY)FY/C9BJ+<265[S6%3- MZ>$'RG6`>Z)GQKISM[9RC9LB'.),D74*M7*-N?8ZNG2[Q\.);E5N)&PU%)F' MN8:!R=!E^SCIM%*-N?;,7%\*,?'!1Y5,,FP(8^V9L>YL13C5/L8:!L;(NGH: M3G6`:^:;L3;VM(G(*A29CZF&@=&0X86HP40Z`2Z]KZ'NZ:X`AWHX,J_@WT;S MU1S7'7\0'%XNO>,?KL=_`0``__\#`%!+`P04``8`"````"$`./Z!S[,#``"V M#```&````'AL+W=OJ42?5I\_#`_SKMN:"K$N(^P6/27[B;A\&]!7+!9=\HT9`YQNAPYBG_M0'IL6\ M8!"!3KLGZ"9#]WBVP@GR%_,V07\8/;T_N^.&S8,4W5E/(-M1)5V#-^9.& M?BWT$"SV!ZL?VPK\$%Y!-V1?JI_\\(6R[4Y!N6.(2`F4CTR38F\?"\5K_X:$#Y2 M&9+P2!*!^N-\.`HG,8Z3]UE\HZ@-\($HLI@+?O"@:V!/V1#=@W@&S*?(C(XN MUK="A1@UR;UFR5"*/(A"0GV>%TDT]Y\AI?D1LAQ"L(U8G1"Z$J"NDPB!]R5> M3OI)B09K);H(6MK2#`!W)RUT]KV`2#N(I002=+L2#@+7Q^'\VUN`,053GC6-G8P.)VTI%XV",SP&WRE9]0(BG/>66+NC>VQ.B MP8ZNQ-%E($FKZ^ZB,`MQ15EB*]-]'<&YO]X\>I&CT$G,TD"N*;005Q3":>GG M[C:%>I&C<.+DT$"N*;005Q3JUY?C#>_G4"]R%$X=A09R5(B3$+LGT@)$,0[/ M5F&UW]06>+VX&FP+2P-'F(&88W$7Q4D2.M)7%@(NK9^Q/1+]9:QX_]R]A;M]/"@3_K6 M/2C5Y4D[+XZIWY@78\QPW6AW M/;T/]4O>&5_J:ZL>][L)N#4V9$N_$[%EM?1*N@'*8)1"GH2Y=YH'Q9OV[K;F M"NZ+[<\=_#^@<.,)1@#><*Y.#WJ#[A_'XA\```#__P,`4$L#!!0`!@`(```` M(0#7&%1#,@,``"(*```9````>&PO=V]R:W-H965T+CQ_F>R&?U98Q[8!#K5*RU;J9>9[*MJRBRA4-J^%.(61%-5S*C:<: MR6C>/E257NC[8Z^BO";&829O\1!%P3/V*+)=Q6IM3"0KJ09^M>6-.KI5V2UV M%97/N^8N$U4#%FM>(D'3HMYSJ$"C-V1K$C)0S!;!0'Q%O,VH-^<[=79;T=MQ?Z3Y/E7 M7C-(&_J$'5@+\8S2+SD.PQ=-/;0>^2R=G!=V5^H?8?V9\L]70[A@JPL)F M^=LC4QDD"C9N&*-3)DH`@+].Q7%J0"+TM?V_Y[G>IB0:N_'$CP*0.VNF]!-' M2^)D.Z5%]<>(VHHZD_!@$@']X7[HAM,XB,?_=O$,45O@(]5T,9=B[\"L@7>J MAN(<#&;@?*S,<'2U7BL5:D23!W1)R80X4(6"_KPLXL2?>R^0:7;0+"\U@:U8 M'178"L#K&*'R<\;W4S^BH!A1L`O(MC0#X-VQA;WWOJ.8=!*+!!(Z)\&T1E?G MP9$('TH)[`4G@&FO]*711!WUZFS`(AC9!,-9H#@E4-[IS#KN96WBM MVN:+@C[?030(>-"8A7W77]DV(6Z\-[<7#MJ+!)-1+\&#:)C0&%W1&$)S))L3 MJV)RPU:L+)63B1T>MR'L#-UH]RGP$.(VVAM?XB<"CGO=#3BA&[IAWZC<\%HY M)2O`TG&PO=V]R:W-H M965T3GE!C,-"7N,A=CN>L`>1 M''-6:&,B648U\*L#+U7CEB?7V.54/AW+NT3D)5AL><;U:V5*G#Q9?-T70M)M M!G&_!&.:--[5ES/[G"=2*+'3+MAY!O0\YKDW]\!IM4PY1(!I=R3;Q>0^6&R" MB'BK996@/YR=5.>SHP[B]%GR]!LO&&0;ZH05V`KQA-*O*2[!S=[9W8]5!7Y( M)V4[>LST3W'ZPOC^H*'<$42$@2W2UP>F$L@HV+BC"B,1&0#`;R?GV!J0$?I2 M_3WQ5!]B$D[<:.J'`N3.HF@\ MF4W_Z^(9HBK`!ZKI:BG%R8&N@6>JDF(/!@MP;B(S'&VLET(%/#2Y1Y>83(D# M42BHS_,JFLZ7WC/D-*DUZW--8"LVC0)+`7@M(T3>97P_ZPT*BA$%4X=L:[,` MWBW;J/?<=Q335F*10(:Z))BM\<4^:(CPIIC`7O`&,.N%OC::L*7>=!8L@K%- M,)P+%,<$PFN?',W\-C*3'J.95$6;^M6/K=@8!0"U+N&;B04'J>BF9Q@.Q3;< M:/Z6=@-G-`8N&DV#:33IP5F*,+`4%MOD%C84VVS16U MOJ:R1M/EZS15)=D,2BRZ^2UT*+;I0K_?=T9C^FZ,[X1-OS'7+]!;:`%4\_K, M56H;+IKU6GY=BYK."WJIW=37KZ+#+??JN@9F@[;WDW[J:M&%IYO*#FOL_.'F M?#VAV MW."F`Z-2]^G.#O+!`Z&N\*#&KO!-IP:.76?YZ[V>ZUK4.4[KE?>/.8-CIC\S M'.5,[MF&99ER$G'$R6X$^WR[VDZ=]R,\L7OK:YQ&<=UK+\`P6-(]^T[EGA?* MR=@.+'T7YS9IQDGS18NR&LFV0L,86'T\P-C/8([Q71#OA-#-%WQ`^X_$ZA\` M``#__P,`4$L#!!0`!@`(````(0"HN+<97@P``!E#```9````>&PO=V]R:W-H M965T1(\_="0CZ6-K;TDV9+%P^]_[=\3?VZ/I]WAXS%I MI3+)Q/9C?;P^)J>3VF]WR<3IO/YX7K\?/K:/R;^WI^3O3___W\.OP_&/ MT]MV>TY(A(_38_+M?/XLI=.GS=MVOSZE#I_;#_GDY7#]K.9`KI_7KWD=012L=;8AQ>7G:;K7O8_-QO/\XZR''[OC[+\9_>=I^G M(-I^$^+%[WYW_]H(F$_M-J?GZ<3BN?[S+>?]EY=:; M(+;W!X7?[S;'P^GP.VY?'I&.5'->V MDNFG!Z^&9KOMKU/H?>+T=OA5/^Z>.[N/K52W)$JEX,?A\(>2-I\5DL)I*EWS M4C`X)IZW+^N?[^?1X5=CNWM].TN^\W)*ZLQ*SW^[V]-&JE3"I.R\BK0YO,L! MR/^)_4YY0ZID_9?W^FOW?'Y[3&8+J7PQD[5$GOBQ/9UK.Q4RF=C\/)T/^[D6 M>6=T"6+[0>35#V+E4SD[7[R+$R7K1Y'7($HA?I2<'Z5PC6*G[+N\E2_$.*.B M'T5>@V.QXQ^+M#*OK-I7C\M%B!1]2;2YS;#T,:AJY2>1,4 MMU)W^7RN<%>\O=588E$=)^S5VP\C\*AEF#1N9@./6F&3_@>?!7:UKZFUB_'C MV$&.[6NEV-G_$">H'?O:?M2AW=BC98-FH][X.;;SJ:*5N<]^G^*T[F2]/MM= MG]=/#\?#KX2,A-)Z3I]K-:Y:)14YZ*UUWWKIO_^M^Y9^6T5Q5)C'I)RA],PG M&73^?,KGL@_I/V6[,KVIJC97)>*TP)YTO MM)]65)1[,TH[0I//F)I.E`9:8C=*`Y73B])`W]&/TL!Y#:(TD/%AE`8R/HK2 M0";&6B--X-J7Y:`.)Q&:/&BF$9H"U/,L2@/U/(_0X/$L(C0%B+.,TD`N5A&: M'-2AXT2)X.0=OXT:M8@N<_Q&:HCHZ_Q6^F\BHU^1X3Q&OZ+41K^"H(+`15!% M4$-01]!`T-1`->N@AVNAIHV@@Z"+H(>@CV"`8(A@A&"L@9&,/'13DQLTTQLT MLQLT\PA-`3JAQ0V:Y0V:U0T:QXD206_FE&\1^>8SJKJ`D7Q#FJ)KQV@T#KG] MB-$XE/HQ*4W]T@MBYU76DNS%M14$+H*J!@5O_"KD,_J?.?;4;M#4,7`#01-! M"T$;00=!%T$/01_!`,%0@R_/>(2%Q@@F"*8(9@CF"!8(E@A6"!R'""7=H:P[ MX;0;#I2[U1@.5&K3@3C$EK4DY$`$+H*J!O>>`S,IO$FI??UQ'<,U$#01M!"T M$700=!'T$/01#!`,$8P0C!%,$$P1S!#,$2P0+!&L$#@.$1. M/H;)E-HT&5XWE;4D9#($+H*J!KK16W>9O"U3-7"%5#,TA;Q=+-Q;<#E6Q\`- M!$T$+01M!!T$700]!'T$`P1#!",$8P03!%,$,P1S!`L$2P0K!(Y#A#+L5$@3 MSK%A-YD7B6$WI3;MEB_`]759:T)^0^`BJ`9`3<[`+4;MB\_JP6?!=6<#01-! M"T$;00=!%T$/01_!`,$0P0C!&,$$P13!#,$,0H8PZ%=*$ M@UO`LM:$/(;`15`-@.K#T&'!9T$_54?00-!$T$+01M!!T$700]!',$`P1#!" M,$8P03!%,$,P1[!`L$2P0N`X1"B-3H4TX40:IE)K@3%76[]>U%(/)9#K8-PK^R+_ M1E+6@C/@RXJAN%=]FSF;YGXGJ!H"6\W)F1%JOD#F+"]3@5G0U"^:P,D-(DTB M+2)M(ATB72(](GTB`R)#(B,B8R(3(E,B,R)S(@LB2R(K(N);;1NCMR04N"*D M"GS@(=.W:C(ZAF_UW+5\Y\4-^2+,N)?5(S-B[KQ>IRR0IRJ&0&9(T'3N=X*J M(?!L"YZL^8IK)=2)-(@TB;2(M(ETB'2)](CTB0R(#(F,B(R)3(A,BJF>@8+M43UZ9+87:MK![(@C%=$]W? M9L65ZI_9';I4JNH3OY?V5S7,4C4J53=+R9.L^$T-0Q'1,S=-`4=H&8)L\8[& MC[:AL(L"S#;-J2P MK)Y*AK:-Q"5-E4B-2)U(@TB32,LG?A^1R>4CFB(>8(?"=(GTB/2)#(@,?:(/ M)_*6>$2%QD0F1*9$9D3F1!9$ED161,2Z6&-B54(51D;FS8LA-?$?PXIZG<"T MXG7YW7M`L:R>O`4K(G%)4R52(U(GTB#2)-+RBHPLC(LVD\M2(0PWAZ`<$T'BXD MJ4>UP7B:Z.MR2W)O9:"02X6J/O$+>:N9,"]7,R5Z,=,<1.H4MT&D2:1%I$VD M0Z3K$WW$ZL+)/):>\7G$L-DW!*I[-`,,Z"N'1@DKPZ/Y"!084,6(PS4G5P%A"]JA2R^S.:C%BW!S4,^N MJV?8OYE4T6L>9K/`]2^U]P":A2;^X*QF4-[_2RB.D[7!.S<.VDXA.]KBK[)O5@+/;S_EG5WV!>Q:4052-$,164O8:` MZ_T:A:@3:1!I$FD1:1/I$.D2Z1'I^R18;>IPGAU41N%8H^YKK M?7V%B$NDZI,O[CUJWTOJ%+=!I$FD1:1-I$.D2Z1'I$]D0&1(9$1D3&1"9$ID M1F1.9$%D261%1)[VIY4WSKL\R4\J(_.F$]5"R^V=JZW79&G MVK$N!GYZN&"]G[YOEV33A*08^,`NR=X)YD.[-(SB([LD.RE8W[1+LOF#><,NR;X; MX>E+*N5W"3[7K]ON^OBZ^S@EWKI?-M!_G`^?WE;:'X>S_"*! M]_9-?H)B*WM/,RD1OQP.Y^`/]067'[5X^@<``/__`P!02P,$%``&``@````A M`"1+X:]A!```R0\``!D```!X;"]W;W)K&ULG%=M MC[(X%/V^R?X'PO?A552,^F20UV0WV6SVY3-B53)`#3#CS+_?6PK87GPFNGX` M.9R>]I[>6]KUC\^R4#Y(W>2TVJBF9J@*J3)ZR*O31OW[K_!EJ2I-FU:'M*`5 MV:A?I%%_;'_]97VE]5MS)J150*%J-NJY;2\K76^R,RG31J,74L&;(ZW+M(7' M^J0WEYJDAZY16>B68J*F6V2DX5K=-]`7%_FK,T&[2[AXE\ MF6BQU4!.YP.=QNSJK@Y*V_4AAPB8[4I-CAOUU5PEIJ'JVW5GT#\YN3;" M?Z4YTVM4YX??\HJ`VS!/;`;VE+XQ:G)@$#36)ZW#;@;^J)4#.:;O1?LGO<8D M/YU;F&X'(F*!K0Y?/FDR]*T8!.Z]B.EH,\M9+)]1L7L5N`\J MEF8M'=.9/S&66:\"]YN*.3.>T8#(.U,6HL;3(X$2ZU3@_K]'XO8:= MU?E<=ZGCIVVZ7=?TJD`]PFPVEY15M[D"Y2%G^`R/6?2S)(+L82*O3&6C@D>0 M'PUD_L?6L8VU_@'9FO43#F(X4\9CFW+ M*L&4@U3".XR%+!)-*>Y2IL13BF//9$YRC^.,',E>*/C'[67DC0HU-;II6:AO MCW/L<0IV&/`Q$&`@Q$"$@1@#B0!(\<%2),;'RLV&A?[[-&*--BJX.,;IV//1 MOZX(/,X1XL2`SX%Y5YTSH_O)&H'(,)U[E!"K1F(;:WFO38S;)`(@F0-KK6C. M]Z8P,C8%Y:_'.8(I''`[#Q8:'^UX-8,75$4^%@B>%`BQ0"0*F)JU6,Y:X0]1@N`QSF"QQCP,1!@(,1`Q`&GFR?; M@;22,S7(!D,*&3]+C*<7(.%Q7[MGC'%Y%]AQR1WZ_X^]O=O@8"#`08B#" M0(R!1`"D<-E67OB:?U]!C(S"G:%P/,ZYA;/#@(^!``,A!B(,Q!A(.-"O53/' M_LG7`C8L8KB/)35KA,-&&P:/!^-ZI+@T03Q)TC0([RR MD4?AA!Y-D'B"L",5F]!N(#QH?D+BV]R2U">R(T71*!E]9ZN8+LYQ0-S!5M(P/6Q`1RD+NF)_)[6I[QJE((H[N\9CLP$]IR&!N0CI>WPP#H8#^';_P```/__`P!02P,$%``& M``@````A`!Z@ZI."`@``O@4``!D```!X;"]W;W)K&ULC%1=;]HP%'V?M/]@^;UQ$DBAB%`5JFZ5-FF:]O%LG)O$(HXCVY3VW^\Z MAHR/KNL+Q/:YQ^?<#\]OGU5#GL!8J=N<)E%,";1"%[*M%OP M1K>0TQ>P]';Q\<-\I\W&U@".($-K!%'Z0:EL;Q-5-O<99%4[K':&AKRO6?%R#U9@ M0I$F2C//)'2#`O"7*.D[`Q/"G_O_G2Q1NDT2[+K_[.PH*@W>,\=7\R-WA%L&KS3=MRW8#)# M9N]LA/D).@:O_[**'CW)G6?)Z802#+=8GJ=%ED[G[`ES*O:8Y24F.46L#@A? M"I0W:$3GQQI?S_I!B@=[*;X*7MLR;"#WH"T]N_<5Q&2`G"C!#!TK.63K;44^ M**?X%/P5D,8#?Q`9,*-!]>IHXT3!^%3!VS=[<$[1WG!SEMZ*T=#D[_6>,["5CY.$)PJ;4[ M+'Q?#2_OX@\```#__P,`4$L#!!0`!@`(````(0`J1IBG2@8``'\;```9```` M>&PO=V]R:W-H965T[\GS8F'__%3XL3:/MLO,N.]7G8F/^+%KSR].OOSR^ MULVW]E@4G0$1SNW&/';=93V9M/FQJ++6JB_%&;[9UTV5=?"Q.4S:2U-DN[Y1 M=9HXMCV?5%EY-D6$=?.9&/5^7^:%7^'O*XN$.*Y/)7=SSZH:53Y.CF'GO4L;@*(2Q')='RNL3=`#^&U7)4P,"[:+BQY2-/(7]JNKOX5(B9#B2".##*%WLOO76OFN(OEF"@S&05> MKU$\BA?>9B-"5Y#IK6PAKX_N;;]./D.>9]+C2PG$`5V,'4(9[ M0J,X@(&/08!!B$&$08Q!(L!J)4:,.I5JWPY9JED!)^,(*[@:6X%V6T]H%"LP M\#$(,`@QB#"(,4@P2`682VL@%][*!CBH1EC`U=@"='9X0J-8@(&/08!!B$&$ M08Q!@D$J@,@.UW)@ZU;^EL'#D#!:3O`?$[@,^'AKY*VP,>C`](1&,08#'X,` M@Q"#2``QRIGE*$.$MPMUE/WI'^,`"0:I`C1CH&33C'E_Y^1J;`@ZI#VA40S! MP,<@P"#$(,(@QB#!(!5`+!:7S=]:*KPH'.%`+\<6#.=Q/QV>%"D>$.(3$A`2 M$A))(D:U6DW13A63%@DAJ4JT7&"\M%-7R?O)T,NQ%<.>+*T0Y:)J!2:^##1H M`D)"0B))A!7.3-T+Q:(@31)"4I7H7O"Z:X07HDS3:PI4#WI,B&2/M=V[[_%6 M$[`Y_'S2ZU)?%TRG2E+W$0)=X*Z(*Z%4#&9'A,2$)(2D*M&=XT7:".=$3: MZ8VP312&NFVXB&6XG-P2XDLBDI(QDC`!:1(2$A$2$Y(0DJI$]X*7>:H7G_LE MP^\JX>/)&0H"F4I"-.3_5C8;B"^)]&2VO&,*CA)J;=S5PD855$0N$Q.2$)*J M1/>(%X.J1Q]LUJ)VU/,%G1X>PQ7GEA!?$NG-O2T(!PE)D(B0F)"$D%0ENA>\ M*ASAA2@B=2_0='D,EYY;0GQ"`D)"0B)"XANY>V,I>?_K]/8UW$O1;>%%WPA; M1(VHVX).((\IA62_H+:$^(0$A(2$1(3$DLA4X^2#Q6I&E4WA]>'(\P1 MY:1N#CHS/"9$HFZ?6NY'=?MV;`-?-ACVJH"0D)"(D)B0A)!4)9IU\+1@C'6] M'-6)#BZ9I6@8V)80GY"`D%`2><.$D1(J(DUB0A)"^`,2?K3TW1->B.<=XEYS M532'8EN<3JV1UR_\688#O]%O]/:L M.93GUC@5>PAI6PLX=!KQ`$5\Z.I+?X?[N>[@P4?_]@@/N@JX(6Q;(-[7=7?] MP"]P>W3V]!\```#__P,`4$L#!!0`!@`(````(0`<`:]R6`8``'X:```9```` M>&PO=V]R:W-H965T%R<+NI45=>!]O.G[^71 M^I;735&=UC:;.;:5G[)J6YSV:_OOOSX_+6VK:=/3-CU6IWQM_\@;^]/+SS\] M?U3UU^:0YZT%'D[-VCZT[7DUGS?9(2_39E:=\Q-,$\S(M3C9Z6-53?%2[79'E296]E_FI12=U?DQ;B+\Y%.>F\U9F4]R5 M:?WU_?R45>497+P5QZ+](9W:5IFMONQ/59V^'8'W=^:E6>=;?AFX+XNLKIIJ MU\[`W1P#'7(.Y^$#Y8_5E6X(_:VN:[]/W8_EE]_)H7 M^T,+Y?:!D2"VVOY(\B:#C(*;&?>%IZPZ0@#PURH+T1J0D?2[_/PHMNUA;;O! MS%\X+@.X]98W[>="N+2M[+UIJ_)?!#'E"IUPY<2#Z-5U/N-+G_G!`U[@?C(4 M^+QXF1C*'&G)+"5IF[X\U]6'!:T'@3?G5#0R6X%CD1XHAR+3)^Q6OB!1PLFK M\+*V%[8%RQLH\K<7+PR>Y]^@,)G"1$,,,Q%QAQ!5$&X3:MB@029W#@1Z%I!@ MG<7UXG;!"K`(MKM-A`;PW4?/2617$`L3D@PAX=*$;(80+[RX,0BYCQ`2X+4- MWB_QA^:M(X3XLC2,.8P4)\;K\+=WX3JFBZ2#=&G;:`8C=NCRZ<408#-V1O,6 M(<;M"Q930T(-&S0$DJ_/`N="Q@@5.GYZJ`)LALH=TL(18O"^G'M.&/)+A653 MQP3B>AZ%)`BY$-YH!B/^X)'X!=B,?W%)BXPM0@B&_^3Z09N[..0 MI(/T\6L&(WX&0<'\7,)0[G0A; MDG$2*1!&R8*0+4BWQ28B]!TZ3Q*%T$N!MQZ.&`8I^Q],Q"K24R$=G=+UVD8F M8;`,/#(9XU%$HA`Z$[SU%29"X;2:C-0"]5"OA1<.:J&+)G>X/RC%""!A"-#C MURQF3PE)T^*?V%,HA#H/%A)]B<3C/90+*['T%E2DXS%`H@`ZCUL*S(2::3Q& MZH#:9\;OF@H:29==_-P).1MTDBZR+&2N1TJ5*!\Z@UNRRX3F36>`"FDR\"@# M!&$%/,Y<,H!C><^.XA5`H@!Z_+>DF0GAT^*?V$DHER8/DN=(NN["A!'J$*+Q M&"!1`)W'+9UF0@`?YX&R:?(@W1!)UQT/QN"ETRQ8/`9(%$#G<4NO.='K:?60 MJ^B,I3P4"/L*#E*H*L=C@$0!-!ZZQ9A0G,BVX.'!&+B_P^4JRH.T?Z1`R(,M M_"M$=/6^ADB4#YT)KI$6DPETA]Y9(PP$FC(@K[(11]#=)Y`>(YZ@GI8!4@6DP'1[1$&0[T>OJGQ3EEOO_+&/48R8`'IQZ2_?F'0>:4/@5P(X<.[ M6ZXR:^&1-$8*TS53X'@^4?:80A;>L!B:4,LGW(U:=*6=A!9J5$:*@O^.3 M6&'4[/*]@#RV)+V32S/=DFS^D&1+M-E$W!F,I$Y>[U'09=T-O,&[O[J37H7. M[6`_$-4>::*A6G.']$#$$:0V0A@PDN'8`+@L')9`TV:U"32+.9&(6H_$/U1I M>+`S13CBG:+>*\$X)NG]7!JI6T6K((YZIV]EB38;:7""I##JI#'@@R(8`-=G MG+S<)@J@-9%NP2+@<3\>9)=YO<_C_'ALK*QZ%T?Y'([]>FO_,\,K%^_JQ!ZQ M%9PRB[3T%^#T_YSN\]_3>E^<&NN8[\"E,UO`/*GQ]P/\TE9G>7S^5K5P[B__ M/<#O/#D<7#LS`.^JJNV^B!OTOQR]_`<``/__`P!02P,$%``&``@````A`"GF M*WPG`@``C`0``!D```!X;"]W;W)K&ULE)3=CILP M$(7O*_4=+-\O!A*RFPA8;12E7:F55E5_KAUCP`K&R'9"\O8=VPG:-JVZS47` MR9EO9LX,Y(\GV:$CUT:HOL!)%&/$>Z8JT3<%_O9U>_>`D;&TKVBG>E[@,S?X ML7S_+A^5WIN6J7IKH.^3\F4F6!$AE M7@GHP-F.-*\+_)2LUC-,RMS[\UWPT;RZ1Z95XP$V`PRA)W\=167;`L\6478?SQ*0HQTW=BL<$B-V,%;)'T&47%`!DEX@ M<+U`DC1*'[(D6_R;0D)%OL$-M;3,M1H1+`WD-`-U*YBL@.PZF_^U,VC)Q3RY M(!\*:@/3.);SY3PG1["0733K6TTZ*0@DGRJ`K*\K^+.GU\Q.7&!XK*;,21I/ M7%_=.FC\.OR2:/8_B9RXP(":$LV7V6^)@B;S!J19#)])$!*'A0I^#[3AGZEN M1&]0QVO`QM$].*W#.H6#58/W=:&IYV!Z'(&X5LI>#VYAI_=(^1,` M`/__`P!02P,$%``&``@````A``C&!8V8!```EQ```!@```!X;"]W;W)KOP-JOW6_;7_^:7UES0L_4=HZH%#SC7MJV_/* M\WA^HE7&Q^Q,:_CFP)HJ:^&V.7K\W-!LWSU4E5[@^S.ORHK:%0JK9H@&.QR* MG"8LOU2T;H5(0\NL!?_\5)RY5*OR(7)5UKQ0V!5ET;YWHJY3Y:OO MQYHUV:Z$>;^1,,NE=G?3DZ^*O&&<'=HQR'G":'_.2V_I@=)VO2]@!AAVIZ&' MC?M$5BF9N]YVW07HWX)>N?;9X2=V_:4I]K\5-85HPSJUV>XO6M*\I7M8.=?! M%=DQ]H*/?@?(AT%X1\!!^/]RF*<)CN*I8?3//AL^D^0R$U*B`0W$;A>Q??!; M!@G&P6)*IH^HA#<5N$J5\'$5F'D7%+C>51;3:3A;S+^,BBDK79=MVP MJP-;!V+(SQEN1+("E8]7")8&N4](WKASR*&-RR%-7K?^VGN%1,AOC$@PX+]B M$),12P:N.HHF4E0"J09XX%)9A84<;A7):%6J1A*X.PLL9WW&Q&0D@J'/+C09 MZ6<,8S*04<,G@V1C,C80VT`B`-WJU++:9\P4P[`*:3O<*I(W+H1!)*9-/JTC02"<:DRW3B!\'4MX(82X:R M:@.I!AA69X]81;)IE=@[3U#TL!)[ZTF*,FL#J0889F'+#X\KDBVSUE:+!"7L M`AOZ"W+/O"Y'8O%]UW!$D;"!5`,,I_C>,;B>(=ER:FWY2%!$6'PL@Y.#B#ZDES)B MU[(;YW/+0D=+9O64G$2J(Z9E;"C#+8OV8UBVBFM$!.=SRY(C#2;J*8FD.F): M!ND'+"/;2@R[#!/!T2T'5OF+%4<:3'I(JB.F9>PGPZ,LNH\>97M_143K4**D MW9!I5T.F_F(^65CS3'H/I3IB.L:VHCD>N`M%,S*[I&O>0Y(;, MNKD$))Q-PL#>JJE!"OWN3_57P_PRV+;F58[E4_V=&P8`=^KWG#(<]&ULE%;);MLP$+T7Z#\(O$>R M-F^P',0.TA9H@:+H33FS<+9[BZ?:Y* MYXE)Q46=$-^=$(?5J2@M64>6*AM6PDPM940V/DU=!65CX?F)A55`Q0[7G+] MTI(2ITJ77_:UD'17@M_/?D33,W?[<$%?\50*)7+M`IUGA%[ZO/`6'C"M5QD' M#S#LCF1Y0N[\Y=8/B+=>M0'ZS=E1]?X[JA#'3Y)G7WG-(-J0)\S`3HA'A'[) M<`E>]B[>?F@S\%TZ&[LF-(/'"F)DQZ4%M4?`_)/5(8D M.)&$H/ZT'[C!//;CZ?]9/*.H=?">:KI>27%TH&K`IFHHUJ"_!.:S9T9'Y^N_ M7`4?D>0.61(R(PYXH2`_3^MX$:^\)XAI>L)L+C&^C=B>$9@*D-=I!,_[&L>C M?I:"8)2"64!M&[,`W)VV8&!W!#'K()82B-#U2A"<$.@!G>$P"#M>(\Y@PD[M MMK=@68[>8QG!"0&W>I:C@66#B=MD3>R][?B>I0?J]OI(('BH9U@>!A..ZAG? ML_1,WZ,'P;:>>#&U8[`QF'$]XWN6'C@+U\<'P<-*&>HQF%ZE]!8LRSAT>B?Z M[=."8#L283"L%(.9MIF9A[,Y?.Q8;2U$,(W\\/5H6]H6[]&&X*&V8=48C-$6 M1=!1!\KZ^T$<1:_O6[I\&`G7!ZU%V\KBQ2`FFQ/H%+8H".-H>,QL2#!?Q+/7 MK-OZL#5>G53?-%+[_%_H,R"C[V8^+M#&O*D0F^CU"DW+M12&@_!L8*)C`4!' M?&UC`PQ._3WSN.?>:R^KF133H MF2G-99OAT`LP8BV5!6^K#/_Z>7]UC9$VI"U((UN6X5>F\\TP.;H)?0":*>=MT5E:(#BBUON'GM23$2 M=/E0M5*1;0.^7\(9H0-WOSBA%YPJJ65I/*#SG=!3SZF?^L"T7A4<'-BR(\7* M#-^&RWR!_?6JK\]OSO;ZS3/2M=Q_4;SXQEL&Q88VV09LI7RRT(?";L%A_^3T M?=^`[PH5K"2[QOR0^Z^,5[6!;B=@R/I:%J]W3%,H*-!X46*9J&Q``/PBP>W- M@(*0E_Y_SPM39SB>>\DBB$.`HRW3YIY;2HSH3ALI_CA0>*!R)-&!)`;UAWCD M1==)F,S_S^([1;W!.V+(>J7D'L&E@9RZ(_8*ADM@'IPY':/7#\K<;WJSY(L6`KQ7;! M:MNX#>`>M45'>=]!+$;(1`E4Z'(E%IQA&`%CXC@ZLKQQF'A4F[_9F&2>?22S M!6<8;(V9DS0=';FR.$R:]MT*O'@VC>?GXQ-=<'\OKX@%3W7-@V":=^,P!UU' MHO,SP8FB^4<46?!441S]Z[VKE,,<%%W-XJG@_&QXH@K>CV,`#<"FE M&19V'(P?S/5?````__\#`%!+`P04``8`"````"$`T=Y#KGH"```C!@``&0`` M`'AL+W=OG73=ME-8NR7A_>\!YA?W\L6';@V M0G4E3J(8(]XQ58EN6^*?/]874XR,I5U%6]7Q$C]P@Z\7'S_,CTKO3,.Y14#H M3(D;:_L9(88U7%(3J9YW\*566E(+0[TEIM><5GZ2;$D:QP615'0X$&;Z'(:J M:\'XK6)[R3L;()JWU()_TXC>/-$D.PFFA;KODTO*GMA^<(*7@FEE5&TCP)%@]+3F*W)%@+285P(J<+$CS>L2WR2S M58[)8N[S^27XT3Q[1J91QT]:5%]$QR%L:)-KP$:IG9/>5>X53"8GL]>^`=\T MJGA-]ZW]KHZ?N=@V%KJ=0T&NKEGU<,L-@T`!$Z7>!E,M&(!?)(7;&1`(O??_ M1U'9IL19$>63.$M`CC;#&S;EQD_Q44!OHQF%1 MQ.F<'"!"]JA9GFI>*%:O*"8#A("_P224_MSD^^:N\O2O]R02]`4WMU%FA?3Z:F]%YKW_,'F/C\])Q[[*^++<33+H(&` MAH2S>"R!:\!AWI"$WH9S'HY!3[?\*]5;T1G4\AJX<30!A@ZG/`RLZOUVWR@+ MI],_-G`9<]@Y<03B6BG[-'#WR'"]+_X```#__P,`4$L#!!0`!@`(````(0`( M+8W4C`0``/P1```8````>&PO=V]R:W-H965T&ULE)A=;^HX M$(;O5]K_$.6^)':^$7!T2-7=(^V15JO]N$Z#@:@D1DE:VG^_8X^!>(`V](*2 M\'C\>F;\FC#[]E[OG#?1=I5LYBZ;^*XCFE*NJF8S=__Y^^DA=9VN+YI5L9.- MF+L?HG._+7[]97:0[4NW%:)W($+3S=UMW^^GGM>56U$7W43N10.?K&5;%SU< MMANOV[>B6.E!]<[COA][=5$U+D:8MF-BR/6Z*L6C+%]KT?08I!6[H@?]W;;: M=\=H=3DF7%VT+Z_[AU+6>PCQ7.VJ_D,'=9VZG/[8-+(MGG>P[G<6%N4QMKZX M"%]792L[N>XG$,Y#H9=KSKS,@TB+V:J"%:BT.ZU8S]WO;)KSR/46,YV@?RMQ MZ`;OG6XK#[^UU>J/JA&0;:B3JL"SE"\*_;%2MV"P=S'Z25?@S]99B77QNNO_ MDH??1;79]E#N"%:D%C9=?3R*KH2,0I@)RBCE#@3`JU-7JC4@(\6[_G^H5OUV M[@;Q)$K\@`'N/(NN?ZI42-UO\AQ)2H4Q!N@@2@WGS.)SR-6!1_'<5# M17J!CT5?+&:M/#C0-3!GMR]4#[(I1+Z^(E"AV.\*UD-`;`=E>%OP>.:]0>9* M@RRO(#:17R&2$^*!K),V6/%X;0J>N[#CSMK24U@M?XE(H+.JUI,/;E@30R+& M3ZS@N0NASA-G9&)$(ITQQGQ&DI;CY_!Z"A'XIQ"6LO`>90JVE07L%!93@LB- MF362(Q)CN:/L1JV@C\>G3,%$&"?"$,%9KZ5L^#F_J2J^1Y6"[0X*`J(*D4$' M#6Y8=4KNF5C!)!TAF1@1DPYP?^;3'D+B1B4M;>I4&KWE%4RT140;(I]I0V*, MMNP>;0HFVDA6EH@*Z.D3=T;9:E49*=YT9?-V&.*TC39!#%EG>7N:LO1I`] MV/.GTRPDFVYIF&'SXRA]QY[\+@]G:,C#!@NIB1O&+/RJF1ID5(O=9?7LTNM# MZO6&^53?>+=GRGS';U"T:BM_9/\M=<1C7P1>R!NKMAL(:A#W_VH9D;8$R'<6+_2F4" MV^5S$].CB$IZ#!C&=%KJ1SRF)F8C<<23`6)M5*YL>72C:9K((W,O#8/R.`_] M+.,DT3EE@C`<,+9`9=GC!:+!#W="1(JXY,B@P`<>]G4-R%(P[4-7S*3E0(WHD&,8\ M)/%K7]4LY,IW-7Q^Q\?;?;$1/XMV4S6=LQ-KV#+^1&V:%I_>\:*7>_TX^RQ[ M>.K6;[?P*XN`9T-_`O!:ROYXH7X?./UNL_@?``#__P,`4$L#!!0`!@`(```` M(0`QT6&PO=V]R:W-H965T&ULE)9; M;]L@%,??)^T[6+S7U]BY*$[5I.I6:9.F:9=G8N,8U386D*;]]CM`;I`T2_+@ M&//GS^\V\5X)%Y1U.8K\$'FD*UA)NU6.?O]ZNALA3TC.'0B1[64_20(1%&3%@N?]:2#GHKQ%DMH\E4@>DYP MJ0>U31"'81:TF';(.$SX-1ZLJFA!'EFQ;DDGC0DG#9;`+VK:BYU;6UQCUV+^ MLN[O"M;V8+&D#97OVA1Y;3%Y7G6,XV4#<;]%`USLO'7CQ+ZE!6>"5=('N\"` MGL8\#L8!.,VF)84(5-H]3JHC-$JS_[L$AD@'^(@EGDTYVWA0-3"GZ+&J MP6@"SN/,.C(.]O0YC;B2)SJZ*:W'TP`*`A!P#7)Y8B7,$5H>) M4V=B(QGKS(5^9/[!4>)'9R1/>7<2,[CG.^S<(:WX"BQ@S-V<(QD M5TNA6TP?=EM0ZH"Z^NU78ALJ"QTH(S'5E*6FG!S-XK+&PAO?@J?$#IZ3E+F1 M&+QH%*9Q-AHZ>5U8FBR-A]DX.FQR%AX<.3>D3ZL=0&=OG&\UEPEMT0>(YBPS M6WV/5^0[YBO:":\A%>Q/H3^$-XB;D\PT).OUUKYD$DX@?5O#%P>!_3'T05PQ M)G<-=5;NOV%F_P```/__`P!02P,$%``&``@````A`!CT7M0(@0``FT8#`!0` M``!X;"]S:&%R9613=')I;F=S+GAM;-R=ZW(;R97GOV_$OD.%0CV6(BB*($5= MW&U-0"`HT4T1'`)L3>_&?@"!(@DW","XZ-*?_`Z[7S9B-T*QCZ)'\9/L[W]. M9E6AJD"QW9[V>B<\MEBHS#QY[K?,^NY?/]Z,D_?I?#&:3OYPK[&]+Q3)A[&3QAWO7 MR^7L]X\?+P;7Z4U_L3V=I1-^N9S.;_I+_IQ?/5[,YFE_N+A.T^7-^/'NSL[3 MQS?]T>1>,IBN)DO6W6\\O9>L)J,_K]*6/WJZMW?OY7>+T7#>/4CN/_SN\?+E=X\UQ(L&883HL M_]Q-9]O)WLY6LKO3:-3^N/O4?MRK_W&__L?6].8&F+K+Z>"G\L#3>7J9SN?I ML/[GL+6S]&JT6,[[;/BD?Y.6)SEI]HXZ)\WCI-LZ:I_TC@Z/6DFK8^?1]QL'G*;ST51$&28'_65E M;!.R#8UTA^/^57F6U@I#^F_?G&F8Y$1:-\/WF7CL>/?II,/X#F MM+^`,8?)T6*Q2N?_6E[B9%I^4ISHA^EX-5GVYY\`85PS.GOW=XOD+)U-YTOD M`MKUEZM%$J"O+!G`M!F3%DBYFLXK&._>],>L6)@5OIGU)Y47PVRGJXOQ:)`< MCJ?]97E'X94BXVTEW>O^/%TDG=72Q!>XR\,RH@?T!U(>(FR+\KN'/Y:?E$<; M\6K'ONJ/^Y-!"D2(_V*3L!:E<:>\6.O\[`Q63YK=;KO7_7WEY_[BNOSLR^',06-6'5R:>3N(+ M&T`\G4]G\U%JO+9,!]>3Z7AZ52&VKS7)9ZM?KM?I(?Z^4AF4B*KCH^:KH^.C MWE&[BJ_F\+THLD@NY],;4'$Y&F`!RC,=CR:I\-1"7XTJ3"=Y*C]C@'OKRPX[>` MP?(+W5ZG]?V;SO%!^ZS[N^2@C0H^ZE78,M?V"QF#K>3^=F,'2.?)^_YXE6XE M3[9V=G;T_\G"I;6_6EY/YZ.?T^&W"5R0)B-IM:'9O6DNR3"Q\(W(+-.;"[1( MM&+V(N:L*D!NE#(X=AI%.)[N&Q2;(&D\W]G:QQ8^?_;"%F@\W=_:??9TZT5C M[V\&<"M!.\W2P7+T/AU7Y*`YA.,01@1OUA\-'XTFR:`_&R&(94HT![@&JS$$ M'R;#%$:N?A:()8CMCTZ71A^T_^:_-"GL!@^=_*Z^7,99[&5L*"R0_B MJZ^^&4Q#,V.VNXXP&UOQHRJ0E$Q/U?*L6ZJ-@*^_]E6H:U^O![GVU5M,I2R^ MD= M;K=,J0=Z^#`Y.FEUWK:35^W#SED[Z37_O=TUSCTXZK8ZYR>]]D$2YNF'CH#4Y9'& MKT'A).T_KQ2T;`A4"NKN5.KN:(+?^%5U=W"+NBL#\XJ08C(1VDJ:-PJT MDOY2=B0&0CO/[S`R2.+71G9FYD^)LT>X$.6)@PR:7HYFA)`NN>@/?I(YEX6+ MKDET9W_='+[C\AQA-\'2"H(!GCBR:.[@II7-_9DN*N)*('0'++\H`U$>5H_B MRK"OP5Z_XTV8'^!&;]IO&/;A3A'.;ID!BC)8)7,T/Y*)PD*;O0.QYW$->S:'?UHMEG(X%LER MB@]&!#0@]$TF;!:X%:-)@^CZD5_X(N,WIO+7_%W:W3?)X7'G73IWDM/EC`GX237%ZUCD$EI`K;)_]<-3" M+3QK_]OYT1D.C=X^:Y_B\^`+G!\<]?@?Z'%X=(P'R?!_.V^>]=IG+*S'S9.3 ML5YCEU8_V3= MFX[_(5#XH=L^[;7?OL(=\V!VYQF@F/2P+#X6/[)G=VN%D_:[,#"',P+7>W/6 M.7_])OGC^4D[SO9<4!R]/F%0^_"P+6EL0[V6+]G8\RSP=IDUX//#]JLS4/&C MTL0[!NJK3O/,&/<`1+9ZVLT/,(2AM.`"V[MO.V1A6.F',T/C<:=EK"OB')RW MV,\Q#%-DG8!B9F-M$(.PU>+AX!PR=6R-UOG;\V.F94>^-_S20Q"*Q]J&?.R2 M1<0HX*V-5R_RB2)Z9&I*^"0\VWS`&*= MO^K"1V+"`,./[29H0*`!O$+*Y[9W5GCA3)"33*REH1I9I++S<(?-^\1P*6K% M]R`.9!7@:2:O.R8`)(K:9R?)JV87<(F\WL!&O3=-W@!ZQ4#5H&1;J/LQ>7=T M?+R5O.F\$[:DNG+\;QYK04#;%?N[H]X;H\(AZ\"JQB4($7!U*^QTTGX'`D^( M(\3,2'2W@$I(A7([[PJ#MPKYJS-M6D23D)G`A063D"]#\`Z0:!/]XQ\1[$0K M5UA-ZS>/NYVX'U9^]^:H]<:PLH8+D.WL"#/&;38"52FS;-IOLT5A0L&1@`#@ M3GO4<_J"$+B+Z.R4?QF>43/)V?EQB&[/VJ^-[XEI#93NF\[Y\4&" M@NJP$CWO$M203I9'%/= MD&QNK^DB'\334E@^,Q(BE&KP.6)Q#`=(KP>K4.$H(XWITU[&764MV;M.$[P8 ME2^2#^0F1U00YU1++"N'F]=+/RIC.4G^N"*GN;N[!>/N[RF+27UH3H)LDKRE MMG+5O\KFV4XZ/"0*;%"#:[QXP7^33,M6P5[C0^*;+A?)A!J9W-83"]C(GG6Q MKQA;DH&\[W"02[09FQCW<>+:'C"^-F5K/%T-D[?DOU6?HN2Q)#SL3B^7'\CN MK4]^L)K+O%=![0^(_57RTV)Y"D.N?'N84L'ZM""WM-BB.C?83A[HV4.AII]\ M('LP)@[^H/K68G6Q&`U'U*JV?9P0G4Z$,[GHX!W?)UE29S7WWA*U6G%.S8&, M.*"QX&"<]BT+@)LS7`VHSMI5;K`UY4LB!7*IIUV+1RS`VCP[/M MY%!%@_7<,[M^QO[FT]75M>WSDTIYJ:JNI3NR3HAHYL MP@%>,'AP;3L8IJ2'I[.8(5VD-R,B%H$.(>I]-1O'3]0W2*?97\P\[X\60D)( M(XM?+E>$'6*@PLX5B>!!&@#;21Z],@,#SVJ60"=)2?3,4GU^70"\_LD<);"O*N)R@IB+,$7Z._3C)D&!JU8 MJZ-)S%>JCP8=%@:/P/ZK:7\.^%:`6"1OY]O)VQ%BF8Z3UW/X]@:AUO[T MP^MY2M7TY_[%="MY3[4&69@6RV_VXH<1;P]5TQ6`!9K`MWH2%`R5V+=3JDZI M^51:X3@B[30P=7*Q@M:0W^;UF<`E<\QI4!B9`$1U%2)%Z-M/CD5'/Q741JZR5*5!EP(9VT0%A3HIW(^ZT>3J M5%@H+1!XO_@W816%K&5RD:+IQ(9SJ02PK M#7Q)^5JNQ%'K@`//H0Y-64@[@L\;@EJ15&29I!^*;URD5V#YPW3^DPG?I,AR M\W1LP\!\`>NF)M%:9@Q@0+9&!N!"R6FDZ4$Q<`!%..+/,KA; M9>"$MZ'(+QJ0:#5T7;#W=6P+\VHHT0Y\SH+<`/PZ70TG@5A.A&RX4?`_ M3JB,+\>.OR!TA:R,J4QZ>N"?`I[AM/'*4IY4+A>I]*L802A?)'_]R_\BVS); M&04&@[E*F;'.P8__'8YP/%,377[ZZU_^M^R-MKI63(O\K!^*O*7MQ`G8*_Q8 M@@W[F5SWG8N]4(T0(5N7EZA(6T=D"5IBM1Q,;UR%:J'"QIV2Q95%'>-H&>64 MGJ7)$CN=L3>_PEE@!F,,2K3D>CU3`A`,447I6FIAE]2"!S,X@Z=$:T0+'CHZZ74*ZLJBS5.HX-8'XH=LD)@B)A_-0J,# MA&@5,SZ@3(HR#`.22YS)#EVE$]2$G!=D7%7J3.;/)Z9B#18RI7#(ZV;S%-(_ M!'_F*"V*[`7N;OH_I0E)G1'=9$PM249IKVY"=<'$(Y#TP>CAE\^B'GO!I1`3 M6I'#]$I]3G`K>3"*HY09)`>ZPOD!`U+JR!6TU7KJ&='2!;Y(O`,)$-./]&ME M^A;K#Z3&7[58E.LX4SL/_7!#S`BS`D,$H@2Z(%$^-BIW>SV3H8)A'[K_J=WC MR-&31:Y+G@Q694@X6,C[WO2'J1,OE.#%H1J',Z/E5BRI_WDLC^28VN$.O7^*8FTNG-S-C9Q7N5*3P)0.X40HFKJ:#G-9B8X/'-]`.N]WP] M9I0AZ)M\6NW$72)$Y4,ZQE33!JKFT_HPJ-&0K-W?VW^Z]7077T8>7[67)91G MRVT^&DE#SBX#7SS#!1+=)FF*S!H"S79!\Y&IB(`A\X0*)C4@TWS."N:8]PX<,:3NA"8)/,Z.4"4%X3(U M?S.ZNI8JE#!GXDL,::9;Z#1_=)6I'4)E+5X$.D(J1P2E3:]SB*5F(A.J9C5# M#G*1+^\T!':(Z/22?B2UG.4NUY9QF#<4:J'YZ&+E-7!KM"NPF$V;?D0WJ`$* MT+T%3TK6Y06HT%?YU$9B35#`^O3"R%H@N4):<>V"N!J]HNFP%>.I+`X.`8K8 M#+H2,U<$B.8](?>+Z]',S1L#I.+Q\J.#8@M/65FQ9YPW,OKE:FZ_%,)=>W\M MJ"UOFP4L]V!OQE"MPHVFTYZ@T[KG;]\J_:Z4-@E\M3LWR9TJM:C\%9G0T\ZQ M*B)5'TA5FB?F:/[MD_1R!I)>EJ["$8(VM7H-*9/RFP^MX_7OX"'E2DQN,$$\ MC*+&<*VR,@<%RH:*DDPF"NF2$),R=*4Z=N[FO;WF2C5S5ZKL%9Z%5,.99P_$ MR)M>"5(KEP/FT5D"2>,BG2N+04!:1&+FL\A[]V2&24?M4.D_\0_>'U9:?"F! M96ZIRSFQ3`CW3)@76\EE*A<1/)CXN?7'*;DV]Z98&F MB&Y<)^$\)P/K>Y.&BF/*Y.L2OK"*M((VC3]C.G1=8P9.$WZR!2]"2[=A3>:4 M#>)#SN59YJ^)\/:H;@JA0JQ@"8%`Y='D_12&&0:WW1`W=+MPH80B=@PL+I;. M4,!;V+%9*N+9*!D(*?HO%U[3N!<,SIR]N%F/$?07+'AA"`U4E%&7M+OI-!X3 MF6JVL\[B'\@-8$."VY:')N`VP_\FI6>"\61\(A^JC#@*6`>9(%`.0M!V$[F!SU0B-!IA!%1H" MJR^]O=_7_@2$RNB:$V#SN^3C2`3,K6^!?.=<^7?L-_DZ"`Y$`CPC.8XGFT0A M`$O&77HCEQ)(`;?(][EPB?!D;/7T0DLM.=JJ_4,=A2@9-E-I_NCE7"\]:#D[ M4,XJUSA02/J88W,?IJYL_`3(;ZQ M'`";DZG`/<"RK7,7S64EZZ^$F+VK#90'`8FR2&$VC`Q/>$,HN^I.? M,E(?'G#J"7RCIHTQY*L2])-E7T`]::/[N][57M&@1^A&K(GU@Y0U(CV5I-., M'^VEI36-2%>9>1KR"U-SBDMVPZ#B#4.RI8'D?+/4@\><,IT*6]$ M=`!/:$<:*X:[)3\1-TQ4F,NIYPA,%87\AK,MF$LG&#U!R=3C/LUHPJ12."L, M&%+%8WE_/)_-MZT) M/82344.[P,-LO&AI#Y>+//@UI.(5BHJ!`@(U)%X"@$%1%T&``S';8Y4V2G2> MZ^!@CQT$[Y]H8FJ)*-MJ=%,,\TWR^CW"^D'R[,G.5A0\)M!_3OFOT6..%/ZL M4QL<56SN^S?C!`X&[FK!W9(,O4' M)*>G,CU&/.1/=-R1_^1\^ZBIO[&&,]7W+'9'GZUMI&8? MO\4>'MQ;@^+>0U1G$;_FF4E3$C@O/TP?$8/-Q(SS:9\(W?C`BU7&WC#O#6Z9 MY[8RM\G8V(1=P8L;'C=8-IL,/X$/2,<%0\J"I,4!9H5EM?"F#7-8F^@7:M&1 MUYL^I!9M@M8LI95[H-2J$![)D>OV&X58X]%/G&5A/9Q3]+E2!<&QR98V70_3 M+K#<($&F`T>6!#IONQ(4!.@T#B9&JL8<-TB"U>%8%#"`7SG901QJ!1W"!'*+ M0\R[8'\F^6#7\>%XS-%Q08Z6$!89,PSAO-*4R9^F46+&A*&V-=O3_LXW<8]@ MY2)U4%WZW&02EYL74Z@DK'M&N3DBQ,8O#\D&LY+19P8!4EH`H[FTB"@8Q)CR MGQ1#1*CK-ST)VP$-KKQNJ)@%;RAH-N2[D%&`+>NM5&$QM!]Y%2RS^SC"+@AP M)TQNBGRK34SIE@7E43B0W-4IKT<<[>3+YR+(#@KL$01)M652PZ83.4\.[:`;Z#$28)5A>8\&`S$T MG[;Y:DR[_Z/N@%8']HB&1J(?44D8:/S-=$@YF47(3)OA#3SA3+P.J0\UZ6#? MV@]E"/U/Q3(L7T(!,0-,=C!"SIA;W;[':G\^90M&IC)-?(S;N.2!G/2'VHJ? MW#-7$X+:7%(GM$A;1*?4_?J87)F@HU#H.BN^$%_$HR+!]W7U`V@48^?R5W-G MN#B*#1?.!1:*`+F/X'8=QTSXOF5:@P*%MN8U"YJ^54C%)SD,X>7BXL*G3Q]D M]B;Z\7F$97%\5(N4D!04%^805T22$/"I4H_?G&$Y^%TN"WE":R@B*N=@$WN. M?THNE8`14='1R\!84@Z!-SQH\+R6\#G*F^(M"LI(8\,-3M)U\P%)41B=>,T% MRF1C80P/JRLOJ;TCC,*6)K*('!F,-+/I"G`:'N.`;,L,T`0MSZ*7/!ON0PA< M*RXLH`?*:=1"_5!H=20<+B^]$SC$>8*BC*4EQ*5Z#PF4CP?#ZK0S?B/_@$D$+N?Z/6";Y_A)NAW,.G/I36$L_*@G+/_$++("/(5TE(D*9D\_/ MZI<#Z5;^#LKA?+N[3:YKJ")KC'L`GI7%;]\FUYN*%1.,F?QGHFQ>9'Y9-*<\ M>[>27(S;K:&AE`C/:E_:3*A@AU*2X2ODJQ&!$#='"M?CS[C-%HTJP?V+T?5T M:I9+)=^Y-:)3B(* M\=(PO5@:@_>N4^9%#WU"5_!;7J(6*C:#8D[R1_>OP#\[1HK"$6I6RQ)(!;M( M=B2RWH*#Y3G8O#$Z![/P&;*1%43-JWO)W+T\2,JI[R8.+H3&=!-ES0V,MGI>_F9T,BT5 M%'E460/U.Y)+](J05@WB("5F('H`A4@4)G/_VYLC<4]P1.6;$FG(K9,Y0?EE MMB%S8"WEIB[&X+%:Z"]+ZXUHEEVV9B>@B#ZX'%K-KB3R7)$7ZB]VHL4\2V#H M&1U&.)7@`K\P1&4A(C)W6+YO=>>$6RJ(T5O&1G]6C*4\63#OQ>%K&/`:,3ZK MMN+K/W)WN]@W8=XRB)1?GJ56BR](--=I;GFX1V.J)DKEH?QID_7&@0+Z"V"9 M#X"6-]<([TTI/0-J-,%5#6YUV(V8+#.QX#3#?XYL[!L;DNHOK&'-+D$5K$<[ MZ#E>)G/XBR!&R3OSHYX;6`'7J;SX]BL_ MU\.\>V>8S0TC3[H.MZ7XZ5U5_2D`*MZY%5)7#A%/$DFY0E/:V>9>4]*D(G4- M'[C7C!Q/U@%!17E_Z9!^]X%:XIA#F1+_JYCA"`N#P(`Y5PN"02Y*3!/`N]#P M`B@,S=]JPCC=^N2L$QL1_\:YZVFS=V?:"/;5I(!!T6!1*-D&;JP7U?+J$AXO MY%HP9>X%36]@2WJHJ&X+LFB%$UQL%0)"`(%$Q42\KKJVRX2BT(9GF'_KAR$-H?[Y7?/BV_`1^PSS. MZ?`]E+FQZ$$A&&;6.HAG^&+\8?IY4?*[EB^!1F\6LL=@8$)[@!\SJ+B^)Z3N M\_:!:.8M=6)^'ZN%I2R$!33@9`4$6DPNOS8K`1#U**9#C(.G3H\@PAI-3HB- MK/B:N=A9]FZKV.`"1UH4=*GFAK1UDGW:0#N=%);1K._:69#\I@>D\,$VH[JJ+=#S"7J'>/!0, MQZ9,XU[([\X<\&!Q8Y")$I$G1ZU!;4;^?CSMD'4+13/]^K2;8YC]AE,E6<\- M)033"W)8L+OQN0%COE0LQ4SK#E?9,0A%I.8@P0%9\SUJW9U`\&%-YWZ`(3NT MX+8%`7"Z@1:A&:?/^X?6@_ M[_I?<(&@M%H\V?4JHC`[VZ5W0S[%DB'(5P6]@28E7K4X2+*8-:%J:Y%^ZQ+/ M#ZZ%M]:LM1;/5E.*=8QTF2E4TN`K5&7&(HL49_(D+C%I:%EW1U6Z(.O6E.7U M?E`6S"46)1$O0"H6/^\`?.#?.P"M+%"P20Q:(V6.#)V4(%E52,)O?M<(G@_U M1HH-\[HOM]ZYE4=G>T]WMES#%,+$WZHJ2#T]U]8N.FER!,5&2(OXQC*PHTS6NM`/Y;Q+>U$<&!G44,482=%EFWHF9>2%1P!@P%.?U0DJSE MRX)+$PF27_=Z*FQ9O,KIK@M'PU?>W%',2,6T6OF%PY+Q M(+)3%Y0GYI;)\V]RFZH.B/+P;K$&,^2<(#IX4IJCL?M->=@YVA0#@;(LOUQ< M4'FX[.2:GUJ+^Q2,EG>1!B+R[:NW&=/XXO'>#CBA% M\U/A\M!A6N'"5BQSZE!K>?*..W,(W29.*+-*>8;L=V)&.E;*/Q^KJF)-=VO[ M".MB'\L#L.U9_4ALXWOGY)#=\^+Y+K*IZR8-*]W'LELK.W(I'R&Z7-%]"\80 MEZ_N:#MG4&7J-W7[=B:%`/"9XK^=?=)7N.\F2*IU,+$.G`S4V@HZ\P.GU@P6 M3FJU_"*ZY#"TEC\X;QT^%(3<=37GW`C'?%J'--$-ED M&C/3<(I>0A_KV]R%%![CV01&%3.*)D!\NS<,*[ M'=(2.A;5?D-R07' MG`N$(^((!I+"<$3K,-;YC(3<+%PZM!4F);A':XH-K&`$@KD`]E%0#@JGX@!1 MSMIDR4:2G>1:=DCG(P?]D'0L#H4T0*O&E$(UP,JCQ)?D8UF)1`YY_2EG5B:# M3S2YP"*T1U`'1ITKKB-T,"TGY`O"*5UC1V55S(ARJZPY.IDMQI`6J$02*:UFV4B"1TB8. MK2Q!A$D9V.94P8YS#LX+@6=UQ2[[[T)>**_EXUU0<\-+`,R391,24T9@1N@J M@##B8CJ?4V[C<'=V1,C)@<2#^T'(!.#X`PH!B0QC@3ZY#XXZ+SH=Y@QI5+%# M&JQ9`4AXDJ29=0OU`3G&(F:AZ8X-"3GF6?N=SZ1YK-[D"BZ@(5]%-"B0%T-D MA1^4!HH<[P'%#C/(+!FV]`^/P#@39X=+A$,O+E-[SG4+??E"QO:3_6\TCX#B M1\CFP&AJTT/8T0PF79B/%J;6)O'@-SFL;`T'C.$7,BF,5X(Q'EC%#9ZRY M?Z'D:16C;)O&QY+'^XUG^W87MSPO-LR5)*2XQ&;]R60%QV?>FN`4`,^_47T\ MZC$B;CP\X_W@<>JFDD<^6'GP<)<-B1V]E`'0X('63]7[:'!GJ1.36VV"C18Y MHP>1BW4N*U$%#`RYI`4[;_=X2\%2;U/>`"[7NOXFOWI7QX6U7X-?O1SOB:$XTXQR<:I)'6"<-8X50(*?_K0G0AK^,*2. M%AMW"0,1M3^[I<=3)HCK!^":9-?(#0"BYQVH9AU(N9Y>)L+5D[VH"2S+QDPF M`*C&K&O,RRM<_$-KO$E=0+7,HK5&.038-N??2+.\[2E+YI-H[&WCU3>V1M.84(JN6HW!.49 M[X50(&]!E*9P16$5I5QE0H`9K.)]%-#KZ4XXI^LP%7NVQ`V!!]U1-^ND(,W/ M"`0?%[1:^&_;V[4[_">FFDG)F(T5Y]YO[+\PQ<8+!$:Z<`'9 M-*XLQPEV$MI)X'-:U2(<'K0>JCY$!*H0M)M39^ICB$<@?:QSGA:5VP(@U%R. M+#]NO@=8+4XCN;*@L7C-#^*I2S(R-F7,TV^DCV=49X:P4V8A;*A=CQ9LK\&/ M$O0=F/C'3`,I=S":31JM\73VR;43/Q5Q:*9Y1(J;."#<7*:MLU>*DPMK>CC` M,0?'0OR?5W1*H*!`\UJV352&LKRR#I39`+NV";#N<\R'SUE8\,!>OS:!+F?I MDR7"60![12O'X/N-)\^-X`)6D&4;-AOLQ_,AEG4Y2__%VKU`)_FR$P[^\!6(06."[%L$@M._$#+@J-\\\5@/IHM[:S+;W!D9A%2 M8`6@?I/TMMGMC',]HG$CNE9X#R5Q.7'WT5_/=IX$;0N\V<$`:5Q]2^WW"TJG MG">:!3?_WDO8TF\L#$J56Q"570@91S(N65.?Z0GG'5THL>^Z2&^@_+RU/->( M%%JIZJ/K4"/AP)]\D\=X[>%F.L5KDL']8-G=U8&ZYA?K3'$EU$[Z-,3;-5RP M-7W[>,_ST*"%OO+^F1BG45I"RTJH.0C+Y61C+V1(H\8`QK26-799AY%LBRX% MU'602"W_+;5P\5"Z3G8"URAFD=Q62Y]E)V=+JVCAM74B7&`#K\T1M:YN$`.- MDC86,%A.9`/%?15?\%F+)=@UD(U,)Y`R@3.Z6DB^Y+'MN<^\B772P MZGM-QEG_=-+%=:8(I;X4Q,>HWC4+(O8KA8_/])82H0O")*==)# MC*!;!C=*#SR_44RLV5TI7KS'!%5XK M+[2L^2.6%U2C(+A38^=7^EB>ZL:]7[+P&0G86&3)%+:R%+?<:21&LK2*>62Y M7@*+TF\>)]Y_MK7[9%_9K-"^7OT"F'7>/`-37&'.W>\'W&Q_UN,^Z+/F25?? M4JCYCM%9:).`"6FI[>6]P%_M\'DFS-Q]H:,:9_&%F0=(-9,U"C$SD5+\P%M4 M]C+'V%U/K6`\[)18E@`QPQ2R-1:!RP8+;8W=9\\]+^)?#O5^(&6,=L,;C#F7DM9?EO._M;SW'>2\S+4KRCRM)`;=4&6D% M9=PIAIW"A3OHM-28Q0D'7X"]=.6F:4U"0B*(5SK,K]WM/36%"K!V'Z_94\N4 MD'"*!3Z]Z!E/+5W(9K-'O@G'\O>?/-G:W]NOP%Y#*I/7?`.!5`W/_TFW_TI2 M/7/[W/4,BLQF3J8UE+/E$GZ<2C'C#\FRM(;"(?*QBJW*Y&&+P3]0AV>1-F'A M_"N#OW)G+P('^I$Z,Z]_GZWMF9Q4=M8K\!FJB)I1K%J2H;5N!',;2W5+M4BU MZ([G>NWL?JV.WZ^5/!!Z.'>1_8()I)@)@_=)\^*N>J/L7OYBODPSWL>KU('G[%GWBT\0JA?Z)9+K4$;YSED]7`0\]P)#&SC?VNN6_ M)0)$VLKOR/ID>XOZQBZ[(IY8N[W"\46'K"X!SFY5W;*LL7TPDY%3:PZT4M^SKM$9%2R.T[4>)60`!?S`Y%&BJM4V[` MYLPS5ULC8#K\\\`^`1G#8#6]:TM8K"X.IZ"SE65BN44V=N5I3'$%."U"@50,WYA M))JK@(2UZ85LM?LBVOEM^=Y8(-+FL^C%@Y/F5O[(4P$934R'JK&W2T*18YKT MR91)5-UZ$]:7.O:;Y='.X68Q-G"_L:4L"+D/5W<5M+VOTAO-"``4C.!I7',C M^R^=M#HKEEZ8MOX,5^_1P$FZN..48%7V"+G6NK8HP)X(7-<*XOT6"". M^5O\@$,O.D.-W]0/^/_3#:@U^HW==1GY9S?ZXKB-J@JA^`=JPKTLI,PT8?;( M->$SO_?L#GKP=JVG6&BSUON/D/RRGK8DP'.2`/HZ4>_'\L]MOX-C4]KC#FEU MW4J'%[4>-G&NVFIS"B3LU+#ZA#`$-$'U(8964)A9* M7=3+D8HC^;R6!G"Y#%6=(L(BFG3U:(8Z<[?B;9)BPJB)Z/?4G?D.S=8:*`(M M`JPN$[[K)&?-$0'#B$-+0.E'/$5#:6-_QS[,XS$`3XE+<2&H7PIH0F\2/-;$ MZE_ON?#C6A%=S*]VDJ(_5\$VODLH(YK$[1I$T:@'7F_L/3,S$B=R)UEJ[OX3 MSQ)IF_%E3\3'=PUI^+HX,7]:33RDR()'PE.+-*-3%NO@=5`>4$BR6T>MT,2W M[82Z$J#X@Y:TBHOG@)HF*#BPH*8UFG')3I<4+O0(!7A:AMT[)ZM\RTR_!.Z8 MP=#7U108UL%]^VI%QWL#W'4("TTA,7-2@ZY=KJBO)M9$UX@/5&F\BI1_&NC@ M=F:IU/I<1S>V,ASE([,,3?GXZ&9+`%M^'?Y(;D3@^_E4(?.A7^O8FZ\(B8^/ M3TWWU-#>+1;+ZS^Z2;*N"#:_NOC#O<-#,,3_J6[^][A*\F`ZH'EZH8O-[)(0 M"-KT;^T)P?I.-5?L;-&4H%::Q6@V&YD5DD;@5=M*N/)`?Z%(`SVH_.E.#'P@ M3SHVK-NGGMT:3Y\9W45I#8_7W678LK21ZM!Z0VN&2,0R08`1^%@GQ8*FM!Q( MD)U;R,$6ZQ)D&8/P+;6[;&#OV7-32+]BI9#!LDN&PQYR\-\1JH_H@95:@PU' M:>0O]DX\^V2_J@Z#!,)*A3+F+:3@LOB!NML]0U^O`'*`(AV*JD#`S=/PSJ[5 M/Y]DNOX7:[Z*!KD%]K#F"PO^,QZY16>T_HXZ8_E2A4*O_-6S=R@%P]F%[MK? M4*LM7_KG--U0U2M\1]T_$,3FZDHZDH^51&FN6--&+2*1.317_K'-KK7KG^;- M@KI^U5+A+0Y"@/;)J)KY+/2UD4X.C9YH&=*.7M/RRG^]E><[U"CD#98+;863 M+IUE9;68PK3V6"MSR2-JM3LFV['R9K\&]2J%*/N&+T6&28+94'M&K^!M>&NW M.PH4WP"F1NYT((#>0Z5QU7',QIB12L`EE\+B"3)'`"&4E4S-AIO)=*L'`^SJ M)3V_M1[IH@[TRM@T=G9MVI"4I0"WN_-$[=;*W8=;$/4MAO4-!8%^1OO.'C6" M=;84P:]'NFY*01<;,K-C[FELFU$H1!8NI-:X"W_M"WR_N*K:H/?7M5LLN8%$ M_R*%Y\+,B*QTQ%IIP)VM)UF\DI?TBP2+"FL3T]QO>$4'38E,* M#\3HGM)ZT*43;GW:.'8M4VWGU1_>B:(A/2,F*";893FXL][$?!.#<'/+VIB\ M!EN[\BT!&ID-=[?XX*,%=S$A;"&FW5^+/J$ZXI=*$\'JNWRH*]5LN+0F*!K) MXX5]"!;$^LU,\CJ]\4X=;))J_:\RT+PRYELG=JCJ??A*G%7]@YJ(JX8(5^^7 MXTH#FP!/A3ZFE@*=6>0LSY$$;\T4>J>800GN!5G(="N69THI9W-,U3_[ M8+QG!P_PWF3B==Q9)ZK,#CEB?DUR;5'(1F[<<_:IEG_6Y)H^]G2GC>8NE']` MTGU)Q%B:2=[IO]@%(:W#3B&BCSGQW!9^U2&P[!N<;<6\%_OK3@66HT_)Q'U. M\?_]6_I]Q&VQ2EZ6$QS;#?;&[_PNBV*1O5BV(.#:T)K6D51$ZLN>:I>&E@HJ/W(PR(E5J@W0V'`,G/X+&!=U:3?K(DC/T+_BY]8I, M6^'C!86/;J_3^O[1JV:7#DA:-T_;=#^J^;&L50_R+E!V*G60)5MB6Z0NU0#8 MKOSXG=FZ@QI$H?K0% M5W@G=#_Z$LDI!X<*9W5C"M08&%<]Z<#E9MHCZ?&Q^":K=/5,S5(R8*R^86*L M2'8&KN%GX.Y:9OD/2>D)4550==*Z6.['F->EONRU8H/8),DRW2[PX2!_*]P[ M6&V-PO#;@3E$F6#:4=,-`C/^0 M0!VSNU%&`4<$R^5-200"60.-76%Y0Q]Z:E_C65GB7VIC3=X?X-:*].'(LW5N M86=URZ%.?1O3A!\?TB%$4UY<*S1[:?#=EF*D7@Y?/LB6E.L>OD_!YY\KT.B* M"'4'<<4D7&HO.B#FG^L[7N#-T5'TS!W;YH/8JC54+,*#KK"I.&:?JWD%5Y^BE5*C"TIR)G7?K(EJLK)%+1@T820AS)".(ANI:VUO:RM%X".^'$QY;BODFZ! M`8UGF9][U^.V[C2?164]J8LU:4HD9)B.9N@BJ:H1'4E2VO22?X%9T`2 MT``9J4CO:835FJ9#?V<`;H/K]_'[X!:S4]U[NG MTIT>7D-N#$\!TB#"&,`JI).[YLR\(0S1*=#P"XXFK9DT)F<)IAY48>G?BB-#P&ID][DUXBX]=?KOH/ MGGNWN.?^>MQ5%'>GNCN!?.PBF=VK1$1D?T41WKHLA5.`4O''NW%`)!3/2V*[ MTC'`6X#D2@;I>5$"#PY[*:;HKP,?N*)<86K_<''@PI88/&<[[N#_(!-[N$4! MQ.7FO@%,+!T.H!*;70B]_PLOM=N*R^W[\??7WPIR!\1,H>4WB]RMT#N)2E16 M%#BMX?'K4";@V^7<$!8<;$VIPKFQTA34(F91BV+WLKZ2#!C`"/$EF`RK\;817&P1 M<+_6T[$BB!<%!B#P3A@!GKB@"W:B_`$(0[4269AP!CD-<8.2!(F8'K).=""> MUOE5?(D]%J>>+5^,P$D6\#""JNR3,Q':Z7I"=UY@),=F/EXQ)8?E-P*74=IO M18?\)#7::/Q>(+X!"/FGZWF$M#GD?`T@)AX0)WA3AQ!1*QX3?23TK&A/ID0/I40'U<[2.$\W; M5-VCX[96QXMA5K-C60-D`X1"O3F_(`'/$1V`H8E7HBP)4P=\5)68K9W3&8P# M!H=Q-.[2ANC"^C3I%!(.Y@2^`U'L7/S4MVC\G_E&,!*B`>#F8!`(\;3OI$[I MS_D@IR%+P<$74S?G![(-E\;`.Z3EUOTS1)RH<'8\E!P#^P4W[(X](L$#\"XW M`4C#34`6K!-$,]'X2(P0(B*1X:,HG1`03TRN7[9%7J>C!=Z5* M?C2.]>`!TL!@_3^SM56P]<)``=AEG7^O,:,!BPH`TZ'/[C[ M9.<1*EZ_?3*:Y7KO_O"[NW]\//K,R[4EB52"@^`.,%([X(!#U-T0F0]O=92I M*X=G/B`O##A"(TN;+F0*GTJ]$AP]?W?WE'8>@"RSBB M:799E5B2Y]V=22\?"(N!_@[@Z]TGKQID(!N"(-0`D9,(7$_PZA8K(:'2Y2]$ MRE`Z\A9A5R<7$T\W,!3P8+D.TFJP7G`,.%BM6L+?$87EU4)(#<0@H0T'7ZP/ MZ71*/)D=%1I,_P#@DF-QB]4IK'UTI!VT2FC.Z>FZ6/\.' M260D.__A]S\.Z;U7*7*MX,3\>:1%<(/IMCV+[9)OQD&,[0@K0P#1"*MCQD\(JS)IMX!CUL:DL14<',<8*]D` M9QI!F)\Z_H3!2A4>;-T(]4@$'XK^?O;B!Z00CK*3@W^.ATR\:)>+Z8/)8_LB>=N<>603([7$1T81NV/'D*5Z.0"=)#KUAL^\"[(=?_1SI/' MHY'H^,O^T^]VGGP[TH1OPA1)!/?E.$=05]S@KX+"\#!J+$ECPN9`VZ$?PEO MQ*#;#?!03!X2!+!'E7.'!35M`V%OJ_(&R*$[QE^01GA,B'[YT-4=\!,W2=9K M/J`?_(65&S#']Q%4=(?GX)COAMQ"__T"#64?_QV MI!6PR#ETM/2(3*XS?`&9QUM*?J8J1WQ<GUT=-((WMRSOV98U@=6Q%%]$84+K3YZNA],))C^98/BS93ZIFLIDSVC5AF><1I[7#)+JH$$_D M$UR[(L_1O*V3OP03PXT>`J=Z3G1\#%WW)3-C=_NJ'XJ`QB MN"[,)@_>"0#*MB'Z(&&$1M= MUL,0/5()UN&('XWQ%,@*@"\=HCUR_8)H7K`+8`S+C/T@B.&.:(_P__8FC6!F M5KUE#A&`97"1\3WOQ[5T+=WL#@:`$Q*F&`T\LOJYR>G;QP_Q!4`=MQ9"W,KB M"#I[H&F-"OHA,+5F`G\`0T[4+JAV;W1V".X\%MU@C>/>#L@>4/ZUF9Y+5`I: MNUUM!C`&-%(5!$][8.C@^Z%B^9Q3Y-?Q%[]`<81'MO?+?W4F2G;%?;DFY M-MD%6N[D*K0<7'>2#ET91B_X+Z6?L;N3G<._Q3L1V(!5@4)'B<_PM8ROXO0, MBO4XDSK(JU)^H7=,44PH5YF\%47%+_DKNS#90)[S.$S)CMX)^N<4&C)D3YG3 M5&CS'21U"`:D2"$;1#!#I(*\5Z("/`\[>0"L]AE,"O4#.='!@VX!:CGY`1VJ MPL*\5BV#<`@HA*60V&\3*,)W_ETD1/^NP=TZ\<#OLU(=4S@0#853'3,J$(L, M_"*%N/A-$*DX*N[$V6'`B%38KS:=X+U/P7L?TI6E:E[6H;\Y&!\AO,V#S(KW M`+A,0NP43"=%6S$M^E)`ZZG1F5%HYJ`Z!#T&7?_3[O%NZQ3Q"G2,F-^"DT6S MA"\5ER(/#HG-" M`58/R&I:PI.=4E3@W[LL#5S?]M2T\W/^3ZV^BU2H&G_`I2CK]"AT\I>\+T,ZE+X3@8A\I'9/CN81: MA+RWON,1!^DC!(O'4H]P2';')YX:(1PP\Y[6I-25@!6!4M$7O!0EET1&&Z22 M/`F(@JL9,P<'>Q=<0`'FFSKYZUFI1V-N/0%_&F3Q\)(CZG=1HSU$C8Y?/S_Y MQ\&/1]G!X?_\].+X!;-;8(NYD^!O`-5E_\BXJ4S2 MHL[R'@!2;8L5+^65+.+".WEU5][% M,VYYMI2QZ,G`3/M3'H[Y49R$OV"J`U/.3R6.@N./0+55C@S*/>A<-U90'8<) M!@>HRX,^AN:G@19XP?OWA!,N>,C48CT;,A$H-C38/I8&VX?DC]BVP,/>Z!K2 M&$`A),:4-BY6P&KFQ`^QJ$#G0".$EA`>B9TGAW@GG-YX>G9(`CU#-'L]/((` MCM>M.OJN.Z`C:(":E`Y;Q!^!!A1=YM%1A*&B+Q^]$CY/K/PY//KEZQ<.V^V\ M1;\)#R#`>0#I856T?)T,Z*)!0BV@0$_&^,%SQEV>WO]_HPAU]/;WW9U)\XA@ MH32(-(].C!T`%C4-5*LN/W08-J=X0U0*%L\"=`D(+;)'OK1Q+E-, MQE39/]6^Q\E.M)D$!_*FUH'/S'6=11!*Q(<_U(DL!5FVWU^Y7N$0D`%SPU=Q MDW$8J,$=V=I%PZD;/`.-[88\C%#:/S%ZLJ700M1`._>*L&N/ZE\N4'%1`JXC M@D'%H`K15XOO-J)C(8!NBJ#\OOM)&,KJZD8=<&,G#4S?5R#PTMK<9RM[/03' MQ\#Y2&ZD$+JJ$M#P<37GAPD),B?K:9",6O0&07^LG]HWD*D-7`+^VD[*"'*5G#IGK9U?^A$ZA:F4`04 M?'I_&Z]8CGR=_%46)M#?ARR%_IMECL;VPVBJSB,`(0[1BZ;P^(R`Z\A/I!Z7 MF-*(@(."R#X0QE,"+I;4[`42W^ MW!9."K47K?#RY,9>8,"A;7OQKXD=)2R%>=([2:`(SS8'84TJ^Z=IF+0J[_@2 MXWWG,%G9IGWEG`7H68E&]EI;A1`'^(V=+N#ID9SND1!7.!W".Z@)VO;6:!7&Q/?(Z(`U[HBI.//I9[0!9T M/A#EU)0!>;P>](Q^D-8]/*30E_Z5O[?)V@-(M$N,'!HA#8(0YWBS0:?HI!4M M)YV-]^>!>Q[6*5UI/%-B`7X2]'=`8WV/5(`"^6":;;-\IP4>5'%Q"9)U>AC_ M@'\5NYR/&_W.&^K(,Z%]16P(4!+Y>6B-!X3)[*$.L'ZWQ%,Y[/;3L8I7Y7)@ MO)X`<>F`2&$",_JJ]_6_RQ`[=A$`+NY'DHX(G@TX!>&.*RX?;+\=D5\]<>@E M^U#74,W+H]JBW>`VK>2@_-N4X,,/Q=2G\D378KF$P("MC?X#LC0J4>0QKJB* M-,CS2ZB/R@R%"2X3U6.TOOJBQA-5C\9GZ7OS),VR*00`"EJAGO\"VF#[@U&< M#;Q9RA$A+5P(3YBUR+`%90,?07Z-HI$UOC_?Q6"GMOX4ZDWZ1AQE`@'@=3RD MS?[*E:1]1,X]8G4<6V`B=J.X(8@"C3CI9*BL>2>J&NQ.O<_@-C)*[ODN"BCJ MB-^!.H0A(8ASU5TH[?>#\\&:8;J#.Q4`UB<@3S>.V&0LD9B6#[^3*_5!SQ?! MTIU04#BCFRCW@3P4J&\:^B.`R@D^?C-T-IP8Q9NWF=<+9/X0O_KKP<$;H@%G M;+$W$J-X`[^[!>C8C;;,GO;;CGHH/D?@[U62@=C92@!2!L42%*Z26>IN^?+V M=`2*(RJY^@>I2@2-+']JRXV[APVO*JXOYO.X"4-#.4HP=P[]V)F'KPAO6:0< M"Y7:""-!#7KL[13W?7G=U`->,6*91SWXU@T+I3-+/P5H(VENB"6ZP6`@NL&P M3_NEY7C/I4MC#$_'$WP4-8BTZ:2[>"A,SG(O.*@(`[11I7F*K!M'FN"AHHD= MB>&G,+I&9'`<(NRPDV(X@,`)MRIQH>Y`(> M_O6]PXXN?8)#!@T[M.6]1":IHQ1BA9P+H`S%X[]'4'33;9P#28)SJ6U?(NJ^ M-$"`E%W@MXXY^$8/GM.IU:O(KUTG9+2J'6=.W:5AV4J#W:1:]>X\L>,\> M.>+?KJK+.J15][V(*YIB7A2&>!^+>!P/'%X;"NJ>,N1P^4M+JX=>!XF/,8I9 M?-"`%(M]+&'$TR#%2Q'W\`0OI)1$3%AP2ROUP-`10@R8'#[DKK#._O#C$VD. M_KN8ZELF>#`4AC\X#G&WGUHM_MJ;;#B0T^'`!DCMC=?APR=\(I"&CW$G[_!& M#R+X+7X&Q_`GV+`6[*8W(B<.4/N(07B(@0Z_ZB`"<%^/\"-7AL(B@@:+G)C4 M@7/0K5L8^%K;W!KQW-PDD$48]HO`DG-4'7/&A/GPX`XLV_<WYP_'W&NIJG3Q`"Z!FY%-J^[`0\U(EZUV@)GY_0%-74$X^M3=!6 M+_JO2WJ::3&,,CR%M@@%00@C0:B@VDV$>5O2(5DRDO%J@-FK&ZQQ_5=NK[5C MND?R2`A;.D\A:/@9C@".;Y1]]G4N,$NG9,10:U<=!!]47%`7!=R[9K#Q;9P+ MW$T&Z/73]WP1Y'1"2V,IKI?L]`OS3[>CJSY^)ZS5)DJ<0S]@JW96?Y]9(FK! MV7,T;_!0[T7#1/7E0I"DT_(4*2?V31?>7\)Z_5?70)MN+5TT7AM<12@6(FL'H1UEZ7LZ=2 M:C/(*)Z14(MX$A)5TL&RHW663LAD&[ MO-/82NZQ0VLG?8(N(`<'7;@-!@*0P.F#ESZ0&'X(]##B)BB,.DYC=PQN83=C M16P&>?K`U$.(!YX-[`P@4_[>EN,[@W.`,;%.O70#>6RET/CSUC7!P5D[N(#[ M&>N(?H[*>->42W/H>@L;4HBA"]?#=3<.O!Z0$)%\.FH1WG[?P-X=B>1`-4/! M(4_IX'*-57JRC4C$*]'S"@L;DOLZ1Y;QS_NOGK&$"1%CGY@8!\+#Q&KOUK:_ MZM4H<)P&ZHJ!6'&)X<5##Z'P7TIG:%/*9!9$K64B*;Z#:#O_A0P/<$MX=A"` M']$=MLAM'Q1>(,S,13F3%B]9FX#G(1N$X'8Q88$BRW=(Z"Y=A&(%OM/ONJ=K MA,"#U!B'"AS4(7,X-ZQ@Y/I=?DD<3`$2;S:9L>:6\6`P2/W#GQX,0' M>-:IC6Y\=J\\:BLY6?LZV19PY[BKU!%RM63V7X\<4TRP&%!"G\C7;7`^9Y3$#;*&E&J`TDSG@KJ+QAGXI$72.'[7E;6X>R+K&#"OA2FM3DJZV_-9(BAQX-[6D5+[HF.C%`]@N`OE_2. MWL^K;%$U7`SP.YAE3)S^PNBHGZ#2&0':'N7)BSR`G=SK,@@+)&=ZP^9<8;J? M5K8MK45"=5@#9%@@*\\&P[<33<'2X'G)"S"-$@+0@8@![ M#,5PC1R@=@R&]W-:IB@S!,Y=VD_J5KI#LDJ8\&,\7R@@G%:.)SDEB')O4PYO M!"!=%;G]"33;-W@D,REFJG\6"*Z#1;"7!"3NJNWYVWM)-:.`H=MP'(,(#\W\ MEK=H<+W%?13*@'A#+;A@PK,`A;Y$]J2LLEJU&4=?=HL@MWP=PBK(J0^QKX?W M2-PX"716-0AJ?_<0N=S+`#^B9_#UT0[A`S=^#P3]D4_8<0<7I`E6*7#YE@[[ MC[SK$,$)E(VSSAP<_[=(&5-3S<:<'N'G+'MLBJ%HL" MD_!=UP1[ZI!"Y.WW_!(!=U^T%#`8"O$(TFA"3P@SNUGA16J@?'SDV+X;0/%8R"A(+]@W*(^%E,4"%LG:#AC)V]L.N!^@ZJ')>A)$&_-9 M+H(JXFV"$;#(Q6&N!*Q_WN5CR39P-W[+&B"IY2:Y!#7F'"TJZ=$K6@TZ$HLB M!_B44#+!$]%\`5^UOT+@$]*GW\7MOP0!@W_BST/A@SN$9+%0UMB*;GYE2_>( M1AO>O*=/^L;!Z-`\'YIE*!=!"*+8O#4*XQM:+IBF`6+<`TCR:B\4?6(=;!?H M-6DC!N6QJLR-_Z*!CM=!K>(BN)H,2Z"F:Q]*[#[`!V)]"\ET?\()MB=C4;'0 MVIVB;E@&)A1+V.GKL8'*N_I[@.'AQ/1>V/I\=]^\>G#TZL<'/[ZZ1S!+[E>( M37X9S$B\#X`H&T0$0'DH5I*I#G+2S2*T'B,E.;*GCL:_@@"'4^P"&R0Y7]\) M\(!27#T`?(\+Y`?!>!A&OI[LRH%X'9^YCV&XSZ;&4F:K.J&@_8^L)E;B3KN!MG`UI"%C\X>P/0)C0U-ZR$>[G&R8H MWWR)R#V%!F[:5H5&Z89M6P[H`:;B3H2'"K%Z7XD"%&]LG:<1I%\=__B&+-5B M-F")\';;5QYXY[3!]/;($8=BB-T";;\"GNP$[>.'?^!K@K,$6T#V`H]>BZ9Q MC'"N89\"XKS)__4/D`+FGO1U@*:\CC^#-!)A2I M:DZX&T'\`#ALCRVPA'W%\HIP28SW]><-Q+0-$J93O,(%/]GB$EIV:-P\>/9`+!>P/Z-M/^AW8OV M',)3,W2&<.M)\&$D`-'`IX$J\!X**+#GQZ",<5:<%G,6%T^SE_6F6E4H0/.F M=>=#;3U_Z_%`E'3F<(]MJ_Q1%H:N6Q1S3KRGU3,_MBG#D45?V$H-&9?SH+0' MSX&E("&-0%BKK)6[';`0/0!;8K#$\.%#DSNN:;MG.]GM?#K-L81!KC3^0I<) MHE/BXDB)>#\*S?ER&]=J)F<\QV(.\7N$1>@1\24@"I1[X")MBR2^W+?6PM8! MH$HV1TBRBB*0,<<-G%:H.9=!Z$4-%K"NX'3WX`1D^N;/^!EA#!*0[2''+/!Z M$9J^W%:*O6NC_:'H$)-0D-)N2J"4(J67^A#;A9@XQIJL"P$]C`X8:<&:A>4M M/T9?%J1.KT0]Z%6*&J$CMC-A:BR^QH_*!90*D"H8.<,DB`TD%V?Q\-D>6YR+ M`.^4`\^6^`V!&`@_E"5"PS%1",T'T3$BIT/GK!R+C7(W&$/49!#`WA.1F#=N M(7TN^T]&X?7C4!+4N]RVX!%]Y^'O[K5^^-E#*P,=J.O')YZ@/G`X?:.]I[M/3<"SA6'.]0>"@&XAP^M M()9S7"F#9Y!#VH.80B=?:%]O"P968,NA*6!5("0L!A"<-]3II`.$'X[8 MDS0W13]Y.?\BK[U8)[MVG&5W/LZ3_"W48$Z!`#X(EJ0S8.%FB">(Z.Y74%T? M!H#_@&@$2T/A3;.MD)%5`M6G[R66F@R(N8K4;=4D0@FAVGJ*_'4Z&$@5-T+F M?E9,`DD;9WN)\<(K2P>9A-119R]=C/NKA,D_)&$8]J$\/FIG%S^C+RR?,@(> MRHP34M*MY"WT95,2.T(#HPF@0B*WK5!)"+6[&M8WE2]TB%>%16U13S]FYZD0(@JE(AIP"%G,DN6^<5U*>R- M5\_8]B+I2I0]H"1R<>YB^:%)A+#RN58-@$QU3=)@4Y904JC4NRV?G"7$]GO- MNVVO/4Y`7F/RV1)Y.J%XA9&0T/)6\9PM!?3*18)F0/>;AB)MR:*K9MB*$,1Q M=GI/=D*A7B7=@=-YSW&88$\$"WC2`>2VAC#G4@J+TN\0!O;>$RJJ0@9!`IM2 M!NS+=H.'E=(M3Z@>*I7M;BH(XL1]H:)K6TF94%>R3EG#T+875YEEID20J\PR MVUNG(_T\'J(^PXEJU-1]_!$.H)8'BH=A4BI:>C5EFANI0)* MFI].&'F:+V>R=:4:%QO>E*L1)^IS%84:RY:+=-RADN:VUX;II5)CMF)!I;]M M+XZ61O89I4-Z.HV2]Y4'%(4L6L3@'A^&8S\]V@MDT9"OSOB$I,:C(_['J&@\ MO\(%S2?)\!>78/<22C!!4C)XY"HQ8LK+<50DU>[%N081IM#(55$\6WFNJA5?+.%BDI7WP!48@5E-V4_YR_3^0]Q5G-#'9JY M+_K]!OVHZ`@O5/1JRRKIB`.==&A;YQC"T(4[*BR;DSU?EM:>8_ M&JS9,BK!E8YHXC)3&4\Q!4C\1%R?.N7&P3!TB[.V,%+1U2>_P8:6>3$I0468 M7I>]P/)P5')C;K0&K;84]4KS:E,`8M@"-D1C5H#F!+:7Q^@3S'', M@4N804YX<55,P1;?F+FO(3932H\+*YW%L9](I[(\<:R0Z3D.@S-J6Z`573Q%%LP'8;5 M+!J8[#_=_W;_Z6\J/A+")"[/6O]:`RA3XOF$(B0S;L(TW63WCN/CK#"8Y%\9HWGX#+*O3^+:L<:F!A2TQI-,FN=Y%-!,(&`;?%!C/K8&[ M*-B*@W2V6XZL<#NMN&_*=JNE]!U:IJ:<2DK;*HA2Y0+^7BP7D$1"F,MZ MIZ]B^<''#;5[?(#_?/^;BF5=P-96+B8TDU#7H^*"W\W%_0K8=,I0%4,Q%?CQ M0`96L?9VX8[@\H&QYZ8'S/\/=IQK3V!+F>/,WXT"`.!,>_\'VM>;$D"<0E&_ ML$AH/(=EJK*$D0NA1R"ZKL'4U%B<:%YMBADD;I"._H)M90WD;452J8KRF6(] MSH^Z*)\M,)8:/)C"(M_H:LI,&5_?O&08Y%:]W!;=F/Z0#N&-*GQE>_%INFLC M:+VBFZHY@>WE=S-]S;P9O8<%TMXLYK9I61C-*DIL.EU-FFK)K;3&`.=G7!/$1=CMW^EO?\S24S,P;C2OMB6?="(CKB]UPUAM8:'; MEV2K,!/JC5FFG_5D1?IQ(L"J3N4$%E,#XE##CK\;,D@I_Z86F6YV=Y:%=\SO75<\'Q""])O+`FK\XNU#(_GC/E>H/9-JRA.5/$QSE65S3T MNR&&"Y6VMKVV2E7=``DH]VB8,H5*@9G"(H=FT/"B+0VDDX-Q,9`RS)J.'W)) M1I[",(#'M,+J.32^):.).&)TS&G+(9C1IM-7ICP2AT=""Q,C5V7&:9F]O\"4 MTW16U*V#3/Q`?C"/CH)-2>@31M-9N2-N>W(R89*G"VK'B>&9*JEN&[E.QZGY M8IJI4OBV%U=9&;:/M2\VI8*9&ZNYO6V ME)#.8LF?Z92TZ;WC1*CSQVWIH)C\.V%"764NV5Z\08@X7=U5G!!2^KO%HD;& MI,D0N58.N[.,$5X!%UTOA2FAQ$_$Y-)XD7%"59+0]I:XF@35DNF3.)(0XU-A MY/?BC\6A4:>$1;KH>QP8NCB5J4#1#:DQ-3]T"Q1M;YW4S$B7>8J3'P=R)Q.6 MN5K%FPK&.$1TIH\M5[S7H,*6*["[.V4#?1P7*84C9@N_JV09K:QR[!?Q?$W" M]`9P((\)^W.*D7OIDICY99:R"E@7/;05&0D=UX4NB&9Z[[B\4*YR,-4F^6%" M^E?5%=E>.V'09II.7=[7O-H6X*J(I2G3(6(I6XHU=S>U4N)C#'BU*G38#<@/3`*@RYO,C#I@I.F`,F1B:Q4 M:0Q;ODCHTK'K6X/R&YA>UALJN=T!GBZ2G]_+7J>3Y'G"BR./A6C8(MO7$(DP MI]7DT=Z6I8]H^#=ES+CD?KRKBZ#;BJKBM-:5<-T`1!+FR!&$485"3*&1JT(A MMG0P504D;*^M"DC87OL9&B(NL4)JG:U*]*'W@O0[H;M&(ZE,X1(7%[I"`%MH M]AH8N0F`(C M?J"T09N7Z4A#Q;FV4F.2[M:ZQ?>F`BOATLLXZ>MXT98$D%U8WK8$4),R_:,R M(4WE8GZF84=3,HC394)]*:5KZBI+4YCDEQITV$JH;S2OMB5"K&"IS];O69N` M"@'FZ66BJHHM;/&`T&TZ<,BD$\WK;>^.N+5NIH@M'5YFJKIOV[NK#"/;>V,* M7C*IP-=S,:6#LKY:3F=EM-TQ+#;OGJK M_#D.JNJ>*ME@BKS\Q5EVIK+!3&5(GC"T/I?*PZ,S5>;)F%!;,KGILNB4LUP2 MUNOD[Y)!/,[["=5E_$#/X!4E%$6#*C'%PG"6$A2HX:0J+_*+"4.9DK)*? M:UYM>W.5+K15Q>DLR#CMRQ+1+Y+^X_"X:.K-.0F2JF#%5F24Z21E'`^Z$G1;@UYE3=O*SUH5S;6E@90=;`FG:,7I3SF>T)0` MXR=*6V#]1J793<&AVQYIRX^J<0VVMTXGD?.%"MFF4BA.^\K]SK:(.-%8\K;D MI[+D3?&0Z\H6;:^=SBC,SU2D;WKM..DW*5M4VQ5PTVHU0<-_HUWI>@,`2IAO MSN?5JBF73;E"J7O*9;NJS(FIG(@3;;U882[K%^EWHYL7'3DJP6W*)/DZ4P4@ M;77E6:8J^K*]>3HNR+_4-4D%!(Y'63.><1__"^PHBLB^(=%L_#.&ZJ/4[\ M.P-S!MNGFA+CNKE$%RK\K&[.2JP]H(&S6M>3MUF!$1RHW_XR>:;F"HAT"8 MR^);;(5R]B+B8]R)C!T7Y6I=G,ZJU06LQR4&B*TN.,SM73%+:(ZC7%S-JGMW ML*VU>5ZC>`N'_\N=PV)6G385/STKYM7LTGV\SP]6DPN4ZKL/YM6B;OCA@^8- M@@WK_-^;`B/V:QC7FC.8$HH%Y=I&1=)QL6Y#DNVM53&1&Z"`3"@U9FL(C M3I:%ZD"F4-+E:$V52RYB,J%>5=:^F!)"GM".5U4CV*(D*-J'JU M+:&E&VT;%W:ZJ(XM!:B(SY;R78PQ&?%;X,(6(/79636IL%/GEL$D87ER'$E- M.:DE,HT"78:KI^R65QHQMFRD*AFUI9H*A9LK79;9=/5D_E6<=GZ>2IS::C75 MG`)3ZH\S*3-(&D%F"XUTR;= MK%8E!A3*`$>JJAJU8]4"P:!"-B57LME`5DVL5`QLRRTJU\N6:%!7UY3S`AFD MS6(J.W(U0L.4>^+4HXOMV@)'Y9>:PB+7+;.VO;:*$VROK=(;IDP8I[YZIE*B MML"`29W.L(W#PUN["8&B&O=JRQ?5;?,,=<1I"HPX>4A-TWK3+%Q-4S)5DJ?C MFUQ8!#7KM,6@5F%UJ-2[J0B)8TG7:',#9`,8+;+)IFG0!)U0M*C4O2E8H.ZG MSA9-EWVPH!53C9PR$Y3.!(JCH5AO.#@A8>59GK+@1(4.6\Z\8"^^;EBKJ0C7 M53^:WCU.BBG3)2F+;;X:?UV<594]M&6'GS5&Y0VP@R_9UYS*%B`JE]D4('DY M^SJR1F;W-._*.[#A5A?5,J']JBINLZ6$>C:MTK4,4.$E(@+IE M.J;`T*V>L^4[])3H5K&:\EZ<#+#]7<.2M@!1E3+9DD%"8_5+'8>NZR2R17>Z M3J)\):YS.B9[GU#=JQ*XMK)%%2ZR;5N[*EC[-AD1Q&6_;BVY+4.J1+\M9:04 M_^V1;8J&&"*[#CA(XB>#A@J<6P*#)WM:VI\YHU*'MM>6_5JVVLC M<9`Z?*^A=-O+,W&`M('F`+9R)V'21B*0-2:4%>S#O&T",.$*C+A$GM3S^691 M31RTU.7@MO(B7;%9'#CU:LWI=QH^L@6(BGQM94C9,*N%-N>$&5`LT]+`WE:& MW39B3)EA1()/@PAC2M2\VI;_E-MS3.\=%TFZ;AU;:"241MH:"-N+JSP'4R+0 M5=W9WKK,$CKLBVQ58/0JS)/E1J4$;&&0$@+GV5DQJ695NNO'15#"V2OQ`Q4K MOP:C++'0"V7:F,Z23F>H["5;81&\'I6\,F68.()T,P5LS;B5"A^FP,A5'K@M M*:B$ABW$=7D/6XBK\AZF$(]3?DJC757R80J+A)OBNJS^E\%.90,8DD,[VG*9M2N+2Z627CXM?7<+1EA#F MFS5VA*C*H$W%?QPBM\]]XT;=A`Y;.HL!/N[G4L+\I M#^8[[:NW>YSWVL\_HLG8%!QQL:`KF[,EC<_&DS+%`XK7TK%CG`B4IH(M.%0" MPI8`556$IO(AC@==(M(6#2]5:1E;/*ATHRD>R(R<0J"1RK9W3SG_`'RO,M1- M;QYG`9U]:DP+Z:@@W;2\O)QLL!9H588Q9K-5GI M9X>E(Q`5D)"4)&_*MN[J\!N>_&U MKJ#6]-YQ^M%QG2C(<$;`(9.&-@"`\V*J@BS*3@2YO]RM^DVF]?3"IN2 M/YLY0;;81Y\BVU6Y3/*EC-+#JBL9^XAI:CM;/#YHW2$>MN0`2GZ6C@4F>TF((C+HM$>];-3M"C.IO.EE96 M%PE]#>Q@5@ZOMO5N4U:S8?J%2D';WER%=%N*4R5(C6^M\VUO0!2D'/1:J_)0 MMIBH5%EZ4P*\0B8O"ET/C"EQY`DMQ#@\Q.75V?2 MC&D+\*^;(YJ2Q?78I0?[66,JVTHA5&9@"K;,5YH7MVT>94K`R+(`"7$5"6W& M0A54,26-N)*8%:5XOUMF[8O:7.X?%K#IM*GYZ5LRKV:7[>)\?K"87 MJ&IS'\RK1=WPPQ#\[2H*/J(UP?;6C]6WWOL=W'K:07R[221=(4.<(;XVB=PX M1ZBTA*E,S!.VI^C:[6VOC1IH77#15@0BN*A[O>GMXWS_+J$1&S\1T[D:76&+ MHZ8Z5U79W(!-NTX(#E5HU!06>9VI>H9LR4`5<+&]]S(9\'@@[Q83+-T M]4ZY*N)G2P5880IUP?#'*N%2OCA%)"U_JR<;-NU\L25/R:1#OI.I:H=L^2%A M>E"5E+*]=;J(I\Y,M[VURNBPU?NJ.)7MK541`=-;QZ6\;H"_+2PJ%3!,W:1< M-[G?]MXJ46-[[7E"";M6L9WMO566OBG;Y0O=4`);4H-E/56AW!;L"65\D:G8 MS!;L9;JY=KG.9C:]=US%*$N@;;E/18$W`(R4.?^XF/R$,D`S MJ%P4R!`P),_`.*9NUMEIPZAU^M+[*"A=,7)51L+VX3"&[2MSK8OZ6 M((E+'%TU@"V@4#^5CC-4.7G;>TN1%K7/+)M<%(MS)W:+Y;(L('$QV[<^:Z6N M!D!R2K-:&E5@QA9`RL$[EER2?Z.&N)G26&7E8GI_@VI7&INOCC1X_W'S\R"J/$%>:.KH[,U'Y*J`D6"=T)%?W9 M*L#-E#O8&7&0@`W_95JN$L)"GW0QDP/5*0)1U2+;UXA!6U70>?X?46=N2PF/ M=Q]FQ6G]3N7;VBJ![O;;71#_OI>]6`B1)CRG M&^2%>=RKBWHSFV:3LEAA+D5-^76Z654+3&_IC2EQ\9(V2*WA;UL*3RG=?&!^ MHDH:V5Y_H<\@VDEW%2G;WGNCH3A3V1'G(F7KA*F-EPX6ND)M6PI0I7%,*2!' MB#@ARR,:G8SXI6K`C7R4V0`,FA>K53VI"N8%6CR`KIRJ:(U;*LU>&)2 M;QI85V=-/>\,+^Y*2J=1XXA*F;1'LTFEDG2F='+[X-&42\Z&`51@D@=S7:,) M3.&3-C-7+2#6RE4Z\M!9/J8B-;_*J6_N92<:>K`]E:I[UY04XZRJL\A-P\#Y M'0T:3&&1+^OWJN"&+1$T7PO/FO[5,L+ZI)-M^L,$9M]KZX3`:/N'S\A$UO9NX0!D+[`I)D0/F$/DNK MZ\?Q,=!1H_T!O$\#<%1L/Z56B(2&)F%$WEU>;T7VC""W^8U(MIM49&#!.E MV$I2);3O\P,-']O25-C[OI,M:I@XFH/8"A25"+>%P3M=6:[MO1.J=!*_JQF" M[S\OL/(&(]:D`&VY:98UDF%@#?:S7M0S*:!$KN-=56]6JDI.4W#%N3YA1BQ^ MH.)]T=!L3L=.*\VK;=EI#3VEW"AF:B1_RD:QWS:,Y(HS4B8_5%;+#7"L;KZ' M+7VF]-\^81N"%6EJYUR;\F1"[=YD-0K_H=?_4,;2+O4')4-Y?9JV*!X#1G`&?'EZMU M.<_@R!9(=-8;^+RGH/2WK$QROSQ%]\`T>U5.T04[RXXWZ(>]O.Y9.]EJ64YD MI_H,WT3'5'6^P!/H):SF4F:*E\SQO,V\?>R;I@`58:_L3O;LU=$W^)^_U1B! M\[>RF*TOT*Q0+\[OTRO/#F4Q.5WSXTUS7N(RA[A&V6"-.7L?WE3!>=.4NRC=-F\TY M*-U!KRI7O_XR?/;^;O8CCIJM*QQZLZ[P"ND8EAC"6;7`\(D*?P[/0+/]9HXZ MVLOQDQ[MXK+OX5,#&'"NUVXW/2,.X^\^WLW>%$TV*]^5LP=-6<-Y@,(")(F] M\=>?X)#_S,J?EU7C#G?U5_^XFQUL$`SQ0&C*^_)P$H54.G)2D4=8AMHM;(RJ M5A<`JGR_`C:V`02N7.??"QVQF#@[+9I)#<=QQ:W"?.BZG%PLZEE]?KD3SDU. MQG^Y<7WU'[>+9T\$Q@3?:[+F_/0O=YX_?_CPR;??F>WVN995W)4^<"S8#//R M+W?,)-NOOX`S6Q8"1E"6LP%EO*^;M[.ZF*ZRT\NL`*JPXHV`["@L$'58U[S: MS4[0R1BN^,WJ.A[&:_Z]J5"6Q_A.M0"&9RC^!A7N(+5]?P71GZWJLS7\57C[ M8&LR/.C[`OXK/W.O6I3OV]=EK\_.2-&];GH0"YZ#!R):@/**B^Z[44$E$FI9 M-.L="JNSC9,MLPH\"\)[5Q42@GA!6;`HW;J[_B7"$5U?/T%5+MY53;T0*0C) MP3;/=DK(63$!#Z\O(^F#=0[IN=EB9IQ'&!\@!U_CV3L9EJ@!+JQM7*QP1)$# MLQ*#P%994Z-4F,*P;)JZV; M-A)%_\H\=*54@A1"D](^5'*,R;H%F]JFV6JU#PYQ$K0&(]NDY=_ON7=L,#.V M0U9]B9)X/NZ]B0)9E@7,J@I3$><:1GHB06I&HH5&6Q$AT MT+BPT2'1NFOA()6N[I"-+OH=<='K%]C@T(9=,5EMPC4F?T+=>:3KSVAQTNBI MM%E94.7M:.9R`T#NK\`LH2!,S`[<#>>KVQ17_5"%DMWCB'T3_R53W4-!TC6F MF]1HT:#')DKSG;R++>OP5P3L[WJH^G08/R8IYEH)7/\`B3`#>3HX+8$B"=6. MY*$R`=_&Z/B(/B18))O#'!O\9YUCLE68_I_$]XAH0BZZ#`^.<4E_,_Y-6@HZ8YYY/H88E!@C;0EH4EC(LN1*"H:.0 MH1A;YK@%APH<"@"D)7UP&\L]^*5V&C\T7*\2QH7WY9JL[<*C.3EGXCJ,^9XK_RF*BIWK(>98Z8]DPL`U MOW:O#1^3F>YT9CD^S]0GAXU0(H*D9X(>NH'6@L$X5@F1-"3'?(KT2F*C@D M_\PVZ/?)".XXN#4\"Y[S;6[[-AG\DP@\`\8PZ0]Q;06WEN4("PL3D#_-G9'E MD<6F>$KKY;F31B6OBS=M83244I1,2(V2"\&H5.L:&%D6(42Y-56T(LG(\#*Q MV$"HJM92FPO29G[M6]_F$%58W_&SV?@5=T56P,`9LDD!""F+*7+43XD91Y9O M>O:,+858O)[[MF/YF'<4Y>$2-H]NB+%)_@L0CW%0-_;W"G%15,FHW*S)M^ MD;(V\383%W]04L3)1(08TFL86W8`-6]<2BE8;-/R'&'[_IP<6]=1G,W]D7BC MZ;:T@0]S>\@\:C-?(AD[RU!;D6:P)R"L9%`%E)R)VF,&C^!>E$V! ML`BTBQEMX+66O*M'N99X"1L9.4E<3,)EMGZ24727RR"IB2^YA>`M6$6$<13F M"$I5B%'T@)T'O'HL>0D"@G6YMTS,H!B`*VE^=:3C%JU6]2*D8]IJ\0)^3'1:VV@>0#ON?+;30<\U>C`):[`L,ZZ&JX.).9IB!"O*[61PN)"DV MUD.[@$#8-?.:J>.4",GZ%:6+90:'K%M_N8C10[B-`:::4^454@W!##N84D4W M',)I#&XM1R+;TPN0!QLUP2S.5Q\PF6=-C`!H<&9XP8\J"'I5K3LA<0SD?K`^ MPF5NZ/=5XW+XRZ2N/Y3YZ"-O,[5AY69%+ID888<$9T>X+A/"&P<0TI'QJ\$/ M7D3J4,1WF12J?55A`5W!G\(#D.OE;V\1/$7(M76T.XRYRU(L&`H&7O>FA ML7U$O;ABGQBH2G&-:GK(KM;G2M/7>DY#*D-2(.TA2ULXJ49WL$!-#Z5`%RRM MUO-+B(K:U%/.R>56#PRIBI16"RFNQ445'ZH66N!%IV3UJ4)P2("DMAM'=["' M%%RS!PO>]!"A`:WD`FDJ%],7)P[U4[/F$FCHY%(QP%J#L2'9`;8C@VO,I'?$=5#^2DT=? M$9"I39O$\/`2>?JL)PFM?>OHU1Q1:HCR&F;%`?0!=59;,H5)C2`[D1^JS!)' M=1KJ98&R_HQ`9X$=X3_I\V)1JHYC8?<,_&$2K[$GH65WM>GQE$UR,7]56Q*( ME/4E$P=\T39'H55'EOE#A5`EX@+;2KETJ[X$*H>02+9/HHU[.BF<,)ZQU2;@ MJTY\&Y$CT88,@!1G?;`3-\4@L,[`N($V&=U-KQ04"QAD. M-C&-5F.%=.(./)Y&T;VL1P'(J[Q>>;BAJK8'1!4.4)P5)R'U',J)4A[3A`>A M50E\?/TMCLVPJW^(B/^BP]D%L9(YF$3P5IJ?4X>HT@AL-]%E_"DA=?##5K-I MM$;#-Q&9!TT::1Z<>M'A!C8S*"0QG1?A)&E/A:HR[I>@HC?N?VJ@C7\K9=I5 M2<9:LO-EC:O82$?0!NIR.=;#ORXF6%<8='VH1 MCU]\V*$<0WY*(F/2\9Z8_&3#YX9TIJ9E/+FVOY5C/GV[5Q2&^ETJ<[MM'`GW MED5-]9W\LPDB:3Y1'06K;*EU>RTM4&^#%C06= M_M6+K%#PS,`']&J'.J=_8B,/84Q?]EOVZ9[Q?:IP+"E(>G4/,O)SO58 M=@]Y#_O>UH;EN'Z(4Z_ZEM5-V$`U*LXET_NN9(_@`,!633RKW!TU;(`*L2DD M<6B8/]5+4D6FJB!5Z$@;;!DB:JOJ""6N0S:5K=L:,Q`^P,;:2EP=G-M7G+@1 M:5:!*D'32A_`&&6>=UF6?_X/``#__P,`4$L#!!0`!@`(````(0`&:>MV'0X` M`(V,```-````>&PO[Z]$H6C_;GA5=!CO;AV^V0>A9 M,7P,GT;1+K2M341V\MR1/AY?C3S+\=5$PK6WYA'B6>'G_>YB'7@[*W8>'=>) M7ZDL5?'6U^^>_""T'EV`^J(9UCJ333\<=1A$P3:^!'&C8+MUUO8QRL5H M,0))MS?^WC.].%+6P=Z/EZJ>;U*2;]YMENJ5JB0FKX(-@/C=O_=!_.UODC]O M_O#FS?A?WWS[CQ_LS3]__/WQ=S]^HXXR-4@F^*!:YN6X4BQ\G4@>I1;U-]+/RQ7)ABT;@K0,W")48O`SVT2V^ MY=G)+U:6ZSR&#OG9UO(<]S79K),--##2WWD.N(EL'"4:AM7S2-!D-LT)#,:F M"=F";?+`)(MLK+;)^NF$38RN:;VN+OPQNJ@5U78)TW4<%T<<=M&5^PKI"9\> MEZII0@W1QF-"*W983\H6JS'H&TS9U70PRR;FQ)P)M8R)Q6._$8434R25-0K- MM[/[P>@4KZS,NK0,#Y4!).'$LNA`ZE;D]\PDKR'B9."&UH_':*-EBCY-O:(V M?G(\.U(^V%^5'P+/\@FQN*G17S,]N?)3\9LT7X'TX)UZ.QB$B699AECP+S7BRX^)!#V`QK' M!%YMD#>.CC+Q%?RUTL%0)MX,48'8V+93,8ZYHZ86M;1;$:I3=I#.W90Q'J.2 MDR;1FW4U"K4'[5X3VM8KZ!2OK*PI]D9GC4+Q%E;0.7D@+](3!D@%3= MSA:"I@MT:!_!F-]QW7P=GQ`XY&C"^ MG"T6B[EV-9_/%\9$,PQ*\F,:T8Z_L5]LD153^-%/@V)SD M7$4()'D5(9#DU9G@"@P'+R5[%2&0Y%6$0))7Z;1)8*[",6_)7D4()'D5(9#D M56&#S[0"+Z1[%2&0Y%6$8&BO9M.JU<.#25??CD=FPL;'J2XRB&^NB\X:89[Z M&(0;.`J1G7&CD9EJLNWVQK6W,#O*]LC^5NP))SO!>4U+-7YVUI]!6;),FH^T$VE$15\:\JIGD-F$,3/&,V.J M7R43ML2ZSJH]>^/LO6/KCG2M)P*([GCH@74O=Q[D%=33W- MN0/$1!82G'N(L+$XMX'71K0'GXUH!TX;T1Z\-D*PGTJNC,E-L(?S[`X=;)KS M=)6Q<;R<%HB`GXB8VGV.^:S=Y02CM?OP>DA-WR5M8]D[?)D.%Y`,85+:37KJ38NUV[NN'O?=HAR8] M!YJJH%O)\GKQZ8Z.<8K/]!P,SZ9KBFHBYOLPB.UU3,_1IN%9AF=2@D=+!?'@ MZ:+?*-$//''ST44_K%F=="+P(E4_!!>W?I'Q0,Y&3X,:7("#N@J/2`2P,I$A M`"?(0$#.GD\Y@/"4@0!F?!D""-`"`<"IB(HN>:"A:@8Q4*@$_7VIA!J36J_&L8@J0/C:)#4@C$$I@=75PFA.8$]P71(21@`CY2L*.JUQG2,`6E` M$&152!0-NJP2B3'(JI&%*W19)1)!D%4AL2=DE4B,05:-1*Z052(1!&!$2H7$ MGI!5(C$&636R<,5$5HE$$&152.2)2<\EQL\9;OH;6[I/]`G-1>J;BZ&5;OM@+2+(%CL-H9!&68BKTPU*VJ@RKO%8; MG4G7KH8?>(-=4:[U2BT($@:R,9!5'=D82+"E&'X!J2$<8M-,@2Z9T<6=IJ)# M%[F,&T-IJ<#EZZ=]%#O;UV8%0[A+.B/J3DK3J.#P"%F>8JMW-N>G#:'L0%MW M6S"=].`];D\2V@/&DP=`KE`TARN%F"`?%@XWEHI0TC^VV`">'2QAL=6,!FO2@0Z/4 M:Q4ZR'M]X#M7KLAI7,VZ-ED#R^*\#Z9PE4^+:"UY:#C<`-[IT57G\.,%C0L7 MYO1P<>WPHI=6@J@6;N&L,#;<-O8$,/OC`\E7*4)/2\?^X'(/+53[E;40*6;;C\@'; M>DH]TAD1GN3V/?YN49-0CO>!KHGOAF2J178S,Q5F6%-7?^1WFZ'A=J67[8Y0 M]]GZR>:N?'J'ALM++^#:IH=\F.BMP=M\*C%4AV6L8(/Z;(*DC/0:N&=,.NH1 MU>,:-B]+>VIM4\#'C7%7J-;.PV`I)MSGN2>57#B/NP,/T%89Q0T-@4#@%4MFBOM6@WXX9Z` M8NG`X=L.49_G';5#A,[W`D<]TLLRTLM26WFM-F28PHABIF:*P5,8V=$>5V!Q M3HM*03.=^RC2Y8+&E0%5\K-<=\6!4,TI6]C[_.2@H##R1V8K@X"%B+5_,J2%L9+5B[^S&7,W=>28] MM&SBQ,Y6HH7D`VR?%AVB+!()K@DZ/>LX"76EMA'"H*D;]U,:SGF/V$5N-.D?/ MD=0("VH+3$^M">HF?:#+.=5]PLL7*SH`G)3EG0C^Y\`R[N(IJ-J$OBE:VI;9* MT)MDI0=]P[+MSGGBSODTOP+(@W)KBROU(VC*2->7D_NJD']E8):,B'EQ8 M5N%'-E8GG+&*915^9&.5F-P45^%'D(KX(F.(IK(*/[)UPN"L$]C&PH\L]U-. M[@\K*AOQ.F?$)U(*W\$[Q!$Y"LK#42*E\!H;Y60>PB^E\!<;WP9G?"=8"D^! M/&21`5_P8\E]-&'9-3C9O;,V6=5E`X;T&1X8\.C;]=ZUR.V/,T%D'0\91!:? MN20]V^O/R@IN#9T+8O.!M%$>00\O.]?RK3@(7Q5R^Y!<'.OT*:>X/P9!SA$K M08>//(#^9%L;QW]2@)=T0,`01$:63<3DN<#20VXFV$0,[)V@8>./G)'31`SL MG8AABRH9/_&(>>?O]KF'V%I*6C>/B/>._]G>L)'#5@D=0/)(^F#OX]#*XX]- M*7CX+)\0-O5NB3;&%2]R!&2RPJ[I`$ MH__-2W%S>AMY_/Y`-"[L;?6WHT_Y5\NU>+]G^G#6""8TE]][WP) M8BIBJ1;OWY.GW$`6P[WHH=R\C^#)*?!7V8?.4OW/P]UL&UL[%E/;]LV M%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L# M/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=: MZ]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'- M)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J M6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^ M`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q M-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I M(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0 MWEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK M//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A M5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+ MDXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O M2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6& M`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RF MB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W M4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]< MQ+P]6.RJ=KU9GNV]147TQ*+-JF=9`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`Y/_8;JN](5VR^NO\^7/[?'I]BJ=SB6P^E?9$'ONV.9ZJ6QTR M'EO_.)[VNUD@\DRH((AO@LBG">)E$QD_FW^X)TK:1)'/,$KN_B@9$R5WC>(G M_(>LE\W=<49Y$T4^PV/Q[S\6J;)SY\KG).^)>.*H(,': M6B9Y?L++I.[I#N]B$_ERC7*O3[S0*/K+)*%#M%?+LWO3XO4H^D3^7*) M<_MA2&$$72I?PN9>XB&;S>0>\K=7C2<6#>+87KW],$*/>HY)[\ULZ%'/-NE_ M\%EH5_^:6C]]?QP_S+%_[10__Q_BA+V3OOH^G4GDO=1C^HXE+WUZ=I]/U>:5\0I1(J M](RK#Z^*H!;N)U34$300-!&T$+01=!!T$?00]!$,$`P1C!",$4P03!',$,P1 M+!`L$2AC@N#JY.R*2\K#;E:7!%^(2:?5RJ3/(B9_%J$$*LJ@HA0JRJ%<'IZ- M>XZUL(1 MOHF:%H(V@@Z"+H(>@CZ"`8(A@E$`[&3(CV]W0!O?H)GH)E%:+)0B_,; M-(L;-,L;-$JQ*.?#**.*MXB,^>RNYDC&D)^+C$EM438',XPRQOU<9,S\N<@8 M_'-1:'IK?,CY8"1ERL".E//QP$UIN*+K'.*,#_)3[8[Q0:N=\0%!"4$9005! M%4$-01U!(P#.^(":%H(V@@Z"+H(>@CZ"`8(A@E$`KM?28P03!%,$,P1S!`L$ M2P1*$2D2,>F['JPR^;.(2:!%3`8M8E)H$9-#UY-X'1'F]3+JJR8=HLGK.;3C M9+E=<(>3M?HI+M0^2@H$)5OPF))_[JA?_L7VBKW= ME_#0OAILEY'QWI_`/->BU;X.U1QS6Q!1%=,;6WYU.Y=!I^ZL]L@:]W`=?Z@.QNZ M9O$KP=(6!"9T?:N4K8BPE#+5$)@_PI/*J8Z(CE1E9Q<1IE)NL>2T!`[3U$IP M%)$GXA1/5+Z44SU>U%Z<^O&B3M:I("^5S5)6E5-#@?FZ*Z].6+:Z=G;,S22]G%W`ULO M(QJU&+H"')I'&'",8()@ZD;,X(/K&3:8(U@@6")0B@C92!D?78VER#?*&,?2 M&*-8Q!@C2!GWN2*?*#**,DX)!\V'/-X_,A&"7CKR^4/7 MD3V1`9$AD1&1,9$)D2F1&9$YD061)1%89:+>(/ZXW/XJ,PBQ;*LZKXL0J MSJSBU,IB`SH(3JXL-R"5DUZW".16I%,$OS"_EKOFS_DP/13URD&GJTJ&/`8W M$1.IX*I3:N#\SZO\!G=7RA2BXH3()\*VUQ#PFZ%*(6I$ZD0:1)I$6D3:1#I$ MND1ZA@2]DI)><4>$/K48$!D2&1$9$YD0F1H29BA'*9E1FSF1!9$E$:DDM(=B MQ\B*'5*Q*:222,5YETH*5/_6T5)7%(:-('5EA_$2W$>RKL<*Y-:97AM@KWC[ M19T%2PGL&_,YO.M=U"MJHZ+97"(!5G M5@J#5)Q;6=!&*LZN6-]2N=;7#[7OL'[P#%RB79[WY-)PB5?4J\'!^DC*1A-< M<47=":E0E"J1&I$ZD0:1)I$6D3:1#I$ND1Z1/I$!D2&1$9$QD0F1*9$9D3F1 M!9$E$7$_)E"F!4(E1F&>K6LN3JQ<8%$L3JU,!*3BY,I$0"HGO:[[]:/;.]P? M/.EUW0\7!D7],@.X'TG9:(('5!&_?BL4I$JD1J1.I$&D242_#>4><)M(ATB7 M2(](G\B`R)#(B,B8R(3(E,B,R)S(@LB2B)@?.TC,3ZC$*$RS8WYJR)F5H9]4 MG%L9^DG%V3V_['9);V#^X-VU8,G_;G/XOBEMWMZ.L?7^AWXOS=-78A<]PNR/(7YP"\,HOC0+\AB%=;7_((LWV!> M]PNRB(-YPR_(N@WF3;\@JS>8M_R"K.%@WO8+LD2'N7ZK,(J7O8*L4V=]T2_( MPA;F);\@RUN8E_V"+')A7O$+LM2%>=4OR((7X4@S^..T_SF^`?-N?Y.W"\]=7>9UT(Z],I!(B?MGO3^$? M>@>7%U2__@,``/__`P!02P,$%``&``@````A`-#R49";`P``/0P``!D```!X M;"]W;W)K&ULG%;;CJ,X$'U?:?\!\3Z`"287)1E- MFB87S4BCU5Z>"3@):L`(NSO=?S]E3#JXR*Z2S4,<#J=.JD[Y-O_Z7A;6&VM$ MSJN%31S/MEB5\BROC@O[KS_C+Q/;$C*ILJ3@%5O8'TS87Y>__S8_\^9%G!B3 M%BA48F&?I*QGKBO2$RL3X?":5?#FP)LRD?#8'%U1-RS)VJ"R<'W/"]TRR2M; M*\R:>S3XX9"G+.+I:\DJJ44:5B02\A>GO!87M3*]1ZY,FI?7^DO*RQHD]GF1 MRX]6U+;*=+8]5KQ)]@74_4Z")+UHMP\#^3)/&R[X03H@Y^I$AS5/W:D+2LMY MED,%RG:K88>%_8W,=J'M+N>M/W_G["QZORUQXN=UDV??\XJ!V=`FU8`]YR^* MNLT4!,'N(#IN&_"SL3)V2%X+^0<_;UA^/$GH-H6"5%VS["-B(@5#0<;QJ5)* M>0$)P+=5YFIF@"')>SN>\TR>%O8H=.C8&Q&@6WLF9)PK2=M*7X7DY3^:1#HI M+>)W(C!V(L1W`I^.)X^HC#H5&"\JY'&5H%.!\:(":=U9")3I$;3%DIJ35U`W`Y=M3%^:L"OJFHMI8 M8`M8;F_+D$SF[ANLD;3CK(8<2GV3\W2#$X0F)[K!H2.3\WR+$YB<>,A!V:R' M#$I1-ILA)_009SOD^&,SF=V00NF5XT)S/CL$"\?HT']W1K$7-DRUS\Z,II[Y MYRO-&;6[AVKG$P8B##QC(,;`&@,;#&PQL.L!1L6P]SQ0L6(O;-#ZK)B.44=6 MFD/;F>I3#QGRU']-X.@DN*61P?#@8UKZW'\?#%['_==DXE$_G)H":X/A08KH M'S::<&W:UH@(J3_&FCN#T5S1!*VVE.==4GS`0:2!L^T$@ M,U3L,PZ(,;#&P,:0O-7#+0[9]0##$=C^'G!$L4U'X'@PN[O2G)XC&(@T\.^. MX(`8`VL,;#"PQ<"N!Q@&P)GY@`&*C0VX[F7M@;'2G)X!&(@TH)?HK2F!`V(C MP">$^'@_QR$;#&S[&CZ=HJSARJ@J:[/6_N@;H#Y`Z^3(?B3-,:^$5;`#[#Z> MH^XGC;[_Z0?)Z_:7E0-\S/B__R%P```/__ M`P!02P,$%``&``@````A`,&-9SL-"0``NRL``!D```!X;"]W;W)K&ULK)I;<^(\$H;OMVK_`\7]@`V8@"O)5^%D&VPPL(=K`DY" M#6`*D\G,O_]:E@]2O]Z9D-JY&)-'K;:DMW6T[O_Z>3S4?D279!^?'NIFPZC7 MHM,VWNU/KP_U?_]K\JU7KR77S6FW.<2GZ*'^*TKJ?SW^\Q_W'_'E>_(61=<: M>3@E#_6WZ_5L-YO)]BTZ;I)&?(Y.E/(27XZ;*_UY>6TFYTNTV:69CH=FRS"Z MS>-F?ZI+#_;E,S[BEY?]-AK%V_=C=+I*)Y?HL+E2^9.W_3G)O1VWGW%WW%R^ MOY^_;>/CF5P\[P_[ZZ_4:;UVW-K>ZRF^;)X/5.^?9F>SS7VG?X#[XWY[B9/X MY=H@=TU94*QSO]EODJ?'^]V>:B":O7:)7A[J3Z:]-GOUYN-]VD#_V4_1E&RI18E-XV6)3QMXP,5@/ZO'?[#>O.:)MD7GN.DNMD+US6:]OWY!H?_RN-S,R5=-+*G-`S<](J??PF7SO+ M1\\LGVDV>I;5Z?;NZ.V_R=G)95[H67CY=/M39TXK0L\\,\E]:T7ZF1=ZYEY:#;-CW-(8)@6P MC"<1R5FL*,'PR8`RB["D'X6;3[>'F0>D^%%D;]PLBID'J/B1^S&_X"GN-YBH*N.2\$3.?:0O78D#M4+O+P:@88O_7 M"$M#J_#R)-P\U*FA*'M"T\*/QZ[1NV_^H*%\F]D,T,;4+8:YA1BWA=L1!V,. M)A+(\5ED<3AP.?`XF'(PX\#G(.!@SL&"@Y"#)0A6C4ET`TT5EN M%$VX$:+ES3W(0:EBZXY)E)OD>48AT&>1,$$3J\->Y%39,#^NM.GW MTH#KT-C=T4OK53GIZS;3"AO+T&UF538L>/TJFY;N)ZBPZ71UFWF%C=76;195 M-JSN896-I?M9H@TK\0HM+(N5>%UE4\JI12Y-+%KD5J_;\E%%6#_4:=@L0JG- MXV0@;3KILC$=-(9`1D#&DK2+T)]PX'#@U=,SOJ>GMNQYYT'O&5#5HW:&'F6I@8KH/Z>P-@6K0%@[HGUZ(N30I MVV6AYDF;A>4(58-JITO5Q!1-!^]=\?>NM3PR2_EF+:1H%KHAI(0U"RFS=)QV MYX&T44,*R`C(6)*RZ28<.!RX''@<3#F8<>!S$'`PYV#!0@?X6RN2RVDO5WNP95HNWYTJS,'#*6NL&2IVT**'%D!8EOU]` M"6L>#&PM.9`V:@<&,@(REB2;H>6,H(LPD19E&SD+G5BXX;JQ]?U`VN2=N"K*AZ5)T8<1C24JA9IP MX'#@*5:EG=L9#D9"S<6:G MZBFM2N*`C0O$`S(%,@/B`PF`S($L@(1`ED!60-8JT?44IPQHBFB&2(?48!H MCFB!*$2T1+1"M-:0KJXXHN#JBH]BOU_?B`\5)!/YS048Y*@CU[:\"V89Y+=! M><99QDU$65&!3EHY2+R$$T1 MS1#YB`)$0AFB*:(?(1!8CFB!:(0D1+1"M$:PWI(HH3!RZBV:=F M^L-X*D\J-!4S)%6$&3!+554LD*HB^W0S%M]DN8J`'+1R$7F(IHAFB'Q$`:(Y MH@6B$-$2T0K16D.ZBN)(@*LHECQ_$%&>)&@B9DB*R.:VH?C`S8BFB&:(?$0!HCFB!:(0T1+1"M%:0[J(XJA`%?$/XLF3 M!4T\B6@MFB]RAN).@>@])1HA&N=('2FSC"5RT,I%Y"&:(IHA\A$%B.:(%HA" M1$M$*T3B2EHYVDAYY!4S>1?B&%U>HV%T."2U;?PNKH^U#5H^%EC>;:/5L2T* M2BJP%%HDVZ*\F$)K95L4&U-HR6R+TF,*K9QM40E,H05T?KV.E8#V"K:0#?/0 MEL$6ZF$*[1QL(2*FT`;"%EIB"NTC;"$IIM!VPA;*8LH3I3Q5I@PH1>R8,,_` M[%%*E3?:3MDBLC$/[:KL264*;:YL$>>89]"UZ>M$!;^S1^G%"-;.`RI6I9^^ M/>I7^3$-JD?:V[@GTZ24].(*2Z$[E$_5;4(5KWH'-6*E?=NF+]\5=>O8]`VV M@ELV?4@CWBP*1%GI':(7JAO&`VQ,;O(RY?RCVM\3J\2/<=7 MNC29_GRC2[(17<@Q&F3\$L?7_`_Q@N+:[>/?````__\#`%!+`P04``8`"``` M`"$`C[<5;Y<#``"6"P``&0```'AL+W=O]CI-@ M&Y:R/!!R.3[Z?*[C>/7EHZZ"=RHDXTV&LOJS,7;_)(J0K`H9$9.BK5+J-(%D=:$QGREC;PSYZ+FBBX M%8=(MH*2LAM45]$DCM.H)JQ!QF$I'O'@^STK:,Z+4TT;94P$K8@"?GEDK1S< MZN(1NYJ(MU/[5/"Z!8L=JYCZ[$Q14!?+KX>&"[*K8-X?>$:*P;N[N;*O62&X MY'L5@EUD0*_G_!P]1^"T7I4,9J!C#P3=9^@%+W,\0=%ZU07TG=&SM'X'\LC/ MOPE6_L$:"FE#GW0'=IR_:>G74I=@<'0U^K7KP)\B*.F>G"KU%S__3MGAJ*#= M"J8H6D:)O-XBD$> M[*A4KTQ;HJ`X2<7K?XT(]U;&9-*;P+4WP6DXFR3SQ<^X3'L7N`XN8/@@PJP? M#-=A,`X723)+%_/_G4AD0NDRSHDBZY7@YP`6+DQ;MD0_!G@)SCK<%%IDHACC M_E':$+,V>=$N&9JC`(9+6"+OZS1.5M$[M+7H-1NC@>]1@UW%=E#H'FK;W"I$ MP#M"0V@V].V5,+!IL68;7#>F8(-,/)!K19),74U^K4GC=-0XN-#NQW&U.$.P M>8TQ36?ST;?+96,TTW%*6[^06P4'!5ILH^AV3Z'=]Q/4@S($$[X@S6<>DM$D M7>]QC/%DXH=J%!?HW"HXC+"8?YY1#_(9_15H-&G'^'0+T0@L1*O@(*8NXOWX MM-A'\SMJ-`8-Q]W'#7AK%!:;57#8X"GTX]-/]'U&/*F[ MO'HCMQK^V+:#S?;O[#L+?U'V(IO;#+M4\E[S2+!Z5[=`[W<=3CW7;5^X*6UZ MT05G>U71QR=MU.^>-Y,TQR/SZJZI.-`MK2H9%/RDCSX8]K2Q.A[+7KI3633^ M`:>BEASH-R(.K)%!1?&PO=V]R:W-H965T8\YK&Z?FQH] M,:FX:!/L.2Y&K,U$SMLRP3]_W-\L,%*:MCFM1NX;*QWUWDXFF`XL=K[E^Z4TQ M:K+E0]D*27/EUS3&("3NM5SJ$"$SN2 MK$CPG;=,0TS6JSZ?7YP=U-E_I"IQ^"1Y_H6W#,*&-ID&[(1X--*'W"S!S>3J M[ON^`=\DREE!][7^+@Z?&2\K#=T.H2!3US)_29G*(%"P(Q,U`,`O:KC9 M&1`(?>Z/!Y[K*L'!W`DC-_!`CG9,Z7MN+#'*]DJ+YK<5>09J-/&/)@'0'Z_[ M_VTR.YK`\63B+T(OG/\;A=BR^I12JNEZ)<4!P MR@MJ-"9WQB7!$480A8(>/ZUGL;\B3]"8[*C97&N\J6([*$QTQC8]6R#`.T)# MGN?0K_=R8#-BPS:X;NP">(^P%ZC;5Q31E#6]EL2+43*!A::?PYJ$9V]NP`': MW)1@F$$CHQ<$HW^?SL9J@K&P[>5">K8P08)&GR/]/3\C3C#4>T)QW0L4JPG[ MSM\$X7SNQU/%=J*`]V<13@7I1!#XH1>=NC*!A^S>#V_$4_CHU"8;HY4M[)"FVX-D+5&4ZB&"->,Y6+>IGA7S_G3WV,C*5U3BM5\PSON<'/ MX\^?1ENE5Z;DW")@J$V&2VN;(2&&E5Q2$ZF&U_"E4%I2"T.])*;1G.:^2%:D M%<"&7@JFE5&%C8".!*&WG@=D0(!I M/,H%.'"Q(\V+#+\DPVF*R7CD\_DM^-:W$[`3A:<&/GPE%BQ-;&*ODG@)(#52!I M'4C:H/[PO16U^MVDF_Z?A01%WN",6CH>:;5%L&A@3M-0MP23(3`[9RGD\[XS ML.1J7ER1+P6T@6YLQIU!>T0V$"$[8":WF-8E8OH.HG>"$-!W$@G6ST7>%^?` M&8;K25R2#DZ\WL`D8+I>>@)[*8G32\0T(-I^69Q+@8P>E^+`5U)Z\>5$DX!) M[T@)"+B>#+7_D5SDU/F(.`>^$I?VK\0%C$_!!S<]>W$Q,RSCQV-QX.N9KSL4 M,/=B"8C;#J4?D>+`5U)N.A0P]Q9+0-SM4#A;PM9KZ)*_4;T4M4$5+Z"M<=0# M.SJ<+&%@5>.WV$)9.!'\8PD_``[[+XX`7"AECP-W=IU^*>._````__\#`%!+ M`P04``8`"````"$`B2)_%(@$``#R#@``&0```'AL+W=OP<78NTL[#S/!Q_/E\YX:]_OK2U-8SZDB%VXWMS5S;0FV)CU5[WMC_ M?,^_1+9%^J(]%C5NT<9^1<3^NOWUE_4==T_D@E!O`4-+-O:E[Z^QXY#R@IJ" MS/`5M?#FA+NFZ.&Q.SODVJ'BR!8UM>.[[L)IBJJU.4/#[;UUU_*-J$40;\D0S<,#XB9I^.U((%CO&ZIQEX*_. M.J)3<:O[O_']=U2=+SVD>PZ*J+#X^)HA4D)$@6;FSRE3B6MP`'Y;345+`R)2 MO&QL'S:NCOUE8P>+V7SI!AZ86P=$^KRBE+95WDB/F_^XD2>H.$DH2."O(`&Z M#ZZ%79@#\%>L7&%;,BA< MPA"F'T4)PD-)=I1E8R]M"P)`(+7/VS!:KIUG2$;] M\4!)`$7#2XER0#%"4`8E811-E`BCU9"9U$`RCLP7O!P]-YJD:C\8R%SE*J() M`P6JL`<"8`9(!=28*9"\"4<"B-NHR0UT3>E@))=E`@D'E7N!\/%$6R17;327 MH9E5EVEC!S`SWW:=+M)=YX@/D5%<#R>N"R,VO'GG/ECF17-]V5X8\0QY+OSH M!OG``B'1Q,&DF8KSYI\L-,JA:^6('PWQ3@TDXT@XSH2]0,95N5C%JE-SFQXE MC&'[2;`VM M\+V$W>@H^(ZO(.*]KF(WFM@<] M8OC-2^OMUF$+=6<%%$&,E.:9=$$JK%0%$E(D"&@YZLPU*UT$_2PJA?:.Y_PC M"B-7UD;B<6A24PN]/=/12B[,)*3,+`DI0TM"9M70N:]ZSL\CGVP11C))!?_( M0F^KJ3`$#5:C(`Y!PX\+S381.T;^#_M$6/CF4(`S[T^0S+_)L(OT/&&\<%Q5 MYT+H3DYEZ6@E%V8">F:W@BR,X;,,ODWP=!73SC%?9*LX>_ABOXKW#U_D*[AX/**"&\F.!72R=T)O M*@^V3OP8#G.F2TD0PYG)Q'=AO(,@P0MGV`%N'-?BC/XLNG/5$JM&)PB,RQJ@ MXW<6_M"+`7K`/=PU('9P=H>[)8(S@4NG[`GC7C[0#8;;ZO9_````__\#`%!+ M`P04``8`"````"$`_F:JOTL"```%!0``&0```'AL+W=OU< M]N][C!N:;K;5]@5A,YZ9,^>8[.$L6W($;83JH94OX9#597@L%'\(*&SGD1#RRSZ-XWHS85- M\M?02:;WA_Z.*]DCQ4ZTPCX-I)1(GC[6G=)LUV+=YWC*^(5[6-S02\&U,JJR M`=*%WNAMS#B\.;T=&O!9DQ(J=FCM%W7Z`*)N+'9[A@6YNM+R M:0.&8Z!($R0SQ\15BP;P2:1PDX&!L'-.$Q06I6UR.ID'LT4TB1%.=F#L5CA* M2OC!6"5_>%`\F/)<@[4-LZS(M#H1;#>B3<_<\,0I$E\\>8;1Y=],HCM'LG(L M.5U0@OH&@ST6T_ME%AXQ#?X+L_88?(Z8>$2$Z&:TA#:N+;T!-_NT^BD==+>\QDR/NZH.F?0B[C.4[/OPMSAX9> MCX+3Y7-!CT'9*\SS4/TX^IY+T#6\@[8UA*N#&[48FS7NCK=@E0PUC!]P"GM6 MPR>F:]$9TD*%1Z-@@6.G_1S[A57],%$[97'^AM<&?S>`?8D"!%=*VL"B8&&.]1O:]G9`YL2E]`I;C;;[DIHU2'%6C;2/?6DE"B1W5>M-GS=8-V/ MR9B+`W=_.*-74AAM=>DBI&-!Z'G-4S9ER#2?%1(K\+83`V5.%TFVG%`VG_7^ M_)*PLT?OQ-9Z]\G(XHML`>.A]X:\PF)U%W_4-^&9(`27?-NZ[ MWGT&6=4.NWV-!?FZLN)I!5:@H4@3I=>>2>@&!>"3*.DG`PWACSE-,;$L7)W3 MT22ZOHE'"<+)&JR[DYZ2$K&U3JO?`93TH@)7+VW%'9_/C-X1;#>B;&;M'G12=/J&NS@JE[OKP7WVP=[]31BJX^HF MI[S>SLD_[?1!I_S[&XQ\KC=]V<&P8F&.%9@*/D+36"+TUJ]/B@,XW`Z;O4A] M0U[>C[-%O_%L^(`;U_$*OG)3R=:2!DJDC*,;+-R$G0T'ISM4CGNG'>Y:_UKC MKQ5P!N,(P:76[G#`Q&SX6<__````__\#`%!+`P04``8`"````"$`M8,$/;T/ M``"L3P``&0```'AL+W=OU-G(VQ21S8WMN[;]^AR-%P^"A.G.N; MR^U/,T-Q^)`<2K8__>WWI\>3WU;;W7KS?'V:G4U.3U;/MYN[]?.WZ]-__]K\ MK M\_/=[CS/)Y/Y^=-R_7SJ M(UQMWQ-C;J]LM^>-]OEUT?J]^]9L;SEV/T_(/S3^G:[V6WN M]V<4[MS?*/9Y<;XXITB?/]VMJ0?/_4)^L]Z]7,7 M_?_)[F'STVS7=W]?/Z\HVS1.;@2^;C;?G:F]UA3\,]HQZYCEW=_5&M=K>440ISEL]VD01E9 M_GY]FE/#Z[O]P_7I='XVNYA,,S(_^;K:[9NU"WEZAO")+/SK)B,G/"_$ M\UVW2O.E;Y'^'G>KB^!(?X^\U8S$T+?I_B?X%F<7V60QO1C-Z[D?VUXJU7*_ M_/QIN_EY0O./1F_WLG2S.;MRP5@D/L.#;%Y3#_D3QO@\W-B(VV*-G":=&%K5)0IZ!)@4E!FP*;@BX"YY26(3)((MV*5*09V")@4F!6T*;`JZ"*A$T.2%1$Q)+.,K"6O" M>5V?TJR(-'&I.WKC;8I^(>N'O`12`:F!-$`,D!:(!=+%1*6`UB%(@5M,CYPG M+@Q--4ITE)1THGBC@F09&2UTYLK!:-`(D!I(`\0`:8%8(%U,5)XH)2I/AR7B MK/MT<"=N/"GR8;:40"H@-9`&B`'2`K%`NIBHCM)NH3KJ%LZ"K(\4A`NC,^`) M92`:_N`E(#:8`8("T0"Z2+B4H*;0`J*8='WUGKOGL2CSZ0"D@- MI`%B@+1`+)`N)JJCKD9.M\T/C+X+HS/@23+Z63+Z@]$P^D!J(`T0`Z0%8H%T M,5%)H3I&)>7PZ#MKW7=/XM$'4@&I@31`#)`6B`72Q41UU!5*JJ M'&NQX-`-(L-(6FL9T:(O==?E5(>W8L7A.X5T5ER=%&?%+Q3]1-@_K&^_WVRH M*=+\B$*FU,-PN/+5EDJ61RI9@*HLH/F0Y1I1@\@PBK,38EWVB<\G65*26/:Y M'!KK%-*)<755FIA\X1Y$C.6"\)`,YYG,%H\*NL-HX`H]<*6KULF1=FD>N(J1 M=+-F)"EK&(F5822Q6D9B91E)K(Y1;Z4SXHJJ.",CDHC3X&LPI0F/=3%>XQYEEJR!)59L)I&4O-H*EJH@]64KAS* MZ-`B#YC!\"W'DO"6T<'P'<<:$:2K\_Y\#GVUJ'+H4:Y'/QG<,@M6(ILJH$(> MI=2,R/A0#H<6)8<0ON58$MXR\HM>,4G6O"YSYZ(DBYU'2H'3 M]("0!:-8@!X5]$F.4AO*QU!EML`SKVGLFW?<%>;*W)H_QRN`8[ZV,1",U(UFD&D9B91A% M>RLCL;*,)%;'J+?20CFN(,^Q(`\H6;/2S96M9)@J1H>G7;":^DF0S1?91;*G M-!*(=6@827,MHX/-V:2YQ6R2;N2=!$I7MORX2K\W3S3ERWJZPETI@U6$*D8R MZ#4CD4;#2*P,(PG?,A(KRTAB=8Q&!.2*WW0U?_L)N%NDD^4[("VD1;*OE&PE M(ULQDK6C#BBH9C&_G!=)U=:@EV$DL5M&$MN^';M37GJ^N5([3M?A6M85_6F: M/')-R&ZU2+>YX$CCQD*J&,E(UXSFX>22SV!N#:UQ',-.$KIE)*$MHU=#=VPQ MHBE7=A^1)%^EQX54#K5\B:AB)(-;!T0"YOXV:&48Q4(9C@KL:#%6QXXC6Y,K M9N,^N[K\'?/(U\"J[T-9'`LD.8Z4>;"24:P8R2C6C/PH7A87DT1H#5N(DV$D MH5M&8F49O1JZ8XL1@;@2-4[6&[/(5[0J24/=&R:)1N@,C3;^HPJD8Q9KQ M5F&QR2>+/(/%9FB.U6$X4*PAL++!BK>_138MDBG:<:`13;GZ\(@T^7)2I1UIPZ(;MM] M%H4^>)8>W1MT,HPD=,LH5I:_@==#=\I)*RNMG5VRW'O#PTO[U!?,2EFAAM;* M2M::,CC&:Q8C&?Z:41C^B]E(MH;F.,6&O6)I@95EJ]=C=VPRHBU7/[]_:9\Z M\V2U\BC15'I\#8ZTQW#O*D8R\'5`;MV0E2\].#7H:!A)^):1A+>CX1?)$;,3 M1[D)DO>P$FBYN;HVSI^36W@/]_Z'(E-?'2OU#05S?!=)U50&1Z4^[Q@_!@U6 M;SP&Y5@B6\,H%B"$MV/A\TE2*'8<*YY.KZ0^GS>?%+-$7HW<`<\$PTC::SG2P?8L6PWM M713SI#,=!^_G@=;NV%$AUBX_W7MCZ<2C@U,:+1/1F]02486H1M0@,HA:1!91 MIY#.A2N9XWG\1I]]A:TFK$>JSX"J*:`:48/((&H1642=0KK/KMP^HL^^.E=] M]BA^1SH%5#$B40QS)Y\D9Z1:K'A>-(@,HA:11=0II-)`'XT\)@V]N=X"`XK3 M@*AB%*#5XUXMT]Y'*I$!@)!MQB:@* M:#:\_$ZVNEH,)#&^,?)A9#!R*XZ^4(77ZF+`83J%=)I<;?K^2>,^993FPR/U MO#]/CV5E<(R?]S.2#;IF),_H&T9B91C)@]B6D5A91A*K8]1;Z32X.O2(-/BR M-5X[BE#)TH(8K0K)@:L4*QZ;BA$M-(,CODP/5N$,,847BXV$XBI972P M,:L;FUU>7";U;R=QJ#6=R>,J<">;5%"A`J>$#@G))^FI+CC&I2(C$4'-B*J\ M(58&%3A;B:-A%)6*C,3*,O)GE7Q6S-,RD2U&).CHOTEJSXSA8UQ5I\7RX MENG-DPTM%,"Z5D\T709'I:C!D7M2LU4XGB[F63+D#5N(3@RC6$T0VK*5#SW- M%JBFV$E/.U>B'J$F7]$J-7F4J"DI]TMZ7PUJ&APE21Z]I29P-!B^921BM0$= M#M\I1YTL5[4>D2Q?Y*ID>:0>T^7I3EP6P4J&O6(42W%DM0^.063S'$4VW``G MW7!H::UE=+`URU9!=[,L3XJ5CBU&5C%7'Q^12E].JU1Z%!\TW`=`:,F*4(6H M1M0@,HA:1!91IY"2C_NLB^JS/\T?_4V./HY>J0)RAX`GN& M!79`2A/>*D(56M6(&D0&48O((NH4TGUVA6R\-CI-+#Z@"1)1H(GD_6LX&*UDG`-5HU2`RB%I$%E&G MD,Z/JPGC_+RA"5]"JC1X1(\\N(/E#%"%J$;4(#*(6D064:>0[K.KY>(^]_6$ M^[CFL9N'+PI5-CQ*1)$^EJ!'3K!0`*K1JD%D$+6(+*).(9V@XXI,^N(7K)<> MJ84"4!4<(ZL:48/((&H1642=0JK/5/RB*!9Y_WV7(V71A]+[1T")+-)G+&+% M4ZE"5"-J$!E$+2*+J%-(I^BX.G..=69`T8"7B"I$-:(&D4'4(K*(.H5TG\?J M3)>B8S6!=>;<(]=V=/9('R>)E6AB<&14HU6#R"!J$5E$G4(Z/\?5F7.L,P-2 MFL`Z$ZUJ1`TB@ZA%9!%U"ND^NYHNW3\^H@E?&\;;!_W:4-@88DVD3\[$B@50 M(:H1-8@,HA:11>1^&$GV,)\?_T-'_M=KGE;;;ZMR]?BX.[G=_'`_8D2/9C]_ M&K#_A:6;N?N)I;YT@"LY7>D/I'!E2E?ZIRYPI>`?;$JOS&97KDJD?,&5.5WI M7UK`E0NZTG_'`ZYF4^H7OK/\^;7BG(AYY^C-T;^="Y M?^P*Y8U.QV-7*&]T+AR[0GFCT]/8%O^(=E72E'+U"[\ZI M=V,#2*^3J1MCT>A5ZE7CJ_EDF.A5*/F,)C>;7MW0=XE'[HVNE*-7Z(OB5^Z; MS>A#7_V^MF3[^21I4;_BG[@:N*^JW:_V>SY'W13 MY\/O['W^'P```/__`P!02P,$%``&``@````A`&M,7;1M$P``Y7T``!D```!X M;"]W;W)K&ULK-W9S5Z].3[=WU[M/-W9?WI__SW\F_WIR>/#Q>W7VZ^K:[ MV[X__7O[ M[;YO[V3+Y]W][=6C_._]E[.'[_?;JT_[0;??SN:O7Z_/;J]N[DZ'&2[N?V:. MW>?/-]?;:'?]Q^WV[G&8Y'[[[>I1[O_#UYOO#W:VV^N?F>[VZO[W/[[_ZWIW M^UVF^.WFV\WCW_M)3T]NKR_R+W>[^ZO?OLGC_FNVO+JV<^__!]/?WES?[QYV MGQ]?R71GPQWE8WY[]O9,9OKP[M.-/`*3]I/[[>?WIQ]G%_WY\O3LP[M]@O[W M9OOCP?OWRA^2=#,O@,HY-]!;K[DT_; MSU=_?'O\K]V/;'OSY>NCE'LEC\@\L(M/?T?;AVO)J$SS:KXR,UWOOLD=D/^> MW-Z874,RO%S,)/_EM^_"8W)@I3T^N_WAXW-W^ MWQ`T&Z<:)IF/D\C?B4F>&+@8!\K?<>#L[:OE?'7^9G_S3XQX?_#RU][\RCWX)VY]/0Z4560'_N3]?CN.E+]VY,_=Y$QVC:%2+LL_FZR9 MS;/YA[W9-Z_>K%;+]9MS>?1//-29S;39J^S8GWRP,YLG\P\[]F=O]]P^7OF' M'?OT[9X-^_9^J417CU[L3UF>UV/,Y42,CMC8"+,6S;11"'$( M20AI"%D(>0A%"&4(50AU"$T(;0A="+T'9U*-0TED)_X5)3'3F)+89%Y:<#6: M!_FW$79(%$(<0A)"&D(60AY"$4(90A5"'4(30AM"%T+O@?+^R> M;Z+?G\K1SNWY\]0"!)#$D@*R2`YI("4D`I20QI("^D@ MO2\J\7(X58E_X;'(3".',RFO*PD.1D/04M:@%W2NZ[8Y!!T6!"2&))`4DD%R M2`$I(16DAC20%M)!>E]4E>2Y3E7IZ>5AHO?%L"F\'&0Y/QR8-I`($D,22`K) M(#FD@)20"E)#&D@+Z2"]+RK-BPYT-B2`)) M(1DDAQ20$E)!:D@#:2$=I/=%E41:,E62I_=\$ZTS/XB_YT,B2`Q)("DD@^20 M`E)"*D@-:2`MI(/TOJ@TFT96Y=D<]!>S5_(D<6P_9F;2-=A/_OYT*:=?WBE/ M<*JZ<5&'_9\4DQ)22LI(.:D@E:2*5),:4DOJ2+TB72;3N?E'J*>7PVQH].2$ MU*;T M61U#.RCSV91>FDMQ4AXOI1M21(I)"2DE9:2<5)!*4D6J20VI)76D7I%.O&G9 M_,2_='4,K9^JR-@-RN[OGCN6L^#4R5P/U76+2#$I(:6DC)23"E))JD@UJ2&U MI([4*])%,@V?7Z1G5L?0'ZI:^"WC<#7)7'\.$P^*&9604E)&RDD%J215I)K4 MD%I21^H5Z<2;MLY/_$M7Q]`>JHH<.D9_=8075\V%_K!(H)A1"2DE9:2<5)!* M4D6J20VI)76D7I$NDFD*_2(]LSJ&'E+5PF\KQ]4!BLPK';H6,2DAI:2,E),* M4DFJ2#6I(;6DCM0KTHDWK9^?>+,ZEG(,.;;O&%I(59%#5^FOCD7XW'&(LJF9U#'VFJH7?>HZK`Q3- M0#$I(:6DC)23"E))JD@UJ2&UI([4*U*)GT_UY>:IYLC5L9]'=^4C!7W',E@= M+NJP.D@Q*2&EI(R4DPI22:I(-:DAM:2.U"O213JN*Y^S*Q_)[SM($2DF):24 ME)%R4D$J216I)C6DEM21>D4Z\:8I]@]++SRSF@_-M7^\&BE8':MP=;`K=P/M M@HE)"2DE9:2<5)!*4D6J20VI)76D7I$NTG%=^9Q=^4AJ=:!1CQ@5DQ)22LI( M.:D@E:2*5),:4DOJ2+TBG?A?U)7/V96/%*R.X&TW&Q=EET)$BDD)*25EI)Q4 MD$I21:I)#:DE=:1>D2Z2Z9;]0]C39U;F_7_2/J@CU4!J=8"B<:`7%9,24DK* M2#FI()6DBE23&E)+ZDB](IUXTP'[B3?/'0LYW3KVS&KHI%5%#LVUWW>$;_&8 M'Z+\BD@Q*2&EI(R4DPI22:I(-:DAM:2.U"O213+=LE^D9U;'T%RK6J#? MWLQ!$2DF):24E)%R4D$J216I)C6DEM21>D4J\>9I0B7^A7W'?A[];#Y2<&85 MOE7$11V>.T@Q*2&EI(R4DPI22:I(-:DAM:2.U"O213JN*U^P*Q_).P9M2!$I M)B6DE)21LRH MA)22,E).*D@EJ2+5I(;4DCI2KT@7Z;BN?,&N?"2U.MB5,RHF):24E)%R4D$J M216I)C6DEM21>D4Z\;^H*U^P*Q\I6!WA:^4NRJV.82ZOE#&C$E)*RD@YJ2"5 MI(I4DQI22^I(O2)=I..Z\@6[\I&\E&Y($2DF):24E)%R4D$J216I)C6DEM21 M>D4Z\:8#]D]I7]B5+X9.VC_7'2E8'>%KY2[*K0YVY8Q*2"DI(^6D@E22*E)- M:D@MJ2/UBG21CNO*%^S*1U*K@UTYHV)20DI)&2DG%:225)%J4D-J21VI5Z03 M/]65O^#5P`6[\I&"U1&^5NZBW.HXM/.68D8EI)24D7)202I)%:DF-:26U)%Z M1;I(QW7E"W;E(ZG5P:Z<43$I(:6DC)23"E))JD@UJ2&UI([4*U*)ET\Y\KGC M!:MC/X_NRD<*5D?X6KF+LDLA(L6DA)22,E).*D@EJ2+5I(;4DCI2KT@7Z;BN MW'Q,,GB]8R1_=9`B4DQ*2"DI(^6D@E22*E)-:D@MJ2/UBG3BI[IR<_7DR-<[ MS!H(*W)HKKTKNJOPM?)QH%>WB!23$E)*RD@YJ2"5I(I4DQI22^I(O2)=I..Z MD$_^+NO(E MN_*13-'=.]A7X6OE+LH5B5TYHQ)22LI(.:D@E:2*5),:4DOJ2+TB7:3CNG+S M)M)P=0SD+87-&.511(I)"2DE9:2<5)!*4D6J20VI)76D7I%._%17_I(S*W;E MRT-S[:^.\+5R%^56QV&@I9A1"2DE9:2<5)!*4D6J20VI)76D7I$NTG%=^9)= M^4C>4MB0(E),2D@I*2/EI()4DBI236I(+:DC]8ITXJ>Z^/#37 M_NH(7RMW478I1*28E)!24D;*206I)%6DFM206E)'ZA7I(AW7E2_9E8^D5@>[ MRPS/)'CHO52"1Y+SSJ<2/$1YO?9J'"?G6]XX=V5=WUW3H/AW]YF[ M:<*#@^)`:B&"HA4H)B6DE)215G>D")23$I(*2DCY:2"5)(J4DUJ2"VI(_6*=.+#%N>9PQ([F=5(\L<[ M"H;7B&W46W>IOL6DA)1RKHQ1.:D@E9RK8E1-:D@MY^I(O2)=B["3 M&8Y4K\Q9P^/7F^O?+W>283E#FZC10KX@=__AVX\K-C@CR><<;:8WI&@D\S*< M5\C@:**%\HL76C8J851JR2#US:#&](D26WY\66W,Z? M6')1J24W?6;)1>66W%R%)1=56G)S599<5&W)S=58. MUB_1V/:Z.[89H[SE$HTD[RRT*RBVI`Z!Z^!PGMBY7"I22^X6,SN7FSZWI*;OK3DIJ_L7&[ZVI*>/CB=:.Q<;OK6DIN^FYH+YPYJG"ZMZ>C]TCZS MS(8+`'Z?:J[BR#+3ST8\=QBCW($YL@/=X3L>23T;C0-=5&H'NKDR2RXJYUP% MHTI+;J[*DINKYEP-HUI+;JZ.U"O2M9B^F'#D*?J:EQ)&TJ=W/&$8!JJ5-Y+; M!6,[ESOB))9<5&K)[:B9)1>56W)S%99<5&G)S56-Y!T1:DMJ39V[RWO[HWUC MYW+3MY;<]-U/S=6K@;J0.650F/#C%&\B_X+`&1:28E)!24D;*206I)%6D MFM206E)'ZA7IQ(<7'%YX.6[-*Q$C247\LPEW/78\FQ@&>G6+W$#W[(6HA%$I M*2/EI()4DBI236I(+:DC]8ITD<(K$<\\Y?"2PWH@+\L;4D2*20DI)66DG%20 M2E)%JDD-J25UI%Z12OQY>)W@A:MC/X\^7HT4K([P8K6+LDLA(L6DA)22,E). M*D@EJ2+5I(;4DCI2KT@7Z;C+`^=##^R?D(WDKPY21(I)"2DE9:2<5)!*4D6J M20VI)76D7I%.O.G3_3/AEZZ.H=]7%1DH6!WA5>SS0Y1;':"840DI)66DG%20 M2E)%JDD-J25UI%Z1+E)X5>"E1>+E@O.!5)$6X44U%^1J=!AG*6940DI)&2DG M%:225)%J4D-J21VI5Z1K-'VUX.@WMLE/;8:GQ2.I&LW.@[9_XZ)L12)23$I( M*2DCY:2"5)(J4DUJ2"VI(YE?*S4I')X*AB(-OSXZ_*3B[?;^RW:S_?;MX>1Z M]X?Y95%Y7OKP[L##SYY>KM]>F+,*26:XY?RU_"+J_M(QMIC?2MW_LBBVS&7+ M_AH0MBQDR[X-PY:E;-GW;.&6E=R.O$]FXKZM5K)EWUEBS%JV["_'8,NY;-G_ M`F&X92U;I.^8N)WU&]FR;_G#,4NY!_*&SHDQ2[D'\I;T:DM2?=Q):5U$?>OC6Q92%CY,6XB2U+&2,?Q)K:(KF63PI-;9&:#CL9 MV+&2,?!/"U!89(Q^_G]HBN9;/AT]MD5P/%PK"^[:0 M7,NG9J?&2*Z'EX[#,7,9(Y>Z)L;,9T)[;,98Q\Z^G4%ADC5W^FMDBNARL^X3V82Z[E"PBGQDBNY?7$ MJ2V2:_E:MHDM,QDC;_V?VB)CY`O6I[9(KN4;P*>V2*[E:Z>GMDBNY7N1)[;, M)=?#B]3A(Y4ADR-F,D)^5&=BKIED6G[U96J+9'HX]0MO92:9EM_"F!HCF98? M8.`6^<'ICY-5,S<_$7]IRCSE9D%-^,?EQQ00?F1[>]77[;UU?V7F[N'DV_;S_)4^7I_7?9^^)GNX7\>=]^E M+9:?VMX]RL]K[__Y57Y.?2N_#/S:_";6Y]WNT?Z/W-VSPP^T?_B/`````/__ M`P!02P,$%``&``@````A``@GH#N<`@``G08``!@```!X;"]W;W)K$+\?GW'/\P?+F1=?D65JG3)/1:#*E1#;"Y*HI,_KS MQ_W%%27.\R;GM6ED1E^EHS>KCQ^6.V.?7"6E)\#0N(Q6WKAK9DKK62Y]TD7;-X.KUDFJN&!H;4GL-ABD()>6?$5LO&!Q(K:^ZA M?U>IUAW8M#B'3G/[M&TOA-$M4&Q4K?QK1TJ)%NE#V1C+-S7X?HEF7!RXN\$) MO5;"&F<*/P$Z%AH]]7S-KADPK9:Y`@<8.[&RR.@Z2F^O*%LMNWQ^*;ES@W?B M*K/[;%7^5342PH9EP@78&/.$T(<<2S"9G5A MM>=@"'VE^>N==`("!9I)/$(24E8NN\T;\#*.J:"EQ=:W?<\]72FAV!Y0:T:SENGB@%XK_W`DT@ M=HW@C"XH`1D'^3VOHB1>LF!-"YW#'6$\W`O=:P6_`0D':3H!<&&,/PQ`F/4_EM4?```` M__\#`%!+`P04``8`"````"$`GS0"]YX"``"U!@``&````'AL+W=O<<^W+_/I9-^1)6J=,F],DBBF1K3"%:JN< M_OQQ=W))B?.\+7AC6IG3%^GH]>+CA_G&V$=72^D)(+0NI[7W7<:8$[74W$6F MDRU\*8W5W,/25LQU5O*BWZ0;EL;Q.=-.Z.Q%&=P"Q4HWR+STH)5ID]U5K+%\UH/LY.>5BA]TO M#N"U$M8X4_H(X%@@>JCYBETQ0%K,"P4*T'9B99G399+=7%*VF/?^_%)RXT;O MQ-5F\]FJXJMJ)9@-;<(&K(QYQ-3[`D.PF1WLONL;\,V20I9\W?CO9O-%JJKV MT.TS$(2ZLN+E5CH!A@),E)XADC`-$(`GT0I/!AC"GW.:0F%5^#JGL_/H["*> M)9!.5M+Y.X60E(BU\T;_#DE)3RI@]=1NN>>+N34;`NV&;-=Q/#Q)!L`[3@%A M8/DWDL`.09:(DM,+2J"^`V.?%DEZ.6=/X(;8YMR$''B^Y@P9#-@,E(#&F-+; M]NPJ8S)61KN0RDT(C,ND;Y>9_4\93,XI7,17\NG5@!LJAYQ9;_=8S^FT$%H\ M@\/SOB["V8/"VUC1QJP4&[=QDN0/C[G<)-4_QM9"HE MV9,2QD2XBUK:2GZ23>.(,&L<`2E3.,3:)(YLL^S^?6><"[EP?2%D&)_C,S=F^?"6I?B*,-RR.6RIP'Y)UK\K#Z^&&YE^I%)YP;!Q!R'9#$F&+ANCI, M>,;T2!8\AU]BJ3)FX%5M75THSB)[*$M=W_.F;L9$3DJ$A;H&0\:Q"/F3#'<9 MSTT)HGC*#-Q?)Z+0-5H67@.7,?6R*^Y"F14`L1&I,.\6E#A9N/BVS:5BFQ1T MO]$)"VML^S*`ST2HI):Q&0&<6UYTJ'GNSEU`6BTC`0HP[([B<4#6=/'H4^*N MEC9`?P7?Z]9W1R=R_T6)Z+O(.40;\H09V$CY@J[?(C3!87=P^MEFX*=R(AZS M76I^R?U7+K:)@73?@R(4MHC>G[@.(:(`,_+O$2F4*5P`/IU,8&E`1-B;?>Y% M9)*`C,-<9T=#_SQO0RB%O> MQ\I[8H:MEDKN':@9H-0%PPJD"P`^K@>$H.\:G0,R(P[<54,27E>4SI?N*P0N MK'P>2Q_X//@T'BZ0-LS`=CTS.B,S1A:O\E@:VC3^<9KQ+33H'!!HVL/E?:_! M+9E+G[$ME[:>R2U$Z`PA!Q4'ID$H*Z>VR':\.]&$,KH^FNALV9MP5I:R"=JJ MIEU<6_=S\#Y?*'BJ2U!9H/$.@GW:A+:C!0KL>BWHW*6J+$,M.(Q;M8Y:QA[< MZ+P6/-4EJ"Q=+2?*;][E/$^%SEVJRC+40H&]+X;Z%\788UV*VM25,SZ>&HKM MW8KA>3W6N\>&`&`ZHJ@W$#`]_N2RHFH2^(?9@&V%')W&\2-CI%L!&'W1T M^IKV&ALS//'FHXOCQ![LU5'3Y>V!;RN:]125 M.U>YE&1<;?EGGJ;:">4.]RD?UHS&VNQZ:]M_??MDL89;8(::7V`'*]B6_V!J M*W+MI#P&3&\T@Y)3Y197OAA9P-UA%9,&UB_[-8%MF\.JX6%]QE*:^@4)FOU] M]1\``/__`P!02P,$%``&``@````A`-A6YK,X!0``UA,``!@```!X;"]W;W)K M#P#7GU[*T[.JZCJ7)9KEXU] MUQ%E)G=Y>5B[__S].)J[3MVDY2X]R5*LW9^B=K]M?OUE=9'5?*Y'NVD7%R>.^/_6*-"]=9%A6 M0SCD?I]G(I;92R'*!DDJ<4H;T%\?\W-]92NR(71%6CV_G$>9+,Y`\92?\N9G M2^HZ1;;\?BAEE3Z=P/<;FZ39E;M]TZ,O\JR2M=PW8Z#S4&C?\\);>,"T6>UR M<*#2[E1BOW8?V#+AW/4VJS9!_^;B4ANOG?HH+[]5^>Y'7@K(-NR3VH$G*9\5 M]/M.A6"QUUO]V.[`GY6S$_OTY=3\)2^_B_QP;&"[0W"DC"UW/V-19Y!1H!GS M4#%E\@0"X*]3Y*HT("/I6_O_DN^:X]H-IN-PY@<,X,Z3J)O'7%&Z3O92-[+X M#T%,4R$)UR2P0I,P/N;SD(73SUD\5-0:C-,FW:PJ>7&@:N`SZW.J:I`M@?GJ M#'5T7C^R"AX5R8-B6;LSUP$7->S/ZV8Q77FOD-),0Z(^A-F([16A\J=88QI( MC(`'^CL3D!K3Q/O;-^3[1AAA# M&P;"MHI&03B=U\CQ!C*:2"F@<0(6-K4:#;ZWGUM"DRS.B': M$&-HPX#.ZB3P:>7'UQ6WTQ&0PY%<(6HXF0UO8:L?5K=J$75!3DZ$&,,%!M#% MB`><$=^Q!5B$(7F>&(R6!0;G;/@.M&@JOC=B%"67VO"0:T=+:%M0\,HIHV#8PG&*PM497)+,BTB#3"BZ[1>(>)C$CME(U M>PRE]\N=X:2R^S;)2J1!F-H%5#>IW:T%X&$/$&L`3)HN$;T#T&'H"6!J0`UW MA./,=D3&2M12VN6#R_09#A?P7@XA@VC.9F*3VEJ@A-=P`CC3+`",9 MCQB";B6RU1&4-YF$04\_+D'`B$UFC&0E,4EM`VI@&08&5C^..=L(.9.1^FY- M#C)&4"?G"S\DYF.]1B,8GQ/2Q"2UC:CY91CYY'#@M+,-D(D9,6,DMDUDJR,H M;SZA:8ZMYR/F\X"TA,3DM/6K&3=A8T(!WFJJ:>HJNIYR^QGMO^[+U1 MX\]P,_"0X-`$D5UG9+3U1,R8K-H5C<0]3&)&+*7\2_.X19-Y3(LDTB"C'W61 MFS':\N,!F*3#T+'`R4B^?Y9;-'5!2CG2(-/%=13?<_$Y)C&9[;V`>C:KYA,7 M"DU=T'$-UR.DI>H(_M!B<*/$?'+*XV[1QT;5O4M'C";P&@5O&0I1'<16G$ZU MD\D7=47"X6=&%^VN;Q[:VQL2C^!:I[T#\;H'<*MR3@_BC[0ZY&7MG,0>*/WQ M#,9#A?&PO=V]R:W-H965T M&ULG%C;CIM($'U?:?_!XMV&;NZC\43!P&ZDK+1:[>69P7B, M8HP%3";Y^ZWN:J`O'@=G'HQ=<_JX3U5U5;D?/WQK3JNO5=?7[7EKD8UCK:IS MV>[K\\O6^N?O?!U9JWXHSOOBU)ZKK?6]ZJT/3[_^\OC6=E_Z8U4-*V`X]UOK M.`R7!]ONRV/5%/VFO51G^,^A[9IB@(_=B]U?NJK8\T7-R::.$]A-49\M9'CH MEG"TAT-=5FE;OC;5>4"2KCH5`^R_/]:7?F1KRB5T3=%]>;VLR[:Y`,5S?:J' M[YS46C7EPZ>7<]L5SR?0_8UX13ER\P\&?5.77=NWAV$#=#9NU-0ONNJPM3Z2AYQ2RWYZY`[ZMZ[>>NG]JC^V;[]U]?YS?:[`VQ`G%H'G MMOW"H)_VS`2+;6-USB/P9[?:5X?B]33\U;[]7M4OQP'"[8,B)NQA_SVM^A(\ M"C0;ZC.FLCW!!N!UU=0L-<`CQ3?^?*OWPW%KN<'&#QV7`'SU7/5#7C-*:U6^ M]D/;_(<@(JB0A`H2>`H2XFTBW_>"*%S.X@H6>,XL-/*)']RQ%T^PP%.P4'B[ M4`ALEGL#GN,6X@WQG'LV$`@.>(X<9*E';8P.#W9:#,738]>^K>`$@?_[2\'. M(WD`XNO1A;`R[$<&YDL@<#VDY->G,'BTOT(6E0*2F!`-L3,1OLJ1FH@P5"'9 M%4BD0O(KD'B"V"!_\@%DE^P#ENDNG)?;OF"+MA:\3KZ(G(F>NRM!"&3=!'$U MR`XA/O#!\J(ALYWP]V+I.X/CAKHE!4AS^CFBW25&NYE"!$4JT;4MV0Z88< M#;*CWE/!YK[%C82!M=UK;2)!B+1[W9#JA@P-N-FU2WT2:D;PD(014D\&D8Z"501E#JN9">VO=D,@1:0D1@T-`\G"L8 M\%7L!'/-5KQ!H!LN#RY':W[0FG,B,#<=(3"R)\QV,!&-%3,S++EL476Q&4%* MVF5A)CA90$>=@AAI(4H$1DI?PY(:ELRPY)-E_BYIAE#%L!8OB;G=WP@.!+*( M>*Y/6/P%1A:!JV9+:F`RPY)/E@4B6/->+@);O2PBTK(\(8B9M[PS+*EAR81% MU!+XV1)IU36_A5#CPEJX)&EADF'CEZ7%\^D4\1FGA:M^Y9@=40:(J^5$@;Q3 M3Q0,*RBAZWK:?G(51,(H@$'S>L]COR1_PBDX."A.T4I\PIEA@)=.IW1BA%.0 MYP>519I2^+)LHAYK32Y;U*"SWG]_T'%BD/7I>9<0>:KPK@U@.P5"_&N85&#F M8Y$9EOPVCZJ7#0KWZ\7Q0M%K5%)Y!.%ZIXP2P90!J%9%I$1&K+T0'*(B,H&8 MO9$K:XCGRFM4Y6RFD)3_H.SB!"(K-LLN8N;-[(@\MU`>4%5`*A#SFLRPY";+ M1*(J8H/!0*9JVPH.:JO\W`9E!F:M+5"$=Q M[0`J`!(Y/C4F5@4"+<:)8V-D53!K&E`:Q_IM2*Z"2!QZ83AO6/4(I.3R-(:K M5'UXC^?>Q9,R$1@,V/72JT#0%^;,*D!SNF2&A5WMLOUP#,K"FUJ\O+L4+]4? M1?=2G_O5J3K`'.ILV(5HA_>T^&%H+_RR[KD=X'Z5OSW"?7H%5Q7.!L"'MAW& M#]#1[.F&_NE_````__\#`%!+`P04``8`"````"$`?8A?'=8%``!X'0``&0`` M`'AL+W=O:5=:K?;CF1(G00TX`MJT_W['@R%XL`/N2]-,9N9P[)GC`=;?/_*3 M\\[**N/%QO5G<]=A1>5Z5'EF>5#-^9@7\LN=EGM3PM3QXU;EDR0Z#\I,7 MS.<++T^RPFTRK,HI.?A^GZ7LB:=O.2OJ)DG)3DD-UU\=LW/59LO3*>GRI'Q] M.W]+>7Z&%"_9*:L_,:GKY.GJQZ'@9?)R`MX??I2D;6[\,DB?9VG)*[ZO9Y#. M:RYTR/G>N_<@TW:]RX"!6':G9/N-^^"O'A>1ZVW7N$#_9NQ2]?YWJB.__%IF MN]^S@L%JPSZ)'7CA_%6X_M@)$P1[@^AGW($_2V?']LG;J?Z+7WYCV>%8PW;' MP$@06^T^GUB5PHI"FED0BTPI/\$%P%\GST1IP(HD'_AYR7;U443/[N(X6MPM M(8>E2Z?/8 M^,#?SL?O/#P`[9`!;3JRDAT*:630K*WWLIJ0@5,7TWAC.C=WMWIJ=RKD+>AA+,*)2U#*CZ@4RY^/+HO&*9"M":5SKV>CB^ZN[>$ MM_F@-T$3"<"D820Z>GIJV?_!51%$,T'J1=@(T]P/#1RL%,%OVAV2=[W2FC0< MB`:("A,"/[),G1A<(:1)V93%W$!(-._TE9.MWB:-(0TJC`NK!J`HAK*B]*F"4 M"M&:U!TR##NAE2J@-T$SJD*H487QDL,H`J$5!<.X$UJ)`GH3-#D]^`-1"(DH MW%8W]":I&S&XCCN&LR>TT@'T)D#&Z2#4Z`#<$(Y)-881#-UXL#3,.Z&5$*`W M03..!Z%&"$0+C.S.4`@P$:`J?;,TS#NAE1"@-R%D%`)Q<%(A\.>C6X1A*D9K M4AD9BBZR4@+T)FA&)8@T2G`_ND4812!T2K`T##R1E1*@-T$S*D%DI03H35)3 M)3"4F;C7[=?"[:)&;P)D5()(HP03-F4X$6`B0%6J+#"<-Y&5$*`W(604@NA+ M0H!1!$(W$2P-0VA$A$#,OO"D<'P4P4`"W&A"\UA4&:3$8X+I=8#>:FIINAX] M!J&.K50`O0F0405BH@*W:QF]26IM]QMFZ=BJ^]&;H,GN'XZ>L57WHS=)W77_ M]7&4B8:5`(B#G-P2M*;A.!-K!"!8CLHRAA$^VE'`<$\06RD`>A,THP+$&@68 M\(0-PPB&5@(,-P4QD8"1PI8'?^\6!!/`!0Q+3O54BT@1]?RTUP\8L MK%H?O0F6;/UAJ8EGR'T:^(#@#HKU]E)A&,'0:H#AL!&L^[`C:++A>QN#"?0; M0S0`97]\2`-IIPW:FI3C(:5S9NSYDO-S[`8\-Z* MU_#""_\]PAM.!B]WYC/8S3WG=?M%/%'IWIEN_P<``/__`P!02P,$%``&``@` M```A`/D!07`*!P``[A\``!D```!X;"]W;W)K&UL MK)G;CMI($(;O5]IWL'P?C`\P`P*B`2N[D3;2:K6':P\8L((QLCV9Y.VWJ@]V M57>#F5%NPO"[NOQU=5=5AUY\_%Z>O&]YW135>>F'H['OY>=MM2O.AZ7_S]^? M/CSZ7M-FYUUVJL[YTO^1-_['U:^_+%ZK^FMSS//6`P_G9ND?V_8R#X)F>\S+ MK!E5E_P,3_95768M?*T/07.I\VPG!I6G(!J/IT&9%6=?>IC7]_BH]OMBFZ?5 M]J7,SZUT4N>GK`7^YEA<&NVMW-[CKLSJKR^7#]NJO("+Y^)4M#^$4]\KM_// MAW-59\\GF/?W,,FVVK?X8KDOBVU=-=6^'8&[0(+:>J^HJFGW#`&OU)K,"?M;?+]]G+J?VK>OT]+P['%I9[`C/"B=-^ZE`E[ZW?6G:JOQ/ M&HD9=4XBY00^E1,8>\,^5O;PJ>Q#^//&@$0-@,\W4P9RQB*`:=9FJT5=O7JP M*V%.S27#/1[.P;&.G,3H8GDME!!#=/*$7I;^@^]!E!I8_V^K*(H7P3=8LZVR M6=LV(;?8:`M<('2;$B$`W@X:0OP3H-$+0NO7K;5`9F$0:@L])"4"(X25I(3N MC:BCA\9+'XH1B5["W[R6-HG(`Q&YRM(( MDIT:3?AD-IU1%T>J,'3((8I^.Y!H+`BUW[54DJA;Y(VEI%1A[Y[R=V/8IE"; MWI@;Z(5#206@:(RF1HPZ(SV7E"J,$_+N_ABA,<>1"HV1I:148>_&%FK4CW?$ M"+UP**D8,7HP8M09=3&B"N.<<<[;^PB-.8Y4:(PL):4*>W<(F^8G!$FXX5A* M,L+T:(2IM^KBQ"0.BT67K.CM2(6R1$-1T*[72J*QLJ6421P`:RH!>&?:89TR M%E%)1K1F9K3D0,*?]@-AEAP6:RZ!'8B6K-`L6JIH]P'&R&J[/2.R!5ON0$."W66D([$"Y9F1D3+=:R M#^)!SPP7E3@`%E$"@.&:07H.@,C2RT"4!+/ONV%LG6B4E3QTRC--)]&!41=5 MCHMUU\#%\CJ`*ZLUPU42QS6:]R945A2WDRAN?SKAN%A^#=P$UF(`5Q9MAJLD MCFL>(T)E17$[B>+VO97C8L4V<$/,G0%>6>@9KY(XK]FN0F5%>3N)\O8%G/%& M5_K(;5PQBK<-+7%R77(FP)QN:]`UR;4(W)NXPY5,C#*BBXXL7#/5]$"*JP9RW&NI!E84 M=R#%T-K`E!)IXAO\+<%H5$SBR8-MPK&\;VSKD>HV_?%BK20@HTEA);\<2/C3 M?J!Y"HJP21#8@6BIED*9I$3>MA$^^2F(23Q:6/8)P'M/09%J'Q1-2CQXELPDE?TCFNHY$,UX[8;B1:XKAF9=96%-?52.(KE3EV-)+A4Y`8 M9437U4ABLS+K@137U4CB*Y4Y=C22.TY!8IC!JQH"#Z]9FO5`RNOJ)/&5TAQC M';\[>X2U@8D.6&79*"N24"F3^'8T>@-FSQW;T>X1L9)XO,Q*K*UHO-1`^"#G MFKXF<5Q')QG^+T]L-PXM,5SK&*:M**[RQ7`G5XYAL=%+,+I8+6X723'*6&;5 M9CBNE>S*BN)V$HGNI!_(H^OH/'?@VGTF5A+'M9)=65'<3B*XR;5D-UK/G7O7 M;D&QDCBNE>O*BN)V$L6]DNOP>_<;7W(-_GIU'C;Z@4O MO>"0N5ITLKR16\?)'$L./40Y@D_@SK(0I@G_#[I>A+! M$W$0,\G"&)[$SC$0:?C/E>T-;D6?W+Y@@,-^#2]WVL.K76]^2N9/L%GL%Z^! MR`6TAK5R+A6LE'.A8)VI#<6Z\4[Z'C3D>/4!+ MJ.5]K?S25A=($[ASK5JX9Q5_'N%>/8?;P/$(C/=5U>HO,+&@NZE?_0\``/__ M`P!02P,$%``&``@````A`)@_L#7("P``Q#H``!D```!X;"]W;W)K&ULK)M;<^HX$L??MVJ_`\7[!'PA$"K)U,%W^_=B^]']7AN*WW=WWO M:MCO5?M-_;#=/]WU__-'^MNDWSN>UON']4N]K^[Z?U;'_N_W__S'[<_Z\.WX M7%6G'GG8'^_ZSZ?3ZW0P.&Z>J]WZ>%6_5GNZ\E@?=NL3_7EX&AQ?#]7ZH6FT M>QGXP^'U8+?>[OO2P_1PB8_Z\7&[J>)Z\WU7[4_2R:%Z69_H^Q^?MZ]']K;; M7.)NMSY\^_[ZVZ;>O9*+K]N7[>G/QFF_M]M,BZ=]?5A_?:%^__+"]89]-W^` M^]UV/IBMP-Y!?%/M\,;@;DZ?[V84L]$++W#M7C7?^+-UV%P_[@_K81 MZ+_;ZN?1^'?O^%S_S`[;A\5V7Y':=)_$'?A:U]^$:?$@$#4>0.NTN0/_.O0> MJL?U]Y?3O^N?>;5]>C[1[1Y1CT3'I@]_QM5Q0XJ2FRM_)#QMZA?Z`O3_WFXK M4H,46?]J/G]N'T[/=_U@>!7ZH_'$(_O>U^IX2K?"9[^W^7X\U;O_22M/^9)> M?.6%/MG+]=5H/`P:)V<:!JHA?:J&OG_EA<-K$?Q,NU"UHT_5+KP:>\.;8'R^ M'5UMNDN?'&]D=/=,Q&O5DCY5R^N+(HY5._KDB!?UD`9H\TWI\T,]O%'MZ)/C M7=A#CY)/YH+(0GF;+^NCUV:1OA]G[^-`9F&3U/'ZM+Z_/=0_>S13D*/CZUK, M.][4(V>#'S20-LIFAC:> M;1&QA1@UPFWL@L0%J0LR%^0N*%Q0NF#N@H4+EBY8&6!`TK;ZT@#]._05;H2^ MK,R,@1;<=\1D"VX2NR!Q0>J"S`6Y"PH7E"Z8NV#A@J4+5@:PQ*1)RQ*S>\[E MG!36=WT:SD9..ADWDS9RO6A2+@(2`TF`I$`R(#F0`D@)9`YD`60)9&422T(: MXI:$GQSOP@U-&72C#''=`2^-0AH:AI&;IJU1FZ=`$B`ID`Q(#J0`4@*9`UD` M60)9F<32F]8]2^_S*2NL&UE9C)DDH=^._`A(#"0!D@+)@.1`"B`ED#F0!9`E MD)5)+,%HN?^`8,+:%DR1B18,2"S)R%RNO$E@SY]):\3W(@62`MYMOLYH&$@VGCB0*:-&52[%P8DNBR(V6!$@LR6C2K-W^ MT',FRJ2]WJH!)`.O>6LC*@+RZLP017N=O98FL;01^R>S4.G0@$I8%D%8VR)( M$M#$:$Q&SCV/6B/^/K$B8:M=HHBL[465DH)-!GYRL"G`3VG:6'VGTO(#?1?6 M=M\E\>V^AW:^1ZU1VW=%:&YK)?,F([M9HHR$]#_NG?N;MA[89P91\M;F3)3B M7)2R]4!1+-U$@6T)]ZD!U7BQ!57(ISO62A/XCC21MN+NQPJ%NI)+&,FAYRK( M/O3@S1CI*2YG']IMP:C3;V9J*2-0?:YS23]3`5"-SUF=BS4%Y2%C** M$,4*!31'MLIBTK'5N#/KV*T>M!DC'3QG'VT7M+*0#%;Z?Q(%`J:>,M*\"?966E=UG475^ MH,^R2"5_W,&9)Y$S4UW;4TZDK;AAS$C?\H21,5$STE89(S,QU)?05@5;:5\E MHXY;+XK!#\@@:T=+!HFY/[D9C9U9HF1/C7,[HT21::KRN8R2I:HEED0^C:]V^`6^,[0B3UGI M*2=6R,HH:170A^%KXF951T1Z(&!;91@QQX@%(SOBC>VK9%]F'\V(MM*BI/WK M2LO"V%):(M^<>(+`Z7?D*2N=3+%"(_/DHJ.^D`W'E'FM^-[8.;I(V;V9OA`Q MORABH:S.1RRMB+;2H@@^I_0?]2O5L)U[1V/?Y`DW3JTKD7D$H:P,%"-*$*6( M,D0YH@)1B6B.:(%HB6AE(4M7OWL+P<]*+CX@;_S8PBI$*NHD"]R%,=)6O-C$ MB!)$*:(,48ZH0%0BFB-:(%HB6EG(UMK=>IQ?K7S<8RAD)&:$*$:4($H198AR M1`6B$M$WA\K9!Z_,:+"K2WU@L#93*3LRZPWS:JW.6;)V,K,/_E5 MC8C%11%+]O561#L-Q3;@KRLM-Q.6TAW[B\`]+(A\9:73*%8HU.,N46@DA[A3 MJZ?L@V8+XS[`"(=(.48JSD8JWXMD*RL*^G/*7E97BZ,<=S61R*I5`,6JH6&5 M($H198AR1`6B$M$T0+1$M+*0+?G'=CN M=SHIN!X[1XNEUG]L7C.R([L,)]O561%MILK)FV\]-#<*+,PE+9*=OZ&ZW M`F6ELRE6Z)TS3V5U_@0R9?$&/$26(4D09HAQ1@:A$-$>T0+1$M+*0K;78,GT@5^4.R\I5 MB8R!'06`8D0)HA11ABA'5"`J$$J_-NZP]_VI>+K4=268IO((WA&# M'LU0FZ[NS3Q*!WJ\C-YF/MTF>AC:=86TI<=\=&70!J)W"%_73]5R?7C:[H^] ME^J1TGG8_#;\(-]"E'^Z:*W12OZH?+PBN::Q[H^\1\B M0/O^Z?W_`0``__\#`%!+`P04``8`"````"$`F)+WC&P'``#*'0``&0```'AL M+W=O"<8QB&PO(9O??=^;,',X%&MO;AV;SG9EAOC-7PL/G;Z>C\[5L MVJH^KUU_,G6=\ES4N^K\LG;__I)]BEVG[?+S+C_6YW+M?B];]_/CSS\]O-?- M:WLHR\X!"^=V[1ZZ[K+RO+8XE*>\G=27\@PG^[HYY1W\VKQX[:4I\YU0.AV] M8#J=>Z>\.KMD8=7<8J/>[ZNB3.KB[52>.S+2E,>\`__;0W5II;53<8NY4]Z\ MOET^%?7I`B:>JV/5?1=&7>=4K'Y[.==-_GP$WM_\*"^D;?'+P/RI*IJZK??= M!,QYY.B0\]);>F#I\6%7`0.\=J^M]F^G/=3O MOS35[O?J7,)M0YPP`L]U_8JBO^T0`F5OH)V)"/S9.+MRG[\=N[_J]U_+ZN70 M0;AGP`B)K7;?D[(MX$;!S"28H:6B/H(#\'_G5&%JP(WDW]9N``^N=MUA[8;S MR6PQ#7T0=Y[+MLLJ-.DZQ5O;U:=_2-P..$)_"3C<23>#:+ MYO'B=D_F;`1^LA%_LO"GR_"Z#8]N1EQTDG?YXT-3OSN0O<"]O>18"_X*[.(- M0T3Y/OH[_[\KA[M&(T]H9>TN7`?46\B3KX]1'#UX7R&V!XA*IH>,D(=A_RC*!#[4/.P1W4.54H:' M4/FVA_X2*'X<>=0R762$7+0:R)8/-1=[1'[A$T(:$%G!U?;F%"[NBV-*R[WP)(3/@HZE9:9[V0K(J,ATQPN$#,ST>(\1@ M1DMF0MH,!$,AE+KFD9W64BI43"04]5`J(16X3$)"RO0<9XZ521BG*PQH4D&; MDW>S\0D*3`9VUDLIG<&(HF^WS%0JSJEG3GT_"*R`95)FA"5.)8WE%78TPPQV M!`5Q3WB+/1X25(,2":E,2QFBO5+D;&9(F<'`6:2Y2?O+!*?.[77CTT"#IZC8 M$!3`#RV[['IG19"2B@E#X;R'4@F9)6?5929MZ=D`KQOCK<+'`6?1]F?WTD8C M5E$1I$5H*QYE!8VD9NJ^4I9:*-J95!2A-8.&P\_V'A9SCMF7^B)ZW1T!1(,6 M$X*L`*KQ10T;=T+,2#V`!$70N?K(CQ0727('!7W76X4`.<@T12!@.&=`8$+13/S->E3`8XEP<,[JT?'NXZ(8*LEJ[F M/1-B*3WK"(*VH6YB).M("KH;OF)!=_"G@S;2>P`MR>2,L]CB?'_/H(%NM$J" MC)XQ@!*?H$B]3*424D',&*+\-;P/K'V!_A1P9\2$$;-/,&1&++9*>2NEM(@Q M=*5/L)3L$Z,AD\:'?2(8637TD-W6)X05BS5M$!$,Y+[)A0/2O5`_W=@4Z$DH M'4*9`9E1Q`W`SD'5^6_:<@/:(O049"@&AQ6=V%YJI:+J$`E#,]J1HNDLLM:O M5$E(QID!F?1&MA$]7K?Q&VXC.,5@3)E+>VPMP:6&\Y=:`I:P.SE74JI!I$P!&U$*0[[)$O%`4WG\:KK78#; M,DGCW+:35)O.MT61AK^1I;P/&#NE_6>R+?YETEI)&+K6:DCQXU;#QD=:S=A* MHBKSQDXSW$@"@F+5.;<,Z?.<(7TCD8K:1B(5AQM)@)/>"EGHXT;Y\0HE]*S6 M2$M##.FAI::]^;.BP4'?-L2@3UE*WTFDX@@'G-P:ARN>TYPW\HM'OYE?UH*P MA3D]R"^&1%:PYPRIQI%)Q9'?Y#+V'8"R#O#4($65W"WN%94=L_$H:N M=0DR_W&7Z%VPNP0NO#;INWN],&*29@A;F)9_]DXLI519)0Q=Z1(L]6&7D,:U M2-,G&OIR<"J;EW);'H^M4]1O^/G%CZ'1]C!_&UJNGL`07)MUL`G@JQ&L",,3 M&%=P(BA9.M`S5ELHG3&=^2H9/4E!!RMPJ)/!239Z`A^TGL1N8SU_`RZ/>;P) MP-#($S9`9(S'4[1Z$I5OV4^6JTR,;0N'M[?5%EYCAAS@)6Z5C)[`N]PJ'3V! M5SJ@,6HM0"*"B=>[`%_2+OE+^4?>O%3GUCF6>P@U#?^&OL7Q)L#OZ\]U!]_0 M(!O@,Q)\,RWA"\X46_"^KCOY"Q#Q^J^PC_\!``#__P,`4$L#!!0`!@`(```` M(0".]G?A_`@```DH```9````>&PO=V]R:W-H965TU5_:UZ+HAT`P[:Y'KZV[6XV&C7+ MUV*3-V?5KMC"E>>JWN0M?*U?1LVN+O)5Y[19C]SS\XO1)B^W0\DPJT_AJ)Z? MRV415LNW3;%M)4E=K/,6[K]Y+7<-LFV6I]!M\OK;V^Z/9;79`<53N2[;GQWI M<+!9SM*7;57G3VL8]P_'SY?(W7UA])MR65=-]=R>`=U(WB@?\^7H<@1,-U>K M$D8@9!_4Q?/U\-:9/;J3X>CFJA/H?V7QWAA_#YK7ZCVNR]5]N2U`;9@G,0-/ M5?5-F*8K`8'SB'E'W0S\50]6Q7/^MF[_4[TG1?GRVL)TCV%$8F"SU<^P:):@ M*-"=[N6I?KX>>>S:>G'L.F`^>BJ:-2D$Y M'"S?FK;:_%\:.8I*DKB*!#Z1Q#_9&2R[.X!/Y0PT)P:&6^Q\X5/Y.N>?OOL+ M10*?>`-GT_'8OYA.3I<`UE-W)_"))">/XE+YPN?71^%`ZLB9%#DD9\D]>1PC MF19=EH5YF]]XI\$"!1P,8@;2]OI#K_X:^@D;HB\K,$=""NT1,M$"7D`(+"D04B"F04""E M0$:!.PK<4^"!`H\&8(GI$3'W%T',26%]/80%V^>DYY*,FTL;OZO!7RE#E9_`1)IQ+>]UPAEUH2AH02&4^[:NF>.T3617\=62.&Q(PU MZ6U$#0964H33_CJR9B9B:0/[I:7-'@V@AT`1A+4M@D0\2,4^>3R7S'G0&^'] MA`KQ>^T6"I'MC=@7(F83,YZ$V:2,)S-MK+%#HGYB[,+:'KM$7'OLOIWO06_4 MCUTAD*Z]9,YT;+LME)&0_OL-F=^H9T#.F$5)>IL#4=)#4;*>`:)8NHEC!V\G M/KF>!(DMIT1"(<>2L37V^9"(7+14>T4@5ZU,:-,&&5ZB#(S*2VA MH!?\=:$$B2V41"#O4(.`(:%$/,C]`TFFC"9[DTQQZB4:LRC)*5'20U$R,XJE MG6B%+?$.5Z;.W)9)09!0O4X<"A'2";%0D*<;AHA;Q0AI^@0AS95RKLRRLL?&`=T"V?J M3:;PS]8XTDRH<8R0F3'J%@[&2TD\]\)W/-))9$C>Y9XMI^@333F_U/\XLMN$ M,#B>N8)(LM&*K:W0,5005">$%@J"GJP[5_KP\((**F_`U5D5<^J$4ZU1)*0D62!.(+3O%.0KAP+985)YKO>V*>;&3)I MMQ@A,\D8>4K(W>GE>$*J1(9,>S)*M).F*E_+*-F46F))".98+S_/)4LK$(_& MA'ZZY(0*LC)*6GG0QO1+V7.G-*OV1(2GG[95S",F/&**D!WQTN;*D,L?UUI64+;"DM(=OBJK"?AKJPEY>A$A MO9F^+&)R4L3TI(B9%=%66K2[AY3^N]I!?W'T&9GLFD%J/7!_2@8^=Y25'GC` MH5!!1P[4V@J+:<2AF$,)AU(.919D*R;ZWD.*G72N=F3W;.6F@DQU&!0JQX_/ MUMI`"R-IP`>A&./K8(EV_.!\K0V0)K,@6R;1XIHR'=E"A#EI9"5$UBK)JCA4ICWVA[)$=#]W M&NC,;1$59&\M=/P!6AE;"T*Z[U@@))L54N`CO*H=8H0T;8*0MDH1VDN;X57> MI+CTV/"E[;AC(9JITP1D5E_%/8]T3X%R-#J<4$'FH1PA6($&%^DY(N0R(YJ; M8_V7VV%>T'$H9A#"8=2#F4./1H0;;Z M,$?_0EX+%E)!%&0JS:!0I#TX?KR5:P,MB>0P\<>K0@6W)Q\#!+R>&V0/R03[551Q>SV8T"Y6A5YSV.O(57CNK\ MZ8ZG%Q?N):O7/17*%_.`"4)Z8E+*[GG.Q834N\SRL]43QP13O:\58GG8L`JQ M.G]`=AG;%-ORE)4NCZ$K(?,$BI!U'F1G>&4E,J6/N&?+8Q$3I-=/45*$[(CT M4=&QB+;2XJCRZTJK`X_Q]`A>J!$9;7>U/NUJT4IO]:&"CIQ`E=61$RC2Z\R, M$=(1DY,BIB=%S)"^BRB5EN\%R3MT,EM6;>.<'CJPW5STL7TB" MO0G>2.JRCUWQ9Q'D$BQ'<@5J(?CLNP*O-]UV$T,\YO#:4_>.$,5=(-H380XW MM>^>;OW9+8R"W]*M,X'(^ZAN88"W(!7W"?T9_-*[!Q_/X+=3CB?C&?SZR7$X M7<_$X7;?E>DL@O,!%K%W^4CSD]4NY;0;KXADF[;S[-:R6 MKW+)+ZUZ?O!4M?`*%LPKO(<#K]P5\%,GO.XT'#Q758M?(/2H?XGOYA\```#_ M_P,`4$L#!!0`!@`(````(0#W$5CNM1<``.B)```9````>&PO=V]R:W-H965T M'YL-$@"!"D(IC_\^Y_''R=_;YY?'K9/ M'T\G9Q>G)YNG^^V7AZ=O'T^KTO[7]>G)R^O=TY>[']NGS3O_]Z7__ MY\.O[?.?+]\WF]<3RO#T\O'T^^OKS^7Y^/?P=-IE6#Z_)\?VZ]>'^\UZ>__7X^;I MM4ORO/EQ]TK[__+]X><+9WN\?T^ZQ[OG/__Z^:_[[>-/2O''PX^'U__LDIZ> M/-XOO6]/V^>[/W[0/IY\GRW9Q?7K^ZU="Z3/)U\V7^_^^O&:;W^YFX=OWU^I MN1=T1.K`EE_^L]Z\W-,9I31GTX7*=+_]03M`_W_R^*"Z!IV1NW]V__YZ^/+Z M_>/I[/)L<74QFU#XR1^;EU?[0:4\/;G_Z^5U^]AT09,^59=DVB>A?_LDTQM) M7U%U1\H.>]+7NY+OK/*J[X@_* M_NU++LZFUXO)XE*=J@/[>M,7I'^/.ST3Z@Y=ZZA^T9WYR[/Y='%UO6N>`W5. M]@U+/QQYH!-N3_5#7_;J[&IR<3-[HU4FW*#JAR./E5MT0C\<>:QT^KO31#_T M12>79Y/YQ5LM,Z'NTY64[O#.?C3A[J!^.')_N4-,I$>\;W^GW"&FTJKOW-\I M-ZKZX;C]G7*KJA_X_,[>=]%,N5G5#WW9PWM\WHU0NP%O??=Z]^G#\_;7"=U% MZ)!??MZI>])DJ;+Q4-==!?O![_\;^VC04UD^JS0?3ZF]:5A[H0'[[T_3ZXL/ MYW_3('O?Q]QBS$2/6'&$&E%5VK4)E@FV"8X)K@F>";X)@0FA"9$)L0F)":D) MF0FY"84)I0F5";4)C0GM`,ZI$^Q[`O7@_T9/4&E43^`VO&48=`VCV3F"BZQ- ML$RP37!,<$WP3/!-"$P(38A,B$U(3$A-R$S(32A,*$VH3*A-:$QH!Z`U.XT^ MT.QS&O+'GW7X>E>E/I[2(#VXWHVK^;:+F>\>M7:7\PID#6*!V"`.B`OB@?@@ M`4@($H'$(`E("I*!Y"`%2`E2@=0@#4@[%*WY:/ND>._RH-W4*HDPTZ MA'D#Z(+F-``-@J;&8+`/VH\&(!:(#>*`N"`>B`\2@(0@$4@,DH"D(!E(#E*` ME"`52`W2@+1#T?H(=0>MCQP>&E3TKBMP`]YV0NW.L@)9@U@@-H@#XH)X(#Y( M`!*"1"`Q2`*2@F0@.4@!4H)4(#5(`](.16MD>FC7&ODW'P15&KWU.S&N^IEQ MU>^#N(NL02P0&\0!<4$\$!\D``E!(I`8)`%)03*0'*0`*4$JD!JD`6F'HG4( M>IC7.L3AJUY%Z^W>R7PJ5SW(&L0"L4$<$!?$`_%!`I`0)`*)01*0%"0#R4$* MD!*D`JE!&I!V*%HCTQ.=6K-'KK=T*M/[S7SXVK?A^TO^I!+!`;Q`%Q M03P0'R0`"4$BD!@D`4E!,I`B=0B:/-$ZQ.&K7D7K[=[) MU5RN>I`UB`5B@S@@+H@'XH,$("%(!!*#)"`I2`:2@Q0@)4@%4H,T(.U0M$96 M4Z!:*ZO+7GWH._*I?Y=';_^>C`M_85SX$K6_\I$L)!O)07*1/"0?*4`*D2*D M&"E!2I$RI!RI0"J1*J0:J4%J-=)[BIHM&LX/'AX/U`2Y,2#T-'P.0%HC64@V MDH/D(GE(/E*`%")%2#%2@I0B94@Y4H%4(E5(-5*#U&JDM[Z:-!JV_F\^'JAY M`;-;=$0WBN$#PJ4Y3NRC9)P`LOKT@YN.C>0@N4@>DH\4((5($5*,E""E2!E2 MCE0@E4@54HW4(+4:Z3U%33"9/65&MYEC[RC=1!55Q`U^J[[UHLYCW%&NS)ZR MC^*":RG(9"'92`Z2B^0A^4@!4H@4(<5("5**E"'E2`52B50AU4@-4JN1WE/4 M-)/94WYCQE%]HVF.*?T,%HT0@PG&:[.G[*.X6ZS[7(-[E(5D(SE(+I*'Y",% M2"%2A!0C)4@I4H:4(Q5()5*%5",U2*U&>D]15(!5*)5"'52`U2 MJY'>4]0DUK"GO/&4VLUY:1VBGP:3^\Y*+6/0VW6-9"'92`Z2B^0A^4@!4H@4 M(<5("5**E"'E2`52B50AU4@-4JN1WOIJ=FO8^K_[E-K-DFG=8C]Q-KBCW!C? M:ZTF^R@>`=9(%I*-Y""Y2!Z2CQ0@A4@14HR4(*5(&5*.5""52!52C=0@M1KI M/45->PU[RAOC1#=+IG6(X<19]Z6V6JIDCA-`%D;92`Z2B^0A^4@!4H@4(<5( M"5**E"'E2`52B50AU4@-4JN1WOIJ/FS8^K\[3G3S:EJWZ$C_C')C+(A8J95I M9D\!LC#*1G*07"0/R4<*D$*D""E&2I!2I`PI1RJ02J0*J49JD%J-M)ZB5@2. M])0SM5#S\)"Q*ZG/B/8TG^T_TJZ0UD@6DHWD(+E('I*/%""%2!%2C)0@I4@9 M4HY4()5(%5*-U""U&ND=X;CI3[6`E"[PX(8RU%8Y$28?H M:Y1EFAY'27J?24]OS-$&$L7I0Z2(2=+'3'IZ8[HFD2A.GR)E3)(^9QJFGUT8 M]^1"HCA]B50Q2?J:24]O?-'52!2G;S72.YF-\A>](%!^@B^0Q27J?24]O3.L&$L7I0Z2(2=+'3'IZ8X8GD2A. MGR)E3)(^9QJFGUT80W$A49R^1*J8)'W-I*N(#3&^/J<22*#]!%\I@DO=_3E2PY#)!"I`ASQ4S# M79U=&',`B43QKJ9(&9/L:LZDIS?&\$*B.'V)5#%)^KJGP9EHD%J-]&ZC9C>' M-[SN0]/N4?CU^\/]G[=;>A:AYYZ1[C2C7P39W>$^J]_E,A^,.AK<]%9]U(#6 M2!:3'*3=TY4L-7>07"0/<_D8%2"%2!'FBC$J04J1,LR5BKV1JL\+T-1>44]@@M1KI_>2X*=@I3L'V1%V1=WW5T^5B]QM%LYNK MJ3'"KK&0Q31\<.YJ&Z1V..IRE_KJ8O<_??[?Y1C9(X])DOM,$A4P=I.RL79W!@K4@Z0,AF39,Z9)*I@ZC+/Z1K73TC) M`5*F8I+,-1/=&_8]=7)MY&HXBGJG1%T9[=MRU*Y&OZ%/=-*_VZ:ZC MP4BSFNY)=FIV87S,64L4GP:+22XMFTDN0(>I^SUT]5N3+I-$>4R2RV>2J(#I MX#49)S227 MB=.36IXCE[QYF;A8T&.2]#Z3I`\X?339R0X3,%:>1S#639&XD\^#(S"9HM8): MEU-M=T27VX7K=[^>AB.5D.P4WOTD:C]2,8PR27K,DF4QR2Y?":) M"I@.7K(A1TG!B$G2QTP2E3`=3)]RE!3,F"1]SB11!9.X7QV3]0SN?570L-N8][@)(H+6DQRJ=A,DM[IB0Z*"[H8 MY3%)+I])<@62:[BKQJQ0*`4'41/C\2KB**DQ9I(:D]$:)\8L9(H%,R9)GS-) M^D+2\\DI,:IBDEPUD^1J,%>K1>D]2-^LFG(?WO)ZT`:B?ENX_@%Q< M3\Q['A:RF.0RL9GD,G&8#GW>XQ@IYC%)4>N-:?O9,TI@9ZT=1STTB[]@_5*HGC072-92#:2@^0B M>4@^4H`4(D5(,5*"E")E2#E2@50B54@U4H/4:J3W%!I@M)YR^//\3(4;3\D= M:>,$T+HO.(BRD&PD!\E%\I!\I``I1(J08J0$*47*D'*D`JE$JI!JI`:IU4AO M?7-*^C?7>\UPKKHG[:4&LXDQ$;N2*!DGNER#=V%8&&4C.4@NDH?D(P5((5*$ M%",E2"E2AI0C%4@E4H54(S5(K49Z3U$S@L,[RAOC1#>!J#W,=C08`58SH#62 MA60C.4@NDH?D(P5((5*$%",E2"E2AI0C%4@E4H54(S5(K49ZZYNSOK\[3N!T M\*PCXWG"^-)N)5$R3NP+,ED892,Y2"Z2A^0C!4@A4H04(R5(*5*&E",52"52 MA50C-4BM1GI/4=-]1XP3W>R@-DYTI(T30.L9D(5D(SE(+I*'Y",%2"%2A!0C M)4@I4H:4(Q5()5*%5",U2*U&6NO3F^STUO_-<6*71W_,[,D8)XSOV%82Q8/" M&LE"LI$<)!?)0_*1`J00*4**D1*D%"E#RI$*I!*I0JJ1&J16([VG'#?-JAXC MC<\=/0W'":0UDH5D(SE(+I*'Y",%2"%2A!0C)4@I4H:4(Q5()5*%5",U2*U& M>NL?-S6J+GJS]3NZDEFT51\UH#62U=-"YMIL)GH:W7^'-KTQYE4=B>*AQ47R MF"2]SZ2G-R;_`XGB]"%2Q"3I8Z9A>EC$FT@4IT^1,B9)GS/IZ8UQMY`H3E]J MI+?^<7.3]&LAT/H=#9IZU4<-:(UD]:2U?I=K,3S`Z8VQH,7A@K(N/[E$"B^/R%2!&3I(^9ANEAE6TB49P^1 M^N;=8>CA%PDCTE.EL^DGRSC2[%` MHKC&$"EBDO0QDY[>F%%))(K3IT@9DZ3/F>2P"Z12([U=S9G$[MGOR&6PZA5; MYE#?D=;<0.N^X"#*ZDEK[JY@]YUNF)OIO=O6>?UI+-S1'=Q6(>DR3WF>CCYKYA8*5F MP/7Q^AKCR^M0LG##14Q25\QTL*Y$KVMA/$>DDH2KRIBDJISI8%6%5#4X>',) M3BFYJ$:]V]!0=<1DP%R%&Y_Z.AI^`]Y'$+38#')(Z/-))>*PT37 ME32X>/^\S[R;OAO,^/6DC1!>EUGCMVV(&"QZPH,4D/=YF&HX2 M77KUO>@^_02;>K\3W),\SB7I?29)'_1T.'V(!2,F21\S2?I$TO-^I1B5,4FN MG$ER%9BKU*+TIJ;F.*:I5;AQ57>D7=4=];_',+^8+XPQ=#V'0A:3]&.;2?JQ MP]2M:YF.WPP@N[1$_#JU](+D\9I(^[_1T^/)TL:#').E])DD?O"M]B`4C)DD?,TGZ1-+S8:<8E3%)KIQ) M> M38RG39>CAENL?-W&WP(F[GK0+O8O:?Q#`-8U8R&*2KFTS2==V M>GKK(N]V8+!/'N>2]#X3#;+RN&`NM0_>56,HN;@K1TQ28\QTL,;D736FDHMK MS)BDQISI8(W%NVHL)1?5J/>BXR8`%S@!V!/-,?+1K)#62!:2C>0@N4@>DH\4 M((5($5*,E""E2!E2CE0@E4@54HW4(+4:Z:VOIMR&'Q741)&Z0H]+B1(GBSK-&LI!L)`?)1?*0?*0`*42*D&*D!"E%RI!RI`*I1*J0 M:J0&J=5([RET^]1ZRAN/E2K<>-;HB+Z)XJ9>+8#62!:2C>0@N4@>DH\4((5( M$5*,E""E2!E2CE0@E4@54HW4(+4:Z:UO3CK^YF*"!=9(UE(-I*#Y")Y2#Y2@!0B14@Q4H*4(F5(.5*!5")52#52@]1JI/>4X^89 MU5=]YCC1D?8\`;3N"PZB+"0;R4%RD3PD'RE`"I$BI!@I04J1,J02/44XWG"^/)V)5$R3NP+,ED8 M92,Y2"Z2A^0C!4@A4H04(R5(*5*&E",52"52A50C-4CJS][WC4;GONLIW9^Q M[_ZJ\^/F^=MFM?GQX^7D?ON7^A/UUU?T-=&>3YXW7S^>WBXNEVK$H12PY8JV M[+XEA2W7M&7W:Q';8L:,ON,[ZY94;9Z%>)1O9@1MGH5T?&ME`V^K6"L2UTWF@9^=@6.F^T MQ'AL"YTW6E(ZLF5"]="E/+:%ZJ$77H]MH7KH!<=C6Z@>>OGMV!9J'WK9ZE/R8QMF=*6W8=9LW4FU#KTIR+&RE#K MT)\&P"V?)\O/X[FHP$C\+54^&J\ZQDC\Y_GR\W@WIST:VZ%;U?=&$MU2&XXV M(;7@:`-2^XTU'ZV!6JKE3'@J:'T,;1D["%I.05O&]I:^C*622W5BJ>Q+3/:,K8'M.*"MHSM`7U?3UO&ZJ'U94NU%@'KH65F2[5B;&S+ MC+:,[0&M6*$M8WM`BQMHRU@]M`1MJ58P8#WTOD?J1V-[0"_KHRUC>T`O7Z,M M8WM`K]NB+6/UW-(>J.4>N`>TN&^I5GW@%EKCMU3+]<:VS&C+V+[9=';4RI^Q M,@O:,E8/O65SJ5Y-AF7H99M+]=[,L2W40T;/#KWYCK:,[0&]ZXRVC-5#+^)< MJK>783WTLM*E>N_HV!;J(:-[0*\)I"UC>T!O@:,M8_70BTR7ZE5O6`^]SW2I M7DTZMH6NT]$]H)<+TI:Q/:!WQ]&6L7KH-<#4=\:'NNGR=K3,BO9-O5X/]XW> M-+M4;]G#+?3"V:5ZV1YNH??.+MW1(Z67AM*6T?Y&1ZI>WCB6C?K;:#WT3MJE M>D4?E3G?WSE>/GWX>?=M$]T]?WMX>CGYL?E*#SD7NX58SP_?U*?H[C]>MS]I MMN3TY(_MZ^OV__]CO1M^;8[=M M#W=C_\8;CYK#IGW:'E[NQO_Y(_]M/AYUI_7A:;UK#\W=^&?3C7^___O?;C_: MX[?NM6E.(U`X='?CU]/I;3F9=)O79K_N;MJWY@"?/+?'_?H$OQY?)MW;L5D_ M]8WVNTG@>=/)?KT]C*7"\GB-1OO\O-TT:;MYWS>'DQ0Y-KOU"<;?O6[?.E3; M;ZZ1VZ^/W][??MNT^S>0>-SNMJ>?O>AXM-\LJY=#>UP_[F#>/_QHO4'M_A=' M?K_='-NN?3[=@-Q$#M2=\V*RF(#2_>W3%F8@W#XZ-L]WXP=_68>+\>3^MG?0 M?[?-1V?\?]2]MA_% M6?^X&P?0\?;I]'HW#J9?:^1"HOD?Q'VQIC-OM>*0U"&90W*'%`XI'5(YI#:)Y0+87*Q<.#]U80TK"ORIYQ[-9FSNTBB.=&(D M#DD5B>62\N8^6U29-L!4R1U2.+*E(N9Z]>>A/;Y*&Z%T;1++.[#-6=Z1N\B- MV$-/K]O-MU4K=_$!KX4P-;F'")'>:=C?2A+30PY)%9EJ+V8.R1U2.#JE(O/> MTX'G>\P;^G,<76T2RQO3`6\$"W$"7E@QHJ'M`4DB<+Q.)'\>V4-+E)$\8/M] M4S?#P6:*D)MRQZ9P=$K'IG)T:M/&<@-DEY44`\$'EV#TA;4]=TD"EVEDH240IDB,/XS;M2]:3[]#%HYTZ4A76KHOPCRVC=6FJ.4R4?S]NL]Z%=MI"EGI%CJ5G^@=[@%&NJEV M$8R8G,375J:LXO-+F<:@DQ`1]5A>U6.%/:KE'#O+&97[@]WVL:@TG6H;;CPP M17%,_M&^@>_4+U>=F;ZL7:'2P(FM%()]$U'BHE0A,RD14<,<&QHYB(BL2FQ( M"5XA(JL:&_9:MEM$WVN4E;8W2+V^&E=DQ!T9Z>7*%N_X$Q9Y5K. ME,C8G1+?02DB"GJ&B%(C1T16!2)S*U+R9%6A%6G5B`822!2GYIQ%Z7#YRB:> MW?#U))&=2`MVK"2JH;'II(AH[\@44F%<3.?3B-5*N=NJ0&1FC1X4YE9U6;M& MH8$=2!2QIKLNK#=9\UHI(I%UROD+YYA35A3IU-<-<2H9HJFZBP0Q*\YRM*#T M*!"1=(F(K"I$GTK7:#&04Z)._8*39%EK.4E5NA3)Q'=0BLA,'&D%"8Q.REVK M`A')EXA(JU+(T*HM*WOO$"6F.>*5]WDV]N>TFA=AFPQ\+H!4%/$5$`<\0R8!'@1^R"TV.%M2H0$32)2*RJA!] M*EVCA9M+P5"I?/D`ZYLQ9\D2F>442X5$-30/,$04]TPAE5-0^GO,Z;G;J$!D MI!0BDJXN2M=6(SNCA@KH*YSE5L^!1"RS6&XG:$7A3Q%1^#-$,OR^#]]JV(]A MO[GGU)O>K!"9F>5(5Q>E:]3IQV-GEJA#S2U=."N"ZNO"GB7+5_/\$RDE M;OCP@Z[S_.Z[(6PJ1=HE"I%TA^ER[1I.!W!)U MJ>FN"VZ29:SE)EW9FF[BUU?Q*%DXDP*?(C)S2EJ)C8!EL?Q5:Z?YFT91-ID;Q@:URZ*I@YBX^W;NP)[A7!UCF8K5/Z?:3 MN"AU4>:BW$6%BTH752ZJ+62O8U%8FPEW8+9GLE5 M+JI<5%O(=@,OW,^''@H>$4$S]`I9;I!6!DK1RG2#\QUV1E;D!J5%3ZL+UZIT M4>6BVD*V&T0A;:Z`OW22A;(\/^+4L"945/3Q-$5'M MER&BTSA'1%8%(M(J$9%5A8BT:D1NW1B*TO0+;I"5K.4&5=S"46'L"NS"E?3] MV'4C(MA)=4/?.8J5%>2[B'H8&05;(J(DR!"!L=;RG0H9F(%@,IQTOM"RO/K:FA)NXO(68P`X\]/4K0BK(@ M143[5::0.%;..4KWB$XO4(OD2T0D7Z&\2M]IQ!.\MAK9&27*UR]DE*QVK8R2 M2%P;]>0"C^5T$BHK"GF*B$*>(5+7T\749R'/T8(:%8A(ND1$5A4B*1WZ"S>; M]$2<9<>+WPO9Y!:YH42BOC*FT*5LTCU2-BE$\J4K7UTE M7UL-[8R".7XEHX0Y*Y$DLC.*O[*6P)O?_0*EL*>(S%0LL5G+:N6@*?)(.?P,T`1M9?$ED_4"S#)T-J4"@N(?A>_[CH*/\:0?YR4B_6/+8G^"L"R`]XT1W^ M:J2!=\P]\?;-<]N>\!?1@?X[E/L_`0``__\#`%!+`P04``8`"````"$`]=/N MO$,.``#Z0@``&0```'AL+W=OKWYM#L?M_NV^4+XN%:XV;^O]T_;M^WUA-FW_<5NX M.IY6;T^KU_W;YK[P]^98^//AO__Y\GM_^'%\V6Q.5^3P=KPOO)Q.[WZQ>%R_ M;':KX_7^??-&1Y[WA]WJ1/\\?"\>WP^;U5-2:/=:K)1*-\7=:OM6T`[^X3,> M^^?G[7K3W*]_[C9O)VURV+RN3M3^X\OV_0BWW?HS=KO5XFA:O=V@^^O^T/JV^OU.^_RK75&M[)/X3];KL^[(_[Y],UV15U0V6? M[XIW17)Z^/*TI1ZH8;\Z;)[O"U_+_K)R4R@^?$D&:+[=_#YFOE\=7_:_.X?M M4W_[MJ'1IGE2,_!MO_^AI,&30E2X*$JWDQD8':Z>-L^KGZ^G>/^[N]E^?SG1 M='O4(]4Q_^GOYN:XIA$EF^N*IYS6^U=J`/W_:K=5H4$CLOHK^?R]?3J]W!>J M-]=>O50MD_SJV^9X:F^59>%J_?-XVN\66E1.K;1)-36AS]2D7+HNUTHW%WC4 M4P_Z3#WN+FX'!772&?I$.Z[KY=)=M?[YOI1I"O2(J+G0O:V8SIP9A+(92OJ" MZDO7M8I7OTT&\US9"BJE+Z92,PWG2M90DKZ8DI5;K^PEHW^N*`V*[BE]28MZ M/%[G2MZ@)'WAKGZJO9BC,D]2Y?IS[;U#K?3EHO96,*?JRV7MK6!FU)>T*'W[ MY,*H8&6H+VGI6J:WYVV*>JTF2[^Y.JT>OASVOZ]H/Z4`.[ZOU.Y<]BLT[UCT M>LK,-O!ONP`M?^7R5=G<%VC!T0(_TM;UZZ%6O_U2_$7;S3K5/$I-V58TH%![ MB[)MNJ#E@K8+.B[HNB!P0>B"G@OZ+ABX('+!T`4C%XQ=$+M@XH*I"V8NF+M@ MX8)E!A0I"$PD4"C^/R)!V:A(P!P^`G!H5)QIAP)%FBYHN:#M@HX+NBX(7!"Z MH.>"O@L&+HA<,'3!R`5C%\0NF+A@ZH*9"^8N6+A@F0'6M--N(J:]1KMX_ED? MZUV5NB_0OFO6>^766:_:YXR.$:'ZKB"!L`Z-)AN_-[9USXA@W1=D(*PCH\E:.Y=`0R." M]4B0L;".C8:MJR5GMYT8$:RG@LR$]=QHLM:>/2`+(X+U,DNL&**+^`MB2*GM M&-(D&T."-`5II2030RFQ8ZAF]ZMC1.A75Y!`6(=&PT-6N:O;UCTC@G5?D(&P MCHPF:WUG6P^-"-8C0<;".C8:MJZ6G)U[8D2PG@HR$]9SH\E:.XMJ842P7F:) M%4,T:1?$D%+;,:1)-H8$:0K22DDFAE)"'YF3G;,V.D:$?G4%"5+"UJ$F=9WZ M4'"S(3U M7)-,[Q>"++/$B@ZZYK2B0]^P7JNTS.EEN_[QN*>AH'N:KA(5L(LLP2*QPH?V.%0\ZT4^80\Z[4]KQK0ID/ M-+FAR8TJ].NA>E>O.+MD4Q1II21S[2HTG93<)+;U4O*?O5"[HE`@C$.AZ5G& M7J5>KGO.YML7A0;".!*:84KT0%#VT5G\(U%B+%QCH9E8KC5:M_8@3$6)F7"= M&PWO3>5;QVAA*LJ(ZLY<+HT33;\55RIW>T%@)7([LE)4XJ+PL-@-@Z`J*! M-J`CB[58JRVQ4C;E2UY-QX-%F%86@!978M(-X-.T#Z M@8^Z5.D"L2H`8J\0B%4]('6J1IJX[(Y?'RHN.`!B^PB(54,@;NH(B%5C(/:* M@5@U`6*O*1"K9D#L-0=BU0+H;+>74"4%[;!1J;L+PD9G^BA)@ZE^5`D;BB1K M*]+H1I^/:'W?.B>-IBS4`N)ET@;B9=))$6U#9Z:Y*PL&0&P?`K%]#_9Z9_*J MY9P3GBPV`&+S".B#O4F/%'5'71#DG`?9!@,^!N+*8B#NR21%J7-5G@MEF1D0 M.\^!V'G!SF>F8&D5M$-.Y0LO"#F=7B0_C,!C62-KIS*(&Y5S]C,J>+7@Q M$+7DW'63:/L`!=D^`J(09R_WWFD(U=D:1U!Q4\=`7&,,Q*H)T%G[*51<<`;$ M]G,@5BV`SMHOH4H*VL&G4I,7;&,ZDZG.IF9(:W5GU3^6M:K.36](U)2HE2*/ M.]@&HB29J;%RYP1SAU58O%V)`B"V#X%L>V?'[;$*]GV)!D!L'P%E[<7SC"&K M8#^2:`S$]C&0;>_<4$Y8!?NIA>R`("\."+JN_>#&3B`(C'+P2R[9UP[K$*X]>7:`#$]A%0UEX\B1BR M"O8CB<9`;!\#V?;.TIBP"O93"]FSKY*/9COX>/9UKM*ZJDG3E]FU+U!3O<9& M89.)D5:*K-G7*II]-+T#%:.N1`$0#U8(9`^657)O^R\_D^/$LHZA6A-MT:9B6RDJ@QJ2M1* MD37=VLOC:ZL.5(RZ$@5`/&`A$!?L2=27:`#$7A$01:/9A,0#@2&K>&Y%A\90 ML7T,Q$V=2#2UD#6WZNU,:V[/[]B)W-ZQ4Y2]$TE1)F?B;+I-6:@%Q#UI`_'% M<2=%59W4J%`"K^8^4^[*8@$0FX=`-,QF8D3"M8?ZD-1P[ACZ[(*)&P!Q71'0 MV;J&=EV>U@Q(V2>0]681A:0'S::`/Q4ND`G;W:[4+%!0,@M@^!6-4#.FO?AXH+#H#8 M/@)BU1"(\PLC(%:-@=@K!F+5!(B]ID")RIYJE=;+[OX?[!`Z"YC=YM5KW.K. MD)=Q@U%FJL5=)JMXJE,OCOBV5'52]$%F518,@-@^!.+6]SYEWY<%!T!L'P&Q M_9#MT>V15(V!V"L&8J^)])I:*GNJ54KQ@JG6&4AKJD52LJ%>PZ?9-\F$FN?L MHC%&&7:.@=AY`G1V5YI"E12T0T*E^"X("9T1M$)"(VOU M&Y19_>+Q+L6#LVVT@#CFVT`<\YT4?;3ZA7T`+[8/@=B^]RG[OBPX`&+["(CM MAVS/JU\T=8R"[!4#L==$>DTME3W5%".73+62.Y>"&E$5:'I#_1I-[?W4`W.5 M594;O5&A8`L%.;S;0&S?`:+R&7OG:K,+5;81])M)^SE]`!77&`)QC3V@;(WR MV2Q47'``Q/81$*N&0'QJ'@&Q:@S$7C$0JR9`[#4%2E3V[%NYO(^OZ$PN#S/V M2#^Y=-9K(T7F1D`FDF6A%A"'=AN(0[N3HH\6N6A3`"^V#X'.7C/W/E5CG[TP M,`,@KC$".EOC\%,UCM@+-8Z!N,88Z&R-DT_5.&4OJE%'D?ZQK/[%W&YS^+YI M;%Y?CU?K_4_U0UA/G:$--K_2_9H\!W7X(_UZ-WG?T^45^E6OVEA<7O7I5QN2 M?ZWY7REUG7.@?.-_I2[((Y1Q]57R-.](G8XD"12G>DK>T)%DH,61.SJ2A*QS MA+*QOKJ9E_504M97^=6\(W4ZDM<"RN_0D;P64':`CN350]EL7V4^9#V4U/95 M?CKO2)V.Y+6`\F-T)*\%E$JA(WGU4,+;5_D26<_<\^F]^1Q^X].[T#F\[M-; ML#G\UJ?7(26G)PR^2BK)(_0(P5>Y)7F$GB3XZJ%`WI$Z'67N MZ$A>/6//'^>5B#V??J8@G6(*E[Q6Q10L>6V**53R_&>>3R^<2O_0\^E''3F< M@B2OWI!")*_>D`(DSW_@^?0NKO2//)]^\9'#:8'FU1O1\LRK-Z+%F>??KOGT M^Q[I_^CYCWGZAN#U>'[]NUX];IYI@VYE+P'?M!_NT#_X[1_ MIZLY^IGU_D1__@$``/__`P!0 M2P,$%``&``@````A``OPH5P,$0``0FD``!D```!X;"]W;W)K&ULK-U;4]M(%L#Q]ZW:[T#QOH!OD+A"IFSK?M?67IX).,$U@"GL M3&:^_9ZVU&IU_[7[Z]OU_=7N9/NX?I`MW[=/]U=[^=^G'Z>[QZ?U MUUG=7>SG^ MW>WF<:>SW5^_)MW]U=/O/Q__<;V]?Y04WS9WF_U?AZ3'1_?7\_C'P_;IZMN= MG/>?H^G5M=3R?3UR\U&SD`U^]'3 M^OOE\6(TK\_/CD^_?CDTT'\VZU^[WK^/=K?;7^'3YB;;/*REM:5.J@+?MMO? M56A\HTAV/L7>P:$"U=/1S?K[U<^[_3^WOZ+UYL?M7LH]DS-2)S:_^G)_,+LXF(PD_^K;> M[8.-2GE\=/USM]_>_[<)&K6IFB3C-HG\'$CRS(Z3=D?YV>XX^GPR'<\N/AU> M_ID]I^V>\G/@)5]YW'*&AY.7G_KE9^;DGWGU\W9'Z45ZQU<>]^=V3_FI]WS= M2X[DTF@J95KYM8TUTNVL_J%?]M/)I]EL>O[I0L[^F5,=Z9965Y7>]Y4G.]+M MI/ZA]WWMZU[H\Y5_Z'V??]W3YMH^=!7O:G_U]1C#]R]>X>K]1H-IJ/ M))WN),UI=]WF__4:Z2XJRT*EN3R6_:5#[*2K__%U>C'Y0B_HB2 MJ#2J)+HQEQI,C<9.^^L(O8OG@N]"X$+H0N1"[$+B0NI"YD+N0N%"Z4+E0MT# MJ_UE(+#:?_C]0E_Y*OKR6$:[[LH?C<_L=ETV,=/#V]7APEY!/(@/"2`A)(+$ MD`220C)(#BD@):2"U'VQ&EZ&4ZOAWSD6J30RG$EY34DFGYV2-$'39X-675#7 M(2`^)("$D`@20Q)("LD@.:2`E)`*4O?%JI*\UUE5>KY[J.A#,703+AN1EM>R M@G@0'Q)`0D@$B2$))(5DD!Q20$I(!:G[8C6SW!98S:PZPV1T(O%O?&M6B>P* M-#*5?MCK(,Z8M>J"=)D\B`\)("$D@L20!))",D@.*2`EI(+4?;&*(C#[][3/CU`JVNX?C?1'*(@'\2$!)(1$D!B20%)(!LDA!:2$5)"Z+U8S MRSS-:N9WOEVK-';[-^)<^>Y#KAZQ1,W646US=I,N6^H,6R2/YI(`4DB)23$I(*2DCY:2"5)(J M4FV1W?!J$MAO>#6(3=_^CJYF&\XHUI+3.YQ%D96)TJ7T2#XI((6DB!23$E)* MRD@YJ2"5I(I46V072AS&-6:::J41S?I4CUG:6JA:47R2#XI((6DB!23$E)*RD@YJ2"5I(I4 M6V0WO)J)]AO^L"0F,YXWKKZ,FAFM59%NDMOO0Q=V'UJU.UJC6K>C+J7/J(`4 MDB)23$I(*2DCY:2"5)(J4FV1720U-^T7Z87>T4QEK5KT9[?M>S[(&X%\4D`* M21$I)B6DE)21ML\?\QY?DO6 M>SZF_AZC?%)`"DD1*28EI)24D7)202I)%:FVR&[XH7F^6D=[XSQ_S'E^2T[O M<)_)F"C3.SC/9U1`"DD1*28EI)24D7)202I)%:FVR"Z2FG_WY_GO?<]OYO'V MZN7,>=JR''>S_?Y[OA.U,E&F;MV.FGQ&!:20%)%B4D)*21DI)Q6DDE21:HNL MNJEW&:MNS[_G'\+MU8"6^J,:R2/YI(`4DB)23$I(*2DCY:2"5)(J4FV1W?!# M4W\5_L91;=)-_?45O6S)&=7<9S(F2N_HD7Q20`I)$2DF):24E)%R4D$J216I MML@NDCO/?^>H-ND6`/KCE?.T9=E&.75SHE8FRM2M2=_K@CZC`E)(BD@Q*2&E MI(R4DPI22:I(M45VW=QE@A=&-:X&3!KJ->F*Y)%\4D`*21$I)B6DE)21?Z$\_R6>DVZ(GDDGQ200E)$BDD)*25EI)Q4D$I21:HMLAO^@^;Y M$\[S6W)ZA_ODRT29WL%Y/J,"4DB*2#$I(:6DC)23"E))JDBU17:1W'G^"W=6 MW71>-^ER@BGXBN21?%)`"DD1*28EI)24D7)202I)%:FVR&IX^6U1>Z*NIB+J M%]*?+\!A-WO"KDENLQ]C'.S2_'9V_?,"< MSTY;>N&`VZC^`7?4/V"S^&T?\-!<[URF`2\T<#>UZZYP-7H_>4?I[6=6(^W#?=L41_UVGSHF\W++EOIO4R2/Y),"4DB*2#$I(:6D MC)23"E))JDBU17;#?]`49\HI3DOVV]2YNZQIHO05YY%\4D`*21$I)B6DE)21 MH=#5F]`^2IFW?[@:=/"D@A*2+%I(24 MDC)23BI():DBU1;9#>].<5YH>,YDIBW)G5=O%'17+W74Y^YCM%Y+QO-]>_+[?2PO(> M.5"CB7QIR^'#EHLI)S@MR>?:=$NO2%Y+ZI:F5TAG.=,W43I70`J9/C)1_?3. M>E!LHG3ZA)0R?6:B^NF="75NHG3Z@E0R?:5)6K]KG`MG0E+KH.9[K?K?"3-U MYTH#)93/&W0UY)3HD.'R6'W4JCN`T;ES!"L=->DJ[6F:=N1K,K=>@283%6HR MN2)-)BK69'(EFDQ4JLGDRC29J%S3^>$;B.1[6,Y&9\[U5^@8LUNIR22O-#V3 MJ=8QA]WLCOBV2=.4DZ:6U$-R4ZT+W+,W.\I36GTU>GI',T[Z+K6C-WIO5\ MWSJ$VW?6+)G/E^9K,Q1]H,E&A)I,^TF2B8DTF5Z+)1*6:3*Y, MDXG*-9E9L?$WFG`--)BK49')%FDQ4K,GD2C29J%23R95I,E&Y)I.KT&2B2DTF M5T6J+;)KH6:G_5J\Z]YAULQQ^_?5+5E]HXGJD==&R2JM[D&^)FL(/'>&\T"G M-TT1:C)-$>E<)GVLR4[OW$XD.I=)GVHRZ3.=RZ3/-=GIG=N)0NX==)09F#U-9OCV6^J_&S$JU&1R19I,KIBY M$D:EFDRN3)/)E3-7P:A2D\E5D6J+[%H,+R:\\19]QJ6$ENS;.]PPZ"AS<7F: MS"7H:S(C3J#)1(6:3*Y(DXF*-9EB-"KLGJ4Q=F>>\PVA^O&E8A90U:1)NY"A`DR M->KVT^0S*B"%I(@4DQ)22LI(.:D@E:2*5%MDU4B^ZOY#!L!#'GL`;,FJT>C" MF2JM3)2NB$?R20$I)$6DF)204E)&RDD%J215)/57!\Q3G*9(S5\1:+X:_7[] M]&.]6M_=[8ZNMS_57P@X5^N`';=_OF`VFR]D*)7&=+8L98NZ!1G:-7&?Q?CS?"$?V^86 M^=60N?IUAX$M$SG39IKIOLY$_O+$8+;%9"PU'3PVV:(^@#ST.G*F\@G9H2UR MIO*QS*$MYZ@7X]%\T:R9.%N6LD7]\OI`MK$>/PQMD?.17[(;VB+7FRPI#&V1ZVWP"!:C MR7PAOPHVL(]L45]%-K1%CEJ^*VMHBQSU8+;%Z%S:8+#/R1;UY4!#V>1\Y-MK MAK;(^#>\C+#[ZZO/C@:\M+#^59C,ZD MC0>O&=FBOL1RX&A'<@7*MRP.;9$K<#";_/F7Q?"KR`Y#F=2E/.2J^PWX0B[C MP3JIX6<@?BD7P^"5)04?RB//G^?JZ3+/69XFS]6S8FZ19\-S]>276^3IJ60; MJI\\^)1L0UODF:5D.VPY[88$^0LVCU<_UOG5TX_-P^[H;OU=WK_.#@M,3\W? MP&G^9[]]/#P+_K;=R]^N.?SS5OY6T5K^[,:9^I;Q[]OM7O^/'.YI]]>/OOY/ M`````/__`P!02P,$%``&``@````A`+;-A5O["P``&3L``!D```!X;"]W;W)K M&ULK%M;;RNY#7XOT/]@^'UCS\UVC"2+Q)+:!5J@ M*':WSS[.)#&.[0ELG]N_+SFZDM3:L7'ZT.SY1&I(BN)'R3-WOW[?;@9?V_UA MW>WNA\7->#AH=ZON>;U[O1_^\;OY938<'([+W?-RT^W:^^&/]C#\]>'O?[O[ MUNT_'][:]CB`&7:'^^';\?@^'XT.J[=VNSS<=._M#D9>NOUV>81_[E]'A_=] MNWSNE;:;43D>3T;;Y7HWM#/,]Q^9HWMY6:]:U:V^;-O=T4ZR;S?+(]A_>%N_ M'_QLV]5'IMLN]Y^_O/^RZK;O,,6G]69]_-%/.AQL5_/?7G?=?OEI`WY_+^KE MRL_=_T-,OUVO]MVA>SG>P'0C:ZCT^79T.X*9'NZ>U^`!AGVP;U_NAX_%W$R: MX>CAK@_0G^OVVR'Y[\'AK?OVC_WZ^5_K70O1AG7"%?C4=9]1]+=GA$!Y)+1- MOP+_V0^>VY?EE\WQO]VW?[;KU[K+X=CM_V? M%2K0J#!)[2:!O]=/`H_K+8&_;I+9S:QIZLEL"M")IT^<(OQUBL7-M!C?5GF] MD8U`'U"U/"X?[O;=MP%D*?AX>%]BSA=SF`LC6<%ZV">'V/Y5:"$<.,DCSG(_ MG`X'H'Z`?/CZ4-63N]%76,.5DWF2,@656'@)C#).JSB@.6`28`0>!;=@9;E; MF"`7NH6SH%O>H"Z@.\$(@2B!:(21%B,6R%GQ!UG`72$<*2^,*SR0K5L/Z)T(PZO`A" M834$H@5B4H2X!PF4NG=Z05"X]\(_^\DB=1G2:2$0)1`M$),BQ#[8OZE]N)=K M$+XPZ7$6:KA%P/`TUK(+MAU)C3V=-RA,3;8(I+JW9B$0)1`M$),BQ+Y;:I]GTPOS!F>A MAEMD!FL<]VC#BWX0\MXI@6B!F!0AOA1`7A\/=B]-C790NDTEI"2D)60(1,U$ MXDIRXEK>M?P'M=)'[ZFP$,MP3E-1RBLJ"6D)&0)1EY#'$I=.ISF6=Y8N#B*1 MMU()I*24EI`A$#43V2LQ\\IL+RP)PG-\`)\5%9Q:%@)2$M(0,@:B92%R)F=?FO.4_8G^@Q+32U#SR02I& M7D`:VT1(S"3E#(&H2\A?S"5LP,^L@&4]XH&#ZKYYYC6R<*/V+&-;XP"E+C?! M96HF4M/E9EI"(V8ZR)HIBHH;38V8Z2!KIMB!;C0U M,T"IF;%_IF8B^3`SB]OSJVXYB]CI(&NGR%09)(20EE*&0-0EY*[$I3.1=TR76FXA$GD!J5)`6D*&0,1,O/U,S>PC MCX1VX7&XGX=N6@>QI.>T'Z5"Z"6D)60(1'UB%(L^3:YP27)O%;@WK:"\18A2 MT:6@Z"$MI0R!J$N,CD]G4R59UT%I-DE(24A+R!"(FLDH%B./ZW1I,DGNK0+W MII&/G;6[X`U2/LPJ*GI(2\@0B+K$Z/A,Y"7K5H(\%Q)2$M(2,@2B9B+W)>7F MVIRW%)IV[55@U33R\;#@(A^D?)A55/20EI`A$'6)T?&9R$O6K2Q$DP2H7(2TA+R!"(NG01PZ)]W'(+D<@+2#G%1$I+R!"(FOD7#'M\6Z\^ M/W78-V>O/"JX:>NS]K&6Y.J@*502F,#]HCWE!T.O>!ON@)6#&MC;B2([U^@H MY5?+$(@Z>!'?UI)O'814F=C$.WXO527.V+E`T9NIO52\[#$>ZJ6HY1D*QN;G MS!Z6C(LU#)(+S].)![QQ]E*I!QG%8L;:4^T5)_;R=5P49/\!5O%4FO*#+6%\/HF M61L6XD64\J8J!T$?X2'M(;KM6$]K_%QI-L`+6/FK[QI9EKE=-)>Z;:F:N&TA MLF@"4OW3[X=-/,5J!TVCV\9!<":%2-!%0ZKDUL.K2F[-?N_>^_)VP0):[B6> M6(@M(&]GZR#E5TLY"/^$E<]L+JO8%&YSC?%_8:WZ"FS\Y')S-8S^L:-)E\]' MX'1)Z6>A;8&#;,QM]^*@2=QARD'3N#6U@V;)IO.*O119/_!:K-_Y"MAK,7-M M8X#7%B'6U91WODZ1>&`5)ZD'%II&/XU7S'C`N@![@+UP_T#^\^;`0:RD\X;2 M2R4EW4%X_`B1D%GGI*"ZXLG82EHNP&Z8C.VE1=.$:J)MUXYZ$R= M<%*0B;AB17[)@@F\4#9(]"><_F"=L.U"6AW[B?N?@V.Z5<)IJY?TL"KJ^3AH M"1D"TZH9;VR=5!$KA'(0_,'EJ<=-S=HO M'26\QX9`U+U,-W+Y%I/=2&,AVKC/6#.W<%+$/ZLXBXVM=E()9`A$'=*C54\76KKUF,&VCYBE?7C%#U<+ MITA\L(II3^*DTI[$*V9\8#W)&WDLE5<)!9ZJ$DSI9)?SDLDI,?D9#TD_"\B]T M`['"53/>$SO%M"%QT)DJX:1.5@D_>6:E?TI#`A_1<$)P$%Z(A;HN&I(H%%-7 M]"A:2N%7._A`V\E8@K-?X=B/1K;M_K5=M)O-8;#JON`7-M!%/]P%V'[^\U3= MSO%*%Y[-1^KQ'&]1#$R@Y%^#_*1$G3@G8#,<&H0.QMJ=8/E)!K.W=D!B!6,-/JYGG5!!K^#4S,U*"#KP=E1L!'7C)*#<" ML;8;CUM00JSA))'3@5C#&RFY$8@UO-B1&2G`4WC7.C<"5L,KR[D1L-KV'-RV M`JR&EVUS.F`UO-^:&P&KX;X_,P(J60U0R,J#DUD?(36RF0&)DUB*GLFC`=2CT&==A1&5'X")HKK,C!D;P1B4W&ZPN'(I@9!2R M#CY,?%^^MO]>[E_7N\-@T[Y`6;4GA[W]M-$=(]QEWZ?N")\D`A7"UWKP"6H+ M'\J-L7][Z;JC_P<^('S4^O!_````__\#`%!+`P04``8`"````"$`/[_SZG6-7=]=$2Q5GE M89U[NIMS3E6S3O.K]?[O?]S=GOR^?WB\.=Q_.&W>+4Y/]O?7AR\W]]\^G/[/ M/X>_79R>/#Y=W7^YNCW<[S^<_KE_//W[QW_]E_<_#P^_/G[?[Y].<(3[QP^G MWY^>?ER>G3U>?]_?73V^._S8WZ/EZ^'A[NH)__/AV]GCCX?]U9=QT-WMV7*Q MV)S=7=W@+_Q^\W/Q[3T>ZN M7W.XNZN'7W_[\;?KP]T/'.*7F]N;IS_'@YZ>W%U?_N/;_>'AZI=;Z/ZC65U= MIV./_R,<_N[F^N'P>/CZ]`Z'.V.B4?/V;'N&(WU\_^4&"BCL)P_[KQ]./S67 M0W.^/CW[^'Z,T/_>['\^JO__Y/'[X>>_/=Q\^8^;^SW"C411"GXY''ZEKO_X M0A`&GX71PYB"_WHX^;+_>O7;[=-_'W[^^_[FV_?Q!P'O7@ M7SG(1LF)$LXX'F-XNZNGJX_O'PX_3S!I(?CQQQ6=`LWEYO0DQ96/D"/]7*`1 M&SK()SK*A]/STQ.$\!'3X_>/[<7V_=GOR.BU]/D<^S2VQR[UH)#383L/]!X8 M%'`&15D6,O0&LN@H)"L1^IR`HG/I-*0>:4CG@=X#@P*,AM9JJ$_UE`'J_.$4 M]:YD8+NPW#YSG]5XIHT!W@6D"T@?D$$CAC&F]!M$G8Z"Z8BP%"UA-G&G%?)? M.FW]A,J=3KN`=`'I`S)HQ/## M^:OYT;F\0N>9YS(=Q1)G!,1UK/W$SYV2WBX@?4`&C1@MJ"5:R\NQILZ6,B.8 M'HG-+B!=0/J`#!HQ_&AE\=?K)AW%$F?D8C,6T>6B:>TYO,OM25@7D#X@@T:, MC*V5\7*8J;-ERXB>T@'I`M('9-"(X==@I>#CW`*;.:?'PUCJ`IE9O=RXDKDK MO7*\(]1':#"0E42>I:;.RS%OV.%0#1.!SP+IJ$>HBU`?H<%`EB;9DJ))U>28 MR+.[&?X,NPBU$=H,)"51,:E)$U$GFT.ARN1%^A M/D*#@2Q-,B!%\]@U&?N8X2_6AM!FUUQN?"5O9:2-!%Y M=CC#7)L>KUUH^>\G2(#ZV&LPD*5)=J1H'COGV=4,_VQT.O*^N#>Y5XE\@/K8 M:S"0E40.IB1-1)[]SC`7"]1S/D!=$Z`^0KA$5"FS-,FA%$V*_/:(.L]&9_@S M9*I-NPV1S[U*Y`/4-P$:#&0ED:DI21.19PLTS+4KRIP/4-<$J(_08"!#<_DV M#CL>QCJL0";RR\W:+6A*KQSY"/41&@QD)1CPY;!I;(AUZ#Z64ED?6IR?1RM:%[7FXI+Y") M?+#3+O;J(S08R-(D.U,TCYWS[(IFSF>CU`Y[X2.?>Z4P=\L`]1$:#&0ED:DI M21.19PLTS+4KPXZ' ML0XK4+E;X)?RI4,.>H3Z"`T&LFIFF6L;S54@76@BU$6HC]!@($NS8J[-^AV> M4_375IP3SI2OH]KMRM6:TJL$/P],4!][#0:RJF;Y:QO]52`3_.BOL5N-0*9R',O M!76Q5Q^AP4"6)IF9HGEDE6_9$PW_;)-ZSOLUI0PTDO+`E(P^]AH,9"7-\M1:B+4!^AP4"6 M9L5ACXE\=-@50R;RJX5_%EAZI3!W$>HC-!C(2IKEL*OHL`*IDVX7H2Y"?80& M`QF:ZXK#TA7BS"O8\3#6804RU6:U\`Y;>N7(1ZB/T&`@*VF6PZZCPPJD(Q^A M+D)]A`8#69KD@\YACXD\VZE>5:X9PU&,A*<@[+MT/& M*_.G[S?7OWX^T/V1ZAMG+=Z*&&^0?5I'XTW0-M?Z780Z@=;\@L6J65PXR7WI MD?0-!K)BG`^_?`MJ'>U6(+J6SG:[6GB[+;T2IRY!JRRW3Q"_`$EOT`T)&GM9 MYLYNTY7BA()HNVN&Z-:T4N!OAJ1>;:;;)4@/;"[G'"F@7^S]YG&5*/ MBD8R1G?VR$V@&5.-W=6<.PSASF1*QPX3BM8C"NH$@J&E7GV"RL`A#1RGKR7VG0PDG\@#*PGC@:AI]!YH-6%RZ$K":A:/ M5VSQ@U0:_GGX\5QIP".'7!NBP:_%X$LJ=@)M2KGH!#HOV>G3P/+.Y)`&CKUL MPIR;JX1-G%71V-<,78!XCO5JX4Z.G?0R(GC@1HM@Z+Q('=+`*&+CO/YEYF-O M:^D"N>GE;Q257GEZ)4A5M`2IBI:@.'DVSM)5^%]_MH\'<8+8_.DYA$I%$)1[ M%4$,T8HV#XSGB_SBQ?+9\T5ZX`D##FUFW*:R/)A=X,:#.,GL\2:'JX6_Y20# MT:M(EL4!9MQ+DKG7"R4B';J2Y8GEP^MJQ":N'P32"[H(=1'J(S08R&;,+1AX MDLY>2F_B2D(@MZ#SMTQ*KY(S/I82WL=>@X&LI,I*@IZS3%0.7C9H6]TP=+'E M,\':_$Y:\5908/(` MR[,IZQC+D]S1+5JHZ$W09$\UX61(:/HEY89;#;>#WQ(G!741 MZB,T&,C0/'>V.]:%Z7".PVSM%@CA+-%9MG[E(+UT6`M4!J[4"^B6;\5LIV?I M.3NB#J]`CJZW&NEEZ/*Q`&FZ9?I8NC6C7$R>_.=L5(8O0X;OJ@GAY5Z&;X8T MW[*,L'QK+O>*Z1!M[9PAPW?9EI.:7SB17H8O#W3Q+8FQ?"NV1B-?/MO.HXL) MY.CZXB6]#%T^EJ-;[,_2)>-016$\V^B%P@F^[#=F.C!D^*Z:8D$27NYE^&9( M38?E,YYP7O&N:8L=1[GB8*PKS-KL4ZG4=7(,&]9EF3XVK&0@+JROH,FV8Z+* M$*)*UY#E')%H9I\J-#.DH_F,)>`"+]"DFVH3R6?7,309$IKEU!":V:8*S0QI MFF5VVVB2R[AHOJ+$LC<9F@P)S7)*"$UN-7,S0YKF,Z7U`I&;3W,<9>>F0$+3 MGT+2JFD62-,LD]I$\Z)B6,VT`XS#'$\V'O`L/QL-5@8:OC7'6I;9;?F27;CL M3T]27$7ZQV(".;I^LDHO0[=F6,LRT-*M&-8KZ$:_NGB57TDO0[?F5\LRVRW= MBE]-5ZJ+Z%<"N>B6,YK/,>EEZ-;\:EEFO:5+9C%_,K#%Z%)PP9"C6WY5Z&9O MRI5+!D)!F?2K]AF[H@=I@2[2\W*!'4>Y4RW;5?G5Y:JXC]"-MB7'BR]1BZ#!FZ M<2D[_IR]`"N0IEMTVNB2F;CHRCVJ"<;L0H8Q0W@O(H5N1^SI6JQ`783Z"`T& M,HQIU@3&9#8O\QV'V?DK$'Z*[X6[6QK2C'^2G*Y`.K3/6.^VYFG3R]AQF".: M/6TD6DX4/L-DA"%:,S-UF6DCZLQL(I#1Q+8,Z3<,(M1%J(_08"!+DRPD3-79 M-^>V[$1ZX@IDWS!HB_5+F'D@>I7Y$*"^'"OU&@QD)3FCFXA\-+@M0^KNX"Y" M783Z"`T&LC3)<5SDJ:;-?,-@R\9E(L^0O2W:EE6,1#[W2C'MY%A*>!^AP4!6 MDC/!B/Q,%7_5X-ZM=:>^]$B9&0QDQ.`Y;YQ'LQ]%\5&L-27L'+-"W>4O MJPV>1ZD;OG1-=+N$8?&:,.S50$2Q54[!L%F#QIRNBL>VBYFOJS0+=DM]>B2, M/APJNMIRP9)T\5#]9D$:.O%D,7631XO+=7AU(O6H/%IL%LZSCWJY(X;P>L,63,9/0^(9"L\C=4O(@G+')&L+=7JHA;.(:Y2$T85E,;]5 MN9^4S(^'HIO*7\"@+&!0IC&K;-R=2.7$F7LZ<68 MRX._6%+=TE`HRT,3!F4!@S*-.65NM3"5A\H2P6S^)&=OQ,"6QZIK*[`-&-AJ MS+$EIU5G+Q77(RY9&_IX!(L"FP?&7!["Q88,57,?RO)0E8>`09G&G#*W4)C* M0V5%8+:"2GD0JR\3#FP#ACP$#&PUYMB2_[D\''4^L(_:/##F\E#N@R9EN5N* M.90%#,H"!F4:<\K(%)6RJ3RPAUH!XJLEYJA+`0/;@(%MP,!68XXM&9UB2^?# M,3XMFT19&6*B.!N53[M;!5"6NZD\!`S*`@9E&K/*QCV>E+*)/,B64$:`8*K> M[)J(86]!]E_5#YL+!@R["VK,L:WX]#%U2;:,LC+$1%$[5!["!8P,Q5W)DH>( M05D^7.H'91ISRL@49^2!/=0*8$S%%WD(&/(0,+`-&-AJS+$EHU-LZ7PXIB[1 MQ87W!\'H3K;*@[^=W)1N*;Y0)OZK+R0C!F6ZGU-&IJB439T/[*$V#XQ!0&*& M/`0,;`.&/`0,;#7FV)+1*;9'YX$-T\H0$\6OJSR$FV>R$Y52"V5Y:(H`E`4, MRC3FE)$I*F53>6`/M0*TKXJ;F4VF1@QL0S^P#1C8:LRQ):-3;"D/8QV;>R$G MNTM9'>*B^'F5B'`'0H;B.40*.J3EH0F#M(!!FL:<-')%)6TJ$6RB5@!CJF3B MA`@8V`8,;`,&MAIS;,GI%%M*Q%$&P8YI98B+8M*6/*S#!37=*4)-4VJA+&!0 M%C`HTYA51BJTLHD\C-W=RELP8Q`1P^ZZVH#'DP3;ZP8,^^MJS+&M&/4Q!B'; M3YD\"&8-8ATNJ$NW-/>A3`RXE&8H"QB4:D4VV.-FEY0]PLFP=SY$"ZH2[<4 M7RCCPZF9"&4!@S*-.67DBDK9U/G`)FKSH(U5C-KL5B5&'3&P#6/!5F..+1F= M8GNL/\@N55:&F"ABI?PA7%#+4'L^Y*$I-U`6,"C3F%-&IJB43>6!/=0*8,R> M#P'#K`D8V`8,;#7FV)+1*;9'YX$-T\I@##)T'L(%M=GN*LVP/%3E(6!0IC&K M;-QR2BF;R(/L4&4$"&;R$#%L&:_]5WPZ8M@T7O=S;-_(IV4'*RM#3!3_J/,A M7%#+4'.C+V+8#3\?+N4&RC3FE)$ISL@#>Z@5P)C-0\"0AX"!;<#`5F..;<6G MCUDOR7Y65H:8J,U#N*"6H38/>6B*.90%#,HTYI21*<[(`WNH%:!]5?S!['(E M9V_$P#:,!5N-.;9D=(KML76)EJ'V?,A#4VZ@+&!0IC&GC$Q1*9O*`WNH%:!]->4A8,A#P,`V8&"K,<>6 MC$ZQ/3H/;)A61C91=3[$OP]D-LU*9WH>JO(0,"C3F%4V;EREE$WD0?:Y,@+, MWE>2AXAU3<3P1U.T)X]C\5=3-.;8DM$IMI2'8Z[C\*Y%J$N"D3N5NK0)U].E M6XHYE/'A,#1A4!8P*-.84T:F^!;*V%QM@K+A:F7A"M7LI"4S+&)0E@^7U$*9 MQIPR,L6W4,;F:I4QYG(6KOED6RV5'^0L#TTJH"Q@4*8QIXP,]"V4L1%;9=F< M=<["591LNV65Y:%*6<"@3&-.&1GH6RAC([;*&',Y"]6!?5Q^*05G`H$QC M3AD9J%(V<3[(CE;F?#"[7,GY$#'D07MURD/`P%9CCBV9HF)+>:!)-K4A8&`; M,+`-&-AJS+$EHU-L*0_TH&UV'M@PK8QLHBH/X7NQ1O;74F<_E.6A*@\!@S*- M.65DBD[9_.^79%0;O(]!>[VQ8^RTM''"6.5CWMT.>7S M9ZGL]&64"T;WZ#+]RD=9T@WO*!7E::@.6D6Y=,/5]OB->4UY.GKEBXIQ!S"O M?/87%94-R)JT`UFY?;E+&#*A9/(RP7R5E<;JK[($P_S%6)>^ZG)B_)APHNY7 M=B)K!)OZ*DNZ62V\,&".8LG2SWR5E<;6M,Q;0,@.8W;.L>'3"V]JSH4K,QEJ MYYP,U>]*I'[EY4?\Q5G=SR6#3-G-J/E5I+*'62.8JR+ASD[JIJN(8'2+-H>D M=B[Q@N*E*I*.7JLB9/!.^1%5A)<)-J.R=-!5I/)9%EU2X@&$S:@,G:HBW.W% M*B)'5U7D[/'[?O_473U=?7Q_MW_XMM_M;V\?3ZX/O]TCS/2D3N$G#_NO'TX_ M8]5V"1L:CY+'Y+8UM8TS+;9MJ&U\TRVTK2_0ALM4E(;8MJ6V,5^A;;.@8XYE M)K8UU#9^(A7;EM0VWB6(;2VUC94\M*UI'&X?5GG2.-R`J[91S'`+J]I&,<-- MH&H;Q0Q+GVK;.;6-Y3GP7-$X/*JIC5O1.)Q)U3;*`QXM5-LH#[@Y7VM;4QYP M*[S:1GG`Q*RUK6@<'G57VV@8/2U MMI;&X56A:AN-P\LVU3;*`UYMJ;91'O!R2+6-\H!7,:IME`>\S%!K6](X7G^% MN"QI'(IO;5Q+><`52[6-\H"7ZZIME`>\RE9MHSS@9;!:VY+&X5WU:AN-XQH8 M-5`>\&YU=1SE`6\G5]LH#W@7N-I&><#+M+6VAL;A6Y]J&XW#US+5-LH#ODVI MME$>>.T?]5$>\"U%;=R2\H"O$2IM6U#!(^I:"XA@KXU*"SYQQ?'PG6NUC3CB M2]%:6T,<\5UFM8TXXLO&2AN5SGKEW"#A]7I+5E-WF@T(\M+-Q_`"+=A9JL)@ M"P;\P:D?0^6R7BVI6-9KY0KAJU?*%1C4ZR25R7J57"-P]1I));)>(5<84Z^/ M*RBM5\<58EVOC2O$NEX95SBQZG61RF*]*K884Z^)+6)=KX@M8EVOARUB7:^& M+6)=KX54"NN5D`IAO0Y2&:Q7P1:QKM?`%K&N5\`6L:[7/RI_]>JWQ)AZ[5LB MUO7*MT2LZW5OB5C7J]X2L7ZFYE')JU<\C'FFWE$IJ5<2Q+I>ZY:(=;W24:&K MU[FQ]#Q3>?`[U;K3(-:\&/=G?8-8X^O?2J5H$&M\:5MK(9.I>@R=/K41&%#M MCS!7HXP@5RLY0ER-,`)(KYPH8/F&:TD5%LPP81 M+:*`C5UB&\:UB$*U#=LJM(A"M0T_19.JVD:W,M&&&Y/Q]_"E.TW39^;I.%&? MF:GC5'UFKC8T6:NS%7_P"].R%DO\!:!+^@,ZD2/^$-!E5VW!WP.Z[*LM^+-` M^)WJT;8T<6LMG[?@QAL7N'G[>8N3C-][#RV0RF]GAQ:<:/Q]U5EN>OSX_L?5 MM_U_7CU\N[E_/+G=?\7E+N]>]7#SC>[>RU96\I>5?CD\/1WN<$5\>O)]?_5E MC[\AMJ`_O_3U<'A*_P,!._MY>/AUO*3^^/\"````__\#`%!+`P04``8`"``` M`"$`Q$Q)1/(%``"7&```&0```'AL+W=O:FJNV-997Q)LJALY??D M!O]SRHLLJN!M<;;*>Y%$Q_JB[&IUVNV!E47IS:0&I_B((S^=TCAQ\_@E2VX5 ME13)-:K@\Y>7]%YR6Q9_1)=%Q?/+_4N<9W=0/*77M/I>2TTCBQW_?,N+Z.D* MW_N;W8MB[J[?('V6QD5>YJ>J!3J+?E#\G1^L!PM,T_$QA6]`RFX4R6EB/MK. MP>Z8UG1<%^CO-'DKI9^-\I*_K8KT&*2W!*H-?2(=>,KS9Q+UCP3!Q1:Z>EEW M8%\8Q^04O5RK/_(W+TG/EPK:W8=O1+Z8<_SN)F4,%05-J],GICB_P@>`?XTL M)4,#*A)]JU_?TF-UF9C=0:L_;'=MB!M/25DM4Z(TC?BEK/+L'QJRF8I*.DP" MKTS2&;3L7GOP"0?\MOJ#P"MS#%N=4=_N?T;RP"3P^NL2N\MK`C\PS:@UZO=[ M@]'PXT6Q!UP#/WQ:8]$^U6UWHRJ:CHO\S8"Y!)TH[Q&9F;9C#TV#-YRVIQD" M_S4"H/7$\D@T$Q.NA^:6,&Q?I[UA;VR]PE"+66:&,[::F/,$&5=$Z^I@H8.E M#E8Z\'3@ZV"M@XT.`AV$.MCJ8*>#O0X.$K"@&TU+8-C_'RTA&M(27LP9!Z)' M':W^/,$O<76PT,%2!RL=>#KP=;#6P48'@0Y"'6QUL-/!7@<'"2CUAVFJU/_] M>Q\?^20],6']:T:^W6FK=9W13*^^]=8#>XZ(B\@"D24B*T0\1'Q$UHAL$`D0 M"1'9(K)#9(_(029*X7N?*CQ)PUT+NMA4OC?L:Y5G(:4]`RTT9Z&'9JJXE'1' M#5D@LD1DA3P>ROB(K!'9($^`,B$B6T1VR+-'Y"`3I1FP,BFS@"X,+;)B59%Y1&OM,P>*[B'2-IM6.4=.1Y9@^TWSYGH6XS85Q&>@U9,$(?&\GROD29 M%?)X*.,CSQIE-L@3H$S(R*!^7(&;=MMN:X-LBR[:(?'^YYJ#?)'2&WA@^D1O M2%KM#24=^;G+'FJKSYR%Q,W,943<\!:4=,6T7*+,"GD\E/&19XTR&^0)4"9D M'OL'O4$7[9!X_W/-0;Y(Z0W9TLI/QC^>-R2M]H:2CI@2ROC(LT:9#?($*!,BSQ9E=LBS1^0@$Z7,<)?_1)E)6BTS)5WE]C34-Q8L M)'KA,B)5GA&I\BBS0AX/97SD6:/,!GD"E`F19XLR.^39(W*0B5)Y&TX'E-+_ MTA)?6]26,"0/?8QC0RK_D+M&[%4>BP1YW";W/D:K75O\U M=PG]AB.A#[A+Z$..5+WV!+#E+J'?<23T^_=<:,E7KE-;2_:6'[]YV70K2@^6 MZB>W&4/JTH*6?9Z2UA:.I,6%(7EUP:D51\+E<21E]-@L2XIS,D^NU]*(\Q=R$@J=GXX;W!S3/M:GM!J?D>-;<=!S8..(N=MW8#^%N==W M8#.$>=!W8"<#W&J^&1P+WZ-S$D;%.;V5QC4Y0;':]0:RH`?+]$V5WZ&(<#B< M5W`@7/]X@3\`)+!!:+=@5W/*\XJ_(;^@^9/"]%\```#__P,`4$L#!!0`!@`( M````(0#F?/)4,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**`` M`0`````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````"YMFE2FAS4!E3PX$)P[?8G*W!ILT)-%V_]ZLZ^I$GX2\A'/NEW-/RD6OF^03 MG%>MJ1#)AY_4RO4&)#]Q(WK0&*K0'CQ;L\J(4EHK6P:-K+;B@ MP">19#P5MD)U")9B[$4-FOLL.DP4MZW3/,2KVV'+Q3O?`9[E^1QK"%SRP/$! MF-J)B$:D%!/2?KAF`$B!H0$-)GA,,H*_O0&<]G\.#,J94ZNPMW&G,>XY6XJC M.+E[KR9CUW595PPQ8GZ"-ZN'IV'55)E#5P(0._33@SP;^()P(;&UL/([!"@(A%$7W0?\@;]]H,42%.E#0 M%]0'B/,:!7T./HGZ^URU/%PX]^CIDY-X8^58R,!^4""0?)DC+0:>C_ON!(*; MH]FE0FC@BPR3W6ZT=\G?@HLDNH'80&AMO4C)/F!V/)05J2^O4K-K'>LB>:WH M9@Z(+2=Y4.HH`U5Y4`]R%_;9@-9@2+3*=%:\HITLCD1K$3'0F71*S+>I+^^0PF.[=0D%KD8%#EO MYO'-##W!]?.FZNU$HTI93[S!1=_KB3J715D_3KPEG7V\]'I*\[K@E:S%Q'L1 MRKL.__@0+!JY%8TNA>J!BUI-O+76VRO?5_E:;+BZ@.,:3E:RV7`-G\VC+U>K M,A=3F3]M1*W]8;__R1?/6M2%*#YN7QUZG<>KG7ZOTT+FAI^ZHR];(!P&T79; ME3G7<,MP7N:-5'*E>^@Y%U7@'Q\&P(Z(_*DI]4O8#_SCSX#DO!(Q.`Y7O%(B M\`\;P1?!C6@+7C8J#';Z:B=R+9N>*G^";$.O]YTK8>A,O!UO2EYKH&7,NH]V M76V5;L)[V?Q0:R&T"GPPZ#;;Y;'M\;HX897O,X%([]=SF+" M@!H4REIHR!TDZM7,"-?1()IK8:I),;EB*91DF^03Z0[&:_"WEE4!]<[0OT_` M^7\XC;E:LUDE_SOO-$DI8@,V123.\(+B-&'IC-TL"4X0(6?]MY`ANXD()L9X MD2&"$AJUX,@.&;';%">W+$Z3&&4)PX0LD2/$F)'E?!YE#R8(P;<)GN$X2BBS MA_B333$!_Q0G2S1EZ0)E+2U'E$_`9S['=`Y78%$R-?0`?HOL43ZS#'V+*`18 M1!E]8#2+$A+%%-LAEPS]O<3TP6[Q%R,TC;^"JN`7*"T0^#22VB&#/L,)F")& MHW]<2@X&C*0S>A]EB$4Q$"&X319U^!Z"^C<$6!M=T!W\.D2TIFI@CV#%#.T8 M:WX=<:S".C!OE&64?X?'QL[+*K`KQAF%VT".,+8^=80YWW5L"N__Z\MR>)#: MWK9F9O0.S-B.L6;S/17@X&9M<8=LUAYW8/9-#N)J7E:*);PQ#_K.+H&U.!T2 M6#$."=X6-(8I:2.@W.S4K!"'`F\QE#^SN!%%Z0AC>YL<"EC;S:7`N7:;P;SC MH'8.8G)[##D94=X,)=_*^H=:;JF?THBKW-[P=F1KSK!N%P,+[HC_HP_AWM!?YAY`U_`0``__\#`%!+`0(M M`!0`!@`(````(0"$YM"'"`(``((;```3``````````````````````!;0V]N M=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L` M````````````````000``%]R96QS+RYR96QS4$L!`BT`%``&``@````A``IZ M.`0S`@``J1H``!H`````````````````9P<``'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*BXMQE>#```&4,``!D````` M````````````9!H``'AL+W=O&PO=V]R M:W-H965TH.J3@@(``+X% M```9`````````````````)$K``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`"I&F*=*!@``?QL``!D`````````````````2BX` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A``C&!8V8!```EQ```!@`````````````````N#T``'AL+W=O&UL4$L!`BT`%``&``@````A``9I MZW8=#@``C8P```T`````````````````RM0``'AL+W-T>6QE&PO M=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`9G.ZWD0L``.4Z```9 M`````````````````-?I``!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`-#R49";`P``/0P``!D`````````````````G_4``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/I-&BO3`@``(@<``!D`````````````````@P8!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/YFJK]+`@``!04` M`!D`````````````````^Q`!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&M,7;1M$P``Y7T``!D````````````` M````(R8!`'AL+W=O@.YP"``"=!@``&`````````````````#'.0$`>&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`)\T`O>>`@``M08``!@````` M````````````F3P!`'AL+W=OP,```0,```8`````````````````&T_`0!X;"]W;W)K M0P$`>&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`+>YA4+1!0``YA<``!@`````````````````C$@!`'AL M+W=O&UL4$L!`BT`%``&``@````A`/D!07`*!P``[A\``!D````````````````` MH%0!`'AL+W=O&PO=V]R:W-H965T,;`<``,H=```9```````` M`````````.!G`0!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`([V=^'\"```"2@``!D`````````````````@V\!`'AL+W=O`L``,PR```9`````````````````**0`0!X M;"]W;W)K&UL4$L!`BT`%``&``@````A`/73[KQ# M#@``^D(``!D`````````````````49P!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#W*R2&8&P``A9<``!D````` M````````````0,@!`'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`%2=:!==`P``.`L``!`````````` M````````9>T!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#4`-0!<#@``^/$! #```` ` end XML 18 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Operations (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
OPERATING EXPENSES:    
Total operating expenses $ 340,417 $ 21,964
OPERATING LOSS (340,417) (21,964)
(LOSS) INCOME BEFORE TAXES AND DISCOUNTED OPERATIONS (340,417) (21,964)
(LOSS) INCOME FROM CONTINUED OPERATIONS (340,417) (21,964)
(LOSS) INCOME FROM DISCONTINUED OPERATIONS (16,212) (35,121)
NET LOSS $ (356,629) $ (57,085)
Basic    
Continuing operations $ 0.00 $ 0.00
Discontinuing operations $ 0.00 $ 0.00
NET (LOSS) INCOME PER COMMON SHARE    
Basic $ 0.00 $ 0.00
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic 180,526,879 165,276,879
XML 19 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Sep. 30, 2011
Accounting Policies [Abstract]  
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

 

Revenue Recognition

 

Revenue includes provision of services. The Company recognizes revenue from provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.

 

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged off against the allowance when it is probable the receivable will not be recovered. 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

 

Income Taxes

 

Deferred income taxes are provided to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company adopted the provisions of ASC Topic 740, Accounting For Uncertainty In Income Taxes-An Interpretation of ASC Topic 740 ("ASC Topic 740"). ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2011, the Company did not record any liabilities for uncertain tax positions.

 

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.  The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.

 

Basic and Diluted Net Loss Per Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  

 

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

 

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt.  The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

 

The Company adopted ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

•Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
•Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
•   Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

 

The following table summarizes fair value measurements by level at September 31, 2011 and 2010 for assets measured at fair value on a recurring basis:

 

at September 30, 2011               
   Level 1  Level 2  Level 3  Total  
Proprietary Technology             1,200,106   1,200,106  
Total Proprietary Technology             1,200,106   1,200,106  
                      
at September 30, 2010                     
    Level 1    Level 2    Level 3   Total  
Proprietary Technology                     
Total Proprietary Technology             —     —    

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current year presentations.

 

Recent Accounting Pronouncements

  

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.
XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Tables)
 12 Months Ended
Sep. 30, 2011
Business Combinations [Abstract]  
Business Acquisition Information
1.On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.
2.On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.
3.On November 30, 2010 – 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.
4.On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.
5.On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.
Assets Acquired under Common Control
Cost Basis for assets acquired  under Common Control  Cost Basis
Cost basis of Consideration:     
Absolute Medical Software Systems LLC development costs from inception  $1,011,222 
      
Impairment of software on September 10, 2008 to value   (11,222)
      
Total Value at September 10, 2008  $1,000,000 
 
Software Update to Operate on Cloud Based Platform		     
Absolute Medical Software Systems LLC development costs  $200,106 
      
Total Cost Basis at January 1, 2011  $1,200,106 

  

 Purchase Price Allocation  January 1, 2011
Value of Consideration:   
Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control  $1,200,106 
Total Purchase Price  $1,200,106 

 

Cost Basis of Assets acquired under common control:

     
Assets:     
Software source code and development costs of software  $1,200,106 
Cost Basis of total assets  $1,200,106 
XML 22 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 12 - SUBSEQUENT EVENTS
 12 Months Ended
Sep. 30, 2011
Subsequent Events [Abstract]  
NOTE 12 - SUBSEQUENT EVENTS

NOTE 12– SUBSEQUENT EVENTS

 

In accordance with the Subsequent Events Topic of the FASB ASC 855, Management has evaluated subsequent events, and have determined that the following events are reasonably likely to impact the financial statements:

 

2013

 

In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.

 

In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.

 

In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.

 

In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.

 

April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.

 

April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.

 

May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.

 

2012

 

During the ten months ended July 31, 2012, the Company issued the following shares:

 

The Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106.

 

The Company issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees.

 

The Company issued 1,055,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $20,871.

 

The Company issued 90,000 common shares for $18,000 in cash.

 

The Company issued 200,000 common shares to Krooss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.

 

In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).

 

Software asset purchases:

 

On June 22, 2012

 

The Company acquired Doctors Network of America in Flowood, Mississippi for 500,000 common shares and the acquisition was valued at $10,000.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

   June 22, 2012
Fair Value of Consideration:     
Common Stock (500,000 common shares valued at $.008)  $10,000 
      
Total Purchase Price  $10,000 

 

Fair Value of Assets acquired:

     
Assets:     
Software  $10,000 
Fair value of total assets  $10,000 

 

The acquisitions terms are as follows:

1.Cloud-MDs will provide medical billing services under Cloud-MDs Corporation. No need for a wholly owned subsidiary to be formed to accommodate medical billing.
2.DNA will provide personnel, network access, facilities and expertise to deliver contracted billing service support to Cloud-MDs for clients that Cloud-MDs sends to DNA for billing support. DNA will be compensated on an agreed upon schedule. All revenue will be reported as Cloud-MDs revenue and tracked separately.
3.Goal is to grow DNA related gross revenue within Cloud-MDs to 3X, or greater, current DNA gross revenue over the next 3 years.
4.Cloud-MDs will acquire the assets of Kroosss Medical management Systems, LLC once the revenue goals in item #3 are achieved. As consideration to Bill Kroosss and Marie Kroosss (collectively “Ownership”) of Kroosss Medical Management Systems, LLC for the acquisition of DNA, Cloud-MDs proposes the following:

 

a.Current Ownership will remain in their current roles at Kroosss Medical Management Systems, LLC with current responsibilities and will take on additional responsibilities of sales and marketing in the territory of the state of Mississippi and surrounding states and will assume new responsibilities within Cloud-MDs corporate.
b.Current executive management will remain for a period of not less than 1 year after the acquisition and Ownership salary will be established as $200,000.00.
c.Current Ownership will be awarded NSCT class 144 stock in the amount of 500,000 common shares, with anti-dilution clause, that is restricted for 12 months during which time Ownership may not sell the awarded stock. These shares will be awarded as follows:

i.Upon acquisition, 200,000 shares of class 144 common stock with a 12 month restriction with applicable anti-dilution clause. This stock is non-refundable to NSCT in the event of any misrepresentations by NSCT to Kroosss Medical Management Systems, LLC during the acquisition or the first 90 days following the acquisition;
ii.After the first 90 days following the acquisition, NSCT will award to the Ownership 300,000 shares of class 144, common stock with a 12 month restriction with applicable anti-dilution clauses.

d.For one (1) year after the acquisition, current Ownership will have the opportunity to earn up to 125,000 shares, per calendar quarter, of addition shares of NSCT common stock based on meeting certain performance criteria. The shares will be issued with applicable anti-dilution clause.

5.The acquired assets and customer base of Kroosss Medical Management Systems, LLC will be merged into the current asset and customer base of Cloud-MDs.
6.Upon the purchase of DNA by Cloud-MDs, all liabilities of DNA as of the date of asset transfer will be the responsibility of Kroosss Medical management Systems, LLC.
7.DNA cannot add new clients. New clients will be sent to Cloud-MDs.
8.DNA ownership may be called upon to act as a reference for Cloud-MDs and/or work with Cloud-MDs senior management in an advisory capacity.
9.DNA will become a Cloud-MDs software (PM/EMR/RM) reseller and will acquire an enterprise license with unlimited use:

a.Enterprise license is $100,000 and includes all updates, hosting, etc. and DNA receives 100,000 shares of Cloud-MDs 144 class stock if done prior to stock roll-back. If after roll-back, stock award shall equal $100,000/then current share price. Leasing is available.
b.DNA can resell licenses to current DNA clients or other clients:
i.MSRP of software license is $50,000/provider, leasing is available
ii.A commission of up to 40% of revenue on each software license sold goes to DNA + up to 3,000 shares of stock per software license sold and support will be provided by DNA staff after training.
iii.All revenue other than commissions goes to Cloud-MD
iv.DNA takes 1st support call on all software licenses it sells
v.Primary, non-exclusive, territories are the states of Mississippi, Alabama and Louisiana with additional non-exclusive territories permissible based on a specific sales opportunity

c.DNA will become official beta site for Cloud-MDs PM/EMR/RM software releases.

 

10.Upon acquisition of DNA by Cloud-MDs, Cloud-MDs will assume employer responsibilities for all current Kroosss Medical Management Systems, LLC employees. All employees of Kroosss Medical Management Systems, LLC will remain employed by Cloud-MDs in their current positions for at least 180 days after the acquisition after which time each will be evaluated for their then current responsibilities or considered for new responsibilities.
11.Independent Medical Practice Support, LLC (“IMPS”) assets and customer base are not part of this acquisition discussion or negotiation and any IMPS related expenses or liabilities must be removed from DNA accounting records and will not be considered in future acquisition discussions or negotiations.

 

On August 14, 2012

 

The Company through a comprehensive agreement with MediSouth, LLC, has purchased a complete source code license and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

 

   August 14, 2012
Fair Value of Consideration:   
Common Stock (100,000 common shares valued at $.025)  $2,500 
Total Purchase Price  $2,500 

 

Fair Value of Assets acquired:

     
Assets:     
Software source code  $2,500 
Fair value of total assets  $2,500 

 

2.4. Principal Conditions and Consideration. Subject to all of the terms and conditions set forth in this Agreement, and in consideration of the sale, assignment, transfer and delivery of the Purchased Assets by Licensor to Licensee, as of the Effective Date of this agreement Licensee and Licensor agree to the following (the "Purchase Consideration"):

 

a) MediSouth will provide Cloud-MD with the software source code for the License, expertise to install and integrate the License into Cloud-MD product offerings and deliver the MediSouth software source code to Cloud-MD.

 

b) For as long as Licensee makes use of the License, Licensor agrees to provide Licensee with all software updates for the License within 5 working days of Licensor implementing those same software updates in its own production version of the License.

 

c) Licensor agrees that Licensee shall have the right to modify the software contained in the License to meet Licensee's operational needs.

 

d) Cloud-MD shall provide back to MediSouth, with the permission of each affected Cloud-MD client, the de-identified purchasing data it collects as a result of Cloud-MD clients utilizing the embedded Medical Supplies and Pharmaceutical Inventory Management functionality provided by the License.

 

e) MediSouth shall receive 100,000 shares of non-diluteable, Class 144, Cloud-MD stock with a one (1) year trading restriction if this agreement is executed prior to Licensee's planned stock roll-back. If this agreement is executed after the Licensee's stock roll-back, the stock award shall equal $300,000/then current share price of Licensee's publicly traded stock. MediSouth shall complete the Subscription Agreement.

 

f) MediSouth will grant Cloud-MD all necessary rights to use the License and related patents and those rights shall be transferable to any Licensee who may purchase Cloud-MD and its assets.

 

g) In the event that Cloud-MD is acquired by another entity, the use of the License shall transfer to the acquiring entity with the provision that the License may be used only within the Cloud-MD software application as it was used at the time of the acquisition.

 

h) Other than 2.4.g above, Cloud-MD may not sell the License, transfer the License, allow any other entity to use the License as part of that entity's software application or transfer any rights to another party to use the License separately from Cloud-MD products in which the License is embedded.

 

i) If from the Effective Date of this agreement through the end of the 1st year following the Permanent Transfer, Licensee discovers any misrepresentations on the part of Licensor to Licensee or Licensor, Licensee or Licensor will have the right to dissolve this agreement. Should this occur, Licensor will be required to forfeit the stock awarded to it as described in item 2.4.e above with that stock having an established per share value equal to the value of a share of Licensee's stock as officially recorded on the date of Licensee's stock rollback and any assets from the original acquisition that still remain under the control of Licensee will be returned to Licensor and in their then current condition or status and both parties will exit the relationship holding each other harmless in all matters.

 

j) Licensor agrees to provide a software device in the licensed software that will offer an automatic logon from Licensee's software.

 

k) Licensor agrees to provide software operations, communications and hosting services for the licensed software in same computing facility as Licensee has its operational software until Licensee and Licensor mutually agree that this service is no longer necessary,

 

1) Licensee and Licensor agree to execute sales agreements for each other's products and services.

 

m) Licensee agrees that if due to Licensee modifications to the Licensed software, data from the modified Licensed software cannot be processed by Licensor, Licensee shall provide data in original Licensed software format and make that data available to Licensor as in 2.4.d.

 

n) Licensee shall have the right to copy and use all forms of documentation, marketing information and data related to the License.

 

o) Licensee shall have the right to brand the License with a product name selected by the Licensee and Licensor.

 

p) Licensor shall change the appearance of the License's end-user computer display screens to match the appearance of the Licensee's computer application's end-user computer displays, including the branding described in 2.4.0 above.

 

q) In the event that Licensor should cease doing business, Licensee shall have the right to continue usage of the License and all associated documentation and related marketing material without recourse from Licensor or any entity representing Licensor's interests.

 

r) The "powered by MediScan" text or graphic must always be displayed on modules and application web pages provided by Licensor.

 

2.5 Holdback Stock. Pursuant to the terms and subject to the conditions of this Agreement, no provisions shall be made for the purpose of withholding previously awarded stock by Licensee to Licensor other than those already cited in section 2.4 of this Agreement.

 

Cloud-MD Inventory Management System is a ground breaking Cloud-based Medical Supply Inventory Management System, specifically designed for small and medium Medical Practices, DME's, Home Health, Long-term Care, and Surgery Centers that will offer:

 

1. Centralized management control over medical supply and drug inventories 
2. Real time utilization and financial inventory summary 
3. Low price notifications 
4. Par level/reorder tracking 
5. RX expiration tracking 
6. Auto supply re-ordering from a practices established suppliers

 

Based on a barcode scanning technology, Cloud-MD Inventory Management is designed to reduce workloads by automating inventory control processes. The Cloud-MD's Inventory Management System requires no installation, on-site software or special hardware. The new Cloud-MD Office application suite, of which Cloud-MD Inventory Management is a part, is fully delivered via the Internet and requires no special computing environment at the end-user facility.

 

Manual inventory is time consuming, labor intensive and leaves room for error. Benefiting healthcare professionals across the country, Cloud-MD's Inventory Management System is a low-cost, low-maintenance, easy to use automated system that can provide effective solutions.

 

On November 21, 2012

 

The Company through a comprehensive agreement with CipherSmith, LLC, has purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks,, service marks, internet domain names or world wide web URS. This security software will be part of its ever expanding Cloud-MD Office product suite.

 

The fair value of the consideration and the assets acquired is based on the aggregate value of the common stock issued in exchange for the software as shown below:

   November 21, 2012
Fair Value of Consideration:   
Common Stock (800,000 common shares valued at $.018)  $14,400 
Total Purchase Price  $14,400 

 

Fair Value of Assets acquired:

     
Assets:     
Software source code and security software  $14,400 
Fair value of total assets  $14,400 
XML 23 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 10 - INCOME TAXES - Income Tax Expense Reconciliation (Details)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Income Tax Disclosure [Abstract]    
Statutory federal income tax rate 34.00% 34.00%
State income taxes and other 900.00% 900.00%
Valuation allowance (4300.00%) (4300.00%)
Effective tax rate 0.00% 0.00%
XML 24 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 3 - GOING CONCERN ISSUES (Details Narrative) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2009
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Net Loss $ (356,629) $ (57,085) $ (325,172)
Accumulated Deficit $ (26,229,970) $ (25,873,341)  
XML 25 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 1 - DESCRIPTION OF BUSINESS (Details Narrative)
 12 Months Ended
Sep. 30, 2010
Accounting Policies [Abstract]  
Compensation Related Costs

Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues.
XML 26 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 8 - EQUITY (Details Narrative) (USD $)
 1 Months Ended 10 Months Ended 12 Months Ended
Oct. 31, 2012
Jul. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2010
Aug. 26, 2013
Jun. 26, 2013
May 10, 2013
Apr. 17, 2013
Mar. 21, 2013
Oct. 01, 2012
Aug. 01, 2012
Jun. 22, 2012
Jan. 01, 2012
Oct. 05, 2011
Apr. 11, 2011
Sep. 10, 2008
Apr. 17, 2013
custom:CipherSmithMember
Feb. 22, 2013
custom:CipherSmithMember
Jan. 22, 2013
custom:CipherSmithMember
Dec. 06, 2012
custom:CipherSmithMember
Apr. 17, 2013
custom:MedicalMember
Dec. 06, 2012
custom:MedicalMember
Oct. 15, 2012
custom:MedicalMember
Jul. 31, 2012
custom:MedicalMember
Apr. 17, 2013
custom:KroossMember
Mar. 21, 2013
custom:KroossMember
Jul. 31, 2012
custom:KroossMember
Jul. 31, 2012
custom:ConsultingMember
Common Stock, Shares Authorized       650,000,000 650,000,000                     650,000,000                          
Common Stock, Par Value       $ 0.01 $ 0.01                                                
Common Stock, Shares Issued       180,526,879 165,276,913                                                
Preferred Stock, Shares Outstanding       0 0                                                
Prefered Stock, Par Value       $ 0.10 $ 0.10                                                
Common Stock, Voting Rights       1                                                  
Preferred Stock, Shares Reserved       4,000,000                                                  
Preferred Stock, Voting Rights       150                                                  
Stock Issued, Shares, Cash 137,500 90,000 90,000 25,000                                                   
Stock Issued for Cash, Value $ 46,000 $ 18,000 $ 18,000 $ 250,000                                                  
Shares, Issued   30,000,000   15,000,000   120,000 25,000 20,000 378,500 270,000 10,000 100,000   200,000 30,000,000   10,000,000 220,004 200,000 200,000 500,000 95,000 200,000 10,000 706,333 167,000 500,000 200,000  
Shares Held by Shareholder                 1,045,500             4,000,000                          
Equity Cancellation, Shares                 200,000                                        
Shares, Issued, Value   $ 1,200,106   $ 1,805,269 $ 1,652,769             $ 2,500 $ 10,000 $ 4,000   $ 105,000 $ 1,000               $ 10,401     $ 4,000 $ 204
Stock Issued During Period for Services, Shares   19,000                                                      
Shares Issued, Price Per Share   $ 0.0102   $ 0.007                   $ 0.020                     $ 0.0160     $ 0.020  
Preferred Stock, Shares Authorized       4,000,000 4,000,000                                                
Preferred Stock, Shares Issued       0 0                                                
XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL - Assets Acquired under Common Control (Details) (USD $)
 12 Months Ended
Sep. 30, 2011
Jun. 22, 2012
Jan. 01, 2011
Business Combinations [Abstract]      
Absolute Medical Software Systems LLC development costs from inception $ 1,011,222    
Impairment of software on September 10, 2008 to value (11,222)    
Total Value at September 10, 2008 1,000,000    
Software Update to Operate on Cloud Based Platform Absolute Medical Software Systems LLC development costs 200,106    
Total Cost Basis at January 1, 2011 1,200,106    
Equity instrument of $5,000,000 promissory note converted to 30,000,000 common stock on October 4, 2011 value under common control     1,200,106
Total Purchase Price   10,000 1,200,106
Software source code and development costs of software     1,200,106
Cost Basis of total assets     $ 1,200,106
XML 28 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 5 - DISCONTINUED OPERATIONS (Details Narrative) (USD $)
 1 Months Ended 2 Months Ended 3 Months Ended 48 Months Ended 60 Months Ended
Jul. 10, 2006
Jun. 15, 2006
Sep. 30, 2007
May 27, 2005
Sep. 30, 2011
Nov. 01, 2010
May 31, 2006
Apr. 27, 2006
Nov. 01, 2005
Discontinued Operations and Disposal Groups [Abstract]                  
Note Payable, Fair Value                 $ 175,000
Effective Interest Rate               1200.00% 800.00%
Shares Issued, Lending Arrangement                 1,200,000
Per Share Conversion Price                 $ 0.0525
Price per share issued, lending arrangement           $ 0.043      
Debt Discount                 51,600
Beneficial Conversion Feature           9,933      
Deferred Financing Costs           24,000      
Related Party Debt 20,000 16,625 13,300 159,000          
Related Party Interest Rate 1200.00%   8.00% 6.00% 8.00%        
Repayments of Related Party Debt     11,000            
Accounts Payable, Related Parties, Current     148,000   59,704        
Interest Expense Related Party     13,300            
Origination/Placement Fee             500 500  
Warrants Issued             100,000 100,000  
Warrant Exercise Price $ 0.036 $ 0.036              
Debt Default Amount         $ 11,625        
XML 29 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 12 - SUBSEQUENT EVENTS (Details Narrative) (USD $)
 1 Months Ended 10 Months Ended 12 Months Ended
Oct. 31, 2012
Jul. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2010
Aug. 26, 2013
Jun. 26, 2013
May 10, 2013
Apr. 17, 2013
Mar. 21, 2013
Oct. 01, 2012
Aug. 01, 2012
Jun. 22, 2012
Jan. 01, 2012
Oct. 05, 2011
Apr. 11, 2011
Sep. 10, 2008
Apr. 17, 2013
custom:MedicalMember
Dec. 06, 2012
custom:MedicalMember
Oct. 15, 2012
custom:MedicalMember
Jul. 31, 2012
custom:MedicalMember
Apr. 17, 2013
custom:CipherSmithMember
Feb. 22, 2013
custom:CipherSmithMember
Jan. 22, 2013
custom:CipherSmithMember
Dec. 06, 2012
custom:CipherSmithMember
Jun. 26, 2013
custom:SoftwareInvestmentMember
May 10, 2013
custom:SoftwareInvestmentMember
Apr. 17, 2013
custom:SoftwareInvestmentMember
Mar. 21, 2013
custom:SoftwareInvestmentMember
Apr. 17, 2013
custom:KroossMember
Mar. 21, 2013
custom:KroossMember
Jul. 31, 2012
custom:KroossMember
Apr. 17, 2013
custom:KroossMember
custom:CompensationMember
Aug. 26, 2013
custom:SoftwareSalesMember
Jul. 31, 2013
Third-Party Payor [Member]
Aug. 02, 2012
custom:MedisouthMember
Common stock issued for cash, Shares 137,500 90,000 90,000 25,000                                                                 
Stock Issued for Cash, Value $ 46,000 $ 18,000 $ 18,000 $ 250,000                                                                
Stock Issued   30,000,000   15,000,000   120,000 25,000 20,000 378,500 270,000 10,000 100,000   200,000 30,000,000   10,000,000 95,000 200,000 10,000 706,333 220,004 200,000 200,000 500,000 25,000 20,000 95,000 270,000 167,000 500,000 200,000 167,000 120,000 1,055,333 100,000
Cancellation of Shares                 200,000                                                      
Shares, Issued, Value   1,200,106   1,805,269 1,652,769             2,500 10,000 4,000   105,000 1,000       10,401                     4,000     20,871 2,500
Stock Issued During Period for Services, Shares   19,000                                                                    
Stock Issued, Price per Share   $ 0.0102   $ 0.007                   $ 0.020             $ 0.0160                     $ 0.020     $ 0.0160  
Stock Issued for Services, Value   204                                                                    
Stock Issued for Acquisition, Shares     500,000                                                                  
Stock Issued for Acquisitions, Value     $ 10,000                                                                  
XML 30 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 12 - SUBSEQUENT EVENTS (Tables)
 12 Months Ended
Sep. 30, 2011
Subsequent Events [Abstract]  
Fair Value of Consideration and Assets Acquired
   June 22, 2012
Fair Value of Consideration:     
Common Stock (500,000 common shares valued at $.008)  $10,000 
      
Total Purchase Price  $10,000 

 

Fair Value of Assets acquired:

     
Assets:     
Software  $10,000 
Fair value of total assets  $10,000 
XML 31 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Cash Flows (USD $)
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2009
Statement of Cash Flows [Abstract]        
Net Loss   $ (356,629) $ (57,085) $ (325,172)
Adjustments to reconcile net loss to net cash (used in) operating activities:        
Discontinued operations   16,212 35,121  
Changes in assets and liabilities:        
Stock issued for compensation   143,000     
Net assets and liabilities from discontinued operations   (23,214) (9,554)  
Net cash used in operating activities   (220,631) (31,518)  
CASH FLOWS FROM FINANCING ACTIVITIES:        
Common stock issued for cash 90,000 25,000     
Advances from affiliates   159,515 36,000  
Line of credit   44,535 (14,719)  
Net cash provided by financing activities   229,050 21,281  
INCREASE IN CASH   8,419 (10,237)  
CASH, BEGINNING OF PERIOD 11,016 2,597 12,434  
CASH, END OF PERIOD   11,016 2,597 12,434
SUPPLEMENTAL CASH FLOW INFORMATION:        
Interest paid          
Taxes paid          
Purchase of proprietary technology   $ 1,200,106     
XML 32 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES
 12 Months Ended
Sep. 30, 2011
Notes to Financial Statements  
NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES

NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

 

In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
XML 33 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 5 - DISCONTINUED OPERATIONS
 12 Months Ended
Sep. 30, 2011
Discontinued Operations and Disposal Groups [Abstract]  
NOTE 5 - DISCONTINUED OPERATIONS

NOTE 5- DISCONTINUED OPERATIONS

 

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC by prior management in which he was to pay $100,000 for that technology the former officer never paid the required compensation. The Company discontinued these operations and began selling Medical Business Software and is the current operation of the Company.

 

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and operations from discontinued operations in accordance with ASC Topic 360, Accounting for the Impairment or Disposal of Long Lived Assets.

 

Details of those classifications are shown below.

 

 

   September 30, 2011  September 30,
2010
Net assets of discontinued operations:          
Cash  $—     $2,197 
Accounts receivable   —      —   
Deferred offering costs   —      400 
Net assets of discontinued operations  $—     $2,597 
           
Net liabilities of discontinued operations:          
Accounts payable and accrued expenses  $169,176   $195,072 
           
Disputed salaries & vacation of former officers   968,645    968,645 
Disputed salary – former employee   20,256    20,256 
           
Disputed payroll taxes for back pay of former officers   84,701    84,701 
Disputed interest   209,215    191,346 
Interest expenses   42,137    42,137 
Former officer note payable at 8% interest rate   59,704    59,704 
Shareholders demand note payable at 12%   11,625    11,625 
Shareholders demand note payable at 12%   20,000    20,000 
Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010   175,000    175,000 
Note discount   —      (860)
Note beneficial conversion feature   —      (166)
Net liabilities of discontinued operations  $1,760,459   $1,767,460 

 

 

   Years ended
September 30,
   2011  2010
Discontinued operations:          
Revenues  $3,400   $58,788 
Cost of sales   —      25,462 
Operating expenses   —      36,485 
Interest expense   19,612    31,962 
Interest income   —      —   
Loss from Discontinued Operations  $16,212   $35,121 

 

Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:

 

On September 7, 2005, we entered into a factoring agreement with United Capital Funding (UCF) of Florida. UCF is a specialized financial services firm offering Accounts Receivable Management and working capital funding via factoring. We expect to improve our cash flow with this arrangement.

 

Under the arrangement, we sell to UCF as absolute owner, invoices that we submit to UCF to be factored. Upon purchase, UCF assumes the risk of non-payment on purchased invoices, so long as the cause of non-payment is solely due to the occurrence of an insolvency event. As collateral securing the obligations, we grant UCF a continuing first priority security interest in all accounts and related inventory. Notwithstanding the creation of the above security interest, our relationship with UCF is one of Seller and Purchaser of accounts, and not that of lender and borrower. However, as there is certain recourse for non-payment, the accounts receivable are recorded at the estimated realizable value, net of allowances and the net advanced amount from UCF is recorded as an obligation at the end of fiscal 2010 and 2010. The initial and periodic factoring fee is .45% of the face amount of factored invoices. The factoring period is five days and the purchase price is 80% of the face amount, excluding sales tax.

 

UCF typically advances to us 80% of the total amount of invoices factored, excluding sales tax. UCF retains 20% of the outstanding factored invoices as a reserve, which it holds until the customer pays the factored invoice to UCF.

 

On November 1, 2005, as an important phase in the current year’s financing plan, we entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program include a five-year Note payable at maturity in November 2010 for $175,000, at an effective annual interest rate of 8%. Interest is due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares include weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the Note has various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs are being amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs.

 

On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 our Chairman Michael Grollman made new personal loans to the Company totaling $159,000 to assist us with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company’s iBus software and designs.  During the quarter to September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.  On September 30, 2007, the Company converted unpaid interest of $13,300 on demand notes payable to Michael Grollman into a new demand note of $13,300 that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1st. The balance of the note at September 30, 2011 is $59,704.

 

On April 27, 2006, we secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer’s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer’s purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009. The note had an approximate maturity date of June 15, 2006. At September 30, 2006 and September 30, 2007 this note was in default. As of September 30, 2011 $11,625 of this loan was in default.

 

On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA’s order and b) in any receivable resulting from the fulfillment of the Clover Park purchase order. The interest rate on the loan is 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009. The note had a maturity date of July 10, 2006. At September 30, 2011 this note was in default.
XML 34 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 3 - GOING CONCERN ISSUES
 12 Months Ended
Sep. 30, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NOTE 3 - GOING CONCERN ISSUES

NOTE 3 - GOING CONCERN ISSUES

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has a net loss for the twelve months ended September 30, 2011 of $356,629, an accumulated deficit at September 30, 2011 of $26,229,970, and needs additional cash to maintain its operations.

 

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.
XML 35 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Details Narrative) (USD $)
 12 Months Ended
Sep. 30, 2010
Sep. 30, 2009
Aug. 26, 2013
Jun. 26, 2013
May 10, 2013
Apr. 17, 2013
Mar. 21, 2013
Oct. 01, 2012
Aug. 01, 2012
Jul. 31, 2012
Jun. 22, 2012
Jan. 01, 2012
Oct. 05, 2011
Sep. 30, 2011
Apr. 11, 2011
Sep. 10, 2008
Business Combinations [Abstract]                                
Shares Issued     120,000 25,000 20,000 378,500 270,000 10,000 100,000 30,000,000   200,000 30,000,000 15,000,000   10,000,000
Asset, Fair Value                           $ 4,296,000    
Share Price                               $ 0.10
Common Stock Value 1,652,769               2,500 1,200,106 10,000 4,000   1,805,269 105,000 1,000
Impairment   1,000,000                            
Payments to Develop Software 200,106                              
Acquisition Costs $ (1,011,223)                              
Acquisition Purchase Price ($1,000,000)                              
Business Acquistion Terms

In accordance with the revised LOI the following occurred and on December 1, 2010 the NSC reported that change on Form 8-K:

1.On November 19, 2010 - MDLG was appointed CEO, President, and Chairman of the Board. At that time there were now then 3 Board members.
2.On November 29, 2010, 4,000,000 shares of Preferred A were authorized by the Board. These preferred shares are not convertible but entitle to 150 votes per share.
3.On November 30, 2010 – 3,000,000 Preferred A shares were beneficially issued to The Private Companies and 1,000,000 were issued to another Board member.
4.On January 2, 2011 the sale of the software by the Private Companies to NSC was finalized which included the exchange for a $5,000,000 note convertible to 500,000,000 of common stock at $.01 per share. At the time of this transaction the Company did not have the available authorized shares to issue these shares for the convertible note. Therefore, the Company agreed to issue a $5,000,000 promissory note for 8% interest rate the note matures on April 30, 2021.
5.On January 2, 2011 10,000,000 common shares were beneficially issued to MDLG via an affiliate for compensation.

 

                              
XML 36 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Summarized by Level (Details) (USD $)
Sep. 30, 2011
Sep. 30, 2010
Proprietary Technology $ 1,200,106  
Total Proprietary Technology 1,200,106   
Level 3
    
Proprietary Technology 1,200,106  
Total Proprietary Technology $ 1,200,106   
XML 37 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 6 - COMMITMENT AND CONTINGENCIES (Details Narrative) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Commitments and Contingencies Disclosure [Abstract]    
Rent Expense $ 0 $ 7,245
XML 38 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 10 - INCOME TAXES - Income Tax Expense (Details) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Current:    
Federal $ 0 $ 0
State 0 0
Current Tax Expense Benefit 0 0
Deferred:    
Federal 8,378,837 8,264,131
State 44,703 25,445
Deferred Tax Expense (Benefit) 8,423,540 8,289,576
Valuation allowance (8,423,540) (8,289,576)
Provision benefit for income taxes, net      
EXCEL 39 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V-U\X.60W M9C%F830Q,#(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T871E;65N='-?;V9?0V%S:%]&;&]W#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DY/5$5?,5]$15-#4DE05$E/3E]/1E]" M55-)3D534SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DY/5$5?,E]"05-)4U]/1E]04D5314Y4051)3TY?03PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DY/5$5?,U]'3TE.1U]#3TY#15). M7TE34U5%4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DY/5$5?-%]354U-05)97T]&7U-)1TY)1DE#04Y47SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DY/5$5?-5]$25-#3TY424Y5141? M3U!%4D%424].4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DY/5$5?-E]#3TU-251-14Y47T%.1%]#3TY424Y'13PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DY/5$5?-U]214Q!5$5$7U!! M4E197U1204Y304-423PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?.%]%455)5%D\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,3%?4T]&5%=!4D5?04-154E3251)3TY?5#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,3)?4U5"4T51 M545.5%]%5D5.5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?-5]$25-#3TY424Y5141?3U!%4D%424].4S$\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,3)?4U5"4T51545.5%]%5D5.5%-?5&%B M;#PO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DY/5$5?-5]$25-#3TY424Y5141?3U!%4D%424].4S(\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/ M5$5?,3!?24Y#3TU%7U1!6$537TEN8V]M95]483PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DY/5$5?,3!?24Y#3TU%7U1!6$537TEN M8V]M95]483$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,3)?4U5"4T51 M545.5%]%5D5.5%-?1F%I#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,3)?4U5"4T51545.5%]%5D5.5%-?1&5T83PO>#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S1E,#!A.60R7V5E-CE?-#%C-%]B,#8W7S@Y9#=F M,69A-#$P,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T93`P83ED M,E]E938Y7S0Q8S1?8C`V-U\X.60W9C%F830Q,#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^3D%424].04P@ M4T-)14Y4249)0R!#3U)0+T%:/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^4V5P(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!A(%=E;&PM:VYO=VX@4V5A M'0^ M3F\\2!A(%9O;'5N=&%R>2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^1ED\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V-U\X.60W9C%F830Q,#(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&4P,&$Y9#)?964V.5\T,6,T M7V(P-C=?.#ED-V8Q9F$T,3`R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)FYB3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)FYB'0^)FYB'0^)FYB'0^)FYB7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'!I M'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!F:6YA;F-I M;F<@86-T:79I=&EE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED M,E]E938Y7S0Q8S1?8C`V-U\X.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-&4P,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q M9F$T,3`R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'`@6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2X@3VX@36%Y(#$V+"`Q.3DV+"!T:&4@0V]M M<&%N>2!C:&%N9V5D(&ET2!C M:&%N9V5D(&ET2X@161E;B!W87,@ M96YG86=E9"!I;B!W871E2!T96-H;F]L;V=Y(&%N9"!P6QE/3-$)VUA'0M86QI9VXZ(&IUF%B;RP@=F]T960@=&\@9&ES M8V]N=&EN=64@86YD('=I;F0@9&]W;B!T:&4@;W!E2=S($UO8FEL92!$5E(@86YD($QO8V%T:6]N(%!R;V1U8W1S(&)U M6QE/3-$)VUA'0M86QI9VXZ(&IU'!E M;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V-U\X.60W9C%F830Q,#(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&4P,&$Y9#)?964V.5\T M,6,T7V(P-C=?.#ED-V8Q9F$T,3`R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'`@6QE/3-$)VUA'0M86QI9VXZ(&IU2!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE2!A=F%I;&%B;&4N(%5N8V5R=&%I M;G1I97,@=VET:"!R97-P96-T('1O('-U8V@@97-T:6UA=&5S(&%N9"!A6QE/3-$)VUA'0M86QI9VXZ(&IU'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@2<^/&(^3D]412`S("T@1T])3D<@ M0T].0T523B!)4U-515,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E28C.#(Q M-SMS(&-O;G1I;G5E9"!E>&ES=&5N8V4@:7,@9&5P96YD96YT('5P;VX@;6%N M86=E;65N="8C.#(Q-SMS(&%B:6QI='D@=&\@9&5V96QO<`T*<')O9FET86)L M92!O<&5R871I;VYS+"!C;VYT:6YU960@8V]N=')I8G5T:6]N28C.#(Q-SMS M('!R;V1U8W1S(&%N9"!B=7-I;F5S3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V M-U\X.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-&4P,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q9F$T,3`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`H;&]S2!A=V%R9',@ M=F5S="!R97-U;'1I;F<@:6X-"G1H92!I6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA M'0M86QI9VXZ(&IU M28C.#(Q-SMS(&-A2!H87,@97AP;W-U&-E960@86UO M=6YT2!L;W-S97,@:6X@6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2!O9B!C87-H+"!A8V-O=6YT6%B;&4@86YD)B,Q-C`[86-C6QE M/3-$)VUA'0M86QI M9VXZ(&IU6QE/3-$)VUA M'0M86QI9VXZ(&IU M&ET('!R:6-E('1H870-"G=O=6QD M(&)E(')E8V5I=F5D('5P;VX@2!A6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M2<^#0H\=&0@'0M86QI9VXZ(')I M9VAT)SXF(S@R,C8[/"]T9#X\=&0@2<^3&5V96P@,2`F M(S@R,3$[(&EN<'5T6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T.R!T97AT+6%L:6=N.B!R M:6=H="<^)B,X,C(V.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U<'0G/CPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU0T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@;W1H97(-"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@('1H86X@<75O=&5D#0H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("!P6QE/3-$)W9E6QE/3-$)W=I9'1H.B`W<'@G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M2<^3&5V96P@,R`F(S@R,3$[(&EN<'5T6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@2!496-H;F]L;V=Y/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E2!496-H;F]L;V=Y/"]T9#X\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PR,#`L,3`V/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O M6QE/3-$)V9O;G0Z(#$Q<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,7!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M M86QI9VXZ(')I9VAT)SY4;W1A;#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^ M/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3PO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)VUA'0M M86QI9VXZ(&IU6QE/3-$)VUA M'0M86QI9VXZ(&IU M65A2!A7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$ M)VUA'0M86QI9VXZ M(&IU2!P2!T:&4-"F9O2X\+W`^#0H-"CQP('-T>6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V9O M;G0Z(#0N-7!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E M6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^,BPQ.3<\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W!A9&1I;F6QE/3-$)V)O M'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF M(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXT,#`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`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^,38Y+#$W M-CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L M:6=N.B!R:6=H="<^,3DU+#`W,CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/D1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXY-C@L-C0U/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/D1I2`F(S$U,#L@9F]R;65R M(&5M<&QO>65E/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,"PR-38\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX-"PW,#$\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,#DL M,C$U/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/DEN=&5R97-T(&5X<&5N6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT,BPQ M,S<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6%B M;&4@870@."4@:6YT97)E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU.2PW,#0\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M-3DL-S`T/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/E-H87)E:&]L9&5R6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,"PP,#`\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^,C`L,#`P/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXQ-S4L,#`P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXH.#8P/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXH,38V/"]T9#X\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT)SXQ+#'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#0N-7!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)V9O;G0Z(#0N-7!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W9E6QE/3-$)W9E M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/D1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ M(')I9VAT)SXS+#0P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^-3@L-S@X/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S8L-#@U/"]T9#X\ M=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`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`Q,"!F;W(@ M)#$W-2PP,#`L(&%T(&%N(&5F9F5C=&EV92!A;FYU86P@:6YT97)E2`Q2!U;G!A M:60@:6YT97)E6)A8VL@65A6UE M;G0@=VET:&EN(&9I=F4@8G5S:6YE2!A;B!I;G1E7)I M9VAT2`D,3$L,#`P+B!!6UE;G0@=VET:&EN(&9I=F4-"F)U7,@ M;V8@82!D96UA;F0@;F]T:6-E(&9R;VT@37(N($=R;VQL;6%N+"!W:71H(&EN M=&5R97-T(&]F(#@E(&-O;7!O=6YD960@86YN=6%L;'D@;VX@3V-T;V)E3H@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!I;G1E2!I;B!A;GD@87-S971S M('!U&EM871E(&UA='5R:71Y(&1A=&4@;V8@2G5N92`Q-2P@,C`P-BX@070@4V5P M=&5M8F5R(#,P+"`R,#`V(&%N9"!397!T96UB97(@,S`L#0HR,#`W('1H:7,@ M;F]T92!W87,@:6X@9&5F875L="X@07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$Q M("0Q,2PV,C4@/"]F;VYT/F]F('1H:7,@;&]A;B!W87,@:6X@9&5F875L="X\ M+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2!I;G1E2!I;B!A;GD@87-S971S M('!U2!T:6UE(&)E9F]R92!-87D@,S$L(#(P M,#DN(%1H92!N;W1E(&AA9"!A(&UA='5R:71Y#0ID871E(&]F($IU;'D@,3`L M(#(P,#8N($%T(%-E<'1E;6)E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU&5C=71I=F4@3V9F:6-E&5C=71I=F4F M(S@R,3<[*2!O;B!*86YU87)Y(#$L(#(P,3,@*'1H92`F(S@R,C`[16UP;&]Y M;65N="!!9W)E96UE;G0F(S@R,C$[*2X@)B,Q-C`[5&AE($5M<&QO>6UE;G0- M"D%G'!I2`Q+"`R,#$X(&%N9"!S M:&%L;"!A=71O;6%T:6-A;&QY(')E;F5W(&9O65A6QE/3-$)V9O;G0M2<^#0H\=&0@'0M86QI9VXZ(')I M9VAT)SYI+CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2!S86QA M2!A<'!L:6-A8FQE('1O(&]T:&5R('-E;FEO M&5C=71I=F5S(&%N9"!O9F9I8V5R6QE/3-$)W=I9'1H.B`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`P('!E6QE/3-$)W=I9'1H M.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYV:6DN/"]T9#X\=&0@ M2<^26X@=&AE(&5V96YT('1H92!%>&5C=71I=F4G2!E;G1E6UE;G0@06=R965M96YT('=I M;&P@97AP:7)E($IA;G5A2!R96YE=R!F;W(@86YO=&AE6UE;G0@06=R965M96YT+B!4:&4@16UP;&]Y;65N="!!9W)E96UE M;G0@<')O=FED97,@9F]R.CPO<#X-"@T*/'`@6QE/3-$)W9E M'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`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`U M<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU&5S(&%N9"!A;6]R=&EZ871I;VX@97AP96YS97,-"B@F(S@R M,C`[14))5$$F(S@R,C$[*2P@:6YC;'5D:6YG(&-A2!I=&5M6QE/3-$ M)V9O;G0M2<^5&AE(&ES2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYI=BX\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y)SY4:&4@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&]N(&5A8V@@ M86YN:79E2!A8W%U:7-I=&EO;B!G2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYV+CPO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYV:2X\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!J=7-T:69Y)SY!(&UE9&EC86P@:6YS=7)A;F-E(&%L;&]W86YC92!O M9B`D,2PU,#`@<&5R(&UO;G1H+CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$ M)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^ M=FEI+CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2!P86ED("0P+C`P(&-O M;7!E;G-A=&EO;CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'`@F5D(&-O;6UO;B!S M:&%R97,@=&\@-C4P+#`P,"PP,#`L(&%T("0P+C`Q('!A6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M M86QI9VXZ(&IU6QE/3-$)V)A8VMG6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B!B;&%C:R<^1&]C=&]R2!46QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2`S,2P@,C`Q,B!T:&4-"D-O;7!A;GD@:7-S=65D(#,P M+#`P,"PP,#`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`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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`P+C5I;B<^)B,Q-C`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`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT M)SXU+#(W,2PW-38\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT M)SXT+C6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E M>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^-#`L,#`P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C$U/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^,"XT,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXS+C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#4L,S$Q+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BDM/"]T9#X\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@2!V86QU97,@86QL('=A M2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS#0IS=&]C:R!P M6EE;&0@;VX@=&AE(&-O;6UO;B!S=&]C:RP@87,@ M=V5L;"!A71I;64@ M870@=&AE:7(@9&ES8W)E=&EO;B!D=7)I;F<-"G1H92!L:69E(&]F('1H92!W M87)R86YT+B8C,38P.R8C,38P.TYO(&1I6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU65A65A6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;2<^)B,Q-C`[/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0[('9E6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q M,24[('1E>'0M86QI9VXZ(')I9VAT)SXN,3`\+W1D/CQT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I M9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXP+C$P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E'!I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T M9#X\=&0@&5R8VES86)L92!B>2!T:&4@:&]L M9&5R2!T M:&4@0FQA8VLM4V-H;VQE6QE/3-$)VUA'0M86QI9VXZ(&IU2`Q+"`R,#`Q+B!/=7(@2`Q M-"P@,C`P,2X@5&AE(#(P,#`@4W1O8VL@3W!T:6]N('!L86X@=&5R;6EN871E M'1E;F1E9"!T:&4@4W1O8VL@3W!T:6]N(%!L86X@ M=&AE7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)VUA M'0M86QI9VXZ(&IU M6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B0\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H M="<^,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT M+6%L:6=N.B!R:6=H="<^,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE M/3-$)W9E'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$ M)V)O'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M M86QI9VXZ(')I9VAT)SXP/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE M/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^."PS-S@L.#,W/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX+#(V-"PQ,S$\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXT-"PW,#,\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@ M'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX+#0R,RPU-#`\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M."PR.#DL-36QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXH."PT,C,L-30P/"]T9#X\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0G/BD\+W1D/CPO M='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI M9VXZ(')I9VAT)SXS-"XP/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SXS-"XP/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXY+C`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@'0M86QI9VXZ(')I9VAT)SXH-#,N,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O M6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZ(&IU&5S(')E2!D:69F97)E;F-E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I M9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*/'1R('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXH,C4L-C@X+#(Y M-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F"!A6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F2!H87,@82!N970@;W!E"!R97!O2!C875S92!L:6UI=&%T:6]NF4@:6X@86YY(&]N92!Y96%R(&EN8VQU9&4L#0IB=70@87)E M(&YO="!L:6UI=&5D('1O+"!A(&-U;75L871I=F4@;W=N97)S:&EP(&-H86YG M92!O9B!M;W)E('1H86X@-3`E(&]V97(@82!T:')E92UY96%R('!E2!B92!I;7!O2!S M96-U2!H87,@<')O=FED960@82!V86QU871I;VX@6QE/3-$)VUA'0M M86QI9VXZ(&IU&%B;&4@:6YC M;VUE(&%N9"!L97-S97(@=V5I9VAT('1O(&ET'!E M8W1A=&EO;B!O9B!I;7!R;W9I;F<@;W!E"!A&%B;&4@:6YC;VUE(&EN('1H92!5+E,N/"]P/@T*#0H\<"!S='EL93TS M1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT+6%L:6=N M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA'0M86QI9VXZ(&IU2UT:&%N+6YO M="8C.#(R,3L@=&AE(&1E9F5R"!AF5D+B!3=6-H('!O&%B;&4@:6YC;VUE M('1O(')E86QI>F4@28C.#(Q-SMS(&5F9F5C=&EV92!T87@-"G)A=&4@;6%Y('9A&%B;&4@:6YC;VUE(&]R(&QO"!L87=S+"!F=71U'10 M87)T7S1E,#!A.60R7V5E-CE?-#%C-%]B,#8W7S@Y9#=F,69A-#$P,@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T93`P83ED,E]E938Y7S0Q8S1? M8C`V-U\X.60W9C%F830Q,#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@6QE/3-$)VUA'0M86QI9VXZ(&IU2!-:6-H865L(&1E(&QA($=A6QE/3-$)VUA'0M86QI9VXZ(&IU&-H86YG92!#;VUM:7-S:6]N('=A2!M86YA9V5M96YT('1O(&EN2`Q+"`R,#$Q($%C<75I6QE/3-$)VUA'0M86QI9VXZ(&IUF4Z(#$Q<'0[(&UA2<^3VX@3F]V96UB97(@,3DL M(#(P,3`@+2!-1$Q'('=A2<^#0H\=&0@2<^3VX@3F]V96UB97(@,CDL(#(P,3`L(#0L,#`P+#`P,"!S:&%R97,@;V8@ M4')E9F5RF5D(&)Y('1H92!";V%R9"X-"E1H M97-E('!R969E6QE/3-$)W9E'0M86QI9VXZ M(&IU6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS M+CPO=&0^/'1D/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2!I6QE/3-$)W9E'0M86QI9VXZ(&IU M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT+CPO M=&0^/'1D/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF5D M#0IW:&EC:"!I;F-L=61E9"!T:&4@97AC:&%N9V4@9F]R(&$@)#4L,#`P+#`P M,"!N;W1E(&-O;G9E6QE/3-$)VUA'0M M86QI9VXZ(&IU2!I6UE;G0@ M;V8@=&AI6QE/3-$)VUA'0M86QI9VXZ(&IU2!E;F=A9V5D(&$@=F%L=6%T M:6]N#0IE>'!E2!V86QU960@=&AE('-O9G1W87)E M#0IA;F0@7-I6QE/3-$)VUA'0M86QI9VXZ(&IU4UE9"P@86YD($UE9%!A>2`H)B,X M,C(P.W1H92!P2X@3VX@2G5N92`Y+"`R,#`Y M('1H92!T6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU&-E961E9"!T:&4-"G1R86YS86-T:6]N('!R:6-E("@D,2PP,#`L M,#`P*2!W:71H('1H92!P2P@=&AE('!R:6]R M(&-O6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE M/3-$)W=I9'1H.B`Q,"4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#`Q,2PR,C(\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(')I9VAT)SXH,3$L,C(R/"]T9#X\=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G M/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@ M'0M86QI9VXZ(')I9VAT)SXR,#`L,3`V/"]T9#X\=&0@6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$R<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,3@E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q M<'0@'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,24[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/"]T6QE/3-$)W!A9&1I;F3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V-U\X M.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&4P M,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q9F$T,3`R+U=O'0O:'1M;#L@8VAA'0^/'`@6QE/3-$)VUA'0M86QI9VXZ(&IU0T*=&\@:6UP86-T('1H92!F:6YA;F-I86P@ M6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2!I6QE/3-$)VUA'0M86QI9VXZ(&IU2X@ M06QS;R!O;B!!<')I;"`Q-RP@,C`Q,R!T:&4@0V]M<&%N>2!I2!42!I2!C86YC M96QL960@=&AE(#(P,"PP,#`-"F-O;6UO;B!S:&%R97,@:7-S=65D('1O(&9O M2!I6QE/3-$)VUA'0M86QI9VXZ(&IU2`Q,"P@,C`Q,R!T:&4@0V]M<&%N>2!I6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^1'5R:6YG('1H M92!T96X@;6]N=&AS(&5N9&5D($IU;'D@,S$L(#(P,3(L#0IT:&4@0V]M<&%N M>2!I6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU'!E;G-E6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2!I2!I6QE M/3-$)VUA'0M86QI M9VXZ(&IU6QE/3-$ M)VUA'0M86QI9VXZ M(&IU2!A8W%U:7)E9`T*1&]C=&]R6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$ M)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`W,"4[ M('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3@E.R!T97AT+6%L:6=N.B!R M:6=H="<^,3`L,#`P/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE M/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W!A9&1I;F6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXQ,"PP,#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$Q<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2<^#0H\=&0@'0M M86QI9VXZ(')I9VAT)SXQ+CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U<'0G M/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2<^#0H\=&0@2<^1$Y!#0H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@=VEL;"!P2<^1V]A;`T*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&ES M('1O(&=R;W<-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!$3D$@65A2<^#0H\=&0@2<^0VQO=60M341S#0H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@=VEL;"!A8W%U:7)E#0H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@=&AE(&%S7-T96US+"!,3$,-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!O;F-E('1H M92!R979E;G5E#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@9V]A;',@:6X@ M:71E;0T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(",S(&%R92!A8VAI979E M9"X-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("!!6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$Q<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2<^0W5R7-T96US+"!, M3$,-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("!W:71H(&-U0T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&]F('1H92!S M=&%T90T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&]F($UI6QE/3-$ M)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`S-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^ M8BX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SY#=7)R96YT#0H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@97AE8W5T:79E(&UA;F%G96UE;G0-"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("!W:6QL(')E;6%I;@T*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(&9O6QE/3-$)W9E'0M M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`S-7!T.R!T M97AT+6%L:6=N.B!R:6=H="<^8RX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SY# M=7)R96YT($]W;F5R6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$Q<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE7-T96US+"!,3$,-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!D=7)I M;F<@=&AE#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@86-Q=6ES:71I;VX- M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("!O6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=F;VYT.B`Q,7!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2<^1F]R(&]N M92`H,2D@>65A<@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M869T97(@=&AE(&%C<75I2!T;R!E87)N('5P('1O(#$R-2PP,#`@6QE/3-$)V9O;G0Z(#$P<'0@5&US(%)M;CL@ M;6%R9VEN.B`P(#`@,"`P+C'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<] M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,7!T+VYO2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SXU+CPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T M.R!T97AT+6%L:6=N.B!R:6=H="<^-BX\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M)SY5<&]N#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@=&AE('!U0T*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&]F M($MR;V]S7-T96US+"!, M3$,N/"]T9#X-"CPO='(^#0H\='(@2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SXW+CPO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU2<^1$Y!#0H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@;W=N97)S:&EP(&UA>0T*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(&)E(&-A;&QE9"!U<&]N#0H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@=&\@86-T(&%S(&$-"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("!R969E2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SXY+CPO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)V9O;G0Z(#$R<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V9O;G0Z(#$Q<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2<^16YT97)P6QE M/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`U-7!T.R!T97AT+6%L:6=N.B!R:6=H M="<^:2X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SY-4U)0#0H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@;V8@2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYI:2X\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y)SY!#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&-O;6UI6QE M/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SYV+CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U M<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$Q<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2<^1$Y!#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@=VEL;"!B96-O;64- M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("!O9F9I8VEA;"!B971A#0H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@'0M86QI9VXZ(&IU'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$R<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z M(#$Q<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3`N/"]T M9#X\=&0@2<^57!O;B!A8W%U:7-I=&EO;@T*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(&]F($1.02!B>2!#;&]U9"U- M1',L($-L;W5D+4U$65E65E65D(&)Y($-L;W5D+4U$6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$ M)VUA'0M86QI9VXZ M(&IU'!A;F1I;F<@0VQO=60M340@3V9F:6-E('!R;V1U8W0@6QE/3-$)VUA'0M M86QI9VXZ(&IU6QE/3-$ M)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S M='EL93TS1"=W:61T:#H@,3@E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@ M'0M86QI9VXZ(')I9VAT)SXR+#4P,#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT)SXR+#4P,#PO=&0^/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXR+#4P,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B`C M,#`P,#`R)SYO;F1I=&EO;G,@83PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO M6QE M/3-$)V-O;&]R.B`C,44Q1#%&)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`R)SYE;3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B`C,#`P,#`R)SYA6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYS971S#0IB>2!,/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`R)SYI8V5N6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYA M6QE/3-$)V-O;&]R.B`C,44Q1#%&)SY,/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYI8V5N6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYA*2!-93PO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYO=71H#0IW:3PO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C M,44Q1#%&)SY#/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R M)SYL;W5D+4U$('=I=&@@=&AE('-O9G1W87)E('-O=7)C92!C;V1E(&9O/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYR#0H\+V9O;G0^ M/&9O;G0@6QE/3-$)V-O;&]R.B`C,44Q1#%&)SXL(#PO9F]N=#X\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYT/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,#`P,#`R)SYA;&P-"F%N9"!I;G1E9SPO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B`C,44Q1#%&)SYO/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SYF/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q M1#%&)SYT=SPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYS/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYO=7)C92!C;V1E('1O($-L;W5D+4U$ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%&)SXN/"]F;VYT M/CPO<#X-"@T*/'`@6QE M/3-$)VUA'0M86QI M9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYB M*2!&;W(@87,@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYL/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYO;F<- M"F%S(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYH M#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,44Q M1#%&)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYM M<&QE;65N=&EN/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYG(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYA/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYM92!S;V9T/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYW/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`R)SYA6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYC/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%&)SXI#0H\+V9O;G0^/&9O;G0@ M6QE/3-$)V-O;&]R.B`C,44Q1#%&)SYS/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`R)SYO6QE/3-$)V-O;&]R.B`C M,#`P,#`R)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYE6QE/3-$)V-O;&]R.B`C,44Q1#%&)SY,:3PO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%&)SY, M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYI8V5N6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYO;F%L M#0IN965D6QE/3-$)V-O;&]R M.B`C,44Q1#%&)SYD/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`R)SXM340@6QE/3-$)V-O;&]R.B`C,44Q M1#%&)SYL/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYL M#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`R M)SYW:71H('1H92!P97)M:7-S:6]N(&]F(&5A8V@@869F96-T960@/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q1#%&)SY#/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYL;W5D+4U$#0H\+V9O;G0^/&9O M;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,44Q1#%&)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SYN=#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q1#%& M)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYH92!D M93PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYE;6)E9&1E9"!-961I8V%L(%-U M<'!L:65S(&%N9"!0:&%R;6%C975T:6-A;"!);G9E;G1O0T* M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYP0T*/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYT:&4@3&EC96YS93PO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYV M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE#0HQ,#`\ M+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,C@R M-S(X)SXL(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYK(#PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYI M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO<@T*/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO(#PO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYP;&%N/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYN960@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO8SPO9F]N=#X\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYR;VQL+6(\+V9O;G0^/&9O;G0@ M6QE/3-$)V-O M;&]R.B!B;&%C:R<^+@T*/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SY)9B!T:#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`Q)SYC:SPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYH92!S M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO8VL-"F%W83PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SXO/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT:&5N#0H\+V9O;G0^ M/"]I/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYC=7)R96YT('-H M87)E('!R:3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYS#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYL/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYI8VP\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYD/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE9"!S=&]C:SPO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYF*2!- M961I4V\\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SY#/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYL/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYO M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYU9"U-1`T* M86QL(&YE8V4\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE;&$\+V9O;G0^ M/&9O;G0@6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYH;SPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYI9V@\+V9O M;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT;R!A;CPO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO2`\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYP=7)C:&%S92`\+V9O;G0^/&9O;G0@ M6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SY-/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`Q)SY$#0H\+V9O;G0^/&9O;G0@6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT:#PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYV93PO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYA8W%U/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYI/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYR960-"F(\+V9O;G0^/&9O;G0@ M6QE M/3-$)V-O;&]R.B`C,#`P,#`Q)SYA;F]T:&5R(&5N=&ET/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYY+`T*/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT:&4@=7-E(&]F('1H92!,:6-E;G-E M(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYT:#PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYC/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYQ=3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE;G1I=#PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO2`\+V9O;G0^/&9O M;G0@6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYP0T*/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYB92!U2!W:3PO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYA6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYA<'`\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYS(&ET(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYH92`\ M+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYT:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C-$$T M031")SXN#0H\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XM=&]P M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYH/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE M6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SXT+F<-"CPO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SY#;&\\+V9O;G0^/&9O;G0@ M6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SY-/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SY$#0IM87D@;F]T('-E;&P@=&AE($QI8V5N6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT:&4@3&EC96YS93PO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYA;&QO=R!A;CPO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO2`\+V9O;G0^/&9O M;G0@6QE/3-$)V-O;&]R M.B`C,C@R-S(X)SYR#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYT>0T*/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT;R`\+V9O;G0^/&9O M;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE(#PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYS/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE#0H\+V9O;G0^/&9O M;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYR="`\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYT:&%T(&5N=&ET/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYY/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X M)SXG/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYS#0IS M;V9T=V%R92!A<'!L:6-A=&EO;B!O/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYR('0\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYE<@T*86X\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYS#0H\+V9O M;G0^/&9O;G0@6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYH/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYR#0IP/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYY#0IT/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO(#PO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SY,:6,\ M+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYS#0H\+V9O;G0^/&9O;G0@ M6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SXN/"]F;VYT/CPO<#X-"@T*/'`@ M6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SY)9@T*9G(\+V9O M;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYH:7,-"F$\+V9O;G0^/&9O M;G0@6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYT#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR M(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYW:3PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYN=`T*/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SY4/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYA;CPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO2`\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYO;G,-"F]N(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT M(&\\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SY,:6,\+V9O;G0^/&9O;G0@6QE/3-$ M)V-O;&]R.B`C,C@R-S(X)SXL#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE M#0H\+V9O;G0^/&9O;G0@6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYA9W)E93PO9F]N=#X\9F]N="!S='EL93TS1"=C M;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYU;#PO9F]N=#X\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,#`P,#`Q)SYH/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYS#0IO8V-U/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SXL($QI8V5N6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYO(&ET(&$\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYD97,\ M+V9O;G0^/&9O;G0@6QE M/3-$)V-O;&]R.B`C,C@R-S(X)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYT93PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SXR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:R<^+CPO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYT:`T*=&AA="!S=&]C:R!H879I;F<@86X@97-T86)L:7-H960@<&5R M('-H87)E('9A;'4\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYV M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYA/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYL/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYU90T*;V8@/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYA(#PO9F]N=#X\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYF#0I,/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,C@R-S(X)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYC/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE M;G,\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYS(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYY#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYT M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYO8VL@/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYR/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO;#PO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B`C,#`P,#`Q)SYC:PT*86YD(&%N/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYY(#PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O;&]R M.B`C,#`P,#`Q)SYC/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYO;CPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYL#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT:&5N(&-U6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYC/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO;F1I=&EO;@T*;SPO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYH('!A6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYS#0H\ M+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYL/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYL(#PO9F]N=#X\9F]N="!S='EL M93TS1"=C;VQO#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYH/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO;&1I;CPO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYA8V@-"F]T:&4\+V9O;G0^ M/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYH87)M;&5S/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYS(&EN#0IA/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYL/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYL(#PO9F]N=#X\9F]N="!S='EL93TS1"=C M;VQO6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYS/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SXN/"]F;VYT/CPO<#X- M"@T*/'`@2<^/&9O;G0@6QE/3-$)VUA M'0M86QI9VXZ(&IU M6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYJ*2!,/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYI8SPO9F]N=#X\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYV:61E(&$@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYS/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO9G1W87)E('1H870@=VEL/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYL#0IO/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYF9CPO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYI M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYC#0H\+V9O M;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYG/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYO;B!F6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE93PO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYK/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SXI#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYS/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYO<@T*/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SYA/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYG/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYR93PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO M6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYV/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYI9&4@6QE/3-$)V-O;&]R.B`C,C@R-S(X M)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYW87)E M#0IO<&5R871I;VYS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SXL(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYL:6,\+V9O;G0^ M/&9O;G0@6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`Q)SYO9G1W/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q M)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE#0II M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYN('-A;64@ M8V]M<'5T/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYI M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYN9R!F86-I M;&ET/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYY#0H\ M+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYO/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYP M97)A=&EO;F$\+V9O;G0^/&9O;G0@6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYE#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYN6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYN/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYD($P\+V9O;G0^ M/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYM=71U86QL/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYY(#PO9F]N=#X\9F]N="!S='EL M93TS1"=C;VQO6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SYH870-"G1H:7,@6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYL;VX\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYC/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYE;G-O<@T*83PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B`C,#`P,#`Q)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,3(Q,3$S)SYX/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYE8W5T90T*6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SXG6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYP6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYI8SPO9F]N=#X\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYE(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYM/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYO9#PO9F]N=#X\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYE9`T*/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SY,:3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYR90T*8V%N;F]T(&)E M('!R;V-E6QE/3-$)V-O;&]R.B`C,3(Q M,3$S)SYY($P\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C M,#`P,#`Q)SYL;`T*<')O/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,C@R-S(X)SYV/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYI9&4@9#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B`C,C@R-S(X)SYI9SPO9F]N=#X\9F]N="!S='EL93TS1"=C M;VQO6QE/3-$)V-O M;&]R.B`C,#`P,#`Q)SY,:3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYT:&%T#0ID871A(&%V/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYA:3PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SY,:6-E/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,#`P,#`Q)SYN6QE/3-$)V-O;&]R.B`C M,3(Q,3$S)SXR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:R<^ M+CPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)VUA'0M86QI9VXZ M(&IU6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYN/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C@R-S(X)SXI#0H\+V9O;G0^ M/&9O;G0@6QE M/3-$)V-O;&]R.B`C,3(Q,3$S)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,C@R-S(X)SYN6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYL;"!H83PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT:&4@ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S)SYR:6=H/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYT#0H\+V9O;G0^ M/&9O;G0@0T*/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`Q)SYA;F0@=3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYD M;V-U;65N=&%T/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,3(Q,3$S M)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYO;CPO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYI;CPO9F]N=#X\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R M.B`C,3(Q,3$S)SYT:3PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B`C,#`P,#`Q)SYE9`T*/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,3(Q,3$S)SYT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`Q)SYO(#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SXI($P\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SYT:&4@3&EC96YS964@83PO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYP/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,44Q0S%%)SXI#0H\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SYN M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYS93PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q0S%%)SYP/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYU=&5R(&1I6QE/3-$ M)V-O;&]R.B`C,44Q0S%%)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SYC96YS964\+V9O;G0^/&9O;G0@6QE M/3-$)V-O;&]R.B`C,44Q0S%%)SXG/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,#`P,#`R)SYS(&5N9#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO M6QE/3-$)V-O;&]R.B`C,44Q M0S%%)SYA>7,\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SXN/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SXT+C`-"F%B;W9E/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q0S%%)SXN/"]F;VYT/CPO M<#X-"@T*/'`@2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q M0S%%)SYN=#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B`C,#`P,#`R)SYR97!R97-E;G1I;F<-"DQI8V5N6QE/3-$)V-O;&]R.B`C,44Q0S%%)SXG/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYS(&EN=&5R97-T/"]F;VYT/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B`C,44Q0S%%)SYS/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B`C,#`P,#`R)SXN/"]F;VYT/CPO<#X-"@T*/'`@6QE M/3-$)V-O;&]R.B`C-#,T,C0S)SXF(S,T.SPO9F]N=#X\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q0S%%)SXF(S,T M.PT*=#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO3PO9F]N=#X\9F]N="!S='EL93TS1"=C M;VQO6QE/3-$)V-O M;&]R.B`C,44Q0S%%)SYE/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C M,#`P,#`R)SYD(&]N(&UO9'5L97,@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B`C,44Q0S%%)SYA;F0-"CPO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO M0T*/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SY,/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B`C,44Q0S%%)SYI/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,#`P,#`R)SYC96YS;W(\+V9O;G0^/&9O;G0@6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R.B`C,#`P,#`R)SXR+C4@2&\\+V9O;G0^/&9O;G0@6QE/3-$ M)V-O;&]R.B`C,#`P,#`R)SYB/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B`C,44Q0S%%)SYA/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`R)SYC/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,44Q0S%%)SYK M#0I3=#PO9F]N=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SXN(#PO9F]N M=#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B`C,44Q0S%%)SYI/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SYO;G,-"G-H86QL(&)E(&UA M9&4@9F]R('1H92!P=7)P;W-E(&]F('=I=&AH;VQD:6YG('!R979I;W5S;#PO M9F]N=#X\9F]N="!S='EL93TS1"=C;VQO2`\+V9O;G0^ M/&9O;G0@6QE/3-$)V-O;&]R.B`C,44Q0S%%)SYY($P\+V9O;G0^/&9O;G0@6QE/3-$)V-O;&]R.B`C,#`P,#`Q)SXN/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`R)SXT#0IO9B!T:&ES($%G6QE/3-$)VUA'0M86QI9VXZ(&IU2!);G9E;G1O7-T M96TL('-P96-I9FEC86QL>2!D97-I9VYE9"!F;W(@2!S=6UM87)Y)B,Q-C`[/&)R("\^ M#0HS+B!,;W<@<')I8V4@;F]T:69I8V%T:6]N6QE/3-$)VUA'0M86QI9VXZ(&IU2PF(S$V,#L\9F]N="!S='EL M93TS1"=C;VQO2!-86YA9V5M96YT(%-Y2P@0VQO=60M340G2!T;R!U6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU2!R M:6=H=',L(&%L;"!C;VUP=71E<@T*&-H86YG92!F;W(@=&AE M('-O9G1W87)E(&%S('-H;W=N(&)E;&]W.CPO<#X-"@T*#0H-"CQP('-T>6QE M/3-$)VUA'0M86QI M9VXZ(&IU6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q,"4[('!A9&1I;F6QE/3-$)W=I M9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT M+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT)SXQ-"PT,#`\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$R M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)W9E M6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&IU M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$R<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T M871E2P@86-T=6%L(')E6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU'0^ M/'`@2<^06-C;W5N=',@4F5C96EV86)L92!A;F0@ M06QL;W=A;F-E(&9O28C M.#(Q-SMS(&%C8V]U;G1S#0IR96-E:79A8FQE(&)A;&%N8V4@:7,@2!O9B!I=',@8W5S=&]M97)S('1O(&UA:V4@2!T:&4@;G5M8F5R(&]F(&1A>7,-"G1H92!B86QA M;F-E(&ES('!A2!B87-E9"!U<&]N('!A2X@06-C;W5N=`T*8F%L86YC97,@ M87)E(&-H87)G960@;V9F(&%G86EN6QE/3-$)VUA'0M86QI9VXZ(&IU2!O9B!T:')E M92!M;VYT:',@;W(@;&5S&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P M.R!M87)G:6XM8F]T=&]M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);F-O M;64@5&%X97,\+W`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`H;&]S2!W97)E(&]U='-T86YD:6YG M+B`F(S$V,#M$:6QU=&5D(&5A2!A=V%R9',@=F5S="!R97-U;'1I;F<@:6X-"G1H92!I6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU'!O'!EF%T:6]N(&%N9"!O<&5R871I;F<@:&ES=&]R M>2!O9B!T:&4@9FEN86YC:6%L(&EN'0^/'`@6QE/3-$)VUA'0M86QI9VXZ(&IU'!A;F1S(&1I2!TF5S+"!W:71H:6X@=&AE(&UE87-U2!S<&5C:69I8R!I;F9O6QE/3-$)VUA'0M86QI9VXZ(&IU2!F;W(@ M9F%I6QE/3-$)VUA'0M86QI9VXZ(&IU2<^#0H\=&0@'0M86QI9VXZ(')I9VAT)SXF(S@R,C8[/"]T9#X\=&0@2<^3&5V96P-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(#(@)B,X,C$Q.PT*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@:6YP M=71S#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!T;R!T:&4-"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@('9A;'5A=&EO;@T*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@;65T:&]D;VQO9WD-"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(&EN8VQU9&4-"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@('%U;W1E9`T*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@<')I8V5S#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("!F;W(@6QE/3-$)W=I9'1H.B`R M,'!X.R!P861D:6YG+6)O='1O;3H@-G!T.R!F;VYT+7-I>F4Z(#$R<'0[('1E M>'0M86QI9VXZ(')I9VAT)SXF(S@R,C8[/"]T9#X-"B`@("`\=&0@"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VUA'0M M86QI9VXZ(&IU0T*;&5V96P@870@4V5P=&5M M8F5R(#,Q+"`R,#$Q(&%N9"`R,#$P(&9O6QE/3-$)VUA'0M M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/@T*("`@(#QT9#XF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ M+#(P,"PQ,#8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^,2PR,#`L,3`V/"]T9#X-"B`@("`\=&0^)B,Q M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T* M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE M/3-$)V9O;G0Z(#$Q<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,7!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E2!496-H;F]L;V=Y/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^)B,Q-C`[/"]T9#X\=&0@6QE M/3-$)W9E6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)VUA'0M86QI9VXZ(&IU'!E8W1E9"!T;R!A(&AA=F4@82!M871E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y M7S0Q8S1?8C`V-U\X.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-&4P,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q9F$T,3`R M+U=O'0O M:'1M;#L@8VAA2!,979E;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M M.B!";&%C:R`Q<'0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M M.B!";&%C:R`Q<'0@6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[ M/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PR,#`L,3`V M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W!A M9&1I;F6QE/3-$)W!A M9&1I;F6QE M/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)V)O6QE/3-$)V9O;G0Z(#$Q<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,7!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)W9E2!496-H;F]L;V=Y/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$ M)V)O'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W=I9'1H.B`U M-B4G/D-A6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O M6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A M9&1I;F6QE M/3-$)V)O6QE/3-$)W9E6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXR M+#4Y-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C M:R`Q<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/DYE="!L:6%B:6QI=&EE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXY-C@L M-C0U/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,"PR-38\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M="<^,C`L,C4V/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/D1I7)O;&P@=&%X97,@9F]R M(&)A8VL@<&%Y(&]F(&9O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX-"PW,#$\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^.#0L-S`Q/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ.3$L,S0V/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT M,BPQ,S<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H="<^-#(L,3,W/"]T9#X\=&0@6QE/3-$)W9E6%B;&4@870@,3(E M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,2PV,C4\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ-S4L M,#`P/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`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`U-B4G/E)E=F5N=65S/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^,RPT,#`\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXR-2PT-C(\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXQ.2PV,3(\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S$L.38R/"]T9#X\ M=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)VUA6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE M9G0[('9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)VUA'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E M'0M86QI9VXZ(&-E;G1E6QE/3-$)VUA&5R8VES92!06QE/3-$ M)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I M;F6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[ M('1E>'0M86QI9VXZ(')I9VAT)SXU+#(W,2PW-38\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[ M('1E>'0M86QI9VXZ(')I9VAT)SXT+C6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-#`L,#`P M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U M,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,"XT,SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS+C6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^*#4L,S$Q+#6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/BDM/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^ M)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M M86QI9VXZ(')I9VAT)SXR+#,P."PT.3<\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[ M/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B0\ M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H M="<^-3@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q M-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXR+#,P."PT.3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXD/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V M,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'1A8FQE(&-E;&QP861D M:6YG/3-$,"!C96QL6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXP/"]T M9#X\=&0@'0M86QI9VXZ(')I9VAT)SXP/"]T9#X\=&0@6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q M<'0@'0M86QI9VXZ(')I9VAT)SXP/"]T9#X\=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^."PR-C0L,3,Q/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ M(')I9VAT)SXR-2PT-#4\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/BD\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q M<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE M9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[ M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[ M/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0G/B4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@."4G/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B4\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(')I9VAT M)SXP+C`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[ M('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V)O"!#'0^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@ M,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^,C4L.#8V+#(Y-CPO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I M9VAT)SXR-2PS,S$L-C6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)V)O6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H M.B`Q-7!T.R!T97AT+6%L:6=N.B!R:6=H="<^,2X\+W1D/CQT9"!S='EL93TS M1"=W:61T:#H@-7!T)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y)SY/;B!.;W9E;6)E2<^#0H\=&0@2<^3VX@3F]V96UB97(@,S`L(#(P M,3`@)B,X,C$Q.R`S+#`P,"PP,#`@4')E9F5R2<^#0H\=&0@2<^3VX@2F%N=6%R>2`R+"`R,#$Q('1H M92!S86QE(&]F('1H92!S;V9T=V%R92!B>2!T:&4@4')I=F%T92!#;VUP86YI M97,@=&\@3E-#('=A&-H86YG92!F;W(@82`D-2PP,#`L,#`P(&YO=&4@8V]N=F5R=&EB;&4@=&\@ M-3`P+#`P,"PP,#`@;V8@8V]M;6]N('-T;V-K(&%T("0N,#$@<&5R('-H87)E M+B!!="!T:&4@=&EM92!O9@T*=&AI2!D:60@;F]T(&AA=F4@=&AE(&%V86EL86)L92!A=71H;W)I>F5D('-H87)E M2!A9W)E960@=&\@:7-S=64@ M82`D-2PP,#`L,#`P('!R;VUI6QE/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXU+CPO=&0^/'1D/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`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`Q+"`R,#$Q/"]T9#X\=&0@ M'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M6QE/3-$)VUA'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q,"4[('!A9&1I;F6QE/3-$)W=I9'1H.B`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`Q<'0@'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PQ,#8\+W1D/CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M6QE/3-$)W!A9&1I M;F6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@2!T:&4@0V]M<&%N>2`D M,3`P+#`P,"!P;'5S(#(E(&]F(')E=F5N=65S+CPO<#X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!496-H;F]L;V=Y/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#$L,C`P+#$P-CQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR,"PR-38\7)O;&P@=&%X97,@9F]R(&)A M8VL@<&%Y(&]F(&9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;G-E'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^)FYB'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4L($9A:7(@ M5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!$96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M,"PP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&]F(%)E;&%T960@4&%R M='D@1&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!3:&%R96AO;&1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T M7S1E,#!A.60R7V5E-CE?-#%C-%]B,#8W7S@Y9#=F,69A-#$P,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T93`P83ED,E]E938Y7S0Q8S1?8C`V M-U\X.60W9C%F830Q,#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^-"!Y96%R65A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^,R!M;VYT:',\'0^ M)FYB'0^)FYB3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y7S0Q8S1?8C`V-U\X M.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&4P M,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q9F$T,3`R+U=O'0O:'1M;#L@8VAA"!% M>'!E;G-E($)E;F5F:70\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!%>'!E;G-E("A"96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5S(&%N9"!O=&AE"!R871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T93`P83ED,E]E938Y7S0Q M8S1?8C`V-U\X.60W9C%F830Q,#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-&4P,&$Y9#)?964V.5\T,6,T7V(P-C=?.#ED-V8Q9F$T,3`R+U=O M'0O:'1M M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2`Q+"`R,#$Q M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(P,"PQ,#8\2!I;G-T2!N;W1E M(&-O;G9E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@2<^#0H\=&0@ M'0M86QI9VXZ(')I9VAT)SXQ+CPO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U<'0G/CPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE M/3-$)W9E'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR+CPO=&0^/'1D M/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2!T:&4@0F]A2!N;W1E(&9O M2<^#0H\=&0@2<^3VX@2F%N=6%R>2`R+"`R,#$Q M(#$P+#`P,"PP,#`@8V]M;6]N('-H87)E2!I M6QE/3-$ M)VUA'0M86QI9VXZ M(&IU'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M M87,M;6EC XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 92 212 1 false 17 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://NSCT/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Balance Sheets Sheet http://NSCT/role/BalanceSheets Balance Sheets false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://NSCT/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://NSCT/role/StatementsOfOperations Statements of Operations false false R5.htm 00000005 - Statement - Shareholders Equity Sheet http://NSCT/role/ShareholdersEquity Shareholders Equity false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://NSCT/role/StatementsOfCashFlows Statements of Cash Flows false false R7.htm 00000007 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS Sheet http://NSCT/role/Note1-DescriptionOfBusiness NOTE 1 - DESCRIPTION OF BUSINESS false false R8.htm 00000008 - Disclosure - NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES Sheet http://NSCT/role/Note2-BasisOfPresentationAndGoingConcernIssues NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN ISSUES false false R9.htm 00000009 - Disclosure - NOTE 3 - GOING CONCERN ISSUES Sheet http://NSCT/role/Note3-GoingConcernIssues NOTE 3 - GOING CONCERN ISSUES false false R10.htm 00000010 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://NSCT/role/Note4-SummaryOfSignificantAccountingPolicies NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R11.htm 00000011 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS Sheet http://NSCT/role/Note5-DiscontinuedOperations NOTE 5 - DISCONTINUED OPERATIONS false false R12.htm 00000012 - Disclosure - NOTE 6 - COMMITMENT AND CONTINGENCIES Sheet http://NSCT/role/Note6-CommitmentAndContingencies NOTE 6 - COMMITMENT AND CONTINGENCIES false false R13.htm 00000013 - Disclosure - NOTE 7 - RELATED PARTY TRANSACTIONS Sheet http://NSCT/role/Note7-RelatedPartyTransactions NOTE 7 - RELATED PARTY TRANSACTIONS false false R14.htm 00000014 - Disclosure - NOTE 8 - EQUITY Sheet http://NSCT/role/Note8-Equity NOTE 8 - EQUITY false false R15.htm 00000015 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION Sheet http://NSCT/role/Note9-Stock-BasedCompensation NOTE 9 - STOCK-BASED COMPENSATION false false R16.htm 00000016 - Disclosure - NOTE 10 - INCOME TAXES Sheet http://NSCT/role/Note10-IncomeTaxes NOTE 10 - INCOME TAXES false false R17.htm 00000017 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL Sheet http://NSCT/role/Note11-SoftwareAcquisitionTransactionBetweenEntitiesUnderCommonControl NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL false false R18.htm 00000018 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS Sheet http://NSCT/role/Note12-SubsequentEvents NOTE 12 - SUBSEQUENT EVENTS false false R19.htm 00000019 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://NSCT/role/Note4-SummaryOfSignificantAccountingPoliciesPolicies NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R20.htm 00000020 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://NSCT/role/Note4-SummaryOfSignificantAccountingPoliciesTables NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R21.htm 00000021 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS (Tables) Sheet http://NSCT/role/Note5-DiscontinuedOperationsTables NOTE 5 - DISCONTINUED OPERATIONS (Tables) false false R22.htm 00000022 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION (Tables) Sheet http://NSCT/role/Note9-Stock-BasedCompensationTables NOTE 9 - STOCK-BASED COMPENSATION (Tables) false false R23.htm 00000023 - Disclosure - NOTE 10 - INCOME TAXES (Tables) Sheet http://NSCT/role/Note10-IncomeTaxesTables NOTE 10 - INCOME TAXES (Tables) false false R24.htm 00000024 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Tables) Sheet http://NSCT/role/Note11-SoftwareAcquisitionTransactionBetweenEntitiesUnderCommonControlTables NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Tables) false false R25.htm 00000025 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS (Tables) Sheet http://NSCT/role/Note12-SubsequentEventsTables NOTE 12 - SUBSEQUENT EVENTS (Tables) false false R26.htm 00000026 - Disclosure - NOTE 1 - DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://NSCT/role/Note1-DescriptionOfBusinessDetailsNarrative NOTE 1 - DESCRIPTION OF BUSINESS (Details Narrative) false false R27.htm 00000027 - Disclosure - NOTE 3 - GOING CONCERN ISSUES (Details Narrative) Sheet http://NSCT/role/Note3-GoingConcernIssuesDetailsNarrative NOTE 3 - GOING CONCERN ISSUES (Details Narrative) false false R28.htm 00000028 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Summarized by Level (Details) Sheet http://NSCT/role/Note4-SummaryOfSignificantAccountingPolicies-FairValueMeasurementsSummarizedByLevelDetails NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Summarized by Level (Details) false false R29.htm 00000029 - Disclosure - NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://NSCT/role/Note4-SummaryOfSignificantAccountingPoliciesDetailsNarrative NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) false false R30.htm 00000030 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS - Discontinued Operations Balance Sheet (Details) Sheet http://NSCT/role/Note5-DiscontinuedOperations-DiscontinuedOperationsBalanceSheetDetails NOTE 5 - DISCONTINUED OPERATIONS - Discontinued Operations Balance Sheet (Details) false false R31.htm 00000031 - Disclosure - NOTE 5 - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://NSCT/role/Note5-DiscontinuedOperationsDetailsNarrative NOTE 5 - DISCONTINUED OPERATIONS (Details Narrative) false false R32.htm 00000032 - Disclosure - NOTE 6 - COMMITMENT AND CONTINGENCIES (Details Narrative) Sheet http://NSCT/role/Note6-CommitmentAndContingenciesDetailsNarrative NOTE 6 - COMMITMENT AND CONTINGENCIES (Details Narrative) false false R33.htm 00000033 - Disclosure - NOTE 7 - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://NSCT/role/Note7-RelatedPartyTransactionsDetailsNarrative NOTE 7 - RELATED PARTY TRANSACTIONS (Details Narrative) false false R34.htm 00000034 - Disclosure - NOTE 8 - EQUITY (Details Narrative) Sheet http://NSCT/role/Note8-EquityDetailsNarrative NOTE 8 - EQUITY (Details Narrative) false false R35.htm 00000035 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION - Outstanding Options (Details) Sheet http://NSCT/role/Note9-Stock-BasedCompensation-OutstandingOptionsDetails NOTE 9 - STOCK-BASED COMPENSATION - Outstanding Options (Details) false false R36.htm 00000036 - Disclosure - NOTE 9 - STOCK-BASED COMPENSATION - Warrant Activity (Details) Sheet http://NSCT/role/Note9-Stock-BasedCompensation-WarrantActivityDetails NOTE 9 - STOCK-BASED COMPENSATION - Warrant Activity (Details) false false R37.htm 00000037 - Disclosure - NOTE 10 - INCOME TAXES - Income Tax Expense (Details) Sheet http://NSCT/role/Note10-IncomeTaxes-IncomeTaxExpenseDetails NOTE 10 - INCOME TAXES - Income Tax Expense (Details) false false R38.htm 00000038 - Disclosure - NOTE 10 - INCOME TAXES - Income Tax Expense Reconciliation (Details) Sheet http://NSCT/role/Note10-IncomeTaxes-IncomeTaxExpenseReconciliationDetails NOTE 10 - INCOME TAXES - Income Tax Expense Reconciliation (Details) false false R39.htm 00000039 - Disclosure - NOTE 10 - INCOME TAXES - Tax Credit Carryforwards (Details) Sheet http://NSCT/role/Note10-IncomeTaxes-TaxCreditCarryforwardsDetails NOTE 10 - INCOME TAXES - Tax Credit Carryforwards (Details) false false R40.htm 00000040 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL - Assets Acquired under Common Control (Details) Sheet http://NSCT/role/Note11-SoftwareAcquisitionTransactionBetweenEntitiesUnderCommonControl-AssetsAcquiredUnderCommonControlDetails NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL - Assets Acquired under Common Control (Details) false false R41.htm 00000041 - Disclosure - NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Details Narrative) Sheet http://NSCT/role/Note11-SoftwareAcquisitionTransactionBetweenEntitiesUnderCommonControlDetailsNarrative NOTE 11 - SOFTWARE ACQUISITION: TRANSACTION BETWEEN ENTITIES UNDER COMMON CONTROL (Details Narrative) false false R42.htm 00000042 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS - Fair Value of Consideration and Assets Acquired (Details) Sheet http://NSCT/role/Note12-SubsequentEvents-FairValueOfConsiderationAndAssetsAcquiredDetails NOTE 12 - SUBSEQUENT EVENTS - Fair Value of Consideration and Assets Acquired (Details) false false R43.htm 00000043 - Disclosure - NOTE 12 - SUBSEQUENT EVENTS (Details Narrative) Sheet http://NSCT/role/Note12-SubsequentEventsDetailsNarrative NOTE 12 - SUBSEQUENT EVENTS (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Balance Sheets Process Flow-Through: Removing column 'Aug. 01, 2012' Process Flow-Through: Removing column 'Jul. 31, 2012' Process Flow-Through: Removing column 'Jun. 22, 2012' Process Flow-Through: Removing column 'Jan. 01, 2012' Process Flow-Through: Removing column 'Apr. 11, 2011' Process Flow-Through: Removing column 'Sep. 30, 2009' Process Flow-Through: Removing column 'Sep. 30, 2008' Process Flow-Through: Removing column 'Sep. 10, 2008' Process Flow-Through: 00000003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Apr. 11, 2011' Process Flow-Through: 00000004 - Statement - Statements of Operations Process Flow-Through: Removing column '12 Months Ended Sep. 30, 2009' Process Flow-Through: 00000006 - Statement - Statements of Cash Flows nsct-20110930.xml nsct-20110930.xsd nsct-20110930_cal.xml nsct-20110930_def.xml nsct-20110930_lab.xml nsct-20110930_pre.xml true true XML 41 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheets (Parenthetical) (USD $)
Sep. 30, 2011
Sep. 30, 2010
Statement of Financial Position [Abstract]    
Preferred Stock, Par Value $ 0.10 $ 0.10
Preferred Stock, Shares Authorized 4,000,000 4,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstandng 0 0
Common Stock, Par Value $ 0.01 $ 0.01
Common Stock, Shares Authorized 650,000,000 650,000,000
Common Stock, Shares Issued 180,526,879 165,276,913
Common Stock, Shares Outstanding 180,526,879 165,276,913
XML 42 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 8 - EQUITY
 12 Months Ended
Sep. 30, 2011
Equity [Abstract]  
NOTE 8 - EQUITY

NOTE 8 - EQUITY

 

On April 11, 2011 the Company amended its articles of incorporation to increase the authorized common shares to 650,000,000, at $0.01 par value and 180,526,879 are issued and outstanding as of September 30, 2011. and 4,000,000 preferred shares outstanding at a par value of $.01.

 

The Common stock holders have right to vote one share for every share that is issued.

 

The Preferred stockholders have designated rights and preferences of a Series A Convertible Preferred Stock, and reserved 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock.

 

2013

 

In October, 2012 the Company issued 137,500 common shares for $46,000 and issued 10,000 common stock in conjunction with the sale of medical software.

 

In December 6, 2012 the Company issued 500,000 common shares for the acquisition of CipherSmith software, issued 200,000 common shares for the sale of medical software.

 

In January 22, 2013 the Company issued 200,000 common shares for the acquisition of CipherSmith software.

 

In March 21, 2013 the Company issued 270,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

In March 21, 2013 the Company issued 500,000 to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. Also on April 17, 2013 the Company issued 167,000 for compensation for the salaries for the entire year of 2013 those shares were issued to Krooss Family Trust LLP in accordance with the Agreement. On April 17, 2013 the Company issued 378,500 to Krooss Family Trust LLP in accordance with the Agreement with total shares issued to William and Marie Krooss of 1,045,500 common shares.

 

April 17, 2013 the Company cancelled the 200,000 common shares issued to for the acquisition and reissued 220,004 common shares for the acquisition of CipherSmith software.

 

April 17, 2013 the Company issued 95,000 for the software investment in the Company in accordance with the Software Investment Agreements.

 

May 10, 2013 the Company issued 20,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

June 26, 2013 the Company issued 25,000 common shares for software investment in the company in accordance with the Software Investment Agreements.

 

August 26, 2013 the Company issued 120,000 common shares to two Software Sales Personal located in California.

 

2012

 

During the ten months ended July 31, 2012 the Company issued 30,000,000 common shares for there the reduction of debt from our CEO and reduced debt of the company by $1,200,106. The Company also issued 19,000 common shares for services rendered by professionals and recorded the expenses based upon the trading price of the common shares of $0.0102 and expensed $204 as consulting fees. The Company issued 706,333 common shares to third parties that have purchased our medical billing software at the trading price of the common stock of $0.0160 and recorded a revenue contra account of $10,401.

 

The Company issued 90,000 common shares for $18,000 in cash.

 

The Company issued 200,000 common shares to Kroosss Medical Management in accordance with the acquisition agreement and recorded it at the trading price of the common shares of $0.020 and recorded an investment in Krooss Medical Management of $4,000.

 

In August of 2012 the Company issued 100,000 shares to MediSouth LLC for the acquisition of its software. The stock was valued at $2,500 (See MediSouth LLC software acquisition below).

 

2011

 

In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.

 

The Company issued 250,000 in common stock for $25,000 in cash.

 

2010

 

No common stock was issued.

 

Common Stock

 

The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

 

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

The Company has authorized 4,000,000 shares of preferred stock, at $.001 par value and zero are issued and outstanding as of September 30, 2011. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been issued to our CEO & CFO on April 11, 2011 valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

 

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.
XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Shareholders Equity (USD $)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning Balance, Amount at Sep. 30, 2008    $ 1,372,770 $ 22,658,682 $ (25,491,084) $ (1,459,633)
Beginning Balance, Shares at Sep. 30, 2008    137,276,879      
Options expired      19,945   19,945
Common stock issued for back pay of officers, Shares   28,000,000      
Common stock issued for back pay of officers, Amount   280,000 (244,200)    35,800
Shares issued for compensation, Shares         28,000,000
Net loss       (325,172) (325,172)
Ending Balance, Amount at Sep. 30, 2009    1,652,769 22,434,427 (25,816,256) (1,729,061)
Ending Balance, Shares at Sep. 30, 2009    165,276,879      
Shares issued for compensation, Amount           
Common stock issued for cash, Shares           
Net loss       (57,085) (57,085)
Ending Balance, Amount at Sep. 30, 2010    1,652,769 22,434,427 (25,873,341) (1,786,145)
Beginning Balance, Shares at Sep. 30, 2010    165,276,879      
Shares issued for compensation, Shares 4,000,000 15,000,000     15,000,000
Shares issued for compensation, Amount 40,000 150,000 (47,000)   143,000
Common stock issued for cash, Shares   250,000     25,000
Common stock issued for cash, Amount   2,500 22,500   250,000
Net loss       (356,629) (356,629)
Ending Balance, Amount at Sep. 30, 2011 $ 40,000 $ 1,805,269 $ 22,409,927 $ (26,229,970) $ (1,974,774)
Ending Balance, Shares at Sep. 30, 2011 4,000,000 180,526,879      
XML 44 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheets (USD $)
Sep. 30, 2011
Sep. 30, 2010
CURRENT ASSETS:    
Cash $ 11,016   
Net assets of discontinued operations    2,597
Total current assets 11,016 2,597
Noncurrent ASSETS:    
Proprietary technology 1,200,106   
Total noncurrent assets 1,200,106   
TOTAL ASSETS 1,211,122 2,597
CURRENT LIABILITIES:    
Advances from officers 180,795 21,281
Line of Credit 44,535   
Net liabilities of discontinued operations 1,760,459 1,767,460
Total current liabilities 1,985,790 1,788,741
NONCURRENT LIABILITIES:    
Note payable affiliate 1,200,106   
Total Noncurrent Liabilities 1,200,106   
TOTAL LIABILITIES 3,185,896 1,788,741
STOCKHOLDERS' DEFICIT:    
Preferred stock, $.10 par value, 4,000,000 shares authorized; none issued and outstanding as of September 30, 2011 and 2010 40,000   
Common stock, $.01 par value, 650,000,000 shares authorized; 180,526,879 and 165,276,913 issued and outstanding as of September 30, 2011 and 2010, respectively 1,805,269 1,652,769
Additional paid-in capital 22,409,927 22,434,427
Accumulated deficit (26,229,970) (25,873,341)
Total stockholders' deficit (1,974,774) (1,786,145)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 1,211,122 $ 2,597
XML 45 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)
Sep. 30, 2011
Accounting Policies [Abstract]  
FDIC Insured Amount $ 250,000
XML 46 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 10 - INCOME TAXES (Tables)
 12 Months Ended
Sep. 30, 2011
Income Tax Disclosure [Abstract]  
Income Tax Expense
    September 30,
   2011  2010
Current:          
Federal  $0   $0 
State   0    0 
   $0   $0 
           
Deferred:          
Federal  $8,378,837   $8,264,131 
State   44,703    25,445 
    8,423,540    8,289,576 
Valuation allowance   (8,423,540)   (8,289,576)
Provision benefit for income taxes, net  $—     $—   
Income Tax Expense Reconciliation
   September 30,
   2011  2010
 Statutory federal income tax rate   34.0%   34.0%
 State income taxes and other   9.0    9.0 
 Valuation allowance   (43.0)   (43.0)
 Effective tax rate   0.0%   0.0%
Tax Credit Carryforwards
   September 30,
   2011  2010
 Net operating loss carryforward  $25,866,296    25,331,677 
 Valuation allowance   (25,688,296)   (25,331,677)
 Deferred income tax asset  $—     $—   
XML 47 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 10 - INCOME TAXES - Tax Credit Carryforwards (Details) (USD $)
Sep. 30, 2011
Sep. 30, 2010
Income Tax Disclosure [Abstract]    
Net operating loss carryforward $ 25,866,296 $ 25,331,677
Valuation allowance (25,688,296) (25,331,677)
Deferred income tax asset      
XML 48 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 9 - STOCK-BASED COMPENSATION - Outstanding Options (Details) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Shares Available 7,000,000   
Shares Granted 5,271,756 5,311,756
Weighted Average Exercise Price $ 0.43 $ 0.43
Weighted Average Remaining Contractual Life 4 years 8 months 3 years 8 months
October 1, 2008, Value      
Grants 40,000   
Grants, Per Share $ 0.15   
Grants, Value      
Forfeitures    (5,311,756)
Forfeitures, Per Share    $ 0.64
Forfeitures, Value      
Shares Available   7,000,000
XML 49 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 9 - STOCK-BASED COMPENSATION - Warrant Activity (Details) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Shares Granted 2,308,497 2,308,497
Weighted Average Exercise Price $ 0.10 $ 0.10
Weighted Average Remaining Contractual Life 58 years 3 months
Aggregate Intrinsic Value      
Grants      
Grants, Per Share      
Expired    (2,308,497)
Expired, Per Share      
XML 50 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 7 - RELATED PARTY TRANSACTIONS
 12 Months Ended
Sep. 30, 2011
Related Party Transactions [Abstract]  
NOTE 7 - RELATED PARTY TRANSACTIONS

NOTE 7– RELATED PARTY TRANSACTIONS

 

In September 30, 2009 the Company issued 28,000,000 common shares at the trading price of the common stock of $0.0012785. The Stock was issued for unpaid compensation to officers and reduced accrued compensation by $35,800.

 

On July 19, 2010 the Company assumed the line of credit of new management from Chase Bank of $36,000 to fund transitional expenses of which the net advance totaled $44,535.

 

In September 30, 2011 the Company issued 15,000,000 common shares at the trading price of the common stock of $0.007. The Stock was issued for compensation to new management and recorded and expense of $105,000.

 

In April 2011 the Company issued 4,000,000 common shares at the trading price of the common stock of $0.0095. The stock was issued for compensation to new management and recorded and expense of $38,000.

 

The Company entered into an employment agreement with its Chief Executive Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement, will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 5,000,000 for DNA, 5,000,000, and 1,000,000 for MediSouth, LLC
v.An automobile allowance of $1,500 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation.

 

The Company entered into an employment agreement with its Chief Financial Officer (the “Executive’) on January 1, 2013 (the “Employment Agreement”).  The Employment Agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the Employment Agreement. The Employment Agreement provides for:

 

i.A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

 

iii.The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
iv.The issuance of common stock on each anniversary date of the Employment Agreement of 5,000,000 and issuance of common stock for every acquisition granting 3,000,000 for DNA, 3,000,000, and 750,000 for MediSouth, LLC
v.An automobile allowance of $1,000 per month.
vi.A medical insurance allowance of $1,500 per month.
vii.In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

 

For the years ended September 30, 2011 and 2010, the Company paid $0.00 compensation
XML 51 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 5 - DISCONTINUED OPERATIONS - Discontinued Operations Balance Sheet (Details) (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2009
Nov. 01, 2005
Cash $ 11,016       
Note discount       51,600
Note beneficial conversion feature 22,409,927 22,434,427    
NET LOSS (356,629) (57,085) (325,172)  
Discontinued Operations [Member]
        
Cash    2,197    
Accounts receivable          
Deferred offering costs    400    
Net assets of discontinued operations    2,597    
Accounts payable and accrued expenses 169,176 195,072    
Disputed salaries & vacation of former officers 968,645 968,645    
Disputed salary - former employee 20,256 20,256    
Disputed payroll taxes for back pay of former officers 84,701 84,701    
Disputed interest 209,215 191,346    
Interest expenses 42,137 42,137    
Former officer note payable at 8% interest rate 59,704 59,704    
Shareholders demand note payable at 12% 11,625 11,625    
Shareholders demand note payable at 12% 20,000 20,000    
Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010 175,000 175,000    
Note discount    (860)    
Note beneficial conversion feature    (166)    
Net liabilities of discontinued operations 1,760,459 1,767,460    
Revenues 3,400 58,788    
Cost of sales    25,462    
Operating expenses    36,485    
Interest expense 19,612 31,962    
Interest income          
NET LOSS $ 16,212 $ 35,121    
XML 52 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 12 - SUBSEQUENT EVENTS - Fair Value of Consideration and Assets Acquired (Details) (USD $)
Aug. 01, 2012
Jul. 31, 2012
Jun. 22, 2012
Jan. 01, 2012
Sep. 30, 2011
Apr. 11, 2011
Jan. 01, 2011
Sep. 30, 2010
Sep. 10, 2008
Subsequent Events [Abstract]                  
Shares, Issued, Value $ 2,500 $ 1,200,106 $ 10,000 $ 4,000 $ 1,805,269 $ 105,000   $ 1,652,769 $ 1,000
Total Purchase Price     10,000       1,200,106    
Software     10,000            
Fair value of total assets     $ 10,000   $ 1,211,122     $ 2,597  
XML 53 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 10 - INCOME TAXES
 12 Months Ended
Sep. 30, 2011
Income Tax Disclosure [Abstract]  
NOTE 10 - INCOME TAXES

NOTE 10 INCOME TAXES

 

    September 30,
   2011  2010
Current:          
Federal  $0   $0 
State   0    0 
   $0   $0 
           
Deferred:          
Federal  $8,378,837   $8,264,131 
State   44,703    25,445 
    8,423,540    8,289,576 
Valuation allowance   (8,423,540)   (8,289,576)
Provision benefit for income taxes, net  $—     $—   

 

The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows:

 

   September 30,
   2011  2010
 Statutory federal income tax rate   34.0%   34.0%
 State income taxes and other   9.0    9.0 
 Valuation allowance   (43.0)   (43.0)
 Effective tax rate   0.0%   0.0%

 

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:   

   September 30,
   2011  2010
 Net operating loss carryforward  $25,866,296    25,331,677 
 Valuation allowance   (25,688,296)   (25,331,677)
 Deferred income tax asset  $—     $—   

 

The Company has a net operating loss carryforward of approximately $25.0 million available to offset future taxable income through 2030. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.

 

ASC 740 requires the consideration of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considered available positive and negative evidence, giving greater weight to its recent cumulative losses and its ability to carry-back losses against prior taxable income and lesser weight to its projected financial results due to the challenges of forecasting future periods. The Company also considered, commensurate with its objective verifiability, the forecast of future taxable income including the reversal of temporary differences. At that time the Company continued to have sufficient positive evidence, including recent cumulative profits, a reduction in operating expenses, the ability to carry-back losses against prior taxable income and an expectation of improving operating results, showing a valuation allowance was not required. At the end of the year ended September 30, 2007, changes in previously anticipated expectations and continued operating losses necessitated a valuation allowance against the tax benefits recognized in this quarter and prior quarters since they are no longer “more-likely-than-not” realizable. Under current tax laws, this valuation allowance will not limit the Company’s ability to utilize U.S. federal and state deferred tax assets provided it can generate sufficient future taxable income in the U.S.

 

The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.
XML 54 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 6 - COMMITMENT AND CONTINGENCIES
 12 Months Ended
Sep. 30, 2011
Commitments and Contingencies Disclosure [Abstract]  
NOTE 6 - COMMITMENT AND CONTINGENCIES

NOTE 6– COMMITMENT AND CONTINGENCIES

 

Rent expense for the years ended September 30, 2011 and 2010 was approximately $0.00 and $7,245 respectively
XML 55 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 1 - DESCRIPTION OF BUSINESS
 12 Months Ended
Sep. 30, 2011
Accounting Policies [Abstract]  
NOTE 1 - DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

 

THE COMPANY PREVIOUSLY HAD INSUFFICIENT WORKING CAPITAL TO PAY FOR THE PROFESSIONAL SERVICES REQUIRED TO PREPARE, AUDIT, AND FILE THE QUARTERLY AND ANNUAL REPORTS REQUIRED BY THE SECURITIES ACT OF 1934. AS A RESULT, THE AUDITORS WHO AUDITED THE SEPTEMBER 30, 2007 FINANCIAL STATEMENTS AND REVIEWED THE QUARTERLY REPORTS THROUGH JUNE 30, 2008 RESIGNED EFFECTIVE DECEMBER 13, 2011.

 

IN FEBRUARY 2010 THE BOARD OF DIRECTORS VOTED TO DISCONTINUE THE MOBILE DVR AND LOCATION PRODUCTS LINE OF BUSINESS REPORTED IN THESE FINANCIAL STATEMENTS DUE TO THE CUMULATIVE EFFECTS OF SEVERELY DECLINING REVENUES RESULTING FROM THE 2008 RECESSION. SINCE THIS DECISION WAS MADE SUBSEQUENT TO THE YEARS ENDED SEPTEMBER 30, 2008 AND 2009, THE QUARTERLY AND YEAR END STATEMENTS FOR THOSE YEARS ARE BEING REPORTED ON A GOING CONCERN BASIS RATHER THAN AS DISCONTINUED OPERATIONS. THEY WILL, HOWEVER, BE REPORTED AS DISCONTINUED OPERATIONS COMMENCING WITH THE FISCAL 2010 FILINGS.

 

NEW MANAGEMENT HAS SUBSEQUENTLY INFUSED SUFFICIENT WORKING CAPITAL TO BRING THE 1934 ACT FILINGS CURRENT. ADDITIONALLY, A NEW LINE OF BUSINESS HAS ALSO COMMENCED WHICH WILL BE REPORTED ON IN THE FISCAL 2011 AND 2012 FILINGS.

 

ACCORDINGLY, THESE FINANCIAL STATEMENTS ARE BEING SUBMITTED ONLY TO COMPLY WITH SEC RULES AND REGULATIONS AND SHOULD NOT BE RELIED UPON FOR YOUR INVESTMENT DECISIONS. THE OPERATIONS REPORTED ON IN THESE FINANCIAL STATEMENTS HAVE BEEN DISCONTINUED AS OF FEBRUARY 4, 2010. NEW MANAGEMENT ENCOURAGES THE READERS OF THESE FINANCIAL STATEMENTS TO SUSPEND ANY INVESTMENT DECISIONS PERTAINING TO THE STOCK OF THIS COMPANY UNTIL ALL REQUIRED 1934 ACT FILINGS ARE BROUGHT CURRENT.

 

 

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue is derived from sales of electronic devices, recognized as the product is delivered.

 

In February 4, 2010 the prior Board members Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operations of the Company's Mobile DVR and Location Products business and operate the remaining Company assets in a Limited Liability Company named NSC Labs, LLC, a company controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC entered into an agreement to pay the Company $100,000 plus 2% of revenues. Since as of this filing neither Mr. Grollman nor NSC Labs, LLC have paid the specified consideration for this transaction the transaction has not been recorded in the accounting records of the Company

 

In November 19, 2010, the prior management was terminated and new management began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, new management has deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities to former management including those captioned as “disputed accrued expenses – related party” on the Balance Sheet. Since the transaction was related to former management who had the ability to affect the terms and outcomes of the liabilities, the transaction has been subsequently recorded as an increase to additional paid in capital.
XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 7 - RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended
Jul. 31, 2010
Sep. 30, 2011
Apr. 30, 2011
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2009
Apr. 01, 2011
Jul. 19, 2010
Related Party Transactions [Abstract]                
Stock Issued During Period Compensation, Shares     4,000,000 15,000,000   28,000,000    
Price Per Share Issued, Compensation   $ 0.007   $ 0.007   $ 0.0012785 $ 0.0095  
Increase (Decrease) Deferred Compensation           $ 35,800    
Line of Credit Assumed 36,000              
Due To Related Parties, Current               44,535
Stock Issued During Period Compensation, Value   105,000 38,000 143,000         
Compensation Expense       $ 0        
XML 58 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Sep. 30, 2011
Accounting Policies [Abstract]  
Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.
Revenue Recognition

Revenue Recognition

 

Revenue includes provision of services. The Company recognizes revenue from provision of services at the time evidence of an arrangement exists, fees are contractually fixed or determinable, collection is reasonably assured through historical collection results and regular credit evaluations, and there are no uncertainties regarding customer acceptance.
Accounts Receivable and Allowance for Uncollectible Accounts

Accounts Receivable and Allowance for Uncollectible Accounts

 

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged off against the allowance when it is probable the receivable will not be recovered. 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2011, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.
Income Taxes

Income Taxes

 

Deferred income taxes are provided to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company adopted the provisions of ASC Topic 740, Accounting For Uncertainty In Income Taxes-An Interpretation of ASC Topic 740 ("ASC Topic 740"). ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2011, the Company did not record any liabilities for uncertain tax positions.
Share-Based Compensation

Share-Based Compensation

 

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.  The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted.
Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

 

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  
Concentration of Credit Risk

Concentration of Credit Risk

 

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt.  The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

 

The Company adopted ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

 

The three-level hierarchy for fair value measurements is defined as follows:

 

•Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
•Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
•   Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

 

The following table summarizes fair value measurements by level at September 31, 2011 and 2010 for assets measured at fair value on a recurring basis:

 

at September 30, 2011               
   Level 1  Level 2  Level 3  Total  
Proprietary Technology             1,200,106   1,200,106  
Total Proprietary Technology             1,200,106   1,200,106  
                      
at September 30, 2010                     
    Level 1    Level 2    Level 3   Total  
Proprietary Technology                     
Total Proprietary Technology             —     —    
Reclassifications

Reclassifications

 

Certain prior period amounts have been reclassified to conform to current year presentations.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

  

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.
XML 59 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 9 - STOCK-BASED COMPENSATION
 12 Months Ended
Sep. 30, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
NOTE 9 - STOCK-BASED COMPENSATION

NOTE 9 – STOCK-BASED COMPENSATION

 

Options

 

The Prior board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminated in accordance with the plan provisions on December 1, 2010. The Current Board of Directors did not extend the Stock Option Plan, allowing it to terminate.

 

Under the 2000 Stock Option Plan, the purchase price must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option was granted (if the option is a nonqualified grant), or such higher price as may be determined by the Board of Directors at the time of grant. If however, an incentive stock option was granted to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all our classes of stock, the purchase price of the shares of common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option was granted. As the price of the Company’s common stock was quoted on the OTC Bulletin Board, the fair market value of the common stock underlying options granted under the 2000 Stock Option Plan was the last closing sale price of the common stock on the day the options were granted. If there was no market price for the common stock, then our Board of Directors may, after taking all relevant facts into consideration, determined the fair market value of our common stock.

 

 According to Section 10. Of the agreement captioned “Exercise of Options Upon Termination”

             “(a)   Subject to Section 10(c), upon the termination of a Grantee’s relationship with the Company and its Subsidiaries, the period during which such Grantee may exercise any outstanding exercisable installments of his Options that were exercisable at the date of termination of his relationship with the Company shall not exceed (i) if such termination is due to death or permanent and total disability, one year from the date of such termination, and (ii) in all other cases, three months (six months for Nonemployee Directors) from the date of such termination, provided, however, that in no event shall the period extend beyond the expiration of the Option term. Notwithstanding the foregoing, all Options shall immediately terminate upon a termination of a Grantee’s employment if the Committee determines, in its sole discretion, that such termination is for Cause.

             (b)   In no event shall any Option be exercisable for more than the maximum number of shares that the Grantee was entitled to purchase at the date of termination of the relationship with the Company and its Subsidiaries.

             (c)   The Committee may, in its discretion, extend the period of exercisability set forth in clauses (i) and (ii) in paragraph (a) above; provided, however, that such period may not be extended for Options granted to Nonemployee Directors or for ISOs.”

 

Accordingly, upon termination of employment with the Company, whether through dismissal or resignation, the options granted to former management expired. All remaining options expired three months after the resignation of Mr. Grollman in 2010. Additionally, current management did not extend the options of any prior management.

 

A summary of Options activity for the year ended September 30, 2011 and 2010 is presented below:

 

     Outstanding Options
    

Shares

Available for

Grant

 

Number of

Shares Granted

 

Weighted

Average

Exercise Price

 

Weighted Average

Remaining

Contractual Life

(years)

 

Aggregate

Intrinsic Value

 October 1, 2008    7,000,000    5,271,756    0.43    4.75   $—   
 Grants         40,000   $0.15         —   
 Forfeitures         —                —   
 September 30, 2009    —      5,311,756   $0.43    3.75    —   
 Grants         —      —             
 Forfeitures         (5,311,756)-   .64-           
 September 30, 2011    7,000,000    —     $—      —      —   

 

The Company values all warrants using the Black-Scholes option-pricing model.  Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company’s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.  The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.  No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.

 

Warrants

 

During the year ended September 30, 2011, no awards were granted, no share purchase warrants were exercised, and no warrants were forfeited.

 

Summary of warrant activity for the year ended September 30, 2011 and 2010 is presented below:

 

   Number of
Shares Granted		  Weighted
Average
Exercise Price		  Weighted Average
Remaining
Contractual Life
(years)		  Aggregate
Intrinsic Value
 October 1, 2009    2,308,497   $.10   $58   $—   
 Grants    —      —             
 Expired    —      —             
 September 30, 2010    2,308,497   $0.10    .38    —   
 Grants    —      —             
 Expired    (2,308,497)   —             
 September 30, 2011    —     $—     $—     $—   

 

The Company values all warrants using the Black-Scholes option-pricing model.  Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company’s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.  The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.  No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.

 

Stock Option Plan

 

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminates in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan therefore it is terminated.
ZIP 60 0000721748-13-000671-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721748-13-000671-xbrl.zip M4$L#!!0````(``9D2D-1XH\55[```#H;"``1`!P`;G-C="TR,#$Q,#DS,"YX M;6Q55`D``XO65E*+UE92=7@+``$$)0X```0Y`0``[%UMDZ)*EOZ^$?L?``ULO\^CV9@(*B`H)*M3=N M5*N0>9[SG),G3[Z0_/&WMZF!7K#MZ);YY8*]9"X0-E5+T\VG+Q<3N2+(;4FZ M0'_[^N__AN"_/_ZC4D%='1O:->I8:D4R'ZW/J*],\37ZADUL*ZYE?T8_%6-. M?K&ZNH%MU+:F,P.[&"YXDJY1];*NH$HE0;4_L:E9]F0D+:I]=MW9]=75Z^OK MI6F]**^6_\KK$)!;B*.W<6`I@WQO_/*_['VX-MZ-?D+P+N3>?ZS=&_7(1T>JU> M6O;3%<*A7==%S%5/%%4,K0S5]QY=A6JW5%KP:WKMU)A`[=J@>W:GCE/@>KET_6 MRQ5NL(/R+J@M?/U#"D ME56"`I=OCG;A7R;XOEPX.HD/%^@JJ,IK(ZIENOC-1;KVY:)K6U.H@*G`_PSK M6J2R"M.J+.4OBF'3U=WWQ:^+WW6-7'G4(2!1E#A"6\!`6_I^\15:*\MP',_P M?URM%EZ*NXJ5YTN;`>66MHX"VH[MDC#S=:E.4-/RVEHQ"()!(5_OI7@M4B3X M/0(@^-&G=#//@C-X]*S?JG#UDG'K12;WZU*!A0C_2@$D\7_Z@>!/Z.:FEBF[ MEOKK!YX^8/MH]"V]#3]-<4COQ24-P+S-#%W570\KTG2XTTL#?(6N25>&2?FV MH3B@,U5->-.=BZ_!+6LZ_W$56WT8VE4\MIQLSA_4YD.(;]BVL?9[F3U.[0]N M^7)V-R&25OJ-0DABRDX24R1)7A(#`I9)3#D)"R\1M M\9]SP$U&W98)7YW3B]VER(*9YMEI3LEIEF$ZL$R1?1D(.%O_-*W?.EPF<[;^ MJ5F_V!0MFNR?K7]RUB]T%.,GZ,UEXKC6"WS<29[M;G#TB9[(F*.9(65<[38. M/N8XN\X)N$YY1AMG=SEZ;W.4<<;9[L>W^S%&&&>[']WN1QE;G.U^?+L?>U0A M:)KN`HF*,51T33+;RDQW%>.W\H>M')Q'&VE'&V>7.F&7*L\HY.Q&)^9&1QZ= MG/WA=/WA&*.6LS^3\5DX1K_QY M7)-PA]S9B4[4B4JY_>_L1"?E1.49#I\=Y^B.<^0!\-D#3LD#CC'D/7O`"7G` M40:Y9P\X)0\XTK"VS,_LG-[(+YIOE8S;XZ0DY27I$+WV:LSN*KI-S^20S-G< M=7KX!1O5CQ&X%ZK=O"\^WH()[;'G#J:]`H0F0)X/SIV3+2%@D`?+523MK&>&YD*EO'E!5N!I--.$S7^$: MY>:9JI,NT?3U+I3G1H7\[R7TC5+F4Q&>?772\=PX0$)?3FY#P;5Q@-%EXT,= M:Q6H13LC3TXR+!>W463WC>*04XUE9\Q=@536^[A(AP8EC.WL7/S M#E]FEJ,8WVQK/G.@"F-.SLJ-YRDZP$Y`Z6\V^W)VLM_,R0YPNMK6;3]GA_L= M'.[$=Q8EV.-X]M/?S4]/>1LEI.A5)O#31OE2Z95X0-5)S7,CE($7'<[4"EX2\[*$ M#S-K&ZAS0IE2V!G9LCLC6^P$#N?E#^4EB8LF0(6T6$^&UWW0S^7.97QUTK58 M7^]"6RS(X"I,_4]U[KC6],^V/GO&MCS5W>=R#UXTK%_W\)-BB!2O-\(@;\.Y M7E/QB+,L/OM%AYNPA7]@35?+_I3O9NM&U/O@EJ4O?N*X<]L]UIM,"/M%6[A: MX`M6%?QB)OLTQG;KBZ^?11._95 M#8\ZYU9@.XJW[SEK*[]EXR-D^=>(LT7(PM>(.3)O6N[E3Z:X9WB7)#7+3E*S M:)(\%R_;>C&GJ3IK_OLN!RU#V=`7_TB8&/:OUT M"X9)9"V>OY@_./B?AUI36[6WK!CXP^XNBE'RN%8N?%&PZL_3!\_ICI]U6QLJMOL^ M5-XM^P,:.DC?8C4]KK4/O2ISWBIXD-F;@]BU66&X\+R<8\T_[MS-BH+'M6XS M],!24=:%WIXK[=1TH$#!BQPE7RYC\UXNFYNZQ]!$[JS1,L4*.8'B*S2C&LH++@4E0$J6U#_?(SI$S.1A%^RZ,W998!^(8;Y&CZ"]ACG5M2MC^?DA,Q MK)@YGA0EL+$MO5E,%G+1-KDN/,(:3BU3=BWUE]>;#N8NR3/(F5.;,?"+Z8%0>7]LL43G=\\A M@%*_"\2PM7H5^M=ZQ/&VX,@?]=#&CQ@\74L%O,;0_]+"#N87VHKS'`R;3^3+86%=_&0D_0-#A"E@@]3D4%P/':_.\G)ZR-UIA:8E88- M\KHZ5(-[^@LD`-`_FT_Z@X&]$GV<76..))TAG;>+V1]4QNC@UVF9ZIX67M5W MM>(L@O?2*;LF+,N2*8UH=)#"!+(R@M?(A.P7)/=#UY/-_'@L0WIAYZ9IEJ-KX98 M"E>95ES&YI*B"4E\$TAH MU.K,H4G(T8JM)M]H,6&_SD=X,O::S4:-32-\:^LOHG=,)B]'F%G[T@3>5#P_ M.\3F#[I`MGP/A&O[\U9EFWRSE9*W.`!%*I*IR>:E2'2"@+XS,G-/'DB6.8-=8I9%X`7O@2#0QP-6JM5JQ.`XP^9Z>E=SFXRMLO9Z:O1%V%=W$ MFJC8)O1>#N1[\^F<#G`Z^)'L_+25/EN&AFU'_.=<=]\SL\6V&K5&(Y08K->=37HB,F`D4&=K?.[2O2XR MY.0[E@X3M;%DDEO'DKS6L`\G>37`)9&\;;15E!=L6_:.Z2"K#:[1*`#6JHND MA+4ZD,JYQ9X:K%7G2@EK=;Q;E&]MZ/B2I']1U17E? M)G1K27'.?K8'=IJU[+ M`L)[UWS/\A] M8^4-.QWXX+BZ6@AY>^`I5K6]C7%0S8YDFUR`'H#IF*W)Z\NPWQ3=#"H)-@?3 MYWS6;UVQ7"[LLW6.#4U9Y`SQ\`RD-VN59SGV8`STL9MWQ\#7ZUPHGXA(2"L^ M/7U\@VGR>4EO+J7G,JUVGF(U*^`42>Z`LD?@?ZH"'$EBV"YZT"LZ+:F[]4J.ZP_O3L8DUX`3:?<']. MHL[@<6V"(".'R6=-4@')6XL=G&^=8\E/BR0S0&DWRP70=^X=2R([Y7:Y/&6G MW3"7J^R46^:2KI;MG(7+Y!`9CHNAF^>BCIP/MC2;YY(WLERPI=I!=VAL:;;1 M)0^Q.[$)VO_-O=.VG;&U8=\4K>1!<;`6?MN"8&KB&[95W<$0[0C.P6QC@K!M M4+ASP^#NS?5'UR'[CC.VU0IOL"Y`E].AZ\2(Z/@A/5+8MA7S"1.Y=[K[+)GT MP,>Y+RMN16M/#]]TG%=SM>O(C'8OM;N*;M-%Y""CR9^!F/6:YAZJ;T!\"BQD MCQ(5KE;C/B(ER::U=IZ:.3W;F^!7C3GSY--PC#:PU3E+; M[3$M)D]JGJH:K52Q;.7HFL+T"">$7.\IWGZ2.2Z1##()5N2=O,^<[KVPE.T M5^M$OH:K_]9?>]& M1AML.>\_"80"5$C?"-A:@VWEI\.&1M353<54([U)+L,&KL7PS,XF'",]5]P9 MGBB,O*\B.VQ2#'H*\@\YNN-%,PL::3GC#R#HS-([+?17]\O_CKD_N9 MU/)`/O0'8Q&QJ((ZHMP>24/R[DXTZ**;B2SU15DF-UX]!$6N9O337]BJ_R# MT7>I_XU*;@M#:2STT'B`AL(]Z@Y&B%0S'`VZP(S_DE-Q]%-JBS(:B?^82".Q M0^\>B4-A)'Y"PJ0CC>&??@=UI9Y(B_]C(HS&X@B$DY^%?G\"U4"!P6@9`B+00IAB3<`.;X=#2;? M;M'?)WTQJ+%)D$C?^E!0[';%]ECZ*8)/M3VQ;)7X- MVO2%N<2M.I,VT-N#AA=N@C[O(O%44H,LQENO0P0,J(SVY,>D)Q`;4!2>1612 MJ2S^%$A0' M]1P(!W!=+GF#Z(MW8/J^\(T:!Z*I''(",*+4[TYD8O=%@*7"_2"+0@'V9D1^ M($R1X$8#G4\1./-H!"4AX'4@I-&PV[N'H(J(]+7&0C`(/7D06`&DW]U*[5MJ MR[`%*1)P%:]1^0:B4"8TF/3'H/;[1P$.:`?DNWPXFO0Z"+,.COB=!-9,AT$[: M\?U@,@+^?XKRF/I/$%*`\*#S"S6K'@EOA9\$O-B/-E&!1L!%!*_1/HFY M1"M>#$X#N.";O$`Q$B&^C6CQ+6*!&7DB#T7:K=_'*H9`G;'@Q5T_1LKC0?N[ M5[,D+W*4"8#N@2-[(6.1%JPU#FHFVAV/%PWE!'*V5'^@@F<;.?J_`!![@4S+ M>58T^.Q_N$!4_I<+%;)FLOC@8W_5-??Y&O&UQNSM,_*_U<"@]9G[&?)IP[*O MT8.AJ+\NT%6A[6J%C(*I'S_CX`W_"%$8PJF*B'Y;M/BE/B[HNT0!^5-X16R=WM^"O&Y*D/I-M MI2#`=9"I3#%R+=17O"4B)*LZV$9_U%6XW\,"%VB-PLS6#8K"RP&YW=6V#6NN M(?]U,JACJ:YE(]EZ=%\5&T<%>&L&,7`5%<9L-E1,?K06\W(4B/6(1`V;2'YW M7#QU/B$8SEVB_R*__3>A2$&OSY9AO"/KU80:G/F#HVNZ8@-%M!PA'9N$.\KW M*Q!O(Q<&@O1Q`J28GE2;;#TV"#P0J!I8(1N0T351)]``%+T*=8\4N9PZ^,C.`7Q*%\!!RI0GZE&&G[!AC6C&H(^ M#I[J,&0EJH!Q0"DP,R8OO`>W59]-:'Q/[[0<7%)A)(P=^@UJMA7=H<\H^:^H M`(,__G][;]K<-I(D#']_(I[_4-'KCK7CI62>.NR=B9!EN5>SMJ2UU-//?MH` MB:*(,0BP<4A6__HW,ZL**/!$D00!4M`"3W#6QS$S)D3PC,!-O%E0]R;$"`, M<0CN\D$4^!X<#C$(4%S`!_ZC1]7=@)@01DD7,`P!87,7A@("GJ][[*$6_ MJDV_DX>5]:5#)P%"C,;E.1E;#A%FPGU$-U^@4XM]=<8.`J@N:UZ2IY#?V>SF M_I)]M?I`%%^_7@)Y@N22K!'6@FM'&L$9B1GU7P@$@0.!F&.F_T7/9L9D)#:) M5P&2\(G'@`N2A[\GP/%UQOFFU6PVFLTFF[AQR-J_(K(DB0/!WX.P$3+%DF@$ MLA\*+N=Q!P8*LM!XL+=9:$;6$VRZY0@F&4[X`.2&2(\`-JLZHL/Y%8-'@>6% MUH`^Q!>TOPF.$0#B^1'K<^#,>*P"6[!E?-@2%P0(G?AJ>N_W6[&'(W7C/PFV MWCH79ZJA'2K8`$ND@M"D*+>`$L:.1ZH"$HK'G[6G`(F/L&?/?O"#V)^G'YI` MW*X@S>@(U(776(ILH'.BB%#*[&.0L$`E(7RG+.!6(Y50N"42+-QE^',:_,8T MH+CK-A(Q4I$5B=WT%I:$F1^`BJ4#ZZ@6OO"XC\YJBSS"4O#"A`J)[>9'X&&3 MF'9'=,!D7-4I3##=^ICLQ03;KR5OPQ?RD'RR7!1K['[$>21/[?3IH:5JFRK@ MEA(P@1TT(4"V+1$L^!=RD>$0A)H8$K9.B&H_CK!63#@',8V9V7$'ZL7_ MC&$RT+C4`5:8`6ITI*^=IDVBD@0'(46`U`A-3*8N?',W_)QBFDDLK;Q>O/3# M*/R->T!'[C+W_=P+B'GN>SCBDXC.\\[X^#QDY5UJ)AQB#BXI+@%4+-BI%XQ( M1#>5W16D,M0>/Z%VY!=W]__?G4X=R`D M&#@PC831#L4-(O(UK.=,Z=!`7S0I;!3R!#SQSR#9=6$*O!3>FJ""^RC(PT63 M:X!&1B)\?_=([Z%"T2%[JS&YWRXN[C2N]0X(DZRU4.>:0--CZX=0-K#VY)B& MP5,!VE4\EHGAQ/TE-WKKO$O1*!0SL!2)F8XI3@!7+%4S'"?#G]XZTV_;"?&2 M`4>:Y:.2I?.'83\\4C=]8-M.&#$KX86V4A;G8ASMVDG<=YUPQ.T&C0KPK%B. MLF4]'B4GFUY-1(9F9=C"4";=@*XP0R0%/+1@8C`M&1Z0;G.QX?#]A+B\D/A@ M79$YD^P%2'QB#-@X!AH9 M\``S=`E[T[.&,1B?B_<>L>9XH'*J39&$EX/&/Q(U!RB4W1>T":,8OH>I8S?" M"_P8K&[;`;(*A#$'P\+J$U#VW"$,VEAZT$)-A0/U"`P9-(PM5'I2JJ#)WY** M'BK3V,/]1:1A-V[\C%06RPW?);H\1PT3S7\T^E"EM]C0<@)%>I;4!$!M(U5` M*$H9FU=&O9G+F=G8F8K*I`[(I,QEU0%*'3QLI)8@F(?0S3C,(%GKE6"X%\T^F=-$[:YPWI<]IS!/1"[ M'EKHG`S)XP@2V(_[$1J)<;3(@!6X3JVQ``+)82C[4?.R0D2'&A6\<37!4#F M96WUTFM*$(%0'X*9!3);(Y*&-A4YJYQ^+"1SLH!Y\/&?(#$BYPF7!72,_CXT M/PE[G,UQ`6NVIS+:_3X1K4;0Z$,6/H*`OM5]X_A.QH.\"`WJ M(H#>4/[%N9:9B9B[A[.`]S"6%UTDC/+.=X%?\+`:`J^;<67<__[M&][&8FS* M]6\WUU^N+R]DF`!>5^,]*(C&N]NO&#]P4$)1R0HI[$(B_7E,1.FV0F6E4[)5 M28@.HH1J,J-*ND%-6WEDAK[K^L_AAT.YEOA=6#57&2OC(K4R*D%G0SBN'UBK M/8G8@X,>MAO^S+[[P,,;XH,&*`*!,U33UVZ`V@U0NP%J-\#R.;[+F^OO@C[( MZ#F(!4EM.Q0*72@)(.0!W;Z3YBSKUD8#F'CT0I$15E`LX_W6H*]HQ*RY]2ODL>0_+GS1+8-R7[4;TC)0JL= M.)/$+'POM%+YWGZO_C[N8\E>M(J0L%QWF:EBJ24+)I^@JR^O&9WL[7"`HB-] M#`\!$^)$O;_FM0/)XO`L+(VF'9_:,+/UA M[*83.N'"M?5AD(2C*R3(B>DFVN\3H/($H3N'4V2'(_%!YURZ/Z>7ES'20:X! MFA.'2P)SN`!H_%0!9JN)Q>$F=X,42!(=RG`'F-&.4.>P1&-U$^@'1<@=N!U_WQ56G1Z7P<<6V]1(F5KE&E1,+(+5CGC"[ M*83B,\`]!]*O1FX>T(LPT!0C(R4U1'Y$'C.:_X5106#A1*'Q!1=^23`HW)CZ M4@8C.)<8FC8$*?$("`AEQ$)"ML^X6"Y;WH_DJ'WY?'T)7Z#*$DK-V0;3)43V%$\0X#?M'L4H[+DF M(5HD,6J4N-\K406%*:8<@[%Q2<(LE:G'N&T!'Z)&E##<2'39$U$\`R$=AW&$ M%C/&=Y'Q*ZPH\76?1\]XRZ/>18:ZQ"A7!.4$FCP21C`($J&\2L->L&:@3NZ) M^"TQ1AH]\7(JNGC0(BHR<0%!9KXK9^QBS&RFRZ(A!,@!1_1@;;U0.H[ MPNT@L&']I*$$^H[9/Y6ZK4M[>C]$9SK9^8+WI]>DA&`['N!ID;N!X$K<2""E M@J*#T>=2/8-]_>N`XH9U%FK9/KF69,"T,,Z$*_/^DCWX$U`_3KO-1A8N1U/W M%<5\$;J]NDW!`$7]&!]=X-^@8DXPBE^Y$#*33*V=)I'>K4[WXYQ'X=-WQ]DQ MR"9$?4!0,8N>_:,PXA,DR\"W!B-!#<(Z):T);Q?`(!1NG,18(PHAUDJ7=Z1J M"36-1G/$=8@P_GAR[M0+I`@&FA.`%)B7Q"JED'NA"CU3,R(ZJ\I[D]K`CH?A MGQ%YLG'.,5Z^N,X/[J*^1L'`42.-UTRF)\T&A%<(NT[%VIF$P8I!Y6YH\9-X M#>/&:CN4S0'(`J(7HA!&?!3[E20>-!!X2G!!M(07? M$Y&,J+^A(X^.G;HY5DNDM?6:OZJU`FA]+L`59U$HBZBWDY&1AI!F[8-401CC MG_+Z4N@#R".4]2[I0*JRRI^71K-GB$%PSW19H8)^;+THFT#R/*!)[6X22%73 M$PB*5%?0[[IMT%]0+Q6:/EUQZMP;B6L1H>ZWM*0:B4=4N`C!0#V;;F8# M0?U`BERM09X#?6Q<_B?,(3RZ'XQ\RN@AM_/1)'"P\@IP`)NC>D82(3ZI*H M#]N1.@--0+2(7X7$>#3WG;Q=)7\G#&;)2X3,D"F\BL0$>TR6GO79[CG_4!M+ MCKG,L:)$,4P.MLC$+.11.!Q=4V(L:J8TYMDQ)!RJ>YX MLG23V0O-'\*>$Q+JXYU!Y!P)$GN2D6)BE]6`"H:YOIC]WK)+#(;#6RVEDHNZ M<.R[$_[8[Y5=++\16>XK0U)3?G[AO`[XHPA3HV!,E3:ON==!$7*B6#/?]$A2 M,/-%``**"H'A`#"LG`&P!(J40&ZA;B46`HAJ&==B(:0C6;'DWX_OC]F08QZF MJ]QUPHF''.HC&RV*=D4+`-T1@8.VH$S@0E,@N3"A:WSE]J>4P`4QB$D0.JF9 M(A;/^4OZ49+<6SSLTO6N=FH^/I,M(0`2\Y.,-6?D^Z23HL86X)OJ6B#@8V`$ M>\Y2L><7.:%(MGQ)T'.=Z-U[[K!\T`W?=,*$$-*/'&W)R8YG6$ M_8ZGII'>>R8O3$2E4;KT2CZ4J9KI!RKR1O-#B1(*_6BN$,!XA!0FT#XPGEA[ M=YS>OJ*:!61LOE3R*/U,+!,G4!$V(+4TR)/K,/$.1J.0)$\0K=0^HZ\ MF@!;7QYZF^F3B6!8IBYLI=\5K"$]J"GDFBU8HE]@![[+U`%XUI[KJ=0.[3=A M<*<'U`O&<(J0X"'4X4;02VDT1R MI:0I5B5*?U"Y#_0M_'0PSHRJ=0"S%_XS4J+[/'%2")<M790F M\)/D<8#$34HW.)ZXE0/YB$Y-+9]976I(\:[0Q!X5B0C*AT/3&;I/I&K2J*4 MIOY-`OC=C>$39$ZLB`N^X$JB[6 MZB$`^GL!>C.T90.#/1'KCNP$C.EA>AJ,\.YS^QVM%ZD(;VX(3>I^43MDCE#;+5(1)`\) M/Z[X6E^@0NK[*,@B^2`WB58;1EP2&D3;D@9*.,2CX@4HZ6RRZ$#&^4 MOBU5D"&44!:4NR%^'R^F+95Y4!88LGI!^0RCW,W0S,]R`<$+R;(/AU<=@5HN MOQ)%+TL%P78"/HC:\58YQU7RKYEO)3\VWLC_5X5N;.IE3?S*..M<9W&YB5Q%Y6Z'? M-7QD^OU$V]CSO'36T\G/>3W?_UZ7[]"`LO6),0R%K]EG3Y M:36;OXIS**X(EU=%^B4G8Q`KE>=;1"WCAZZ]C%WH.)$-BO#IN:499RZ6XY(XDC"&L>%:W`HAIP6@RU)OEQD@O# M'YD\=&H&RGG!>;`#D6/K=]%[`65[+Z#L%`/E1I`]8+6+'1T)``@`P"(?GGTD M.[8%C_VW[6:WT>Z<-=J]WKLL<-(8\9W6FNHA:4VU,A3@5V-L*]$T M!8K+ARN9Y?00TV/DXKC;AZ-&0H61T&JTF\U&JWE231P8`+UC_O+'R(GX&AH= M\466DYUL@BZ3#5K[@)A.6"]HJPM:?7IWN9YJ'=`\"D"E-_?@J+5>T-()]\@& M72@0B_-Z-`]Z[^L%57U!>WXZ3[JPA?3'_W`NM)BX"AY/1_K$^^N&M8.UGGCZWWZ M5"V94`2[ZV7-97,'+&=I4W$<+W)?9DO<"]*QTC)ISGAB#2)5KW=>B;RT&)NJ M]]S0&[L")%2:;HBU2>:V/KO(;\=IMT<=]OHM&XF63>3K)M)ULTD M-VPFF?+`+#>;YG6RWZ'6OY'8XTO"''?,_NJ&DG5#R>TTE$Q/P$H:GST42>/! M7H-)G3LO8K;3;!G[.EYX-OZC=7LY%I=.D+1K'/5@_RZ7FN@UEW8:R;D.Y"Z9:MZ&LVU#6;2@/L0UEJ@DL$NK3 MPI_:VE$/2+T-X2VY$T&3N*8&2UATO5Q/E#MRD=IG= M*^FG[GBI_=0=+^5/W?$R_:E,@ZY20:@[7J8@U!TOIW[JCI?I3R6ZW=0=+Y,? MJ^YXF0!2>HO%NN-E^E-WO!0_= M[AS*NN-EW?'2I/K[="A`1?L<&@QRN,T>:R0\UATOU^8O= MUATO]X=:ZP4=+D/KHK: M25$OJ'(+>D5ZV.RQK#M>[G47QQI7>ZOSB('KCI8W04%95YX]M\J'A-+S88/R#37H],ZF+(.IBQDLCTRT>I@RAU"60=3UL&4=3#E8<81UDAX MK(,I=WY#40=3U@NJ@RDKH@!4>G,/CEKK!1WR-6$=3%D3\P$O:,]/9QU,60=3 MOOJ-J(,I*[(1=3#E/K@J:B=%O:#*+>@5Z6%U,.6!!0C6N-I;G:<.IBPCF'*K MD48S'6:M*+W^\__\)L/G#&EAMB MS-'?V[TF_&CM,^<-/@W!M2?;N_&OV)GMJS/`YHD7CP&7M?'6!*;5;C9;S9,4 MFE43;1&P_Y5C_&^R8]=4:)$4_\XW\NGM%/A+'[N8#J+8&U9F)M@%8 MXH",$,?^%O=\B#@K?P"+QM`[PJW#YV0DG?FBYOX$B-PFO5:EB M^!CA<+P8&$\2?ODY:0I95B0NCM+'7VYN'ZY8[XA]OKZ_O+UYN+[Y_>HSN[V[ M^G[Q<'U[L$\^MI+TA^PS%;KV@Y#UN>MP[(0I MFTFS9TM&ZXJ@VSXV:TVZMF8;9&/0KIWNO'@^#K&U:)A&X:J7?KN[3S^D7M-/ MV)Q3O4#]H9$"L&>E(V!(!@.@DDZ<@8@6OE'CW`\<[%XW=`8-]O7K)?:U%L'L M:;-I+"4M>H0"'#26#\;#"WO3:C8;(*ID;Q-LSID8"DFO$XD[?P@SP+\>=L.6 M[4%'V$GTS]A!D`:`$^#%!%6VH;>&(GH'NW&F(I M%]\GN7J"XMX?1L\8,4V=<4+1*5M&W<^@6LY<7@/=K`CY*>CL/, MW/(?#QA<]24RO<2&PG3TUKT]['!$/GI-E`@IEJ:JQE M3\C.0^P:L.H$HLMMP)0H0D"_^O`8"4@F=&*B2AIQSP_!9QY9CBNWW`?6,95] M1%D4XKG21=U>Y:)64`)XIJL54W2/>]N?X_"R'G9A\:Z(L58. MM1RAS#DR,"H-,6F$`7N/W\R)I"C"K;E!'$CB$KE9R,#+9\^V'Z']9M6HGQN_-I=M&\+RM#@*D,:SJY(5\L8933;=*Z^2\T3K=1?9_U19^WFLT3Q?7=ZF\ M1^EUL8U`I#A'A^W#"28PQ`:'E6@'*2P%DY^PC>[(&251%-@ADEK&5NR'G M)V>-DV[O0,AKNZLIVTTPA\Q>5/A(K_E1418?3US_A<^ZM:+<.11MJG;<:G6Z5I-;&G.E:A9,O]!.4B_)NN]'J+':L M[Q?];'4QY3&=+U-1^'[$4]=3Q,Y^39,4`BNJFAK=.P?.WST0BMKJ8BK!D.Y' M5L!'OFN#`L1L/D9?YC2%M=J_5FP?6JW&2?M@Q-PV%U,>F]I/2FI3%M2!4-)6 M%U,)]O0[Z$@#S)Q>*O;LF+,;_TF$NF-H>R/]#EX1B4:.!U0YM&(WPM?/WW>: M[RM83[!UVCL@@MSN:LKC;3=(?'27''M5L_G6C##:+T)Z>W9B2$7O*L;.%@>A M$G'UN<=!O\?DR('O`4@A7K\,N14!]UNX\H.-8*GC4;>*U;>MD\5NE/RX*^), M;2&:.QM\FB\"*#Q+)7L8*-R>V>-T[.S[:][ MET&YE[ZH&A9:;N6N>5^%SZC=`YU]<61W!7G67)!D44'OL:HQ`Z^"F#HGC>Y9 ME2[IMAZ*4C&$M\X;)ZUMG=ZR%]-I-ROF+&\+M=[,+=RLXL5EL7\*F31KMJ?,IT#9U>H]4N*CJW$F[,M8M07OKC ML1.)"`*,:!&$^,B]`=XO4.'<9^")V6L&"YYEP"AC-R)09-%25<97%3&593+F M5_2E@KX6!JV[KO\LO1Q[6\OSUM-:.9YB]<1FKP&88^2I$@'5/B!M:&%M9D`P MS6VIXNZB>.KO6`O<9I?6Q,$N)U^`VZ!:_/;WRR_O$*=?@/$XMG7,X`,L%&RQ M<,+Q2M7Y"U[3JL_R`*O%`FZ=8)R6_DGR>K^GE;80BF]I,66D@&<_^$&5@B08 M0PG&DZ.!?\S^X*18865;GSGC2>`_<>;'`;P7CM@0]E0L"BL^,RL`TA!S['G1 MUM\]FXN2M=J::*>QQC/B`C<'#T@_]-TX$BCVGST>8-#.DT\;(\\5"^,^G#[U M%OS3YQ+'W(9MGO@>F\3!8&2%O"$'#N,Q%S6B`R?\@63A^=Z1C`)BV@MV,EV# M8`A]YF(M74M6F+9BK%:=?1VV"J#F[@N%'`$\^*0_$-6H!_2XY<&X\-`3?/#" MT.L4';.+4-PE`*T3_<$+2#+T=A^0*`L1$QRP[$?`7"36(QE.3,6`G0`#FK#" MMQ.]R&'@%R=5RY@%2+84(2.YJLK/L%@`Q0]>CMF-'R'IA9$E*)>6&W`"0N=7 M5A]I=F::!I$QC8M0CYR)/)[BU/D>X>$>MALH`4&XDQ@GQJ>`:S`9("@V&[YQ M.=&.JE[=]X/`!]YZS/X3_GE"^A!;`]P6IAF`)F+!@@,.XP6P59C=H^U56I!Z MJGH>E0W&MP*\T+!$Y6E8EC,F/`$>@%\DA_\)FP>("M$(//)BK.8L<(MO4IEI M^PD_A-%$\Q#26B0ZTIGP'6V[8>KT0!(,'A6H'X(D`2)!QSQ-@K\<$RQ861W[ M(2`/PV]`$W)\&T1%PG;8D!-RCKN]7Y64@2^Y`@R'E\DD62U"H\X.$.*#9SIKS)FL`_Y,]$H0/#+.P]IV[(1=ZF:`&##Q`;CM) M\#B#AHA:_9$(2Q"?,#>U`_,11'038.EK+X2]3X;TXR@YL#-[F&@<(-F`6D7! M?V"<&(XKBNAC/7%7ELX/89E4R/\E5)N6&4[RVR+WRI7-*:8VK9\HD45I(4F8 M:$LI(>)<@H3V@:'`5DV(N&4/"-5GX(5;@8!5M)4@H*1&@6?&15UUCCJ3/A'X MP-7'@E/>1YBH\0@G]P^I3.@Z38-]O1.'$L8:R_KG<,S4$`ZU'A&'T:)#>H3@ ML9NI"-DQQHX)QIV-CB56^4;&9C;P44``!S5H$.&)MSPO!E`R224(Q-FOV*A" MB9H01:"`P;.3:4,^=H[$`'!`@,E]LUY8*Q2:4XI[^`!AX!:0*<&>=*D@EHH+ M04FBD?R#TI^!5HEYNB"O)2:$O&@UVK*E!0((O"D2K2G&\'2(L>F"C5E:?-U[ M.(`C5%*8/Z%18=/$MT(J`(>#W9L@NQ7'F`;P7ECL41<,K3D(@8#OT"[0]D_- M#6\C;Q5_ZT%^@H\"@M\TCYN]=H_V/N3J1;E()NY.49#`BZ"0`B"1[)`%@!KF\1B[D,6\SF_2@)"J;]Z[4:)\VF)+,THI.@F(WJ MI%?.&^>=CI@X&4KT15D2#THJ3)_C*H`P@XCL&S0SIERZS'\2RKB@3D[63G+$ M$CD!FS$!\OE)&A#LWTF3P<)!011PX:HMJ=WBNW(KA'U+O`X#ZT4=U93A42%5 M6F*[BWN:JC`+'YZW*K$"8\@%=>*`BD?`+\D93=J/T/9KS3W"J4*PY:DKVY=\ M7W@_B+$"!^R'%'W?+%#E6/LL_1N^3>0B()`^.!4,!3^ELW(YPE8D(#*^P1Y8 MW&6_88X]?C"V;%2(GY'/A>3/<'U@VN`+`&E&K;0A`]091)[]2+R1T@R)W4F*0S(%_Q!Y7 M2H?B\&(5Q%I4F@LNPLM8=*2&^),7P78)#/GIO'97SJ<8;52M8Q*L'<@!2'F. MO_AS:H?^";2!'!FV8KK11?.T(9LW:0"3`+3!<\&S)3MR"MIMJ M@*=S$9/Q5V46D%"Q5!1@^"EM0)G0;UJ=1@?6X'LZ5:9EXP#,F1,D]48\0SHE M:Z/E)&JQ*WD(FZT@Z@6HA%4EB$0>%<;$PF1)!/F7.*QRDW77@A"RT0R26RUD MZF]$GNV>&XLX"OJV=3_WT=`:.^[+AQR!H[?B9%V`GN(B$T82/)&>-,$K+.Q^ M%$1')![Q5`DZ.<%T4K&UEA#6(BLSY9S`58-`--=B8/3#>D@`O@F=FDSS]PA%A3@&XF3.C+I9G.&F MB:^#)B8$2@:+[=7F&J^]TQ.4G$'D,Z%3F)=]Y1J;N=$ MF&I"JXV`7D!;`AQREJ&1_90-D\(N=EX M7ZD2G`K;E&9#[3O-LEPD"."(OQ$ISW25]1Z/!=*[,G,)C5-#[35 MGF'A<5YZCMNR/^.VSC&;>X930+9^CB]=4M[OP.QJL#\N,@=+'.3,D25(C(^M MF"3=19QMWK&==F>L/K*"[VWQV#+]R&H$,7-@DS-*(*3G%*1NJ[GDG,+)6G@8 M4^I.&_)NVM%VND-NVJ;;:.1K"B:Y5S;9)Z$MW(\XCRX\._5.I!"$"0A&375? M73)(Q7(-Z@9ZI>1-U`WT#G)!=0.]7*D$:P;,'6QJ1=U`KVZ@5]=3V%NL5J3D M0MU`KWQ2.&2LU@WTZ@9Z6SU?=4V3:36P;J!W<%RSECO[@<$J>XKJ!GJ'N:"Z M@5[=0*]NH#<'2:^+#1S<@BK0#*9NH'>@JRG;33"'S.H&>@>PF+J!7BW/]H/G MU`WT#G$Q%="9Z@9Z.UA-W4!OYRBO&^A5C^G4#?0.8XC`B6.AYUJUBM&^B]W@C4 MNH'>-C!8-]"K&^CM0\YT[F-6-]!;A9BZ@5ZUPGOK!GH'LJ"Z@=[4FW4#O>E[ MEKJ!7NTSVM@;7C?0JXEI6XNL&^CM&.%U`[WJL:*Z@=[K6&0E^%/=0&]G:]A1 M`[VT=&,)I1:GJSWBK5MX)^()OEA.\$_LE)2^F*G,>!'>#K'P^1$69&S]PF+/ M$5_\?O_Y%V;S@3.VW!!=B7]OG?::S6:ZTA733$/UF?>C:R^,@A@7J/CM=UCP ME6IPG@M3FSH0_WJ^<=/G._^XE M32\^JT8@:QZA'C"5YJ+-GC//-@!3E5;_5P[RO_?\$=^>SX>^D=M[>A$_0^># MY[C`+X,8"/C]5N!J;@Y7!KE'9R?;P^VEZ"&`A9@_)?$+ETGXPA?9[F4=:IT" M^_R\TUD$=CXH9E)C>BV;R-!C%X-!/(ZI+^&%0!BA_X(: M.%!UYRVLN-UM9D]!<>!.H^8N\`?8JP0A_R[Z+P(SB%X0[?.7UFP?M;NX-/R] MEV7G6@ MG9RT>SL#[41A[00QV%J.M79S[0W5OW](RY>C,#>GM;FJ`PBXDQ2V)?-M"-IR M4EL$VMEN0)NM*5X1T):3VFI=T`@R%0Q\.RR$=[0RIV#9=-.@*1WV2OCB],<+ MX&I+9ELN\+]P?C%>I-O-:O)S=+O%FETR]F8@](XZ*]3+-4"X=*T09OA#-$ZX M#;ZCZ7RK-7W*A8Y%UL*4L;!JLBT!-X6H+0.'_9K#""@-_T'N(Q26&3`<8?;Z9MP+GL*-EW!SQ:>B3G\?A[G MRJ@6RR?);1.D.C@MI97;(%R"N=XTG+EFG@99E?"Z\&QRT'Q/:FMC!&DYYJ$Q M3%LP#5>;K,+JN)7ED*,U\S@G+MDWF[CP[+`/%S%92_=L226G9_-M&3[MW M?IKB)YEZ$7E+7RCZ:T7)O*]IO'8^/^PV,#AE6)VW3C4384U0"USQMO>L==YK MGK:WON(K6R$?D.=O/\Y.RDJPF)E4!M917;WJ&-5W$;C7A0B0UI M-]L][73E`VQ[R]DZO]O&]IL94[_`F`V`WO;F%\; M;'%O"$]<_;3&LLN@LH'E*+LY".?M5D\WPU>"M:65;%]^M#K=DXU6\KL7\('_ MZ.%M`[PH//=1J-ZZ]9(Q>;C#/>JV6QU-G5D#RH(6NG6M=NL+U:^Z-9<2,D%T M&CA#A]L[9'*@EC:[\R_B5T"WY85M>^>VMS#-8M9'V>$F33D>E@.T.?A;YX.; M@#_E>U3J]6XD47.)%U1!L@'`VU>ZU@&8-@&,F:^^Y6G^E-\"/]RENC4W)F@Y M6%M:R=;I??.53)F:\BER>GF#7>[)2;/;.U]H`L^#:TM+V?ZFG)QV]:B.-9:B MTJ-R-B3>&NR=;O;&3$!A`!V`DT*W=4E[=GIVMAH\$67AV?(Z;1=(7.4!S`%2 MH9AK][HG;5TP9L&9L>Y5CDL%46D"6Z$X[9QTSS1E8R%<*^Z6=WW$6^V6!P#M.;``O+)#21LI`K0;&[`MHW,U7QI/';HMA,I]I*&?>3>`*R5 MU*VWW[Y=/WR[NGE@%S>?X<^;A^N;WZYN+J^O[BG(O9^$ MOR^KIK$Y:%-A]P5/^QU5&)D?1N73@9C8BU8/(JD!09-BEWG<%NJ(A'O%GJV0 M69-)X/^$,Q9Q]X6]:1XWF_3`F]-&N]MC0*<3$;/MOJ0KT66'"O%P M]9G=77Q_^!_V\/WBYO[B\N'Z]F8W!S!_R9RUY[CV6*:F"D-JH",'9V!B>2_, M$;D)[3.LJDB5%7%VX.UCWV,4"QQB<4M\)0HL"OZ94/R*/Z0/U9,1[BQ\1H>Q MU3X]ZQVS!_C^GK[`0RMGPC,?>Q/+09_D&(E)]`6*_+1M`H*`YSG@=CS@:2NT MS`M]./F=7N.LV3R>B\`E18$JO6>W'OM'#&RM==X0'$_?+@N0.`9,X&>NXW&: M%]`^`%0Y5!S`X\\PF6>)L&V1[G8Y@B/,/EF>V*+."6XT8GP8`Y8C/*\RSRG) M",<'GT?.8$13>=B"UW["`'!X#=@`@/"FVVWT.KWYR-\;;,\Y(2!MYIR05F^; M)^1TR>F8/A93.RH.Q@`+\=C)25$2%<=O-0G4_=^8"\"CNW!#NMOD<[9X/_9P9QZTO:"R4*)[B0_KEIVW!%H>`RX0].Q$(^9$(?`A MAP\)DJN??!"CAL9N91."M[@W2CJWF^D3B<0^_?B.P0;\P_)B;/O5HK/:F7TQ M!>%"@9!\W?KX[IBE2,*EI,\39,D[#8#;)8;H!'QJUC/:8R`V>,"*`6$6Y3`# MUPXX4@=2C>7Y:"BQGE1O8\_E8<@P\A'O,PEI*-F`9HBO(I8(`EP/Z+=/#D8; MAHILYRU+T.R\;\0`MFA1]*%,3F!4+X]*>H7.7UP4PTL@60#8B:IPMC2C'%Y> MLH`$SIE:0#,%%]/T9N=X86JSJA*E@;8R!5H'Z((!=XI&0$JRO1URD':S<=;I M,#"5Q;4"<+M90"%!9QU=:S5_I<:2]1$J`YATZ892<29VK M3GS7&;R@:07_TIZA1D84''+/`8+FZD2&1/U*6Q/-:M$B>P(80"O#43_Y5H"/ ML,]P>`:1'X09C*69W'G+`A2QB87NXL`*1ZSO>S&=X';O5_QGY(1JL_JX47*+ MN05Z%NX4$H]!+OGNPS+T9W+JBW`T'!1CZ"RA*:LXDGK('%:,5):4](AW8T`J\D8# M1*1%)QTK,I*<`5)SB`I!+7*!043L3:+,SA2$V,FQ7(;"_DY0^.\AG+K``S(+ M69^#D.1T\&RT.%6?6E&31K;Z(RZG);NFM;-PE6]U!>33]<.%KG%@[PA9A4*P M!0`OL$#N@QX`I]\!ZP.`B",%B.2L`"+Q#ZS^NFA3A:+Q(IF'M)R376XEN\S\ MH&8`NQ$J!4H5I%]')F)3(4!A[?`_D0V`N&[]JK1%^)^G3!@2UEKREGQ+/$FK M3+P+Q%#D)V`^(<3`_"XXS':VT4?/#SS44C_:A!([W2>4<<2KJ7$/8&*1'K*G8R!CT86G#40^B#%V8@+AAI0 M5!-/;'UXSY%).H$%-EW`QZ"[X^'VQ:R))V4ITHN5X3OP*WU9=AO(])M`FE1T MY MMEF'\F&JV#MVOK7:6=%7.]]JYUOM?*N=;[7SK7:^5=_YM@,-=84R4C.RVHE8 M.Q&K[$3LS#H1.UDGXFFO=B'F<2$VJ^XCJUV(M0OQ<#61HER(*<0KRX3F22&X MEKZ"SUS\>^VI(F"7>JCAG%#^LS10OGF>(Y2_TSO+ENG,,_%,H@$8L[?#2PHQ MOA`!R*WY4?S-4P!(Y1F;&G1ZWSY54K MNKV.7@!PX033H-RC^P"^_L-ZI(QEZ5D-5VSA)FDA>::<`1,5-?1W9+98J^S] MZ25]Y$Z4E[UXM@+[=D+D?.-3.4EN_T&=-KE]`8P8YO\-E8?/@*8\909R%V-L M:@5$=@=YI7`V_UPOPQFE6[QZO"&M=4T*?S;/*X$TE5EY)U)BUN$7>9,W%TR1 M)T%L]11),9]"%[)JEFVLY5,<@B@*PXO45@KOXF"`6314_?4"U-H!$M^&%2"BGG;-L# M,E_Q]>Y9MGC->E!2]M'(=VU0(:Y@OZ,7K+Y2M93-,W;$KO[[]^N'_R$M_`"R M,G$4=$6J@61_NSXV4UDYPZ91PJ67W'#J_D&+P)FUO8ZIV]Q[7#ZNE(9-,KG8))#F2.)?U(>,F*4! MA!X%`/$PHCM25YT\CVQD/7'AFL#=>?+1'^AQ@9?4GT>0B,^BD47.`[$I!X"6 MNY08-$8E$&/S$-Y!?D>3$I[$-9$@(>X-Q(&P@`;19&(73*NEIHU-3+`ALRI# M'CSIJ86:FWN2A899CY;C8>/22%S\*-]K@X7Q8"1V+FQDP,$Y%.`H6(_9%?I] MQ?9)9^\48#+JA=;\9F:4JQAV*!2T1)C+_@K03-%R<@Z'_C`"NXGO.8,"O'[F`R';3A:CMKEP,:W"`=MM&80XKX+%-C!='JJ*N#,'S'VSP'9C[=82O)TN MPYM"#'.2IC)XTF4>O1AG)HN9OKY7;Z;M:-+KRW#_:7(U9O6S#T+YOP(?0X6^ M6&/'?6$/`0S'OGZ]6T2>*XV$SSZ%]C$PO)_]@$H97(Q!UQE8N"5?7/_9]^T& M^P;0X'\G$R=1U%%YD/J&1=TUQ%]6I#;UF%VXH8]ZAK1#3A&-P/N:(^BJ234RS!W@+JTX)V;Z<7D<`PM9#.Z1E= M4&XPF_P(*Z2H=:1+^,-Q7<<:)[=/WQ`K:BJ,&FTTNSV"(',.CW>H$2TE.!,= M;. M?'*8EDB*RUS52C0]]_(A2 M;AE:6^U%JB)P55!"4@3=6^B/O.-!2$7%Z,I`Q/Y=PM2P"YYC%>QYZ,]!7-'V M_#R?0OOP?`J?8^Q3)T)$N2>"N52T#96NZ[12BS@3&ZHTK<35/%_&RGCP0(\' MM[&E+E6S0Q?6Y=4MTRL$TK=I@2^:#`L$MAJH$;2:)\<$AQ[&;Z&&JRC[?`$P MZ!!TT'<7X/("X5*;!/Z0AR$5S`LS]=A$A)R!@L68V,`)E;D2SQ M-9+OO=G6"XG96`2HBVYU#$2/78K;'')0#]G#[$D];9XT.IW.K)<_&CF!C4YT MO".2LAO4?O(O3N0]GTT85EZ$/FJM&/"KSK9I;36@Q2R.+)4N(>/5A%DB*LS+ M`G:-[J$X]C-:TP*2IUG?M*A*'/G1K'!T>*N?[[R*?)I56$$AQ18CU7U+R^LM M$,89[3VQOS*$YD2YB#6U$23%MJ<)UIO2%:3--@=8'*%[(-47A4(@C//Y?F/- MP9&RF"0\'"SFRT56$]Y;)M;25.5%NMZSZ0Y29%Z^O>=\:MB4&Z7C$AQ][OK/ M[UZ);M$Z/-VBKL=:T8V9Q]%E4@A=_:1(I4GIYDC:8;E%&KJ4/H"9,8G8@S/F MZ-M\9M]]0'9#?-"@V]RA@AL`KMR9;%;J3!;AC+OQLV+,>E%%`L M92Z-(36S#,*8%_9`H/\KIM(*5,;A)8G4B+!,RIPA\!DM'$G7>F;#0P0@2^(N MA/FY"(&V$T:!TX\I3$18D#B`ZX"R8Y,@:N`SH>_&B>8#*WEV1*14/%%3RNL= M,O)PLCEX@_?TZ6"7AA'(WHF(<::5NZXPL"G(BZI2N&D_8A'6HHT@W.T>[(BX M9LH@UAI3([&4)D2X2O*^P,,4XJ:1N_^2-,_)\OPH0QP3-'(FF#"&,4;]C6B1JF6(VSODX:I9HO\+V2W(F(54V&F(E;_XH&OA:K.I+$O#E,50*6Q MM&#^`[]TPI&FY2?D&>I4OITHQ'!Y%*+`QW0D8I(!OILH1(&(>9&(S#`*D5W` M*'G"+E-W99\GU0E4B(7R#`OR[9Q]9)=?;K4H!A5-G7H8S*S$\]Z48RBD(FR) MK2<<>;*$<"K_.K((X\&/7GI$Z4_)&([J9;47I M!/H(9DF34A.-L")-(SWJ@BI2[84@T?1:31]+I@R0Z.E%_QDF/F;HO-(*U'QW MPA_LBT5+T.K4,*OO/_%%L1Y:GEK>G(UY??)\CU[_)P'X70"<-[6CE>V?-F>H MZ1D3)D)/7EH3)[)MO%@`Z-O`;("TE[BY!T8"..VNT-\+)E:#I'[1R4T3[=^J0*!>)J MI@RJZ&#Z<>MT/4!:)Z?;!F3UI)W3LUY!JU^'$I$4NX5`8WA"SWO;W(L>\,N< MYW!KCM>*MQH>>YCF]KRQ2&BF1O30K;HMX%Q[I=.?U" M0:.B#=-HS-Q`;5?_6"3V$[1I%\@E*@2;XVW[@G$+>[EUP;D%F+8N6*=AH@#; MW+2T71R1\)//_^\#!A12#;0[Z\4/\O.H7F^;8E`7R&::]_9%8UOGVR&&+!EQ M[A6PW-Q?/L@O_I.[-OTF_$$+:R*U<@CKQ'>R>/SU(,AMC;2:W5[/``+A_;H4 MZ3^B(HWP&F\"1%O'PJ(9YM91$;LD0J/O>.#XMKY[7_S@7H42SW$;M32W46ZM MMG6>)18C*):1-A7Z@;?ILT*JNLV;:".(9I&V'*)6L[TCD%8I<2O@/%G`#K8* M9\ND;%J[<(A,94P54)A#`!6`UM3O?SO4M4Q9"^H2.Q70BY^TLG5A->HZG2>W M(JV6N("Z?[B]_*^C3Q?W5Y_9Y>VWNZN;^XN'Z]N;`[[Z3J:5900K$#*XM2M] MH%P_C>R2=V?J\LZR_4F4)NTVY46S0`.[<_%>E>[S,!PJTPZJV3IFMW&0+0HT M](.Q"&RB7CB+!B8@:'"8Y`OO!V+8KAIW^O)R)@>:P@)FX9W@D$L[NXL^4_A8 MVFQ*Q-MHA43$_713!A_(&G&SW7R8[=@B.NAGA#%J41*YK*&O(8IOXTVD0R6D M$O#JA/+HX^^8S;6$^$38DLJ(DJ$!8\R'P$`G$:,D^GR`SIXT3!A:3H!`_.!1 M6J1L)H3JK>PSY(OIJ"L1UFG#.^8GE0@AOGS7P`OEI*>(;&2DIB(H5DZGHAPH MDC*=%J-VJ0$`D.L(`>%,!07,G(><0+?=%;S1#KS=D*`%\!=3+2_7#H+H.@-P^+4^_YU=A MDDDPGXN1EQ1V(`.4YM"3'#849LMTSX8!L#$9(4LX7X`.1#OR@CX&=X84ZBG8 M7*NU@C!I5#6Y"*JS+;%EJU%_S"Y"V3M/6XJ,XM)Z"(:SL8TXRI\Q10;):6\? M+MFGV'4Y(%202V,QV#-A'#&>9?>%JMT+*9K0!WTETQP7RAF$![]V\8BA.D7I MCEA,:4E$4!9?:EXJ6I)@Z'HHDUEA!@+"\]5JQ,@J.4H?NB':KN`QGG-P8+=5 M@&YD_:`(-FH'X/(GF!00-L`@,.P.2>WF8/4J6C@YE@DZ:8 M5=)N:HT;6N]6_[LO0A!5ON2[L#;`8BI-.4Z M1:<(PZ1RW%QO9##35K5"1!@4]$F_1WY!"-&D5I)&. M"N1V5JTNI,!.H4L..*D"[S`TG]:@8P]&LF-*Q;"Y!8,`YX+UCRU/I<`)X6@C M;)@8\-*0VJVL\22R.31PIV<0P:]O'9Q?E+<407D#*Q0(#Q";HM3`V]#YJ7Y' M'GH#TU`#%7@DX97O:,Z$VRV>5S9O!9F3:!^BEJH'B)']6@2>M%V7JG>?O_A> MDO;O!`FID5@30@8G$^4';OP(=R#9?^+"H&D\^O`7*>S)EHL)=?TET=\%>5OY MB%MO+)/IU35V(J3/1"Y@2H8G\W)=2L@8!%P@B+`QCR(0]Y?8F&8W4J*DW][V M5S"C:T])=YU8\'A)"NAG#RZB+54PD0C&UD]G'(^9%Y,=F'9E(]3C$XJ?H+*2 M20I1*J4T2A9P!$62YKSNL+=VL&)K'V8.#&E@\J3HAT2SQ26+`)0GNTXLD86@ M:<'F8VMN#S1-/#DA<5R=]4VL`+0':S)B(`5%6+!`^B(^12=3SJE9`P(@F<-\ M.Z48`^7,99K(U_'YZ_M;V/DI#60?M4!1VTCI<:X42T)!R!X/C5-.'PQL97$!WX)C8!,^Z!!D$TM7TH5M4W4$T9)1-1Z8@F..0TG!('.V M)N3,2U\[F%3?"S@_X['L]:V.";;R>L(3JRPTTF'F]!,C0%1/,<(XRL4T#8;* M4:SN"+]&XOL"FV=!NL64,=0\[CE>SN-GU&&UCXDQ`4[M6I.0?V#JMX],]=]K M-G_]R.2"6ZL6/-7,;V$S0+'1\Y;_AU@^M7Y]IMX\^+1KIR/CC0J-/K>%G\N' MT3Q,K6K]A^]]9//A7'>\5>\M_GIJG8`;V#SO;[]@<[3,"9JA+'0$\6#JLD*S M8>9?7*10Y6_HN&(/EVV8I,SDO+>F>SR:[&*NP3;=VJ(A7O+J(EKH3)]B-=PG M=(W@H(PZ8"^"S!2DF*\>^O#V[89LE02JK?WX MPV(V2D8'"4/*?HT[IEK3%776J.%=,8,G#E,*AWC5F[?U`U?HQGU71DTQPU_* MCL?8N_ZK,RQH$6^IG_"[UTAV%X^/`7^THH(P>PW;YWBA,V#4&],(P]O0+(/' M_MMVL]MH=\X:[5[OW3(E4QDPOZZOJ,DAVF=SQEBJ4/C("YFS5!%N`L?5K M?B+=_N338Z0]VD^3BB"O%P>]1ONTU3CMG;QB'#2/NYU7O/SN\6EO/Y?_9H-5 M2SAZK?E^_:WC8R?.BYUXF\CL"7./M35/TQ;7.$,&I;C."EE0=[E$*V4QB\_I M(H;<6LR1]FL[#HZ^UN2;NV>6)OKX3OCF%S\8<@<+!-7,L]H+*I:X*[+(>D%5 M7U#U>6PU%-+IFIO-\YH.]F>1O4:GM=P#L290V"_EK(WG+1R MVFIMY>_!@@Y;,KRF1=8+>@6*:NT!J/R"WJZICKX[JMA"CD^ZLR#MYYX<')%5 MDD563@.=;:5Q(-N_.NY@O]:S3WJ:J5F_3VM[%1M8[45.,^+WE/*2?K1?R6YZ M-R4JZQ!28O&S%9!S@,6A2CVFR,&C^\'(=[$$""5R'&%E"I7//O9M[A[/P_QE MX)`$P`9S\5AF3:EDJ67C,AH3"XRXL[)1 MNAZF&^)X6+F6RID,1MR.79JL(:J28.)Y0W0@U'*3IWHUP5B$64$Z2+>QT[>($XRA] M_.4/M=,X53]A5WN[,%&7="JADL:?51L;6'S!`D*RLV5UZ'/*CD]SWQ/>IM?( MP$?Q:,'CV>^'PJ`OLUWM5N:X3_-6Y0(%1\B;N\HVSULM$#][E7::+[MT3BR_ MD6V50_'9=JZ!#I^(WP@TJXR2Q!YLID M/IN3F[0/RYJWE"1;)_.IEF23P(7)-IF']!R9"B\_R6?)`#\O#67'ONPE,GV5RO+8]C$U?[M@N!;#,(9%W87H%CL%[D/MZK'=R"2HFEV"G+NA*%SFJ> M=3#4_RH662^HUKCPU<2MNC5+6;IG\P<;["='7&WK[D6\07.9X;I?C."XL]@< MW:^5E!(Z<'BJ66U-'IB,?Q6+K!=4:V:OQ[!\NZ8>-7M;5PE:KSG4ZU[0X2M5 MVS<8<_P8!^3O)S/<)R9RR('M]=I>:QA['=!>![37`>W[$M#NEMOX?*8?ZTYF M7\[`MC(']BA7S<]9TOAYD3"&G3 ML1'P$3SS"?P>,%ZN^I?-;6^>'GEL;^Z$6O=U[;#\Q_LX/'JTK,F'SW!"73^, M`WX[1#;(O9".Y'=LB,?M2S^,0HI/_F2%W+ZSJ!%8^`!`?')AZK__W_^#JL%_ MJ.'N)?NY':8OZ<,2O+(USH4,R']`?I2,B`UZD72^\^'??OD2^&/$UA'\M]F* M?%33CYKG1YWF+W\GE6"?@N'K'DRY],NZ!],2K-<]F.H>3'4/IKH'T\'M6-V# MZ1`V;^L'KN[!M&J6N@=3W8.I[L&TF$BW/WG=@ZGNP53W8*I[,&WG+JONP517 M9Z[T@NH>3)7:CH.CK[V)1Z]<3=&Z`O.^+&@O@G?J73OT!56?QU9#(:U[,.WS M(NL>3%7;D;H'4ZVMUE;^/BSHL"7#:UIDO:!7H*C6'H#*+ZCNP52]/3DX(JLD MBZRR3GE;)E,=Z`P]ED8N35],Z=N95&WLJA;6=2M+.I6%GE_ZE86=2N+62]"WVX;F51P%U:7;"J7F0%%EDOJ%I74G7%T?HXUXNL>=:>WA'M>672NI7%/EW; MU*TL*KB24FY@#D\UJZW)`Y/QKV*1]8)JS>SU&)9U*XO7?*`/;D&'KU35K2QJ M)K*.H5FOK5Y;;K:Y(AK0+'9O.@CPVAOX8_Y@_4QKA*\7Y[?%JO@WMP]7K-5D MUS>7M]^NV,/%_[NZ)T3T$Q255!C_`(,9EX1A&4N-W0V=!)*=+@TDRYLGL+'B MD@O7.<5A12+LEJH8U8%QVF&[-:73\``IC"!_!RYSW),8D=T?/E13NZJ<1*[. M@DJJ[MH[`9&PB)B^<#@1EKMPA7*,LS*BQ-J+*V6N?'?SP+C#7W)Y?2P64>-] MI,HR;UU$9%4HPTK3JXG&9-P\FUJ=9AJO#W&[YM-&1Z3*V[V8OU5PEVM\55A: M&%#]@2F)![>@LKCI-`E]YD,.AI-=VTW[MJ!2.<\B`VDK.#;U%I\U.J=GC;/. MGD?%P2$^Z39:G6T5TJBTPO;:;)INMW':7%R"\C`TM\*PU^XUNMW%52]K/:X@ MH776Z+8[C5[W4*)U@8F=G3=ZI]NJ9EM^;)@1T_UGTB/<=G)`45;J@JXE8=F_415U+PTC3`;3PDBT_.7>`_.2&>G#[W^-")L,\L<^A2 MGT763[P\]GB4&S_M%;S?@"QH*&;[<=_EV_&H+!YQXPB-!6C?EJ93HW4#M"Z. MA]E]`,CF,_L;`79_#!),8J/_T79DTF M[@O6](E@B*$P=`$<*XHC/WB!1X.)'V!%'!R`?K$\F\G>I'/&=D)FA<`O4.2& M'XI;\6L,J]F6MIDKSJ6.9ZGC63;30_38@\4ZR6+S\#[A0HHO:?PF6.91*>[Z M/G_LP))[_$[W>/VK_%_K55?*%EU.OSRC-I/L]$'2!A5S%9POV9K]@X*.P+*'ZJ!4+V2CHB0?);DU'`\D(8.F`\!AT$C='9,XF#BAU(AHP?A MO*L/CQFZ4\BI0?P`*U7#0"&?#Q;!`$,#_&"3X>BV6A^.884ACV@>U['ZC@MP MIXN=!`"Y,P&1_2(7C@"3\P0&^C#7+;9\@[9-#L4Y<&JWS;INFU:K]MM4WV^S M/(FL^GZ;[KI^FQO@=_Z$@_J$S-#UPY`-K"!X`3[[;`6+RVTH?U&UJA&W>XVS MDY-&^WSQ?>#VW"<%K-W`=[,4"9U.JW%RNNVZX_J:JF/W+)=]YT_`_3L'?(W9A7`_ MM,[/3@3L,B(K%.Z"N0`BMAU.?@U$.&SF"[S&'%@TEKMC@"0"&G_UP"`)(LN! M?YU@$(_#"+67\)A@N0)P8:;GD3,8T2@#"]"26;%TR5AC$!8$Z5R(HI$5Z9BG MP>+(<9V_<"<9?N1[G&&7*-Q`-P8$$0C]."*$>WZ4`!WY@#P&P,:N1-)9(TMSWKD0,F1 MV#'L(!%Q3R["1$])5OIQ*@OR1.1&&#-%NN0'*&H`5ZD;:5`*/]2+\XH8(-%;*$ M$'%/D>82N`0'36!#)VU`="AI;N[DUQ[C<@09@B9$:C-!H!Z42Y\`JPFF)1=YA#D\-STOG&"4+-,\UNHM# M9LF\?FE('[68C^:>)YE5[*%D>L)O#P.%L!KD`?,\Z0^P'(8H-*?$3PJWQ%2BZ>")3KB[O-?Y2S":""0&^S.V`CR9 M.+/`KOPD9*%#+'#$7Z2"`&#`8@*FU+IV\R.*E2,A5HY0K!P!SI*O6Q\5?X3= M$@H/J6%`)E1B`(!E[CXH@43:PB+E4J<>I?7\?GQ_G,2UX?)"RA%$ M*.;PNU2LPRS`JMDC((V.JW8,YFO(4F#C?/LM*3,L+"'1$#%"VZ`H,Q6+*(&6 M$Z*0F8)\X=@H7?A?H+:%MD-<`;8?*`_`=-R7V0UK@*D`.PK;`"HR<2TK%#J- M./32ADG4-ZGO&-`H0CCG0I&6K*M![!Y!$*P0>1D("S[!XR_U,OCL><0Q]@R' M#'@RPDH*(E%,LXAESI7D#PM(G^LA%6)?D&Q1D7Y"]D]FC!!3.)'\32B1:)VD M'(H#*8R)MTS!A_8,Z:HOF8U+V9N4F`M4E:&0&ZB\`XZD2H\+0[XX0.4Z>&DH4B&1[P^20%;!!F6D"0QL"TDDF85&CP,_ MC,+L[?;48K6SG=;S7%:&%*S/M)\.IL"_#7WKE[R2U? M7>RROF2N/(QULU,DJ=9ZJ\I-ZV*7A[*@NMAE7>RRDBRFMFGF;&Y=['(3[-7% M+LL16G6QRVJQV`V345YY"DI=[+(N=ED7N]QDQ`HD2=1H+0JM9LU?C0-`%L>2 M)`55DG&^@W'PG0]\;^"X#DFL.IBD+O%8\0B)5QW%D??&?9U2`76)1[/*2:]I MU=6QP.H2CP>ZDHI8*'69B;K$XU[AK#JLV;BX1%WB\;$N\5A%W)G9Z.:&]8R1 M'H_'5O!R.X1W+P-N.]&E5J4AK`WR@@SRNGC?/ECD=?&^NGB?J6%<%^^KE$I8 M6U5U\;Z",5<7[ZN+]U7KIJ]&Z_;1NNPXSK72#D15B\9*`BRI=5&Y"58F8!,X37D<, M:"3L,H"%\:C+XS<'WN0NLSES+?:;%?QEL;=JG]K-C]\^?_TM^;/U\1V6"@DX MO'AS?RG*TJGB6E3("<\DE%*<;N3P(;L84/T.K(OV M]O;RXIWZ]CZIZI?4=KKZ*0L/PB:.G9"BB;!$$Q;9BEW9:3.M?9B@`BM^8=TM MGM:ZBP++"RU1CPJ'2.JHP3_P>^1BI411%<_W?V#5&H(`]DG48`%(M=I>HE87 M#">+-^DU'K%2C#T$4#8BF=9+,C!FFLN?"PXSX)MV"[SF#IY19_S9%KX M)<9?U)%LR2.I,6&@#G8OB99@N&"*5>.F]AU/V`^B>A22`/QQ"3PX\$4:19PL MYC#8UT7\"!^P=I=PU=09_@VA`KC`/544PL*"-/>E[".+>-(9#]!MAN^$,!]5 M#W-YA(6_J+=+1+6)_("XD:J3&8@"<7>29UPJGI$`<_I1%2?:>X3?^$_"(=@Z MGT6YX-%PNI&)2P0*P8$5]QPLI#2#3)(;<]&WY\BZ!F$Y0(XIR[/)92I$?+V] MSK;8H:G]`95\L\7=O<<^\X%$M\0VOH)8%@6%B:T"NU;%9CVL.SQF9T?_M;#? ML9%?G#RVH?,7%T[O9/D"&PG_6FP)PH-+=B&!:<;[,Z,8I\IWZWBE]TM9%XN> M,Z+O(T'-*`&MR<1'LK79Y=5M`RB6HW#S(E%/ZW)D.0&(5"6=/_F@8XMJ?M/% M)+'F&:=2@<_XI\DWVY&/%O@G`1.]5`N.=`C`N2FQ.\>E.@GP=Y1*!A'D1@8X5 M7T'-PSK12NGV2;>;8=9T`EK)L#2&>(W$I$=Q2!DBKP3&N]O#^#Q+*K3<1)5/ MC`U)R;,H!$0A:T=.@_5VJ9@BK424/9?5R(4FS96>C\J(Q=[T$M0#JGF&^&'8 MGOB.OL=B?D(Q#",TT8$MO3ENMK2CH"JX$K>26CW5'=4M`MU0M!V;CAQ5PZ4: MM4G=8^T$2_)"2P,)0S:RDY^J%GDZX+@2,B4"K$`OR[#K\Y+U::I"B164@Q1A%Z`\>?*<]-N58),>\61:2NE M#$46R]D`HILDXI-CP<$6^AT8K7C5+[",1C,'0DFK02Y`7\9K-=>LWB^53T-O MZTQC`Z)>,.@,>/B$]J8IQTFW1<$=X9'/#MK7?B"XJI4H=9(UN*(@Z1?>#V@N M.=6>Z\N`O%M8-,JLWAQGE"2^BW[HN[$L3_Q-^GF42G(L8.X;,SY=Q[M!ZSU;%I$%B+ M.$SJUA,:TDVG$,H$C8C.1E.&7=K8"/(UL9\:5KD9@9GX<#%`D MV%QYFJ2CCN;#4K0S,"75J4'**EIAR^D$AGC3Q6M'(A5B]`TK^$SKZ;N[-^K#OB>G=QWW4& MR7X_I"K$X3FDC'W;CFKH(CO'"'(&I08D!%VGS#JB&PE9@P%JO7S#K@GD\JW[N/$PMM`H3;B]$T[T-7Q.F;`5=(CT!+E^\_FN,RSMP=LY%)3V1A.,=^K/^NA:Q`#2)4B@B2U4#.: M\T04,)^SII"`)H9%M;N'POQ'9BS<(&)/;P"*1JMYLN<(SMZ#SMZ! M:C+N]O)"EV@$Q(BN$U67,L%>M'9%3[[H;R.NCB4IS_&#S;T(31ST?1X]8SNT MB170!6PL&K:0?)!G@:[=C@GR`/FY*SH6O0@_R32$N4]B>OCH4)-?$SN\N2XU MHQGYL8O@I6T=R*T"+XJ!A0FZYQ1RKUKNA%Q2_UMD+ZU6H]WNO$/O&.?2529P MH&VAD%%O4W;T+KV=F<>G&]HW8BZ87!`!;21UQ4L9JB^OYC4A3R"0TI*5@4AG MU-S+>5*=AM1$&L![OE4/HU2;G?;NR8:.R!C#N!_R/V.@9O=%G1]\5J`T:\#C M`1>]")V0N$**=XW0J6\F?"QP/B-;A4\UI,YGHM-?5E,1]W'3VDJ&LX"!IUMW MV$?4,>XBV4>7GY/OB!@>A.C[-@GVAWR_PN- M,(F.FA.4&"^*"*EP?!%<$OJM7': MS)%GE.[02N<@^09GM6SRUJ/V,4E\6,O26)IE9"&=+4S`43I2>^48U6IIL8)0 MZQ-4=%'=].!_`CDYS_)S,K<_2DV4%'2*"`S*/$I5)\@-DC%6\X$^@%[ M3SX:)1I^3ZX7;E.7IW!X?B*'YYUT>-9RO0*9R1NKR-63]=MN]B.][%L0\>6> M<"-J*+HH1R65N?46777YOF:2];3$U[Q0(/:GTI9>D\PWY0=;KIQ[*6$QQJ:=?NK/!BEN-U"4[=TV;^&FWK)7J?MSU]);5 M,DF#?@\UF+7TE2Q#K164`W=*Z+I0?LDLU"0]N[4_9]73P>X@:V6L53:O+>=3E/.IR'G4YC[JV(Q?,6GF&C/"'I&\A,G]Z>6;]2\_N'1!:=^!0G5H%UIU7L%V M_!EU7D%%O4UU7D&=5U#G%=1Y!7L8BE;G%53*\5KG%=1Y!75>09U7\!KE>IU7 M4.<5;$WOJ_,**KW9=5Y!?0^_DWOX.J^@SBNH\PKJO((ZKZ#.*]@O#T6=5_"J MG!)NG5=0YQ74>0451W>=5U#G%53'L5'G%53`GZ'U1=\XIFPZ2DT\^L5R`C+W M/COAP/6IG[(>?'81W@ZU@#,0M8[XXO?[S[\`YQ@X8\L-T;7Q]V[[_`0,EA3F MA3/,!,QAP)^P[6?G;I[AW*VIN>_HG5`'X?KFRR]_/VYI`*3C3L^87MW?#J>Q M)Q#K4H7KV3@\`">)PP.X5J.EU:2?%*J<%D,U24ADA22LDV@(''6ZUVNZ-1TM0L.?)50F7CT/ZG+J/_ MX58@#Y%X\#.U\:88IKS`_UTOQ;XT;'0=*&9.1U)G_.J)]F2M*-$M]DNZN7VX M`JU>C^>___W3_=5__WYU\\"N_@G_?S]7YR[..UO8'`MZ(J=[PL2FL`=_(EN* MR'#[+Q?WG]C%_24[Z_4:>O\9K`7/1?,M#$I/1^(T4D,VT5C0<"'IOBP?9Z(B MOQ7Z'DB-%^8Z/[BL1X]AZ;'5.&SW9$"H;6H^ATF^ZHGT<4IMZ88['T2&N^*_8 MDTT(U`E0F26J\5;2<&OO\9IT,#]9C-J>UFMK%K64@9+R=O*D.Y,1#^['B#Z% MJH8:K3TW_T&-=+B83E)!VG/:/69QLQFF]Q]5WRS0(UB[M011I\L0E42G.MX3 M#R,21+)]BVJ!Y2P0=>K-Z_3-B[1MW"O`K'[80:;^5^#[88@[YHX99\`6GO^S9H$``-_GV"S?TTZ2RUNGB9;9.3I-^HGH&EZGB753F9B+L+>`^A)*H]YSV47,I./)63JG9RCW-IE- M?D1>#]6#-UG"']ACTJ)F9P3"-\2*F@IP`+9!MT<09,[A,9%"]I*ZC(,S]7]; MF7()=0T0Q:XKTT87L_,4O_,.$E)[P!6K:^,@W07R\O#EP>JS?-Y31SDY)$LD MP.4KE@#?K!<9G;U(_]!4,YJWEJJKYJ`6H>V3)4CMU4@U/O3Q(TJO96AMM>?9 M$=AG[MDG2-*P9;`I0G;'@Y!Z=));2C3TNX2I81<\QRH27Q5R#K0KZQQ8X_H\ M5PO8B'L,Z",:A8Q3G]Y_Q*`<=80&W)ZMBNI"+?JDINK5I,0:O>=QL-=LTK!S)QC[$76P4B[U&I].90^+4E=0)[*1-,)F3Y(Y.V],CB2MW5!^M(60(F?[H*S9#!#/* MO3AI9K986+?PYQ/W8G&[%5@D[V,91`EB[NRT=7C[&M?KX7-!*:B[2N5?Z5=IVR0!?,&(^)69]A)4Z4BU;3LR$)MIVE5_AC2E5= M#"R.T#V`AO+7'I/ZJ/#YS+]_T&S]5!=%K-S[,6P3YLPM,-J=*.TG3A68),O` MTE04\&Q3V:@V>5G>WG,^-6S*C-)QA7#AH+^\>PVJ;:+KDV9CJ;O;E,&=G?]*F=.IKB+G'/V=Q#IK]Z M*ABTK!B%"Z&U3`4F.TI%E0JJ]0B2Z!'SOJ<&U"]/ M$3LK^!;_=22[S2&I*F>024[&$BY6?DVP19&D&`#(\J:4Y<;EZXD++[X"F"R& M=T_\Y^U\EJ^Q]N-F\VRZ(D_UZWTM+T92S6)?ZW&=[3&LNA+!SDYNG<=G$IA_ M*)6%#CAE+ROV+[*:<9V=5PISJ;/S=BJC5^?B54]L;SV[SHQ5'YZD_I+U'[S. M1+H2Y/5.J@(5ZGG2O&LAPTP0D>R!W1GH&G[Q[;MQCQWA=GGO86U[-Y_D/]0> M/%2.\>C;YS`Y5CO^>79<%V_`GQR;EP7#U.5N66`D`0)4X:$L*!**8)=^,/$# MV5>B)&AN?.9ATQ%U+UP""!9['OG8D,-_]N3U0@E08.:<8SM6\%(6!)'/^N2= M'Y>'!6QN-"!7'9:6K0B_J$3/FFVU#_M\<_&:1<&$@D0][C;*@L"35Y9`YSP, M2P-C")J3ZV!,5&E\5T:LP6D)2Z,'8#@V52@H3?R(B+!!5![336+>A'Y2G@2< M@#H2J1BI$B!(5:,2U9&!ZU`F/$8JEH^(D'MV:1P"#B>(JS(W(SD:@C9+4Y,1 M#20^^Z4=SR2)LCQ&1?$ILDUA63!0>'8HZQ>51@\70`HRI+A4;:Z/>0-X,LK; M$"MDI3LY5'2WRJ$M`034(7Y@!18^L;`7A_M2";-E6SUX?_,MMRS4.A3I^QCX MSV6R_T"T.B\+!%A^&);/",GQ@7Z+],#"0LH#H4.&(:K2;WU8K[M+/&ND9,M*BM/.>E"0IC;Z',@^G M-`A4_L\XR?\I"Q+9I:J!N3'EF2(#E39;*M][]#&G%&2B`R@I"XA_ZXBKW,'( M`6S8Y5E%83:;H43UX!-RK9)/+#I8]6H^I0'R%E,D^"!RGE0QQQ*`4`4^V\V/ MM\\>#\*1,TD^:WU\5W/V;S5GAY\Y.9PED@;H]8WR[9U)X$_\D-+G2Y-T2;&. M#\O4ZRV$2FTY*FIQYEF1P^TP9FH&QA,M6&GK<52=)7%45H%Q5,+.+HOX$XE% MYE!Y;LZQA:HFI7\ZY=V029]'X+LEWEY'M=A6/U40VU0J8U#N*0UX.$'[HU^! MR`IRFT36C_(\=:\4A+R(LARK(.ACP$D:!@W'[ M)"):;56%VA:UJ9]'SF#$(J<0C3+U!XZM%Y(-(4=[?Y3N$6T*59LL)+M"]4.9 MHHSI=-X-W/1K%.\0_SD^[3E>P57@\E9W*]57WEO"D9SB.-+ODQ+%B4=D)5A520W]Y1P(>Q9Y>Y+Y$O]+IROZ;2SMLK-T5U05+CGMI.U-!?2KTA2; M0':`#L+2B.&\R6SK)4R#DDJ-3$_W9*:0UDX\'TOMC`(-C0MT"):%^?*)L#I4 M.$V&I9E>0EJ6Z0\5GA!J4U<>ER[?,\TZE3"",U9P>519!3LX-81+@X`,\"I8 MPE4QA:MA"TMC>'G>8D$>V]I-N_SBR"Y.>_H"BK3O<(_C"6NZ[/0..J25.BQ)@&XY$4_+&/;)8<87(!FJYJ,EWNQC0:C^ M2[K_I;DV+&`0KF.5';`N46*%)=X<(FE@U>HR+R^)0T6!Y87#\KB3DAHE.D`S MB11E)AI51)TI/Y)?5V>J)ZU.BY-6)59F&U@>AH:"E5AF4I,L:%Q>BXD4AK(Y M8ECB`00=NL+JXME!'D!?#],N,4,#]L[E-M4N+I'\K$&$&II5GE(`2A%'[V:) M%<73TNI@2+XO#P[J04'^UM*S/($K.GY0`1W%$?7%[26WN7M,KVL M^M=V)55DNZK,R2@O@^1-2T;9E<@H'6_@QC:6;RDOZ#*>H.,53L/(#S&DH31W M.(\&QW1#5*(^$_`!=YY@0R1QE*91)%$MI2LWF*0NPD!+#<%TALS&B"O@6N49 M?F"(BSB@P'?=(VP>7IIG[GHH(\024$H[N`(E%+M=XGD!E9/_&9>79:7DR?MH MQ,M+S931@<0_R@("CNB`'[.OW`I+S*MP0*H^68Z+JF/UBIH46`*KW$L3:8"6 MK%>&)69]5J"MD.J#69ZD]($+!@J.=:W.@S7[2BHN\NW^^UV)]_G*3?:*; M4!%D(^_R6I^Y0C:7B(I$-K^NK-M2T^BP8FZ)J5+``D3>2+?Y:YE`E-QV"M-' MN#48E3QI43`G65 M)FFS1$!<6];XIORWT@!1\4]29RCOH/9?*$XXC*QA>10JLR(#R_%`?RG'KE^N M/!2I/918FB'ITTV677E@4"WE5)DIKSI"(KB4A[YZM/ATD$XFZLP2LA8""LP9 MH2FQC@QA3H%1LJC`4$7J'5,BGY@6X.4=4$<4]@TK=RX+/)9W@3.V@I?2_`I8 MC9'_'+AQZ#P54D$ZUX_JDE-F&ZF`IXURRDSMTCKEE+8?%Z[5M\96F9$67WTL MH6%Y5JFQ6.4W]M9K%5A,INJSUO(H=6B:@UGV2 M\?'$]5^*\4Y.MY<4O>U@;A7NLX-B[VEAI4Q)`+5N8%%@:KGIGP5MQ]1*%X)5 M5"EAV4I=+M/.D$;28#W9EXDO:+,0;!`11!1.$;'6F:PI/;=TH_BT""#2;EGB M7EG=&/$GRXTMU61+8*6HX-2DK_ST,8&9!_B!S0,)B,>?=W%`JY<"VFH5QXFO M/9M/.-5!+)(#W076`-#$V;UP=8N#_E;H'F?M=O/C];>[^^3/UL=W!9;GTZN) MB;)>Z'7#JAT3*XA$JVJ,`BY6/ME."$#@710CXG[T(\<2!]ZSJ24*H@2U2#R* M14#`?TY$S"O,K]638F/`#?(!X)?^$QZ^P!\7%69A#0;8NA!CR@(PHP*;@.9=9CP(4>0\4=D(_>^W$T(B[78",K3.K7P8?P4?(H$ M;B?77BGU.U[$'[$/-WW$O1'5"(Y4[ZPAMXAJJ3QBF'`N)PJQG5.`A]NB!O.) MCL-NT5-``2%V/(A8&#NJR?=>[]#0`OT$518N6'?*,5)VJLJB":&2UH`%-I^X M4TGO>H2M?$2D3PV8]A)0=9-1D_P)>^H]8L"/AR'_V@'^Y_O.',I%L M9+7V@0/SX&C@NZXU"?D'IG[[R)2BTFS^^I'EM6Y_R:DUB96*<8^>.:H^^*%K MIP,@IQ8ZS9QUSU-YY'(3++:4CC3WU>P4N&Y`C_>W7SJ_S%.A!E0CX".3^%)3 M?'(M(!#$2NB[C@`^Y90LX9(IN/D52R,43>WG,OB^X/'YIZ+V2_WH?"@`#^V,$3&X9AB19GR)5ZSOL\B$HY'/6F7Z(CX#J?=R5 MB[\47.*>N,3;UKR^R8*MV&C[O3ENMGOO5BGV+81K(VQ/C??K*J*=10/-]68E MI&>&0Z<&3KO1:S97CC\?$0O`+92H@L?^VW:SVVAWSAKM7N_=,OJ:!KE]W%M& M0P]^9+GL3FH+8#>!Q,Y]"FEL8\J8NV4">X5Q:!9NL5HU7ETOBVP\HW%.B'+\6_9$U2DNG2GUG+\N)D M^4D^S`\8&CX&K40!*(?VOB3UML`,V.#ZU\H44O'.=_0P)E8[I0:H`\9+QN[==7ZW/I"8[-+4VA\3P1)8K7;/*]JDWFF0A# M/XA&XE;4"=G%8V`Z,3>>>%SX%/"@X12-E+D8S(-[YGA3?DBYJQ@S:0Q%OFW7 M(0A#X!GHDQ8K4/TIB)QL[CH@)U\0)%-0\F%0@P26?)..3(^@S;/ST>TB8R5+'672!>=F2LO_3)S:+SB8"TVB`!(QEN\2,5P";`M M)0MS- MV/;16-AT@K[!M+-V]&XE:DYY7Y:4[[]CV`;=,K=EC86O+\N(KC'7NFHPX`JK M#,1A$CPB&5UC2C%.2DW*`BV)!6$,JO%Y=8S-X-%Z5HKQ!KLY&:*^QZ:3Y&.( MNI91^(:H+"594SV))_JJ]8%P/-:C#D)H0U&X^!K6^[H6]%KLUUC?P;`XM%F= M?/XX;:J<5F5&=2Q<\DI-T5C$YSLV.MZ$&KYS,@62Q'A#C'.3.A7ZN4")"C5_ MEXE^WKG"_^Q6B%;#63\PW;QW:W%DVHSBU2ASCYN5S_#0)MF!0UHX'J.1%:7" M652,'UE/PHJA^RY4%L>^#=N=-8E-(`.A1LU[EK*V,28OPJK!"^ZD;\E20VF$Z]WP9'X%U7!%:%04)ZB15<> MW#9F"^MZ.]="^,!X8XV=T47=?VIJF,'N;2A7;(/5F/C_-N'2F!99^"1#1PIP MF2,D[+O(PD)T\+@+M!Y2#U],58W=2._NE'1LB"/'-::?OXPI5/I3S/T'.?4& M7?L:][EMPRE7Z>*8.NIB?B)Z:^]&5C"V!CRF8"]V[3T!&E0#65/HOAD;0C)Q MW?A<,&/G0VP\"5IAQHRAC:XXZJ(6EF\,MDR M$(>M=JO5ZJQE0XMI$DU(VH+4^\]T:@.24XM#6%LRI-)@IH;I3/"+UD<0"__9 MCAM'/&FZ833Y.AB^I+:!K6XWUXOML_9I^TQ,9R!EU%3&*EZZ.@/'B)@M\G/Z M>=(Y?A@O*2E4:;$Y48DKIN/L;1H$C_*7.3,@6_,%_\D&,-LXDIY\KA<9``6U)=]U:U&^@Y,MY MC.G$P(_3TOTXIA3\[^8G?QV^-G$M8]KR\MJYVCPY;QPVV4IS/K86QD23TL(/ M_^!'GC?ZF/L@%:MU%G.-![WPTYQE)`1HPDS2`E,&%P$;R+N=G<1U)+'JQEL1 MZOJW[@7\YY.QUV6#4XQW%3M@%>+H6\\Y7:/I7`9A0F(N6V_HF\8`O^E(M7F= MT-[--&G3);\W)F15F&WFQ?=+UZ73I][\%[OPF@)M<&^E&S-@7>R(#1EKP?G8 M4$;DKG-B#9SR8IK8F%L9>*&5"I7OE8PZG]\IJ`MW8X9@'"+*,>'0S\F`M8F$ M@#?P"ZKI,IZ!I-`32MS[N!\.`F=".O^%$M&F\O$UN'2T?1B^DQ=/Q@>E>.&Y MUHG/F7&@S6-\&EUF$$NA3J(7K;4<@QNU-5=COO.).P>/H,<'QMS?6+X8*U%K M>"?68LG&TV`T"S4GP_A5/0(1[UP*5]^X:RP1C(^MNFO+&^.A*05XSY;3@,_H MI,6SHIPW'ANI4.NP!V,*`/HK'%OKJ6K&&",-H,^9RKRU^L:\SP#I&=,V+Y7J M_,+8R91$Q#V/1!S[V/CPFD^JRF@:GRES087W`J:S&"N,!O<.FA)HC&A,[C*= MQ)@_AEJ%35,\O`:U5EMNSBR[36\JK_-&A&K<-!__U24#,U:PGHQ#?8SY6;2> M28JAO@?%6HQ].3DSI;2)L/B;Z2S&5E`@]39C_X>YC+$\:E7,,!'%F`F^K'?C MC:KV;,J8,2FNI:2D]4%,I\-Z(H6+E9RWAOH4QCKD>HJ6L1@V]I.N<;#,56X9 MT[>&.93S>&A;D_,TZ@X3X_7(Z(BNH0VO181]8AQ8 MP-S<;0VE?Q232N<$J@C3>$,=V[UPGGO:!$*"R)@2K.HJU7H0MT0&>Z]F0X3_?80+?4>5/?S^DCT,,SU@G^-9TDGSS7YMB9 MI3^V7JAC5LA=-UMW1'J@3>'(:=M-6;%&J0J;!HI;6%,PK[=[(S/$6/%;0W\U MG6*]L-T=^-[,?5O:1#E]`]IB8F-Q:FX5JF93IC.91SN;SF`>J&5\M'9T MLT@MSTRG"LS57./P@YSEUM(9UO07@LJ^GH/2=$/7#(5+6Z%AUN9`ED`VET%K M1)6!L#-7B&051'-)4E!^AC;'XVC-N[C"99:?L]2Z+DU\<\EHSE),R4S$A!BK M'^;SF)YS\^.]UKV7>6J.L2(L`XJ*%XJ[B2@VJ.RU@>Z54\9M0F)6Q-<,^#46 MC=A'.*E<8#JG\>D4%D@@#O/Q*6TN8]UQK/HC%*X^&)M5 MYA9ROGH!&SNVJ8=$\3;2#FX;9.JCL?PTCYTOG.^)1)'=9`12DW,Z.-RSV9KW M'"WS=,RUEF=>1L!BK<(BK>?UKB-6.^&((E2MYUPX&-IXIT$QX^=,."3@(?` MN'A"VOEK!/P:BPC.)I;Q`8QR^OXRC!27E,_^WP1YN_`7&"\^4/5O M"UJ_;H4:*S#&.5#Y\)4Q0G>B[N8N5*WYHW(:NKK6017T#3&P-KLK7!U=XW9W M[=U)6F8\.]-5MXTU$W-?B\AK`LD1^B[-O(MH>LP,-U9OC#4H\TM=@YHWVCP& MO=G6S66,C?5G>T?&5.&B2TK]P<`XS-18*6Q,G<4^G$+^9^P$W,9\X:$?#+DC M0J!%Q059\R6P,6- M.6!D+%_&:YW.0D+9-*ARU:+<8'S9/[5OS/[,*XF:QQ:ODR;P;ZIU!K$#E-U8 MV-KR&`^Q3;L3CK"Z(0]DV:$GRS5F8GE3#S7`L#"44JT+RQ`Q]MOJ\M]T!N/+ MNSBIOF0ZE;6+A#2@!>,S8&(J;L+,UE']"]?'"ZJQ-Z-F%+[WQ"=V(,3]X=`9 M.)CY:#C5FD55^,`G+8C2Q#C6]N?Y>[=M&`F1MQBJ%MI?*?+8*#IID+-XLK%G M62!B,R+^E8N!I5W7IFJQ=;FC5"C(_O>M?)-G\"%=M8VII'SI'-[)(Z7[C. MM=Y5IGG\BDSF(Z/_.:<%EG%2KZ7M[R!VVUQ,6SLJ`Y/O.D1WD/GCHO2\3+C0 M.JO/&;*J9SV:3N%[+&=6@4[8Z]TV%G35H+N?]K@]SXQ-B'+!=#4YV\48RU1C M;INI>K,C%:H:96J-VV88E*G5B&H'(9[&E%%0W0.=71F4[]@D,-U<-5TCO&\M MKA#Y;!U5T]AP`-44&)"Q-#6=!Q4DH>9,>$#U#HQIPKR$T<`?CV-/UE<(UVK3 M8.Y]`2:R9M%0LF%AI2.T+5^CT,!:NM`:(<2F<^0-TBW'E"A<=UY# M%XU@(\,5&?.A'71*7(]S&1?]6*-NOZET7^^&NS+N1QU9NX@5 MVXGKPGC;[37C#>'W MM5SS[IOK",:J)K&1FGJ]1O-ZVUH+, M$XAS:B@[T-?W(BJD&M<'QD57WJU9\2'O7=EF98J-R6DW[OV\Z>+Z^5LC@-Z8 MET0&'C7=NV*>D[M&WJ#Q8OS=%2-!;]O8MYTA>O4+GU"5CJ%\R*1\O\U4_>8& MYBM9*A>D>$P;=W#QC3LF`6:-U[&>H-N-ADJ[97S.S,^SX0QK7.`+GCFP/&QD MT>=X/3@`$QL6N$;?QW43,!JIT]M8=QV9Q^"Z1C%WFY2$Q(O0?(=E$X%D[.VV MUKUZ,>84QD&7CG$0$J;)[8I5B*-?C.9C?(-C7`%Q(]9B.L.N8DS!_AQ;$5W# MCRWC\)EU6HU(3RX):CY(:";A=G2L?G58+T2QZL[6:L_ZS5F:@(2T]B.-W?B,`M(#85TN&Z1&=,I;7\0 MCW=5!=9T"E%D,I_)O9$V93J#N>I4N,ZY1A]KPQG6ZY69,Q%6U\^-F8"QX;1& MVJ>QOF9\@-?,D@7.9!L+)_,B`CD;B>GT'%3E)N[P_;9NHWBE^#8Q5;9K<-_91'/(` M2>FC".8R';"B6N]L'`0<#A`^7UUZ<0&%D%;*A:#T;(MW95HV,V> MBG0/0+76V[;XJ;$CD^FYR-=\7J>@4`;/)FO,V0-/VSL#LUPR.F-1;KWDFZ3; MZ;:[NJU;."%ZQLS4H'R]W"-;I=_AV2*-!$LKVSPTGMO`YA!S.WU.E>ERN;[- M7=/:3-WCIBJ)_61\L"NB,^Q*4_CS';L694>,,6406-CS6&0L:6V=QTV:3Q-SLL(C>.;SB!U3.-=&9J439)F8FH-4HE>H$$K#/V! M8Z']EWJ`L6PN/A!@03[I60$^\(-'YAO[R,R5--,Y0/P[QG@WR<=+IS*I`JEL M7C^.&!;7C@-`/`6H)>P"_INW4+)F=Z]E/L'.YLW'W<3$3]K)*=FOUKH#Q=/Q M@!)XSEK/VE3&BN!K$-NZO'G'\G5SU'F-Z288,'1-6Q88ZG2-#_+$?S;V#@1K M>8@2:$N&9QO%*R6GLBINXYBZ,PE4B M8P9NO`99UON9]]G$>H0=REW@9P.+Q+%WQS]VX\DRE^JO07)J2&H?]]A_&E.6 M:\S+C:G*^$P:GWK1"N3>6$1@3[[#;\8J%8`H?`3.^8,_<+8*I2IHL(;Z&$%,M,Y#:(GQ)Q/.3VBFS'> M,+D7I>:,8\OFE`Z+F)[$P<0/R1V/UY4CJI_^"&OG3XX?A\;N5W/S17:"7,LV M-#8CJ)'4&M>N!F&;4O)H-]*F&K:Q,#9)]5Y76)G6NZ M:;,9Q&Y*2D5'*AX68]9O[,@/N&5\N[*>VC)P(N&W#X'_HAMJ!_Y[L6N2L5\H MQKOYO/NKV%RZ?FP???O,KKTG0(4?B,W\9GF@*R-RV/U+&/$QELJQP)CS8Q": M?:"2'\BMQ=M]"Y-^OG';&5@NNX\G$_-Q,O1=8`&I#'C88)^_7?T[_/.?_IBS_^26&XT:[*OO/1ZA M:&>7E"6*(]S'P2,'("XY.HS"I%JX"X)GR(,/^[U[K6-:6`!?_<4QOR?!-"@R M4>##*I_DY>E8XC`4VX.XL8/X$0Z@V">'AUF(^P%[G\#3` M?*GO>.AXEH?="Y/!7F":,2SC9\UP/X_Q_C/R>.J.27YYV38W81@UXH,1;P(YH. MZ9X\NQA@)>DQTT"6GG>`V.;N>R&!.SL@M4]TR'''6=\*!KXM@]XP,Q91$O'! MR`->^?C2R((SGYGV3L^;"QB0QC"RC#89%GA1PC1@@P)NQT!#SW[PP_4M6VB= M?:#QF,K/(W0I8:J#H?)XPV/V`.JH`N/?PV6<2_47I[)AC@>;[KI$3PW`S%$( M$BU)4A>B)A"LSL(;P,#&S\5T'G].IF2WV/R3ZY$;0$,P5H.4XY$S&+&E6!*\ M&1MJ-?#782RXJNO`V9?Z[9-CD=9]C5S0XY&\\TD7H\`4,1:(,NX].8'OT026 MZ**>!`[)DI\OQ_O-/@&%LY/'`'D2N)E MDG]P9A$DZI#"00P"$WM"RG5CXK][OJO$R-4O,?YRZ[$;$(3COI2%[5:#M9LM MH7#&B1+7WW]UCE@9'&'+`Q(8@;;V*&+@+#K8`1\I"E:ZKX@5OG0F8,G-JBV+ICH@Q&Q??&ZRXF_P:=(N#:0&E*=BS'%>(R`HB8\B%Y$9#(H9Q1: M*6.VA+!0/5OP+M1]!*4C&HUE6QH4+@'2H"T;JF9@HCOL"DPV M,?D]/VQ(<$/+"=B3Y<9)<"7R3D!@D.J(D4QUL$0?7^K:BW=L@->^TBPH4/,1 M*/,1MWAJP/$8Q2*Y49PPC(7IR'^*T-W$JY1L#9!O./*?/=@>8)#SU?P"^,X\ M)$>4GCZ`@S*Q;"2*O_W2_(7^#B<@1^7?@$;Q'4@95!'ZH,'N05<=_I+"@Z`$:AZ@T@CM M`;40L3XQ[M$SQY.%'[IV.@"#'QK$GD-<\D/Z6LTAEYO@#H"=1Y?RU>P4N&Y` MC_>W7SH);G3$#\B>^\@DOM04GS"S'2="3N((X!7K9QFVGP+\/@J*0-+4CBZ# M\`L>H'\J>K_4#\^'PK&[=#/-<=.'Y0DWP9'4]O\8`9M;AB%)V*=(U_H>NWP8 M?61SUIE^B(]\8+WCKES\I>`3]\0GWIXUFXUFLYEP#]#!X:008[%1IWUSW&R= MO5N(X>3`_3H7BOS8GAKOUU5D.XL&FNO-2DC/#([UWRPAL&N3V<6\!$2TZVP]^A/XGJ1"QNT"YI?.< M3)K.F%KF[B,-!2I+#"+%F$H,1\Q-'`O0NWN:6,EI%K&-C`(@16M[E6A5N@$H M!5-V1W:-TV;%=N=2-DY6AEQDU:P/*RR=Z9TUI56SK9[_7DINAB]6E]],DYG8 ME5F17J/;_"AOJ"C<*T-!LV=%0,"TE5>,`I9+.=P.A]]4]K]*@?\E:].2^!>V M:RWVBQ3[[\E:7N*I6$-BYC'9_^-]'!X]6M;DPWW<#_F?,=B75^B##1_@W4\N MV!-__[__![?K/Y('!R..,9^WPT\R[><"Q6THXH<^O6A_@4F'+F$8+F/<)4/3 MK03\\9T/__;+E\`?@YG:/(+_-EN1#[^WCIKG1YWF+W^O_0GE^Q/^$7NB]YJCT4SE\=B$^?$!LZ'!8*$%I7' MN5!!1=.,ZU1#0\P!VWJJXGJ+/AQUL78&K3K,M3.H=@;5:D'M#"I;1J]V_51/ M;&_=L6/&J@]/4M=>G'+D=>K%T?PJVW.7*$_,S?WEPX=+C'J389C^\%Y83+H_ MY2*\'8*IWCEJ=H]:I[^PV'/$%^+97YC-!\[8M1I:6#^ M?O]9A[&)$'8UO)K,GA-TL4Y]?W*`31ZJE=CM2>P:0V""].%.T^6#^O?DXP]$T&C>;U`BZ#5(-RQ6R;`P?0I,`U"P7N/K(B M?N'97WT0*=?>P!_SF7<$UXAA.VXGDF/,W?P-4+HN&`4N9Y--V-9RY&8N&*$8 MLEXPV<:@;8&H$I>G'&F]3N=;N]+2]N>K^+/!3==J?7;<[2F.%I M*/08G)WW3D_6!A$5$L+OA>OZSZC)J@'@5?(_7%+X]+5W,<9$E&V@]6@&KZ90 M%+`*8\P?S:!^TU5LEY)_ALX'SW'_]DL4Q/P7]G[]V?*@9M5L5RJ'*)GV.["! M[QQFPSPQ@3:EZR&+B#&U*?.P.1[NXH#/6!?-XXY.>EL`;#=K7;$+%5[K?(X_ MW\Y=8T//CPV7N`B>@M>VS@:6NC;%K::Y6#C+Z+:TE4?=CNF"#8#KH=B&$[+N$D@"FAO;<]]!ZU>R=G9QG\ MYIQQBX#FTE)GT;HFH#.&!0]!SMQB?2/!;*1KPP"EJY3&3:9<4T]5%P^7_KCO M>(21STXX#\."2*-T$IIF0L9F[ M*NW>ZWA5P%E/"_A8>=.M`Z35$V"MDR+O(C$/E$!"CP)F(,>8'F<9_S38QWQ M-!O3Y.'Q]$VDV9VL*=;G([H]B^B-L=J66&VP+MY>4DRD#(8$K`%"!>]@%P(_ M5AR-_(!J(/5?II'Z,.(A)MZK=^0X%N&5V`OA!,BJ>+?N*M7I,]^1'6 MC.6!>*\2&.\4@/%.4]*QN.0]:[=:'UDG0;Z.WA_%_8-&9X(6) M`/*6*%M@N4FI@Z2$@:3D610"HI"U(Z?!TEM4^XM6(FH%.=[`C6TN6@)F*B18 M[$TO03V@FF>('X:5X"X M\MRT6Y4@TUYQ9-I**2,;G+Z(#2"Z22)B[2E+-KH=#LFL%5C&VC`<"`7I9"GZ M,A$E)=122]7K?!KD(KU3CPU0X<,4/8QZN:C\E68?_0^W@O`[Q^(TH&U=V`@D M5NR9&]S2/FJ>'+7;)D$,VP5J]TL&LP/_NWS)H+JWFB>[6O2E-7$BP8\O9=TC M%6QXP^<:,FOLV_))9D""!8(U1+P8S*O/6#C1GXPIM"J,MG+)V8+'VNVV!N'R M.0VP=@W\&W3E&1)8]VYJ&M!<,\\8]4FE0Q55M4543D5'+9C+`(47MKTX#LH4 MONGCE&?>;+`>0/_)"ITPR;_>!M846/.GR,&:KN"WZ.5:BGP1V74;X+\H=41< M5R@+3A;(B@S`F/6F9`_993R.,6KQ:9$7S!S@Q5/D\+.@3_O10T*Y1DO8&3JX M).'HN9")"7BS`1]C94E0<^&[>`QT);Q`XDFP0N!8VO)2,^LNVOK&[!3Z628S MGO@!*&"")D0XI*"(?`ZQ1<&MG>99]UQW&"Z>:#.8`*`=P$3?46W:2TV;O`@" M-'J05#^]I(_<62_XT07Z1&\GQ)VN?O)@X(2XG7]0KBUL).CFUB.7WPBU(+<3 M\F[!&H];>MS=;H"N#J[FT,(27#4K@ZS^ZFG[T],J)HXJ$.D/=,H?P`J7`%VH M$H?`Z`/'"YT!R[OBBUC/B'D7,8Z1+!R&;_!$%%X[8D0;G-U M1-%PA5>PXCZT:BO(TM-:"N+=WJUI=1A6\6NZ\27P,XO[X@=#[I#G"]26JZ2, M_AI&Q9ZL(N>9F0[OF%%E=KF,;NT=[(]%7H&O#+6 MG]^>['5:^[O^0JW0YG&W4PA:=FF&KH\L4S/TL)"U1`?=@HVY(QAW;D!NV4R< MHK'NEJ3J7"AWCH.R#]K9WLX55'LU54**S3D.>K(5J?FV! M4"H+^C;RP+9(415VR!D!NZ8?8>LJ[!QHC1$2FL]180]!\:LQX&?3MT4G78.M MW_)*,A?VVKM%,+V\H,]L_^1`0XZWXJ'1I)3?AQU_^?,$"PYQ7:A6X2RK4!W:86CUKJ91JU6LY7$ MK>!`^8;.EW&%;FC#D1=95U,!$]U.=VKH_WC_LQ^XS@?\?_CS_P=02P,$%``` M``@`!F1*0V;6&V1<"@``Z&4``!4`'`!N_M+Q_,[O__[[WQ#\^_P/24(W#G;M*S3V+4GUEOYO2#-7^`K=8@\'9N0' MOZ&OIAN3*_Z-X^(`C?S5VL41AA\V'5^AP=F%B22)0^U7[-E^L)BI;VH?HVA] MU>T^/S^?>?Z3^>P'/\(SR^=39_AQ8.$W75YH17+OARR?O2P!^-B,X&*_)P_^ MV1_+O>1C+E]<]3]=G>NF_C?AGU_%^7)&/>S/$"+SAA53NW_<30SK$:],R?&(5RSJEE1.E\\\HZ>L!BC1.>_+('X[R5VF& M7<@K-LP`T>L\,+W0M+BM6"Y].,)/$E^N9K4]O/=+R8A\ZP?)&-@F!3`&BCRE M!Y=P`UF[!U6KY:_PW'SABRNV1`-(9,GPE]$SS)A#"[P0.H1I)B:NM^>Y>>\VRX76*&ZNXD?.IT%@QN.'RJFBZ>S'#[!(K@V9L`*3AOL2DA4K MT"D3%K;.&>/(=-Q0,P,RKI[P`>N>/%5B5A%U@%?1<[PL+MV83I#LM]UA,XR# MS6)W(^O\#]O7KQ/\A-T4:)/9OE[/Q[-,'1\?JEO,EF!]:&DQU%ROPF[2I#I8Z^-JQJI&$8XBA,I`'P?H,J-C@ZFC98 ML-8B15BO0M:*[Z6XOH3^0\=."Q^H(&B/58F6!OL1PKJ68_G5%&&V3->*W83Z M!+Y3$O@EPA`.]E8/H5#S%CU<)K+I0Q0RDM!6*OLG3/-HHP)1.AJ'S+X53V'L M`["W>Z[P=RJ"4ID4T1:3ZUL4#I<\1^$'M"-3&,G#$DLSO$^>F(A#Z<$TUUWR MN$H7NU&XO4)_[L++^'@86,@/8'Q^Z?0DE;=$.R#DXJ+P>L;.PV,$\$YJY@T!?0GKQK4?FNYMX,=KJ!3+.X>G'L7 MIPAQ`8DRN;9DD7V'[,0@GP%:&FYE0=8>/Q1F@-TLP67L4Z6T0B:,<&M;Y$P< M\QY6V&2%45JYL-J>,N@W>^;AU'PE]Z(R&X(\9/BD3S]@\AVT&W(5S-'",/3( M@B_9+RD*P&RKTZ<`;M^PZ+7.!Q7JKIU8(VMSRPJ@195T(JH_OK@8M"$NQ)J\ M=1'&PX&K9JZHISV4Z:Q<@VN^@M-/5?7<6V4:^PD*J@KC%'YK*MK9&G^.D"BR MQMX\>EBN.\$JH5D#U!QB;1LDR2U8Y@L\^^'/:GM"Z%/0A<&Z=H(KN5.1CYW9 M^/2C,M_\.^%60+9U,;6Y-\;CE?V6I\\3W"[)H]DZ?PQM.[FE:;I3T[%5;V2N MG>C]+4;&/)6SW7G;7`=ORE:Y\7,Y`\5097)M5SR]+,5+[L:I5)AY=72BK*F.0H:%A+] MW-WE.8'O0N_[L]]ZIQX"&!0^!(`^4"K^)>!!A9(7XBFPYSM@WV61OT19Z>9A MYK\I3T'\N`LQ(X=V4X$0(^Z_.D\!O"BT(1%&J73C*'E>I:>P_DH>G7%"R_7) M.POP1=/G"DJ>K5&,T4R=SE5=0_H-NEX8JJ88AB#0-5ZHIWA\8O(@S]]<#PW5 M(`RF,\50M/DP8334QNA65[5;--*UD3+3D&H8"T44O<)W\"DBETPB)(<<$6[E M%_&S%.0>DT*2619W=\/9=^(-0[W5U!MU--3F:#@:Z0MM3NA-]8DZ4H41*WUG MGR(B,XF0_#-6#7`$(%XH8Z1/E5D25:)0<[W'3R'O,Y&3Q#32[^[4^9U"S`YC M8,/B5M$$&IWC%7\*_(`)GF2JF3(9SL'BT^%L_AW-9T/-&(Y$6G[O-``*Z#D3 M*$E%RG\7ZOR[(%#E9P)0*#\R49(\8\SUT7\D2)`*"82[J0+F)-84-3&QCPV@ MP%ZPYR.24E0-,"IH/OQ#6*0V>#0`Q2IGEB7YQ=!OYM^&,P62(,2,H1+[7V5# M&UTK\V^*HB$8LO"K8J"%-E9FR4"&7\D`GND3408I.&B`8LB>?Y,\9"RN#1@/ M).,H7^'SU)-6\>3%GG^K35Y0TZ=]B"CG#SB#(,NTW\0TC3YL>A#%D_/$`HI7 MY5E;-`G>LPPH%NP9O"AKBZ91>.(!A9T]@>\E<>&`FS[8@"+)GOR;S.G"[5-Z M4@)%F%U'L%.\<.@5CTV@B.34&/EK7O0A58S>-(LB5NE8!8H5N\;(6S@>D9+@ M$Q0H([#+D(ISFH0(DLVQK2B+!;V#0?>O*('S9LA3FX\O2IHI;XX6.PV>S)`U MPX!=^Q35")OVVRXS.Z'T?J[P<*A\I@/%NT9M=#1?USKK@6)7;]?CB!1K'`5! M$:RS,W)$>J4G1U!DRG9/C@C\D),C*$[5]UK@ITP?*.U$>!JI?;0$19==2970 M33M`VQZ$]M>O)#O!3G1DV?&+,D-_H$/0D9]S'KT>Z^C\\L^7 MA\!X0A'QKWGY^[/\L=L45]2=08T\4\(U^0"NT[,VU\A(@,L MP7XSE\5,]I79/S`/*9'$VUORQ(T=X0!-T=Q@_]-VM'KJV![.>NS+'N5P\8#" M>!!Z5AC[\2LC-'K@("EP7LM]A.:T+]#V0A_6[^\?'^ZS1_U-139^?:3]B/BL M&^P9O9+H3IV`6="^1R@F17"$A6M\_I43467O4>R[3E`*C%!R.V2LKR%F?#*9 M3Q[9Z$.-7F@BN=26B.ZIEO,8]0WSQ!Q(_^167PR/UT0/T2D$)6"Z/;8#LQ3A_A4[ZL($6H!WBIHI_Z* MZ=0XQ+091^&(D`52@EN^MNTU.#2K897);8_JR+07#P].]#J9V_Y=Z,]I]Z>C MI>OB!1TNP[LK'/BNKX:T;%W;H_]HGOG$Q:SV!?+4QQ@5V>W1?3+ITNK!C]/Y M9\B?=4?71$Q+'5;9BL?3V"'\VU<9J4=GM MGWYLVC%V?[`1`WELK8RHBBI+#R7A&D;M?;K`=?$#FCDO:NU*+%$#DKYIXWG\ M3&?,@4M9(#[3--,F3E'\C%#(%V*T#5^'=%9E31R'K&W3>I30U_:4&C0^H$/> M+4%_+&@7M9[8S*RD`BS6WHC>Q,A>_PBO^N29M73VB+?0]4 M53.[B"K`R]33WBANGCM^Q%USE\@ABRC9[":R_O\A[_3U`CVA(`5:YVA?[?*8M=%6:\;B:IO4Z3LS(!LVJ1'?S+J=0O(ZZUX5 MOWVV7A@&5$*'*_AQ&R//C(6T'KW,09*]-::GQ.(UI7(E:]&AEF)W*7L$6%LSB`]_W+8P?L1?]'#N^>5A&Y MBUMD>CY=_1'N\DX?E+7+JA8_C'NT:"\MTQ-6T#SNU<-,#S\X?DG0F](M(.9/ M,A_0PRV*2L+-BS:/U0F"<@BY0/.X0AP/RD);RK3:)M'<601QY4:Y%,]CIE_[ M(9\3+NBO.=SH)49T-O"6R%F%%4_HT*^9;'K.T360T%,EM^PT?70W.^G9Y3^ MEGY]LSIS06V#1O3C:AH(G%L4\&??I(5%97L:0.<.5`78:;EUR&_M8Q`MP:>- M2[$')RWZA/DR:(NR`OXTVBO0'?NP1#:/\$.A/5/;8:D&60-3('L&CNCD_F6O MO_^&)>/;20[V,EUN@K2M%[T1M;GM6,LO?`%&)-T"*R`&>U"W0]H5 MK0M%=%>K1(:H](VH+>G$!P@:[!QU4$*0^^$./_4\Y"=LT`_K)-"O;I+E[13= M^21F7F`6F"`@@!85E;SYV(WQB]=B,L"0X>L8E,K9?4A5B)Q@1'H&\1=,/*#2/P3L/G#NQR7-%M#;U)E+(Q$?S@F&CYN)J2`!&MV2A& M#E'RJ75*ON%@$<9.],J#>45.HY5":T5W@`(18LCTG]M?2B:==HH><<3.-26Q MQ=(5I5!B!XB0`(?X^+EU/G@C&5*=[G`D7=CG"NZ`]3?Q0D8_;MWH5XO;P'?/ M`^S$,I-GBNV`P=?1RMXGM#WHO/F:>&PRR1R.DPX]$KD=8*00/DA1%_O<9!V7 M;%C.Z7?`I``6UYH0.6J0AR[VPV_K:6465H5WB(,\9I"!S+;XE]Z:.O1A/VH^ M%""^ZR)W"N#`,(V5OO1S*F(L9>H^IZ!PXT4.WZ$4G_%3KHJ_UX^WX"Z,'-:C M-:QOL@:>&UGIVE'"=V3D$'Y<1YB1,U)!#=[#;_2[]X,>[P<]ZF0I:>HL(`"' MK'\J'O80B^W(@0^9SKH=^EC#6G3,`"C>\=$/J<&QB@+@BXUN3Q+4P("EB/:<8/O@*'06B;<]Z6?VI$$,&1ZR. M9YC_71!^,0.986#8Y6WK=CUZG07YO-!MHD]0>A@S#4JM6\:VVD&-8`Z MCF2UU``RD=<-M`6@]C]7LY`I";60.@Z,;3G[)RC/%A&[?XJ_.DS0\Y_@+:G` M\J!<9=KS7U4GB.XZ#J/53C=OLS6Q+:EK5\DN4@GBNH[3;PUU[>3[AJ-IJ,C#N4("CYP:/PO58,>13@?V MR&8*7$TMVQK/!ERAP?C,^#H9C;\:P\EX:$W'QLBVKZV&M).F_,CI<2S4@QU; M:@]MZ;0?60WZ^T(-^&&FZ\O+P?1WQH4]^CH>G8^&@_',&`R'D^OQC&EW-;D8 M#4=-Z568("2G1U^H!SOR=#:R*0T4\+5U9DRNK"EO4@V!5LH9D@-^(`3.AJ3A MY/)R-+NTF-%I^T^4^&J-FS.Y0C:1'/9#(78V1DVMB\&,VOMJ,)W];LRF@[$] M H]XV\(SF<1T*<;!"R?KL>S7YO!E-Q\I$3X:\F'1DMU@HN MKRQJ3&;+AN8C<7J2'-9/XFF(#2:C,85H&;/!OYMJI35F(,DI!S M[X.I14<_VF#L$;/^2;99&Z?6[+MEC0W:6^E?+=NX'I]94]Z'Z5]9WYU.+AJR MAR2=24Y!\:S+1R#[^M2F?8&--=8W^K/CN4H^9XEGW7)SEO'3\AD-G!O>(L]) M5M&#.B9GXZ?D"0VIJ9@4):=6Z;FZ81U4LZ7DE!#/V[+ANF$MI"E5-O&12EIP>P,H"WN`:/Z45 M&ZN:&]*K5,Z6G%+BE06T36Q/HX:SL^1L(%Y\E)S+3(,A2;)'&UDLQAL8X_;5 MX'!6=OS[>UC+>UC+GS6L9=4U3U]7'__ETV58Y-XGW5(>WZ(JKW>@2SDKZ'8P M3SB\;NI1%&M1LIIN(F1*,@707,90VH70=$&WSB$W[34)G6-R5IA'X>,B)ESO M?M$Y=HE01Q$ZU;HHP*E8*\T'\0SH@RK\'70;+](4@0?Z1Y&(8!]6H3`5NCGZ M8^G?W)5C;D-PUUL0**,QX;9RIJ26K;R^SC>FREJ8-0E\:DL]-P%QNT?;.U760X,#=[:4.R2Z8T`&(;1?)%+G(?V)KIC$27<^=RDG% MM.>D&#TXXFD1,3^9T__YN1XB:20 MP;N]%6#9>Z^<5]9EV=+)=>F&WKOPG5L_X"J,P1A$B M<:I0D6-8*JP]:ZHZR%X8=,C?=1@A%]^%[&0X5>(4A=2V,5EJ,`DS,3.%?%:H M3'M^J^H$\MVMDX-O0=,U6B:8F15SC(EJA$>W[+Z@+RVJUK98C# M)T1A,[="1J-"*N5RVK.G`!\DK&OWRFT\"DD<)8F2ECLCF8-%**`]13+<(#?= M>EEX4Z([V`OLA!E_W=<(D^(5J(*P]IRIZ@#RUZW3)M_DKD/G@:4%I1,X?S&Q MD+%7**H]=VH:@,QUZW,!+B*6[/?$`MJS),,-.`_RU1N@J[,N+ MA/7G3%$'D+]NW2E3](3"S%5=HJP/20GMF<@!!$OTKB=Z6S^S)D9E\O MJ;WYA8#!5\[=.CC2\P?IJSTE/D`1[8F1(P<9ZCHD)7&EI%AE[L)<0>W9$.$% M.>C6?;#R6(8>?VV0.+6*JU59XCNSR337EJEW&V9Z&\`6=:OI5N;"S/>V6EWBJZ5)TJ:<0 MMP:A1!N#QWL4U'L4U$IU@MP/=_BIYR$_(8A^6.>%?G5S@>Z<@%^-]PH$)]%2 M&X4TC2`2005-WZ*1$SQ@<`4MDB_1JXP-@ MRDOD^:XD\R\KE"O3>LH.!1-N`H3,]ZEF\_T:8;H%DEHO6Z3UVQH4C+>!#[+= M<5>;E!H9L# MW?/X%(*'J.K6^9V!37?$DXCKFZ2%NJ)S!M-$B3!(>*>(DRO1Y'JZQIY6E(D4 M$-@IHC:!@\OR3LFYBM+HL0QJI33N!8+ZDZ6D`+B:UXBT\J.BFORN45AM;.SV ME%YFQ/B&V=*IZ"XT0$!_KJ3`P9V>1MTLFT^>3!%!T1-/27F^B!<1SU#)+J=0 M[71JM>E/:W6MP.VI1IRK]4E89M?X4^^9?ZEDR-JS6%87B-6_4#KD7>444@7T M6'5+J=*&;[=V>>I;N\IQD8"W,'GROU"0].Q[''B@RU!85F/C%F`&35RS0S8Y MG3!DRY0@X&=F$E"`E:'BFAM:#ANT==?A@6\["'F8V7I)C=F0(@:)Z-;]H+;: ML.GBWW=E9Y3+U:,_B57T`2GNUB^1Q7P54;C%3B509`>(DT,'.=+)/:'^$DLN MIS];*OA!RG3R+J@MCF&9W:1*:>'\2VZB?7TKNJM\A5PD_HS^Z=<,(SI1(Z_L^1SYQA[/8-.D<0WRU8S'0`1O^&U9E1 MP!;;K>MD>476\FJ70>B)302W,^4J]&\=)54!.-S#.,]"&9]"*-!`3`"G]G1_I9VIG8?WJ+&!!K*TXI7:!M^@!C M^82F5LUQ2Y.'3]P.>T2K44 M)Y`6:2E2,_^@EK6F/X=TH>/'0]JJ7NH;U[%O MVG@>TV>A@4MG3L)KS,0DG:+X&:&0'PWT$;FF]4:)+X,GN<*!F5R0RZ6I`IL% M9!8Z$B=-ZK/X-'MR/OL^F%K&8/C;]<@>L3Y]D@UJ,DZMV7?+&AO6>$;_2NUX M/3ZSICS*B_Z517=-)Q>TI@2AL81H+!A&(P%II"CU-[120-61.+*O5H.V%DK6 M/S#MQ2U!?RSHDL!Z8HNYMR3VDSD[CNI[:>`CN\HWUQ"ES4X<(M@_X"G+3FWK MMVL6(VA]HS_7\M7CN9%[KD$GTXT&UG1;VK2+6N,01PX":K]'WKU'WKU'WKU' MWKU'WKU'WOVU(N_*AXO5;^.:P\5DYJO[#7OUP,6VDZ57"EQL)/4Y=!XDW3*, MPB=$^)484HM"Q76,")5BA>Q;=V!HV>YF4$#3#5L1;)`8W6@I2EDK$6EY MLZ=H\D*"-$\Z7"='6NXM&-VH86<)!32!^%2(1TB_9S]N'8+H-_\/4$L#!!0````(``9D2D,7XA+^ MA3D``.="`P`5`!P`;G-C="TR,#$Q,#DS,%]L86(N>&UL550)``.+UE92B]96 M4G5X"P`!!"4.```$.0$``.5]>Y/;N+'O_[?J?@=]9.Y\''COT6WD7D[#5?0'-',V^#WZ@$,< M.VD4_P']X`0[^DUTYP7_U\??W-EQ51 M_-9)R9=OKJ[?_NK-[?45^V-Y_>W[-]^]_]VUX0-2)]TEQ0.NOEQE_W'V/P9^ M^/-[^L>3DV!$WD:8O/^2^']Z53+K\]MOHGC]^LW5U?7KOWV\7[C/>.-<^B%] M*RY^E7-1*2*^ZW?OWKUFO^:D#7UV\NWY*WDWBO\L9G+1A'`7[$*\3,?)_NMP2H MB4]Q]BK[[CG&*[$R01R_IORO0[PF+]RC#WI''W3]+7W0?V1?WSM/.'B%*"6! MG]2N=Q59&=-KV\H^X-B/O$G83>LZ]T#JD[X3IT<84.:W;L(R2IV@D_)E3NMJ MSW"W%C_PV6]I,HK@;BU=XJRJ'=`O[\FGBN+X2TJ&'^SEJE-9"@?''L7\;B:[ MD!ZY%;D!=991+&P1)G+E)$],[BZY7#O.]C4=DU[C($WR;R[I-Y=7UYEW_(_L MZY_(8+N)PD4:N3]_Q)LG7#R$6?BG5PJZUW6M*<TIQ]%4<;Y>.S!HH41#\%3X4\WI+DD1+%*V0Q3MC`W^I%EK77M5ZFV28@ ME#24PN'EI\6K_^%TB!'^\?5!TG#XH/$)WN`P'0=.DLQ73+71%S^16*J@MXD7 MK=IEW$B)P>!'IV$#1Y0,12N.)/0/2OK_8`#J@+4\4/L39PX],-UHH28C-@FMM0*ET$EI@2#)J5Z#1BY M[FZS"^A,$-WBE>_Z*0S\W#E^S!8,I^%VER;W^`4'UTH0*3EL(LE`]3*<%.1@ M,*77L0XL1H*N@8'I9E]\_-[',6G-YSW35!%GF3(/`C$C@X1H4W+"`YZ)NG4, M4@Z^ZW"!"B90\9BH7[UI[>7>0/%R;]IYN3=GX.7>&'BY-W#!]+8UF-Y"`=/; M=F!Z>P9@>FL`IKA&VUPL1YSXP1TLWWQC'$Z"KW#7)A: M$T3)CK3OS9[\8QLE3O`ACG;;A(@(=C2I0]Q(B@#0UL-M]@F[#5KN5G:>#*9G M6C57T+F9',0$L7224JWZ*W=W21IMWC?(^_3C"7:_64O4[>`@(P0!A0TVDD@(>,ZF1?8;'&8L&F#R@\T MJ2QZ`IF*)5]0)X$!`:E>4G]0IX>QUK+8/27XEQU->WDA?RS)\U192#)JJRM\ M:I4KJWIBTL$A9*9?'4H':L3($:4_;=B?^ZR%$V!%D"@DLSZJ")1L#"@EFL%1 MH%%,,XR4&&"XDN6S'WL/3ISN'YQ]%"NW#22T-MV(4MVR$Q$2#@X>$^WJ"&*T MEXP8,>K>%OX5JP;$7-7Z8(/$ZLJ!0+G*VD'I]\'?N$(IQ?I!B1B&FRA6QY?. MT^%05'U@K!$-DM]<45"8T,PH!@>&4JU&$)$3H7\P,B![?H5:]WZ(I^2C-A&^ M1#@(.AJ*"A%24,%#25TU!5(H*6*TO<+%=&N!+W`_XK6?I+$3IG1K2[!F+B:S MM1;+BHXT!(F"EMJ=+;?NU#-.@`J1*"0(-),"@E.C`@UJRLS M!#I&1!&/*G,7.&N!7;7?;:%!J%:.@LJ/(-Z^2*/&T:*!?'5$<_ M<9W@[]B)Y<'E&&09T##U9^Q$'PES#Z M'"ZPDT0A]J9)LFLL51G0VPTG-6I7PTH),0@0F6A81](TR7.>'$0Y+W^FK"CG M19SYS\.!ZH-D\^_9*06Y[#*I6N366%M(#0HU10"J)?)ZC@R&H=HDS2@&AB M:!Z3<70=Q?(5D!J57>P(5:Q"ID("""DBO20K'UG!SXQV.$`\[)X"W[T+(B>5 MFE6AL0L&@7I5*)0(``&AJ94$!IP0,!>+,J,0]Y!HA``,BH5J- MG8C%8K)<0()"MCY@A(@&K7U@2-1MXJ-&"`PF8NT:FQ*?'A\GLR7BJ'D/`S9C M)WF6V,9_LEJIO*1,I3@Y^1[,*R\ITWC#Y"<8KY7C MI).I33_32@P82';7O8[@&4Z1PZ31",@KU_")BL(@D"">N5X3]SS@`*<=V*Q" M*2U=@J)O-MD!#RH$N=E&.\<,)&#,R"MJ$0R)R.W#1:YT$SE-6F#^2*I@P^D4 MA+!B(S(!]%-\[[]@;QJF1&/_*<"9;5@&)QV3U>J'1@94"B`J.<``S$C-Y@4- MT3;V,=N33['['$9!M.YUXZP_GV78L8;U42:^">+`UM!./+:%![<$;WA3&C@$ M+.1@@`@!V8N?+T?W"-*RSKWO//F!G_HX&87\%IKG*/!PG/`+033!C3F[3<2T M-:J,*5->,&-52X4;==>FHYOI_70YG2S0:':+%LOY^"_?S^]O)X^+7Z/;R=UT M/%W"P.K(=:-=F"8/SIX>]Z1E*%TW)G/'4A/D2V6A9QZ@'RW6JC?LJ1$J?O1( MF6#Z0D^&*/K(^?6$_L`/'N\]0?R<46VV15`"-)"Y<,W&1\RN]J'U/0[&F36/ MA'5`S"J-48!4R`<5E2IEFW>`O=!BT@FBS8:BU M])9)[`:V3>6JP>OA=S!`$2C5&&!I489HA3@1#""TV.QHX:`E;72JA]D$YVD; MK`SSTSP)3(5$`4#-B8= MI=<5@W-8)^AO=>#,UP3,MQ+GLS.=0^GW?DRYP$<8W`9#ZXU@*%N_[39[SV![M_6&KG`#%TB$^D!D8=(= M^#8UNV568K:0TB:0%*J6$20@`P,=N6[-U+6,$B7\-/9_?G-]1<+)&+WP6\A_ M=W%U=47_1PD_I^WLTN?/??[QB^KK_]_<6;__[VXMWUV\[XO$#D*5OL MIOX+#J!D1RAJ'A5E5E'A1<\MA- M0@H75,JH30@H2"%;B^KM9BR#PDH3J8&NV]Y"22.4G:A<>W>H34,WVN"BSJXF M:TE*;1-@&I7+V)*0@H&56K_&332,&I4N9P96_C@[9A6N)U^V.$RPKA*R@MXF MH+1JER$E)08#*IV&=5C-'R:/H^5T]@%-_O8PF2W`G,]H&&)J\,#P,8(-7+@H M-SFCG!KAC!P85KB3O(\2+5K*E(/@I:FJ$#$',GB8:>@F=R[W\P609.V#TG?D MQ8SYT5UB3'%*.+G!JRC&G&[I?,')+?F0I+ZK',<[2K0?.QUE>C.^ZB0.#):/ MMZ&.^=]0J/\636?C^<<)NIG?9LO)+?YX7GI!U9KO4E:Z[F2 MMNS]*9:KB)RBB6KE0_I\!)@^=!J[##H<&P&@]KD93K4Q=(W&)MZ%ZI716B$` M@S615HTSZ9,EH"@Y3YO.M_XT:SER/ M\QE:?#]ZG`!9SJF;<^,DOML2536>(:$E5%^%KPH#6)")M*PCC=$<"ZHP<5,* ME>NK=V^O&%!FB_%2K(_!3*0MLPWH=#.(8J@=Y^!@ZJ1N<\,L)^VQB%H;E!V" MO&Y`D_(/BS6-66JX29@!(TZM<>.ZVS(UN.)]0@/GZ3..J=Y!E.QB[29;2QF# M#ZDZ\[1#K$S`X)@]1FM1L%>=6=:C/L`(;M,N`!!IC#RK"'O!\5.4X/NV0#ME M3-8O4B5,5?DP33F_PV@_I>(]NG(#>%Y%G MG:IP<\HWT+4(Q!N0;T&NI\&+&&UH$408'7CD_7.7I#2!-%E&DN(\##A/3H*] M<;2A>5Z\>G[H3;[@V/433/P7;9#Y5I45<)(GV:W"=+*FJE9PZOTQ8,*ZT]G6 M2#7CO]+$1#^&+(7[1S]]GA*G_N)[NZP=U">'CI!G-2OA M6+,K^0==A8'I!,=:H*KZEU?J6T4Q>G+(O[?.GM;HRZ^),HD"@/:'.\>/V4'2 M/%KNKVM(18/M)9K&Z-QA)'+/L^^HC3FN&T&*X=APR&V[W<4DU'S@42RS.5_K MJ[:9*JYM*\EZ+;ENIC;F&>W$@.D"W75O%+OFQQ!+6'=+3+"&"HG5K'OW`7&E M(``(-S#4`.`**=#QK5>]+;S/QH7S[^^B>.PDSUV\0DT``#@K##/VTQ5NZ/"5 MJVP:A[B$Y7Q\\A&8%?$#@*S<+%/'>U:`E6K<#J]Z)PLG/=SN4K/!9I%8/>$E MI(1@J)7];GLK0ZSK3T*OW=Z*K,DG_/Z#,]]:>0OP% M\RZ(/NLR\]0L=L<_O?)59,GI`8UR6B4;\X>BM`J]7)TP(<9E6&@%SK!FMYNG MI.>V&-1DO9L.:O>:06V@7=)'3-^1'^"*)^22/&FR?M.?&DFZ4]O0<,/[JA,8U+]DI'H72",7YPU"8!9;T M6_J91O3H-SOR&.2'ORU5?W&*1P$Y76;8,,*#O++\A2-E6JVZUX?YE;)\QP@$ MTZ?ZL$)^9(3T"F@G1HBOB+&3X%O,_R;FTH,%!YN3!*?T=I'R9XL0)N6>D( M&YISI/JJ7XGK1,IOM9)@N5Q+6]-JRQJF[(/CN;O.(C"SF5+[]'=_?S'!:^&=3>=C69C M6B)T-%Y.?V`W&`*+&/O/73B7"%&E>YMM81C>JCG_&;DNW4-*'IR]\Q3@1\RN M_7UP8@IDXUF41LJPLU\C$]6S7:4(,!ZJF][-M=$7NKN8Q8W.:D7B2,(%9+R] M]T,\7XUC[/GIG>/2&'=?MYOT4]YYBW1*F<'-\VAQHY" MC_Y%G(#NG?$^6.^(3FI.M/A)5;P6K9UE/UA;I*PH4BP\LF\AG=AO:"6:@%Z@F\F'Z6Q&IYWS M.UH\:SJ_M3SIU#8JH(1)@5;B9IW,;LT:U&)JWFZ[#5A:EQ/DF6#3D,Q,-_PP MH29+SY3;:L)>.Y,JBQ1FK&`<=3M]&[M5GQX>[BF88I)TZ6T,()T?ELFL;NHT%2NNF)P^!T,<`1*-6_4XR1H2VB@X*"X M9D8)A1J5_+W5."?]D1;_EW[,0T>6.R6F$WG8?<=$F[]/H$FU@\ M0=.4<=RC>#!]H'^;ZOTGET;7G\C\?AO[F`3K>Y1B]SF,@FB]A]&OLN5ANMD1 M!;YKD*FM8+":;ZU5O)(U+:4&@TFMBHU5^H(!Y1S@KL/-.]HM3MS8WV8UK6@I MQV2^>B!-2&-:^NT2?TEOB"(_:WIL&T%#..'VAHI\K;D4,/#MK'IC672^G*!K M=(EN)XOQX_2!3E#H=/KFTV(ZFQQ_-9`LORY*<;*,LN5;)RC.0+@\_UCS>.U$_K_8N:/2?1,`A`O;XMRT\Q7YAZU9]E6+[3NLSDJ M5V#W(7CPCG,*:QJU3TNR+U!%.LN'+LNGLS+1@``N?FXQ:)BQV,UA,1L.3.C! M0+BKHW]+'#U<=[[PUZ&_\ETG3)OS4!WB3)FM[@ZU,JBR.63$"0:/K=05(O-W M!)F+3Q\_CA[_3H.0Q?3#;'HW'8]F2S0:LVO:*6H?YO?3\10*7L4'8\@HDM]7 M_"&.=EM=H-%:RN"W6NM-U-Y:+14CZ(8<%`+@AQ2>#&_:JAT]`- M=K3NC[AAS&.#X\5:[@&]-$*M2QPE$U(?Z<,0X8CP>[KZ!OF"=GK,PN?%.V@" M&S-XC4,WJV/`3=4X_Y8RK&8C=C&ODH[81@`82'?16G0`)Y/!''U%"CJ(`>?Q MC8S7^?>V0L"!6NF[VTDX+U@;^>5OB5^FU_A-ES2;BZT0US9U9"W[K->?;F*4N[2QA M!H/`MAH+G=AWQ(E-_OIINOP[#&@>U)^ORL6S,I\]CI(T.5QN^.#L37:`CQ5J M>YWV^`:H+]MVEP@&[KV8(5K4S6;PM#YU22S*PU,F.*M.?\EDHUPX.,=NW$8W MY38R6.8]3BK(_J-N@DX=2"SR_'J0T@[A,/*.;OHMY^._7-Z,%A.ZCO#Q84)B M81H*P^@:Q3D5XQ5=)<<@IX/,5FL5Y&"@J->Q>;",?+!*?:Z.G>=9P%#439G9NRRG:CT&-EK\N1A.D1 MG./%#WPZ\JA&T1R-["0;7-?HR2"QGZ9G>Q;SN^6/H\<)&HW_^FFZF+(J!.7E M6'0S6?XXF1K\['!&=O!@L;LC)[9;/ M4"M=K9=T@[0*OG'Y(4*D7<&7$8&%EYM_>L'S: MF\7DKY_H+OWD!_(GD&#T4X+GJTF2^AM:SE-B=9W()H#$"I914Z4``Q6A6G5\ M?.+U``HREJ$T2I+=9@NH%/\C)F#?87K]UCID,0!+)]_K=\RU?';WR0W-J.Z. M:YC``,Y4TV82!^-#)48HL'.Q_T)K%">F>),SV`6:3O$JPF34@*"E45%2B2)! M!T[NVH(@^DPK2;,:Z)]"-PH"[*8^_3WG@0$^22E,(QP:\@(H9ZI'IQ$C&*"V MT;:1*$PK[[(,8?JAQ`X#D,4JJ!D&Y>2#K$<;($U&"P9<&@7EVQU0"C:++S6; MYZ59B,($[OX+?B!V9)U&-@_J(LGJO+.[J949:7LQ8.#:7??&Z@A+G&"B*@D6 M,%`]<>+0#]>T3#53U,P_:KFLIE":F5#)J52S@$&AF9Z-[14G\=WL7&:PHSD\ M^47HB`CBF3PPT#>.6#_*UL/]Y&=^207])(M15!QVS]]H5:\>MI&2@T&;7L?F M\;`2!\L@8QR(LL!`V)WCQ^Q.TE(-E&E(-UXVA^!6TAZ&O#91U\J<,OZ,&,$@ ML8VV=4Q27L28JV5I2OPPH/D0^_FE.V2B'SA)P@I/L`C#^^2JK!7T^`$P7.H55BH@GD\-/9RQV MFXT3^__B5Z'=XQ<<0.MJK%/OAR;9%=#[EL. MP=T%#].!CVT(<7_L*A5@]SK2E$8%W%V:I$Y(>RB:0\HH*EDL/`+]HQ/'#@D` MYO&COWXVR';L+F^@GM#-;$D':"<,(NX[65"'>T:/\CX"#>NT3T?*%]G-\@T.\\M.6`T`'B!Y,,0 MP]0D/>[.#_T4WY.QQIN&9#*\ILGF?`'[9O_1^6<4C^G6I'GHT5WP,`'(L0TA M#D.Z2@73*WHSI7'V@7&@7"K:A6162_,F-Z3#T&*_1#5HG47@(HC-I7\518I3 M>H^2[V4+K^:]IHFL:<3\Z6CS`#M673>J\J`IK?G"RW/-@=#)9F:X/ M9(H?.X%!`7=#=LNEVUL952O:;L0+!M@M%19<0"`I2:@"Z`E?WB-.'=(_O3PU M>^2ZN\V.Z76+5[[K2VJ9Z[A^>F/UE;W@^"E*\+WBS;7067"",2=%&2T,?S(E MX<3J$*G<^RY=]1BM8\QS)B1-H6>S>R[,S(CJ^3`U#QA_8:AH'7%D3K:-?8+8 M>(^6V'T.HR!:`]G#J)G$HEC'37=.P'=FS%I"P#8@Z*1&*$#7X($*.IFBC76I M*'4"!!EZ]#3NW>UT/`U9>MEH0S,P92.UF-;V06NINO6#U0U",'!2:=<(RPD= MR@@1IX0!G;RBP"CTV*WOAV($,RR#D(;')I2,U"]#2LD`!EHF6DKK2<0%,0R( MD=`0QS3K=47^)B$FB^LEADMHK9;65JE;*9@M(@0#(95VC8S!C!9%&3%R=7,O MBQZ*K5@HO-'A=ZN>IZY6Q.9,T*C))@>`B M\WE1J2*P?*( MKU&\-JA+J,&@3:NB%&%;SH)2RL-J(SXY[L_T:[!.L92R[&RR&Q!H:7C2J&G6 M$-*E2@/.0:K4Z4T1%JR3LX&!IKFN4HSZ&3D,^'T*8UZO]E_8(V9E"?-);M,\ M+"S&B1J.G219+8'=W=1*G>SV8L#`M[ONS81QS@)LYL-60K/Y7NER8QJC9(53 ML*<>U5M)L%I_I+UIE=(CYNQ@X-I>Y\:>2F7(1R$1>)B_I^B[7Q7N&,5$/`P0 MCZ/P!<>LFG.Y!=2XU3%9KHAG8$"M*)Z"`PP@C=04EOW,#F4B#V_HNE$=B-=O M?@4#>[?X*3W41RM6QZ0;"!)JNYLQ2I6KVS%"4F@K\&HUSQI?K-O0BC>1$Y:V M+#_$4:*9;AMQ6A^0S4QI#,1J-C#^SES7QHTL)"9T62:#:LSU=AC-HA>\>2*# M,T',U<7AMVU^M;0?$E2OG%V04O9WK]]>4;A=PGMALE55P=5D8#KQ(3I4_EO8`:2FD*2 M.\"`O&Z6SD5PG%5TD+WV)IG=M0*QDM75@2H-&#A(%&L>72+Q+'$.B1-`P496 M\R_+^=.#1$%O=<==IW9EDUU&#`8_.@T;A>AR>F#+[OEN0*:^=/.L1F5W8-(;6B8?`B5AA$5RJE.!0(U1/"AZ?4<'` M3GF)W3Q+5\LUU*:=8=:MA@4,OLST%,[D,ZX+=*A$``-QU76BO%/0FFI%I;4' M'-,[#)RUV9Z(5L9PJWR&YLE7_#0"P""UB]9UW!:4J'"5CV`VC.>?PX1N`MUC M5J-X1,NWKMDA:;8WE$R31)ZW8\IL-U_Y7VT,?%,NY#[+OXVJC_*OF'\Z8&9LD]J8(9#%3;:MRHRY!?.(D. M#(AQ](G2!+O?K*.7UQ[V.4#)ASHNR5<_3<+43_?W?L(N-')X]))?KEEK`0-Z M&[@S5IOB3$L\.*Y,-6S6]R"005N")N8YD9^YOR!S?XZ9^SN_S51PNWCF*C_-8=WW1LZRF5HD`,70;&&HUB"CF#.YX>E&\4=3UL M39<&MSM(6]/Y^7U^#2IF"\[RZ)/&E`59J8;7B'?QVL65T@8^Y2.'J/=PRL83 ME8TXQ?,`];^3&RDM8I%=!DS"!6T%09O7`$&WDO-8A=B>N6K&)/3`P*95LDFRHJT MZVB%H/JRVQU>1K4#8>:IEL;<5B/,=B95@D4S5C"P;*>OM`Q/L8E81BF1=8$R M:3"P6DO>*/=#LW2/*L>`*3,BU17I,V5R,-C3ZRC-C#CL!#>W65%8?V@/F#*.0:'6BLUQ3N'V7%@2$72 M[[&3T!*CCS2-+%`GPDMH;:)*J6X93$)",!A2:==ZC:6MKQN]@>2![XL-Z*WWI^&G""`7DK=9NKB)P)_29G_RTJ MDA'@H?3>#_%\Q2]:'Y&^M,&>+#E;3&HUE%4H6XED!71@T*50KHXE2LHN;F7$ M**.&`1SYWD[KS2`H^V_MMMS``$JK8F-FO<-H&77:3;,_8V+!P-$3)H64G]Y: M?9,ICCO-EDPLZ#Q9`G0P$&^- MC&3S>)'244UZ7*H=)_1WJ-5;_"H/;Y((@.3]B4/81"'3[8>('A53WI8LI;9; MUDJI95AXK*LR>NK M=V^OV,N=+<;+3(_O<>"5;ONHZ:PBM/&B]8K2URVG&ORE:U63%&"BQ.AICTH, M)X+!Y)>=G^['-$`-`K8^QE40&2*GM08&G;H%'F2$,""AT:Y1*HZ1HS*]2>*1 MI<4(6=I*G0;>""[54.V188W01A'E@LPE?5=:B[NM$*NC?"<#VT\7<@F#>XBC MU&ZQ-4<#SIP;8!YC9B)+Q)*443.@'RH>%:HM"TXKQ'#PI]%04SRRED$'"%F- MC>UF7N%-/:^0#\&'0WD)JX"]?';"+..0=,45]NF"'[W\EO2SQ'>UJ;*V-;'> M&X9IZD8_LZL&K!X\B.VJ#7B@KF&RV0;1'N/\"NM1Z*G3@6J-W8+?9C=L;5:Y M\Q@S@X%\6XV%@QABU*AMUL@9#&.S';T8<[[B8_7HQ?$#5FT_BEEF?-]^1/NX MLQB0#!NMEU%'\RRK_6S+YQNI$Z?*=?#3VBH),POR,^^1V8!:2G'BS=)W8\N? M MW<)861_^B@+J2K+`2:-JX9/.J76Y7R6%S0#90O0QN!3G$G1F]NO\.&3?9H$S[RP`9-\9/!Q6']MND)UC+T3T: M8G>T:_I99=PF:W(-E"/*'73^.K)JNA3]UQY7&JW7,5X[:6T;17\+ MW;`JG<45%STV?B^77O2@#]B!:]CV:%R.E^R\BY9V1BZ/NJ'.S]< MS[('&UXI<9G9VE@>LW1)C1J77&![T$!_0Y[1/V@ M89^Z4>1<`T!69X(`ES(6:.#3Z-E(:N+D,`#&;H4BX\4]>430HA?)!K'.XNP6 MI3W.Z&IYVFZRP(#X2`.:)6N).!C85H\-G0842*-]^Q$=#.:,U)2,S(C0Y_7\ M4,8!`V_Y!=[]A:5'2;1Z7?+QIE?N4^XN#@S&C[>A<2-S)A%(;)JKD\4S[=RL M*?,0(#8S2(17-2>TW8A66I\HBI4DO=T6UZ3U$I[V)--:FEQ?YA?Y<\<*A`+= M/HT!'+EJQHYN(PZHB*##J'\N([MF]*[$K[_)>'X+`W=TNY@O.P=!])E>6)1K M390>)0E.Q\]T.7H:CC;13EIQNKT8F\CL:F09JFUE@,%N1\7K8"[$(">7`P/! M[3PF"$_9PD-"]XSM/.)#'+WX"071$Z=CEQKY3`9*G2_TT&>(@4SN)ZL5=E/_ M!1(4`8-%0IGBXOH^29.S$\9[,=&CNGKF/ M;R?")DR[&%<&:AM^,%#MH'0=K#.N,D MOBRCIP._M=WF+F85.\MMF`?'75>-FQ(2T:9 MZ!-!LM!XOB(/2GPOBY!%ALMIK4%-IVX!*QDA#`AIM!/"Y8G!)5JA"@>07"ZJ M4QKO7!8/A-XM?L%!M*5'C*CNLHFSELMJLJR9"95L637+X%AKIV>CP,M3$@6[ M%*./)/1SG0`MHE5*(C^,%OLDQ9L$W=^/D7<0AEPJ#=%FI2,J9N?*@.#3V?JI M$_C_XJ?CB%5Q;LUTLW7\F)V*E36?(;-5M+8RJ`):(TXXV&VC;AW"!PKJ.),< MOV1479#VQ1MVB=D5O\4,I1%Z@5._:(G=YS`*HO5^@>,7W\6)RI-*J>V6/$KY*0";,&`E*(KC3PRNUF:2 M:Z$,I`]$]N-"]C)TSXTI_F`%TG23:'P2-,+8^*'<0,CMOC=1?M5&"H2RRY MF6SA,?'+99U(6("3E%\K,(_IW[1".;-FE"3^.I1>`W<"&@?EP#B%#?32*X M#G"4&8U4""8!^47-,-HO_O/W%U=75_1_M"7OQD\2FD@:1B1F)"_P!<>TX#B) M--]>%70N7\5.TLC]F4:>^=WAO^,!!)]R9RO>&:W;SXKWR;I=(ADL%[NG!/^R M(VWU=^S$25%P?>3]DJA6FOA\R<+?LH8$TW?2()T#NML>;)8[AJ_':Z;>2 MJEMDGVCGKNR3:?9$].Q#;#B9&B7:@]+Q#@[*C@HK-C;)<#$2[FM6O;PRNCJA MV\H,5,3$50K+MY\99.5(]&MLXS`R($%L?>MIO-OL`H=F7$HS/.0,=M-J=(I7 M$VEDU(-W=&,5I0N*7`_2?SW,CDLT=P!+>RTP8">8(M+T]G5(5U:G'M'<7_DT M,JZZ/7J2A'SM!V1PQ@GYC03"7I92Q"D?8KQU?"\[KEC-/3*?KMK09>!%"7O- MK5G6.+TB8+KXD-:K`X.41:4\[6G(&UD5%TU6KFH$-_8+M9-<)AFS7Q5(KS% MB1O[6T$N4^_2@6X!FC1)Q[T_E6@PV._7'E67Z7?/[V3KL(?)YQ)_26_(PW\V M7\X2,@^\TJDP2+,T*>`$AULC=>NPS)D1QR>#YQ+'FZ'6_@9,F@.WDGB,$8V: MWL4"$=0D.NG*ER8/U(`/Q'JD?C];P03&V9AJJL9?+?L`"`(51SIF6'JIC(8) MR,&;D@&&1VX(!QC4&:DIVQ4?-(M%WMLMCS?Z3JT>.U[ROGMN&X3`%IJ%NC6K M7]+5Y7YV!V4I@;383Q"P""!:<:V$B6=".GM)?@HU#]E\`J+!.Y=.L\;&0HF4 M]C-.#*"'L4GJ`_&XSY*E4"DQO)!:KZJJ*UYDAZJVL*[,92IR#6]WL1^N^:7` M+-KB7]]%<7Y86M8P[638O=*Q@WG5>QQ;"!C<;QRCM0J\K)Q13G\!:>M28BGO MJ^75N'8M)>('@%NY60:8;3)#QZM48RU62SP7!J/AX'CE1[PY856F$4)=.Q]HP#6U M0#59:Q](!VKP4M*S`MI-*D"-KE"NWNPETL&1[KKTJK#DP=FS;/30(]_$Q.V5 M=-3T@U82`+VPCHHW]WVY&)3)8>=R,DFH\J8'[V4F%N>'#4+O^-\Q(`TUJM0_?0[,*],H9PPALM(?XVRD@JC-(W]IUW* MWDX:D1<%8]`C^#)[.SH>0-W+6%7%\,AZ$"]D_R=41ZCLH5O1DA M(:#7H=:O48(DHT8/^5+H!3M"Y@[T&G[$_OHYQ=[H!6S>]ZZ\SEX(R,8C+.6Q#H)*H8=]TPS+YCD2)R/(NH'*, MDNHF/B1X46Y[RXV>[6$ES]>"/3?R+8!F%2C3W%DCOPZ[5"#.OBA^!.10FCI) M5P74EW&-0<<"*6]DK+&4/`>2A3F?;"8"8/?.B.L?@SSU_`-8F:),O M.';]1%."X/2/_CK!:F2Q-0@W9M6Y/H-6:^BQN:=A&OMAXKO2\/MD#_LZ\2NQ MT1IBB^2`4&*B9:-";,Z3K7'G:5`&F>&`'4CF M!6FD:7MP-'PT(-C8MOB4KJ:D"[3!D:TBUAJH*.7,ZNHZ;KIS@GM_U;Q+QI`/ M`*HZJ2O;+-#P#^F=GO0=YJG>8?*Z_/G"6L(J)RZ?G3`#\&B]CO':27%UE#;9 MBAA('P"(`]4,)W!N6>)`23_$%$0IT?#@^@HEZR'6D+L[1X\QVG?#%I&2:5UQ2YP[1"2#`-W6B#E\Z7K*;T#0[QRA?N])AQ`D)C2X6;6[&< M'67\B`M`1`+*1*#?9$)^.\2,)E=PD9+0@Q8/CURIE31\]\,="4/X9:3UPSZ] M"`3P[ONU0P:)KH*'2F-(TS$TD1#P5 MA+HO[L:#(/I,C[$+$R#[?00`))W:LD;29?Z*1Z+BF1=TU'&'RW4FVHV)EJ1/.'&\7T4Q'5O-<&7("@@O;35N+`N35\D% MH+*$"]&+%;S/\E?WY!/Y.O^*_$%C'/+-_P=02P,$%`````@`!F1*0Q)Y><;( M+```-LD"`!4`'`!N[3M7:#TI\F<7;(D M9ZO&EK0L>;+F:8JF(!DK%.GAQ8[7KS\`2$F4A"L)&BV/YR'Q.`#8W5\W+HWN MQM__^_LJ]!Y1DN(X^N7=Z?N3=QZ*@GB.H^4O[VZGG>ZT-QR^\]+,C^9^&$?H MEW=1_.Z__]___E\>^>_O_Z?3\2XQ"N>?O7X<=(;1(OXO;^2OT&?O"XI0XF=Q M\E_>;WZ8T]_$ESA$B=>+5P\ARA#YA^+#G[WS]Q]]K]/1&/8W%,WCY/9FN!GV M/LL>/G_X\/3T]#Z*'_VG./F6O@]BO>&F<9X$:#-6E`;9Z$\+Z? MD5^>G9R>_]^S_ND)^V-V^O'SV<^??SC5_$#F9WFZ^<#)]Y/ROZ+[WT,/1OHAR;KXZFO=D' M^LL/!)A\A:*L&\T'48:S9XI2LF)$$L+9*/<)6A`%)TI`/G9Z>O+I_(1^ZC]T M^F;/#\0X4DQU^YWWP9"Z"S^D$IS>(Y2E*G*XC2U^?^(GA-E[E.'`#XV(X?9L M1ADU($2%GXX7XPGYZ M?QG&3T:B.>C4C)Y1G*'33A^E08(?J,3'BXL\Q1%*E51I=&U.VUGGPD\QX7N2 MH)1(@&D%,>HO,5GO>C%1XR0:IFF.M,@U'ZTY!^>=>K3*^C6GZH?.-%^M_.1Y MO)CB9807Q/S);!D$<4ZFRV@YB4,<8#U*3<=J3OV/G3Y.@YB.GJ.Y_ARCT[ MS2G\N:,W5_/:-O_ZI\XTBX-O=,9`<[H!1H1%G:V'5F<+L_8)V;4&\0K-_.]Z M>L7O88&2T\XT7F1/9,7L!@2%%%-.*SIQ@;(GA"*V$2,Z?!N1596J>!Q1W2;C M:%%O[2L6.#XC4]Y=BO[,B8D.'NG*K,6"N-O+S>AMS.SV9WC=+\_\N]`N+[LC MMK=6Z5.N-T*+,YX^J9I#V)[]]`F4]8,P$QIP8OE;K/J,&Y1S14.Z>(.H2;C/-RLWCGTL<)\[==(S_-D^*P6_3%_T;SB^S$>S=^*M0Z^J;XO[P\XXS]A]$P%Y_%"54:,]HWK8-GGZ2@5(ITTB MQ*U8FS$D']/VKGC[\^`[I0$9\&`V4NN4WR`R'P8XQ$R.]OB0CFN=*_)G+T%S MG/6('CPOXH1LWNT;QE%<>IUO'6OZH]DG?>*(;SJ&"7%:YK#.-@A,Z1!"W&B ME!HA^`\9K=V[-$N(5:P'"OT[%++A_Z!]];I^J$-L*5(61K'PTSL62Y&GG:7O M/WR@@2P?4)BEZ]]0MLX[)Z=E2,5_E+_^8W-%S)PF'"[*AOOM]DFNZD0WV27? M3X+UP.3''84X#`0I6WQX8/$%G>`>AQM=6B3QRE2V)2&QE)LX(;;\R[O3DQ,8 M8!"K0D/R8ZH!2*6M8U`$PI4C4"&_1.$,"@J]T$_3\8)MRKO?L0X8AUV.$9-# M+C8&XA29*EW]>.7C2`P)KRTP+$3ZM0<+CY,2#\=PL"T?H^L:K>Y0(D'CL*D* MC)+%\Y.68!`KT[[\16Q6%,4A"A,R%DK(KE,+"'YK32Q^<(Z%C%F;<*0H>+^, M'S_,$2Z0(#_L`T!^]4>Q\;A!2TSW&U%&(X$YPB=-^2TU!=^6W,4;CK7\U=;V>&HF;RZ8+N7<)-7-*T67H+_GRWFOB>JW4 MDC.7+1?R[>4)Y>D2IX$?_H[\1*K:XM::4O_1J=15S+I;+;^B,/PUBI^B*?+3 M.$)S%L'!VR=N5AYA%TTH/@)8/15LN\/CMSC,B(PZN&!%P>MHJ-6G$6N22_$RP$DN:Z:,`XY`KY=0\"W2UK0U!I MK`L`C&.O@%>.^/_^X8`=\H%OUN_A^0GF.Q?O9U['VW!)?BZ[>&4?`!=UX\4E MC@A-F"AW7$2K2.[E]X&3]G;HV"]C2I2,[+>#XE/60&7/N\_G&,8U2T%;N976 M!>6@N6O/LT#"/!@$K,)`@U8SD-PVLG]U[7^6BS'F4`Q)P@7UXT4?IP]QZH=? MDCA_&$9!F-/=&S?10&4-AH.Y=FB;X-=`6I#@+IG5G-;<^\+-IS..U!_6=\I7 M!;M"TAA=69SY(6L)`*]1'`5F*Q*OAVO?N@&*8H9AF!'9\>`,7>%'-!\2"49+ M?!>BDG0D`4?5S[7/72G]V(@=2)#MLZ9O0>Y=\;4LYW5-@2JX`'GJZQZ(7@M@ M5]B_PR%+&>E&10373J4T]1JF/P*8.P)ST$W%!&0:+=+$TXG_3$.,:4Y,$"1D MPUMA9[V7CN9&&Y?&(SN_PC"&-+8L@6/5%*O*8:P/[;EA;`%:7T^.034JB?1; MRK5U0=#;^95-$Y2D>$O%!0/@*QS1[$F6?"Q;YJNMG%_QV`.,QSX,8`P<5P;B M$$/!NSW?5SDJNA=M1'@)U!&;[=-#D3-"> M2\W='O#(3@B[^QHM3YWN`+I:T)X'KQE5FL2`<1OK M(M5B<+4A-A*>88!2B0%7('+84A>.%J.K#>$0<0L#B^Y\SBZ@_'#BX_DPZOD/ M.-N^WL19`T4==)%I,>S:=%&3\PX#H!M:C2U"\X&?1#A:IF3=S5I3E]=V%I,7C:$35\B,!`\9-!DSZ"/4&L.+>M[A=>R*U0)IG[4@C[J[>=4 MVP]7:`5_)^DQ_"Q2QBLD\?>?MZN'?!:SFRWXG\Q7P:U.KM.`FJ`I(%P MP*&IO_Q).[E._K&#'NR%[X!0U:HG[.`Z#\@F6A#7.\.:+2+6ZJQT[=?KLH"9 MWC+W4J?SZOOVG`>Y=T[F/^R=S+=]O7CA57J[4[[BB9X-8>ICN+"#0PLJ)1DM MRY>2-`I82+HX/E\K$-FS%B7K,.:X`S(-D'%_5E8+60$*4#`*5;N*4QTXJHU= MGX)K`W+(,0Q(MG1=$EZ+-RAS]I3@YD50M(@35'E1K4]^2#,B"DT0=W]TM@\L+/RXR1)??!RM65CG6+#*+8=-]]14#+;U#[D^EIMJ M1DN2AJ%&(Y3I+,][S5R?U4TAY'()`X!U],?:*:<^4XA[N#Z.FYTI5)S#Q.?" M3W%@#M)>-]>%.Y2RET/%%4)3O`1/5'*_K;E?H0,8]'==64-/S'$MWEX>H^UB M6!LFX1#.RU[8@4HA(L`SX#B[1PDE/XS3/-%QA1D.X[R0A8TI4B4EP``;`@F@ M^$0]!#10Y*!E%N;WB)*[.$7N`SV_(KR\S]"\2RCREVB4TT<&QXN#"Q#-34[- MX9Q7O3`T[492@V'B1BQ8`AQ`Q8IFR#70@I:FC!>[?:1,\4.==VX>?]R_>:ST M\\J.(`*!Z^4]:G5WFI%QE"_5']"NXK]X4J]>+50QS1<`C- ME^[YW8X1&SXG,%Z\WZ--]>B]H#DP5&0:MW_4X#-4N?T`$QS=ZLOK[:<>&(#R M4H^P6PGC4\'":>HZHJ(.)D*.80`BR+Y6@:/HYCHNH@Y06I*``=I^[K4*+5%[ MUU$.=6"2\PX#'X,(Y08/2;I[.$],>T._P0-[`9$0D&3NW8TO53'`/8[V4\-! M`=F=_RM/,Q92/HL%TSS3Y3L_17,Z"Z$H+6"*YH/O*`EPBLIC_OA!$5W6RL?` MK*UFMZH(PM%=!RBVHQ,*8<)0#S9M%83U\X1LB(H7G0N"US>R MNPPKMA2F@[D.;33;<]03%6BLF8Y:@EHZENMHR:9(:P@*--#56>@R3N3OWIJ, MX3JXTHX)J#!C%"S%Z?5:5[<7J&LBQ*#552XC]@E@C=MQAMZ@((X"'*(=5F1@0O^B=V:/?D@]*H4B[FNHW#>I/XKST@TU\*TCIY8*8E$:3@5' M[O+?="7\$L]3*"5Y+@=Q>MVA_!4%/>0/#R&3@1^N93", M%G&R\GF/-W".-[H#Z*(-Z?QJ*!T8R]0PRA"1;493562'C&HK[1NOUL`QE/3^ ML>&092A@;.J/J_#8:Z@+27L7U@TAX3(.`Y6+/"6GC#3M!F1_4CQ3DT[R)+@G M.Y))@@/4#=G7R>^G^5V*_LR)%'Y'?D(=V(/%`@79."HX%"-J]2.ZVM#>/K^1 M-K0@<(>/`HWB#)UV^B@-$LQ2^\:+-8/\<+.?O(ZW+7Y(_FQ(^D#P,PK2)%S"2T,EXX7 MDXHBS`CP%X20;VIK-AG+#Z6`TZS)+[8[ZWI?Q# M>F8KNEDF?*6S>/.>VC9$56*/[!)5HZ/-LQY?]%>8S/1SG#UOY2JS,CI2G8%< MF9BNH`\/D?7%Y=C(SCNZYO2):T[TX7IK1F/I::QDZ4?XWTPTA*^43)/S-2)5 M@"K/&FJ983F^I>&=7FD86?'&A0_19.V"(KB[`&_%/W2F^6KE)\_CQ10O([S` M@1]EAUL%KF6?GG`MFSU\>7M]W;WYG2Z5T^&7T?!RV.N.9EZWUQO?CF;4ZB?C MJV%OZ-3>7]'>5@J>AHWJ]C^V/:R97!P;XX\=15C;CO&=^/)X(9M4UU:&I\O,L6N'^GZDL3Y@X;Y&0_D]BVX"DG#*`ASFB;)9\%H M16T^LF,[KJD/AT_`61&P8[/_V*&U-#&+R*<7I8SV)8K$Z^X9U_1I%F-O?'T] MG%T/Z%I+3J7%-/!E,'*\TFX93/G>S'[W9C?=T;3; M<[U^BYA3FZRZI]-ZLWSBC$S4:!#']JF+XT%M6F,Y.;;'GSN2!U).?^!:'W7[ M#OYQ.YS][M#2=)]!`?7>R7[U"(J`D0T9#.'8@C3?03&4B&-K^=1A%'?$J78[ MYO,CUWRHFW#,CB1=WZ;B.'RG7(OVB2KK>N;39P`".I]B,/LZ&(R\P6A&_G4P]6Y'_<$-\Q^1?Z5^ MHYOQE4-+70>?$#GP&(/:HH`(U272;E4D!(S(.,Y49VHSG+G*^N M#P812'4_82+JN)XRSSC;L?&9TT`E$/I\D1NT3IG&O%75S7LE-@M*U3V=%UZ3UC+#5%`0,W MEF429:4_!Z??BH)`]"=9[)2DD^MGILP70;4(8&!5>=%NDS(QC*@+;K5=ML6H M:79W7?[0&#\CLN ML&!`/4)/%8Z3."(_!JBBF=HKI?E(SNL5&F-=5UI'XB2=L9,RUT5Z9B/ER_M; M\84W!ZF=@TQPC^9Y2!>6]1K#*YM]C7P*V7P=S MYO#VPZT2:-V$NB`&0#AA\RPWAS!"#4N6S4_\W#A9<#*4">HM2EDP??'=CDPW M"M]C6M8(?C;?R]0?&\#D8CU6V9[,81QK*_QP4S*^^DGBTQ="DQN\O-<+Z:D_ MI.M[[K95IIZ(70?;[02VRU86?L[F07@[A.7D5<6Y;S6,*FT<(?:D[X;:P7>J MR.@"16B!,_,5H,:@1QA-UJ"]%(/JP=F@2RHL+L1Y9;YX7M,5\I-UTN/D0_T*K)@=&0%9"+?+$F,?#)9 M7>((9^B*K$WS(9%[M,3$M@J7^\7SM?^O..G16U:CY;W^V*X7^1KZ8$^DKM>% MPWPHV43/+T_`SXJ",&6_EO2HC;KQROM?/%?^;U/4*:,E5_&\]%D;F;*%CQQ9 M"I9]^;JV:_ZC"7V4^3A,1]1Q1(\F?"L7%!L0/Z+@_:T7 M^`5%1/-"O3)WFB,<6]B`J6P`5G77LT=^-0)1E7=@QOA6^5T9'Y@5[H>K.)6_ M55IM]HIKNW,%4OL)P`PE$-ZLOJ$V&:'Y.C>`S';Y*F>35A\MR'0G+?2H[NOZ M$-6F0NC+KK:6\-\VAQA!VMG$R)7Q<$R"15_\;_K([Q5Z1&&Y!O`7%'YQ"\-( MTXY'*?$8*5Z5%F]+C'?W[#%R-HO2V[[04F'(TG;8&5MRJ-MKIYHF#LP(QE9O MGXUJW#H$%(CAHR'Y4;)^\]K"0(.O2R($*N17WRJ%D!5U\;SY\7\P.0(DP7TQ M&7:_8PDRNOV/""U=EBJ[`@@`5E>10[K[\8IL`S1PU!L&!IQFRBN"68_C[9D` M`MC#Z"'/4L;BZ35:W:%$`UI>)]=;WUKJ*T)2+!48ETD\0L_JP'=F"%]K-3/: M@N_L6.`[KP/?N2%\K55::`N^?D?EC$[&HCQNGI>N&K"YE0"$>2Q*OGM;=3\1"4 M+_\5.5!HQ:O+/A%RQ')*NRM*I.06C=_\Z*[,9%P#S9@5_+J:=2=S=I[ST^IE M6;5%^_4GO>TWO?*C'OLJ")_F7S/]]JB]GY9R5]]5F#;/*8;U5V(!S&4[1D];VX MU*I<5UJ=79^C&QK+_K*D+R\8+A)Z*)&?O-PGB&F[.JK,P!!O>4BD&TQZS$JW M%;M'2'UN%W5S[;77!D2+?1A(]ZRU/.?\8"N MRU4;SXPU10;#0@>KAS!^1JA,`*B0WLL3*BTQPAI=79>RUL926PPP4&/OQ#6` M3K>_ZU+6VOB9"00&B.5L0:8/(I"0U?A1`B?KX[HNM;904;V#]&\T)V64!H71-\SBJE-92 M@EEK,%UPW<<7-)`5#+#9R;3-11@M!5'E0XJCJIPN=>]^+G@1@H-5'=]GVT9#-N4?F?A%TT,4'@@=& MRO/Q>P68UM$J\K$?53Q_7Y(X5>]5M3KK@NW>Z6,@"X@6>1OYJYC,)62)9U<; MTG`MC:ZZP+GWTVC+`09LV\O,B8_GPZCG/^#,#R5G0E$'78C<*QLS)+L"( M'I4U@R4R/VRI?4'N7/8B+F%@4(9*E+>16F!(NNBBXMZ%HN0;!CQKETY)G=UWCK#50JV%\R[Z3JQ#0*)E%V!/#B4?.4%$WQP)@R=[TJZTF>/M&P M>;AA@A+Z+KB_U/8"*XA:LH,!^_@I2ND[3%=DFB>[W2Y]06G)UB#V M/%/*ZG)*;E)U^[L.6+8#M)FT8""\JYR5*ZCBQY35[LR#S#5)$#)NFC MZ.(Z5+HA>&H&X=JEH^N(W4L"Z><(GJ'%HC=3CZ7R,^D&^QZ MH[D.U6YY\M:0))2IH=#@HC0P8BY(\=:#;CHVS2JU@+N%L13HS?^5I]E*>BW5 M[E==AX[;TJWVD8&A@Y,D#A":IY=$D)4PLV=J76(=DO=R'7YN1P=T)`,#PRIU ME;?MZ,%4=G\IZ>0Z)MT.@AIR@0+@0_DT\GBA;X3R7LYCU&UAJ!8-#!#[.9K% M>Y&Z1O$BV@,XCU"WM,B:"0P&RGNWE%65U+Z5W>WD/"3=#IH:@H&!X%[T+T*J M(GC"#LXCTMLX2!T(!`9J+.EAO/A*+P&C;)RP"IKC/$LSGVW')4%#RI[.(]?M MX*@KHC:1_(XK=D_J1_444KZ4P'WU$2X!0Q3RL'QJ*CLI_S MB/2&(&JR"W+4)0O`BOY.9T*5]7,>HVYO7E6+QW$XQ\<. M?>X<,Y4C#&[>^=0N^'M^Q@WIH(]ITK?,A[-K^C9N=]3WBO".+X,1P!*_6R&D M!U+8\*:.ZC`S'[W9C?=T;3;@QAP)1*`VA;5/9W6BXV#;T48 M03^G5:`F*,'QO`@O8']>$+6<5]]Z%7-::S#'IJN+ZT'QV=IR._Z[0\;?W3Y_ ME8N(B^=MDTGA-NL^^0G9PQ0U%&.VNT3SKX@>#="\2UCSE^@+W6CV"1P:Z;\O M28/KJ+&Z.OKB,,$X#@RC(*&+:1\5?P^C]36:WC2FV]]UC%E-M3`3#PQ(R>8% MC1<]0B/.NF367:&Y)'Z,W]IUJ%A-N&2LPP!'[#^O<\?@/BRL)E!J,<"`2[!U M81.YI1V?="S7H6)V=WP:8JN]X0/R=OK4#_V$:/-7LO;3\^UXL<`!(4U31;1Z MNPX%JZL4!J)Q?(;_N3/X,\?TPEKGQ/X#]\1.'RX?_.-V2([JL$[G!6OJL_A^ M.P@OM1SE(SI\@;^]D?-R",!X(T>`*+?VPB)87/%U#6ATT.@9)\^BV^0B, M67J&\!V73;("D(=9>&([$.PNQ0V?0XG2@%T&GYY\.C]A8J,+Y!\]_'"/DND* M9_?"UTQH0TX[9YN6`]'L2DY`KIU#B$",U^1\&OBA5(1[;9R%:&N(C\M.2Z+[ M-8GC5/R4#FVSV\1=2*6&Y'C78?)S1)2GX=+>SD^`+(H'"2DG-P$)'S[#AA',Y5Z9J'7(H[ MN[X0J8.92A3@L--+B!=V<'T[4=^N(&:U3]:.NPJ=6E&?RHZNKR6T<=(4P?%? M;^\R:CZ%ZO9W?<]1$WF#B?1(%:`R(_T6TXT8BV"6UH,4='!]UU%G$N:Q#'$2 M+HO\%A/1#9%K\HCFEW%RF=,,ZW4NK*Z9ZH[F^J*BIM&:"0LBW'J6*.OC.B6\ M)G1P[5$:!%?\GJB8_'U9DS%,>LC1.JP+M9?.I_4%C,&_=Q.!>Z.`5MG2=HJ^4JH;Y5Z187 MV#VZZPE#)I"""H&`Q.6UY:[@O(1C66262I0&K?6&2+LX3I6LM^ER^8<##<]#J MW,ZI^CE/@V[DHH9Z2\>C5;5KEO4YGM>ZU)S#0(@?U7V8/W6QGS]5[+6VI4Q2 M]G#%[-Z/RLPJ,L,O$*:>-_I(+ED%4ASHY+N]-#''\RB80ZQ@*.OZ\?KUX\O= M:&Z:S&$PQ/$\-68L%\=A^I\Z;%;L'-#7J=RUEJI9AN!O*-^)X/^1&\'_B?PP MG8U[OW8NNM,!K85Q/1F,INR-$_)/E6]XY4ME:DC0! MJNTM>"A.G)F?9``\!G6E5$Y/E1FKD%L+^BO^E.O@'5B*JX+D36/WQ+-76$%5 M@!96#\3JFS(HOL7CB&Y2$6V`_;K4/SUUGC# M^RS._/"EU%OOZZZ#"D$JL0EPKT-5=^Y[VMX1<#_F/!H2I"9*<#D2Q4O-.6S) M062=$N>!IFY4MB5$6PIYK5`C6G!IN\-FSD-<[3MN1+(XDJGD:.[V_C@#$)@+ M:SW3D)@5Y\P@FN^Y9F#$,90/RG2###]NZQ'R@Q@^U@EB*#_@K;_P%L$`,X)A MAE8/<>(GST4,EEX(I+23Z[HDK4PT&F)Z<^-6SJIT,G5SL:I-P%N\2W/X7.M\ MLXO59C>JKRWPQ(CUAO##R97:B,?P>0YER')WN4S0DN"PZZ?3JE?DEJK7&W'B M&&C7LR7TC(S6KX"-*7A=P3(O+KY7M4J\@,3YJIMWZ]7/EC<8TW$9>0UL]ZL`-18@C!6L MY.,2$?GZX0$C2K3%'5U?YUA`B`NY2E0P<&4I]F2AN2*?"`UD(-E4U![1]86) M=4UH*EP8*B(72]UYWOWMANW)'!9JZ^>>K2[=C09U[>LTQ]N"#&$I0[DF&9NR M;G_G_CL+@/%50$]R+IUM@JOJ_J8,E[6%GH[;?%CG+BY[NF)'(.Y5Z$56GMJK MBWN'D?45!-8J0>\-"EF&8?Q$BPBOR2>$=],49;U[ZL4:1MU5G,L"C=QF*FK0Q^=-Y6BR*%,4WK M,,3?</1AO>W8WXZDASN69BIB]"'7SMUVM*:&K(__ M@,<7C-DM@D>LQC= MVQG^;8=IFYE2S:+E59RF.[(V60K,1CF^>;Z.E&#L!KAF:@*M]@#'-P4;RN;X M5^4#5R,+(&,AP\66I+R]-/"_"D=PG<%CP1&KD([K]?BT,XT7&=%9U`W^S'&* MZ8BSQ(]2PB/Y\0)E3PA%`[*CR#!*;\FX28^].,92Z>*P4[#%>A.^#QO(5O,? M3OBK^2G-R1]?SKYV;P9>M_>/V^%T2//Q/WNSF^YHVNVQY/R+P>SK8##R!J,9 M^5>RYM^.^H,;FL!_3?ZU-Q[-;L979*2"0F]-HI=3&KV"2*^D$L2FX")/<83( MXA"O[G"D>UDN[V7SCF\7ZAV4:1#KA9]B&;UT#+,A'#N&=/"HWLW5D4]+Y7DV MWZ,AQU&*Y^5!0`"+N+EK+XPI!BK&8>RH*&E9DK,IEJP/??2(POB!QFBS:'!) ML).JH^M]L0E>NCR!0LY_P)D?TB?@:.!]GJ%DO8(.5P\^3ECPO@1`S?ZN=\)U M<#02#0PX9RBXC^(P7CZO7\E4&*"P@^N]:@W`%,S#0$BB5=WY'"O\?WJ]7<>3 MV36V`[&TO<=8?UBUN=BVGR4[/A1>@UN%-/9CS4)@:\U4#J<&"O>(G6:<)D[D7I5E1 M16V;7@3GA7$;>&ITY0/# MXDMJE6O[?CM=A"`=$?F\OH9;K%TG4R]?Y:%/0RED]U;B/KK8MI9U5@-;M0Q@ MV!N'-1H=M8SHX7+(8$@6N+-MNT21SA#(=D62!8P[0&.\![54#@P#'-=9W`6E^=`R2U>V4?2 MQ771E1JH*04``Z?*X4$1FG#8\@COM47LP@##P`%-W<[C1:5A'Z5!@A\$][CF M'F[Y!UR7/6G7NZ\C7%@:4Y'#=I<\0]^S"_+Q;T;G5F[_8XJH,&0-ACOGK+.] M4AH\TH6CLSGW[,6:=J/YKD-+&@-_QG?@T%]/;R^F@W_<#D8S;_`;^9.FM=&/ M>NRK7KSP=K[K^='\(-H=0F#[ON34[AIQ#UBV##7RHR4K5P'92M#'D3J'7N#D MVYH#PA!GZZ=>,""^\NB.UD[1-2<*6($=+3N)=2,(I%U='[P-@=86!B3L6@OU M:.W@70N55[@$BX/D1TA64EK1S_7AVG1YUA(#)(M369K[\VXM"X-[EM6+-3@W M.:K"BAIX)4=05CZ,;G)F-&Q&0OQ>.Y6Y'.@E!*/99Z*:UP`!`V*#:$A^5+U2 ML=<6"!9<31(A4"%_<_:T@4**@O?+^/'#'.$"`/+#OMS)K_ZX0DL_9*%2S]WO MF"=PTNJ@T3%(FD=WQ8WS8A(NOM^/Z7&*+][=%HYERQ/;@6!W*=Y&1=D,\[]& M@=@\9O; MPO"A(%JUS MW*:N$X;4<(AIAS0IOD#H6GN11[HF\7J#UO36XG7-QZ;[E.TXSF.1[&Y6]@4$ MPS:K1++0.$([^YW>FK77Q7F@4IT%C,OVJS7;W3U7;:L5#>,\ELGJEA2HS'<(Y^=]*],P3RR@T2QJ%#8!DS."ZPJN5JQ3$TIQ"%SY+_2/.S]% MY#?_'U!+`P04````"``&9$I#GZZ/<)4+``#1:0``$0`<`&YS8W0M,C`Q,3`Y M,S`N>'-D550)``.+UE92B]964G5X"P`!!"4.```$.0$``.UNOY0?88"N8 MD$WJ3#ZD0.INM?K7:K4>Z/S7Q[F#[@D7E+D7E?I1K8*(:S&;NM.+RHVI-@(FRI@4Z.3C'2M"W$?B6NS?C-T%B*G7G>HE&M/CP\'+GL M'C\P?B>.++:=.)/YW")+6:ZPO'KMKEX_>IR`XAWL0>%QK7[RK^-.O1;\&]5/ M&\>?&Q_K6S;@8<\7RP9JC[7H;SOV+A76DOD_>/J)_?0XI-]GOOO9;^+?AE8? M^[HY[ML/OP___';KM+SCV=GDJ_-E_'0[NVU]$<.GZ??F'9]_'NK=L,ES8O5[]]H,Z"HA8>/1H>Y=%GG][.RL&M3&I!N4 MCV/NQ*)/JK)ZC`592H9:JJ"GKO"P:Z7H;6_)D"3^5`TK4Z0TD_0T)*4QJ4VV MH_.%-L5XL:2=8#$.:*.*JG07K5;73NHQB\M-5[6I`J$&E`13BU MEGS/,Z49>F9[M.207Z0R]=K9B1S'#ID3U[MD?-XA$^P[8,$?/G;HA!*[@CS, MI\233B<6V"(Y4F*/Q:[+P+%A[$8ELFRQH."Y4/"W2`\RA/S/B M4=`RPZSI>K6-3Y0V1A]2LOY=*ILOS2+ZD_Y"9AG02N3&.75J6W]S280\9 MWKNJ4IOW5.F\4@H*Q)3*QCWFD;K6(<+B="%;Z$]:OJ`N$9&E501J>_\DV@,1D:_A_J7J'5C&CW=-$MG^&.MA04%%QXD.@0) MW!6#=62;P2S&74,(GR2P*,"CAN=S)CPR8VDU3<.4P`R&NJGW1LT`J&:O@Z[Z M1N\*M?N]MC[L(<,T;_3RH7:BJ?#)K%4C<9:)A,QK#O8&BW[43'\^Q_RI/S'I MU(5UF(5AG6-9S(?%B3L=,(=:-(G!UAQ*7.JU3%R"'.BFVVT.;^48,8VKGG%I MM)N]$6JVV_V;WDAB-NA?&VVCA&A]TJ3)F+2S#S+7LDXEA1J->B8:,F?J&"8, M$3#[C=Y!_8$^#`)6^4Q_JK79?$Z]:!N@'9AX2MSTX%!2J2$XSH1`YE7M?K=K MC+JZ'`0P3X1P7.F]4@Z!G[0A`8V(#4M/[VG$L2NPM38(%#1J#$XR,9"YUE"_ M;HY@!`R:P]$M&@V;/;/9+N=(^*PE%V*I$K5U/V9:5Z9*^G]OC-%MZ2QYIID> ML^YDTDEL>2!!P%%7NXYJ$K6M/V7:6B9#YJC?_J)!&JK+4-(=Z.#)TI%+9_UZ M33-\E#-/UNF:RB?>`.6E:$!Q$ MT%0B%+>(]T"(&VR!P^1XX]J$R[F3N7+2!#D)0%XN2PUBSF):)D5F_W+TK3G4 M(?V$&&4:H58WT4VOHP^#21MJY60][%^7#_]C6":, M!?GA0V_T>[D1E``THU*-4/9Z.LB9S)N6"?.'S([TK_"_?&-MVQ79[FNY+==T MV6OM8FLZ]"%NK%S'"47@&.&QLPN,$9\2Q.-]+,S1A["I\D&8M_Y>A^P9.C5$ MA5?KY<4C-W]>!^0Y0C4BV8MW5;I=7DC2^?4Z#IFU:N-GK]HW\=@GXEYB9UB,PG?0#F71`U;]N9#=K9>8@"R#WX[Q,/4$3W,94IP M3YX]*=Y@4(.3LV.1?W*,/D0MH&43Y0,KZ^0Q'ZFMJ-4P9>])Y)U;'C`JL`S2 M+C'EP6WF+L'2NL$]E9"7_DGLUM,UN2=.9-'BRZR"\M5^D+WS47`YIB&I4GB# M&R650BNMT/@)!7HM?>G@07D(YX_\G26HO6`_.RN'&)&[[LXI3EZY"E M1/TD>RM&M.V$Y=&TS=W2SS$\T#+']);E1K'`?4$I^'D&RZ@E%#=58B#3)Q.KS_JC!(9LP+(!UQ@9^-_FQ*9>&\+4TX3Q M!\SMS7FQ$)<:Q^R-F"P<)7YA,RC53IG1>_&IH=84@G@BX`;;;A)L8O_7M:GT MG(_9FSE[/_@2P$]2.]@2;KIT.%IOA:!_2U'Z1O6.5<_J>.AF2O]1.*A`\4K(> M4DH(,*A+`% MX3+,5V/E8P$0_25[\A?F2+8#0:*ZCRX[>%RTR\!"G%?LZ[64O]=.@O<5[>2: MP[Y25]NK5O;:81@Z13N<'FVOU-_.LI%D=Z/'N*JKU[BB[^LO=IU#QQGWD+OQ MY)?J!;;P[;AK9@6B%"SRFQ;S:;)(@[A\4C]Z%/9*TR)*K,Q03(F8;P=OVE6_+J=K/9*P2QQ-QR0NUD8-'[$F=0-8. M^FSQCMXVGI+D[(6,TE7.I*O43U^HS&Z*[*Q%ROFH>T^$5]AG$VS1YWQLHD<% MP]0+,K8_VG0Q(]R<4V_6)?,QX95`2XC.&174<>0%U(N*QWT9W>0[D`V(>I39 MHR`XVSZ/?I0;!NOP(<6&S>:8NH9'YI(,>@79'@1%7Y)><>8O+BJA+`HD*FV[ MQ):OIZ4U72]\*_`")Q;UJ5U M5M2_N>[)LZAU2V?4O+F^L2U-[!"1;>9TU9MK+(>_8/YZ_-HL?G--54^C-D$F MQY87J[\=+8X^Q7TJWL>0`J3`B-]#%W7,79`D!C!UR%<#Y1MA5GBGR`\.U%?/ M\(3]+,)0'$!`;Q$)?JW.K2Z\;=^_?)ZW[F*/>-$^FFM?4SRF3K`!>\G9/.\Y MI;"?NS`6Z&Q8-PXO9EY4K."P*.W#<^82#_.G?01M+&;U99R.OCRK;;AX\C:4 MMDUP/*=M0OKN`DOW(X#7]X5-;7N=8;OJ-R*/7 MS$PZO+23BG_L>;?")W./&(W[R$R3$*1W@4Z'3`B'62T( MRC).P9+?6;]-TR(NF5!/E4_M0_?OM2KR,W.A#HN*]NN#`Y]8,"S+@U")-QXGVY>*NY%:_7S3ZD^>N M[&3XVO,L[Z_#B=2#3=+)24[=7Y:8G%?#;5[X^#]02P$"'@,4````"``&9$I# M4>*/%5>P```Z&P@`$0`8```````!````I($`````;G-C="TR,#$Q,#DS,"YX M;6Q55`4``XO65E)U>`L``00E#@``!#D!``!02P$"'@,4````"``&9$I#9M8; M9%P*``#H90``%0`8```````!````I(&BL```;G-C="TR,#$Q,#DS,%]C86PN M>&UL550%``.+UE92=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!F1*0\@! M1/6`%0``\2(!`!4`&````````0```*2!3;L``&YS8W0M,C`Q,3`Y,S!?9&5F M+GAM;%54!0`#B]964G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``9D2D,7 MXA+^A3D``.="`P`5`!@```````$```"D@1S1``!N`L``00E#@``!#D!``!02P$"'@,4````"``&9$I# M$GEYQL@L```VR0(`%0`8```````!````I('P"@$`;G-C="TR,#$Q,#DS,%]P M&UL550%``.+UE92=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!F1* M0Y^NCW"5"P``T6D``!$`&````````0```*2!!S@!`&YS8W0M,C`Q,3`Y,S`N M>'-D550%``.+UE92=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``.=# $`0`````` ` end XML 61 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 9 - STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Sep. 30, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Outstanding Options
     Outstanding Options
    

Shares

Available for

Grant

 

Number of

Shares Granted

 

Weighted

Average

Exercise Price

 

Weighted Average

Remaining

Contractual Life

(years)

 

Aggregate

Intrinsic Value

 October 1, 2008    7,000,000    5,271,756    0.43    4.75   $—   
 Grants         40,000   $0.15         —   
 Forfeitures         —                —   
 September 30, 2009    —      5,311,756   $0.43    3.75    —   
 Grants         —      —             
 Forfeitures         (5,311,756)-   .64-           
 September 30, 2011    7,000,000    —     $—      —      —   
Warrant Activity
   Number of
Shares Granted		  Weighted
Average
Exercise Price		  Weighted Average
Remaining
Contractual Life
(years)		  Aggregate
Intrinsic Value
 October 1, 2009    2,308,497   $.10   $58   $—   
 Grants    —      —             
 Expired    —      —             
 September 30, 2010    2,308,497   $0.10    .38    —   
 Grants    —      —             
 Expired    (2,308,497)   —             
 September 30, 2011    —     $—     $—     $—   
XML 62 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Sep. 30, 2011
Accounting Policies [Abstract]  
Fair Value Measurements Summarized by Level
at September 30, 2011               
   Level 1  Level 2  Level 3  Total  
Proprietary Technology             1,200,106   1,200,106  
Total Proprietary Technology             1,200,106   1,200,106  
                      
at September 30, 2010                     
    Level 1    Level 2    Level 3   Total  
Proprietary Technology                     
Total Proprietary Technology             —     —    
XML 63 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 26, 2013
Sep. 25, 2013
Common Stock
Sep. 25, 2013
Preferred Stock
Entity Registrant Name NATIONAL SCIENTIFIC CORP/AZ      
Entity Central Index Key 0001022505      
Document Type 10-K      
Document Period End Date Sep. 30, 2011      
Amendment Flag false      
Current Fiscal Year End Date --09-30      
Is Entity a Well-known Seasoned Issuer? No      
Is Entity a Voluntary Filer? No      
Is Entity's Reporting Status Current? No      
Entity Filer Category Smaller Reporting Company      
Entity Public Float   $ 5,087,389    
Entity Common Stock, Shares Outstanding     214,634,216 4,000,000
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2011      
XML 64 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTE 5 - DISCONTINUED OPERATIONS (Tables)
 12 Months Ended
Sep. 30, 2011
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Balance Sheet
   September 30, 2011  September 30,
2010
Net assets of discontinued operations:          
Cash  $—     $2,197 
Accounts receivable   —      —   
Deferred offering costs   —      400 
Net assets of discontinued operations  $—     $2,597 
           
Net liabilities of discontinued operations:          
Accounts payable and accrued expenses  $169,176   $195,072 
           
Disputed salaries & vacation of former officers   968,645    968,645 
Disputed salary – former employee   20,256    20,256 
           
Disputed payroll taxes for back pay of former officers   84,701    84,701 
Disputed interest   209,215    191,346 
Interest expenses   42,137    42,137 
Former officer note payable at 8% interest rate   59,704    59,704 
Shareholders demand note payable at 12%   11,625    11,625 
Shareholders demand note payable at 12%   20,000    20,000 
Unsecured note payable at 8% interest due November 2010, interest payments in default at 9/30/2010   175,000    175,000 
Note discount   —      (860)
Note beneficial conversion feature   —      (166)
Net liabilities of discontinued operations  $1,760,459   $1,767,460 

 

 

   Years ended
September 30,
   2011  2010
Discontinued operations:          
Revenues  $3,400   $58,788 
Cost of sales   —      25,462 
Operating expenses   —      36,485 
Interest expense   19,612    31,962 
Interest income   —      —   
Loss from Discontinued Operations  $16,212   $35,121